<?xml version="1.0" encoding="utf-8"?>
<?xml-stylesheet type="text/xsl" href="/html/xsl/rss2html.xsl"?>
<rss version="2.0"
xmlns:dc="http://purl.org/dc/elements/1.1/"
xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
xmlns:admin="http://webns.net/mvcb/"
xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
xmlns:content="http://purl.org/rss/1.0/modules/content/">
<channel><title>Ipsen - DKPHybrids Dashboard</title>
<link>http://ci.beaufour-ipsen.com/traction?type=np&amp;proj=*&amp;sdate=20120831&amp;edate=20120501&amp;rs=</link>
<description>DKPHybrids Dashboard</description><dc:language>en-us</dc:language><copyright>Copyright &amp;copy; 2016  All rights reserved.</copyright><category>News</category><docs>http://backend.userland.com/rss</docs><ttl>20</ttl><rating>A1</rating><image>
<title>Ipsen - DKPHybrids Dashboard</title>
<link>http://ci.beaufour-ipsen.com/traction?type=np&amp;proj=*&amp;sdate=20120831&amp;edate=20120501&amp;rs=</link>
<url>http://ci.beaufour-ipsen.com/share/tsi/logos/ipsenbaseline07.jpg</url>
<width>108</width>
<height>31</height>
</image><admin:generatorAgent rdf:resource="http://tractionsoftware.com" /><item>
<title>Pfizer Is Vying To Acquire Indian Specialty Injectable Business [headline, sub:Hybrids]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology8440</link>
<description>Pfizer Is Vying To Acquire Indian Specialty Injectable Business [headline, sub:Hybrids]</description><category>headline</category><category>sub:Hybrids</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology8440</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8440">Pfizer Is Vying To Acquire Indian Specialty Injectable Business</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=headline"><font color="#e95e0b">:Oncology:headline</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=sub%3aHybrids"><font color="#e95e0b">:Oncology:sub:Hybrids</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8440">Oncology8440</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 30 August 2012 | 18:32</font><br><br><div style="margin-bottom: 10px;">Comment: Strides Acrolab's specialty injectable unit Agila appears to be up 
for sale, with a potential buyers rumoured to be Pfizer, a 
company with whom the parent company already has a US distribution 
partnership.<wbr> </div><div style="margin-bottom: 10px;">Agila has the highest number of generic injectable approvals by the FDA and 
therefore is viewed as a potentially attractive acquisition for any 
pharmaceutical company which to expand its generic business, something Pfizer 
appears keen to do through its Established Product Division.<wbr> </div><div style="margin-bottom: 10px;">Agila's sales in 2011 were reportedly $185 and are forecast to expand 
to $250m by FY2013.<wbr> Hence the cost of acquiring the company is likely to be 
around $1.<wbr>6 to $2bn.<wbr> </div><div style="margin-bottom: 10px;">The slides below illustrate Agila's activity and capability 
profile.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8440/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8440/2/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8440/3/ScreenCapture3.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8440/4/ScreenCapture4.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8440/5/ScreenCapture5.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8440/6/ScreenCapture6.jpg?user-agent=rss"> </div><div><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8440/7/ScreenCapture7.jpg?user-agent=rss"> </div><!-- Comment details --><a name="oncology8440attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8440/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(231,6 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8440/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(248 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8440/3/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(231,4 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8440/4/ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(258,3 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8440/5/ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(196,6 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8440/6/ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(241,4 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8440/7/ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(281,8 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8440">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-08-30T18:32:43+02:00</dc:date><dc:creator>jac89886</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8440/1/ScreenCapture1.jpg" length="237129" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8440/2/ScreenCapture2.jpg" length="253982" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8440/3/ScreenCapture3.jpg" length="236981" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8440/4/ScreenCapture4.jpg" length="264549" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8440/5/ScreenCapture5.jpg" length="201295" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8440/6/ScreenCapture6.jpg" length="247225" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8440/7/ScreenCapture7.jpg" length="288584" type="image/jpeg"/></item><item>
<title>Priority Review Granted by FDA to Zytiga for Pre-Chemo Setting [comp:JnJ, dis:Prostate, prod:Zytiga, :PharmaWorld:sub:Regulatory, :PharmaWorld:mkt:NorthAmerica]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology8438</link>
<description>Priority Review Granted by FDA to Zytiga for Pre-Chemo Setting [comp:JnJ, dis:Prostate, prod:Zytiga, :PharmaWorld:sub:Regulatory, :PharmaWorld:mkt:NorthAmerica]</description><category>comp:JnJ</category><category>dis:Prostate</category><category>prod:Zytiga</category><category>sub:Regulatory</category><category>mkt:NorthAmerica</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology8438</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8438">Priority Review Granted by FDA to Zytiga for Pre-Chemo Setting</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=comp%3aJnJ"><font color="#e95e0b">:Oncology:comp:JnJ</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=prod%3aZytiga"><font color="#e95e0b">:Oncology:prod:Zytiga</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=mkt%3aNorthAmerica"><font color="#e95e0b">:PharmaWorld:mkt:NorthAmerica</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=sub%3aRegulatory"><font color="#e95e0b">:PharmaWorld:sub:Regulatory</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8438">Oncology8438</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 29 August 2012 | 17:18</font><br><br><div style="margin-bottom: 10px;">Comment: The Zytiga sNDA submission is based on the efficacy and safety results of an international Ph3, randomized, double-blind, placebo-controlled clinical study that evaluated the drug + prednisone vs.<wbr> placebo + prednisone in 1,088 asymptomatic or mildly symptomatic men with mCRPC who had not received chemotherapy.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Background in Traction CI</FONT></STRONG> </div><div>Please see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8342" class="defaultlink">Oncology8342: J&J Intends to Extend the Use of Zytiga Earlier in the Course of Prostate Cancer</a>.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8438">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-08-29T17:18:37+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Preliminary Results of the Ph1 Assessing Versartis' Once-Month rhGH for AGHD [class:GrowthHormone, dis:GrowthHormoneDeficiency, :PharmaWorld:congress:ESPE]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7070</link>
<description>Preliminary Results of the Ph1 Assessing Versartis' Once-Month rhGH for AGHD [class:GrowthHormone, dis:GrowthHormoneDeficiency, :PharmaWorld:congress:ESPE]</description><category>class:GrowthHormone</category><category>dis:GrowthHormoneDeficiency</category><category>congress:ESPE</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7070</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120831&edate=20120501&rec=7070">Preliminary Results of the Ph1 Assessing Versartis' Once-Month rhGH for AGHD</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=class%3aGrowthHormone"><font color="#e95e0b">:Endocrinology:class:GrowthHormone</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=dis%3aGrowthHormoneDeficiency"><font color="#e95e0b">:Endocrinology:dis:GrowthHormoneDeficiency</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=congress%3aESPE"><font color="#e95e0b">:PharmaWorld:congress:ESPE</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7070">Endocrinology7070</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 29 August 2012 | 14:34</font><br><br><div style="margin-bottom: 10px;">Comment: To date 39 of 50 planned participants have received placebo or VRS-317 doses, and there have been no study withdrawals due to AEs.<wbr> Findings show that the drug stimulates IGF-I at GH equivalent doses below the conventional GH doses used in GH deficiency adults.<wbr> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 8pt; COLOR: black; LINE-HEIGHT: 115%; FONT-FAMILY: 'Verdana','sans-serif'; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: IT; mso-bidi-language: AR-SA"><STRONG><FONT size="3">Design of the Ongoing Study </FONT></STRONG><A href="http://clinicaltrials.gov/ct2/show/NCT01359488?fund=2&amp;rcv_s=05%2F10%2F2011&amp;rank=158"><STRONG><FONT size="3">NCT01359488</FONT></STRONG></A></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 8pt; COLOR: black; LINE-HEIGHT: 115%; FONT-FAMILY: 'Verdana','sans-serif'; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: IT; mso-bidi-language: AR-SA"><FONT size="2">Doses: 0.<wbr>05; 0.<wbr>1; 0.<wbr>2; 0.<wbr>4 or 0.<wbr>80 mg/<wbr>kg</FONT></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 8pt; COLOR: black; LINE-HEIGHT: 115%; FONT-FAMILY: 'Verdana','sans-serif'; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: IT; mso-bidi-language: AR-SA"><FONT size="2">Recruitment: 24M &amp; 15F; mean age: 46 +/<wbr>- 13 y; IGF-I SDS mean: -1.<wbr>9 after GH washout.<wbr></FONT></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 8pt; COLOR: black; LINE-HEIGHT: 115%; FONT-FAMILY: 'Verdana','sans-serif'; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: IT; mso-bidi-language: AR-SA"><STRONG><FONT size="3">Drug Program</FONT></STRONG></SPAN> </div><div><SPAN lang="EN-US" style="FONT-SIZE: 8pt; COLOR: black; LINE-HEIGHT: 115%; FONT-FAMILY: 'Verdana','sans-serif'; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: IT; mso-bidi-language: AR-SA"><FONT size="2">Pediatric studies are planned.<wbr></FONT></SPAN> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120831&edate=20120501&rec=7070">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-08-29T14:34:34+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Humira's Label To Expand To Potentially Include Ulcerative Colitis [dis:IBD, news]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology1856</link>
<description>Humira's Label To Expand To Potentially Include Ulcerative Colitis [dis:IBD, news]</description><category>dis:IBD</category><category>news</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology1856</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20120831&edate=20120501&rec=1856">Humira's Label To Expand To Potentially Include Ulcerative Colitis</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20120831&edate=20120501&cat=dis%3aIBD"><font color="#e95e0b">:GastroEnterology:dis:IBD</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20120831&edate=20120501&cat=news"><font color="#e95e0b">:GastroEnterology:news</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology1856">GastroEnterology1856</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 29 August 2012 | 10:54</font><br><br><div style="margin-bottom: 10px;">Comment: An FDA panel on Tuesday backed the approval of Abbott's anti-TNF 
drug Humira (adalimumab) for the treatment of moderate to severe ulcerative 
colitis voting 15:2 in favour that the benefits of treatment outweigh any risk 
for patients who fail to respond to conventional therapy.<wbr> </div><div style="margin-bottom: 10px;">However, the panel agreed by a 14:2 vote that higher doses of the drug need 
to be evaluated in a post approval setting to further understand the need 
and potential for the drug.<wbr> A final decision regarding approval is expected by 
the year-end.<wbr> </div><div style="margin-bottom: 10px;">A company spokesperson Elizabeth Hoff reportedly stated that the new 
indication is expected to generate incremental sales of around$1bn.<wbr> Humira had 
sales of $8bn last year and is already approved for six indications.<wbr> </div><div>source: <A href="http://www.abbott.com">www.<wbr>abbott.<wbr>com</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20120831&edate=20120501&rec=1856">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-08-29T10:54:14+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>Novartis to Start Acromegaly Trial in Japan with Pasireotide LAR [comp:Novartis, dis:Acromegaly, prod:Pasireotide, :PharmaWorld:mkt:Japan, :PharmaWorld:sub:ClinicalTrial, headline]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7068</link>
<description>Novartis to Start Acromegaly Trial in Japan with Pasireotide LAR [comp:Novartis, dis:Acromegaly, prod:Pasireotide, :PharmaWorld:mkt:Japan, :PharmaWorld:sub:ClinicalTrial, headline]</description><category>comp:Novartis</category><category>dis:Acromegaly</category><category>prod:Pasireotide</category><category>mkt:Japan</category><category>sub:ClinicalTrial</category><category>headline</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7068</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120831&edate=20120501&rec=7068">Novartis to Start Acromegaly Trial in Japan with Pasireotide LAR</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=comp%3aNovartis"><font color="#e95e0b">:Endocrinology:comp:Novartis</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=dis%3aAcromegaly"><font color="#e95e0b">:Endocrinology:dis:Acromegaly</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=headline"><font color="#e95e0b">:Endocrinology:headline</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=prod%3aPasireotide"><font color="#e95e0b">:Endocrinology:prod:Pasireotide</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=mkt%3aJapan"><font color="#e95e0b">:PharmaWorld:mkt:Japan</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=sub%3aClinicalTrial"><font color="#e95e0b">:PharmaWorld:sub:ClinicalTrial</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7068">Endocrinology7068</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 28 August 2012 | 17:37</font><br><br><div style="margin-bottom: 10px;">Comment: The newly listed Ph2 trial in clinicaltrials.<wbr>gov will recruit approx.<wbr> 30 participants with medication naïve and inadequately controlled acromegaly.<wbr> The primary endpoint is to assess the total-group effiacy of the drug on the reduction of mean GH levels to 2.<wbr>5 µg/<wbr>L, and the normalization of IGF-1 at 3 months of study treatment.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Study Details - </FONT></STRONG><A href="http://clinicaltrials.gov/ct2/show/NCT01673646?recr=Open&amp;fund=2&amp;rcv_s=08%2F14%2F2012&amp;rank=43"><STRONG><FONT size="3">NCT01673646</FONT></STRONG></A> </div><div style="margin-bottom: 10px;">Dosage (enrollment): Three experimental doses will be tested: 20mg (10 patients); 40mg (10 patients); 60mg (10 patients).<wbr> </div><div style="margin-bottom: 10px;">Start date: Sept.<wbr> 2012 /<wbr> Completion date: Sept.<wbr> 2015 (final data collection for PE).<wbr> </div><div style="margin-bottom: 10px;">Protocol: IM administration of pasireotide LAR will be repeated every month for 12 months in core phase.<wbr> </div><div>Location: Japan (9 sites).<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120831&edate=20120501&rec=7068">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-08-28T17:37:29+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Takeda's Strategy in Emerging Markets [comp:Takeda, :PharmaWorld:mkt:Intercontinental, :PharmaWorld:mkt:Russia, :PharmaWorld:mkt:Brazil, :PharmaWorld:mkt:China]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology8436</link>
<description>Takeda's Strategy in Emerging Markets [comp:Takeda, :PharmaWorld:mkt:Intercontinental, :PharmaWorld:mkt:Russia, :PharmaWorld:mkt:Brazil, :PharmaWorld:mkt:China]</description><category>comp:Takeda</category><category>mkt:Intercontinental</category><category>mkt:Russia</category><category>mkt:Brazil</category><category>mkt:China</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology8436</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8436">Takeda's Strategy in Emerging Markets</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=comp%3aTakeda"><font color="#e95e0b">:Oncology:comp:Takeda</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=mkt%3aBrazil"><font color="#e95e0b">:PharmaWorld:mkt:Brazil</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=mkt%3aChina"><font color="#e95e0b">:PharmaWorld:mkt:China</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=mkt%3aIntercontinental"><font color="#e95e0b">:PharmaWorld:mkt:Intercontinental</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=mkt%3aRussia"><font color="#e95e0b">:PharmaWorld:mkt:Russia</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8436">Oncology8436</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 28 August 2012 | 13:07</font><br><br><div style="margin-bottom: 10px;">Comment: On Aug 28, the company held a briefing presentation on its emerging market business.<wbr> Management reported China, Russsia/<wbr>CIS and Brazil to be its top priority markets for future growth.<wbr> When it comes to the integration of Nycomed, it was reported that the acquisition provided an immediate financial contribution.<wbr> A selection of key slide is provided below.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Presence in Emerging Markets</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8436/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Future Growth</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8436/2/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Takeda's Geo Presence in Russia/<wbr>CIS</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8436/3/ScreenCapture3.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Takeda's Presence in Brazil</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8436/4/ScreenCapture4.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Takeda in China</FONT></STRONG> </div><div style="margin-bottom: 10px;"><U>Main Products</U> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8436/5/ScreenCapture5.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><U>Presence</U> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8436/6/ScreenCapture6.jpg?user-agent=rss"> </div><div><STRONG><FONT size="3" style="BACKGROUND-COLOR: #fdfd00">Full presentation attached</FONT></STRONG> </div><!-- Comment details --><a name="oncology8436attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8436/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(93,6 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8436/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(70 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8436/3/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(69 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8436/4/ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(96,2 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8436/5/ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(56,5 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8436/6/ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(60,1 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8436/7/Takeda%5fEMG%2dFull%5fE%5f120828.pdf">Takeda_EMG-Full_E_120828.pdf</a>&nbsp;&nbsp;(4 MB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8436">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-08-28T13:07:23+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8436/1/ScreenCapture1.jpg" length="95856" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8436/2/ScreenCapture2.jpg" length="71693" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8436/3/ScreenCapture3.jpg" length="70606" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8436/4/ScreenCapture4.jpg" length="98507" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8436/5/ScreenCapture5.jpg" length="57832" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8436/6/ScreenCapture6.jpg" length="61550" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8436/7/Takeda%5fEMG%2dFull%5fE%5f120828.pdf" length="4215805" type="application/pdf"/></item><item>
<title>AstraZeneca Appoints New CEO [sub:People, :Oncology:comp:AstraZeneca, :Oncology:news]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10020</link>
<description>AstraZeneca Appoints New CEO [sub:People, :Oncology:comp:AstraZeneca, :Oncology:news]</description><category>sub:People</category><category>comp:AstraZeneca</category><category>news</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10020</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120831&edate=20120501&rec=10020">AstraZeneca Appoints New CEO</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=comp%3aAstraZeneca"><font color="#e95e0b">:Oncology:comp:AstraZeneca</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=news"><font color="#e95e0b">:Oncology:news</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=sub%3aPeople"><font color="#e95e0b">:PharmaWorld:sub:People</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10020">PharmaWorld10020</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 28 August 2012 | 12:34</font><br><br><div style="margin-bottom: 10px;">Comment: Pascal Soriot, COO since 2010 of Roche's Pharma Division, will take up his 'challenging' new job on October 1st.<wbr> His mission will be to review the pipeline and do more deals in order to grow sales and face past development setbacks, current pressure on prices, and future patent losses.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">P.<wbr> Soriot's Bio</FONT></STRONG> </div><div style="margin-bottom: 10px;">- Nationality: French (aged 53) </div><div style="margin-bottom: 10px;">- Studies: Veterinary Surgeon; MBA with major in Finance (HEC Paris) </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10020/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG>Snapshot</STRONG> </div><div style="margin-bottom: 10px;">Mr.<wbr> Soriot served as the Chief Executive Officer of Genentech Inc.<wbr> since 2009.<wbr> </div><div style="margin-bottom: 10px;">He  served as Head of Commercial Operations at Roche Holding AG since December 2006 and Head of Strategic Marketing Pharma division </div><div><SPAN id="hidden" style="DISPLAY: inline">From March 1, 2006 to December 2006.<wbr> he served as Senior Vice President of Commercial Operations, United States of Sanofi-aventis since August 2004 and Chief Operating Officer since 2002 .<wbr>.<wbr>.<wbr></SPAN> </div><!-- Comment details --><a name="pharmaworld10020attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10020/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(15,3 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120831&edate=20120501&rec=10020">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-08-28T12:34:48+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10020/1/ScreenCapture1.jpg" length="15634" type="image/jpeg"/></item><item>
<title>re: NICE Revises Amgen's Xgeva Guidance</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology8435</link>
<description>re: NICE Revises Amgen's Xgeva Guidance</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology8435</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8435">re: NICE Revises Amgen's Xgeva Guidance</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8435">Oncology8435</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/13">fab42334</a> | 27 August 2012 | 17:54</font><br><br><div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">NICE Revises Amgen's Xgeva Guidance</span>&nbsp;<font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=comp%3aAmgen"><font color="#e95e0b">:Oncology:comp:Amgen</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=mkt%3aUK"><font color="#e95e0b">:PharmaWorld:mkt:UK</font></a>]</font></font><br><span style="font-size: 12px;">Comment: Last March, NICE recommended the drug for breast and prostate cancer patients whose disease has spread to the bone.<wbr> But in light of new information from clinical experts, the agency has reported it no longer believed the drug represented a cost-effective treatment.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8322">...</a><br><font size="-1">Brigitte DESCHAMPS / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8322" class="commentpermalink">Oncology8322</a> / <span class="date">12 June 2012</span> /
<span class="time">10:11:42 o'clock CEST</span>
</font></div><div style="margin-bottom: 10px;"><P align="left">The U.<wbr>K.<wbr>&rsquo;s NICE issued a final appraisal determination (FAD) recommending the use of Xgeva denosumab from Amgen to prevent skeletal-related events (SREs) in patients with bone metastases from breast cancer; and in patients with bone metastases from solid tumors other than breast and prostate cancer for whom zoledronic acid would be indicated.<wbr> The recommendation, which is contingent on Amgen providing Xgeva at an undisclosed discount under a patient access scheme, does not recommend Xgeva to prevent SREs in patients with bone metastases from hormone-refractory prostate cancer (HRPC).<wbr> Final guidance is expected next month.<wbr></P> </div><div>Source : BioCentury for the week of August 27, 2012 </div><!-- Comment details --><font size="-1">fab42334 / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8435" class="commentpermalink">Oncology8435</a> / <span class="date">27 August 2012</span> /
<span class="time">17:54:02 o'clock CEST</span>
</font><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8435">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8322">View thread  Oncology8322: NICE Revises Amgen's Xgeva Guidance</a>]]></content:encoded><dc:date>2012-08-27T17:54:02+02:00</dc:date><dc:creator>fab42334</dc:creator></item><item>
<title>Merz Strengthens its Neuro Business in the US [comp:Merz, dis:Palsy, :PharmaWorld:mkt:NorthAmerica, :PharmaWorld:sub:Acquisition, news]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology6529</link>
<description>Merz Strengthens its Neuro Business in the US [comp:Merz, dis:Palsy, :PharmaWorld:mkt:NorthAmerica, :PharmaWorld:sub:Acquisition, news]</description><category>comp:Merz</category><category>dis:Palsy</category><category>mkt:NorthAmerica</category><category>sub:Acquisition</category><category>news</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology6529</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120831&edate=20120501&rec=6529">Merz Strengthens its Neuro Business in the US</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=comp%3aMerz"><font color="#e95e0b">:Neurology:comp:Merz</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=dis%3aPalsy"><font color="#e95e0b">:Neurology:dis:Palsy</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=news"><font color="#e95e0b">:Neurology:news</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=mkt%3aNorthAmerica"><font color="#e95e0b">:PharmaWorld:mkt:NorthAmerica</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=sub%3aAcquisition"><font color="#e95e0b">:PharmaWorld:sub:Acquisition</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology6529">Neurology6529</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 27 August 2012 | 16:22</font><br><br><div style="margin-bottom: 10px;">Comment: The company has acquired (from Shionogi) CUVPOSA<SUP>®</SUP> (glycopyrrolate), an oral solution for ped.<wbr> patients (aged 3-16) with chronic severe drooling associated with neuro conditions, such as cerebral palsy (CP).<wbr> The drug is the only FDA-approved treatment for this condition.<wbr> </div><div style="margin-bottom: 10px;"><A href="http://www.cuvposa.com/"><STRONG><FONT size="3">Drug Snapshot</FONT></STRONG></A> </div><div style="margin-bottom: 10px;">- Background: On April 2011, Shionogi announced the US commercial availability of the drug.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/6529/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">- Supply: 1mg/<wbr>5ml clear, cherry flavored oral solution.<wbr> </div><div style="margin-bottom: 10px;">- MOA: anticholinergic that reduces the rate of salivation by preventing stimulation of acetylcholine receptors that are located on certain peripheral tissues such as salivary glands </div><div style="margin-bottom: 10px;">- FDA approved: July 28, 2010 </div><div style="margin-bottom: 10px;"><UL><LI>Approval was based on the results of a randomized, double-blind, placebo-controlled Phase III study which showed that 75% of children and adolescents treated with CUVPOSA™ experienced an improvement in symptoms, versus 11% who received placebo (<A href="http://clinicaltrials.gov/ct2/show/NCT00491894?term=glycopyrrolate&amp;fund=2&amp;rank=5">NCT00491894</A>).<wbr></LI>
</UL> </div><div>- Commercially available: April 2011 </div><!-- Comment details --><a name="neurology6529attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/6529/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(16,5 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120831&edate=20120501&rec=6529">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-08-27T16:22:25+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/6529/1/ScreenCapture1.jpg" length="16874" type="image/jpeg"/></item><item>
<title>Debiopharm Enrolls First Patient in Triptorelin 6-M Trial for CPP [:Oncology:comp:Debiopharm, :PharmaWorld:sub:ClinicalTrial, dis:PrecociousPuberty, :PharmaWorld:mkt:Intercontinental, :PharmaWorld:mkt:Mexico]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7065</link>
<description>Debiopharm Enrolls First Patient in Triptorelin 6-M Trial for CPP [:Oncology:comp:Debiopharm, :PharmaWorld:sub:ClinicalTrial, dis:PrecociousPuberty, :PharmaWorld:mkt:Intercontinental, :PharmaWorld:mkt:Mexico]</description><category>comp:Debiopharm</category><category>sub:ClinicalTrial</category><category>dis:PrecociousPuberty</category><category>mkt:Intercontinental</category><category>mkt:Mexico</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7065</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120831&edate=20120501&rec=7065">Debiopharm Enrolls First Patient in Triptorelin 6-M Trial for CPP</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=dis%3aPrecociousPuberty"><font color="#e95e0b">:Endocrinology:dis:PrecociousPuberty</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=comp%3aDebiopharm"><font color="#e95e0b">:Oncology:comp:Debiopharm</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=mkt%3aIntercontinental"><font color="#e95e0b">:PharmaWorld:mkt:Intercontinental</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=mkt%3aMexico"><font color="#e95e0b">:PharmaWorld:mkt:Mexico</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=sub%3aClinicalTrial"><font color="#e95e0b">:PharmaWorld:sub:ClinicalTrial</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7065">Endocrinology7065</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 27 August 2012 | 11:52</font><br><br><div style="margin-bottom: 10px;">Comment: The open-label Ph3 study will recruit approx.<wbr> 44 chilren from the US, Chile and Mexico.<wbr> Primary EP will assess the efficacy/<wbr>safety of the drug in decreasing LH to prepubertal levels at month 6 in children with central precocious puberty (CPP).<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Trial Details - <A href="http://clinicaltrials.gov/ct2/show/NCT01467882?term=debiopharm&amp;rank=3">NCT01467882</A></FONT></STRONG> </div><div style="margin-bottom: 10px;">Completion date: Oct 2014 /<wbr> Nov 2014 </div><div style="margin-bottom: 10px;">Protocol: 2 injections at D1 and D169.<wbr> </div><div>Total study duration: 12 months (48 weeks).<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120831&edate=20120501&rec=7065">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-08-27T11:52:26+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Bavarian Nordic Reportedly at Risk Of Financing Difficulties [:PharmaWorld:sub:Finance, class:Vaccines]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology8434</link>
<description>Bavarian Nordic Reportedly at Risk Of Financing Difficulties [:PharmaWorld:sub:Finance, class:Vaccines]</description><category>sub:Finance</category><category>class:Vaccines</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology8434</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8434">Bavarian Nordic Reportedly at Risk Of Financing Difficulties</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=class%3aVaccines"><font color="#e95e0b">:Oncology:class:Vaccines</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=sub%3aFinance"><font color="#e95e0b">:PharmaWorld:sub:Finance</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8434">Oncology8434</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 24 August 2012 | 16:13</font><br><br><div style="margin-bottom: 10px;">Comment: The company's ongoing phIII trial with its Prostvac VF vaccine may 
be in jeopardy as Bavarian Nordic failes to receive a $500m replacement order 
from the US Department of Health &amp; Human Services (HHS) for its 
smallpox vaccine.<wbr> </div><div style="margin-bottom: 10px;">Reportedly the purchase by the US authorities should have been made in June 
but has so far failed to materialise.<wbr> The vaccine in question is known as 
Imvamune and it is used in patients known to be at risk of adverse reactions to 
the standard smallpox vaccine.<wbr> </div><div style="margin-bottom: 10px;">According to a report on Bloomberg </div><div style="margin-bottom: 10px;"><UL><LI>In 2007, the US Department of Health and Human Services (HHS) awarded 
Barvarian Nordic a $500 million health contract for 20 million doses of 
Imvamune.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><UL><LI>Barvarian Nordic and HHS agree that the current vaccine is beginning to lose 
potency (i.<wbr>e.<wbr>, it is reaching its “past due” date) and needs to be 
replaced.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><UL><LI>The company has been expecting HHS to order replacement vaccine since 
June.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;">Since 95% of Bavarian Nordic's revenues are derived from Imvamune, it is 
likely to face a major shortfall in funding if an order does not materialise 
soon.<wbr> </div><div>The lack of any repeat order is seemingly due to problems with the federal 
government reaching any conclusions about HHS funding at the 
moment.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8434">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-08-24T16:13:02+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>New Study Is Assessing QOL of Patients with CD Treated with BOTOX® [comp:Allergan, dis:Dystonia, :PharmaWorld:sub:ClinicalTrial, :PharmaWorld:mkt:Canada, prod:Botox]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology6528</link>
<description>New Study Is Assessing QOL of Patients with CD Treated with BOTOX® [comp:Allergan, dis:Dystonia, :PharmaWorld:sub:ClinicalTrial, :PharmaWorld:mkt:Canada, prod:Botox]</description><category>comp:Allergan</category><category>dis:Dystonia</category><category>sub:ClinicalTrial</category><category>mkt:Canada</category><category>prod:Botox</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology6528</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120831&edate=20120501&rec=6528">New Study Is Assessing QOL of Patients with CD Treated with BOTOX®</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=comp%3aAllergan"><font color="#e95e0b">:Neurology:comp:Allergan</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=dis%3aDystonia"><font color="#e95e0b">:Neurology:dis:Dystonia</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=prod%3aBotox"><font color="#e95e0b">:Neurology:prod:Botox</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=mkt%3aCanada"><font color="#e95e0b">:PharmaWorld:mkt:Canada</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=sub%3aClinicalTrial"><font color="#e95e0b">:PharmaWorld:sub:ClinicalTrial</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology6528">Neurology6528</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 23 August 2012 | 18:48</font><br><br><div style="margin-bottom: 10px;">Comment: Clinicaltrials.<wbr>gov is listing a new observational study sponsored by Allergan.<wbr> The PE will assess change from baseline in Cervical Dystonia Impact Profile Questionnaire Score.<wbr> Approx.<wbr> 250 patients are to be recruited in Canada.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Trial Details - </FONT></STRONG><A href="http://clinicaltrials.gov/ct2/show/NCT01655862?term=botulinum&amp;recr=Open&amp;rank=114"><STRONG><FONT size="3">NCT01655862</FONT></STRONG></A> </div><div>Completion date: Oct 2017 /<wbr> Nov 2017 </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120831&edate=20120501&rec=6528">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-08-23T18:48:13+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Amgen's AMG-479 (ganitumab) Fails in Pancreatic Cancer [dis:pNET, :Oncology:comp:Amgen, :PharmaWorld:sub:Termination]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7064</link>
<description>Amgen's AMG-479 (ganitumab) Fails in Pancreatic Cancer [dis:pNET, :Oncology:comp:Amgen, :PharmaWorld:sub:Termination]</description><category>dis:pNET</category><category>comp:Amgen</category><category>sub:Termination</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7064</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120831&edate=20120501&rec=7064">Amgen's AMG-479 (ganitumab) Fails in Pancreatic Cancer</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=dis%3apNET"><font color="#e95e0b">:Endocrinology:dis:pNET</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=comp%3aAmgen"><font color="#e95e0b">:Oncology:comp:Amgen</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=sub%3aTermination"><font color="#e95e0b">:PharmaWorld:sub:Termination</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7064">Endocrinology7064</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 23 August 2012 | 13:57</font><br><br><div style="margin-bottom: 10px;"><P align="left">Comment: The company has discontinued the Ph3 GAMMA (gemcitabine + ganitumab) in metastatic adenocarcinoma of the pancreas, as well as a separate ongoing Ph2 in local advanced pNETs.<wbr> AMG-479, an IGF-1R antagonist, has also previously failed in other tumor types, including NSCLC.<wbr></P> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Ph3 GAMMA</FONT></STRONG> </div><div style="margin-bottom: 10px;"><P align="left">The addition of ganitumab to gemcitabine is unlikely to demonstrate a statistically significant improvement in the PE of OS compared to gemcitabine alone.<wbr> </P> </div><div style="margin-bottom: 10px;"><P align="left">There were no safety concerns raised in the DMC review of the study.<wbr></P> </div><div style="margin-bottom: 10px;"><P align="left">AMG-479's inability to show an OS benefit in pancreatic cancer should not come as a surprise given previous failures of this class of agents.<wbr> </P> </div><div style="margin-bottom: 10px;"><P align="left"><STRONG><FONT size="3">Ph2 Trial</FONT></STRONG></P> </div><div><P align="left">Results presented at ASCO showed the drug was well tolerated, however lacked efficacy in pNETs.<wbr></P> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120831&edate=20120501&rec=7064">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-08-23T13:57:46+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Another RNAi Deal With Prostate Cancer As Part Of The Focus [dis:Prostate, headline]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology8433</link>
<description>Another RNAi Deal With Prostate Cancer As Part Of The Focus [dis:Prostate, headline]</description><category>dis:Prostate</category><category>headline</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology8433</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8433">Another RNAi Deal With Prostate Cancer As Part Of The Focus</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=headline"><font color="#e95e0b">:Oncology:headline</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8433">Oncology8433</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 23 August 2012 | 09:19</font><br><br><div style="margin-bottom: 10px;">Comment: Silence Therapeutics has signed an agreement with Asutralian group 
MiRiven Ltd to assess the delivery potential of Silence's proprietary delivery 
systems with MiRiven's novel microRNA-based therapeutics in models 
of prostate and lung cancers and melanoma.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Background</STRONG> </div><div style="margin-bottom: 10px;">MiRiven's aim is to develop and commercialise discoveries made the the 
Western Australian Institute of Medical Research, notably to evaluate the 
potentia of miR-7.<wbr> </div><div style="margin-bottom: 10px;">MiRiven reportedly has developed a body of preclinical evidence supporting 
the potential of miR-7 to suppress tumour growth particularly in cancers 
controlled by the EGFR signalling pathway.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Deal Terms</STRONG> </div><div style="margin-bottom: 10px;">Under the terms of the agreement Silence will formulate a miR-7 mimetic with 
its proprietary AtuPLEX, DACC and DBTC delivery systems in order to evaluate the 
molecule in varioius cancer models.<wbr> Silence will undertake the in-vitro and 
in-vivo assessments.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Silence's Technology Platform/<wbr>Development Pipeline</STRONG> </div><div style="margin-bottom: 10px;">Silence's most advanced delivery technology is AtuPLEX.<wbr> It has demonstrated 
braod system delivery to the vascular endothelium and has been used to formulate 
Atu027, Silence's first clinical development candidate (phase I is ongoing).<wbr> </div><div style="margin-bottom: 10px;">DACC is closely related to AtuPLEX and is a novel lipid drug delivery system 
that enables the delivery of RNAi therapeutics to the pulmonary epithelium and 
DBTC is similarly a lipid based formulation that targets the liver.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8433/1/ScreenCapture1.jpg?user-agent=rss"> </div><div>source: <A href="http://www.silence-therapeutics.com">www.<wbr>silence-therapeutics.<wbr>com</A> </div><!-- Comment details --><a name="oncology8433attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8433/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(106,3 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8433">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-08-23T09:19:40+02:00</dc:date><dc:creator>jac89886</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8433/1/ScreenCapture1.jpg" length="108843" type="image/jpeg"/></item><item>
<title>Allergan Expands Global Partnership to Develop Novel Therapy for Eye Diseases [comp:Allergan]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology6527</link>
<description>Allergan Expands Global Partnership to Develop Novel Therapy for Eye Diseases [comp:Allergan]</description><category>comp:Allergan</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology6527</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120831&edate=20120501&rec=6527">Allergan Expands Global Partnership to Develop Novel Therapy for Eye Diseases</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=comp%3aAllergan"><font color="#e95e0b">:Neurology:comp:Allergan</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology6527">Neurology6527</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 22 August 2012 | 18:54</font><br><br><div style="margin-bottom: 10px;">Comment: Allergan has announced expanded agreement with privately held Molecular Partners AG in the field of serious ophtalmic diseases.<wbr> Companies will further develop single-agent anti-VEGF DARPin® (Designed Ankryn Repeat Proteins), a new class of protein drugs that blocks both VEGF and PDGF.<wbr> Wet-AMD is a $3B+ global market, dominated by off-label Avastin and Lucentis.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Terms of the Deal</FONT></STRONG> </div><div style="margin-bottom: 10px;">Molecular Partners AG will receive combined upfront payments of <MONEY>$62.<wbr>5M under the 2 agreements (1/<wbr>exclusive license agreement and 2/<wbr>exclusive discovery alliance) and is eligible to receive additional success-based payments, including up to </MONEY><MONEY>$1.<wbr>4B in aggregate development, regulatory and sales milestones, and tiered royalties up into the low double-digits for future product sales.<wbr></MONEY> </div><div style="margin-bottom: 10px;">Allergan's Full PR &gt; <A href="http://agn.client.shareholder.com/releasedetail.cfm?ReleaseID=701294">http:/<wbr>/<wbr>agn.<wbr>client.<wbr>shareholder.<wbr>com/<wbr>releasedetail.<wbr>cfm?ReleaseID=701294</A> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Drug Snapshot</FONT></STRONG> </div><div style="margin-bottom: 10px;"><U>Advantages</U> </div><div style="margin-bottom: 10px;">PK data suggest higher binding affinity, higher clinical dose and longer vitreous half life than Lucentis.<wbr> </div><div style="margin-bottom: 10px;">Acc.<wbr> to Allergan, DARPin® has the potential to be administered once every 3-4 months (vs 1 month for Lucentis).<wbr> </div><div style="margin-bottom: 10px;"><U>Ongoing Ph2b Program</U> </div><div style="margin-bottom: 10px;">Design: Randomized, double-blind trial in previously untreated wet-AMD.<wbr> </div><div style="margin-bottom: 10px;">Protocol: 2 doses of DARPin vs.<wbr> Lucentis.<wbr> </div><div style="margin-bottom: 10px;">Data expected in 2013.<wbr> </div><div>Source: Allergan; Molecular Partners; Thomson One </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120831&edate=20120501&rec=6527">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-08-22T18:54:50+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>PhaseBio's Glymera™ Has Entered Ph2b for T2DM [dis:Diabetes, :PharmaWorld:mkt:NorthAmerica, :PharmaWorld:sub:ClinicalTrial]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7063</link>
<description>PhaseBio's Glymera™ Has Entered Ph2b for T2DM [dis:Diabetes, :PharmaWorld:mkt:NorthAmerica, :PharmaWorld:sub:ClinicalTrial]</description><category>dis:Diabetes</category><category>mkt:NorthAmerica</category><category>sub:ClinicalTrial</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7063</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120831&edate=20120501&rec=7063">PhaseBio's Glymera™ Has Entered Ph2b for T2DM</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=dis%3aDiabetes"><font color="#e95e0b">:Endocrinology:dis:Diabetes</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=mkt%3aNorthAmerica"><font color="#e95e0b">:PharmaWorld:mkt:NorthAmerica</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=sub%3aClinicalTrial"><font color="#e95e0b">:PharmaWorld:sub:ClinicalTrial</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7063">Endocrinology7063</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 22 August 2012 | 15:41</font><br><br><div style="margin-bottom: 10px;">Comment: Glymera™, a once-weekly GLP-1, has the potential to show less nausea than what has been reported with other GLP-1 analogues as the onset of nausea appears to be related to the rapid release of GLP-1 agonist into the circulation.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">About the Ph2b Trial - <A href="http://clinicaltrials.gov/ct2/show/NCT01658501?term=phasebio&amp;rank=1">NCT01658501</A></FONT></STRONG> </div><div style="margin-bottom: 10px;">Recruitment: approx.<wbr> 522 </div><div style="margin-bottom: 10px;">Inclusion criteria: participants inadequately controlled with diet and exercise, metformin, sulfonylurea or a combination of metformin/<wbr>sulfonylurea.<wbr> </div><div style="margin-bottom: 10px;">Design: randomized, placebo and active comparator controlled </div><div style="margin-bottom: 10px;">Completion date: 3Q:13 </div><div style="margin-bottom: 10px;">Location: USA (72 sites) </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">PhaseBio Technology</FONT></STRONG> </div><div><STRONG><FONT size="3"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7063/1/ScreenCapture1.jpg?user-agent=rss"></FONT></STRONG> </div><!-- Comment details --><a name="endocrinology7063attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7063/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(41,9 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120831&edate=20120501&rec=7063">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-08-22T15:41:32+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7063/1/ScreenCapture1.jpg" length="42928" type="image/jpeg"/></item><item>
<title>Æterna Zentaris - Update on Major Programs [dis:Prostate, :PharmaWorld:func:RnD, :Endocrinology:dis:GrowthHormoneDeficiency, :Endocrinology:class:GrowthHormone, class:Vaccines]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology8430</link>
<description>Æterna Zentaris - Update on Major Programs [dis:Prostate, :PharmaWorld:func:RnD, :Endocrinology:dis:GrowthHormoneDeficiency, :Endocrinology:class:GrowthHormone, class:Vaccines]</description><category>dis:Prostate</category><category>func:RnD</category><category>dis:GrowthHormoneDeficiency</category><category>class:GrowthHormone</category><category>class:Vaccines</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology8430</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8430">Æterna Zentaris - Update on Major Programs</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=class%3aGrowthHormone"><font color="#e95e0b">:Endocrinology:class:GrowthHormone</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=dis%3aGrowthHormoneDeficiency"><font color="#e95e0b">:Endocrinology:dis:GrowthHormoneDeficiency</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=class%3aVaccines"><font color="#e95e0b">:Oncology:class:Vaccines</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=func%3aRnD"><font color="#e95e0b">:PharmaWorld:func:RnD</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8430">Oncology8430</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 21 August 2012 | 13:51</font><br><br><div style="margin-bottom: 10px;">Comment: During the Q2:12 results' webcast the company provided an update on the status of its key pipeline products.<wbr> Ozarelix, an LHRH antagonist partnered with Spectrum, has entered the second part of the Ph2 comparative study vs Zoladex (goserelin) in men with PCa for whom hormonal treatment (HT) is indicated.<wbr> New data on AEZS-120 (oral PCa vaccine), AEZS-108 (for CRPC) and AEZS-130 (diagnostic test for AGHD) are provided below.<wbr> Æterna Zentaris also announced its plans to eliminate 16% of its German workforce over the next year in an effort to reduce overall spending.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Quick Update on Perifosine</FONT></STRONG> </div><div style="margin-bottom: 10px;">Juergen Engel, President &amp; CEO, started the presentation with the new strategy for perifosine.<wbr> Following an 'unexpected negative outcome' of the Ph3 in colorectal cancer, the company has decided to contunuing the Ph3 development study in multiple myeloma.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Development of Ozarelix</FONT></STRONG> </div><div style="margin-bottom: 10px;">On Aug.<wbr> 14th, Spectrum announced initiation of patient enrollment in the Ph2b of ozarelix in men with PCa for whom HT is indicated.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Study Details - (</STRONG><A href="http://clinicaltrials.gov/ct2/show/NCT01252693?cond=prostate&amp;lead=spectrum&amp;rank=1"><STRONG>NCT01252693</STRONG></A> or See <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=6993" class="defaultlink">Oncology6993: Spectrum's Ozarelix Versus Goserelin Depot (Zoladex®) in Men With Prostate Cancer</a>) </div><div style="margin-bottom: 10px;">Objective: to assess safety and efficacy of a monthly dosing regimen administered SC vs Zoladex.<wbr> </div><div style="margin-bottom: 10px;">Protocol: patients will be randomized in a 2:1 ratio to either the ozarelix or goserelin arm, respectively.<wbr> </div><div style="margin-bottom: 10px;"><UL><LI>Eligible patients randomized to the ozarelix arm will receive a loading dose of SC ozarelix, followed by a lower maintenance dose on days 28 and 56.<wbr> </LI>
<LI>Eligible patients randomized to the goserelin arm will receive SC goserelin at randomization followed by two doses of goserelin on days 28 and 56.<wbr> </LI>
<LI>All patients will be followed for 84 days.<wbr> </LI>
</UL> </div><div style="margin-bottom: 10px;">Primary outcome: to assess the percentage of patients who achieve the level of testosterone &lt; = 0.<wbr>5 ng/<wbr>mL from day 28 through day 84.<wbr> </div><div style="margin-bottom: 10px;">Recruitment: approx.<wbr> 150.<wbr> </div><div style="margin-bottom: 10px;">Locations: multiple sites in <LOCATION value="LC/us">the U.<wbr>S, as well as in </LOCATION><LOCATION value="LC/in">India</LOCATION> (through Spectrum's subsidiary, OncoRx).<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Development of the Tumour Vaccine AEZS-120</FONT></STRONG> </div><div style="margin-bottom: 10px;">Preclinical development was financed by a grant from the German Government for approx.<wbr> 50% of the total costs.<wbr> </div><div style="margin-bottom: 10px;">The company is in the planning process to file a CTA in EU, in order to initiate a Ph1 trial in late 2012/<wbr>early 2013.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Development of AEZS-108 for castration and taxane resistant prostate cancer</FONT></STRONG> </div><div style="margin-bottom: 10px;">The Ph1/<wbr>Ph2 study is funded by a $1.<wbr>6M NIH grant, and conducted by Dr Jacek Pinskin Associate Professor at the Norris Comprehensive Cancer Center at USC (in Los Angeles).<wbr> </div><div style="margin-bottom: 10px;">" .<wbr>.<wbr>.<wbr> The primary objective of the Phase II portion is to evaluate the clinical benefit of AEZS-108.<wbr> The trial will enroll &gt;55 patients for both portions.<wbr> So far 15 patients have been recruited.<wbr> We expect to be providing some updated results at upcoming scientific conferences".<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Development of AEZS-130 (Solorel)</FONT></STRONG> </div><div style="margin-bottom: 10px;"><U>Diagnostic</U> </div><div style="margin-bottom: 10px;">Represents an interesting business opportunity for Æterna Zentaris.<wbr> As such, the company is planning to perform additional marketing analysis that would contribute to its discussion for future partnerships, or in deciding to market AEZS-130 itself.<wbr> </div><div style="margin-bottom: 10px;"><U>Therapeutic</U> </div><div style="margin-bottom: 10px;">Dr.<wbr> Jose Garcia, Assistant Professor at Baylor College and VA Medical Center in Houston, is currently conducting a Ph2a trial assessing the safety and efficacy of repeated doses of AEZS-130 in 18 to 26 patients with cancer cachexia.<wbr> </div><div>Source: Æterna Zentaris; Thomson One </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8430">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-08-21T13:51:40+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Diminishing Doctor Contact With Sales Reps - UK Survey Results [mkt:UK, func:Sales]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10016</link>
<description>Diminishing Doctor Contact With Sales Reps - UK Survey Results [mkt:UK, func:Sales]</description><category>mkt:UK</category><category>func:Sales</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10016</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120831&edate=20120501&rec=10016">Diminishing Doctor Contact With Sales Reps - UK Survey Results</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=func%3aSales"><font color="#e95e0b">:PharmaWorld:func:Sales</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=mkt%3aUK"><font color="#e95e0b">:PharmaWorld:mkt:UK</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10016">PharmaWorld10016</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 21 August 2012 | 13:50</font><br><br><div style="margin-bottom: 10px;">Comment: Doctor.<wbr>net.<wbr>uk surveyed more than 1,000 GPs in April this year and 
reportedly found 52 per cent of GPs did not see any pharmaceutical sales 
representatives in a typical week, while 26 per cent only saw one pharma sales 
rep during that period.<wbr> </div><div style="margin-bottom: 10px;">Lack of time was the most common reason cited by GPs for not seeing pharma 
sales reps (38 per cent), but other reasons given included practice policy and a 
perceived lack of reps’ impartiality.<wbr> </div><div style="margin-bottom: 10px;">At the same time the UK online doctors’ network said doctors are turning to 
digital channels for independent product information.<wbr> </div><div style="margin-bottom: 10px;">Nearly a quarter (23 per cent) of the GPs surveyed said they preferred to 
find their own product information via “independent online resources”.<wbr> </div><div style="margin-bottom: 10px;">The research would appear to be inline with more general trends among 
healthcare professionals for content consumption and interaction.<wbr> </div><div style="margin-bottom: 10px;">European online physician networks continue to see significant growth, a 
trend that has been particularly pronounced in the UK – along with Germany and 
Scandinavia.<wbr> </div><div style="margin-bottom: 10px;">Meanwhile, European doctors’ use of iPads and other mobile devices is 
increasing, and in March a survey by Booz &amp; Co found European and US pharma 
execs expects to increase their future spending on digital marketing 
channels.<wbr> </div><div style="margin-bottom: 10px;">Doctors.<wbr>net.<wbr>uk said its findings follow earlier studies it conducted that 
show only 3 per cent of doctors think online pharma resources are credible and 
42 per cent never visit pharmaceutical websites.<wbr> </div><div><A href="http://www.pmlive.com/digital_intelligence_blog/archive/2012/aug_2012/uk_doctors_pharma_sales_reps_digital">http:/<wbr>/<wbr>www.<wbr>pmlive.<wbr>com/<wbr>digital_intelligence_blog/<wbr>archive/<wbr>2012/<wbr>aug_2012/<wbr>uk_doctors_pharma_sales_reps_digital</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120831&edate=20120501&rec=10016">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-08-21T13:50:17+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>Algeta Reported Commercial Preparations Underway for Alpharadin (radium-223 dichloride) [comp:BayerSchering, dis:Prostate]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology8427</link>
<description>Algeta Reported Commercial Preparations Underway for Alpharadin (radium-223 dichloride) [comp:BayerSchering, dis:Prostate]</description><category>comp:BayerSchering</category><category>dis:Prostate</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology8427</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8427">Algeta Reported Commercial Preparations Underway for Alpharadin (radium-223 dichloride)</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=comp%3aBayerSchering"><font color="#e95e0b">:Oncology:comp:BayerSchering</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8427">Oncology8427</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 20 August 2012 | 17:04</font><br><br><div style="margin-bottom: 10px;">Comment: Alongside its financial results for the second quarter 2012, the company confirmed the EU/<wbr>US launch of Alpharadin to occur in Q2/<wbr>Q3:13, with first sales in Q3:13.<wbr> Management also provided information on logistics and administration, and the drug clinical development program.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Logistics and Administration</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8427/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Clinical Development Program</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8427/2/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Expanded Access Program</FONT></STRONG> </div><div style="margin-bottom: 10px;">In Europe, 156 sites have now been approved, and patients are currently being treated.<wbr> </div><div style="margin-bottom: 10px;">In the US, some 50 sites have been approved.<wbr> Alpharadin is currently available at c60 more sites than we previously assumed, which should help facilitate the launch and add upside to initial sales.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">U.<wbr>S Launch</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8427/3/ScreenCapture3.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">ESMO Congress</FONT></STRONG> </div><div>Algeta will present data from the ALSYMPCA trial on the 1) Quality of Life; and 2) safety of chemotherapy use after Alpharadin during the ESMO at the end of September.<wbr> The quality of life, in addition to increased survival, is a key selling point for Alpharadin.<wbr> </div><!-- Comment details --><a name="oncology8427attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8427/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(38,3 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8427/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(47,6 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8427/3/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(57 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8427">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-08-20T17:04:14+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8427/1/ScreenCapture1.jpg" length="39241" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8427/2/ScreenCapture2.jpg" length="48717" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8427/3/ScreenCapture3.jpg" length="58365" type="image/jpeg"/></item><item>
<title>Three New Trials with Enzalutamide for Prostate Cancer [comp:Astellas, prod:MDV3100, dis:Prostate, :PharmaWorld:sub:ClinicalTrial, :PharmaWorld:mkt:NorthAmerica]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology8425</link>
<description>Three New Trials with Enzalutamide for Prostate Cancer [comp:Astellas, prod:MDV3100, dis:Prostate, :PharmaWorld:sub:ClinicalTrial, :PharmaWorld:mkt:NorthAmerica]</description><category>comp:Astellas</category><category>prod:MDV3100</category><category>dis:Prostate</category><category>sub:ClinicalTrial</category><category>mkt:NorthAmerica</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology8425</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8425">Three New Trials with Enzalutamide for Prostate Cancer</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=comp%3aAstellas"><font color="#e95e0b">:Oncology:comp:Astellas</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=prod%3aMDV3100"><font color="#e95e0b">:Oncology:prod:MDV3100</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=mkt%3aNorthAmerica"><font color="#e95e0b">:PharmaWorld:mkt:NorthAmerica</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=sub%3aClinicalTrial"><font color="#e95e0b">:PharmaWorld:sub:ClinicalTrial</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8425">Oncology8425</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 20 August 2012 | 15:10</font><br><br><div style="margin-bottom: 10px;">Comment: Cliniclatrials.<wbr>gov is listing 3 new Phase 2 studies investigating the drug in chemo-na&iuml;ve patients with mCRPC (NCT01663415), vs bicalutamide in patients who have failed primary ADT (NCT01664923), and in combination with abiraterone + prednisone in bone mCRPC (NCT01650194).<wbr> </div><div style="margin-bottom: 10px;"><FONT size="3" style="background-color: #c1c7fb;"><STRONG>Not yet open for patient recruitment</STRONG></FONT> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Trial Details - </FONT></STRONG><A href="http://clinicaltrials.gov/ct2/show/NCT01663415?cond=botulinum+OR+prostate+OR+neuroendocrine+OR+acromegaly+OR+Cushing+OR+hemophilia+OR+haemophilia&amp;fund=2&amp;rcv_s=06%2F21%2F2012&amp;rank=5"><STRONG><FONT size="3">NCT01663415</FONT></STRONG></A> </div><div style="margin-bottom: 10px;">Recruitment: approx.<wbr> 157 </div><div style="margin-bottom: 10px;">Completion date: October 2014 </div><div style="margin-bottom: 10px;">Location: U.<wbr>S (2 sites) </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Trial Details - </FONT></STRONG><A href="http://clinicaltrials.gov/ct2/show/NCT01664923?cond=botulinum+OR+prostate+OR+neuroendocrine+OR+acromegaly+OR+Cushing+OR+hemophilia+OR+haemophilia&amp;fund=2&amp;rcv_s=06%2F21%2F2012&amp;rank=4"><STRONG><FONT size="3">NCT01664923</FONT></STRONG></A> </div><div style="margin-bottom: 10px;">Recruitment: approx.<wbr> 400 </div><div style="margin-bottom: 10px;">Completion date: July 2013 (final data collection date for PE) /<wbr> July 2014 </div><div style="margin-bottom: 10px;">Location: U.<wbr>S (11 sites) </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3" style="background-color: #c1c7fb;">Currently Recruiting participants</FONT></STRONG> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Trial Details - </FONT></STRONG><A href="http://clinicaltrials.gov/ct2/show/NCT01650194?cond=botulinum+OR+prostate+OR+neuroendocrine+OR+acromegaly+OR+Cushing+OR+hemophilia+OR+haemophilia&amp;fund=2&amp;rcv_s=06%2F21%2F2012&amp;rank=6"><STRONG><FONT size="3">NCT01650194</FONT></STRONG></A> </div><div style="margin-bottom: 10px;">Recruitment: approx.<wbr> 60 </div><div style="margin-bottom: 10px;">Completion date: June 2014 </div><div>Location: U.<wbr>S </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8425">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-08-20T15:10:59+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>re: UK Drug Pricing Negotiations to Start in September 2012</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10014</link>
<description>re: UK Drug Pricing Negotiations to Start in September 2012</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10014</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120831&edate=20120501&rec=10014">re: UK Drug Pricing Negotiations to Start in September 2012</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10014">PharmaWorld10014</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 20 August 2012 | 12:34</font><br><br><div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">UK Drug Pricing Negotiations to Start in September 2012</span>&nbsp;<font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=mkt%3aUK"><font color="#e95e0b">:PharmaWorld:mkt:UK</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=sub%3aPricing"><font color="#e95e0b">:PharmaWorld:sub:Pricing</font></a>]</font></font><br><span style="font-size: 12px;">Comment: The UK&rsquo;s Department of Health and the Association of the British Pharmaceutical Industry have outlined details of their forthcoming negotiations on the implementation of a value-based pricing system and in a joint statement set out some of the key points to be addressed.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120831&edate=20120501&rec=10000">...</a><br><font size="-1">Alison Attard / <a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10000" class="commentpermalink">PharmaWorld10000</a> / <span class="date">03 August 2012</span> /
<span class="time">14:13:16 o'clock CEST</span>
</font></div><div><SPAN style="widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 13px arial, sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #222222; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">The ABPI has announced the members of a team that will negotiate with the U.<wbr>K.<wbr>'s Department of Health for the country's proposed value-based pricing system.<wbr> John Kearney, U.<wbr>K.<wbr> and Ireland general manager at </SPAN>Amgen Inc<SPAN style="widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 13px arial, sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #222222; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;"> will chair the group, which will include Peter Butterfield, executive director at Alliance Pharma</SPAN><SPAN style="widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 13px arial, sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #222222; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">; Erik van Snippenberg, general manager and SVP for the U.<wbr>K.<wbr> at </SPAN>GlaxoSmithKline<SPAN style="widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 13px arial, sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #222222; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">; Jon Emms, managing director for the U.<wbr>K.<wbr> at Pfizer</SPAN><SPAN style="widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 13px arial, sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #222222; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">; and Matthew Speers, managing director, British and Irish Isles at </SPAN>UCB Group<SPAN style="widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 13px arial, sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #222222; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">.<wbr> </SPAN> </div><!-- Comment details --><font size="-1">Jacquelyne CANTLE MEYRICK / <a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10014" class="commentpermalink">PharmaWorld10014</a> / <span class="date">20 August 2012</span> /
<span class="time">12:34:27 o'clock CEST</span>
</font><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120831&edate=20120501&rec=10014">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10000">View thread  PharmaWorld10000: UK Drug Pricing Negotiations to Start in September 2012</a>]]></content:encoded><dc:date>2012-08-20T12:34:27+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>Novartis To Start Expanded Development Of BEZ235 In pNET [Alert, class:PI3KInhibitor, comp:Novartis, dis:pNET, :PharmaWorld:sub:ClinicalTrial]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7059</link>
<description>Novartis To Start Expanded Development Of BEZ235 In pNET [Alert, class:PI3KInhibitor, comp:Novartis, dis:pNET, :PharmaWorld:sub:ClinicalTrial]</description><category>Alert</category><category>class:PI3KInhibitor</category><category>comp:Novartis</category><category>dis:pNET</category><category>sub:ClinicalTrial</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7059</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120831&edate=20120501&rec=7059">Novartis To Start Expanded Development Of BEZ235 In pNET</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=Alert"><font color="#e95e0b">:Endocrinology:Alert</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=class%3aPI3KInhibitor"><font color="#e95e0b">:Endocrinology:class:PI3KInhibitor</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=comp%3aNovartis"><font color="#e95e0b">:Endocrinology:comp:Novartis</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=dis%3apNET"><font color="#e95e0b">:Endocrinology:dis:pNET</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=sub%3aClinicalTrial"><font color="#e95e0b">:PharmaWorld:sub:ClinicalTrial</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7059">Endocrinology7059</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 20 August 2012 | 12:31</font><br><br><div style="margin-bottom: 10px;">Comment: As of September/<wbr>October, Novartis plans to initiate two new phII randomised trials with its new investigational agent BEZ235 an mTOR/<wbr>PI3K inhibitor.<wbr> The first will be a head to head comparison against everolimus in paitents with advanced neuroendocrine tumours and the second in a similar group of patient who have failed on mTOR therapy.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Head To Head Comparison In Advanced NET</STRONG> </div><div style="margin-bottom: 10px;">ClinicalTrials.<wbr>gov Identifier: <A href="http://clinicaltrials.gov/ct2/show/NCT01628913?cond=botulinum+OR+prostate+OR+neuroendocrine+OR+acromegaly+OR+Cushing+OR+hemophilia+OR+haemophilia&amp;fund=2&amp;rcv_s=06%2F21%2F2012&amp;rank=14">NCT01628913</A> </div><div style="margin-bottom: 10px;">The study will evaluate the treatment effect of BEZ235 relative to everolimus on progression-free survival (PFS) over 18 months and will enroll 140 mTOR naive patients.<wbr> </div><div style="margin-bottom: 10px;">Secondary endpoints will include safety and tolerability, objective response rate, overall survival and time to treatment failure.<wbr> </div><div style="margin-bottom: 10px;">BEZ325 will be administered as an oral dose of 400mg b.<wbr>d.<wbr> and compared with a 10mg bd dose of everolimus </div><div style="margin-bottom: 10px;">Patients will be expected to have advanced progressive disease and measurable disease per RECIST criteria.<wbr> </div><div style="margin-bottom: 10px;">Patients will be excluded if they have received prior treatment with an m-TOR or PI3K inhibitor or chemotherapy, targeted therapy or biotherapy within the last 4 weeks.<wbr> </div><div style="margin-bottom: 10px;">The trial will be conducted at 8 sites within the US.<wbr> It was first referenced at ENETs this year (see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120831&edate=20120501&rec=6883" class="defaultlink">Endocrinology6883: ENETS Intelligence Part 2 - Novartis & Pfizer Symposia Plus Key New Trials</a>).<wbr> </div><div style="margin-bottom: 10px;"><STRONG>BEZ235 In M-TOR Failure pNET Patients</STRONG> </div><div style="margin-bottom: 10px;">ClinicalTrial Identifier: <A href="http://clinicaltrials.gov/ct2/show/NCT01658436?term=NCT01658436&amp;rank=1">NCT01658436</A> </div><div style="margin-bottom: 10px;">This second trial a two stage trial evaluating BEZ235 plus best supportive care (BSC) versus placebo plus BSC in patients with advanced pancreatic neuroendocrine tumors (pNET) after failure of mTOR inhibitor therapy.<wbr> </div><div style="margin-bottom: 10px;">The primary endpoint will focus on PFS at 16 weeks in stage I and up to 30 months in stage II </div><div style="margin-bottom: 10px;">The secondary outcome measures will evaluate frequency and severity of AEs, Overall response rate, disease control rate, duration of response and overall survival.<wbr> </div><div style="margin-bottom: 10px;">Enrollment of 130 patients will start in October with the study scheduled to complete in February 2015.<wbr> Stage I which will be open-label will enroll 30 patients and stage II (randomised) 99.<wbr> </div><div style="margin-bottom: 10px;">BEZ235 will be supplied in 200mg, 300mg and 400mg sachets.<wbr> These will be taken twice daily after food.<wbr> </div><div style="margin-bottom: 10px;">Eligible patients:- </div><div style="margin-bottom: 10px;"><UL style="MARGIN-TOP: 1ex; MARGIN-BOTTOM: 1ex"><LI style="MARGIN-TOP: 0.7ex">Unresectable or metastatic, histologically confirmed low or intermediate grade pancreatic neuroendocrine tumor with radiological evidence of disease progression since last treatment </LI>
<LI style="MARGIN-TOP: 0.7ex">Refractory disease to treatment with mTOR inhibitor </LI>
<LI style="MARGIN-TOP: 0.7ex">Measurable disease per RECIST Version 1.<wbr>1 using Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) </LI>
<LI style="MARGIN-TOP: 0.7ex">Prior or concurrent therapy with SSA is permitted; a stable dose at least 2 months prior to study start and must continue on the stable dose while receiving study treatment </LI>
<LI style="MARGIN-TOP: 0.7ex">WHO PS ≤ 1 </LI>
<LI style="MARGIN-TOP: 0.7ex">Adequate bone marrow function or organ function </LI>
</UL> </div><div style="margin-bottom: 10px;"><P style="MARGIN-TOP: 0ex; MARGIN-BOTTOM: 1ex">Exclusion Criteria:</P> </div><div style="margin-bottom: 10px;"><UL style="MARGIN-TOP: 1ex; MARGIN-BOTTOM: 1ex"><LI style="MARGIN-TOP: 0.7ex">Previous treatment with any PI3K or AKT inhibitor </LI>
<LI style="MARGIN-TOP: 0.7ex">Discontinuation prior mTOR inhibitor therapy due to toxicity </LI>
<LI style="MARGIN-TOP: 0.7ex">Poorly differentiated neuroendocrine carcinoma, high-grade neuroendocrine carcinoma, adenocarcinoid, goblet cell carcinoid and small cell carcinoma </LI>
<LI style="MARGIN-TOP: 0.7ex">Cytotoxic chemotherapy, targeted therapy, immunotherapy, radiotherapy, or major surgery within 4 weeks prior to enrolment in the study </LI>
<LI style="MARGIN-TOP: 0.7ex">Hepatic artery embolization within the last 6 months (1 month if there are other sites of measurable disease), or cryoablation/<wbr> radiofrequency ablation of hepatic metastasis within 2 months of enrollment </LI>
<LI style="MARGIN-TOP: 0.7ex">More than 3 prior systemic treatment regimens </LI>
</UL> </div><div style="margin-bottom: 10px;">This study will be a European study and include 3 centres in France (Dijon, Lyon and Villejuif), one in the Netherlands (Rotterdam) and two in Poland (Warsaw).<wbr> </div><div>Source: Clinical Trials.<wbr>com </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120831&edate=20120501&rec=7059">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-08-20T12:31:38+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>Drug Delivery Company Unigene Faces Financial Difficulties [sub:DrugDelivery, news]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10013</link>
<description>Drug Delivery Company Unigene Faces Financial Difficulties [sub:DrugDelivery, news]</description><category>sub:DrugDelivery</category><category>news</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10013</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120831&edate=20120501&rec=10013">Drug Delivery Company Unigene Faces Financial Difficulties</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=news"><font color="#e95e0b">:PharmaWorld:news</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=sub%3aDrugDelivery"><font color="#e95e0b">:PharmaWorld:sub:DrugDelivery</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10013">PharmaWorld10013</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 20 August 2012 | 10:42</font><br><br><div style="margin-bottom: 10px;">Comment: In its Q2 earnings statement Unigene noted that it will need to 
obtain significant funding to be able to continue operations with a debt payment 
looming in September.<wbr> </div><div style="margin-bottom: 10px;">The news follo<FONT color="#231f20" face="GillSans" size="2"><FONT color="#231f20" face="GillSans" size="2"><FONT color="#231f20" face="GillSans" size="2">ws a 
recommendation from EMA’s CHMP that calcitonin-containing medicines should be 
used only for short-term treatment because of an increased risk of cancer.<wbr> </FONT></FONT></FONT> </div><div style="margin-bottom: 10px;"><P align="left">Unigene said its cash flow will fund operations into 4Q12.<wbr> At June 
30, Unigene had $1.<wbr>7 million in cash and a six-month operating loss of 
$3.<wbr>1<FONT color="#231f20" face="GillSans" size="2"><FONT color="#231f20" face="GillSans" size="2"><FONT color="#231f20" face="GillSans" size="2">.<wbr></FONT></FONT></FONT></P> </div><div style="margin-bottom: 10px;"><P align="left">Unigene’s Ostora oral recombinant salmon calcitonin, to which 
Tarsa Therapeutics has worldwide development and commercialization rights 
outside of China, is in Phase III testing to treat osteoporosis.<wbr> </P> </div><div style="margin-bottom: 10px;"><P align="left">Tarsa is evaluating opportunities to appeal the CHMP 
recommendation and plans to discuss the situation with FDA.<wbr> Because the 
osteoclast inhibitor is not yet approved in Europe, the companies do not have 
the right to formally appeal the recommendation.<wbr> </P> </div><div style="margin-bottom: 10px;"><P align="left">Tarsa originally planned to submit an NDA to FDA this year and an 
MAA in Europe shortly thereafter.<wbr> Tarsa said that plans to submit the NDA are 
ongoing, but could not disclose details regarding the MAA.<wbr> </P> </div><div style="margin-bottom: 10px;"><P align="left">Unigene said regulatory authorities, including FDA, could take 
action as a result of the recommendation, including the withdrawal of 
calcitonin-containing products from the market or limiting their use.<wbr> The 
company said this could reduce or eliminate osteoporosis drug Fortical 
calcitonin sales and royalties.<wbr> The osteoclast inhibitor is marketed by 
Upsher-Smith Laboratories in the U.<wbr>S.<wbr> to treat osteoporosis in 
postmenopausal women<FONT color="#231f20" face="GillSans" size="2"><FONT color="#231f20" face="GillSans" size="2"><FONT color="#231f20" face="GillSans" size="2">.<wbr></FONT></FONT></FONT></P> </div><div style="margin-bottom: 10px;"><P align="left">Unigene also said in its earnings that due to a lack of funds it 
has placed a hold on preclinical candidate UGP281 to treat obesity.<wbr> The company 
had planned to start Phase I testing of the anorexigenic amylin receptor agonist 
in 1H13</P> </div><div><P align="left">Source: <A href="http://www.unigene.com">www.<wbr>unigene.<wbr>com</A></P> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120831&edate=20120501&rec=10013">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-08-20T10:42:27+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>re: Leading MicroRNA Company Finalizes Two Deals</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10012</link>
<description>re: Leading MicroRNA Company Finalizes Two Deals</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10012</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120831&edate=20120501&rec=10012">re: Leading MicroRNA Company Finalizes Two Deals</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10012">PharmaWorld10012</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 20 August 2012 | 10:28</font><br><br><div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Leading MicroRNA Company Finalizes Two Deals</span>&nbsp;<font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=news"><font color="#e95e0b">:PharmaWorld:news</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=sub%3aDrugDelivery"><font color="#e95e0b">:PharmaWorld:sub:DrugDelivery</font></a>]</font></font><br><span style="font-size: 12px;">Comment: Regulus Therapeutics a company founded by Alnylam 
Therapeutics and ISIS to focus on non-coding microRNAs has announced two 
deals in two days one with Biogen-Idec the other with Astra Zeneca.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120831&edate=20120501&rec=10011">...</a><br><font size="-1">Jacquelyne CANTLE MEYRICK / <a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10011" class="commentpermalink">PharmaWorld10011</a> / <span class="date">16 August 2012</span> /
<span class="time">16:46:07 o'clock CEST</span>
</font></div><div style="margin-bottom: 10px;">Last week, Regulus filed to raise up to $57.<wbr>5 million in an IPO, becoming the first preclinical company to do so since cancer stem cell play Verastem went public in January.<wbr> The filing capped a week in which Regulus announced deals with Biogen-Idec and AstraZeneca </div><div style="margin-bottom: 10px;">Regulus's pipeline of single-stranded oligo- nucleotides includes a compound target-ing microRNA-21 (miR-21) that is partnered with Sanofi.<wbr> The compound is in develop- ment for hepatocellular carcinoma (HCC) and kidney fibrosis.<wbr> The pipeline also includes an HCV compound targeting miR-122 that is partnered with GSK.<wbr> </div><div style="margin-bottom: 10px;">Regulus has at least one unpartnered compound targeting miR-10b, which is in development for glioblastoma.<wbr> The biotech has stated it hopes to file its first IND in 2014.<wbr> </div><div>Source: Biocentury </div><!-- Comment details --><font size="-1">Jacquelyne CANTLE MEYRICK / <a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10012" class="commentpermalink">PharmaWorld10012</a> / <span class="date">20 August 2012</span> /
<span class="time">10:28:25 o'clock CEST</span>
</font><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120831&edate=20120501&rec=10012">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10011">View thread  PharmaWorld10011: Leading MicroRNA Company Finalizes Two Deals</a>]]></content:encoded><dc:date>2012-08-20T10:28:25+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>PhIII Results of the AFFIRM Trial Published In NEJM [headline, dis:Prostate, prod:MDV3100]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology8423</link>
<description>PhIII Results of the AFFIRM Trial Published In NEJM [headline, dis:Prostate, prod:MDV3100]</description><category>headline</category><category>dis:Prostate</category><category>prod:MDV3100</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology8423</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8423">PhIII Results of the AFFIRM Trial Published In NEJM</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=headline"><font color="#e95e0b">:Oncology:headline</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=prod%3aMDV3100"><font color="#e95e0b">:Oncology:prod:MDV3100</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8423">Oncology8423</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 16 August 2012 | 17:05</font><br><br><div style="margin-bottom: 10px;">Comment: Astellas highlighted today the publication of the phIII AFFIRM study results in the August 15th online version of the NEJM.<wbr> </div><div style="margin-bottom: 10px;">As a recap, the study showed that enzalutamide exhibited a statistically signficant benefit in overall survival compared to placebo.<wbr> Men treated with enzalutamide had a median overall survival of 18.<wbr>4 months (95% confidence interval 11.<wbr>3-15.<wbr>8) compared to 13.<wbr>6 months (95% confidence interval 11.<wbr>3 -15.<wbr>8) for men treated with placebo ( HR 0.<wbr>063; p&lt;0.<wbr>0001), representing a 37% reduction in the risk of death.<wbr> </div><div style="margin-bottom: 10px;">The drug also demonstrated a favourable side-effect profile with the three most common side-effects observed being fatigue, diarrhea and hot flushed.<wbr> Seizure was reported in less than 1% of patients treated with enzalutamide.<wbr> Serious AEs occurred at lower rate in the enzalutamide group than in the placebo group.<wbr> </div><div style="margin-bottom: 10px;">In its press release, Astellas noted that the FDA has accepted its NDA for enzlutamide but did not pass comment on the European application which was submitted in June but not listed in the latest (July 26th) list of products submitted for approval by the EMA </div><div>source: <A href="http://www.nejm.org/doi/full/10.1056/NEJMoa1207506">http:/<wbr>/<wbr>www.<wbr>nejm.<wbr>org/<wbr>doi/<wbr>full/<wbr>10.<wbr>1056/<wbr>NEJMoa1207506</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8423">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-08-16T17:05:38+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>Leading MicroRNA Company Finalizes Two Deals [sub:DrugDelivery, news]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10011</link>
<description>Leading MicroRNA Company Finalizes Two Deals [sub:DrugDelivery, news]</description><comments>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10011</comments><category>sub:DrugDelivery</category><category>news</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10011</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120831&edate=20120501&rec=10011">Leading MicroRNA Company Finalizes Two Deals</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=news"><font color="#e95e0b">:PharmaWorld:news</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=sub%3aDrugDelivery"><font color="#e95e0b">:PharmaWorld:sub:DrugDelivery</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10011">PharmaWorld10011</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 16 August 2012 | 16:46</font><br><br><div style="margin-bottom: 10px;">Comment: Regulus Therapeutics a company founded by Alnylam 
Therapeutics and ISIS to focus on non-coding microRNAs has announced two 
deals in two days one with Biogen-Idec the other with Astra Zeneca.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Biogen-Idec </STRONG> </div><div style="margin-bottom: 10px;">This collaboration with look identify microRNA biomarkers in blood from 
multiple sclerosis patients as a means of optimising patients selection and 
monitoring disease progression in future clinical trials.<wbr> Deal terms have not 
been disclosed.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>AstraZeneca</STRONG> </div><div style="margin-bottom: 10px;">This microRNA collaboration is focused on preclinical therapeutic agents 
against three targets directed against cardiovascular, metabolic 
diseases and cancer.<wbr> </div><div style="margin-bottom: 10px;">Under the terms of the agreement, AstraZeneca will make a $28M payment which 
includes an equity investment and an upfront payment to Regulus.<wbr> </div><div style="margin-bottom: 10px;">The two companies will initially focus on Regulus’ lead 
cardiovascular/<wbr>metabolic disease program targeting microRNA-33 for the treatment 
of atherosclerosis.<wbr> </div><div style="margin-bottom: 10px;">Regulus will lead preclinical development and, if successful, could receive 
pre-clinical milestone payments.<wbr>  AstraZeneca will lead and fund the 
clinical development and commercialization of these programs.<wbr> </div><div>In addition, Regulus could also receive clinical milestones based on the 
successful development of microRNA therapies in each target area.<wbr> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="PharmaWorld10012c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">Last week, Regulus filed to raise up to $57.<wbr>5 million in an IPO, becoming the first preclinical company to do so since cancer stem cell play Verastem went public in January.<wbr> The filing capped a week in which Regulus announced deals with Biogen-Idec and AstraZeneca </div><div style="margin-bottom: 10px;">Regulus's pipeline of single-stranded oligo- nucleotides includes a compound target-ing microRNA-21 (miR-21) that is partnered with Sanofi.<wbr> The compound is in develop- ment for hepatocellular carcinoma (HCC) and kidney fibrosis.<wbr> The pipeline also includes an HCV compound targeting miR-122 that is partnered with GSK.<wbr> </div><div style="margin-bottom: 10px;">Regulus has at least one unpartnered compound targeting miR-10b, which is in development for glioblastoma.<wbr> The biotech has stated it hopes to file its first IND in 2014.<wbr> </div><div>Source: Biocentury </div><font size="-1">Jacquelyne CANTLE MEYRICK / <a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10012" class="commentpermalink">PharmaWorld10012</a> / <span class="date">20 August 2012</span> /
<span class="time">10:28:25 o'clock CEST</span>
</font></div><a name="PharmaWorld10044c"></a><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">The company amended its IPO, and now plans to sell 4.<wbr>5 million shares at $10-12 per share.<wbr> An 11$ price would raise $50M, and value the company at $239M.<wbr> </div><div style="margin-bottom: 10px;"><SPAN style="display: inline! important; float: none; word-spacing: 0px; font: 13px arial, sans-serif; text-transform: none; color: #222222; text-indent: 0px; white-space: normal; letter-spacing: normal; background-color: #ffffff; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">Regulus said several partners have expressed interest in participating in the offering.<wbr> Sanofi plans to purchase up to $10M, Isis Pharm.<wbr>and GSK plan to purchase up to $2M each.<wbr></SPAN> </div><div><SPAN style="display: inline! important; float: none; word-spacing: 0px; font: 13px arial, sans-serif; text-transform: none; color: #222222; text-indent: 0px; white-space: normal; letter-spacing: normal; background-color: #ffffff; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">Source: Biocentury</SPAN> </div><font size="-1">Brigitte DESCHAMPS / <a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10044" class="commentpermalink">PharmaWorld10044</a> / <span class="date">10 September 2012</span> /
<span class="time">10:17:49 o'clock CEST</span>
</font></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120831&edate=20120501&rec=10011">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-08-16T16:46:07+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>PhII Results For New Ulceratice Colitis Drug Published By Pfizer [dis:IBD, news, :PharmaWorld:sub:ClinicalTrial, :PharmaWorld:mkt:Brazil, :PharmaWorld:mkt:Intercontinental, :PharmaWorld:mkt:Mexico]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology1855</link>
<description>PhII Results For New Ulceratice Colitis Drug Published By Pfizer [dis:IBD, news, :PharmaWorld:sub:ClinicalTrial, :PharmaWorld:mkt:Brazil, :PharmaWorld:mkt:Intercontinental, :PharmaWorld:mkt:Mexico]</description><category>dis:IBD</category><category>news</category><category>sub:ClinicalTrial</category><category>mkt:Brazil</category><category>mkt:Intercontinental</category><category>mkt:Mexico</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology1855</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20120831&edate=20120501&rec=1855">PhII Results For New Ulceratice Colitis Drug Published By Pfizer</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20120831&edate=20120501&cat=dis%3aIBD"><font color="#e95e0b">:GastroEnterology:dis:IBD</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20120831&edate=20120501&cat=news"><font color="#e95e0b">:GastroEnterology:news</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=mkt%3aBrazil"><font color="#e95e0b">:PharmaWorld:mkt:Brazil</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=mkt%3aIntercontinental"><font color="#e95e0b">:PharmaWorld:mkt:Intercontinental</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=mkt%3aMexico"><font color="#e95e0b">:PharmaWorld:mkt:Mexico</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=sub%3aClinicalTrial"><font color="#e95e0b">:PharmaWorld:sub:ClinicalTrial</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology1855">GastroEnterology1855</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 16 August 2012 | 16:35</font><br><br><div style="margin-bottom: 10px;"><SPAN style="WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 13px arial, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(34,34,34); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">Comment: 
Data published in the latest edition of the NEJM</SPAN><SPAN style="WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 13px arial, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(34,34,34); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"> shows that the highest dose of oral 
tofacitinib</SPAN><SPAN style="WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 13px arial, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(34,34,34); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"> from Pfizer</SPAN><A href="http://www.biocentury.com/companies/pfizer_inc" style="WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; FONT: 13px arial, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; LETTER-SPACING: normal; COLOR: rgb(17,85,204); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px" target="_blank" title="Pfizer company profile and pipeline intelligence from BCIQ">.<wbr></A><SPAN style="WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 13px arial, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(34,34,34); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">met 
the primary endpoint in a Phase II trial to treat moderate to severe active 
ulcerative colitis.<wbr> </SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 13px arial, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(34,34,34); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><STRONG>Study 
Design</STRONG></SPAN> </div><div style="margin-bottom: 10px;"><P align="left">194 adults with moderately to severely active ulcerative colitis 
were treated in a double-blind randominsed phII study.<wbr> Patients were randomly 
assigned to receive tofacitinib at a dose of 0.<wbr>5 mg, 3 mg, 10 mg, or 15 mg or 
placebo twice daily for 8 weeks.<wbr> The primary outcome was a clinical response at 
8 weeks, defined as an absolute decrease from baseline in the score on the Mayo 
scoring system for assessment of ulcerative colitis activity (possible score, 0 
to 12, with higher scores indicating more severe disease) of 3 or more and a 
relative decrease from baseline of 30% or more with an accompanying decrease in 
the rectal bleeding subscore of 1 point or more or an absolute rectal bleeding 
subscore of 0 or 1.<wbr></P> </div><div style="margin-bottom: 10px;"><P align="left"><STRONG>Key Findings</STRONG></P> </div><div style="margin-bottom: 10px;"><P align="left"><SPAN style="WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 13px arial, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(34,34,34); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">A 
twice-daily 15 mg dose of the oral pan-</SPAN><SPAN style="WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 13px arial, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(34,34,34); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">Janus 
kinase (JAK) inhibitor significantly improved clinical response rate from 
baseline to week eight vs.<wbr> placebo (78% vs.<wbr> 42%, p&lt;0.<wbr>001).<wbr> However, 
twice-daily 0.<wbr>5, 3 and 10 mg doses of tofacitinib missed the endpoint.<wbr> Two 
patients receiving the 10 mg dose of tofacitinib had serious adverse events from 
infection.<wbr> </SPAN></P> </div><div style="margin-bottom: 10px;"><P align="left">The 8-week trial was conducted at 51 centers in 17 countries 
(Belgium, Brazil, Chile, Czech Republic, Denmark, France, Hungary, Israel, 
Italy, Mexico, the Netherlands, Poland, Slovakia, South Africa, Spain, Sweden, 
and the United Kingdom) from January 2009 through September 2010.<wbr></P> </div><div style="margin-bottom: 10px;"><P align="left"><STRONG>Current Status</STRONG></P> </div><div style="margin-bottom: 10px;"><SPAN style="WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 13px arial, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(34,34,34); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">Tofacitinib 
is currently in Phase III testing to evaluate its benefit as a maintenance 
therapy for US.<wbr> The trial listed in ClinicalTrials.<wbr>gov as starting in July 
2012 is due to complete in April 2015 and is scheduled to ernoll 654 
patients.<wbr></SPAN><BR> </div><div style="margin-bottom: 10px;"><SPAN style="WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 13px arial, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(34,34,34); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">An 
NDA for tofacitinib to treat rheumatoid arthritis (RA) is under FDA review with 
an Aug.<wbr> 21 PDUFA date.<wbr> The product is under review for RA in the EU and Japan as 
well.<wbr> Tofacitinib also is in Phase III testing to treat moderate to severe 
plaque psoriasis</SPAN> </div><div><SPAN style="WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 13px arial, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(34,34,34); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">Scource: 
New England Journal of Medicine &amp; ClinicalTrials.<wbr>gov </SPAN> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20120831&edate=20120501&rec=1855">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-08-16T16:35:56+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>My NET Manager App [Alert, dis:MidGutNET, comp:Novartis]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7058</link>
<description>My NET Manager App [Alert, dis:MidGutNET, comp:Novartis]</description><category>Alert</category><category>dis:MidGutNET</category><category>comp:Novartis</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7058</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120831&edate=20120501&rec=7058">My NET Manager App</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=Alert"><font color="#e95e0b">:Endocrinology:Alert</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=comp%3aNovartis"><font color="#e95e0b">:Endocrinology:comp:Novartis</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=dis%3aMidGutNET"><font color="#e95e0b">:Endocrinology:dis:MidGutNET</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7058">Endocrinology7058</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 15 August 2012 | 17:52</font><br><br><div style="margin-bottom: 10px;">Comment: The NET Alliance a patient education initiative supported by 
Novartis Oncology announced yesterday the launch of a new mobile app for 
patients with neuroendocrine tumours.<wbr> </div><div style="margin-bottom: 10px;">The new app is designed to help individuals track symptomss, set 
reminders, view important dates, share information and manually input test 
results if a provider does not have electronic medical records.<wbr> </div><div style="margin-bottom: 10px;">Initial user reviews suggest that the app is being well received by 
patients.<wbr> </div><div>source: <A href="http://www.caringforcarcinoid.org/news/mynet-manager-app">http:/<wbr>/<wbr>www.<wbr>caringforcarcinoid.<wbr>org/<wbr>news/<wbr>mynet-manager-app</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120831&edate=20120501&rec=7058">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-08-15T17:52:01+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>New Technology Delivers Sustained Release Of Drugs For Up To Six Months [sub:DrugDelivery]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10010</link>
<description>New Technology Delivers Sustained Release Of Drugs For Up To Six Months [sub:DrugDelivery]</description><category>sub:DrugDelivery</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10010</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120831&edate=20120501&rec=10010">New Technology Delivers Sustained Release Of Drugs For Up To Six Months</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=sub%3aDrugDelivery"><font color="#e95e0b">:PharmaWorld:sub:DrugDelivery</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10010">PharmaWorld10010</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 15 August 2012 | 17:39</font><br><br><div style="margin-bottom: 10px;">Comment: Scientists at the University of Cambridge have announced details of 
a new hydrogel drug delivery technology that can release drugs for up to 
six months.<wbr> </div><div><DIV style="BORDER-BOTTOM: medium none; TEXT-ALIGN: left; BORDER-LEFT: medium none; BACKGROUND-COLOR: #ffffff; COLOR: #000000; OVERFLOW: hidden; BORDER-TOP: medium none; BORDER-RIGHT: medium none; TEXT-DECORATION: none">
<P>Researchers.<wbr> Dr Oren Schermen, Dr Xian Jun Loh and 
PhD student Eric Appel have developed injectable, reformable and spreadable 
hydrogels which can be loaded with proteins or other therapeutics.<wbr> The hydrogels 
contain up to 99.<wbr>7% water by weight, with the remainder primarily made up of 
cellulose polymers held together with cucurbiturils - barrel-shaped molecules 
which act as miniature 'handcuffs'.<wbr></P>
<P>The hydrogels protect the proteins so that they remain bio-active for long 
periods, and allow the proteins to remain in their native state but importantly, 
all the components can be incorporated at room temperature.<wbr></P>
<P>The team are currently working with researchers from the Brain Repair Centre 
in the Department of Clinical Medicine on how the technology might be used as a 
possible treatment for brain cancer.<wbr></P>
<P>The research was published recently in the journal Biomaterials and has been 
patented by Cambridge Enterprise, the University's commercialisation 
group.<wbr></P>source: <A href="http://www.enterprise.cam.ac.uk/news/2012/8/new-technology-delivers-sustained-release-drugs-si/">http:/<wbr>/<wbr>www.<wbr>enterprise.<wbr>cam.<wbr>ac.<wbr>uk/<wbr>news/<wbr>2012/<wbr>8/<wbr>new-technology-delivers-sustained-release-drugs-si/<wbr></A><BR><BR></DIV> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120831&edate=20120501&rec=10010">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-08-15T17:39:31+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>Spectrum Initiates PhIIb Study With GnRH antagonist Ozarelix [class:Antihormonals, dis:Prostate, headline]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology8422</link>
<description>Spectrum Initiates PhIIb Study With GnRH antagonist Ozarelix [class:Antihormonals, dis:Prostate, headline]</description><category>class:Antihormonals</category><category>dis:Prostate</category><category>headline</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology8422</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8422">Spectrum Initiates PhIIb Study With GnRH antagonist Ozarelix</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=class%3aAntihormonals"><font color="#e95e0b">:Oncology:class:Antihormonals</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=headline"><font color="#e95e0b">:Oncology:headline</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8422">Oncology8422</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 15 August 2012 | 17:23</font><br><br><div style="margin-bottom: 10px;">Comment: Spectrum has announced the initiation of its phIIb programme for 
ozarelix which will compare the safety and efficacy of this monthly 
subcutaneous therapy with Zoladex in patients with prostate cancer for whom 
hormonal therapy is indicated.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Study Design</STRONG> </div><div style="margin-bottom: 10px;">150 patients will be randomised in a 2:1 ratio to either ozarelix or 
goserlin.<wbr> </div><div style="margin-bottom: 10px;">Ozarelix patients will receive a loading dose followed by a lower maintenance 
dose on days 28 and 56.<wbr> Zoladex will be simiilarly administered.<wbr> All 
patients will be followed up for 84 days.<wbr> </div><div style="margin-bottom: 10px;">Primary outcome - % of patients who achieve a testosterone level of &lt; = 
0.<wbr>5 ng/<wbr>ml from day 28 to 84.<wbr> </div><div style="margin-bottom: 10px;">Secondary outcome will evaluate the no of patients who experience a 
testosterone surge during the first two weeek, effect on PSA levels and 
safety.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Location</STRONG> </div><div style="margin-bottom: 10px;">The study will be conducted at multiple sites in the US as well as in India 
through Spectrum's subsidiary OncoRx.<wbr> </div><div>Source: <a href="http://www.spectrum.com" class="defaultlink" title="www.spectrum.com">spectrum.com</a> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8422">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-08-15T17:23:19+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>re: Allergan To Expand Manufacturing Plant At Westport</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology6522</link>
<description>re: Allergan To Expand Manufacturing Plant At Westport</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology6522</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120831&edate=20120501&rec=6522">re: Allergan To Expand Manufacturing Plant At Westport</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology6522">Neurology6522</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 14 August 2012 | 15:23</font><br><br><div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Allergan To Expand Manufacturing Plant At Westport</span>&nbsp;<font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=Alert"><font color="#e95e0b">:Neurology:Alert</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=comp%3aAllergan"><font color="#e95e0b">:Neurology:comp:Allergan</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=prod%3aBotox"><font color="#e95e0b">:Neurology:prod:Botox</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=func%3aMSO"><font color="#e95e0b">:PharmaWorld:func:MSO</font></a>]</font></font><br><span style="font-size: 12px;">Comment: Allergan has announced today its intention to expand its manufacturing facility at its Westport Site in County Mayo creating 200 new jobs as part of a &euro;350 million investment designed to meet future demand for Botox and the next generation of biological products.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120831&edate=20120501&rec=6192">...</a><br><font size="-1">Jacquelyne CANTLE MEYRICK / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology6192" class="commentpermalink">Neurology6192</a> / <span class="date">09 January 2012</span> /
<span class="time">12:10:22 o'clock CET</span>
</font></div><div style="margin-bottom: 10px;"><SPAN style="widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 12px/18px Arial, sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #333333; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">Following the announcement in January that Allergan was to expand its biologics manufacturing capacity at its Westport facility in a $350 million investment, Allergan Pharmaceuticals have published a notice today signalling their intention to apply to Mayo County Council for permission for the development at Gortaroe, Westport (to the rear of the existing plant).<wbr> </SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 12px/18px Arial, sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #333333; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">The notice outlines that the development will consist of the construction of an overall floor area of 15,677 sq meters, consisting of a three-storey office block with a floor area of 3456 sq meters and a height of 16 meters, a production hall and plant rooms with a floor area of 8,705 sq meters, and a warehouse and ancillary accommodation.<wbr></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 12px/18px Arial, sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #333333; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">The notice also states that the works will incorporate the relocation of an existing local access road and the construction of a new circulation route to the existing Allergan facility, together with the provision of 223 car parking spaces.<wbr> Other cycle and pedestrian lanes will also be developed, along with a pedestrian link bridge of 140 sq meters and a height of 8.<wbr>8 meters to the existing multi-agency enterprise building.<wbr></SPAN> </div><div><SPAN style="widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 12px/18px Arial, sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #333333; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">Approximately 200 jobs will be created by Allergan when this new facility is operational, along with up to 250 indirect jobs locally, during the construction period.<wbr></SPAN> </div><!-- Comment details --><font size="-1">Jacquelyne CANTLE MEYRICK / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology6522" class="commentpermalink">Neurology6522</a> / <span class="date">14 August 2012</span> /
<span class="time">15:23:37 o'clock CEST</span>
</font><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120831&edate=20120501&rec=6522">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology6192">View thread  Neurology6192: Allergan To Expand Manufacturing Plant At Westport</a>]]></content:encoded><dc:date>2012-08-14T15:23:37+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>Promising Results From New Drug For Polycystic Kidney Disease [:Oncology:dis:Gynea, :Oncology:dis:Prostate, dis:PolycysticLiver]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7056</link>
<description>Promising Results From New Drug For Polycystic Kidney Disease [:Oncology:dis:Gynea, :Oncology:dis:Prostate, dis:PolycysticLiver]</description><category>dis:Gynea</category><category>dis:Prostate</category><category>dis:PolycysticLiver</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7056</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120831&edate=20120501&rec=7056">Promising Results From New Drug For Polycystic Kidney Disease</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=dis%3aPolycysticLiver"><font color="#e95e0b">:Endocrinology:dis:PolycysticLiver</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=dis%3aGynea"><font color="#e95e0b">:Oncology:dis:Gynea</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7056">Endocrinology7056</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 14 August 2012 | 14:56</font><br><br><div style="margin-bottom: 10px;">Comment: Scientists at UC Santa Barbara have produced experimental evidence 
of the effectiveness of a new rapamycin analogue in treating polycystic kidney 
disease.<wbr> The technology platform associated with this product has already 
acheived POC in platinum resistant ovarian cancer leading to one of the highest 
valued deals in oncology this year, namely Merck's $1bn deal for Endocyte's 
vintafolide.<wbr> </div><div style="margin-bottom: 10px;">Previous work with the rapamycin analogue everolimus (Afinitor) in 
patients with polycystic kidneys has produced somewhat disappointing results 
despite interesting observations in mice.<wbr> </div><div style="margin-bottom: 10px;">Recognising the unmet need for a novel therapy, Endocyte pharmaceuticals 
decided to pusue a more targeted approach by conjugating a small molecule to the 
folate receptor.<wbr> </div><div style="margin-bottom: 10px;">It has chemically synthesized a new version of rapamycin called 
folate-conjugated rapamycin (FC-rapa).<wbr> UC Santa Barbara has tested 
this new drug and found that it is highly effective in preventing kidney 
cyst growth in mice with PKD, but that it has fewer systemic side effects 
compared to regular rapamycin.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Next Steps</STRONG> </div><div style="margin-bottom: 10px;">Endocyte intend to try and repeat the FC-rapa tests in the company lab and 
test some other similar drug to try and identify a compound to move forward with 
into phI development.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Company Success With Folate Targeted Approach</STRONG> </div><div style="margin-bottom: 10px;">Endocyte has already achieved POC with a folate receptor targeted drug 
achieving one of the best responses seen so far in platinum resistant ovarian 
cancer.<wbr> The impressive result prompted Merck to in-license worldwide rights 
to the drug earlier this year.<wbr> Based on these findings and the presence of 
folate receptors in other tumour types Endocyte has developed a portfolio of 
projects based on folate conjugate technology including as mentioned above 
the folate rapamycin based analogue.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7056/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7056/6/ScreenCapture6.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7056/7/ScreenCapture7.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7056/5/ScreenCapture5.jpg?user-agent=rss"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7056/2/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7056/3/ScreenCapture3.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7056/4/ScreenCapture4.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7056/8/ScreenCapture8.jpg?user-agent=rss"> </div><div><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7056/9/ScreenCapture9.jpg?user-agent=rss"> </div><!-- Comment details --><a name="endocrinology7056attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7056/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(140,4 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7056/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(123,5 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7056/3/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(83 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7056/4/ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(106,3 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7056/5/ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(88,7 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7056/6/ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(100 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7056/7/ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(91,6 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7056/8/ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(109,8 KB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7056/9/ScreenCapture9.jpg">ScreenCapture9.jpg</a>&nbsp;&nbsp;(105,3 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120831&edate=20120501&rec=7056">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-08-14T14:56:41+02:00</dc:date><dc:creator>jac89886</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7056/1/ScreenCapture1.jpg" length="143787" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7056/2/ScreenCapture2.jpg" length="126473" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7056/3/ScreenCapture3.jpg" length="85012" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7056/4/ScreenCapture4.jpg" length="108845" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7056/5/ScreenCapture5.jpg" length="90797" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7056/6/ScreenCapture6.jpg" length="102432" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7056/7/ScreenCapture7.jpg" length="93778" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7056/8/ScreenCapture8.jpg" length="112405" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7056/9/ScreenCapture9.jpg" length="107845" type="image/jpeg"/></item><item>
<title>Novo Nordisk Earnings Call - Key Takeaways [:Biologics:news, :Endocrinology:class:GLP1, mkt:Russia, mkt:Intercontinental]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10009</link>
<description>Novo Nordisk Earnings Call - Key Takeaways [:Biologics:news, :Endocrinology:class:GLP1, mkt:Russia, mkt:Intercontinental]</description><category>news</category><category>class:GLP1</category><category>mkt:Russia</category><category>mkt:Intercontinental</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10009</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120831&edate=20120501&rec=10009">Novo Nordisk Earnings Call - Key Takeaways</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Biologics&sdate=20120831&edate=20120501&cat=news"><font color="#e95e0b">:Biologics:news</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=class%3aGLP1"><font color="#e95e0b">:Endocrinology:class:GLP1</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=mkt%3aIntercontinental"><font color="#e95e0b">:PharmaWorld:mkt:Intercontinental</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=mkt%3aRussia"><font color="#e95e0b">:PharmaWorld:mkt:Russia</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10009">PharmaWorld10009</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 14 August 2012 | 14:30</font><br><br><div style="margin-bottom: 10px;">Comment: During its earnings call Novo Nordisk provided more detail on 
developments within the GLP-1 market, including the approval of Victoza in China 
and commented on the sales performance of NovoSeven which is being impacted by a 
biosimilar Factor VII from Russia.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10009/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10009/2/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10009/3/ScreenCapture3.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10009/4/ScreenCapture4.jpg?user-agent=rss"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10009/5/ScreenCapture5.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><FONT face="Arial">Commenting further on 
Semaglutide, management referred to it as a best-in-class once-weekly 
candidate.<wbr> The drug has been formulated utilising</FONT><FONT face="Arial"> only a minor change to the liraglutide 
molecule but with that small change the</FONT><FONT face="Arial"> action profile of 30 hours, has been extended to ten days or 
so.<wbr> The presentation will still be in a prefilled injector but what is 
observed in a dose dependent manner is a </FONT><FONT face="Arial"> blood 
glucose decreases that is actually higher than 1.<wbr>8 milligram 
liraglutide.<wbr> Novo is claiming that at the higher dose range the drug is actually 
able to show numerically stronger results than seen with any other GLP-1 
analogue.<wbr> Hence its decision to entertain a huge program called SUSTAIN which 
will be initiated in 1H2013.<wbr> The first study being a cardiovascular risk 
study.<wbr></FONT> </div><div style="margin-bottom: 10px;"><FONT face="Arial">With 
regard to developments with Bydureon, it was noted that everything that 
Amyin has gained with Bydureon  has been lost from Byetta sales and 
not taken from Victoza.<wbr></FONT> </div><div style="margin-bottom: 10px;"><FONT face="Arial">Finally, 
managment noted that launch of Victoza in China has got off to a very promising 
start despite the current lack of reimbursement.<wbr></FONT> </div><div style="margin-bottom: 10px;"><UL style="MARGIN-TOP: 0cm" type="disc"><LI><UL style="MARGIN-TOP: 0cm" type="circle"><LI style="MARGIN: 0cm 0cm 0pt; mso-list: l0 level2 lfo3; tab-stops: list 72.0pt"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10009/6/ScreenCapture6.jpg?user-agent=rss"></LI>
</UL></LI>
</UL> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10009/7/ScreenCapture7.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">Hemophilia </div><div style="margin-bottom: 10px;">Commenting on Novoseven's performance, Kare Schulz noted </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-FAMILY: 'Arial','sans-serif'; FONT-SIZE: 10pt; mso-bidi-font-size: 12.0pt; mso-fareast-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA">With regard to NovoSeven, we have a situation where the market is 
basically saturated in the industrialized world because basically all patients 
that are in a situation where they need NovoSeven, so they have inhibitors, the 
Factor VIII or Factor IX, they are getting therapy, and we have roughly a 70% 
market share up against Pfizer.<wbr> In emerging markets, you have two categories of 
markets.<wbr> You have some markets that are so poor that nobody really gets treated 
with Factor VIII or Factor IX.<wbr> That means nobody develops inhibitors and there 
is no market.<wbr> That is maybe the LDC countries, the poorest 50 countries of the 
world.<wbr>  Then you have a big middle 
category of markets where we actually do see increasing demand and where we do 
see increasing sales.<wbr> However, that is, this year for instance, being offset by 
the fact that NovoSeven has run out of patent in basically all these markets, 
and we’ve seen a generic product, a biosimilar product come up in Russia without 
any real good clinical data or anything.<wbr> But anyway, <SPAN lang="EN-US" style="FONT-FAMILY: 'Arial','sans-serif'; FONT-SIZE: 10pt; mso-bidi-font-size: 12.0pt; mso-fareast-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA">it’s come, it’s pretty similar to NovoSeven, and it has taken over 
the Russian market.<wbr> So it’s that dynamic that results in flat sales.<wbr> So we 
actually do have volume increase in the treatment of people with Factor VIIa in 
emerging markets, but we’ve been losing out in Russia, and so that’s the 
balance</SPAN></SPAN> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10009/8/ScreenCapture8.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10009/9/ScreenCapture9.jpg?user-agent=rss"> </div><div><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10009/10/ScreenCapture10.jpg?user-agent=rss"> </div><!-- Comment details --><a name="pharmaworld10009attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10009/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(104,4 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10009/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(118,1 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10009/3/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(108,9 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10009/4/ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(153,6 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10009/5/ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(155,3 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10009/6/ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(148 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10009/7/ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(127,3 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10009/8/ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(118,1 KB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10009/9/ScreenCapture9.jpg">ScreenCapture9.jpg</a>&nbsp;&nbsp;(131,8 KB)<br>&nbsp;&nbsp;10.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10009/10/ScreenCapture10.jpg">ScreenCapture10.jpg</a>&nbsp;&nbsp;(117,7 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120831&edate=20120501&rec=10009">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-08-14T14:30:14+02:00</dc:date><dc:creator>jac89886</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10009/1/ScreenCapture1.jpg" length="106949" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10009/2/ScreenCapture2.jpg" length="120973" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10009/3/ScreenCapture3.jpg" length="111506" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10009/4/ScreenCapture4.jpg" length="157310" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10009/5/ScreenCapture5.jpg" length="159007" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10009/6/ScreenCapture6.jpg" length="151552" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10009/7/ScreenCapture7.jpg" length="130346" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10009/8/ScreenCapture8.jpg" length="120982" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10009/9/ScreenCapture9.jpg" length="134990" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10009/10/ScreenCapture10.jpg" length="120505" type="image/jpeg"/></item><item>
<title>Sun Pharma Is Chasing Acquisitions in Brazil, Mexico and Russia [:Endocrinology:prod:Octreotide, :Oncology:sub:Hybrids, :Oncology:dis:Prostate, :Endocrinology:dis:Acromegaly, mkt:Brazil, mkt:Intercontinental, mkt:Mexico, mkt:Russia]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10008</link>
<description>Sun Pharma Is Chasing Acquisitions in Brazil, Mexico and Russia [:Endocrinology:prod:Octreotide, :Oncology:sub:Hybrids, :Oncology:dis:Prostate, :Endocrinology:dis:Acromegaly, mkt:Brazil, mkt:Intercontinental, mkt:Mexico, mkt:Russia]</description><category>prod:Octreotide</category><category>sub:Hybrids</category><category>dis:Prostate</category><category>dis:Acromegaly</category><category>mkt:Brazil</category><category>mkt:Intercontinental</category><category>mkt:Mexico</category><category>mkt:Russia</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10008</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120831&edate=20120501&rec=10008">Sun Pharma Is Chasing Acquisitions in Brazil, Mexico and Russia</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=dis%3aAcromegaly"><font color="#e95e0b">:Endocrinology:dis:Acromegaly</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=prod%3aOctreotide"><font color="#e95e0b">:Endocrinology:prod:Octreotide</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=sub%3aHybrids"><font color="#e95e0b">:Oncology:sub:Hybrids</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=mkt%3aBrazil"><font color="#e95e0b">:PharmaWorld:mkt:Brazil</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=mkt%3aIntercontinental"><font color="#e95e0b">:PharmaWorld:mkt:Intercontinental</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=mkt%3aMexico"><font color="#e95e0b">:PharmaWorld:mkt:Mexico</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=mkt%3aRussia"><font color="#e95e0b">:PharmaWorld:mkt:Russia</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10008">PharmaWorld10008</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 13 August 2012 | 15:31</font><br><br><div style="margin-bottom: 10px;">Comment: The Economic Times has reoprted that Sun Pharma is searching for acquisitions in certain emerging markets in order to develop access and presence.<wbr> </div><div style="margin-bottom: 10px;">Sun Pharma already sells branded generics in these markets and has recently established manufacturing plants in Mexico and Brazil.<wbr> </div><div style="margin-bottom: 10px;">Looking ahead the company stated that its emphasis is on registering more complex generics such as anticancer injectables.<wbr> </div><div style="margin-bottom: 10px;">Amongst such developments candidates are long-acting formulations of goserelin and octreotide LAR.<wbr> Dossier to conduct phI PK/<wbr>PD US study with octreotide LAR formulation was planned to be submitted in April 2012.<wbr> Priority development is the US which will then be followed by EU submission.<wbr> </div><div style="margin-bottom: 10px;">The Mumbai-based drugmaker reported Q1 net profit of 7.<wbr>96 billion rupees ($143.<wbr>88 million) up from 5.<wbr>01 billion rupees a year earlier, a figure that significantly beat street estimates.<wbr> Sales rose 62.<wbr>5 per cent to 26.<wbr>58 billion rupees helped by the robust busiiness of Israeli unit Taro Pharma.<wbr> </div><div style="margin-bottom: 10px;">Analysts, on an average, had forecast net profit at 6.<wbr>82 billion rupees on sales 23.<wbr>65 billion rupees.<wbr> </div><div>Source: <A href="http://www.sunpharma.com/">www.<wbr>sunpharma.<wbr>com</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120831&edate=20120501&rec=10008">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-08-13T15:31:08+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>Corcept Therapeutics Secures $30m in Financing To Support Product Development [dis:Cushing, news]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7055</link>
<description>Corcept Therapeutics Secures $30m in Financing To Support Product Development [dis:Cushing, news]</description><category>dis:Cushing</category><category>news</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7055</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120831&edate=20120501&rec=7055">Corcept Therapeutics Secures $30m in Financing To Support Product Development</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=dis%3aCushing"><font color="#e95e0b">:Endocrinology:dis:Cushing</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=news"><font color="#e95e0b">:Endocrinology:news</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7055">Endocrinology7055</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 13 August 2012 | 12:34</font><br><br><div style="margin-bottom: 10px;"><P align="left">Comment: Corcept granted a Pharmakon Advisors fund rights to 
receive up to $45 million in royalties on Corcept’s products in exchange for $30 
million in cash.<wbr> </P> </div><div style="margin-bottom: 10px;"><P align="left"><STRONG>In April, Corcept launched Korlym mifepristone</STRONG> 
its first marketed product — in the U.<wbr>S.<wbr> to treat Cushing’s syndrome.<wbr> 
<STRONG>Second quarter sales of Korlym were $875,000.<wbr></STRONG></P> </div><div style="margin-bottom: 10px;"><P align="left">The fund, Biopharma Secured Debt Fund II Sub S.<wbr>a.<wbr>r.<wbr>l, is eligible 
for 20% on net product sales beginning with 2Q13.<wbr> Payments will be capped at 
$2.<wbr>3 million per quarter in 2013, $3 million per quarter in 2014 and $3.<wbr>8 
million per quarter in 2015.<wbr> There will be no quarterly caps starting in 2016 
and beyond.<wbr> </P> </div><div style="margin-bottom: 10px;"><P align="left">Additionally, the fund is eligible for 20% of upfront, milestone 
and other contingent payments received under co-promotion and out-licensing 
agreements.<wbr> The fund’s royalty rights expire when it has received a total of $45 
million.<wbr></P> </div><div style="margin-bottom: 10px;">Commenting on the deal Joseph Belanoff Corcept's CEO stated "This innovative 
transaction will provide Corcept with a significant amount of low-risk, 
non-dilutive capital that will help broaden and accelerate development of our 
product pipeline, including mifepristone for the treatment of psychotic 
depression and our extensive library of next-generation selective GR-II 
antagonists.<wbr>" </div><div>Source: <a href="http://www.corcept.com" class="defaultlink" title="www.corcept.com">corcept.com</a> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120831&edate=20120501&rec=7055">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-08-13T12:34:02+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>Tokai Appoints CMO and VP of Medical Development [:PharmaWorld:sub:People]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology8420</link>
<description>Tokai Appoints CMO and VP of Medical Development [:PharmaWorld:sub:People]</description><category>sub:People</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology8420</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8420">Tokai Appoints CMO and VP of Medical Development</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=sub%3aPeople"><font color="#e95e0b">:PharmaWorld:sub:People</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8420">Oncology8420</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/20">Alison Attard</a> | 13 August 2012 | 11:44</font><br><br><div style="margin-bottom: 10px;">Comment: Tokai says that Dr Senderowicz brings valuable expertise to the development of its lead candidate, galeterone (TOK-001), which recently won an FDA fast-track designation from for metastatic castration-resistant prostate cancer.<wbr> </div><div style="margin-bottom: 10px;">Dr Adrian M Senderowicz has previously served as medical director of oncology clinical development at AstraZeneca.<wbr> In this role he oversaw the US FDA approval of Caprelsa (vandetanib) for advanced medullary thyroid carcinoma.<wbr> Before joining AstraZeneca, he held various senior positions at the FDA Division of Oncology Drug Products in the Center for Drug Evaluation and Research.<wbr> </div><div>Source: Scrip 10 August 2012 </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8420">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-08-13T11:44:36+02:00</dc:date><dc:creator>ala97794</dc:creator></item><item>
<title>UK: NICE-backed Drugs Must be on NHS Contracts from April 2013</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10007</link>
<description>UK: NICE-backed Drugs Must be on NHS Contracts from April 2013</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10007</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120831&edate=20120501&rec=10007">UK: NICE-backed Drugs Must be on NHS Contracts from April 2013</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10007">PharmaWorld10007</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/20">Alison Attard</a> | 10 August 2012 | 16:17</font><br><br><div style="margin-bottom: 10px;">Comment: Clinical Commission Groups will have to publish a list of all the treatments they provide on the NHS by April next year and will not be allowed to add any restrictions on NICE-approved treatments, under plans revealed by the head of the NHS.<wbr> </div><div style="margin-bottom: 10px;">In a letter to PCT, CCG and SHA chief executives NHS chief executive Sir David Nicholson said that PCT clusters and CCG leaders will have to publish information online in a &lsquo;clear' and &lsquo;transparent' way that sets out which NICE Technology Appraisals are included in their formularies.<wbr> </div><div style="margin-bottom: 10px;"><SPAN style="color: #333333;">The letter is at:</SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="color: #333333;"><a href="https://www.wp.dh.gov.uk/publications/files/2012/08/NHSCE-formularies-letter-August-2012.pdf" class="defaultlink" title="https://www.wp.dh.gov.uk/publications/files/2012/08/NHSCE-formularies-letter-August-2012.pdf">wp.dh.gov.uk/<wbr>publ&hellip;</a></SPAN> </div><div><SPAN style="color: #333333;">Source: PMLive/<wbr>GPOnline 10 August 2012</SPAN> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120831&edate=20120501&rec=10007">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-08-10T16:17:02+02:00</dc:date><dc:creator>ala97794</dc:creator></item><item>
<title>The Largest Product Growth Drivers of H1 2012 [func:Sales, mkt:Korea, mkt:Intercontinental]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10006</link>
<description>The Largest Product Growth Drivers of H1 2012 [func:Sales, mkt:Korea, mkt:Intercontinental]</description><category>func:Sales</category><category>mkt:Korea</category><category>mkt:Intercontinental</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10006</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120831&edate=20120501&rec=10006">The Largest Product Growth Drivers of H1 2012</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=func%3aSales"><font color="#e95e0b">:PharmaWorld:func:Sales</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=mkt%3aIntercontinental"><font color="#e95e0b">:PharmaWorld:mkt:Intercontinental</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=mkt%3aKorea"><font color="#e95e0b">:PharmaWorld:mkt:Korea</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10006">PharmaWorld10006</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/20">Alison Attard</a> | 10 August 2012 | 15:30</font><br><br><div style="margin-bottom: 10px;">Comment: Therapy areas driving most growth in the first half of 2012 versus the same time period in 2011 are Oncology, Inflammation and Diabetes.<wbr>  Zytiga delivered the highest level of sales during this time period (out of the top 20 products described).<wbr> </div><div style="margin-bottom: 10px;">The top twenty products with the highest growth rates (within this time period) are listed below.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10006/1/table.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">The most dominant area is Oncology accounting for six of these products.<wbr>  Zytiga delivered the highest level of absolute growth for the first six months of the year versus the same period in 2011 at $378million.<wbr>   In addition to Zytiga, BMS&rsquo;s melanoma treatment, Yervoy generated $316million for the first six months following is approval in March last year.<wbr> </div><div style="margin-bottom: 10px;">The immunology/<wbr>imflammation therapy area has seen the biggest challenge during this period with the threat of biosimilars with a version of Remicade launching in South Korea and approvals expected in other developed markets.<wbr>   It is understood that over 79  biosimilar MAbs are in development globally.<wbr> </div><div style="margin-bottom: 10px;">South Korea is rapidly becoming the hot bed of biosimilar activity as they have had a simple and well defined regulatory pathway which has been in place since 2009.<wbr>  It is understood that there are 13 on-going clinical trials in Korea for biosimilars in various therapy areas.<wbr> </div><div style="margin-bottom: 10px;">The products making up this list are dominated by products that were either launched as first in class therapies or offered substanical improvements in safety and efficacy.<wbr>  Providing further evidence of the heightened R&amp;D challenge faced by the pharma industry  with regards to the payors pushing for truly innovative or incrementally effective rather than simply new is going to be on the increase.<wbr> </div><div>Source: FirstWord 9 August 2012 </div><!-- Comment details --><a name="pharmaworld10006attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10006/1/table.jpg">table.jpg</a>&nbsp;&nbsp;(103,9 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120831&edate=20120501&rec=10006">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-08-10T15:30:40+02:00</dc:date><dc:creator>ala97794</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10006/1/table.jpg" length="106405" type="image/jpeg"/></item><item>
<title>Medivation's Second Quarter Results [dis:Prostate, prod:MDV3100]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology8418</link>
<description>Medivation's Second Quarter Results [dis:Prostate, prod:MDV3100]</description><category>dis:Prostate</category><category>prod:MDV3100</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology8418</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8418">Medivation's Second Quarter Results</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=prod%3aMDV3100"><font color="#e95e0b">:Oncology:prod:MDV3100</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8418">Oncology8418</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/20">Alison Attard</a> | 10 August 2012 | 15:09</font><br><br><div style="margin-bottom: 10px;">Comment: The second quarter update on Medivation&rsquo;s  Enzalutamide (formerly MDV3100) detailed recent milestones and clinical achievements.<wbr>  Interesting updates on clinical trial status but the majority has been previously published.<wbr> </div><div style="margin-bottom: 10px;"><UL type="square"><LI>Enzalutamide PUDFA date is November 22, 2012
</LI>
<LI>MAA submitted to the EMEA
</LI>
<LI>Positive P3 AFFIRM results presented at ASCO 2012
</LI>
<LI>Completed recruitment of sales and medical affairs personnel to support US launch this year - Medivation will provide 50% of field force (60 sales force from Medivation and approximately 100 from Astellas - selling additional products as well as Enzalutamide) 
</LI>
<LI>Completed target enrolment of PREVAIL (pre-chemo) = 1,680 patients
</LI>
<LI>Enrolment is on-going for  EU/<wbr>USA based TERRAIN (370  metastatic patients) and US based STRIVE (400 metastatic/<wbr>non-metastatic patients)
</LI>
<LI>Completed patient enrolment (67) in an open-label clinical trial designed to evaluate the effect of Enzalutamide in advanced prostate cancer patients who have not had any previous hormonal therapies.<wbr> Primary Endpoint  is PSA
</LI>
<LI>ASPIRE trial is opening with the aim to recruit 150 CRPC patients who are eligible to receive chemotherapy but have elected not to do so.<wbr> Primary endpoint is rPFS
</LI>
<LI>Enrolment has begun with Enzalutamide as neoadjuvant therapy in approximately 50 men prior to prostatectomy.<wbr> Primary endpoint is pathological complete response rate
</LI>
<LI>Enrolment is still on-going for a study looking at Enzalutamide when dosed in combination with docetaxel in 18 men
</LI>
<LI>Phase I trial opened in breast cancer in 24 patients who have failed prior hormonal therapy
</LI>
</UL> </div><div>
Revenue for the second quarter was $42.<wbr>9million.<wbr>  Medivation became entitled to receive a $10 million milestone payment from Astellas upon the FDA's acceptance for filing of the Enzalutamide NDA with an expected additional $35 million in development milestone payments from Astellas in 2012.<wbr>  Medivation is required to share 10% of all development milestone payments received with the licensor of its Enzalutamide technology </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8418">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-08-10T15:09:11+02:00</dc:date><dc:creator>ala97794</dc:creator></item><item>
<title>Medicis Second Quarter Results</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology6521</link>
<description>Medicis Second Quarter Results</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology6521</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120831&edate=20120501&rec=6521">Medicis Second Quarter Results</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology6521">Neurology6521</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/774">bee75336</a> | 09 August 2012 | 17:04</font><br><br><div style="margin-bottom: 10px;">Comment: DYSPORT® did exceptionally well this quarter with the Non-Acne products reporting an increase of 40.<wbr>5% in sales while Acne products reported a decrease of 24%.<wbr> </div><div style="margin-bottom: 10px;">Medicis recorded revenues of approximately $81.<wbr>1 million for the three months ending June 30, 2012 for their Non-Acne products range.<wbr>  This increase is due primarily to increased sales of DYSPORT®, the RESTYLANE® franchise, ZYCLARA® in the United States and ALDARA® in Canada.<wbr> </div><div style="margin-bottom: 10px;">Dysport in particular had its strongest quarterly demand since launch and saw a 5% increase in units sold compared to Q2 2011.<wbr>   This was mimicked by the RESTYLANE® franchise, enjoying its strongest second quarter since 2007.<wbr> </div><div style="margin-bottom: 10px;">Discussion in the Q&amp;A session revolved around the Acne products and whether or not Medicis will stay independent to which Jonah Shacknai responded “In terms of whether we remain independent, I hope so.<wbr> But at the end of the day we are here to serve the interests of our shareholders…we, like any other company; has an absolute obligation to consider offers from legitimate and credible parties.<wbr> It isn’t my dream personally that that would happen, but I can assure you that my personal wishes would never interfere with a thoughtful consideration of something that came along again from a legitimate party….<wbr>So I can’t predict our independence…But I think we have to operate with an expectation that we are an independent company and that we will remain so” </div><div>Medicis have 18 pipeline products and the company hopes to file an NDA for a therapeutic dermatology product in Q1 2013.<wbr>  No further information was disclosed regarding pipeline products.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120831&edate=20120501&rec=6521">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-08-09T17:04:21+02:00</dc:date><dc:creator>bee75336</dc:creator></item><item>
<title>re: BMS To Acquire Amylin For $7bn &amp; Then Integrate Products Into AZ Collaboration</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7054</link>
<description>re: BMS To Acquire Amylin For $7bn &amp; Then Integrate Products Into AZ Collaboration</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7054</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120831&edate=20120501&rec=7054">re: BMS To Acquire Amylin For $7bn & Then Integrate Products Into AZ Collaboration</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7054">Endocrinology7054</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/20">Alison Attard</a> | 09 August 2012 | 16:04</font><br><br><div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">BMS To Acquire Amylin For $7bn & Then Integrate Products Into AZ Collaboration</span>&nbsp;<font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=Alert"><font color="#e95e0b">:Endocrinology:Alert</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=class%3aGLP1"><font color="#e95e0b">:Endocrinology:class:GLP1</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=dis%3aDiabetes"><font color="#e95e0b">:Endocrinology:dis:Diabetes</font></a>]</font></font><br><span style="font-size: 12px;">Comment: BMS has today announced the acquisition of Amylin.<wbr> Following the completion of the purchase, the company will then enter into a collaboration with AstraZeneca , based on their existing diabetes alliance, regarding the development and commercialisation of Amylin's portfolio of products.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120831&edate=20120501&rec=6996">...</a><br><font size="-1">Jacquelyne CANTLE MEYRICK / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology6996" class="commentpermalink">Endocrinology6996</a> / <span class="date">02 July 2012</span> /
<span class="time">15:22:17 o'clock CEST</span>
</font></div><div style="margin-bottom: 10px;"><SPAN style="display: inline! important; float: none; word-spacing: 0px; font: 12px helvetica; text-transform: none; color: #000000; text-indent: 0px; white-space: normal; letter-spacing: normal; background-color: #ffffff; widows: 2; orphans: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">Bristol-Myers Squibb announced on 9 August 2012 that it has  completed its $5-billion purchase of Amylin and its diabetes franchise.<wbr></SPAN> </div><div style="margin-bottom: 10px;">AstraZeneca has also informed Bristol-Myers Squibb of its intention to exercise its option to <EM>acquire certain additional governance rights over key strategic and financial decisions regarding Amylin&rsquo;s portfolio</EM>.<wbr> The right to exercise this option will become effective once applicable anti-trust and competition approvals are received by AstraZeneca.<wbr> Upon the exercise of the option an additional payment of $135 million will be made to Bristol-Myers Squibb.<wbr> </div><div>Source: Pharmiweb 9 August 2012 </div><!-- Comment details --><font size="-1">Alison Attard / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7054" class="commentpermalink">Endocrinology7054</a> / <span class="date">09 August 2012</span> /
<span class="time">16:04:24 o'clock CEST</span>
</font><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120831&edate=20120501&rec=7054">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology6996">View thread  Endocrinology6996: BMS To Acquire Amylin For $7bn & Then Integrate Products Into AZ Collaboration</a>]]></content:encoded><dc:date>2012-08-09T16:04:24+02:00</dc:date><dc:creator>ala97794</dc:creator></item><item>
<title>Antisense Therapeutics Initiates PhII Acromegaly Programme [Alert, dis:Acromegaly]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7053</link>
<description>Antisense Therapeutics Initiates PhII Acromegaly Programme [Alert, dis:Acromegaly]</description><category>Alert</category><category>dis:Acromegaly</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7053</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120831&edate=20120501&rec=7053">Antisense Therapeutics Initiates PhII Acromegaly Programme</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=Alert"><font color="#e95e0b">:Endocrinology:Alert</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=dis%3aAcromegaly"><font color="#e95e0b">:Endocrinology:dis:Acromegaly</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7053">Endocrinology7053</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 08 August 2012 | 18:40</font><br><br><div style="margin-bottom: 10px;">Comment: The company has announced that Dr Peter Trainer Professor of 
Endocrinology at The Chrisite Hospital in Manchester will be the principal 
investigator for its forthcoming phII study of ATL1103 in acromegaly.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>ATL1103's Profile</STRONG> </div><div style="margin-bottom: 10px;">ATL1103 is a second generation antisense drug designed to block growth 
hormone receptor expression and thereby reducing the levels of IGF-1 in the 
blood.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>PhII Study Status</STRONG> </div><div style="margin-bottom: 10px;">ATL1103' PhII trial protocol has now been finalised and CRO ANP has 
been appointed to conduct the trial in Europe.<wbr> First patients 
are expected to be dosed in Q42012.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Study Design</STRONG> </div><div style="margin-bottom: 10px;">The phII trial will be a randomised, open-label parallel group study 
evaluating from a primary endpoint perspective the safety, tolerability, PK and 
efficacy of two subcutaneous doses of ATL1103 in 24 adult 
patients with acromegaly dosed with ATL1103 for 13 weeks.<wbr> A secondary 
endpoint will be the impact of ATL1103 on serum IGF-1 levels.<wbr> </div><div style="margin-bottom: 10px;">Patients will either be treatment naive or have a washout period from 
acromegaly medication ranging from 6 weeks to 4 months depending on previous 
treatment.<wbr> They will also be required to have a serum IGF-level&gt; 1.<wbr>3 x the 
upper limit of normal and a GH of &gt;1ng/<wbr>ml after an oral glucose tolerance 
test </div><div style="margin-bottom: 10px;">The two subcutaneous dosing regimens to be evaluated will be:- </div><div style="margin-bottom: 10px;">1.<wbr> ATL1103 200mg three times in the first week then once weekly in weeks 2 
through to week 13 for a total of 15 doses or </div><div style="margin-bottom: 10px;">2.<wbr> ATL1103 200mg three times in the first week then twice weekly in weeks 2 
through to weeek 13 for a total of 27 doses.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Recruitment</STRONG> </div><div style="margin-bottom: 10px;">The 11 sites envisaged for recruitment will include the folllowing 
countries:- UK Poland, Germany, France, Spain, Czech Republic and Lithuania.<wbr> </div><div style="margin-bottom: 10px;">Recruiting treatment naive patients may prove to be the easiest way 
forward for Antisense as there are two PhIII trials already ongoing in 
Europe one targeting inadequate responsders (pasireotide trial n=186) and 
the second stabilised SSA patients (oral octreolin n=150).<wbr> </div><div style="margin-bottom: 10px;">The main geographic overlap of all three trials will be in the UK, Germany, 
Italy and Romania.<wbr> Please do feedback any information to the CI department 
on progress with recruitment if anything comes to your attention.<wbr> </div><div>Source: <A href="http://www.antisense.com.au">www.<wbr>antisense.<wbr>com.<wbr>au</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120831&edate=20120501&rec=7053">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-08-08T18:40:05+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>re: Inclusion of Octreotide In SmPC Harmonisation In 2012</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7052</link>
<description>re: Inclusion of Octreotide In SmPC Harmonisation In 2012</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7052</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120831&edate=20120501&rec=7052">re: Inclusion of Octreotide In SmPC Harmonisation In 2012</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7052">Endocrinology7052</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 08 August 2012 | 17:38</font><br><br><div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">re: Inclusion of Octreotide In SmPC Harmonisation In 2012</span>&nbsp;<br><span style="font-size: 12px;">What are the potential and more concrete consequences ? Thanks in advance for any contribution on that.<wbr></span>&nbsp;<br><font size="-1">gug93330 / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7050" class="commentpermalink">Endocrinology7050</a> / <span class="date">08 August 2012</span> /
<span class="time">09:51:33 o'clock CEST</span>
</font></div><div style="margin-bottom: 10px;"><DIV style="widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; font: 13px arial, sans-serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #222222; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">Further thoughts from Roz on the relevance of this development are outlined below:-</DIV> </div><div style="margin-bottom: 10px;"><DIV style="widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; font: 13px arial, sans-serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #222222; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">It will be of interest for us to monitor existing national Sandostatin &amp; Sandostatin LAR  claims that are retained and lost (if any) through the harmonisation process</DIV> </div><div style="margin-bottom: 10px;"><DIV style="widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; font: 13px arial, sans-serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #222222; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">
<UL><LI style="margin-left: 15px;">The  Sandostatin &amp; Sandostatin LAR SmPCs that would emerge from the harmonization process would be expected to form the basis of the SmPCs for the generics/<wbr>hybrids to follow for octreotide now it is off patent.<wbr> 
</LI>
<LI style="margin-left: 15px;">While the balance of Sandostatin claims retained or lost will depend primarily on the strength of Novartis' data, it's also likely to be a good indicator for the level of defence that could be needed for the Somatuline claims if/<wbr> when a harmonization is triggered for our own product(s)
</LI>
</UL>
</DIV> </div><div style="margin-bottom: 10px;"><DIV style="widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; font: 13px arial, sans-serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #222222; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">It also suggests that wew should consider the timings one might anticipate for such a process to be triggered for Somatuline?  Potentially, this could occur:-</DIV> </div><div><DIV style="widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; font: 13px arial, sans-serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #222222; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">
<UL><LI style="margin-left: 15px;">due to a trigger from a national agency, in light of Sandostatin harmonization, if there's a high level of SSA class claims being made for Somatuline
</LI>
<LI style="margin-left: 15px;">following Somatuline patent expiry if there's the pressure of lanreotide generic and /<wbr>or hybrids
</LI>
<LI style="margin-left: 15px;">a voluntary trigger on the part of Ipsen if, when bringing forward a new lanreotide product, it's considered advantageous for a new product in the range to be approved through a pan-European procedure such as the decentralised procedure (DCP)
</LI>
</UL>
</DIV> </div><!-- Comment details --><font size="-1">Jacquelyne CANTLE MEYRICK / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7052" class="commentpermalink">Endocrinology7052</a> / <span class="date">08 August 2012</span> /
<span class="time">17:38:18 o'clock CEST</span>
</font><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120831&edate=20120501&rec=7052">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7047">View thread  Endocrinology7047: Inclusion of Octreotide In SmPC Harmonisation In 2012</a>]]></content:encoded><dc:date>2012-08-08T17:38:18+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>GTx Q2 Earnings - Development Status Of Oral Prostate Cancer Programme [class:Hormonals, comp:GTx, dis:Prostate]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology8417</link>
<description>GTx Q2 Earnings - Development Status Of Oral Prostate Cancer Programme [class:Hormonals, comp:GTx, dis:Prostate]</description><category>class:Hormonals</category><category>comp:GTx</category><category>dis:Prostate</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology8417</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8417">GTx Q2 Earnings - Development Status Of Oral Prostate Cancer Programme</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=class%3aHormonals"><font color="#e95e0b">:Oncology:class:Hormonals</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=comp%3aGTx"><font color="#e95e0b">:Oncology:comp:GTx</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8417">Oncology8417</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 08 August 2012 | 17:31</font><br><br><div style="margin-bottom: 10px;">Comment: GTx is to begin screening patients this month for its phII study of 
Capesaris its oral selective estrogen receptor alpha agonist as a secondary 
hormonal therapy in men with metastatic CRPC.<wbr> </div><div style="margin-bottom: 10px;">The study will be an open-label trial conducted in 75 men to test three lower 
doses of Capesaris than previously tested (125mg, 250mg and 500mg) sequentially 
in cohorts of 25 patients.<wbr> </div><div style="margin-bottom: 10px;">This phII trial is deisgned to assess the effect of Capesaris on serum PSA 
response and prostate cancer progression.<wbr> The study is expected to provide 
confirmation of the MOA of the drug in terms of its ability to lower serum free 
testosteron by increasing serum SHBG.<wbr> </div><div style="margin-bottom: 10px;">The safety and tolerability of these lower doses will also be evaluated with 
particular reference to the incidence of thromboembolic events, the side-effect 
that led to the drug being put on a clinical hold last year.<wbr> It is looking 
to establish a VTE event rate of no higher than 3.<wbr>8% </div><div style="margin-bottom: 10px;">Efficacy and safety data from this study is expected to become 
available by the summer of 2013.<wbr> </div><div style="margin-bottom: 10px;">GTx's Financial Position </div><div style="margin-bottom: 10px;"><B>Financial highlights for the quarter ended <CHRON>June 30, 
2012</CHRON></B> </div><div style="margin-bottom: 10px;">The net loss for the quarter ended <CHRON>June 30, 2012</CHRON> was 
<MONEY>$10.<wbr>4 million</MONEY> compared to a net loss of <MONEY>$10.<wbr>7 
million</MONEY> for the same period in 2011.<wbr> </div><div style="margin-bottom: 10px;">Revenue for both the second quarter of 2012 and 2011 was <MONEY>$1.<wbr>6 
million</MONEY> and consisted of net sales of FARESTON<SUP>® </SUP>(toremifene 
citrate) 60 mg, approved for the treatment of metastatic breast cancer in 
postmenopausal women.<wbr> </div><div style="margin-bottom: 10px;">Research and development expenses for the quarter ended <CHRON>June 30, 
2012</CHRON> were <MONEY>$9.<wbr>2 million</MONEY> compared to <MONEY>$7.<wbr>6 
million</MONEY> for the same period in 2011.<wbr> General and administrative expenses 
for the quarter ended <CHRON>June 30, 2012</CHRON> were <MONEY>$2.<wbr>6 
million</MONEY> compared to <MONEY>$4.<wbr>5 million</MONEY> for the same period in 
2011.<wbr> </div><div style="margin-bottom: 10px;">At <CHRON>June 30, 2012</CHRON>, GTx had cash and short-term investments of 
<MONEY>$55.<wbr>9 million</MONEY>.<wbr> </div><div>Source: <A href="http://phx.corporate-ir.net/phoenix.zhtml?c=148196&amp;p=irol-newsArticle&amp;ID=1723612&amp;highlight">http:/<wbr>/<wbr>phx.<wbr>corporate-ir.<wbr>net/<wbr>phoenix.<wbr>zhtml?c=148196&amp;p=irol-newsArticle&amp;ID=1723612&amp;highlight</A>= </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8417">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-08-08T17:31:48+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>Significant New Radiopharmaceutical Agreement [dis:Prostate, sub:Biomarkers, news]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology8415</link>
<description>Significant New Radiopharmaceutical Agreement [dis:Prostate, sub:Biomarkers, news]</description><category>dis:Prostate</category><category>sub:Biomarkers</category><category>news</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology8415</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8415">Significant New Radiopharmaceutical Agreement</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=news"><font color="#e95e0b">:Oncology:news</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=sub%3aBiomarkers"><font color="#e95e0b">:Oncology:sub:Biomarkers</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8415">Oncology8415</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 08 August 2012 | 17:14</font><br><br><div style="margin-bottom: 10px;">Comment: ImaginAb, Inc.<wbr> a developer of <EM>in vivo</EM> molecular imaging agents has announced the signing of a MSA with Singapore Radiopharmaceuticals Pte Ltd, a company with an established track record in custom radiochemistry and cGMP product manufacturing.<wbr> The agreement should help to accelerate the development of ImaginAb's cancer (prostate and pancreatic) and immunology imaging programs.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Nature Of The Technology</STRONG> </div><div style="margin-bottom: 10px;">ImaginAb’s technology enables antibodies to be re-engineered into smaller proteins (fragments) with fast kinetics suitable for diagnostic imaging, while maintaining target biospecificity.<wbr> In this way, true companion in vivo diagnostics can be rapidly developed that enable target expression to be profiled in tissues in a non-invasive, whole-body manner.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Company Financing</STRONG> </div><div style="margin-bottom: 10px;">The company has been seed funded by a Series A financing – led by Novartis Venture Funds which raised $12.<wbr>5m back in March this year.<wbr> </div><div style="margin-bottom: 10px;">The oversubscribed Series A round includes Merieux Developpement, Nextech Invest, Cycad Group and existing seed investor Momentum Biosciences.<wbr> Novartis Venture Funds and Merieux Developpement have both appointed Directors as representatives of the Series A investors </div><div style="margin-bottom: 10px;"><STRONG>Development Pipeline</STRONG> </div><div style="margin-bottom: 10px;">ImaginAb has so far over a dozen development programs with global biopharma companies to develop companion diagnostic imaging agents to therapeutic antibody drugs (in Phase I to BLA), as well as an internal pipeline targeting unmet clinical needs, such as the staging of metastatic prostate and pancreatic cancer.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8415/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG>About Singapore Radiopharmaceuticals Pte Ltd</STRONG> </div><div style="margin-bottom: 10px;">Founded in 2008 and part of the RadLink Group Asia, SRP provides GMP-compliant radiopharmaceuticals production using the GE 16.<wbr>5 MeV PETtrace cyclotron and synthesis modules.<wbr> Bespoke radiolabeling services include the use of Zirconium-89, Iodine-124 and Indium-111 isotopes.<wbr> The company specializes in cGMP manufacture of proprietary tracers for clinical trials.<wbr> SRP is dedicated to supplying beyond FDG tracers to all government and private hospitals in Singapore whilst supporting drug discovery programs for the pharmaceuticals industry.<wbr> </div><div>Source: <A href="http://www.imaginab.com/">www.<wbr>imaginab.<wbr>com</A> </div><!-- Comment details --><a name="oncology8415attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8415/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(48,4 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8415">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-08-08T17:14:31+02:00</dc:date><dc:creator>jac89886</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8415/1/ScreenCapture1.jpg" length="49534" type="image/jpeg"/></item><item>
<title>re: Inclusion of Octreotide In SmPC Harmonisation In 2012</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7050</link>
<description>re: Inclusion of Octreotide In SmPC Harmonisation In 2012</description><comments>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7050</comments><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7050</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120831&edate=20120501&rec=7050">re: Inclusion of Octreotide In SmPC Harmonisation In 2012</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7050">Endocrinology7050</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/657">gug93330</a> | 08 August 2012 | 09:51</font><br><br><div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Inclusion of Octreotide In SmPC Harmonisation In 2012</span>&nbsp;<font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=class%3aSomatostatinAnalogue"><font color="#e95e0b">:Endocrinology:class:SomatostatinAnalogue</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=comp%3aNovartis"><font color="#e95e0b">:Endocrinology:comp:Novartis</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=headline"><font color="#e95e0b">:Endocrinology:headline</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=prod%3aOctreotide"><font color="#e95e0b">:Endocrinology:prod:Octreotide</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=sub%3aGenerics"><font color="#e95e0b">:Endocrinology:sub:Generics</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=sub%3aHybrids"><font color="#e95e0b">:Endocrinology:sub:Hybrids</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=sub%3aRegulatory"><font color="#e95e0b">:PharmaWorld:sub:Regulatory</font></a>]</font></font><br><span style="font-size: 12px;">Comment: The latest list agreed by the CMDh and published in July includes 
Sandostatin &amp; Sandostatin LAR.<wbr> Its selection at this time is most likely 
linked to the product going off patent and the potential approval of 
generics/<wbr>hybrids in due course.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120831&edate=20120501&rec=7047">...</a><br><font size="-1">Jacquelyne CANTLE MEYRICK / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7047" class="commentpermalink">Endocrinology7047</a> / <span class="date">07 August 2012</span> /
<span class="time">16:22:29 o'clock CEST</span>
</font></div><div>What are the potential and more concrete consequences ? Thanks in advance for any contribution on that.<wbr> </div><!-- Comment details --><font size="-1">gug93330 / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7050" class="commentpermalink">Endocrinology7050</a> / <span class="date">08 August 2012</span> /
<span class="time">09:51:33 o'clock CEST</span>
</font><br><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Endocrinology7052c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;"><DIV style="widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; font: 13px arial, sans-serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #222222; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">Further thoughts from Roz on the relevance of this development are outlined below:-</DIV> </div><div style="margin-bottom: 10px;"><DIV style="widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; font: 13px arial, sans-serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #222222; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">It will be of interest for us to monitor existing national Sandostatin &amp; Sandostatin LAR  claims that are retained and lost (if any) through the harmonisation process</DIV> </div><div style="margin-bottom: 10px;"><DIV style="widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; font: 13px arial, sans-serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #222222; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">
<UL><LI style="margin-left: 15px;">The  Sandostatin &amp; Sandostatin LAR SmPCs that would emerge from the harmonization process would be expected to form the basis of the SmPCs for the generics/<wbr>hybrids to follow for octreotide now it is off patent.<wbr> 
</LI>
<LI style="margin-left: 15px;">While the balance of Sandostatin claims retained or lost will depend primarily on the strength of Novartis' data, it's also likely to be a good indicator for the level of defence that could be needed for the Somatuline claims if/<wbr> when a harmonization is triggered for our own product(s)
</LI>
</UL>
</DIV> </div><div style="margin-bottom: 10px;"><DIV style="widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; font: 13px arial, sans-serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #222222; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">It also suggests that wew should consider the timings one might anticipate for such a process to be triggered for Somatuline?  Potentially, this could occur:-</DIV> </div><div><DIV style="widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; font: 13px arial, sans-serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #222222; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">
<UL><LI style="margin-left: 15px;">due to a trigger from a national agency, in light of Sandostatin harmonization, if there's a high level of SSA class claims being made for Somatuline
</LI>
<LI style="margin-left: 15px;">following Somatuline patent expiry if there's the pressure of lanreotide generic and /<wbr>or hybrids
</LI>
<LI style="margin-left: 15px;">a voluntary trigger on the part of Ipsen if, when bringing forward a new lanreotide product, it's considered advantageous for a new product in the range to be approved through a pan-European procedure such as the decentralised procedure (DCP)
</LI>
</UL>
</DIV> </div><font size="-1">Jacquelyne CANTLE MEYRICK / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7052" class="commentpermalink">Endocrinology7052</a> / <span class="date">08 August 2012</span> /
<span class="time">17:38:18 o'clock CEST</span>
</font></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120831&edate=20120501&rec=7050">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7047">View thread  Endocrinology7047: Inclusion of Octreotide In SmPC Harmonisation In 2012</a>]]></content:encoded><dc:date>2012-08-08T09:51:33+02:00</dc:date><dc:creator>gug93330</dc:creator></item><item>
<title>Exelixis Q2 Earnings - Key Takeaways [:Oncology:dis:Prostate, :Oncology:dis:Bladder, :PharmaWorld:sub:Finance, headline]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7048</link>
<description>Exelixis Q2 Earnings - Key Takeaways [:Oncology:dis:Prostate, :Oncology:dis:Bladder, :PharmaWorld:sub:Finance, headline]</description><category>dis:Prostate</category><category>dis:Bladder</category><category>sub:Finance</category><category>headline</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7048</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120831&edate=20120501&rec=7048">Exelixis Q2 Earnings - Key Takeaways</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=headline"><font color="#e95e0b">:Endocrinology:headline</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=dis%3aBladder"><font color="#e95e0b">:Oncology:dis:Bladder</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=sub%3aFinance"><font color="#e95e0b">:PharmaWorld:sub:Finance</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7048">Endocrinology7048</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 07 August 2012 | 17:57</font><br><br><div style="margin-bottom: 10px;">Comment: Having received a fast-track designation from the FDA for cabozantinib in medullary thyroid cancer, managment noted its intention to file in Europe for the same indication in Q4 2012.<wbr> The company refused to elaborate on its commerialisation strategy for MTC at this juncture, presumably because of restrictions associated with yesterday's announcement of a proposed public offering of 20 million shares of common stock and $225m of convertible senior subordinated notes due in 2019.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Updated on CRPC Programme</STRONG> </div><div style="margin-bottom: 10px;">Exelixis's goal is to have about 280 sites for COMET-1 and about 50 sites for COMET-2.<wbr> COMET-1 is designed to enroll 960 patients with CRPC, while COMET-2 is designed to enroll 246 patients.<wbr> Both trials will enroll men, who have previously been treated with docetaxel and abiraterone and/<wbr>or enzalutamide in any sequence.<wbr> Expediting the initiation of clinical sites and enrollment of patients in the COMET study was claimed to be "a tough priority" for Exelixis, particularly as it is in addition to completing the NDA process in MTC and working on various combination studies in CRPC covering usage with docetaxel, but also one with abiraterone trials that will eventually pave the way forward into earlier CRPC treatment settings.<wbr> Exelixis confirmed that it expects to have the first set of top line data in the first half of 2014.<wbr> </div><div style="margin-bottom: 10px;">Alongside its comments on CRPC, Exelixis also expanded on the nature of its CRADA agreed with the NCI covering 13 trials.<wbr> </div><div style="margin-bottom: 10px;">The first trials it will prioritize are six randomized Phase II trials in the settings of first line renal cell cancer, second line hepatocellular cancer, platinum resistant/<wbr>refractory ovarian cancer, ocular melanoma, and two trials in non-small cell lung cancer.<wbr> </div><div style="margin-bottom: 10px;">Secondly, it will focus on other indications for further studies including single-arm Phase II trials in endometrial cancer, bladder cancer, sarcoma and differentiated thyroid cancer.<wbr> </div><div style="margin-bottom: 10px;">Thidly other trials, including Phase I combination trials in additional tumor types including CRPC in combination with docetaxel, melanoma in combination with Vemurafenib as well as a trial to evaluate cabozantinib in pediatric malignancies.<wbr> </div><div style="margin-bottom: 10px;">It was noted that for many of the randomized Phase II trials, detailed protocols have been developed by investigators and are being reviewed by CTEP and Exelixis.<wbr> The expectation is that a most of these protocols will be completed soon and start the IRB approval process during the next several months paving the way for initiation later this year.<wbr> In fact, CTEP has recently submitted the IND for the first study.<wbr> </div><div style="margin-bottom: 10px;">Then with regard to Exelixis own IST program it now has 10 ongoing ISTs including the more recently announced two additional ISTs in non-small cell lung cancer and multiple myeloma.<wbr> </div><div style="margin-bottom: 10px;">It claims that the IST program allows the company to evaluate cabozantinib in a variety of new indications quickly,a process which may faciliate new indications or combination regimens </div><div style="margin-bottom: 10px;"><STRONG>Data Presentations In The Second Half</STRONG> </div><div style="margin-bottom: 10px;">Data will be presented at both ESMO in September and at the European Thyroid Association Annual Conference and the American Thyroid Association Meeting, both of which also take place in September 2012.<wbr> The planned presentations include further data from our ongoing Phase II trial in CRPC, as well as additional analysis from the EXAM in MTC.<wbr> </div><div>Source: <A href="http://www.exelixis.com">www.<wbr>exelixis.<wbr>com</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120831&edate=20120501&rec=7048">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-08-07T17:57:53+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>Inclusion of Octreotide In SmPC Harmonisation In 2012 [class:SomatostatinAnalogue, prod:Octreotide, sub:Hybrids, sub:Generics, comp:Novartis, :PharmaWorld:sub:Regulatory, headline]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7047</link>
<description>Inclusion of Octreotide In SmPC Harmonisation In 2012 [class:SomatostatinAnalogue, prod:Octreotide, sub:Hybrids, sub:Generics, comp:Novartis, :PharmaWorld:sub:Regulatory, headline]</description><comments>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7047</comments><category>class:SomatostatinAnalogue</category><category>prod:Octreotide</category><category>sub:Hybrids</category><category>sub:Generics</category><category>comp:Novartis</category><category>sub:Regulatory</category><category>headline</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7047</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120831&edate=20120501&rec=7047">Inclusion of Octreotide In SmPC Harmonisation In 2012</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=class%3aSomatostatinAnalogue"><font color="#e95e0b">:Endocrinology:class:SomatostatinAnalogue</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=comp%3aNovartis"><font color="#e95e0b">:Endocrinology:comp:Novartis</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=headline"><font color="#e95e0b">:Endocrinology:headline</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=prod%3aOctreotide"><font color="#e95e0b">:Endocrinology:prod:Octreotide</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=sub%3aGenerics"><font color="#e95e0b">:Endocrinology:sub:Generics</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=sub%3aHybrids"><font color="#e95e0b">:Endocrinology:sub:Hybrids</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=sub%3aRegulatory"><font color="#e95e0b">:PharmaWorld:sub:Regulatory</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7047">Endocrinology7047</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 07 August 2012 | 16:22</font><br><br><div style="margin-bottom: 10px;">Comment: The latest list agreed by the CMDh and published in July includes 
Sandostatin &amp; Sandostatin LAR.<wbr> Its selection at this time is most likely 
linked to the product going off patent and the potential approval of 
generics/<wbr>hybrids in due course.<wbr> </div><div style="margin-bottom: 10px;">The products selected for review (6 in total) takes into account 
criteria agreed by the CMDh mainly with regards to signficant differences in 
core parts of their SmPCs.<wbr> </div><div style="margin-bottom: 10px;">Thanks to Ros Eijgenhuijsen for drawing this to our attention.<wbr> </div><div><A href="http://www.hma.eu/fileadmin/dateien/Human_Medicines/CMD_h_/CMD_subgroups_working_groups/SPC_Harmonisation/2012_Draft_List_SmPC_Harmonisation.pdf" style="WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; FONT: 13px arial, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; LETTER-SPACING: normal; COLOR: rgb(17,85,204); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px" target="_blank">http:/<wbr>/<wbr>www.<wbr>hma.<wbr>eu/<wbr>fileadmin/<wbr><WBR>dateien/<wbr>Human_Medicines/<wbr>CMD_h_</WBR><WBR>/<wbr>CMD_subgroups_working_groups/<wbr></WBR><WBR>SPC_Harmonisation/<wbr>2012_Draft_</WBR><WBR>List_SmPC_Harmonisation.<wbr>pdf</WBR></A> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Endocrinology7050c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div>What are the potential and more concrete consequences ? Thanks in advance for any contribution on that.<wbr> </div><font size="-1">gug93330 / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7050" class="commentpermalink">Endocrinology7050</a> / <span class="date">08 August 2012</span> /
<span class="time">09:51:33 o'clock CEST</span>
</font><span style="font-weight: bold; font-style: italic;"></span><a name="Endocrinology7052c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;"><DIV style="widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; font: 13px arial, sans-serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #222222; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">Further thoughts from Roz on the relevance of this development are outlined below:-</DIV> </div><div style="margin-bottom: 10px;"><DIV style="widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; font: 13px arial, sans-serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #222222; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">It will be of interest for us to monitor existing national Sandostatin &amp; Sandostatin LAR  claims that are retained and lost (if any) through the harmonisation process</DIV> </div><div style="margin-bottom: 10px;"><DIV style="widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; font: 13px arial, sans-serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #222222; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">
<UL><LI style="margin-left: 15px;">The  Sandostatin &amp; Sandostatin LAR SmPCs that would emerge from the harmonization process would be expected to form the basis of the SmPCs for the generics/<wbr>hybrids to follow for octreotide now it is off patent.<wbr> 
</LI>
<LI style="margin-left: 15px;">While the balance of Sandostatin claims retained or lost will depend primarily on the strength of Novartis' data, it's also likely to be a good indicator for the level of defence that could be needed for the Somatuline claims if/<wbr> when a harmonization is triggered for our own product(s)
</LI>
</UL>
</DIV> </div><div style="margin-bottom: 10px;"><DIV style="widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; font: 13px arial, sans-serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #222222; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">It also suggests that wew should consider the timings one might anticipate for such a process to be triggered for Somatuline?  Potentially, this could occur:-</DIV> </div><div><DIV style="widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; font: 13px arial, sans-serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #222222; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">
<UL><LI style="margin-left: 15px;">due to a trigger from a national agency, in light of Sandostatin harmonization, if there's a high level of SSA class claims being made for Somatuline
</LI>
<LI style="margin-left: 15px;">following Somatuline patent expiry if there's the pressure of lanreotide generic and /<wbr>or hybrids
</LI>
<LI style="margin-left: 15px;">a voluntary trigger on the part of Ipsen if, when bringing forward a new lanreotide product, it's considered advantageous for a new product in the range to be approved through a pan-European procedure such as the decentralised procedure (DCP)
</LI>
</UL>
</DIV> </div><font size="-1">Jacquelyne CANTLE MEYRICK / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7052" class="commentpermalink">Endocrinology7052</a> / <span class="date">08 August 2012</span> /
<span class="time">17:38:18 o'clock CEST</span>
</font></div></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120831&edate=20120501&rec=7047">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-08-07T16:22:29+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>Recordati Buys Poland's Farma-Projek [dis:Prostate, :Neurology:dis:nOAB, :PharmaWorld:sub:Acquisition, :PharmaWorld:mkt:Russia, :PharmaWorld:mkt:Intercontinental]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology8413</link>
<description>Recordati Buys Poland's Farma-Projek [dis:Prostate, :Neurology:dis:nOAB, :PharmaWorld:sub:Acquisition, :PharmaWorld:mkt:Russia, :PharmaWorld:mkt:Intercontinental]</description><category>dis:Prostate</category><category>dis:nOAB</category><category>sub:Acquisition</category><category>mkt:Russia</category><category>mkt:Intercontinental</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology8413</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8413">Recordati Buys Poland's Farma-Projek</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=dis%3anOAB"><font color="#e95e0b">:Neurology:dis:nOAB</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=mkt%3aIntercontinental"><font color="#e95e0b">:PharmaWorld:mkt:Intercontinental</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=mkt%3aRussia"><font color="#e95e0b">:PharmaWorld:mkt:Russia</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=sub%3aAcquisition"><font color="#e95e0b">:PharmaWorld:sub:Acquisition</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8413">Oncology8413</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 06 August 2012 | 15:15</font><br><br><div style="margin-bottom: 10px;">Comment: Recordati is to acquire Poland's Farma-Projekt, as part of its plans to expand in central and eastern Europe.<wbr> The Polish company mainly markets cardiovascular and urology treatments, both key areas of therapeutic focus for Recordati from a commercialisation and development perspective.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Deal Terms</STRONG> </div><div><DIV class="ArticleContent">
<P>The Italian drugmaker is paying 71.<wbr>0 million zloty (about 17.<wbr>3 million euros) to get hold of the Krakow-headquartered company which has been in operation since 2003.<wbr> Farma-Projekt employs around 135 staff, 84 of which are in sales and marketing.<wbr> Turnover last year reached about 47 million zloty.<wbr></P>
<P>Chief executive Giovanni Recordati said the acquisition of Farma-Projekt is "another step forward in our strategy to increase our business in the central and eastern European markets which are growing at interesting rates&rdquo;.<wbr></P>
<P>He noted that the Polish pharmaceutical market is the second largest in the area and in the last five years has been growing at an average annual rate of 6.<wbr>8%.<wbr> "In particular, the market for self-medication products has grown at an average rate of 11.<wbr>2% per year", he concluded.<wbr></P>
<P>Recordati is already present in Poland, having set up a subsidiary in 2011.<wbr> The transaction is set to close before the end of the year, subject to conditions.<wbr></P>
<P><STRONG>Recordati's Urology Presence</STRONG></P>
<P>The company's urology focus is commercially concentrated on the BPH market, its key product being Urorec (silodosin).<wbr></P>
<P><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8413/2/ScreenCapture2.jpg?user-agent=rss"></P>
<P>From a development standpoint, however, 50% of its development candidates have a urology focus, the most advanced being the phIII in-licensed BPH product Nymox (REC0482).<wbr> <STRONG>Interestingly, the group has 3 overactive bladder/<wbr>incontinence programmes including one focusing on spinal cord patients.<wbr></STRONG></P>
<P><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8413/1/ScreenCapture1.jpg?user-agent=rss"></P>
<P>News of the acquisition comes a week after Recordati posted revenues of 419.<wbr>9 million euros for the first six months of 2012, a rise of 4.<wbr>7%.<wbr> Net income edged up 1.<wbr>5% to 63.<wbr>3 million euros, helped by strong performances in Turkey and Russia.<wbr></P>
<P>source: <A href="http://www.recordati.com">www.<wbr>recordati.<wbr>com</A></P>
</DIV> </div><!-- Comment details --><a name="oncology8413attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8413/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(173,6 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8413/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(184 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8413">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-08-06T15:15:20+02:00</dc:date><dc:creator>jac89886</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8413/1/ScreenCapture1.jpg" length="177763" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8413/2/ScreenCapture2.jpg" length="188393" type="image/jpeg"/></item><item>
<title>Deal Making In Oligonucleotide Therapeutics Hots Up [sub:Partnership]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10001</link>
<description>Deal Making In Oligonucleotide Therapeutics Hots Up [sub:Partnership]</description><category>sub:Partnership</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10001</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120831&edate=20120501&rec=10001">Deal Making In Oligonucleotide Therapeutics Hots Up</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=sub%3aPartnership"><font color="#e95e0b">:PharmaWorld:sub:Partnership</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10001">PharmaWorld10001</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 06 August 2012 | 14:42</font><br><br><div style="margin-bottom: 10px;">Comment: The eveolving interest in oligonucleotide chemistry continues with 
two more deals in this space, the first between Marina Biotech and 
Novartis the other.<wbr> between Baylor College of Medicine and the private 
biotechnology company Gradalis Inc </div><div style="margin-bottom: 10px;"><STRONG>Marina's Agreement </STRONG> </div><div style="margin-bottom: 10px;">The agreement with Novartis covers its conformationally restricted nucleotide 
technology for the development of both single and double-stranded 
oligonucleotides.<wbr> Marina will receive $1m in upfront fees for non-exclusive 
use.<wbr> </div><div style="margin-bottom: 10px;">Marina's current pirplien includes a clinical programm in Familial 
Adenomatous Polyposis (a precancerous syndrome) and two preclinical programms in 
bladder cancer and malignant ascites, the former part of an exclusive 
development and commercialisation agreement with Debiopharm.<wbr> The goupr also has 
agreements in place with Mirna therapeutics and Monsanto biotech.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Baylor College (BCM) Agreement</STRONG> </div><div><FONT size="3"><FONT face="Calibri">As part of the collaboration, Gradalis will share with 
the scientists at BCM the company’s novel bi-shRNA constructs that shut down 
expression of specific proteins of therapeutic interest.<wbr> Gradalis will also 
provide BCM researchers access to its portfolio of proprietary research-enabling 
technologies including SuperClean DNA, reversible masking, liposomal delivery 
and liposomal targeting.<wbr> Similarly, bi-shRNA constructs showing promise in 
pre-clinical testing at BCM will be moved forward into clinical development by 
Gradalis.<wbr></FONT></FONT> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120831&edate=20120501&rec=10001">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-08-06T14:42:55+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>Astellas Re-organises Its R&amp;D Activities [dis:Prostate, headline, comp:Astellas]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology8412</link>
<description>Astellas Re-organises Its R&amp;D Activities [dis:Prostate, headline, comp:Astellas]</description><category>dis:Prostate</category><category>headline</category><category>comp:Astellas</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology8412</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8412">Astellas Re-organises Its R&D Activities</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=comp%3aAstellas"><font color="#e95e0b">:Oncology:comp:Astellas</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=headline"><font color="#e95e0b">:Oncology:headline</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8412">Oncology8412</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 06 August 2012 | 12:58</font><br><br><div style="margin-bottom: 10px;">Comment: Astellas has announced the closure of its North Carolina Urology 
Research Facility and the transfer of all activities back to Japan.<wbr> </div><div style="margin-bottom: 10px;">Astellas acquired the facilities in 2007 from Dynogen Pharmaceuticals and 
since then the unit has been involved in the evaluating the clinical potential 
of all urological development candidates especially in the area of lower urinary 
tract disorders.<wbr> </div><div style="margin-bottom: 10px;">Whilst urology continues to be one of Astellas's five focus therapeutic 
areas, it has taken the decision to transfer all functions to Astellas's Tsukuba 
Research Centre in Japan, citing the the move as a means of strengthening the 
company's commitment to optimising its R&amp;D resource allocation.<wbr> </div><div>Source: <a href="http://www.astellas.com" class="defaultlink" title="www.astellas.com">astellas.com</a> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8412">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-08-06T12:58:34+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>OncoGenex - Update On Key CRPC Trials [dis:Prostate, prod:Zytiga, headline, :PharmaWorld:mkt:Russia, :PharmaWorld:mkt:Intercontinental, :PharmaWorld:mkt:Australia]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology8411</link>
<description>OncoGenex - Update On Key CRPC Trials [dis:Prostate, prod:Zytiga, headline, :PharmaWorld:mkt:Russia, :PharmaWorld:mkt:Intercontinental, :PharmaWorld:mkt:Australia]</description><category>dis:Prostate</category><category>prod:Zytiga</category><category>headline</category><category>mkt:Russia</category><category>mkt:Intercontinental</category><category>mkt:Australia</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology8411</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8411">OncoGenex - Update On Key CRPC Trials</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=headline"><font color="#e95e0b">:Oncology:headline</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=prod%3aZytiga"><font color="#e95e0b">:Oncology:prod:Zytiga</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=mkt%3aAustralia"><font color="#e95e0b">:PharmaWorld:mkt:Australia</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=mkt%3aIntercontinental"><font color="#e95e0b">:PharmaWorld:mkt:Intercontinental</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=mkt%3aRussia"><font color="#e95e0b">:PharmaWorld:mkt:Russia</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8411">Oncology8411</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 06 August 2012 | 12:44</font><br><br><div style="margin-bottom: 10px;">Comment: During its Q2 earnings call OncoGenex noted that the SYNERGY CRPC 
PhIII trial is progressing well and should complete accrual by the end of the 
year (n=1000).<wbr> It is about to commence to other PhIII studies with the drug one 
in combination with Jevtana in CRPC and the other in NSCLC.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Status of the Custirsen Programme</STRONG> </div><div style="margin-bottom: 10px;">SYNERGY is the primary registration Phase III study for custirsen in 
combination with docetaxel and is evaluating a survival benefit for patients in 
the first-line chemotherapy setting.<wbr> The study is being conducted in 
collaboration with OncoGenex's partner TEVA.<wbr> </div><div style="margin-bottom: 10px;">Meanwhile, OncoGenex expects to <STRONG>begin patient enrolment to the 
AFFINITY trial in the coming weeks</STRONG>.<wbr> This Phase III study will 
be evaluating the overall survival benefit of custirsen when combined 
with Jevtana, a second-line chemotherapy for patients with CRPC.<wbr> This study 
aims to enroll approximately 630 patients throughout North America, Europe, 
Russia and Australia.<wbr> </div><div style="margin-bottom: 10px;">The Phase III study is based on an estimated median survival, for patients in 
the control arm, of 14 months and to detect a hazard ratio of 0.<wbr>75 with 85% 
power or an approximate 25% increase in survival time.<wbr> The critical hazard ratio 
has been calculated to be approximately 0.<wbr>83.<wbr> The AFFINITY study will evaluate 
the benefit of custirsen in combination with Jevtana, which is relevant whether 
Jevtana remains a second-line chemotherapy for CRPC or is repositioned as 
first-line chemotherapy based on future results of ongoing studies (Sanofi is 
currently evaluating Jevtana in the frontline setting).<wbr> </div><div style="margin-bottom: 10px;">OncoGenex does not believe there will be an automatic 
migration to Jevtana if its frontline trial is successful, but by 
generating data with Jevtana showing a survival benefit in the second-line 
setting, and having also showed a benefit with custirsen plus docetaxel in 
the front-line setting, it should be able to achieve a label claim that 
would be suggestive of advanced prostate cancer regardless of the taxane being 
utilized.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Status of the OGX-427 Programme</STRONG> </div><div style="margin-bottom: 10px;">OGX-427 is designed to reduce levels of heat shock protein 27 of Hsp27.<wbr> 
Overexpression of Hsp27 correlates to increased stage and grade in many types of 
cancer.<wbr> It is also believed to be an important factor leading to the development 
of treatment resistance, and is associated with negative clinical outcomes in 
various cancers.<wbr> Pre-clinical studies have indicated that inhibition of Hsp27 
increases tumor cell death rates and delays tumor growth.<wbr> </div><div style="margin-bottom: 10px;">Preliminary data from an investigator-sponsored Phase II clinical trial of 
OGX-427 in chemotherapy-naïve patients with metastatic CRPC were presented at 
ASCO this year.<wbr> </div><div style="margin-bottom: 10px;">The results showed a higher number of patients without disease progression at 
12 weeks and greater declines in prostate-specific antigen and circulating tumor 
cells with OGX-427 plus prednisone treatment compared to prednisone alone.<wbr> This 
study has recently completed enrolment at 74 patients so updated 
results will be presented as soon as they become available.<wbr> </div><div style="margin-bottom: 10px;">In addition to this trial an investigator-sponsored randomized 
<STRONG>Phase II study  is evaluating OGX-427 in combination with 
Zytiga.<wbr></STRONG> This study is expected to initiate in the second half of 
2012 but the patient sub-set to be recruited has yet to be announced.<wbr> </div><div style="margin-bottom: 10px;">In addition to its development activities in prostate 
cancer, OncoGenex is continuing to enroll patients in 
its randomized Phase II clinical trial of <STRONG>OGX-427 in patients with 
metastatic bladder cancer.<wbr></STRONG> This trial aims to enroll approximately 180 
patients throughout North America and Europe and will evaluate the overall 
survival benefit of OGX-427 in combination with gemcitabine and cisplatin.<wbr> </div><div>Additional Phase II investigator-sponsored studies evaluating OGX-427 in 
other malignancies are under development.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8411">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-08-06T12:44:15+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>Leading New Renal Cancer Therapy Encounters Unexpected FDA Concerns [news, comp:Astellas]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology8409</link>
<description>Leading New Renal Cancer Therapy Encounters Unexpected FDA Concerns [news, comp:Astellas]</description><category>news</category><category>comp:Astellas</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology8409</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8409">Leading New Renal Cancer Therapy Encounters Unexpected FDA Concerns</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=comp%3aAstellas"><font color="#e95e0b">:Oncology:comp:Astellas</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=news"><font color="#e95e0b">:Oncology:news</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8409">Oncology8409</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 03 August 2012 | 18:16</font><br><br><div style="margin-bottom: 10px;"><SPAN style="widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 13px arial, sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #222222; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">Comment: Aveo stock fell by 27% on Thursday after it noted in its Q2 earnings call that the FDA has expressed concerns about the overall survival trend in the Phase III TIVO-1 trial comparing Aveo's tivozanib to sorafenib in renal cell carcinoma.<wbr> Tivozanib is partnered with Astellas.<wbr></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 13px arial, sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #222222; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">Aveo, which hopes to submit an NDA this quarter, said it is conducting additional OS analyses to address the agency's concerns that could delay the submission into next quarter.<wbr> </SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 13px arial, sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #222222; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">Aveo said the estimated one-year survival rate was 77% in the tivozanib arm compared to 81% in the sorafenib arm.<wbr> About 53% of patients in the sorafenib arm have received subsequent therapy, including tivozanib, while about 17% of patients in the tivozanib arm have received subsequent therapy.<wbr> The OS data are not yet mature.<wbr> </SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 13px arial, sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #222222; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">Aveo said it will conduct an analysis comparing tivozanib's estimated one-year survival rate to historical rates seen with approved agents, as well as an analysis of differences in utilization of subsequent therapies between the trial's arms </SPAN> </div><div style="margin-bottom: 10px;"><P align="left">In June 2012, AVEO and Astellas announced plans to initiate a new clinical study, TAURUS (TivozAnib Use veRsUs Sutent in advanced RCC: Patient Preference), to establish additional data regarding tivozanib when used as first-line therapy in patients with advanced RCC.<wbr> The TAURUS study will enroll patients at sites throughout the United States and Western Europe, and the primary objective of the study is designed as a superiority comparison of tivozanib versus sunitinib with respect to patient preference.<wbr> Secondary objectives are to evaluate the incidence of treatment emergent Grade 3/<wbr>4 adverse events and serious adverse events; frequency of dose modifications; and quality of life in patients treated with tivozanib versus sunitinib.<wbr></P> </div><div><P align="left">Source: <A href="http://www.aveooncology.com">www.<wbr>aveooncology.<wbr>com</A></P> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8409">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-08-03T18:16:55+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>UK Drug Pricing Negotiations to Start in September 2012 [mkt:UK, sub:Pricing]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10000</link>
<description>UK Drug Pricing Negotiations to Start in September 2012 [mkt:UK, sub:Pricing]</description><comments>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10000</comments><category>mkt:UK</category><category>sub:Pricing</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10000</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120831&edate=20120501&rec=10000">UK Drug Pricing Negotiations to Start in September 2012</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=mkt%3aUK"><font color="#e95e0b">:PharmaWorld:mkt:UK</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=sub%3aPricing"><font color="#e95e0b">:PharmaWorld:sub:Pricing</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10000">PharmaWorld10000</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/20">Alison Attard</a> | 03 August 2012 | 14:13</font><br><br><div style="margin-bottom: 10px;">Comment: The UK&rsquo;s Department of Health and the Association of the British Pharmaceutical Industry have outlined details of their forthcoming negotiations on the implementation of a value-based pricing system and in a joint statement set out some of the key points to be addressed.<wbr> </div><div style="margin-bottom: 10px;">These include deciding how VBP will work alongside a revised version of the existing Pharmaceutical Price Regulation Scheme, which is due to expire at the end of 2013.<wbr> </div><div style="margin-bottom: 10px;">It is currently proposed that after 2013 a VBP system, incorporating a broader assessment of a product&rsquo;s worth, will be used to determine prices for medicines that are newly launched onto the UK market, while an updated version of the PPRS will be used to decide the price of branded drugs already available.<wbr> </div><div style="margin-bottom: 10px;">The  ABPI has made several criticisms of the introduction of VBP during the past year, raising concerns it will not reward the <SPAN style="color: #333333;"><A href="http://www.pmlive.com/pharma_news/uk_drug_pricing_reward_small_steps_innovation_abpi_406872" title="UK drug pricing must reward 'small steps' in innovation says ABPI"><SPAN style="color: #333333;">incremental nature of innovation</SPAN></A> nor improve <A href="http://www.pmlive.com/pharma_news/interview_deepak_khanna,_abpi_411832" title="Interview: Deepak Khanna, ABPI"><SPAN style="color: #333333;">uptake of new medicines</SPAN></A>.<wbr></SPAN> </div><div><FONT color="#333333">Source: <a href="http://www.abpi.org.uk/media-centre/newsreleases/2012/Pages/030812.aspx" class="defaultlink" title="http://www.abpi.org.uk/media-centre/newsreleases/2012/Pages/030812.aspx">abpi.org.uk/<wbr>media&hellip;</a></FONT> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="PharmaWorld10014c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div><SPAN style="widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 13px arial, sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #222222; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">The ABPI has announced the members of a team that will negotiate with the U.<wbr>K.<wbr>'s Department of Health for the country's proposed value-based pricing system.<wbr> John Kearney, U.<wbr>K.<wbr> and Ireland general manager at </SPAN>Amgen Inc<SPAN style="widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 13px arial, sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #222222; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;"> will chair the group, which will include Peter Butterfield, executive director at Alliance Pharma</SPAN><SPAN style="widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 13px arial, sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #222222; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">; Erik van Snippenberg, general manager and SVP for the U.<wbr>K.<wbr> at </SPAN>GlaxoSmithKline<SPAN style="widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 13px arial, sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #222222; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">; Jon Emms, managing director for the U.<wbr>K.<wbr> at Pfizer</SPAN><SPAN style="widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 13px arial, sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #222222; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">; and Matthew Speers, managing director, British and Irish Isles at </SPAN>UCB Group<SPAN style="widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 13px arial, sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #222222; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">.<wbr> </SPAN> </div><font size="-1">Jacquelyne CANTLE MEYRICK / <a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10014" class="commentpermalink">PharmaWorld10014</a> / <span class="date">20 August 2012</span> /
<span class="time">12:34:27 o'clock CEST</span>
</font></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120831&edate=20120501&rec=10000">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-08-03T14:13:16+02:00</dc:date><dc:creator>ala97794</dc:creator></item><item>
<title>Xeomin Cosmetic Launched in Canada [Alert, class:BotulinumToxins, comp:Merz, sub:Aesthetics, prod:Xeomin, :PharmaWorld:mkt:Canada]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology6520</link>
<description>Xeomin Cosmetic Launched in Canada [Alert, class:BotulinumToxins, comp:Merz, sub:Aesthetics, prod:Xeomin, :PharmaWorld:mkt:Canada]</description><category>Alert</category><category>class:BotulinumToxins</category><category>comp:Merz</category><category>sub:Aesthetics</category><category>prod:Xeomin</category><category>mkt:Canada</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology6520</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120831&edate=20120501&rec=6520">Xeomin Cosmetic Launched in Canada</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=Alert"><font color="#e95e0b">:Neurology:Alert</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=class%3aBotulinumToxins"><font color="#e95e0b">:Neurology:class:BotulinumToxins</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=comp%3aMerz"><font color="#e95e0b">:Neurology:comp:Merz</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=prod%3aXeomin"><font color="#e95e0b">:Neurology:prod:Xeomin</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=sub%3aAesthetics"><font color="#e95e0b">:Neurology:sub:Aesthetics</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=mkt%3aCanada"><font color="#e95e0b">:PharmaWorld:mkt:Canada</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology6520">Neurology6520</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 03 August 2012 | 11:48</font><br><br><div style="margin-bottom: 10px;">Comment: Merz announced yesterday the commercial launch of Xeomin Cosmetic in 
Canada following its approval by the Canadian authorities in April 2012 for the 
temporary improvement in the appearance of moderate-to-severe glabellar lines in 
adult patients.<wbr> </div><div style="margin-bottom: 10px;">The product was approved based on results from 3 pivotal trials involving 803 
healthy adults.<wbr> These demonstrated that Xeomin significantly improved frown 
lines compared to placebo over 30 days after first administration.<wbr> </div><div style="margin-bottom: 10px;">Key messages about the product noted in the press release were:- </div><div style="margin-bottom: 10px;"><UL><LI>Only toxin not requiring refrigeration prior to reconstitution which is 
  packaaged and shipped using 100% recyclable packaging materials.<wbr></LI>
<LI>Innovative and effective toxin free from complexing proteins that 
  represents an ecofriendly choice of therapy</LI>
</UL> </div><div>
source: <A href="http://www.merzcanada.com/">www.<wbr>merzcanada.<wbr>com</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120831&edate=20120501&rec=6520">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-08-03T11:48:43+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>Auto Injector Producer SHL Hires Over 600 New Employees [sub:DrugDelivery, sub:People]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld9999</link>
<description>Auto Injector Producer SHL Hires Over 600 New Employees [sub:DrugDelivery, sub:People]</description><category>sub:DrugDelivery</category><category>sub:People</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld9999</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120831&edate=20120501&rec=9999">Auto Injector Producer SHL Hires Over 600 New Employees</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=sub%3aDrugDelivery"><font color="#e95e0b">:PharmaWorld:sub:DrugDelivery</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=sub%3aPeople"><font color="#e95e0b">:PharmaWorld:sub:People</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld9999">PharmaWorld9999</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 02 August 2012 | 17:32</font><br><br><div style="margin-bottom: 10px;">Comment: In response to increased customer orders and the signing of 
long-term contracts, SHL has hired more than 600 new employees over a 14 month 
period.<wbr> </div><div style="margin-bottom: 10px;">SHL, the world's largest privately owned designer, developer and manufacturer 
of drug delivery devices, now has over 2,000 employees worldwide with the 
majority of new staff located at the manufacturing facilities in Taiwan.<wbr> </div><div style="margin-bottom: 10px;">Additional employees have also been hired at the company's final assembly 
facility in Florida, US (SHL Pharma) and the company's main design centre in 
Stockholm, Sweden (SHL Group AB).<wbr> </div><div style="margin-bottom: 10px;">Steven Kaufman, SHL marketing director noted that market research has shown 
that there is little chance of a slowdown in the launch of new biologics and 
this in turn has been and is likely to continue to be a significant 
driver of the increased use and acceptance of devices such as auto injectors and 
pen injectors.<wbr> , </div><div style="margin-bottom: 10px;">SHL will continue to focus on the expansion of all its manufacturing 
facilities in Taiwan, especially its new campus near the international airport.<wbr> 
In addition, the company will continue to strengthen the range of services it 
offers to biopharmaceutical companies by also offering final assembly, labelling 
and packaging of auto injectors at SHL Pharma in the US.<wbr> </div><div>Source: <a href="http://www.shlpharma.com" class="defaultlink" title="www.shlpharma.com">shlpharma.com</a> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120831&edate=20120501&rec=9999">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-08-02T17:32:37+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>Cameron's World-Leading Initiative To Spur Medical Breakthroughs [sub:ClinicalTrial, sub:Finance, sub:Regulatory]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld9998</link>
<description>Cameron's World-Leading Initiative To Spur Medical Breakthroughs [sub:ClinicalTrial, sub:Finance, sub:Regulatory]</description><category>sub:ClinicalTrial</category><category>sub:Finance</category><category>sub:Regulatory</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld9998</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120831&edate=20120501&rec=9998">Cameron's World-Leading Initiative To Spur Medical Breakthroughs</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=sub%3aClinicalTrial"><font color="#e95e0b">:PharmaWorld:sub:ClinicalTrial</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=sub%3aFinance"><font color="#e95e0b">:PharmaWorld:sub:Finance</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=sub%3aRegulatory"><font color="#e95e0b">:PharmaWorld:sub:Regulatory</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld9998">PharmaWorld9998</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 02 August 2012 | 17:01</font><br><br><div style="margin-bottom: 10px;">Comment: Addressing an inaugural Global Health Policy Summit, David Cameron, 
UK Priminister has announced that the government is to consult on changing the 
constitution of the NHS to make patient data available for research as the 
"default setting.<wbr>" </div><div style="margin-bottom: 10px;">According to the FT "This will make anonymised data available to scientists 
and researchers on a scale never seen before making the UK the best place in the 
world to carry out cutting edge research.<wbr>" </div><div style="margin-bottom: 10px;">The emphasis will be on access to real-time data and on creating a climate 
that backs investment in innovation and the life sciences.<wbr> He claimed that 
current drug development programmes ate too long and not good for the industry, 
taxpayers or patients and that in order to address the problem the government 
was going to consult on an " early access scheme under which patients in the 
advanced stage of a disease for whom there are no other treatments available 
would be able to use innovative medicines much earlier in their development.<wbr> </div><div style="margin-bottom: 10px;">In essesnce the NHS will be given the right to purchase drugs before they 
have market authorisation.<wbr> </div><div>source: <A href="http://www.ft.com">www.<wbr>ft.<wbr>com</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120831&edate=20120501&rec=9998">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-08-02T17:01:53+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>Allergan 1H Figures - Key Takeaways [Alert, comp:Allergan, dis:iOAB, dis:nOAB, dis:Spasticity, prod:Botox, :PharmaWorld:mkt:Russia, :PharmaWorld:mkt:Intercontinental, comp:Merz, prod:Xeomin]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology6519</link>
<description>Allergan 1H Figures - Key Takeaways [Alert, comp:Allergan, dis:iOAB, dis:nOAB, dis:Spasticity, prod:Botox, :PharmaWorld:mkt:Russia, :PharmaWorld:mkt:Intercontinental, comp:Merz, prod:Xeomin]</description><category>Alert</category><category>comp:Allergan</category><category>dis:iOAB</category><category>dis:nOAB</category><category>dis:Spasticity</category><category>prod:Botox</category><category>mkt:Russia</category><category>mkt:Intercontinental</category><category>comp:Merz</category><category>prod:Xeomin</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology6519</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120831&edate=20120501&rec=6519">Allergan 1H Figures - Key Takeaways</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=Alert"><font color="#e95e0b">:Neurology:Alert</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=comp%3aAllergan"><font color="#e95e0b">:Neurology:comp:Allergan</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=comp%3aMerz"><font color="#e95e0b">:Neurology:comp:Merz</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=dis%3aiOAB"><font color="#e95e0b">:Neurology:dis:iOAB</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=dis%3anOAB"><font color="#e95e0b">:Neurology:dis:nOAB</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=dis%3aSpasticity"><font color="#e95e0b">:Neurology:dis:Spasticity</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=prod%3aBotox"><font color="#e95e0b">:Neurology:prod:Botox</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=prod%3aXeomin"><font color="#e95e0b">:Neurology:prod:Xeomin</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=mkt%3aIntercontinental"><font color="#e95e0b">:PharmaWorld:mkt:Intercontinental</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=mkt%3aRussia"><font color="#e95e0b">:PharmaWorld:mkt:Russia</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology6519">Neurology6519</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 01 August 2012 | 18:37</font><br><br><div style="margin-bottom: 10px;">Comment: Allergan reported a strong set of quarterly figures underpinned by Botox sales which grew by 13.<wbr>6% in local currencies, offsetting a sightly weaker opthalmic performance of 6.<wbr>5% growth.<wbr> Looking ahead, therapeutic toxin sales are expected to accelerate diven by the ramp up in chronic migraine and neurogenic bladder sales in the U.<wbr>S.<wbr> Encouragingly, the cosmetic side is also performing above expectations despite everybody's worst fears of a slowdown.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>BOTOX Performance.<wbr> </STRONG> </div><div style="margin-bottom: 10px;">In Q2, the franchise grew 10.<wbr>2% in dollars with double digit local currency performance of both cosmetic and therapeutic franchises.<wbr> </div><div style="margin-bottom: 10px;">The therapeutic franchise is reportedly benefitting from the recently approved indications of chronic migraine, neurogenic overactive bladder and in the U.<wbr>S.<wbr> <BR>upper limb spasticity.<wbr> Since April Allergan has received the following additional country approvals :- </div><div style="margin-bottom: 10px;"><UL><LI><STRONG>Chronic migraine</STRONG> in the Czech Republic, Denmark, Costa Rica, Bahrain, Kuwait and <BR>Jordan </LI>
<LI><STRONG>Neurogenic bladder</STRONG>, in Switzerland, Hungary, Slovakia, Panama Jordan and Philippines.<wbr> In Canada Allergan received a positive recommendation in the common drug review with action now to be taken by the individual provinces.<wbr> Additionally, an application was filed with health Canada for approval of the idiopathic overactive bladder indication.<wbr> </LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG>BOTOX Therapeutic </STRONG> </div><div style="margin-bottom: 10px;">Growth was particularly strong in the US, Latin America and Asia-Pacific.<wbr> </div><div style="margin-bottom: 10px;">In Europe, government mandated price cuts and low tender prices offered by some competitors converted "reasonable unit growth into low market growth and value.<wbr>" </div><div style="margin-bottom: 10px;">In the U.<wbr>S.<wbr> Allergan claims that Botox Therapeutic market share remains high &gt; 93% with the remaining 7% being shared by Dysport, Myobloc and Xeomin in descending order.<wbr> U.<wbr>S.<wbr> migraine treatments continues on a strong trajectory with <BR>approximately 5,800 physicians now trained.<wbr> Regarding access, 92% of all lives in commercial managed care plans now have some level of policy coverage.<wbr> </div><div style="margin-bottom: 10px;">In the core movement disorders area in the U.<wbr>S.<wbr>, which includes the upper limb spasticity indication, Allergan claims to be growing in low double digits.<wbr> </div><div style="margin-bottom: 10px;">Whilst in the urology segments (neurogenic overactive bladder), approximately 1,800 physicians have been trained since launch.<wbr> Regarding insurance access, 88% <BR>of commercial lives have some level of policy access.<wbr> 93% of Medicare lives and over 90% of Medicaid lives.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Cosmetic Performance</STRONG> </div><div style="margin-bottom: 10px;">U.<wbr>S.<wbr> Botox Cosmetic sales returned to growth in Q2, subsequent to emergency to ship product.<wbr> Sales were apparently boosted by both the BOTOX 10-year anniversary campaign as well as duet dividend promotion incentivizing customers to use both JUVEDERM and BOTOX cosmetic.<wbr> </div><div style="margin-bottom: 10px;">Based on a recent survey, Allergan estimates BOTOX has just over 80% share in the quarter moving up from a low point of 75% in the January to February time frame.<wbr> It estimates that the U.<wbr>S.<wbr> market grew double digit in volume.<wbr> </div><div style="margin-bottom: 10px;">Outside the U.<wbr>S.<wbr>, Allergan appears to have generated strong growth across a wide range of countries in Latin America, Asia, and emerging markets in Europe, Africa, Middle East.<wbr> Even some European countries performed well.<wbr> Southern Europe was the most difficult area due to competitive pressures.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Additional points made during the Q/<wbr>A on Botox were that:-</STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>Approval for iOAB is expected early next year</LI>
<LI>Additional sales staff in Europe associated with new approvals e.<wbr>g.<wbr> NDO are in the region of dozen's rather than hundreds.<wbr> In the US it already had a urology sales force in place marketing Sanctura.<wbr> It wasn't making any money on this drug but at least was ready to execute as and when NDO came along</LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG>Full-year guidance</STRONG> </div><div style="margin-bottom: 10px;">Net sales $5.<wbr>65 - $5.<wbr>8bn ($50m lower than previously at the top end due to negative currency movements impacting Lumigan and facial fillers in particular) </div><div style="margin-bottom: 10px;">Non-GAAP diluted earnings of $4.<wbr>15 to $4.<wbr>19 growth of between 14-15% </div><div style="margin-bottom: 10px;">Pre-tax impact of H/<wbr>C reform is expxected to be £110m and overseas pricing pressure $40m </div><div style="margin-bottom: 10px;">Half year investment in R&amp;D was $457m +11.<wbr>4%<BR> </div><div style="margin-bottom: 10px;"><STRONG>Finally on the topic of internationalisation and growth through acquisition</STRONG> David Pyott made the following comments:- </div><div style="margin-bottom: 10px;">"Well, first of all, clearly we're benefitting from the wave of approvals we had in 2009 and 10.<wbr> And now our job is to internationalize those approvals, which when you just think about the long list of countries I give you, clearly is occurring.<wbr> <BR>Clearly we have a commitment to pushing out the edges of the world to the few white spaces or the weaker spaces that we have.<wbr> We're really pleased that Russia's off to a great start.<wbr> Our most recent venture.<wbr> Also we're very pleased that China really is beginning to hit its stride, both in medical aesthetics but also ophthalmology.<wbr> All that is going pretty well.<wbr> And we continue to think about what are the next markets we might add.<wbr> Really probably when you look at sort of the east of Europe and then headed out into Asia.<wbr> Going back to the bigger question of M&amp;A clearly we want to put our free cash flow to work.<wbr> I think in our largest businesses opthalmology and medical aesthetics a lot of opportunities come to us because clearly anybody who owns an asset that might want to sell it or share it or partner it would think of us.<wbr> It's not altruism because in theory we should be able to pay more for that asset than somebody else given our strengths and our regional, and our worldwide distribution.<wbr> Where we're putting more effort the other way is really looking at neurosciences and urology and one of the great things with our mix is that we can be fairly agnostic.<wbr> It could be a drug.<wbr> It could be a drug delivered in a device.<wbr> Or it might even be a device.<wbr> So very clearly we're pleased with our internal growth motors but we'd like to supplement them using frankly our balance sheet and to intelligently acquire new sources of growth where we believe we can add value in a meaningful way to the businesses we'd license or acquire.<wbr> " </div><div>Source: <A href="http://www.allergan.com/">www.<wbr>allergan.<wbr>com</A><BR> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120831&edate=20120501&rec=6519">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-08-01T18:37:44+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>Roche's Expansion in China &amp; Research Update [:Endocrinology:dis:MidGutNET, dis:Prostate, dis:Gynea, news]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology8408</link>
<description>Roche's Expansion in China &amp; Research Update [:Endocrinology:dis:MidGutNET, dis:Prostate, dis:Gynea, news]</description><category>dis:MidGutNET</category><category>dis:Prostate</category><category>dis:Gynea</category><category>news</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology8408</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8408">Roche's Expansion in China & Research Update</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=dis%3aMidGutNET"><font color="#e95e0b">:Endocrinology:dis:MidGutNET</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=dis%3aGynea"><font color="#e95e0b">:Oncology:dis:Gynea</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=news"><font color="#e95e0b">:Oncology:news</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8408">Oncology8408</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 01 August 2012 | 17:32</font><br><br><div style="margin-bottom: 10px;">Comment: Severin Schwan Roche's CEO in an interview published in 
Sunday's Sonntags Zietung  noted the company's intention to 
create 1000 new jobs in China, a country where currently it is already 
far outstripping market growth.<wbr> This follows last week's announcement of the 
closure of the group's NA Nutley facility with similar number of job 
losses.<wbr> Alongside last week's figures, an update 
on progress with the research portfolio was also provided, indicating that 
the SWOG carcinoid study with Avastin has now completed enrollment and should 
report in 2013.<wbr> No reference was made to a filing for this indication.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8408/12/ScreenCapture12.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8408/11/ScreenCapture11.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">Included in the slides below are all references made to Roche drugs under 
developoment for prostate, hepatocellular, ovarian cancer and carcinoid syndrome 
plus those for diabetes and ulcerative collitis.<wbr><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8408/10/ScreenCapture10.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8408/9/ScreenCapture9.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8408/8/ScreenCapture8.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8408/7/ScreenCapture7.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8408/6/ScreenCapture6.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8408/5/ScreenCapture5.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8408/4/ScreenCapture4.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8408/3/ScreenCapture3.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8408/2/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8408/1/ScreenCapture1.jpg?user-agent=rss"> </div><div>Source: <a href="http://www.roche.com" class="defaultlink" title="www.roche.com">roche.com</a> </div><!-- Comment details --><a name="oncology8408attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8408/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(61,2 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8408/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(84,8 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8408/3/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(87,7 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8408/4/ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(75,6 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8408/5/ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(98,5 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8408/6/ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(101,3 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8408/7/ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(118,1 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8408/8/ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(96 KB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8408/9/ScreenCapture9.jpg">ScreenCapture9.jpg</a>&nbsp;&nbsp;(115,9 KB)<br>&nbsp;&nbsp;10.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8408/10/ScreenCapture10.jpg">ScreenCapture10.jpg</a>&nbsp;&nbsp;(97,2 KB)<br>&nbsp;&nbsp;11.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8408/11/ScreenCapture11.jpg">ScreenCapture11.jpg</a>&nbsp;&nbsp;(121,3 KB)<br>&nbsp;&nbsp;12.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8408/12/ScreenCapture12.jpg">ScreenCapture12.jpg</a>&nbsp;&nbsp;(50,3 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8408">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-08-01T17:32:54+02:00</dc:date><dc:creator>jac89886</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8408/1/ScreenCapture1.jpg" length="62680" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8408/2/ScreenCapture2.jpg" length="86792" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8408/3/ScreenCapture3.jpg" length="89838" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8408/4/ScreenCapture4.jpg" length="77371" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8408/5/ScreenCapture5.jpg" length="100837" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8408/6/ScreenCapture6.jpg" length="103755" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8408/7/ScreenCapture7.jpg" length="120923" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8408/8/ScreenCapture8.jpg" length="98332" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8408/9/ScreenCapture9.jpg" length="118678" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8408/10/ScreenCapture10.jpg" length="99486" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8408/11/ScreenCapture11.jpg" length="124200" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8408/12/ScreenCapture12.jpg" length="51544" type="image/jpeg"/></item><item>
<title>Anchor Therapeutics Collaborates With Kyowa Hakko on Pepducin Technology [sub:Partnership, sub:CompanyProfile, news]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld9996</link>
<description>Anchor Therapeutics Collaborates With Kyowa Hakko on Pepducin Technology [sub:Partnership, sub:CompanyProfile, news]</description><category>sub:Partnership</category><category>sub:CompanyProfile</category><category>news</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld9996</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120831&edate=20120501&rec=9996">Anchor Therapeutics Collaborates With Kyowa Hakko on Pepducin Technology</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=news"><font color="#e95e0b">:PharmaWorld:news</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=sub%3aCompanyProfile"><font color="#e95e0b">:PharmaWorld:sub:CompanyProfile</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=sub%3aPartnership"><font color="#e95e0b">:PharmaWorld:sub:Partnership</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld9996">PharmaWorld9996</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 01 August 2012 | 16:47</font><br><br><div style="margin-bottom: 10px;">Comment: Japanes Kyowa Hakko Kirin (KHK) is to utilize 
Anchor’s proprietary pepducin technology as a research tool to advance KHK’s 
internal GPCR drug discovery portfolio.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Deal Terms</STRONG> </div><div style="margin-bottom: 10px;">Under the agreement, Anchor and KHK will work jointly to discover and 
optimize pepducin research tools to further the molecular understanding of 
certain GPCR targets in the KHK portfolio.<wbr> KHK will assume responsibility for 
application of the research tools against the targets.<wbr> Anchor will receive an 
upfront payment, research funding, and downstream milestones.<wbr> </div><div style="margin-bottom: 10px;">This is the first application of Anchor's technology as a research tool, 
something hitherto that will be part of its business strategy.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Company Profile</STRONG> </div><div style="margin-bottom: 10px;">Anchor Therapeutics has broad exclusivity to pepducin technology intellectual 
property.<wbr> </div><div style="margin-bottom: 10px;">The slide below provides more background on the company and its activities to 
date.<wbr> </div><div><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/9996/1/ScreenCapture1.jpg?user-agent=rss"> </div><!-- Comment details --><a name="pharmaworld9996attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/9996/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(170,8 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120831&edate=20120501&rec=9996">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-08-01T16:47:09+02:00</dc:date><dc:creator>jac89886</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/9996/1/ScreenCapture1.jpg" length="174939" type="image/jpeg"/></item><item>
<title>Telotristat PhII European Data Due Mid Q3 [Alert, dis:MidGutNET]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7044</link>
<description>Telotristat PhII European Data Due Mid Q3 [Alert, dis:MidGutNET]</description><comments>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7044</comments><category>Alert</category><category>dis:MidGutNET</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7044</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120831&edate=20120501&rec=7044">Telotristat PhII European Data Due Mid Q3</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=Alert"><font color="#e95e0b">:Endocrinology:Alert</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=dis%3aMidGutNET"><font color="#e95e0b">:Endocrinology:dis:MidGutNET</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7044">Endocrinology7044</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 31 July 2012 | 17:58</font><br><br><div style="margin-bottom: 10px;">Comment: Lexicon is continuing to make good progress across it broad pipeline of product programmes.<wbr> A number of key data points will be reached in Q3 plus two phIII programmes will initiate before the year-end, one of these being for telotristat in carcinoid syndrome (details of which are shown below).<wbr> The emphasis of the group's partnering activities remains focused on its diabetes product LX4211.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7044/1/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">The efficacy endpoint will be at 12 weeks, similar to that utilised in the phII open European study which is scheduled to report in mid-Q312 </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7044/2/ScreenCapture3.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7044/3/ScreenCapture4.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">Three data events will be overlapping in Q3 relating to our RA, glaucoma and carcinoid syndrome products, whilst Q4 will largely be occupied with initiation of phIII programmes both for the diabetes drug and telotristat.<wbr> Results with telotristat in ulcerative colitis are expected in the first half of 2013.<wbr> Enrollment in this indication is slower but the study is moving forward both in the US and Eastern Europe.<wbr> Also in 2013 results are anticipated from the LX4211 type I diabetes and renal impairment studies.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Financial Update</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7044/4/ScreenCapture5.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">The decrease in revenues observed in the second quarter was primarily due to decreased reveneue from a government contract.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7044/5/ScreenCapture6.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">Lexicon continues to believe its productive pipeline will provide opportunities for future alliances </div><div style="margin-bottom: 10px;">After the end of quarter it exercised its option to make the full payment due to Symphony Icon in stock ($35m base payment).<wbr> The only remaining liability is based around milestones associated with partnership proceeds or regulatory approval based on products for which the Sympony Icon funding has been used.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Key Comments During Q/<wbr>A</STRONG> </div><div style="margin-bottom: 10px;">Q: What has been general response to LX4211 phII data from big pharma and when will it be presented.<wbr> </div><div style="margin-bottom: 10px;">A: Generally very positive.<wbr> HBA1c effects look to be superior to competing compounds.<wbr> Robust result combined with reductions in bp and body weight offer a compelling metabolic picture.<wbr> Big Pharam has been impressed by the level of HBA1c control achieved without inducing less glucose excretion in urine and without inducing adverse gastronintestinal side effects.<wbr> Overall the data has been very well received.<wbr> </div><div style="margin-bottom: 10px;">Data will be presented in full at the next ADA meeting.<wbr> Long lead time in terms of submitting Missed submission date for European meeting.<wbr> </div><div style="margin-bottom: 10px;">Q: What about the partnership potential for LX1032 (teletristat) </div><div style="margin-bottom: 10px;">A: As indicated previously we are planning to move into phIII ourselves.<wbr> It is unlikely that we will be doing anything further on the partnership front.<wbr> Our focus will be on getting the product launched and looking at the ulcerative colitis data.<wbr> </div><div style="margin-bottom: 10px;">Q: Regarding the phIII LX1032 trial are you expecting that to be 18-24 month timeframe from beginning to end </div><div style="margin-bottom: 10px;">A: Yes are enrollment goal is 18 months.<wbr> </div><div style="margin-bottom: 10px;">Q: Could you comment on your discussions with EMA with regard to LX1032.<wbr> Will the planned phIII satisfy European requirements? </div><div style="margin-bottom: 10px;">A: Yes the simple phIII study will be sufficient for filing.<wbr> </div><div style="margin-bottom: 10px;">Q: How many sites are you expecting? </div><div style="margin-bottom: 10px;">A: We are targeting 50 sites worldwide with the majority of sites in in Europe and the US.<wbr> </div><div style="margin-bottom: 10px;">Q: Is there a lot of additional data required for the partnering of LX4211? </div><div style="margin-bottom: 10px;">A: No there are some additional elements of high interest to partners that are expected soon i.<wbr>e some glucose challenge and renal data but there is not really a lot of other data needed for partnering purposes.<wbr> </div><div style="margin-bottom: 10px;">General comment to conclude: Data in Q3 is likely to trigger a pipeline review and prioritisation exercise and determine which products we wish to partner.<wbr> </div><div>Source: <A href="http://www.lexicon.com">www.<wbr>lexicon.<wbr>com</A> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Endocrinology7077c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">Design of the Ph3 has just been published in clinicaltrials.<wbr>gov.<wbr> The TELESTAR randomized, placebo-controlled, parallel group, multicenter, double-blind study will enroll approx.<wbr> 105 participants with carcinoid syndrome refractory to SSA therapy.<wbr> Primary outcome measures will assess change from baseline in number of daily bowel movements.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Study Details <a href="http://clinicaltrials.gov/ct2/show/NCT01677910?recr=Open&fund=2&rcv_s=08%2F21%2F2012&rank=11" class="defaultlink">NCT01677910</a></STRONG> </div><div>Timelines: Start date expected this month, with completion date in April 2015 </div><font size="-1">Brigitte DESCHAMPS / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7077" class="commentpermalink">Endocrinology7077</a> / <span class="date">04 September 2012</span> /
<span class="time">17:22:13 o'clock CEST</span>
</font></div><a name="endocrinology7044attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7044/1/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(53,6 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7044/2/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(60,1 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7044/3/ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(51,1 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7044/4/ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(53 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7044/5/ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(29,3 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120831&edate=20120501&rec=7044">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-07-31T17:58:16+02:00</dc:date><dc:creator>jac89886</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7044/1/ScreenCapture2.jpg" length="54864" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7044/2/ScreenCapture3.jpg" length="61581" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7044/3/ScreenCapture4.jpg" length="52345" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7044/4/ScreenCapture5.jpg" length="54282" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7044/5/ScreenCapture6.jpg" length="29995" type="image/jpeg"/></item><item>
<title>Pfizer - Coping With Lipitor's Patent Expiry [sub:Finance, sub:Generics, mkt:Intercontinental, mkt:China]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld9991</link>
<description>Pfizer - Coping With Lipitor's Patent Expiry [sub:Finance, sub:Generics, mkt:Intercontinental, mkt:China]</description><category>sub:Finance</category><category>sub:Generics</category><category>mkt:Intercontinental</category><category>mkt:China</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld9991</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120831&edate=20120501&rec=9991">Pfizer - Coping With Lipitor's Patent Expiry</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=mkt%3aChina"><font color="#e95e0b">:PharmaWorld:mkt:China</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=mkt%3aIntercontinental"><font color="#e95e0b">:PharmaWorld:mkt:Intercontinental</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=sub%3aFinance"><font color="#e95e0b">:PharmaWorld:sub:Finance</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=sub%3aGenerics"><font color="#e95e0b">:PharmaWorld:sub:Generics</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld9991">PharmaWorld9991</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 31 July 2012 | 16:40</font><br><br><div style="margin-bottom: 10px;">Comment: Pfizer recorded a strong quarterly performance depsite the loss of 
exclusivity of Lipitor which has recorded a 75% decline in revenues over the 6 
month period in the US and a 14% decline elsewhere.<wbr> Growth has been underpinned 
by strong demand for the company's products in the emerging and BRIC markets and 
tight control of costs.<wbr> To further unlock shareholder value he company is 
planning to IPO 20% of its animal health business and sell its nutrition 
businsess.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/9991/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/9991/2/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/9991/3/ScreenCapture3.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">From an individual product perspective growth of some of its key products is 
shown below.<wbr> Not highlighted was the sales performance of Somavert.<wbr> </div><div style="margin-bottom: 10px;">Lyrica (neuropathic pain) - $1.<wbr>99bn +17% cc US +8% Int +23% </div><div style="margin-bottom: 10px;">Enbrel (rheumatoid arthritis) - $1.<wbr>88bn +10% cc (all ex US &amp; 
Canada) </div><div style="margin-bottom: 10px;">Sutent (RCC, pNET &amp; other oncology) - $619m +12% cc US + 24% Int 
+8% </div><div style="margin-bottom: 10px;">Genotropin (short stature) - $407m -6% cc US -7% Int -5% </div><div style="margin-bottom: 10px;">BeneFIX (hemophilia B) -  $376m  +12% cc US +20% Int +6% </div><div>Source: wwww.<wbr>pfizer.<wbr>com </div><!-- Comment details --><a name="pharmaworld9991attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/9991/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(111 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/9991/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(123,6 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/9991/3/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(104,9 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120831&edate=20120501&rec=9991">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-07-31T16:40:40+02:00</dc:date><dc:creator>jac89886</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/9991/1/ScreenCapture1.jpg" length="113687" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/9991/2/ScreenCapture2.jpg" length="126522" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/9991/3/ScreenCapture3.jpg" length="107388" type="image/jpeg"/></item><item>
<title>PROVENGE Quarterly Sales Disappoint [class:Vaccines, dis:Prostate, headline]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology8407</link>
<description>PROVENGE Quarterly Sales Disappoint [class:Vaccines, dis:Prostate, headline]</description><category>class:Vaccines</category><category>dis:Prostate</category><category>headline</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology8407</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8407">PROVENGE Quarterly Sales Disappoint</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=class%3aVaccines"><font color="#e95e0b">:Oncology:class:Vaccines</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=headline"><font color="#e95e0b">:Oncology:headline</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8407">Oncology8407</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 31 July 2012 | 14:11</font><br><br><div style="margin-bottom: 10px;">Comment: PROVENGE sales grew 66% in the second quarter to reach $80m, 
slightly below market expectations and 2.<wbr>4% below the previous 
quarter.<wbr> Vacancies and cancellation of infusions were blamed for the 
underperformance.<wbr> Dendreon's manufacturing is to be restructured with the 
closure of one plant at a cost of $150m and the loss of 600 jobs.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Restructuring Its Manufacturing</STRONG> </div><div style="margin-bottom: 10px;">The company believes that with efficiencies it can now supply up to $1bn 
in sales of the product from 2 facilities rather than 3 without 
jeapardising customer service.<wbr> Streamlining its manufacturing and 
generating $150m in cost savings as a result should mean that it becomes 
cash flow positive when sales reach $100m per quarter and that COGS falls 
from its current level of 77% to less than 50%.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Rebuilding Its Commercial Infrastructure</STRONG> </div><div style="margin-bottom: 10px;">Dendreon is effectively rebuilding its commercial organisation at the present 
time and was keen to emphasize the impact this has had on its revenue 
in territories where there is currently no sales support.<wbr> At the end of 
June, key <STRONG>vacancies led to a number of infusions being 
cancelled, something analysts are suggesting may have to do with the 
impressive prechemo Zytiga data presented at ASCO.<wbr></STRONG> Dendreon does 
not accept this and keeps emphasising that the two products can be 
used in a complementary manner.<wbr> With a number of new hires expected to join in 
July and August it expects to begin to see an improvement in sales in the first 
quarter of 2013.<wbr> </div><div style="margin-bottom: 10px;">Oncology sales of PROVENGE still outstrip urology sales by some margin but 
there will be a continued promotional focus on trying to improve uptake amongst 
the urology customer base.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>European Plans</STRONG> </div><div style="margin-bottom: 10px;">Commenting on Europe, John Johnson Chairman President &amp; 
CEO noted that, "with so much on its plate within the US, the company is 
seriously looking at partnership options not just for manufacturing purposes but 
also for sales and marketing.<wbr> If it finds the right partner it will proceed but 
otherwise commercialisation plans are being put in place".<wbr> </div><div>Source: <A href="http://www.dendreon.com">www.<wbr>dendreon.<wbr>com</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8407">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-07-31T14:11:42+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>Merck Serono Creates Newco To Develop Parkinson's Disease Assets [dis:Parkinson, :PharmaWorld:sub:Finance]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology6518</link>
<description>Merck Serono Creates Newco To Develop Parkinson's Disease Assets [dis:Parkinson, :PharmaWorld:sub:Finance]</description><category>dis:Parkinson</category><category>sub:Finance</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology6518</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120831&edate=20120501&rec=6518">Merck Serono Creates Newco To Develop Parkinson's Disease Assets</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=dis%3aParkinson"><font color="#e95e0b">:Neurology:dis:Parkinson</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=sub%3aFinance"><font color="#e95e0b">:PharmaWorld:sub:Finance</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology6518">Neurology6518</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 31 July 2012 | 10:47</font><br><br><div style="margin-bottom: 10px;">Comment: Newco Prexton Therapeutics has been spun out of Merck Serono to 
develop the company's metabotropic glutamate receptor subtypes 3 &amp; 4 (mGluR3 
&amp; mGlurR4) from lead optimisation up to phase I testing.<wbr> </div><div style="margin-bottom: 10px;">Merck Serono will invest Euro 2.<wbr>1m in seed funding whilst Merck Serono 
Ventures will manage the investment.<wbr> </div><div style="margin-bottom: 10px;">Francois Conquet, Director of licensing at Merck Serono will become CEO.<wbr> 
Conquest is the co-founder and former CEO of Addex Therapeutics which is also 
developing compounds targeting mGluR for PD.<wbr> </div><div style="margin-bottom: 10px;">Prexton is the first newco created as part of Merck's Euro 30 million 
commitment to fund spinouts of non-core activities and compounds resulting from 
its ongoing restructuring programme.<wbr> </div><div>Source: <a href="http://www.merckserono.com" class="defaultlink" title="www.merckserono.com">merckserono.com</a> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120831&edate=20120501&rec=6518">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-07-31T10:47:24+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>re: Exelixis Reports Highly Significant Improvement in PFS in Medullary Thyroid Cancer</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7043</link>
<description>re: Exelixis Reports Highly Significant Improvement in PFS in Medullary Thyroid Cancer</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7043</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120831&edate=20120501&rec=7043">re: Exelixis Reports Highly Significant Improvement in PFS in Medullary Thyroid Cancer</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7043">Endocrinology7043</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 30 July 2012 | 15:52</font><br><br><div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Exelixis Reports Highly Significant Improvement in PFS in Medullary Thyroid Cancer</span>&nbsp;<font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=headline"><font color="#e95e0b">:Endocrinology:headline</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a>]</font></font><br><span style="font-size: 12px;">Comment: At ASCO last week, Exelexis reported additional data from its 
international PhIII EXAM trial in 330 patients with locally advanced or 
metastatic medullary thyroid cancer with once daily oral cabozantinib 
demonstrating a 1 -year PFS rate of 47.<wbr>3% vs 7.<wbr>2% for placebo.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120831&edate=20120501&rec=6959">...</a><br><font size="-1">Jacquelyne CANTLE MEYRICK / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology6959" class="commentpermalink">Endocrinology6959</a> / <span class="date">11 June 2012</span> /
<span class="time">11:45:10 o'clock CEST</span>
</font></div><div>Exelixis has been granted a priority review for cabozantinib for the treatment of medullary thyroid cancer.<wbr> The FDA has set a review date of November 29th.<wbr> </div><!-- Comment details --><font size="-1">Jacquelyne CANTLE MEYRICK / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7043" class="commentpermalink">Endocrinology7043</a> / <span class="date">30 July 2012</span> /
<span class="time">15:52:03 o'clock CEST</span>
</font><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120831&edate=20120501&rec=7043">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology6959">View thread  Endocrinology6959: Exelixis Reports Highly Significant Improvement in PFS in Medullary Thyroid Cancer</a>]]></content:encoded><dc:date>2012-07-30T15:52:03+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>Potential New Stroke Treatment Halves Brain Damage Under Experimental Conditions [headline, dis:Spasticity]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology6516</link>
<description>Potential New Stroke Treatment Halves Brain Damage Under Experimental Conditions [headline, dis:Spasticity]</description><category>headline</category><category>dis:Spasticity</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology6516</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120831&edate=20120501&rec=6516">Potential New Stroke Treatment Halves Brain Damage Under Experimental Conditions</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=dis%3aSpasticity"><font color="#e95e0b">:Neurology:dis:Spasticity</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=headline"><font color="#e95e0b">:Neurology:headline</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology6516">Neurology6516</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 30 July 2012 | 14:56</font><br><br><div style="margin-bottom: 10px;">Comment: Scientist from the University of Manchester believe they have 
identified a drug which may be able to dramatically limit the amount of brain 
damage in stroke patients.<wbr> The drug Anakinra (IL-1Ra, Kineret) is currently 
marketed by SOBI for the treatment of rheumatoid arthritis.<wbr> </div><div style="margin-bottom: 10px;">Professor Dame Nancy Rothwell &amp; Professor Stuart Allan have been testing 
the effectiveness of the drug in experimental studies of stroke in rats with 
stroke risk factors such as obesity, insulin resistance and atherosclerosis i.<wbr>e 
under circumstances more likely to be found in man.<wbr> </div><div style="margin-bottom: 10px;">Their results have been startling, with MRI scans revealing that the rats 
given IL-1Ra up to 3 hours after a stroke had only half the brain damage of the 
placebo group.<wbr> </div><div style="margin-bottom: 10px;">Professor Stuart Allan is quoted on ScienceDaily as 
saying "This drug has real potential to save lives and stop hundreds of 
thousands of people being seriously disabled by stroke.<wbr> This really could be the 
treatment for stroke that we've been looking for over the past two decades.<wbr>" </div><div style="margin-bottom: 10px;">A phase II trial with a small number of patients has apparently yielded 
encouraging results and the hope is that a much larger trial will be 
initiated.<wbr> </div><div>source: <A href="http://www.sciencedaily.com">www.<wbr>sciencedaily.<wbr>com</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120831&edate=20120501&rec=6516">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-07-30T14:56:59+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>Bladder Cancer Drug Instiladrin™ Enters Phase II Development [dis:Bladder]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology8406</link>
<description>Bladder Cancer Drug Instiladrin™ Enters Phase II Development [dis:Bladder]</description><category>dis:Bladder</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology8406</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8406">Bladder Cancer Drug Instiladrin™ Enters Phase II Development</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=dis%3aBladder"><font color="#e95e0b">:Oncology:dis:Bladder</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8406">Oncology8406</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 30 July 2012 | 14:39</font><br><br><div style="margin-bottom: 10px;">Comment: FKD Therapy Oy has received FDA clearance to commence a phII trial 
with Instiladrin™, a gene based adenovirally mediated interferon 
alpha-2b/<wbr>Syn3 for the treatment of non-muscle invasive bladder cancer.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Current Treatment Practice</STRONG> </div><div style="margin-bottom: 10px;">(BCG) is the current first line therapy for non-muscle invasive bladder 
cancer.<wbr> However, over 60 percent of BCG treated patients fail the treatment 
within two years.<wbr> Thereafter, therapeutic options are limited and average 
survival after tumour re-occurrence is about 2.<wbr>5 years </div><div style="margin-bottom: 10px;"><STRONG>PhII Study Design</STRONG> </div><div style="margin-bottom: 10px;">FKD Therapy's Phase II trial will be an open label study of up to 40 
patients with high grade non-muscle invasive bladder cancer who are refractory 
to BCG.<wbr> </div><div style="margin-bottom: 10px;">Patients will be randomised to a dose of either 1x1011 or 3x1011 viral 
particles of Instiladrin™, administered intravesicularly after tumour resection.<wbr> 
Responders will be re-treated 3, 6 and 9 months after the initial dose.<wbr> The 
primary end point will be tumour recurrence, with safety and durability of 
response as secondary endpoints.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Background To The Development of Instiladrin™, 
<BR></STRONG><BR>Whilst Interferon alfa 2b protein therapy is a well established 
anti-cancer therapy.<wbr> Its efficacy for the treatment of bladder cancer is limited 
by the fact that after direct administration into the bladder, it is completely 
cleared within 24hrs.<wbr> Instiladrin™ is an adenoviral (Ad5) vector based gene 
medicine, containing the interferon alfa 2b transgene with Syn3, an excipient to 
improve transfection.<wbr> </div><div style="margin-bottom: 10px;">Administered as one dose, Instiladrin carries the 
interferon gene into the bladder wall cells where it is transported to the 
nucleus causing the interferon protein to be made intracellularly.<wbr> Evidence 
suggests that Instiladrin™ may produce a therapeutic concentration of interferon 
measurable in the bladder for seven days killing even cells that are resistant 
to externally administered interferon protein.<wbr> </div><div style="margin-bottom: 10px;">In a Phase 1 trial of 
Instiladrin™ involving 14 patients given a single therapeutic administration 
into the bladder after tumour resection, Instiladrin™ showed a 43 percent 
complete response (no tumour recurrence) at 3 months, with an average 23 month 
durability in patients receiving one repeat dose at 3 months3.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>FKD Therapy -Company Profile </STRONG> </div><div style="margin-bottom: 10px;">FKD Therapy a newly formed company specialising in advanced gene based 
medicines was established in February 2011 with a working capital 
reserves of $16 million, secured in a private fundraising underwritten by 
Wölbern Invest and supported by the Finnish Funding Agency for Technology and 
Innovation </div><div style="margin-bottom: 10px;">In Sept 2011 it acquired an exclusive licence from Merck &amp; Co.<wbr>, 
Inc, to develop and commercialise Merck’s gene therapy portfolio.<wbr> </div><div>Under the terms of the agreement, Merck has granted FKD an exclusive licence 
to develop and commercialise Instiladrin™.<wbr> The agreement also provides FKD with 
the option to develop two other investigational programmes, a recombinant 
adenoviral p21 (rAd-p21) to treat glaucoma surgery failure and conditionally 
replicating adenoviral technology (CRAV) for the treatment of solid tumours.<wbr> In 
return Merck has taken an equity stake in FKD.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8406">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-07-30T14:39:16+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>Takeda's First Quarter Earnings Highlight Importance Of Nycomed Acquisition [comp:Takeda, dis:Prostate, prod:Enantone, prod:Orteronel, :PharmaWorld:mkt:Russia, :PharmaWorld:mkt:Intercontinental]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology8404</link>
<description>Takeda's First Quarter Earnings Highlight Importance Of Nycomed Acquisition [comp:Takeda, dis:Prostate, prod:Enantone, prod:Orteronel, :PharmaWorld:mkt:Russia, :PharmaWorld:mkt:Intercontinental]</description><category>comp:Takeda</category><category>dis:Prostate</category><category>prod:Enantone</category><category>prod:Orteronel</category><category>mkt:Russia</category><category>mkt:Intercontinental</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology8404</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8404">Takeda's First Quarter Earnings Highlight Importance Of Nycomed Acquisition</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=comp%3aTakeda"><font color="#e95e0b">:Oncology:comp:Takeda</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=prod%3aEnantone"><font color="#e95e0b">:Oncology:prod:Enantone</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=prod%3aOrteronel"><font color="#e95e0b">:Oncology:prod:Orteronel</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=mkt%3aIntercontinental"><font color="#e95e0b">:PharmaWorld:mkt:Intercontinental</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=mkt%3aRussia"><font color="#e95e0b">:PharmaWorld:mkt:Russia</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8404">Oncology8404</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 30 July 2012 | 12:28</font><br><br><div style="margin-bottom: 10px;">Comment: The importance of the Nycomed acquisition in terms of maintaining sales growth is highlighted below.<wbr> With a contribution to net sales of approx 77 bn Yen, the key geographic regions where Takeda is registering enhanced growth are Europe including Russia &amp; CIS and the emerging markets.<wbr> Product wise TAK-700 PhIII trials remain ongoing with approval slated for FY14 (April 2014 -2015), whilst an interesting new GI oncology product has just entered clinical development.<wbr> </div><div style="margin-bottom: 10px;">Leuprolide sales declined by 0.<wbr>4 bn Yen.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8404/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8404/2/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8404/3/ScreenCapture3.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8404/4/ScreenCapture4.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">Operating income as shown was impacted in part by increased R&amp;D expenses due to steady progress with the late stage pipeline including the CRPC drug TAK-700 orteronel (see below), filing for which in all geographic regions appears to be on track with previous stated timelines.<wbr> During its earnings call Tsudoi Miyoshi, Head &ndash; CMSO Office made the following comments:- </div><div style="margin-bottom: 10px;">"Regarding TAK-700, a selective androgen synthesis inhibitor, we are conducting Phase III clinical trials to evaluate its safety and efficacy those with steroids to file in U.<wbr>S.<wbr>, EU, Japan, in FY 2013.<wbr> We presented the updated results from our Phase II study of TAK-700 those without prednisone in patients with non-metastatic castration resistant prostate cancer and rising prostate-specific antigen.<wbr> This study showed 16% of patients experienced undetectable levels of PSA at three months.<wbr> And 32% experienced undetectable levels of PSA at a best response.<wbr> These results show that TAK-700 reduced its PSA without the need for concomitant corticosteroids.<wbr> We are rebuilding our developmental strategy to gain approval for use in broader range of prostate cancer patients.<wbr>" Later he noted that the focus of this new development programme would be on high-risk non-metastatic patients or those that cannot tolerate steroids.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8404/5/ScreenCapture5.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">Also highlighted was a new phI molecule for GI malignancies </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8404/6/ScreenCapture6.jpg?user-agent=rss"> </div><div>Source: <A href="http://www.takeda.com">www.<wbr>takeda.<wbr>com</A> </div><!-- Comment details --><a name="oncology8404attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8404/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(68,9 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8404/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(97,2 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8404/3/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(95,9 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8404/4/ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(73,2 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8404/5/ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(93 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8404/6/ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(115,5 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8404">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-07-30T12:28:25+02:00</dc:date><dc:creator>jac89886</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8404/1/ScreenCapture1.jpg" length="70555" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8404/2/ScreenCapture2.jpg" length="99554" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8404/3/ScreenCapture3.jpg" length="98236" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8404/4/ScreenCapture4.jpg" length="74954" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8404/5/ScreenCapture5.jpg" length="95182" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8404/6/ScreenCapture6.jpg" length="118277" type="image/jpeg"/></item><item>
<title>TGF-B Antisense Product Moves Forward In Development For Pancreatic Cancer [news]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology8403</link>
<description>TGF-B Antisense Product Moves Forward In Development For Pancreatic Cancer [news]</description><category>news</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology8403</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8403">TGF-B Antisense Product Moves Forward In Development For Pancreatic Cancer</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=news"><font color="#e95e0b">:Oncology:news</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8403">Oncology8403</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 30 July 2012 | 11:50</font><br><br><div style="margin-bottom: 10px;"><P align="left">Comment: Antisense Pharma has been granted US orphan drug status 
for its transforming growth factor beta 2 antisense oligonucleotide for the 
treatment of malignant melanoma.<wbr> The drug is in Phase I/<wbr>II testing in 
patients with pancreatic adenocarcinoma, malignant melanoma and colorectal 
cancer.<wbr></P> </div><div style="margin-bottom: 10px;"><P align="left">The product already has Orphan Drug designation in the U.<wbr>S.<wbr> and EU 
for high-grade glioma and advanced pancreatic cancer and this year, Antisense 
plans to start a Phase II trial to evaluate trabedersen as second-line therapy 
for pancreatic cancer.<wbr> The company also plans to evaluate trabedersen as 
first-line therapy in combination with standard chemotherapy in a Phase II/<wbr>III 
trial for pancreatic cancer.<wbr></P> </div><div style="margin-bottom: 10px;"><P align="left">Encouraging PhI/<wbr>PhII data demonstrating the drug's excellent 
safety profile combined with promising preliminary survival data in 
patients with advanced pancreatic cancer and malignant melanoma was presented 
this year at ASCO (abstract 4034).<wbr></P> </div><div><P align="left">Source: <A href="http://www.antisense-pharma.com">www.<wbr>antisense-pharma.<wbr>com</A></P> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8403">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-07-30T11:50:41+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>Additional Data Released During Novartis's Q2 Figures [Alert, class:SomatostatinAnalogue, comp:Novartis, prod:Pasireotide, prod:Octreotide, dis:MidGutNET, dis:pNET]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7042</link>
<description>Additional Data Released During Novartis's Q2 Figures [Alert, class:SomatostatinAnalogue, comp:Novartis, prod:Pasireotide, prod:Octreotide, dis:MidGutNET, dis:pNET]</description><category>Alert</category><category>class:SomatostatinAnalogue</category><category>comp:Novartis</category><category>prod:Pasireotide</category><category>prod:Octreotide</category><category>dis:MidGutNET</category><category>dis:pNET</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7042</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120831&edate=20120501&rec=7042">Additional Data Released During Novartis's Q2 Figures</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=Alert"><font color="#e95e0b">:Endocrinology:Alert</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=class%3aSomatostatinAnalogue"><font color="#e95e0b">:Endocrinology:class:SomatostatinAnalogue</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=comp%3aNovartis"><font color="#e95e0b">:Endocrinology:comp:Novartis</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=dis%3aMidGutNET"><font color="#e95e0b">:Endocrinology:dis:MidGutNET</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=dis%3apNET"><font color="#e95e0b">:Endocrinology:dis:pNET</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=prod%3aOctreotide"><font color="#e95e0b">:Endocrinology:prod:Octreotide</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=prod%3aPasireotide"><font color="#e95e0b">:Endocrinology:prod:Pasireotide</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7042">Endocrinology7042</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 30 July 2012 | 11:33</font><br><br><div style="margin-bottom: 10px;">Comment: Novartis noted that Sandostatin grew by 6% (cc) during the half-year 
driven by increased usage for NET.<wbr> 30 countries now have an amended label based 
on the PhIIIb PROMID data with an additional 20 currently reviewing the data.<wbr> A 
total of 14 countries have approved the new presentation of Sandostatin LAR, 
with addtional filings underway (the countries were not identified).<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Sandostatin LAR</STRONG> </div><div style="margin-bottom: 10px;">Looking at the quarterly trends Sandostatin sales growth in the US registered 
a sharp slowdown in the second quarter compared to Q1 (+6% vs.<wbr> +26% cc in 
Q1).<wbr> Whilst sales in the ROW exhibited a slightly stronger performance than in 
the first quarter +6% vs +2% cc.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Afinitor</STRONG> </div><div style="margin-bottom: 10px;">During the earnings call, management noted that Afinitor's US exclusivity has 
been extended to 2020 from 2018 based on pediatric exclusivity being granted for 
the four indications for which the drug is currently approved in the US (renal 
angiomyolipomas associated with TBS, advanced renal cancer following VEGF 
therapy, advnaced pNET and subpendymal giant cell astrocytomas associated with 
TSC).<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Other Approval Dates</STRONG> </div><div style="margin-bottom: 10px;">With regard to Signifor, Novartis stated that it expects US approval for 
Cushing's disease in H2 2012 </div><div style="margin-bottom: 10px;">Approval dates for other key indications are shown below:- </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7042/2/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7042/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7042/3/ScreenCapture3.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7042/4/ScreenCapture4.jpg?user-agent=rss"> </div><div>Source: <A href="http://www.novartis.com">www.<wbr>novartis.<wbr>com</A> </div><!-- Comment details --><a name="endocrinology7042attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7042/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(33,4 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7042/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(20,6 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7042/3/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(26,5 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7042/4/ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(5,9 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120831&edate=20120501&rec=7042">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-07-30T11:33:06+02:00</dc:date><dc:creator>jac89886</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7042/1/ScreenCapture1.jpg" length="34179" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7042/2/ScreenCapture2.jpg" length="21141" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7042/3/ScreenCapture3.jpg" length="27152" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7042/4/ScreenCapture4.jpg" length="5997" type="image/jpeg"/></item><item>
<title>Cumberland Pharm.'s Crystalline Lactulose Assessed as a Preparation for Colonoscopy [sub:CRCPrevention, :PharmaWorld:sub:ClinicalTrial]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology1853</link>
<description>Cumberland Pharm.'s Crystalline Lactulose Assessed as a Preparation for Colonoscopy [sub:CRCPrevention, :PharmaWorld:sub:ClinicalTrial]</description><category>sub:CRCPrevention</category><category>sub:ClinicalTrial</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology1853</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20120831&edate=20120501&rec=1853">Cumberland Pharm.<wbr>'s Crystalline Lactulose Assessed as a Preparation for Colonoscopy</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20120831&edate=20120501&cat=sub%3aCRCPrevention"><font color="#e95e0b">:GastroEnterology:sub:CRCPrevention</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=sub%3aClinicalTrial"><font color="#e95e0b">:PharmaWorld:sub:ClinicalTrial</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology1853">GastroEnterology1853</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 27 July 2012 | 15:21</font><br><br><div style="margin-bottom: 10px;">Comment: Already marketed in the US as Kristallose (oral solution for acute/<wbr>chronic constipation), the drug has entered a randomized Ph2 trial, to determine its safety, efficacy and patient preference of a split-dose regimen.<wbr> Primary endpoint will assess the cleanliness of the colon during colonoscopy (using the Boston Bowel Prep Scale).<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Study Details - </FONT></STRONG><A href="http://clinicaltrials.gov/ct2/show/NCT01650870?recr=Open&amp;fund=2&amp;rcv_s=07%2F13%2F2012&amp;rank=131"><STRONG><FONT size="3">NCT01650870</FONT></STRONG></A> </div><div style="margin-bottom: 10px;">Recruitment: approx.<wbr> 40 </div><div style="margin-bottom: 10px;">Start date: July 2012 - Completion date: Sept.<wbr> 2012 </div><div style="margin-bottom: 10px;">Regimen: three 45-gram doses (one dose every 60 minutes for 3 straight hours) taken the evening before the colonoscopy procedure followed by one 45-gram dose the morning before the colonoscopy procedure.<wbr> </div><div style="margin-bottom: 10px;">Location: US (1) </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Drug Snapshot</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/1853/1/ScreenCapture1.jpg?user-agent=rss"> </div><div><img src="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/1853/2/ScreenCapture2.jpg?user-agent=rss"> </div><!-- Comment details --><a name="gastroenterology1853attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/1853/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(22,1 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/1853/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(19,2 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20120831&edate=20120501&rec=1853">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-07-27T15:21:31+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/1853/1/ScreenCapture1.jpg" length="22592" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/1853/2/ScreenCapture2.jpg" length="19680" type="image/jpeg"/></item><item>
<title>LG Lifesciences to Evaluate Erythropoietin in Children with Cerebral Palsy [dis:Palsy, :PharmaWorld:sub:ClinicalTrial, :PharmaWorld:mkt:Korea, :PharmaWorld:mkt:Intercontinental]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology6513</link>
<description>LG Lifesciences to Evaluate Erythropoietin in Children with Cerebral Palsy [dis:Palsy, :PharmaWorld:sub:ClinicalTrial, :PharmaWorld:mkt:Korea, :PharmaWorld:mkt:Intercontinental]</description><category>dis:Palsy</category><category>sub:ClinicalTrial</category><category>mkt:Korea</category><category>mkt:Intercontinental</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology6513</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120831&edate=20120501&rec=6513">LG Lifesciences to Evaluate Erythropoietin in Children with Cerebral Palsy</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=dis%3aPalsy"><font color="#e95e0b">:Neurology:dis:Palsy</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=mkt%3aIntercontinental"><font color="#e95e0b">:PharmaWorld:mkt:Intercontinental</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=mkt%3aKorea"><font color="#e95e0b">:PharmaWorld:mkt:Korea</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=sub%3aClinicalTrial"><font color="#e95e0b">:PharmaWorld:sub:ClinicalTrial</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology6513">Neurology6513</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 27 July 2012 | 14:41</font><br><br><div style="margin-bottom: 10px;">Comment: Based on many experimental studies which show that erythropoietin is useful to repair neurological injury in brain, the company is to start a randomized Ph2 trial next year at the Bundang CHA Hospital (Korea).<wbr> Primary outcome will measure changes in quality of movement.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Study Details - <A href="http://clinicaltrials.gov/ct2/show/NCT01650415?recr=Open&amp;fund=2&amp;rcv_s=07%2F13%2F2012&amp;rank=114">NCT01650415</A></FONT></STRONG> </div><div style="margin-bottom: 10px;">Recruitment: approx.<wbr> 80 children (from 4 months to 4 years).<wbr> </div><div style="margin-bottom: 10px;">Start date: Aug.<wbr> 2013 - Completion date: Dec.<wbr> 2014.<wbr> </div><div>Principal Investigator: Minyoung Kim (M.<wbr>D.<wbr>, Ph.<wbr>D.<wbr>).<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120831&edate=20120501&rec=6513">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-07-27T14:41:47+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Theracoat's Innovative Approach to Treat Superficial Bladder Cancer [dis:Bladder, news]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology8402</link>
<description>Theracoat's Innovative Approach to Treat Superficial Bladder Cancer [dis:Bladder, news]</description><category>dis:Bladder</category><category>news</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology8402</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8402">Theracoat's Innovative Approach to Treat Superficial Bladder Cancer</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=dis%3aBladder"><font color="#e95e0b">:Oncology:dis:Bladder</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=news"><font color="#e95e0b">:Oncology:news</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8402">Oncology8402</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 27 July 2012 | 11:41</font><br><br><div style="margin-bottom: 10px;">Comment: The company's technology is to embed any of the currently used chemo drugs (found effective in the indication) in a biodegradable "sticky" gel material that will be 'painted' onto the bladder's internal wall using a specialty made catheter.<wbr> The gel allows for a continuous treatment by slowly releasing the drug for an estimated 10 hours period (the gel is retrieved from the bladder as part of the normal urine outage).<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Advantages</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8402/2/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Ongoing Trial - <A href="http://clinicaltrials.gov/ct2/show/NCT01648010?term=theracoat&amp;rank=1">NCT01648010</A></FONT></STRONG> </div><div style="margin-bottom: 10px;"><DIV class="indent1" style="MARGIN-TOP: 3ex">
<DIV class="indent2" style="MARGIN-TOP: 2ex">
<DIV class="indent3">
<DIV class="body3">
<P style="MARGIN-TOP: 0ex; MARGIN-BOTTOM: 1ex"><STRONG>-</STRONG> <STRONG>Description</STRONG>: TheraCoat core technology is based on a reverse thermal (low viscosity at 5°C) degradable gel (TC-3)for MMC retention in the urinary bladder.<wbr></P>
<P style="MARGIN-TOP: 0ex; MARGIN-BOTTOM: 1ex">Prior to instillation, the TC-3 hydrogel,in a liquid state, is mixed with MMC.<wbr>TC-3 mixed with MMC is instilled to the bladder by a catheter.<wbr>Following gel insertion to the bladder, the gel solidifies and forms a drug reservoir inside the bladder.<wbr> Upon contact with urine the gel dissolves and is cleared out from the bladder.<wbr></P>
<P style="MARGIN-TOP: 0ex; MARGIN-BOTTOM: 1ex">Intravesical MMC using TheraCoat gel is expected to increase treatment efficiency due to prolongation of treatment duration and consequently improving bladder exposure to MMC.<wbr></P></DIV></DIV></DIV></DIV> </div><div style="margin-bottom: 10px;"><STRONG>- Timelines</STRONG>: The company started a study in November last year to assess the systemic and urine pharmacokinetics of MMC following intravesical instillation of TC-3 mixed with MMC for safety evaluation.<wbr> - Completion dates: May 2012 /<wbr> April 2013.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>- Recruitment</STRONG>: approx 10 patients with bladder cancer designated to undergo Radical Cystectomy.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>- Location</STRONG>: Israel (Barzilai Hospital) - Principal Investigator: Shmuel Cytron (MD).<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Company Snapshot</FONT></STRONG> </div><div style="margin-bottom: 10px;">- Location: Ra'anana (Israel).<wbr> </div><div style="margin-bottom: 10px;">- Founded by onco-urologists, and medical device professionals.<wbr> </div><div>- The <A href="http://www.theracoat.com/team.html">team</A>.<wbr> </div><!-- Comment details --><a name="oncology8402attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8402/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(21,2 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8402/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(23,6 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8402">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-07-27T11:41:08+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8402/1/ScreenCapture1.jpg" length="21661" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8402/2/ScreenCapture2.jpg" length="24210" type="image/jpeg"/></item><item>
<title>Novartis Adopts New Approach to Activities in Greece [mkt:Europe, sub:Pricing, :Oncology:comp:Novartis, :Endocrinology:comp:Novartis]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld9989</link>
<description>Novartis Adopts New Approach to Activities in Greece [mkt:Europe, sub:Pricing, :Oncology:comp:Novartis, :Endocrinology:comp:Novartis]</description><category>mkt:Europe</category><category>sub:Pricing</category><category>comp:Novartis</category><category>comp:Novartis</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld9989</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120831&edate=20120501&rec=9989">Novartis Adopts New Approach to Activities in Greece</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=comp%3aNovartis"><font color="#e95e0b">:Endocrinology:comp:Novartis</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=comp%3aNovartis"><font color="#e95e0b">:Oncology:comp:Novartis</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=mkt%3aEurope"><font color="#e95e0b">:PharmaWorld:mkt:Europe</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=sub%3aPricing"><font color="#e95e0b">:PharmaWorld:sub:Pricing</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld9989">PharmaWorld9989</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 26 July 2012 | 14:48</font><br><br><div style="margin-bottom: 10px;">Comment: Novartis is reported to be changing its operations in Greece, faced with the problems of financial sustainability, due to the very serious financial problems of the Greek healthcare system, reports Greek healthcare news provider Iatrikos Typos.<wbr> Novartis has reportedly reduced marketing expenditure in the country, which in turn has an impact on its partners and on the Greek economy in general.<wbr> </div><div style="margin-bottom: 10px;">The source reports that by September, Novartis will redefine its policy towards the Greek National Organisation for Healthcare Provision (EOPYY), having already made the required consultations and contacts with patients' associations and being given assurances of continued access to treatments.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Significance</FONT></STRONG> </div><div style="margin-bottom: 10px;">Reports of a scaling down of activities by Novartis in Greece will come as no surprise, considering the losses already incurred: the EOPYY's debts to the company reportedly stand at EUR90 million (USD109 million).<wbr> The assurances given to patients are important; however, it is unlikely that there will not be negative consequences of this scaling down for patients, as a result of lower levels of supplies.<wbr> This comes after news that BMS is also reducing its Greek operations.<wbr> </div><div>Source: Global Insight </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120831&edate=20120501&rec=9989">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-07-26T14:48:08+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Terumo Explores Merger with Olympus [:Oncology:dis:Bladder, :Oncology:sub:Diagnostic, headline]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld9988</link>
<description>Terumo Explores Merger with Olympus [:Oncology:dis:Bladder, :Oncology:sub:Diagnostic, headline]</description><category>dis:Bladder</category><category>sub:Diagnostic</category><category>headline</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld9988</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120831&edate=20120501&rec=9988">Terumo Explores Merger with Olympus</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=dis%3aBladder"><font color="#e95e0b">:Oncology:dis:Bladder</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=sub%3aDiagnostic"><font color="#e95e0b">:Oncology:sub:Diagnostic</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=headline"><font color="#e95e0b">:PharmaWorld:headline</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld9988">PharmaWorld9988</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 26 July 2012 | 13:15</font><br><br><div style="margin-bottom: 10px;">Comment: Terumo has made a proposal to Olympus for a ¥50bn capital tie-up, and the establishment of a committee to assess a merger under a joint holding company.<wbr> Olympus could expand its lineup of endoscopic surgical tools, and utilize Terumo’s expertise in precise and efficient manufacturing of small, light products.<wbr> Of note, the company 1/<wbr>already holds 2.<wbr>2% of Terumo's total shares issued and 2/<wbr>is also in talks with Sony and Fujifilm.<wbr> </div><div style="margin-bottom: 10px;"><FONT size="3"><STRONG>Morgan Stanley Analysis (</STRONG><FONT size="1">July 26th report</FONT><STRONG>)</STRONG></FONT> </div><div style="margin-bottom: 10px;">- Olympus has a 70% share of the global (EM+DM) endoscopy market and, like Terumo, is one of Japan’s few medical device makers with a global reach.<wbr> A tie-up with Terumo could enable expansion beyond the gastro-intestinal field into news areas like neurology and cardiology.<wbr> Potential regional synergies also exist.<wbr> </div><div style="margin-bottom: 10px;">- Olympus is currently focusing on rebuilding its digital camera ops, so there is almost no improvement/<wbr>synergy to be gained in that field by merging with Terumo.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Ranking of the Future Merger</FONT></STRONG> </div><div style="margin-bottom: 10px;">Terumo aims to combine its expertise with Olympus’s technologies, creating a leading global player in minimally invasive treatments field.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/9988/11/ScreenCapture11.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Overview of Olympus Applications-Specific Procedures</FONT></STRONG> </div><div style="margin-bottom: 10px;"><STRONG><A href="http://www.olympus-europa.com/medical/en/medical_systems/applications/urology/bladder/narrow_band_imaging__nbi_/narrow_band_imaging__nbi_.html">Narrow Band Imaging (NBI)</A></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/9988/7/ScreenCapture7.jpg?user-agent=rss">Olympus </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/9988/8/ScreenCapture8.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">Olympus has developed the CV-180 Visera Elite processor to allow NBI to be performed at the push of a button in HD quality.<wbr> Furthermore, Olympus' new generation of 'chip on the tip' flexible cystoscopes allow these images to be collected in HD, for excellent image quality and a safe diagnosis.<wbr> NBI works to complement to other Olympus systems, including photodynamic detection (PDD) and bipolar resection using trans-urethral resection in saline (TURis) and overall improving the cycle of bladder cancer treatment for patient and doctor.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><A href="http://www.olympus-europa.com/medical/en/medical_systems/applications/urology/bladder/photodynamic_diagnosis__pdd_/photodynamic_diagnosis__pdd_.html">Resection with Photodynamic Diagnosis</A> (PDD)</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/9988/6/ScreenCapture6.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/9988/5/ScreenCapture5.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/9988/3/ScreenCapture3.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Terumo Business and Products</FONT></STRONG> </div><div style="margin-bottom: 10px;">- Cardio &amp; Vascular; Blood transfusion; General Hospital </div><div><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/9988/12/ScreenCapture12.jpg?user-agent=rss"> </div><!-- Comment details --><a name="pharmaworld9988attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/9988/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(35,1 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/9988/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(34,6 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/9988/3/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(19,1 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/9988/4/ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(37,8 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/9988/5/ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(7,9 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/9988/6/ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(34 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/9988/7/ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(25,6 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/9988/8/ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(6,9 KB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/9988/9/ScreenCapture9.jpg">ScreenCapture9.jpg</a>&nbsp;&nbsp;(80 KB)<br>&nbsp;&nbsp;10.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/9988/10/ScreenCapture10.jpg">ScreenCapture10.jpg</a>&nbsp;&nbsp;(69,5 KB)<br>&nbsp;&nbsp;11.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/9988/11/ScreenCapture11.jpg">ScreenCapture11.jpg</a>&nbsp;&nbsp;(76,4 KB)<br>&nbsp;&nbsp;12.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/9988/12/ScreenCapture12.jpg">ScreenCapture12.jpg</a>&nbsp;&nbsp;(33,2 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120831&edate=20120501&rec=9988">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-07-26T13:15:25+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/9988/1/ScreenCapture1.jpg" length="35918" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/9988/2/ScreenCapture2.jpg" length="35416" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/9988/3/ScreenCapture3.jpg" length="19510" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/9988/4/ScreenCapture4.jpg" length="38670" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/9988/5/ScreenCapture5.jpg" length="8068" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/9988/6/ScreenCapture6.jpg" length="34803" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/9988/7/ScreenCapture7.jpg" length="26179" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/9988/8/ScreenCapture8.jpg" length="7084" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/9988/9/ScreenCapture9.jpg" length="81922" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/9988/10/ScreenCapture10.jpg" length="71175" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/9988/11/ScreenCapture11.jpg" length="78188" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/9988/12/ScreenCapture12.jpg" length="33976" type="image/jpeg"/></item><item>
<title>Study - A Subcutaneous Octreotide Hydrogel Implant for the Treatment of Acromegaly [class:SomatostatinAnalogue, dis:Acromegaly, prod:Octreotide, :PharmaWorld:mkt:Brazil, :PharmaWorld:mkt:Intercontinental]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7038</link>
<description>Study - A Subcutaneous Octreotide Hydrogel Implant for the Treatment of Acromegaly [class:SomatostatinAnalogue, dis:Acromegaly, prod:Octreotide, :PharmaWorld:mkt:Brazil, :PharmaWorld:mkt:Intercontinental]</description><category>class:SomatostatinAnalogue</category><category>dis:Acromegaly</category><category>prod:Octreotide</category><category>mkt:Brazil</category><category>mkt:Intercontinental</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7038</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120831&edate=20120501&rec=7038">Study - A Subcutaneous Octreotide Hydrogel Implant for the Treatment of Acromegaly</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=class%3aSomatostatinAnalogue"><font color="#e95e0b">:Endocrinology:class:SomatostatinAnalogue</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=dis%3aAcromegaly"><font color="#e95e0b">:Endocrinology:dis:Acromegaly</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=prod%3aOctreotide"><font color="#e95e0b">:Endocrinology:prod:Octreotide</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=mkt%3aBrazil"><font color="#e95e0b">:PharmaWorld:mkt:Brazil</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=mkt%3aIntercontinental"><font color="#e95e0b">:PharmaWorld:mkt:Intercontinental</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7038">Endocrinology7038</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/199">clm11175</a> | 25 July 2012 | 15:38</font><br><br><div style="margin-bottom: 10px;">Comment: The 6-months results of 2 Ph2 open-label randomized studies (PK, efficacy and safety) with sc Endo Pharm's octreotide hydrogel implant in acromegalic patients show that octreotide hydrogel implants were well tolerated and maintained stable octreotide release and suppression of IGF-1 and GH.<wbr> </div><div style="margin-bottom: 10px;">Study: Patients received one or two 52-mg hydrated implants (52-mg study) or a hydrated or nonhydrated 84-mg implant (84-mg study) inserted subcutaneously in the upper arm.<wbr> </div><div style="margin-bottom: 10px;">Results: In both studies, IGF-1 and GH declined in month 1 and were significantly suppressed during the 6-month treatment versus baseline (P&lt;0.<wbr>001).<wbr> With the 52- and 84-mg implants, respectively, 27% (3/<wbr>11) and 52% (17/<wbr>33) of patients achieved IGF-1 normalization and 73% (8/<wbr>11) and 39% (13/<wbr>33) exhibited GH &lt;2.<wbr>5 ng/<wbr>mL </div><div style="margin-bottom: 10px;">Conclusions: Octreotide hydrogel implants were well tolerated and maintained stable octreotide release and suppression of IGF-1 and GH over 6 months.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7038/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">Source: Endocr Pract.<wbr> 2012 Jul 11:1-38.<wbr> [Epub ahead of print] A Subcutaneous Octreotide Hydrogel Implant for the Treatment of Acromegaly.<wbr> Gadelha MR, Chieffo C, Bai SA, Hu X, Frohman LA<EM>.<wbr> Division of Endocrinology, Federal University of Rio de Janeiro, Rio de Janeiro, RJ, Brazil.<wbr></EM> </div><div><EM>Already presented at ECE 2011, 30 April - 4 May 2011, Rotterdam </EM><EM>Endocrine Abstracts </EM>(2011) <STRONG>26</STRONG> P263 <STRONG>Octreotide pharmacokinetics and biochemical control of acromegaly using a subcutaneous octreotide hydrogel implant</STRONG> C Chieffo et al <SUP><STRONG>Endo Pharmaceuticals</STRONG>, Inc.<wbr>, Chadds Ford, Pennsylvania, USA; University of Illinois at Chicago, Chicago, Illinois, USA; Federal University of Rio de Janeiro, Rio de Janeiro, RJ, Brazil.<wbr></SUP> </div><!-- Comment details --><a name="endocrinology7038attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7038/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(27 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120831&edate=20120501&rec=7038">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-07-25T15:38:38+02:00</dc:date><dc:creator>clm11175</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7038/1/ScreenCapture1.jpg" length="27629" type="image/jpeg"/></item><item>
<title>Novartis' Oral CYP17 Inhibitor to Enter Ph1/Ph2 for CRPC [comp:Novartis, dis:Prostate, :PharmaWorld:sub:ClinicalTrial]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology8399</link>
<description>Novartis' Oral CYP17 Inhibitor to Enter Ph1/Ph2 for CRPC [comp:Novartis, dis:Prostate, :PharmaWorld:sub:ClinicalTrial]</description><category>comp:Novartis</category><category>dis:Prostate</category><category>sub:ClinicalTrial</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology8399</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8399">Novartis' Oral CYP17 Inhibitor to Enter Ph1/<wbr>Ph2 for CRPC</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=comp%3aNovartis"><font color="#e95e0b">:Oncology:comp:Novartis</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=sub%3aClinicalTrial"><font color="#e95e0b">:PharmaWorld:sub:ClinicalTrial</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8399">Oncology8399</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 25 July 2012 | 14:41</font><br><br><div style="margin-bottom: 10px;">Comment: Cliniclatrials.<wbr>gov is listing a new trial which will assess the safety and preliminary antitumor activity of the drug in CRPC patients abiraterone naive or abiraterone resistant.<wbr> Primary outcome is to measure incidence rate of DLT (Ph1), and patients with PSA response (Ph2 only).<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Study Details - </FONT></STRONG><A href="http://clinicaltrials.gov/ct2/show/NCT01647789?cond=botulinum+OR+prostate+OR+neuroendocrine+OR+acromegaly+OR+Cushing+OR+hemophilia+OR+haemophilia&amp;fund=2&amp;rcv_s=05%2F26%2F2012&amp;rank=12"><STRONG><FONT size="3">NCT01647789</FONT></STRONG></A> </div><div style="margin-bottom: 10px;">Recruitment: approx.<wbr> 100 men (&gt;18 yrs) </div><div style="margin-bottom: 10px;">Start date: Sept.<wbr> 2012 - Completion date: Nov.<wbr> 2014 </div><div style="margin-bottom: 10px;">Location: Canada (1) </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">About the Drug - CFG920</FONT></STRONG> </div><div style="margin-bottom: 10px;">Whilst highlighted in this trial, there has been no previous published reference to this drug that may allow its identification.<wbr> </div><div style="margin-bottom: 10px;">Reduction of extragonadal androgen production through CYP17 inhibition is a validated CRPC treatment paradigm.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Competition (with same MOA) - </FONT></STRONG> </div><div style="margin-bottom: 10px;">- Tokai's TK-001 (galeterone) is expected to enter Ph2 in H2:12.<wbr> </div><div style="margin-bottom: 10px;">- Viamet's VT-464 is in Ph1/<wbr>Ph2.<wbr> </div><div style="margin-bottom: 10px;">- Takeda's TAK-700 (orteronel) for post-docetaxel/<wbr>chemotherapy naive is in Ph3: </div><div><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8399/1/ScreenCapture1.jpg?user-agent=rss"> </div><!-- Comment details --><a name="oncology8399attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8399/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(11 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8399">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-07-25T14:41:18+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8399/1/ScreenCapture1.jpg" length="11284" type="image/jpeg"/></item><item>
<title>FDA Grants Priority Review to Enzalutamide in Post-Chemo Setting [dis:Prostate, prod:MDV3100, :PharmaWorld:sub:Regulatory, :PharmaWorld:mkt:NorthAmerica]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology8398</link>
<description>FDA Grants Priority Review to Enzalutamide in Post-Chemo Setting [dis:Prostate, prod:MDV3100, :PharmaWorld:sub:Regulatory, :PharmaWorld:mkt:NorthAmerica]</description><category>dis:Prostate</category><category>prod:MDV3100</category><category>sub:Regulatory</category><category>mkt:NorthAmerica</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology8398</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8398">FDA Grants Priority Review to Enzalutamide in Post-Chemo Setting</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=prod%3aMDV3100"><font color="#e95e0b">:Oncology:prod:MDV3100</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=mkt%3aNorthAmerica"><font color="#e95e0b">:PharmaWorld:mkt:NorthAmerica</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=sub%3aRegulatory"><font color="#e95e0b">:PharmaWorld:sub:Regulatory</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8398">Oncology8398</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 24 July 2012 | 14:22</font><br><br><div style="margin-bottom: 10px;">Comment: Two months after it was submitted for US approval, enzalutamide has been accepted for NDA filling by the FDA (with a Priority Review Designation).<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Contractual Milestone</FONT></STRONG> </div><div style="margin-bottom: 10px;">The <ORG>FDA's</ORG> acceptance of the NDA triggers a $<MONEY>10M milestone payment to <ORG value="NASDAQ-NMS:MDVN">Medivation</ORG> under its agreement with Astellas.<wbr></MONEY> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">EU Regulatory Situation</FONT></STRONG> </div><div>MAA was submitted at the end of June 2012 (please see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8356" class="defaultlink">Oncology8356: MAA Submitted for Enzalutamide (ex MDV-3100) in Post-Chemo Setting</a>).<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8398">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-07-24T14:22:11+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>DKPHybrids Competitors</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/DKPHybrids175</link>
<description>DKPHybrids Competitors</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/DKPHybrids175</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=DKPHybrids&sdate=20120831&edate=20120501&rec=175">DKPHybrids Competitors</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/DKPHybrids175">DKPHybrids175</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/254">Vivien SORET</a> | 24 July 2012 | 14:19</font><br><br><div><DIV class="ii">
<TABLE align="left" border="1" cellpadding="3" cellspacing="0" class="normaltable" frame="void" style="background-color: #f5f5f5; border: #ffffff 1px solid;"><TBODY><TR><TD align="left" scope="row" style="width: 150px; height: 50px; border: 1px solid #ffffff;" valign="middle">
<P><SPAN style="font-size: medium;"><STRONG><a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=DKPHybrids&sdate=20120831&edate=All&cat=%3aDKPHybrids%3acomp%3aAcino&rsin=/link%20%3a%3aDKPHybrids%20%3a%3aDKPHybrids%3acomp%3aAcino%20all%20%27Acino%27&title=Acino" class="defaultlink">Acino</a></STRONG></SPAN></P>
</TD>
<TD align="left" scope="row" style="width: 150px; height: 50px; border: 1px solid #ffffff;" valign="middle">
<P><SPAN style="font-size: medium;"><STRONG><a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=DKPHybrids&sdate=20120831&edate=All&cat=%3aDKPHybrids%3acomp%3aCamurus&rsin=/link%20%3a%3aDKPHybrids%20%3a%3aDKPHybrids%3acomp%3aCamurus%20all%20%27Camurus%27&title=Camurus" class="defaultlink">Camurus</a></STRONG></SPAN></P>
</TD>
<TD align="left" scope="row" style="width: 150px; height: 50px; border: 1px solid #ffffff;" valign="middle">
<P><SPAN style="font-size: medium;"><STRONG><a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=DKPHybrids&sdate=20120831&edate=All&cat=%3aDKPHybrids%3acomp%3aCipla&rsin=/link%20%3a%3aDKPHybrids%20%3a%3aDKPHybrids%3acomp%3aCipla%20all%20%27Cipla%27&title=Cipla" class="defaultlink">Cipla</a></STRONG></SPAN></P>
</TD>
<TD align="left" scope="row" style="width: 150px; height: 50px; border: 1px solid #ffffff;" valign="middle">
<P><SPAN style="font-size: medium;"><STRONG><a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=DKPHybrids&sdate=20120831&edate=All&cat=%3aDKPHybrids%3acomp%3aDaewoong&rsin=/link%20%3a%3aDKPHybrids%20%3a%3aDKPHybrids%3acomp%3aDaewoong%20All%20%27Daewoong%27&title=Daewoong" class="defaultlink">Daewoong</a></STRONG></SPAN></P>
</TD>
</TR>
<TR><TD align="left" scope="row" style="width: 150px; height: 50px; border: 1px solid #ffffff;" valign="middle">
<P><SPAN style="font-size: medium;"><STRONG><a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=DKPHybrids&sdate=20120831&edate=All&cat=%3aDKPHybrids%3acomp%3aDongKook&rsin=/link%20%3a%3aDKPHybrids%20%3a%3aDKPHybrids%3acomp%3aDongKook%20all%20%27Dongkook%27&title=Dongkook" class="defaultlink">Dongkook</a></STRONG></SPAN></P>
</TD>
<TD align="left" scope="row" style="width: 150px; height: 50px; border: 1px solid #ffffff;" valign="middle"><SPAN style="font-size: medium;"><STRONG><a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=DKPHybrids&sdate=20120831&edate=All&cat=%3aDKPHybrids%3acomp%3aOakwood&rsin=/link%20%3a%3aDKPHybrids%20%3a%3aDKPHybrids%3acomp%3aOakwood%20all%20%27Oakwood%27&title=Oakwood" class="defaultlink">Oakwood</a></STRONG></SPAN></TD>
<TD align="left" scope="row" style="width: 150px; height: 50px; border: 1px solid #ffffff;" valign="middle">
<P><SPAN style="font-size: medium;"><STRONG><a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=DKPHybrids&sdate=20120831&edate=All&cat=%3aDKPHybrids%3acomp%3aPooyeshDarou&rsin=/link%20%3a%3aDKPHybrids%20%3a%3aDKPHybrids%3acomp%3aPooyeshDarou%20all%20%27Pooyesh%20Darou%27&title=Pooyesh%20Darou" class="defaultlink">Pooyesh Darou</a></STRONG></SPAN></P>
</TD>
<TD align="left" scope="row" style="width: 150px; height: 50px; border: 1px solid #ffffff;" valign="middle">&nbsp;</TD>
</TR>
<TR><TD align="left" scope="row" style="width: 150px; height: 50px; border: 1px solid #ffffff;" valign="middle">
<P><SPAN style="font-size: medium;"><STRONG><a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=DKPHybrids&sdate=20120831&edate=All&cat=%3aDKPHybrids%3acomp%3aSandoz&rsin=/link%20%3a%3aDKPHybrids%20%3a%3aDKPHybrids%3acomp%3aSandoz%20all%20%27Sandoz%27&title=Sandoz" class="defaultlink">Sandoz</a></STRONG></SPAN></P>
</TD>
<TD align="left" scope="row" style="width: 150px; height: 50px; border: 1px solid #ffffff;" valign="middle">
<P><SPAN style="font-size: medium;"><STRONG><a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=DKPHybrids&sdate=20120831&edate=All&cat=%3aDKPHybrids%3acomp%3aSunPharma&rsin=/link%20%3a%3aDKPHybrids%20%3a%3aDKPHybrids%3acomp%3aSunPharma%20all%20%27Sun%20Pharma%27&title=Sun%20Pharma" class="defaultlink">Sun Pharma</a></STRONG></SPAN></P>
</TD>
<TD align="left" colspan="2" scope="row" style="height: 50px; border: 1px solid #ffffff; width: 190px;" valign="middle">
<P>For more competitors use the search engine</P>
</TD>
</TR>
</TBODY>
</TABLE>
</DIV> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=DKPHybrids&sdate=20120831&edate=20120501&rec=175">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-07-24T14:19:55+02:00</dc:date><dc:creator>vis24524</dc:creator></item><item>
<title>First Patient Treated with Debiopharm's SC Triptorelin Pamoate 6M Formulation [comp:Debiopharm, dis:Prostate, :PharmaWorld:sub:ClinicalTrial, news]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology8396</link>
<description>First Patient Treated with Debiopharm's SC Triptorelin Pamoate 6M Formulation [comp:Debiopharm, dis:Prostate, :PharmaWorld:sub:ClinicalTrial, news]</description><category>comp:Debiopharm</category><category>dis:Prostate</category><category>sub:ClinicalTrial</category><category>news</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology8396</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8396">First Patient Treated with Debiopharm's SC Triptorelin Pamoate 6M Formulation</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=comp%3aDebiopharm"><font color="#e95e0b">:Oncology:comp:Debiopharm</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=news"><font color="#e95e0b">:Oncology:news</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=sub%3aClinicalTrial"><font color="#e95e0b">:PharmaWorld:sub:ClinicalTrial</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8396">Oncology8396</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 24 July 2012 | 11:06</font><br><br><div style="margin-bottom: 10px;">Comment: The multicentre, open, non-comparative Ph3 study will be conducted in the Republic of South Africa.<wbr> It is designed to investigate the efficacy, safety and PK of 2 sc injections of the drug for advanced prostate cancer.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Trial Details - <A href="http://clinicaltrials.gov/ct2/show/NCT01656161?recr=Open&amp;cond=botulinum+OR+prostate+OR+neuroendocrine+OR+acromegaly+OR+Cushing+OR+hemophilia+OR+haemophilia+OR+bladder&amp;fund=2&amp;rcv_s=07%2F16%2F2012&amp;rank=9">NCT01656161</A></FONT></STRONG> </div><div style="margin-bottom: 10px;"><U>Recruitment</U>: approx.<wbr> 120 patients </div><div style="margin-bottom: 10px;"><U>Inclusion criteria</U>: Patients with advanced prostate cancer, and patients with recurrent lower stage prostate cancer and rising PSA following local therapy failure who are candidates for ADT.<wbr> </div><div style="margin-bottom: 10px;"><U>Efficacy</U>: Patient evaluation will be primarily based on the efficacy in achieving castrate levels of testosterone (&lt; 1.<wbr>735 nmol/<wbr>L [50 ng/<wbr>dL]) 28 days after the first injection of Debio 8206 and in maintaining castrate levels of testosterone from Day 57 to Day 337.<wbr> </div><div style="margin-bottom: 10px;"><U>Safety</U>: The safety profile will also be evaluated.<wbr> Additional efficacy measures will include the assessment of the percentage of patients who show an increase in testosterone levels 48 hours after the second injection of Debio 8206, as well as the absence of gonadotropin (LH) stimulation 2 hours after the second injection of Debio 8206 and the change in PSA from baseline to study end.<wbr> </div><div>Source: <A href="http://www.debiopharm.com/media/press-releases/95-debio-8206-sc/3217-debiopharm-group-first-patient-treated-in-phase-iii-study-with-subcutaneous-administration-of-deb.html">Debiopharm</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8396">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-07-24T11:06:55+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Chiasma Will Use the Hybrid Application to Submit Octreolin in EU [dis:Acromegaly, sub:Hybrids, Alert]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7036</link>
<description>Chiasma Will Use the Hybrid Application to Submit Octreolin in EU [dis:Acromegaly, sub:Hybrids, Alert]</description><category>dis:Acromegaly</category><category>sub:Hybrids</category><category>Alert</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7036</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120831&edate=20120501&rec=7036">Chiasma Will Use the Hybrid Application to Submit Octreolin in EU</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=Alert"><font color="#e95e0b">:Endocrinology:Alert</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=dis%3aAcromegaly"><font color="#e95e0b">:Endocrinology:dis:Acromegaly</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=sub%3aHybrids"><font color="#e95e0b">:Endocrinology:sub:Hybrids</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7036">Endocrinology7036</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 24 July 2012 | 08:47</font><br><br><div style="margin-bottom: 10px;">Comment: The company just closed a $38.<wbr>5M equitiy financing.<wbr> Part of the investment is expected to provide funding for the completion of the Ph3 of Octreolin for acromegaly, which is planned to complete in Q2:13.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Next Steps</FONT></STRONG> </div><div style="margin-bottom: 10px;">According to managememt, if the results of the Ph3 for acromegaly are positive, Chiasma plans to submit a NDA (using the 505 (b)(2) NDA pathway) in the U.<wbr>S, and its EMA equivalent, the Hybrid Application in EU in 2013.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Octreolin Development</STRONG> </div><div>During 2011, the company started the preparation for a second indication of Octreolin, in neuroendocrine tumors.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120831&edate=20120501&rec=7036">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-07-24T08:47:44+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Poland Has Plans to Increase Supply of Pharmaceuticals from South Korea [mkt:Korea, mkt:Europe, mkt:Intercontinental]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld9986</link>
<description>Poland Has Plans to Increase Supply of Pharmaceuticals from South Korea [mkt:Korea, mkt:Europe, mkt:Intercontinental]</description><category>mkt:Korea</category><category>mkt:Europe</category><category>mkt:Intercontinental</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld9986</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120831&edate=20120501&rec=9986">Poland Has Plans to Increase Supply of Pharmaceuticals from South Korea</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=mkt%3aEurope"><font color="#e95e0b">:PharmaWorld:mkt:Europe</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=mkt%3aIntercontinental"><font color="#e95e0b">:PharmaWorld:mkt:Intercontinental</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=mkt%3aKorea"><font color="#e95e0b">:PharmaWorld:mkt:Korea</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld9986">PharmaWorld9986</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 23 July 2012 | 14:48</font><br><br><div style="margin-bottom: 10px;">Comment: Poland's health minister Bartosz Arłukowicz has revealed plans to increase supervision of the promotional activities of pharmaceutical companies and to seek to diversify the supply of pharmaceuticals to the Polish public health system, among a series of reforms set out in an interview with Polish newspaper <EM>Gazeta Wyborcza.<wbr> </EM>Plans to diversify the supply of pharmaceuticals involving widening the supply net to include South Korea may be partly a response to the difficulties encountered in late 2011 and early 2012 with the supply of a number of cytostatic medicines used in the treatment of cancer—a problem also experienced in several other European countries, including Romania and Bulgaria.<wbr> </div><div style="margin-bottom: 10px;">The most recent data from Polish pharmaceutical market research organisation PharmaExpert show that, following months of consistent declines in the value of the Polish pharmaceutical market (measured in terms of sales from pharmacies), June saw the market bounce back with 6.<wbr>1% year-on-year (y/<wbr>y) growth compared with June 2011, with non-reimbursed and over-the-counter medicines driving the market's improvement.<wbr> </div><div style="margin-bottom: 10px;">In response to a question about a new law set for introduction in 2013 in the United States, according to which pharmaceutical companies will have to reveal information of all payments made in order to improve transparency, Arłukowicz is reported as stating that he is committed to ensuring all players participating in the system funded by public money are subject to procedures that guarantee transparency.<wbr> Thus, he confirms his intention that all pharmaceutical lobbyists will be documented, as well as who they met, what they discussed, and what the outcome was.<wbr> </div><div style="margin-bottom: 10px;">This drive to greater transparency is already under way, Arłukowicz states, with the newly created Economic Committee assessing the cost effectiveness of medicines, while the Transparency Board and Agency for Health Technology Assessment are also involved in the assessment of medicines and, as he states, the process is all transparently transcribed, as are the negotiations on prices between pharmaceutical companies and the Ministry of Health.<wbr> </div><div style="margin-bottom: 10px;">Arłukowicz is reported as confirming that he is negotiating with pharmaceutical producers from South Korea in order to diversify supplies of pharmaceuticals to the Polish public healthcare system, which have been subject to some problems.<wbr> Arłukowicz reveals that the topic of diversifying supply to include countries that currently do not supply European markets was discussed at a meeting of health ministers in Cyprus (as part of Cyprus assuming the EU presidency for the second half of 2012).<wbr> </div><div style="margin-bottom: 10px;">As Polish medical news provider Termedia reports, in Cyprus, Arłukowicz met with the European commissioner for health and consumer policy, John Dalli, as well as holding meetings with the health ministers of Romania and Bulgaria, in which the subject of diversification was discussed.<wbr> The source also emphasises that recently, the South Korean authorities signed an agreement with the EU concerning the trade of various products, including medicines.<wbr> </div><div style="margin-bottom: 10px;">In addition to these plans, Arłukowicz is reported as stating his intention of creating a system in which competition is introduced for the National Health Fund (NFZ), and of challenging and ultimately getting rid of what he sees as the excessively centralised control of the central NFZ office in Polish capital Warsaw.<wbr> He set out his intention to realise a plan to introduce additional voluntary health insurance—to be provided by private insurance providers—as part of the public health system, which would be available to those willing and/<wbr>or able to pay extra on top of the mandatory health insurance levy.<wbr> </div><div style="margin-bottom: 10px;"><P class="bodyHeading2"><STRONG><FONT size="3">Polish Pharmaceutical Market Bounces Back in June, Growing 6.<wbr>1% Y/<wbr>Y</FONT></STRONG></P> </div><div style="margin-bottom: 10px;">Separately, the most recent data from Polish pharmaceutical market research organisation PharmaExpert show that, following months of consistent declines in the value of the Polish pharmaceutical market (measured in terms of sales from pharmacies), June saw the market return to growth with 6.<wbr>1% y/<wbr>y growth compared with June 2011 reaching PLN2.<wbr>25 billion (USD646.<wbr>9 million), with non-reimbursed and over-the-counter medicines driving the market's improvement.<wbr> The data show that sales of reimbursed medicines continued to decline, as in previous months, falling by 5.<wbr>3% y/<wbr>y to PLN921 million, although PharmaExpert points out that last month, the decline in this market segment was in double figures.<wbr> The main driver of growth was non-reimbursed prescription drugs, sales of which jumped 25.<wbr>0% y/<wbr>y, to PLN502 million, while over-the-counter (OTC) medicines also made a strong contribution, with sales of these jumping 11.<wbr>3% y/<wbr>y, reaching PLN809 million.<wbr> Another change in the prevailing trend noted in June was the increase in the value of reimbursement paid by the NFZ, in spite of the reduction in the value of the sales of reimbursed drugs; the value of reimbursement paid out increased by 2.<wbr>0% y/<wbr>y to PLN660 million, reports PharmaExpert.<wbr> </div><div style="margin-bottom: 10px;"><P class="bodyHeading2"><STRONG><FONT size="3">Outlook and Implications</FONT></STRONG></P> </div><div style="margin-bottom: 10px;">Arłukowicz's plans for a tightening of the supervision of the pharmaceutical industry's promotional activities have not yet been officially announced as part of a policy statement, and it is likely that the regulatory overload currently plaguing the Polish healthcare system will mean it will be a while before they are.<wbr> It is indicative of the minister's direction of thought, however, that he should choose to speak of such plans in such a major interview.<wbr> Neighbouring Czech Republic is at an advanced stage in the development of stricter regulations for contacts between pharma representatives and healthcare professionals, while Slovakia introduced a batch of new regulations in this area in 2011.<wbr> </div><div style="margin-bottom: 10px;">Plans to diversify the supply of pharmaceuticals involving widening the supply net to include South Korea may be partly a response to the difficulties encountered in late 2011 and early 2012 with the supply of a number of cytostatic medicines used in the treatment of cancer—a problem also experienced in several other European countries, including Romania and Bulgaria.<wbr> The fact that Arłukowicz was talking with the health ministers of these countries in Cyprus would indicate that they too may have similar plans.<wbr> The presence of biosimilars producers in South Korea—such as Celltrion, which has just become the first company in the world to gain approval for the marketing of a biosimilar monoclonal antibody, with the approval of its version of Remicade (infliximab; Johnson and Johnson, US) on the South Korean market—could also be an important element in these EU countries' desire to increase supply from South Korea.<wbr> These plans of increasing supplies from South Korea could potentially affect the companies from the US and Europe currently supplying Poland.<wbr> </div><div style="margin-bottom: 10px;">The improvement in the Polish pharmaceutical market in June is to a great extent due to patients bearing an increased amount of the cost of pharmaceutical treatment, a trend that has marked the first half of 2012.<wbr> It is worth emphasising that the decline in the sale of reimbursed medicines has slowed, and reimbursement expenditure has risen, but it is still certainly true that non-reimbursed prescription drugs and OTCs represent the most attractive market segment in terms of growth in Poland in 2012, although once the dust settles from the major reforms of the reimbursement system, sales of reimbursed drugs could again return to similar levels as those before the changes.<wbr> </div><div>Source: Global Insight </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120831&edate=20120501&rec=9986">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-07-23T14:48:52+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Highlights of Leerink Swann's 2Q Cosmetic Survey Results [comp:Allergan, comp:Merz, sub:Aesthetics, :PharmaWorld:mkt:NorthAmerica, prod:Botox]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology6512</link>
<description>Highlights of Leerink Swann's 2Q Cosmetic Survey Results [comp:Allergan, comp:Merz, sub:Aesthetics, :PharmaWorld:mkt:NorthAmerica, prod:Botox]</description><category>comp:Allergan</category><category>comp:Merz</category><category>sub:Aesthetics</category><category>mkt:NorthAmerica</category><category>prod:Botox</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology6512</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120831&edate=20120501&rec=6512">Highlights of Leerink Swann's 2Q Cosmetic Survey Results</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=comp%3aAllergan"><font color="#e95e0b">:Neurology:comp:Allergan</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=comp%3aMerz"><font color="#e95e0b">:Neurology:comp:Merz</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=prod%3aBotox"><font color="#e95e0b">:Neurology:prod:Botox</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=sub%3aAesthetics"><font color="#e95e0b">:Neurology:sub:Aesthetics</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=mkt%3aNorthAmerica"><font color="#e95e0b">:PharmaWorld:mkt:NorthAmerica</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology6512">Neurology6512</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 23 July 2012 | 14:35</font><br><br><div style="margin-bottom: 10px;">Comment: The survey polled 62 U.<wbr><WBR>S based dermatologists (33) and plastic surgeons (29).<wbr> The results suggest a slowing but not declining market.<wbr> Botox captured &gt;80% of the overall market and 80.<wbr>8% of new patients in 2Q:12.<wbr> Physicians cite interest in Merz's new product offerings as well as Allergan's novel filler, Voluma (currently filed with FDA).<wbr> A selection of key sldes is provided below.<wbr></WBR> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">MEDACorp Survey Trends in Cosmetic Procedures in Q2 2012</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/6512/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/6512/3/ScreenCapture3.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><WBR>
 </div><div style="margin-bottom: 10px;"><P><STRONG><FONT size="3">Full report is available on demand to Brigitte Deschamps</FONT></STRONG></P> </div><div></WBR> </div><!-- Comment details --><a name="neurology6512attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/6512/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(67,5 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/6512/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(53,2 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/6512/3/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(57,6 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120831&edate=20120501&rec=6512">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-07-23T14:35:56+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/6512/1/ScreenCapture1.jpg" length="69143" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/6512/2/ScreenCapture2.jpg" length="54451" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/6512/3/ScreenCapture3.jpg" length="58990" type="image/jpeg"/></item><item>
<title>Somatostatin Analog Pasireotide LAR to be Investigated in CRPC [dis:Prostate, :Endocrinology:comp:Novartis, :Endocrinology:prod:Pasireotide, :PharmaWorld:sub:ClinicalTrial, headline, :Endocrinology:class:SomatostatinAnalogue]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology8391</link>
<description>Somatostatin Analog Pasireotide LAR to be Investigated in CRPC [dis:Prostate, :Endocrinology:comp:Novartis, :Endocrinology:prod:Pasireotide, :PharmaWorld:sub:ClinicalTrial, headline, :Endocrinology:class:SomatostatinAnalogue]</description><category>dis:Prostate</category><category>comp:Novartis</category><category>prod:Pasireotide</category><category>sub:ClinicalTrial</category><category>headline</category><category>class:SomatostatinAnalogue</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology8391</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8391">Somatostatin Analog Pasireotide LAR to be Investigated in CRPC</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=class%3aSomatostatinAnalogue"><font color="#e95e0b">:Endocrinology:class:SomatostatinAnalogue</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=comp%3aNovartis"><font color="#e95e0b">:Endocrinology:comp:Novartis</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=prod%3aPasireotide"><font color="#e95e0b">:Endocrinology:prod:Pasireotide</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=headline"><font color="#e95e0b">:Oncology:headline</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=sub%3aClinicalTrial"><font color="#e95e0b">:PharmaWorld:sub:ClinicalTrial</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8391">Oncology8391</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 23 July 2012 | 13:12</font><br><br><div style="margin-bottom: 10px;">Comment: Clinicaltrials.<wbr>gov is listing a new Ph1/<wbr>Ph2 trial, designed to define the maximum tolerated dose (MTD) of pasireotide LAR in patients with castration resistant prostate cancer (CRPC).<wbr> It also aims for a preliminary efficacy evaluation of pasireotide within the dose expansion part at the MTD.<wbr> The Novartis' sponsored study will also explore characteristics of patients who might benefit most from this treatment approach.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Trial Design </FONT></STRONG><A href="http://clinicaltrials.gov/ct2/show/NCT01646684?recr=Open&amp;cond=botulinum+OR+prostate+OR+neuroendocrine+OR+acromegaly+OR+Cushing+OR+hemophilia+OR+haemophilia&amp;rcv_s=05%2F24%2F2012&amp;rank=13"><STRONG><FONT size="3">NCT01646684</FONT></STRONG></A> </div><div style="margin-bottom: 10px;">Location: Germany </div><div style="margin-bottom: 10px;">Recruitment: approx.<wbr> 51 </div><div style="margin-bottom: 10px;"><UL><LI>Prior treatment with a GnRH-agonist or GnRH-antagonist for at least 6 months</LI>
<LI>Prior treatment with an anti-androgen (e.<wbr>g.<wbr> bicalutamide, flutamide, cyproteronacetate) is allowed but not necessary</LI>
</UL> </div><div>Start date: Oct.<wbr> 2012 - Completion date: Oct.<wbr> 2014 </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8391">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-07-23T13:12:02+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>re: CHMP Adopted A Postiive Opinion On Label Expansion For Novartis's Afinitor</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology8389</link>
<description>re: CHMP Adopted A Postiive Opinion On Label Expansion For Novartis's Afinitor</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology8389</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8389">re: CHMP Adopted A Postiive Opinion On Label Expansion For Novartis's Afinitor</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8389">Oncology8389</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 23 July 2012 | 09:40</font><br><br><div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">CHMP Adopted A Positive Opinion On Label Expansion For Novartis's Afinitor</span>&nbsp;<font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=dis%3apNET"><font color="#e95e0b">:Endocrinology:dis:pNET</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=class%3aKinaseInhibitors"><font color="#e95e0b">:Oncology:class:KinaseInhibitors</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=headline"><font color="#e95e0b">:Oncology:headline</font></a>]</font></font><br><span style="font-size: 12px;">Comment: On Friday the European CHMP recommended approval of Afinitor (everolimus) for the treatment of certain patients with breast cancer.<wbr> Specifically, for use in combination with Pfizer's exemestane (Aromasin) for the treatment of hormone receptor positive HER2/<wbr>neu- negative postmenopausal advanced breast cancer.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8353">...</a><br><font size="-1">Jacquelyne CANTLE MEYRICK / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8353" class="commentpermalink">Oncology8353</a> / <span class="date">25 June 2012</span> /
<span class="time">11:05:11 o'clock CEST</span>
</font></div><div style="margin-bottom: 10px;">On July 20th, the FDA expanded approval of Afinitor (everolimus) for postmenopausal women with advanced hormonr receptor-positive, HER2-negative breast cancer.<wbr> Novartis noted that the approval marks the &amp;st time the US agency has approved mTOR inhibitor for this indication.<wbr> </div><div style="margin-bottom: 10px;">The approval calls for the drug to be used in combination with Aromasin (exemestane), after failure with Femara (letrozole) or Arimidex (anastrozole).<wbr> </div><div>According to Evaluate Pharma this is an earlier than expected move from the FDA.<wbr> Analysts think that the approval will  deliver more than $1bn in additional sales by 2018, taking Afinitor firmly into blockbuster territory.<wbr> This promise in breast cancer has not only helped Afinitor to be the number one growth driver for Novartis, it also goes some way to helping to offset the revenue gap that will be left when Diovan loses patent protection in September 2012.<wbr> While approval in breast cancer is the biggest win for Novartis, there are studies in a number of other indications that could see sales forecasts grow further.<wbr> </div><!-- Comment details --><font size="-1">Brigitte DESCHAMPS / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8389" class="commentpermalink">Oncology8389</a> / <span class="date">23 July 2012</span> /
<span class="time">09:40:00 o'clock CEST</span>
</font><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8389">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8353">View thread  Oncology8353: CHMP Adopted A Positive Opinion On Label Expansion For Novartis's Afinitor</a>]]></content:encoded><dc:date>2012-07-23T09:40:00+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Next Launch of GP Pharm's Leuprorelin 1M in Spain [comp:GPPharm, prod:Leuprorelin, :PharmaWorld:mkt:Spain, :PharmaWorld:mkt:Europe, headline]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/DKPHybrids171</link>
<description>Next Launch of GP Pharm's Leuprorelin 1M in Spain [comp:GPPharm, prod:Leuprorelin, :PharmaWorld:mkt:Spain, :PharmaWorld:mkt:Europe, headline]</description><comments>http://ci.beaufour-ipsen.com/traction/permalink/DKPHybrids171</comments><category>comp:GPPharm</category><category>prod:Leuprorelin</category><category>mkt:Spain</category><category>mkt:Europe</category><category>headline</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/DKPHybrids171</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=DKPHybrids&sdate=20120831&edate=20120501&rec=171">Next Launch of GP Pharm's Leuprorelin 1M in Spain</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=DKPHybrids&sdate=20120831&edate=20120501&cat=comp%3aGPPharm"><font color="#e95e0b">:DKPHybrids:comp:GPPharm</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=DKPHybrids&sdate=20120831&edate=20120501&cat=headline"><font color="#e95e0b">:DKPHybrids:headline</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=DKPHybrids&sdate=20120831&edate=20120501&cat=prod%3aLeuprorelin"><font color="#e95e0b">:DKPHybrids:prod:Leuprorelin</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=mkt%3aEurope"><font color="#e95e0b">:PharmaWorld:mkt:Europe</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=mkt%3aSpain"><font color="#e95e0b">:PharmaWorld:mkt:Spain</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/DKPHybrids171">DKPHybrids171</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 20 July 2012 | 16:52</font><br><br><div style="margin-bottom: 10px;">Comment: Thanks to Esther Minguell we have learnt that GP Pharm intends to launch its monthly leuprorelin, Lutrate&reg; Depot 3.<wbr>75mg, in September 2012 for the prostate cancer indication.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Additional Information</FONT></STRONG> </div><div style="margin-bottom: 10px;">Ex-factory price: 107.<wbr>09&euro; (same as Procrin 1M).<wbr> </div><div style="margin-bottom: 10px;">The drug was approved in November 2011.<wbr> </div><div><img src="http://ci.beaufour-ipsen.com/db/attachments/dkphybrids/171/1/ScreenCapture1.jpg?user-agent=rss"> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="DKPHybrids206c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">On November 20th, GP Pharma started the promotion of Lutrate Depot 3.<wbr>75mg in Spain.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Price</FONT></STRONG> </div><div>GP Pharm keeps the price of €159.<wbr>12 PVPIVA (same as Procrin 1M) but the funding maximum price is € 133.<wbr>71.<wbr> </div><font size="-1">Marta GIMENO BAYON PLA / <a href="http://ci.beaufour-ipsen.com/traction/permalink/DKPHybrids206" class="commentpermalink">DKPHybrids206</a> / <span class="date">21 November 2012</span> /
<span class="time">10:56:00 o'clock CET</span>
</font></div><a name="DKPHybrids208c"></a><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">On the web, GP Pharm drug product presentation is made of a small device (mix ject from Medimop/<wbr>West pharmaceuticals) to facilitate solvent transfer and reconstitution .<wbr> This device is not mentionned in the above information .<wbr> Is the final presentation changed ? </div><div style="margin-bottom: 10px;">This device is also used in the Watson /<wbr>US presentation of Pamorelin (from Debio) named TRELSTAR .<wbr> </div><div>More info on the GP-Pharm presentation @ <A href="http://www.packagingdigest.com/article/447084-Drug_delivery_with_ease_and_comfort.php">http:/<wbr>/<wbr>www.<wbr>packagingdigest.<wbr>com/<wbr>article/<wbr>447084-Drug_delivery_with_ease_and_comfort.<wbr>php</A> </div><font size="-1">Bruno TISSIER / <a href="http://ci.beaufour-ipsen.com/traction/permalink/DKPHybrids208" class="commentpermalink">DKPHybrids208</a> / <span class="date">22 November 2012</span> /
<span class="time">09:33:32 o'clock CET</span>
</font></div><a name="DKPHybrids210c"></a><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">Attached some images of the product brochure that is being given by GP Pharma reps to the physicians in Spain.<wbr> </div><div style="margin-bottom: 10px;">You will find some information about the device.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/dkphybrids/210/1/image.jpeg%20%2d%20Windows%20Photo%20Viewer.jpg?user-agent=rss"> </div><div><img src="http://ci.beaufour-ipsen.com/db/attachments/dkphybrids/210/2/image%20(1).jpeg%20%2d%20Windows%20Photo%20Viewer.jpg?user-agent=rss"> </div><font size="-1">Marta GIMENO BAYON PLA / <a href="http://ci.beaufour-ipsen.com/traction/permalink/DKPHybrids210" class="commentpermalink">DKPHybrids210</a> / <span class="date">23 November 2012</span> /
<span class="time">09:25:58 o'clock CET</span>
</font><span style="font-weight: bold; font-style: italic;"></span><a name="DKPHybrids214c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">The device is the same like the mixject device which is used from Watson in US for Trelstar.<wbr> </div><div>Claudia </div><font size="-1">Claudia Schymczyk / <a href="http://ci.beaufour-ipsen.com/traction/permalink/DKPHybrids214" class="commentpermalink">DKPHybrids214</a> / <span class="date">27 November 2012</span> /
<span class="time">09:20:41 o'clock CET</span>
</font></div></div><a name="dkphybrids171attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/dkphybrids/171/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(32,6 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=DKPHybrids&sdate=20120831&edate=20120501&rec=171">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-07-20T16:52:40+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/dkphybrids/171/1/ScreenCapture1.jpg" length="33431" type="image/jpeg"/></item><item>
<title>Leuprorelin (Sandoz) Included on Norway's Reimbursement List in July Updates [prod:Leuprorelin, comp:Sandoz, :Oncology:dis:Prostate, headline, :Oncology:dis:Gynea, :Oncology:prod:Enantone, :PharmaWorld:mkt:Europe]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/DKPHybrids168</link>
<description>Leuprorelin (Sandoz) Included on Norway's Reimbursement List in July Updates [prod:Leuprorelin, comp:Sandoz, :Oncology:dis:Prostate, headline, :Oncology:dis:Gynea, :Oncology:prod:Enantone, :PharmaWorld:mkt:Europe]</description><category>prod:Leuprorelin</category><category>comp:Sandoz</category><category>dis:Prostate</category><category>headline</category><category>dis:Gynea</category><category>prod:Enantone</category><category>mkt:Europe</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/DKPHybrids168</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=DKPHybrids&sdate=20120831&edate=20120501&rec=168">Leuprorelin (Sandoz) Included on Norway's Reimbursement List in July Updates</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=DKPHybrids&sdate=20120831&edate=20120501&cat=comp%3aSandoz"><font color="#e95e0b">:DKPHybrids:comp:Sandoz</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=DKPHybrids&sdate=20120831&edate=20120501&cat=headline"><font color="#e95e0b">:DKPHybrids:headline</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=DKPHybrids&sdate=20120831&edate=20120501&cat=prod%3aLeuprorelin"><font color="#e95e0b">:DKPHybrids:prod:Leuprorelin</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=dis%3aGynea"><font color="#e95e0b">:Oncology:dis:Gynea</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=prod%3aEnantone"><font color="#e95e0b">:Oncology:prod:Enantone</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=mkt%3aEurope"><font color="#e95e0b">:PharmaWorld:mkt:Europe</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/DKPHybrids168">DKPHybrids168</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 20 July 2012 | 13:23</font><br><br><div style="margin-bottom: 10px;">Comment: Norway's Medicines Agency (NMA) published an updated version of the country's reimbursement list for July in which 11 new drugs were included under the funding scheme.<wbr> In addition to the drugs added to this July list, it was noted that Orion's Enanton (leuprorelin) was approved for an expanded population group and reimbursed to patients for symptomatic endometriosis treatment in 3.<wbr>75mg and 11.<wbr>25mg doses.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">About the Drugs</FONT></STRONG> </div><div style="margin-bottom: 10px;">The changes, which came into force 15 June and 1 July 2012, comprise innovative drugs and generic medicines.<wbr> </div><div style="margin-bottom: 10px;"><U>The innovative drugs</U> approved for funding in Norway were Burinex (bumetanide; F.<wbr> Hoffmann-La Roche, Switzerland), Buquel (fentanyl; Meda Asker, Norway), Inovelon (rufinamide, Eisai, Japan), and Singulair (montelukast; Merck &amp; Co, US).<wbr> In addition, Pfizer (US)'s two drugs Neurontin (gabapentin) and Atarax (hydroxyzine) were also included on the list.<wbr> </div><div style="margin-bottom: 10px;"><U>The generic drugs</U> pioglitazon (Teva, Israel), candesartan/<wbr>hydrochlorothiazide Krka and leuprorelin (Sandoz, subsidiary of Novartis, Switzerland), and Ranbaxy (India)'s orfiril retard/<wbr>valproinsyre were also approved for funding as per the current list.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/dkphybrids/168/1/copiedImage%5b0%5d.png?user-agent=rss"> </div><div style="margin-bottom: 10px;"><B>Enanton Status</B> </div><div style="margin-bottom: 10px;">Enanton is market approved for prostate cancer and is already included under the Norwegian reimbursement coverage, and will remain under this status until further notice.<wbr> </div><div style="margin-bottom: 10px;">Back in 2009, Orion struggled with revenue losses from Enanton's prostate cancer indication in neighbouring country Sweden, with a year-on-year decline of 6.<wbr>8% to EUR11.<wbr>9 million (USD14.<wbr>59) in 2009.<wbr> </div><div>Source: Global Insight </div><!-- Comment details --><a name="dkphybrids168attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/dkphybrids/168/1/copiedImage%5b0%5d.png">copiedImage[0].png</a>&nbsp;&nbsp;(43,3 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=DKPHybrids&sdate=20120831&edate=20120501&rec=168">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-07-20T13:23:08+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/dkphybrids/168/1/copiedImage%5b0%5d.png" length="44298" type="image/x-png"/></item><item>
<title>BMS' Brivanib Fails in HCC Trial [news]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology8387</link>
<description>BMS' Brivanib Fails in HCC Trial [news]</description><category>news</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology8387</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8387">BMS' Brivanib Fails in HCC Trial</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=news"><font color="#e95e0b">:Oncology:news</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8387">Oncology8387</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 20 July 2012 | 12:35</font><br><br><div style="margin-bottom: 10px;">Comment: The company has reported the Ph3 BRISK-FL study invesitgating brivanib vs sorafenib as 1st-line treatment for HCC did not meet its primary OS objective based upon a non-inferiority statistical design.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Next Step</FONT></STRONG> </div><div style="margin-bottom: 10px;">BMS has indicated that for now it is continuing the remaining studies of brivanib which include a TACE-combination study and another second-line study in Asian patients.<wbr> Given that these studies involve placebo controls, it is not impossible that brivanib could still succeed.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Competition with Nexavar</FONT></STRONG> </div><div style="margin-bottom: 10px;">Brivanib is unlikely to compete directly with Nexavar even if one or both of these ongoing brivanib trials is successful.<wbr> </div><div style="margin-bottom: 10px;"><U>Currently in Phase III for liver cancer</U> </div><div style="margin-bottom: 10px;">Afinitor (Novartis, mTOR inhibitor) and ramucirumab (Eli LIlly, VEGFR antibody), being tested in the second line setting after Nexavar.<wbr> Given the different mechanisms of action, these agents can be used sequentially or combined with Nexavar.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>About the BRISK-FL Study</STRONG> &gt; <A href="http://clinicaltrials.gov/ct2/show/NCT00858871?term=brisk-fl&amp;rank=1">NCT00858871</A> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Background in Traction</FONT></STRONG> </div><div>In December 2011, BMS announced that the <STRONG>BRISK-PS</STRONG> study did not meet primary endpoint (see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=7988" class="defaultlink">Oncology7988: BMS' Brivanib for HCC Did Not Meet Primary Endpoint in the BRISK-PS Study</a>).<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8387">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-07-20T12:35:11+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Allergan's David Pyott Named Next Chair of California Healthcare [sub:People, :Neurology:comp:Allergan]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld9984</link>
<description>Allergan's David Pyott Named Next Chair of California Healthcare [sub:People, :Neurology:comp:Allergan]</description><category>sub:People</category><category>comp:Allergan</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld9984</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120831&edate=20120501&rec=9984">Allergan's David Pyott Named Next Chair of California Healthcare</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=comp%3aAllergan"><font color="#e95e0b">:Neurology:comp:Allergan</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=sub%3aPeople"><font color="#e95e0b">:PharmaWorld:sub:People</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld9984">PharmaWorld9984</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/20">Alison Attard</a> | 20 July 2012 | 11:08</font><br><br><div style="margin-bottom: 10px;">Comment: California Healthcare is a La Jolla-based nonprofit public policy research and advocacy group that represents the state&rsquo;s biomedical industry.<wbr> </div><div style="margin-bottom: 10px;">California Healthcare has 275 biotechnology, medical device and pharmaceutical companies as members.<wbr> Allergan is the largest company based in Orange County in terms of market capitalization.<wbr> </div><div>Source: Orange County Business Journal 19 July 2012 </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120831&edate=20120501&rec=9984">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-07-20T11:08:22+02:00</dc:date><dc:creator>ala97794</dc:creator></item><item>
<title>Merz and Vanderbilt U. to Test Reliability of an Alogorithm to Diagnose Spasticity [comp:Merz, dis:Spasticity, :PharmaWorld:sub:ClinicalTrial]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology6511</link>
<description>Merz and Vanderbilt U. to Test Reliability of an Alogorithm to Diagnose Spasticity [comp:Merz, dis:Spasticity, :PharmaWorld:sub:ClinicalTrial]</description><category>comp:Merz</category><category>dis:Spasticity</category><category>sub:ClinicalTrial</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology6511</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120831&edate=20120501&rec=6511">Merz and Vanderbilt U.<wbr> to Test Reliability of an Alogorithm to Diagnose Spasticity</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=comp%3aMerz"><font color="#e95e0b">:Neurology:comp:Merz</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=dis%3aSpasticity"><font color="#e95e0b">:Neurology:dis:Spasticity</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=sub%3aClinicalTrial"><font color="#e95e0b">:PharmaWorld:sub:ClinicalTrial</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology6511">Neurology6511</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 19 July 2012 | 18:13</font><br><br><div style="margin-bottom: 10px;">Commet: The newly listed observational trial in clinicaltrials.<wbr>gov will be starting at the beginning of Q4:12.<wbr> Primary outcome measure will assess inter-rater reliability of a spasticity diagnosis flowchart when used by 2 movement disorder specialists.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Stuy Details - </FONT></STRONG><A href="http://clinicaltrials.gov/ct2/show/NCT01644123?recr=Open&amp;fund=2&amp;rcv_s=07%2F05%2F2012&amp;rank=132"><STRONG><FONT size="3">NCT01644123</FONT></STRONG></A> </div><div style="margin-bottom: 10px;">Rationale: the investigators hypothesize that one reason that spasticity is undertreated is due to the lack of a standardized diagnostic procedure.<wbr> </div><div style="margin-bottom: 10px;">Recruitment: approx.<wbr> 100 (reside in 1 of the 5 selected long term care facilities) </div><div style="margin-bottom: 10px;">Start date: Oct.<wbr> 2012 - Completion date: Oct.<wbr> 2013 </div><div>Location: USA </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120831&edate=20120501&rec=6511">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-07-19T18:13:56+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Strong US$ and EU Austerity Measures Could Hurt Novartis 2012 Results [sub:Finance, :Endocrinology:comp:Novartis, func:Sales, mkt:China]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld9982</link>
<description>Strong US$ and EU Austerity Measures Could Hurt Novartis 2012 Results [sub:Finance, :Endocrinology:comp:Novartis, func:Sales, mkt:China]</description><category>sub:Finance</category><category>comp:Novartis</category><category>func:Sales</category><category>mkt:China</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld9982</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120831&edate=20120501&rec=9982">Strong US$ and EU Austerity Measures Could Hurt Novartis 2012 Results</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=comp%3aNovartis"><font color="#e95e0b">:Endocrinology:comp:Novartis</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=func%3aSales"><font color="#e95e0b">:PharmaWorld:func:Sales</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=mkt%3aChina"><font color="#e95e0b">:PharmaWorld:mkt:China</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=sub%3aFinance"><font color="#e95e0b">:PharmaWorld:sub:Finance</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld9982">PharmaWorld9982</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 19 July 2012 | 15:09</font><br><br><div style="margin-bottom: 10px;">Comment: Novartis has reported net sales fell 4% to $14.<wbr>3 billion for Q2:12.<wbr> Sales in Pharma were up 4% (in cc).<wbr> The company expects Gilenya (oral pill for MS) to offset declines in top-selling high blood pressure drug Diovan.<wbr> Emerging growth markets sales grow +6%, driven by China.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Strong US $</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/9982/2/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">Novartis said it expected a hit of 4% to sales for the FY, and about 3-4% on operating income due to the strong dollar, assuming June average exchange rates prevailed for the rest of the year, up from previous guidance for an impact of 2-3% on sales and operating income.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">EU Crisis</FONT></STRONG> </div><div style="margin-bottom: 10px;">Novartis is facing pressures from EU austerity measures as government cut prices for medicines and some countries in southern Europe rack up unpaid bills.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Emerging Markets</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/9982/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Pharmaceuticals Update</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/9982/3/ScreenCapture3.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/9982/5/ScreenCapture5.jpg?user-agent=rss"></FONT></STRONG> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Outlook for 2012</FONT></STRONG> </div><div><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/9982/4/ScreenCapture4.jpg?user-agent=rss"> </div><!-- Comment details --><a name="pharmaworld9982attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/9982/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(41,7 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/9982/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(65,3 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/9982/3/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(11,7 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/9982/4/ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(31,9 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/9982/5/ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(66,6 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120831&edate=20120501&rec=9982">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-07-19T15:09:34+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/9982/1/ScreenCapture1.jpg" length="42740" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/9982/2/ScreenCapture2.jpg" length="66894" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/9982/3/ScreenCapture3.jpg" length="11946" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/9982/4/ScreenCapture4.jpg" length="32616" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/9982/5/ScreenCapture5.jpg" length="68165" type="image/jpeg"/></item><item>
<title>Fibrocell Reports Q2:12 Order Information on its Personalized Filler for Smile Lines [sub:Aesthetics]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology6509</link>
<description>Fibrocell Reports Q2:12 Order Information on its Personalized Filler for Smile Lines [sub:Aesthetics]</description><category>sub:Aesthetics</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology6509</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120831&edate=20120501&rec=6509">Fibrocell Reports Q2:12 Order Information on its Personalized Filler for Smile Lines</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=sub%3aAesthetics"><font color="#e95e0b">:Neurology:sub:Aesthetics</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology6509">Neurology6509</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 19 July 2012 | 11:07</font><br><br><div style="margin-bottom: 10px;">Comment: The strong demand for <A href="http://mylaviv.com/your-laviv/">LaVIV</A> (which uses patient's own collagen-producing cells) was driven by reorders and rapid growth in first-time ordering physicians.<wbr> Last month, the company completed $9.<wbr>1M capital raise.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Order Information</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/6509/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">During Q2:12, 85 new physicians placed orders for biopsies (+60% vs Q1:12), 39 physicians placed repeat orders for biopsies (+200% vs Q1:12).<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Additional Information</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/6509/2/ScreenCapture2.jpg?user-agent=rss"> </div><div>Please see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120831&edate=20120501&rec=5769" class="defaultlink">Neurology5769: Alternative Approach To Wrinkes Wins FDA Approval</a>.<wbr> </div><!-- Comment details --><a name="neurology6509attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/6509/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(9 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/6509/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(11 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120831&edate=20120501&rec=6509">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-07-19T11:07:09+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/6509/1/ScreenCapture1.jpg" length="9211" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/6509/2/ScreenCapture2.jpg" length="11265" type="image/jpeg"/></item><item>
<title>Investor Provides Perspective on LG Life Sciences' SR-hGH (Weekly Inj.) [class:GrowthHormone]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7032</link>
<description>Investor Provides Perspective on LG Life Sciences' SR-hGH (Weekly Inj.) [class:GrowthHormone]</description><category>class:GrowthHormone</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7032</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120831&edate=20120501&rec=7032">Investor Provides Perspective on LG Life Sciences' SR-hGH (Weekly Inj.<wbr>)</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=class%3aGrowthHormone"><font color="#e95e0b">:Endocrinology:class:GrowthHormone</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7032">Endocrinology7032</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 18 July 2012 | 10:48</font><br><br><div style="margin-bottom: 10px;">Comment: Daishin Securities has reported that the company plans to complete its trial for the pediatric SR-hGH soon, and apply for US approval late 2012.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Regulatory Scenario</FONT></STRONG> </div><div>If the drug wins US approval in 2013 (at the earliest), the company will expand into the EU and emerging markets after launching the drug in the US.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120831&edate=20120501&rec=7032">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-07-18T10:48:21+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>FDA Approves the Lowest Volume Preparation for Colonoscopy [sub:CRCPrevention, :Endocrinology:comp:Ferring, :PharmaWorld:mkt:NorthAmerica, :PharmaWorld:sub:Regulatory]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology1848</link>
<description>FDA Approves the Lowest Volume Preparation for Colonoscopy [sub:CRCPrevention, :Endocrinology:comp:Ferring, :PharmaWorld:mkt:NorthAmerica, :PharmaWorld:sub:Regulatory]</description><comments>http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology1848</comments><category>sub:CRCPrevention</category><category>comp:Ferring</category><category>mkt:NorthAmerica</category><category>sub:Regulatory</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology1848</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20120831&edate=20120501&rec=1848">FDA Approves the Lowest Volume Preparation for Colonoscopy</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=comp%3aFerring"><font color="#e95e0b">:Endocrinology:comp:Ferring</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20120831&edate=20120501&cat=sub%3aCRCPrevention"><font color="#e95e0b">:GastroEnterology:sub:CRCPrevention</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=mkt%3aNorthAmerica"><font color="#e95e0b">:PharmaWorld:mkt:NorthAmerica</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=sub%3aRegulatory"><font color="#e95e0b">:PharmaWorld:sub:Regulatory</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology1848">GastroEnterology1848</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 18 July 2012 | 10:06</font><br><br><div style="margin-bottom: 10px;">Comment: The FDA approval of Ferring's Prepopik (sodium picosulfate, magnesium oxide, and anhydrous citric acid powder) marks the company's first entry into the gastrointestinal market in the U.<wbr>S.<wbr>.<wbr> The company now must conduct studies to determine if the drug can be used safely and effectively in children.<wbr> <a name="GastroEnterology1908c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div><DIV class="body3">
<P style="MARGIN-TOP: 1ex; MARGIN-BOTTOM: 1ex">Ferring is to start Ph1/<wbr>Ph2 study in the US to evaluate the efficacy and safety of Prepopik™ in children aged 9 to 16 years for overall colon cleansing in preparation of colonoscopy.<wbr> PE will assess the number of subjects defined by "excellent" or "good" in the Aronchick Scale.<wbr></P>

<P style="MARGIN-TOP: 1ex; MARGIN-BOTTOM: 1ex"><a href="http://clinicaltrials.gov/ct2/show/NCT01928862?recr=Open&amp;phase=012&amp;fund=2&amp;rcv_s=07%2F30%2F2013&amp;rank=13&amp;submit_fld_opt=" class="defaultlink">NCT01928862</a></P>
<DIV class="identifier">n= 75</DIV>
<DIV class="identifier">Start date: Oct 2013 - Completion: May 2015 /<wbr> June 2015</DIV></DIV> </div><font size="-1">Brigitte DESCHAMPS / <a href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology1908" class="commentpermalink">GastroEnterology1908</a> / <span class="date">30 August 2013</span> /
<span class="time">18:36:51 o'clock CEST</span>
</font></div></div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Regulatory Submission</FONT></STRONG> </div><div style="margin-bottom: 10px;">The approval is based on data from 2 Ph3 non-inferiority studies in which Prepopik was compared to 2L PEG+E plus 2 Bisacodyl 5mg tablets </div><div style="margin-bottom: 10px;">In both studies, Prepopik achieved the primary endpoint (successful colon cleansing based on the Aronchick Scale), demonstrating non-inferiority to the comparator.<wbr> </div><div style="margin-bottom: 10px;"><UL><LI>Study 1 : 84.<wbr>2% vs 74.<wbr>4%</LI>
<LI>Study 2 : 83.<wbr>0% vs 79.<wbr>7%</LI>
</UL> </div><div style="margin-bottom: 10px;">
Additionally, Prepopik demonstrated statistical superiority in cleansing of the colon vs the comparator.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">About Prepopik</FONT></STRONG> </div><div style="margin-bottom: 10px;"><STRONG>Description</STRONG> </div><div style="margin-bottom: 10px;">Two powder packets (each containing 10mg sodium picosulfate, 3.<wbr>5g magnesium oxide, and 12g anhydrous citric acid).<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Dosage</STRONG> </div><div style="margin-bottom: 10px;">Approved for 2 dosing options, split-dose or day-before administration.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/1848/2/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG>Availabilites</STRONG> </div><div>Prepopik is available in Canada (under the name PICO-SALAX®), U.<wbr>K.<wbr>, and other countries (under the names PICOLAX® and PICOPREP® in various other countries).<wbr> </div><!-- Comment details --><a name="gastroenterology1848attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/1848/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(39,7 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/1848/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(14,2 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20120831&edate=20120501&rec=1848">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-07-18T10:06:24+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/1848/1/ScreenCapture1.jpg" length="40670" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/1848/2/ScreenCapture2.jpg" length="14550" type="image/jpeg"/></item><item>
<title>Belgium Adopts Pro Biosimilars Measures [mkt:Europe]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld9978</link>
<description>Belgium Adopts Pro Biosimilars Measures [mkt:Europe]</description><category>mkt:Europe</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld9978</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120831&edate=20120501&rec=9978">Belgium Adopts Pro Biosimilars Measures</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=mkt%3aEurope"><font color="#e95e0b">:PharmaWorld:mkt:Europe</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld9978">PharmaWorld9978</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 17 July 2012 | 13:48</font><br><br><div style="margin-bottom: 10px;">Comment: Belgium has adopted several measures designed to boost the use of biosimilar medicines, according to the country's generic industry association FeBelGen.<wbr> In recognition that biosimilars, as copies of biotech drugs are known, are making slow inroads into the country's pharmaceutical market, the government has approved the three measures recently proposed by Minister for Social Affairs Laurette Onkelinx.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">About the measures</FONT></STRONG> </div><div style="margin-bottom: 10px;">- First, the health insurance fund INAMI will provide a flat reimbursement rate for medicines in areas where biosimilars are available.<wbr> </div><div style="margin-bottom: 10px;">- Secondly, biosimilars will be included in the "drug package" for hospital patients.<wbr> </div><div style="margin-bottom: 10px;">- Thirdly, prescriptions for biosimilars will count as part of the "cheap medicines" quote of physicians.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Significance</FONT></STRONG> </div><div style="margin-bottom: 10px;">Belgium is leaving nothing to chance with this three-pronged approach that is designed to ensure that there is motivation to use biosimilars at all levels: the prescriber, the hospital, and the health insurance.<wbr> </div><div style="margin-bottom: 10px;">Importantly, however, although the measures are designed to encourage biosimilars use, they are not worded in a way to takes away physicians' prescribing choice.<wbr> It would still be possible for physicians to prescribe originator biologics when appropriate, but this freedom is combined with incentives to prescribe and dispense biosimilars when appropriate.<wbr> </div><div>Source: Global Insight </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120831&edate=20120501&rec=9978">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-07-17T13:48:42+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>J&amp;J Seeks Approval For Simponi in Ulcerative Colitis [news]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology1847</link>
<description>J&amp;J Seeks Approval For Simponi in Ulcerative Colitis [news]</description><comments>http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology1847</comments><category>news</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology1847</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20120831&edate=20120501&rec=1847">J&J Seeks Approval For Simponi in Ulcerative Colitis</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20120831&edate=20120501&cat=news"><font color="#e95e0b">:GastroEnterology:news</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology1847">GastroEnterology1847</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 17 July 2012 | 13:14</font><br><br><div style="margin-bottom: 10px;">Comment: Janssen  has submitted an sBLA to the U.<wbr>S.<wbr> FDA and a Type 
II Variation to the EMA requesting approval of SIMPONI® (golimumab) for the 
treatment of adult patients with moderately to severely active ulcerative 
colitis (UC) who have had an inadequate response to conventional therapy.<wbr> <a name="GastroEnterology1888c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;"><SPAN style="text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 14px/22px Helvetica, Arial, sans-serif; white-space: normal; float: none; letter-spacing: normal; color: #1a1a1a; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">FDA approved an expanded indication for Simponi (golimumab) to treat adults with moderate to severe ulcerative colitis who did not respond to conventional treatment or requires continuous steroid use.<wbr> </SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 14px/22px Helvetica, Arial, sans-serif; white-space: normal; float: none; letter-spacing: normal; color: #1a1a1a; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">The approval was based on 2 clinical studies demonstrating that the tumour necrosis factor-alpha inhibitor was associated with a higher clinical response rate than placebo.<wbr></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 14px/22px Helvetica, Arial, sans-serif; white-space: normal; float: none; letter-spacing: normal; color: #1a1a1a; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;"><SPAN style="text-transform: none; text-indent: 0px; display: inline !important; font: 14px/22px Helvetica, Arial, sans-serif; white-space: normal; float: none; letter-spacing: normal; color: #1a1a1a; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">Simponi is currently approved to treat psoriatic arthritis, rheumatoid arthritis and ankylosing spondylitis.<wbr> </SPAN></SPAN> </div><div><SPAN style="text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 14px/22px Helvetica, Arial, sans-serif; white-space: normal; float: none; letter-spacing: normal; color: #1a1a1a; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;"><SPAN style="text-transform: none; text-indent: 0px; display: inline !important; font: 14px/22px Helvetica, Arial, sans-serif; white-space: normal; float: none; letter-spacing: normal; color: #1a1a1a; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">The drug had sales of $607 million in 2012 and analysts estimate that sales could double to $1.<wbr>2 billion by 2017.<wbr></SPAN></SPAN> </div><font size="-1">Brigitte DESCHAMPS / <a href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology1888" class="commentpermalink">GastroEnterology1888</a> / <span class="date">16 May 2013</span> /
<span class="time">09:45:46 o'clock CEST</span>
</font></div></div><div style="margin-bottom: 10px;"><STRONG>Background</STRONG> </div><div style="margin-bottom: 10px;">Approximately 700,000 people in the United States<FONT size="2"><SMALL><SUP>1</SUP></SMALL> and 1.<wbr>1 million people in the European Union 
(EU)<SMALL><SUP>2</SUP></SMALL> are affected by UC, a chronic inflammatory bowel 
disease and Simponi if approved will be the first s.<wbr>c anti-TNF formulation 
available to treat this condition.<wbr> It is currently available for the 
treatment of rheumatoid arthritis either as SmartJect® 
autoinjector/<wbr>prefilled pen or a prefilled syringe.<wbr> It</FONT> received 
approvals in the U.<wbr>S.<wbr>, Canada and the EU in 2009 for three 
different rheumatic indications simultaneously.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>PhIII Study Programme</STRONG> </div><div style="margin-bottom: 10px;">Both the U.<wbr>S.<wbr> and EU applications are supported by efficacy and safety 
findings from the Program of Ulcerative Colitis Research Studies Utilizing an 
Investigational Treatment (PURSUIT), which included Phase 3 multicenter, 
randomized, double-blind, placebo-controlled studies designed to evaluate the 
safety and efficacy of subcutaneous induction and every-four-week maintenance 
regimens of SIMPONI in adults with moderately to severely active UC.<wbr> All trial 
patients had failed to respond to or tolerate treatment with 6-mercaptopurine 
(6-MP), azathioprine (AZA), corticosteroids and/<wbr>or 5-aminosalicylate (5-ASA), or 
were corticosteroid dependent.<wbr> Study participants were naïve to treatment with 
TNF inhibitors and had a baseline Mayo score between 6 and 12 and endoscopic 
subscore of 2 or more.<wbr> </div><div style="margin-bottom: 10px;">The induction trial (PURSUIT-SC) had an adaptive design with a Phase 2 
dose-finding portion followed by a Phase 3 dose-confirming component.<wbr> The 
primary endpoint was clinical response at week 6.<wbr> Secondary endpoints at week 6 
included clinical remission, mucosal healing and a change from baseline in 
Inflammatory Bowel Disease Questionnaire (IBDQ) scores.<wbr> Overall, 1,065 patients 
were treated in the study; 774 of these patients were randomized into the Phase 
3 component of the study.<wbr> Patients responding to induction treatment with 
SIMPONI were eligible to continue in the Phase 3 PURSUIT-Maintenance study.<wbr> </div><div>Source: <A href="http://www.jnj.com">www.<wbr>jnj.<wbr>com</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20120831&edate=20120501&rec=1847">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-07-17T13:14:45+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>EMA Validates Active Biotech's Laquinimod Submission [news]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology6508</link>
<description>EMA Validates Active Biotech's Laquinimod Submission [news]</description><category>news</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology6508</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120831&edate=20120501&rec=6508">EMA Validates Active Biotech's Laquinimod Submission</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=news"><font color="#e95e0b">:Neurology:news</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology6508">Neurology6508</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 17 July 2012 | 12:59</font><br><br><div style="margin-bottom: 10px;">Comment: The EMA has completed the validation process for the marketing 
authorization application of Activie Biotech's submission for laquinimod, its 
treatmemt for relapsing remitting multiple sclerosis.<wbr> </div><div style="margin-bottom: 10px;">The completion of this process marks the start of the scientific review of 
the submission and also triggers a milestone payment of $5m to Active Biotech 
from its development partner Teva.<wbr> </div><div style="margin-bottom: 10px;">The submission is supported by data from two global phIII study in RRMS 
involving 2,400 patients treated for two years.<wbr> </div><div style="margin-bottom: 10px;">Active Biotech and Teva are continuing to work with the FDA to determine the 
regulatory path forward for laquinimod in the US.<wbr> </div><div style="margin-bottom: 10px;">In addition to MS, laquinimod is also being developed for the treatment of 
Crohn's disease and Lupus.<wbr> </div><div>Source: <A href="http://www.activebiotech.com">www.<wbr>activebiotech.<wbr>com</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120831&edate=20120501&rec=6508">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-07-17T12:59:32+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>An Immunohistochemical Signature In Prostate Cancer Patients May Predict Progression</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology8386</link>
<description>An Immunohistochemical Signature In Prostate Cancer Patients May Predict Progression</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology8386</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8386">An Immunohistochemical Signature In Prostate Cancer Patients May Predict Progression</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8386">Oncology8386</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 16 July 2012 | 14:57</font><br><br><div style="margin-bottom: 10px;"><FONT face="Arial">Comment: In the latest issue of Cancer (June 6th) 
Antonarakis and colleagues have demonstrated in a post-hoc analysis of hte 
TAX2501 trial that a signature comprising PTEN, MYC and Ki67 may predict cancer 
progression in patients who have received adjuvant doctaxel after 
prostatectomy.<wbr></FONT> </div><div style="margin-bottom: 10px;"><FONT face="Arial">It is suggested that if validated these hypotheses 
generating findings may have prognostic and therapeutic implications which could 
aid clinical trial design.<wbr></FONT> </div><div style="margin-bottom: 10px;"><FONT face="Arial">The study generating these findings looked at primary 
prostatectomy specimends from 56 out of 77 patients enrolled in the TAX2501 
study.<wbr> <SPAN style="TEXT-ALIGN: left; WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 13px/17px arial, helvetica, clean, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><FONT size="2"> Analysis of PTEN, MYC, 
ERG, tumor protein p53 (p53), antigen KI-67 (Ki67), and phosphorylated forms of 
Akt, mammalian target of rapamycin (mTOR), and S6 ribosomal protein was 
undertaken.<wbr> </FONT></SPAN></FONT> </div><div style="margin-bottom: 10px;"><SPAN style="TEXT-ALIGN: left; WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 13px/17px arial, helvetica, clean, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><FONT size="2">Protocol-defined progression included a prostate-specific antigen (PSA) 
level ≥0.<wbr>4 ng/<wbr>mL, radiologic/<wbr>clinical recurrence, or death.<wbr> Univariate and 
multivariable proportional hazards regression analyses were used to investigate 
the influence</FONT> of PTEN status (and other protein <FONT size="2">markers) on 
progression-free survival (PFS).<wbr></FONT></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="TEXT-ALIGN: left; WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 13px/17px arial, helvetica, clean, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><SPAN style="TEXT-ALIGN: left; WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 13px/17px arial, helvetica, clean, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><FONT size="2">In this exploratory study the univariate analysis demonstrated that 
 the factors associated with PFS included Gleason sum, seminal vesicle 
invasion, PTEN status, MYC expression, and Ki67 expression.<wbr> 
</FONT></SPAN></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="TEXT-ALIGN: left; WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 13px/17px arial, helvetica, clean, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><SPAN style="TEXT-ALIGN: left; WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 13px/17px arial, helvetica, clean, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><FONT size="2">In multivariable analysis, only 3 variables emerged as independent 
prognostic factors for PFS: PTEN status (P = .<wbr>035), MYC expression (P = .<wbr>001), 
and Ki67 expression (P &lt; .<wbr>001).<wbr></FONT></SPAN></SPAN> </div><div><SPAN style="TEXT-ALIGN: left; WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 13px/17px arial, helvetica, clean, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><SPAN style="TEXT-ALIGN: left; WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 13px/17px arial, helvetica, clean, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><FONT size="2">Source; </FONT><A href="http://www.ncbi.nlm.nih.gov/pubmed/22674438?dopt=Abstract#" style="BORDER-BOTTOM: 0px; TEXT-ALIGN: left; BORDER-LEFT: 0px; PADDING-BOTTOM: 0px; WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; MARGIN: 0px; OUTLINE-STYLE: none; OUTLINE-COLOR: invert; PADDING-LEFT: 0px; OUTLINE-WIDTH: 0px; PADDING-RIGHT: 0px; FONT: 11px/15px arial, helvetica, clean, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; LETTER-SPACING: normal; COLOR: rgb(102,0,102); VERTICAL-ALIGN: baseline; BORDER-TOP: 0px; BORDER-RIGHT: 0px; WORD-SPACING: 0px; TEXT-DECORATION: underline; PADDING-TOP: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px" title="Cancer."><FONT size="2">Cancer.<wbr></FONT></A><SPAN style="TEXT-ALIGN: left; WIDOWS: 2; TEXT-TRANSFORM: none; BACKGROUND-COLOR: rgb(255,255,255); TEXT-INDENT: 0px; DISPLAY: inline !important; FONT: 11px/15px arial, helvetica, clean, sans-serif; WHITE-SPACE: normal; ORPHANS: 2; FLOAT: none; LETTER-SPACING: normal; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><FONT size="2"> 2012 Jun 6.<wbr> doi: 
10.<wbr>1002/<wbr>cncr.<wbr>27689.<wbr></FONT></SPAN></SPAN></SPAN> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8386">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-07-16T14:57:18+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>Cryogenic Device in the Final Stage of Human Trials for Cosmetic Use [sub:Aesthetics, comp:Allergan, prod:Botox]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology6504</link>
<description>Cryogenic Device in the Final Stage of Human Trials for Cosmetic Use [sub:Aesthetics, comp:Allergan, prod:Botox]</description><category>sub:Aesthetics</category><category>comp:Allergan</category><category>prod:Botox</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology6504</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120831&edate=20120501&rec=6504">Cryogenic Device in the Final Stage of Human Trials for Cosmetic Use</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=comp%3aAllergan"><font color="#e95e0b">:Neurology:comp:Allergan</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=prod%3aBotox"><font color="#e95e0b">:Neurology:prod:Botox</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=sub%3aAesthetics"><font color="#e95e0b">:Neurology:sub:Aesthetics</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology6504">Neurology6504</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 16 July 2012 | 11:28</font><br><br><div style="margin-bottom: 10px;">Comment: Myoscience makes a pen-type device that uses 27-gauge needles to place cryogenic material onto a patient's face, where it disrupts the nerves that allow facial muslces to form wrinkles.<wbr> The Cryo-Touch II is due to launch later this year as Frotox, and according to an article published in the London Evening Standard could be the next 'big weapon in the war against wrinkles'.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">How it works ?</FONT></STRONG> </div><div style="margin-bottom: 10px;">After the forehead is locally anesthetized, the tips penetrate the skin and deliver two to eight 30-second bursts of intense cold to the targeted facial nerve.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Duration</STRONG> </div><div style="margin-bottom: 10px;"><U>Procedure</U>: around 10 minutes (by trained plastic surgeons) </div><div style="margin-bottom: 10px;"><U>Treatment</U>: According to Yannis Alexandreis, Harley Street plastic surgeon, the effects of the treatment are instant, and seem to last 3 to 4 months.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Safety</STRONG>: injection site redness, headaches and discomfort (the same as Botox).<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Cost</STRONG>: £200 to 350 (the same as Botox) </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">About the Trial</FONT></STRONG> </div><div style="margin-bottom: 10px;"><A href="http://www.clinicaltrials.gov/ct2/show/NCT01447342?fund=2&amp;rcv_s=09%2F22%2F2011&amp;rank=42">NCT01447342</A> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Other Indication</FONT></STRONG> </div><div>The use of cold temporarily disables nerves, and was originally used to treat chronic pain (approved by the FDA).<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120831&edate=20120501&rec=6504">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-07-16T11:28:03+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>J&amp;J Initiates PhI Trial With New Abiraterone Formulations [headline, dis:Prostate, prod:Zytiga]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology8385</link>
<description>J&amp;J Initiates PhI Trial With New Abiraterone Formulations [headline, dis:Prostate, prod:Zytiga]</description><category>headline</category><category>dis:Prostate</category><category>prod:Zytiga</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology8385</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8385">J&J Initiates PhI Trial With New Abiraterone Formulations</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=headline"><font color="#e95e0b">:Oncology:headline</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=prod%3aZytiga"><font color="#e95e0b">:Oncology:prod:Zytiga</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8385">Oncology8385</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 13 July 2012 | 18:36</font><br><br><div style="margin-bottom: 10px;">Comment: J&amp;J is testing 3 newly developed abiraterone formulations 
against the current commercial abiraterone acetate tablet to evaluate each 
drug's PK profile in healthy volunteers.<wbr> </div><div style="margin-bottom: 10px;">The three new formulations are as follows:- </div><div style="margin-bottom: 10px;"><OL><LI>500mg coated reformulated tablet</LI>
<LI>250mg coated reformulated tablet</LI>
<LI>500mg coated tablets with a slower dissolution profile</LI>
</OL> </div><div style="margin-bottom: 10px;"><STRONG>Estimated completion</STRONG> - as recruitment started in May (albeit 
the study is only just listed in Clincialtrials.<wbr>gov) and includes only 
68-days of follow-up it should complete in July.<wbr> 30 patients are 
participating.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Study Design</STRONG> </div><div style="margin-bottom: 10px;"><TABLE border="0" cellpadding="0" cellspacing="0" class="layout_table" style="MARGIN-BOTTOM: 2ex"><TBODY><TR valign="top"><TD style="PADDING-LEFT: 1em; PADDING-TOP: 2ex">
      <P>A single-dose, open-label, randomized, 4-Way crossover study to assess 
      the relative bioavailability of the 3 new abiraterone acetate tablet 
      formulations with respect to the current 250mg commercial abiraterone 
      acetate tablet under fasted conditions in healthy male 
  subjects</P></TD>
</TR>
</TBODY>
</TABLE> </div><div style="margin-bottom: 10px;"><STRONG>Abiraterone's Patent Postion</STRONG> </div><div style="margin-bottom: 10px;">The patent on the current formulation expires in 2014.<wbr> However, J&amp;J is 
expected to gain a patent term extension possibly up to 5 years.<wbr> </div><div>ClinicalTrials Identifier <A href="http://clinicaltrials.gov/ct2/show/NCT01640093" title="Current version of study NCT01640093 on ClinicalTrials.gov">NCT01640093</A><BR> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8385">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-07-13T18:36:14+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>re: Study - Oral Octreotide Absorption in Human Subjects</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7027</link>
<description>re: Study - Oral Octreotide Absorption in Human Subjects</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7027</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120831&edate=20120501&rec=7027">re: Study - Oral Octreotide Absorption in Human Subjects</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7027">Endocrinology7027</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/147">Bruno TISSIER</a> | 13 July 2012 | 17:21</font><br><br><div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Study - Oral Octreotide Absorption in Human Subjects</span>&nbsp;<font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=class%3aSomatostatinAnalogue"><font color="#e95e0b">:Endocrinology:class:SomatostatinAnalogue</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=comp%3aNovartis"><font color="#e95e0b">:Endocrinology:comp:Novartis</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=dis%3aAcromegaly"><font color="#e95e0b">:Endocrinology:dis:Acromegaly</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=prod%3aOctreotide"><font color="#e95e0b">:Endocrinology:prod:Octreotide</font></a>]</font></font><br><span style="font-size: 12px;">Comment : Already signalled in April as a preprint but now full pagination in <EM>JCEM</EM>.<wbr> The authors conclude that the results support an oral octreotide alternative to parenteral octreotide treatment for patients with acromegaly.<wbr> Please find the abstract below.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120831&edate=20120501&rec=7017">...</a><br><font size="-1">clm11175 / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7017" class="commentpermalink">Endocrinology7017</a> / <span class="date">11 July 2012</span> /
<span class="time">15:11:17 o'clock CEST</span>
</font></div><div style="margin-bottom: 10px;"><SPAN style="background-color: #ffffff;">.<wbr>.<wbr>.<wbr>.<wbr>then ,it is possible to calculate  the absolute oral bioavailability of the proposed formulation  which is :  <SPAN style="text-decoration: underline;"><STRONG>0.<wbr>5%</STRONG></SPAN> (0.<wbr>1/<wbr>20) , and as a consequence , novartis  will probably need to build a new API plant to produce 100 times more peptide to treat the same volume of patients !!!.<wbr>.<wbr>.<wbr>.<wbr>.<wbr>.<wbr>.<wbr> and also have to  support a huge manufacturing price increase  !</SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="background-color: #ffffff;">it is simply not realistic !</SPAN> </div><div><SPAN style="background-color: #ffffff;">Bruno</SPAN> </div><!-- Comment details --><font size="-1">Bruno TISSIER / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7027" class="commentpermalink">Endocrinology7027</a> / <span class="date">13 July 2012</span> /
<span class="time">17:21:18 o'clock CEST</span>
</font><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120831&edate=20120501&rec=7027">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7017">View thread  Endocrinology7017: Study - Oral Octreotide Absorption in Human Subjects</a>]]></content:encoded><dc:date>2012-07-13T17:21:18+02:00</dc:date><dc:creator>brt29918</dc:creator></item><item>
<title>Study - Poor Response of Children with Short Stature to Growth Hormone Therapies. Potential  New Condition Definition and Treatments Guidelines [dis:GrowthHormoneDeficiency, class:GrowthHormone]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7026</link>
<description>Study - Poor Response of Children with Short Stature to Growth Hormone Therapies. Potential  New Condition Definition and Treatments Guidelines [dis:GrowthHormoneDeficiency, class:GrowthHormone]</description><category>dis:GrowthHormoneDeficiency</category><category>class:GrowthHormone</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7026</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120831&edate=20120501&rec=7026">Study - Poor Response of Children with Short Stature to Growth Hormone Therapies.<wbr> Potential  New Condition Definition and Treatments Guidelines</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=class%3aGrowthHormone"><font color="#e95e0b">:Endocrinology:class:GrowthHormone</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=dis%3aGrowthHormoneDeficiency"><font color="#e95e0b">:Endocrinology:dis:GrowthHormoneDeficiency</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7026">Endocrinology7026</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/22">Paolo Coccia</a> | 13 July 2012 | 14:35</font><br><br><div style="margin-bottom: 10px;">Comment:The incidence of insufficient responses to GH therapies have forced clinicians to find a more appropriate definition of &ldquo;poor response&rdquo; and to modify current drug treatments.<wbr> </div><div style="margin-bottom: 10px;">The review describes the relevant parameters for a correct definition of &ldquo;poor response&rdquo; taking into account History and physical examination, Hormonal status, Radiological assessment and Genetic assessment.<wbr> <BR>The relevant parameters of poor response to the GH therapy are also described.<wbr> They concern: Growth during the first year of GH therapy, Age-dependency of responses, Reference data reported on NCGS and KIGS databases, Response related to diagnosis, Definitions of poor response, Definition of clinical benefit and Biomarkers of GH response.<wbr><BR><BR><STRONG>Strategies for treatment of children with poor response to GH therapy<BR></STRONG>The authors summarize some general rules for approacing the patient treatment: the GH therapy should be assessed throughout the 12 months.<wbr> In the case of poor response they show several options as described by the algorithm of the Fig.<wbr> 5 (file attached).<wbr><BR><STRONG>Conclusions<BR></STRONG>Best recognition of poor response helps the clinicians to recognize the variability of growth disorders applying more individualized therapy that contributes to more appropriate treatment strategies.<wbr><BR><BR>The authors of this article are members of the advisory board for Ipsen.<wbr> </div><div>Source:<BR>Peter Bang, S.<wbr> Faisal Ahmed, Jesu&acute;s Argente,, Philippe Backeljauw, Markus Bettendorf, Gianni Bona, Regis Coutant, Ron G.<wbr> Rosenfeld, Marie-Jose&acute; Walenkamp and Martin O.<wbr> Savage<BR>Identification and management of poor response to growth-promoting therapy in children with short stature.<wbr> <BR>Clinical Endocrinology (2012) 77, 169&ndash;181.<wbr> <BR>Full Text online here:<BR><A href="http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2265.2012.04420.x/pdf">http:/<wbr>/<wbr>onlinelibrary.<wbr>wiley.<wbr>com/<wbr>doi/<wbr>10.<wbr>1111/<wbr>j.<wbr>1365-2265.<wbr>2012.<wbr>04420.<wbr>x/<wbr>pdf</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120831&edate=20120501&rec=7026">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-07-13T14:35:21+02:00</dc:date><dc:creator>pac93336</dc:creator></item><item>
<title>Study - 2-years Results of Octreotide LAR for Severe Polycystic Liver Disease: Results after 2 years [class:SomatostatinAnalogue, comp:Novartis, dis:PolycysticLiver, prod:Octreotide]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7024</link>
<description>Study - 2-years Results of Octreotide LAR for Severe Polycystic Liver Disease: Results after 2 years [class:SomatostatinAnalogue, comp:Novartis, dis:PolycysticLiver, prod:Octreotide]</description><category>class:SomatostatinAnalogue</category><category>comp:Novartis</category><category>dis:PolycysticLiver</category><category>prod:Octreotide</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7024</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120831&edate=20120501&rec=7024">Study - 2-years Results of Octreotide LAR for Severe Polycystic Liver Disease: Results after 2 years</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=class%3aSomatostatinAnalogue"><font color="#e95e0b">:Endocrinology:class:SomatostatinAnalogue</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=comp%3aNovartis"><font color="#e95e0b">:Endocrinology:comp:Novartis</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=dis%3aPolycysticLiver"><font color="#e95e0b">:Endocrinology:dis:PolycysticLiver</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=prod%3aOctreotide"><font color="#e95e0b">:Endocrinology:prod:Octreotide</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7024">Endocrinology7024</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/199">clm11175</a> | 13 July 2012 | 12:32</font><br><br><div style="margin-bottom: 10px;">Comment: An open-label extension for one additional year to assess safety and clinical benefits of continued use of OctLAR for 2 years (O→O) and examined drug effect in the placebo group who crossed over to OctLAR in Year 2 (P→O).<wbr> Us Mayo clinic team.<wbr> </div><div style="margin-bottom: 10px;">Somatostatin analog therapy for severe polycystic liver disease: results after 2 years.<wbr> </div><div style="margin-bottom: 10px;">Background: We showed in a <STRONG>randomized double-blinded placebo-controlled clinical trial</STRONG> that octreotide long-acting repeatable depot.<wbr>® (OctLAR(®)) for 12 months reduces kidney and liver growth <STRONG>in autosomal dominant polycystic kidney patients with severe polycystic liver disease (PLD) and liver growth in patients with severe isolated PLD</STRONG>Methods: <STRONG>The primary end point was change in total liver volume (TLV)</STRONG> measured by magnetic resonance imaging (MRI);<STRONG> secondary end points were changes in total kidney volume (TKV)</STRONG> measured by MRI, glomerular filtration rate (GFR), quality of life (QOL), safety, vital signs and laboratory parameters.<wbr> </div><div style="margin-bottom: 10px;">Results: Forty-one of 42 patients received OctLAR (n = 28) or placebo (n = 14) in Year 1 and received OctLAR in Year 2 (maximum dose 40 mg).<wbr> Patients originally randomized to placebo (P→O) showed substantial reduction in TLV after treatment with OctLAR in Year 2 (Δ% -7.<wbr>66 ± 9.<wbr>69%, P = 0.<wbr>011).<wbr> The initial reduction of TLV in the OctLAR group (O→O) was maintained for 2 years (Δ% -5.<wbr>96 ± 8.<wbr>90%), although did not change significantly during Year 2 (Δ% -0.<wbr>77 ± 6.<wbr>82%).<wbr> OctLAR inhibited renal enlargement during Year 1 (Δ% +0.<wbr>42 ± 7.<wbr>61%) in the (O→O) group and during Year 2 (Δ% -0.<wbr>41 ± 9.<wbr>45%) in the (P→O) group, but not throughout Year 2 (Δ% +6.<wbr>49 ± 7.<wbr>08%) in the (O→O) group.<wbr> Using pooled analyses of all individuals who received OctLAR for 12 months, i.<wbr>e.<wbr> in Year 1 for O→O patients and Year 2 for P→O patients, average reduction in TLV was -6.<wbr>08 ± 7.<wbr>58% (P = 0.<wbr>001) compared to net growth of 0.<wbr>9 ± 8.<wbr>35% in the original placebo group.<wbr> OctLAR-treated individuals continued to experience improvements in QOL in Year 2, although overall physical and mental improvements were not significant during Year 2 compared to Year 1.<wbr> Changes in GFR were similar in both groups.<wbr> </div><div style="margin-bottom: 10px;">Conclusion: <STRONG>Over 2 years, Oct LAR significantly reduced the rate of increase in TLV and possibly the rate of increase in TKV.<wbr></STRONG> </div><div style="margin-bottom: 10px;">Nephrol Dial Transplant.<wbr> 2012 Jul 6.<wbr> [Epub ahead of print] Somatostatin analog therapy for severe polycystic liver disease: results after 2 years.<wbr><A href="http://www.ncbi.nlm.nih.gov/pubmed?term=Hogan%20MC%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=22773240" target="_blank">Hogan MC</A>, <A href="http://www.ncbi.nlm.nih.gov/pubmed?term=Masyuk%20TV%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=22773240" target="_blank">Masyuk TV</A>, <A href="http://www.ncbi.nlm.nih.gov/pubmed?term=Page%20L%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=22773240" target="_blank">Page L</A>, <A href="http://www.ncbi.nlm.nih.gov/pubmed?term=Holmes%20DR%203rd%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=22773240" target="_blank">Holmes DR 3rd</A>, <A href="http://www.ncbi.nlm.nih.gov/pubmed?term=Li%20X%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=22773240" target="_blank">Li X</A>, <A href="http://www.ncbi.nlm.nih.gov/pubmed?term=Bergstralh%20EJ%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=22773240" target="_blank">Bergstralh EJ</A>, <A href="http://www.ncbi.nlm.nih.gov/pubmed?term=Irazabal%20MV%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=22773240" target="_blank">Irazabal MV</A>, <A href="http://www.ncbi.nlm.nih.gov/pubmed?term=Kim%20B%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=22773240" target="_blank">Kim B</A>, <A href="http://www.ncbi.nlm.nih.gov/pubmed?term=King%20BF%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=22773240" target="_blank">King BF</A>, <A href="http://www.ncbi.nlm.nih.gov/pubmed?term=Glockner%20JF%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=22773240" target="_blank">Glockner JF</A>, <A href="http://www.ncbi.nlm.nih.gov/pubmed?term=Larusso%20NF%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=22773240" target="_blank">Larusso NF</A>, <A href="http://www.ncbi.nlm.nih.gov/pubmed?term=Torres%20VE%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=22773240" target="_blank">Torres VE</A>.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Previous presentations/<wbr>publications</FONT></STRONG> </div><div style="margin-bottom: 10px;"><STRONG>43rd Annual Meeting </STRONG>Renal Week 2010, Denver, CO, USA, November 16 – 21 2010 <STRONG>[F-PO1823] Somatostatin Analog Therapy for Severe Polycystic Liver Disease: Results after Two Years</STRONG> </div><div><A href="http://ci.beaufour-ipsen.com/AL_get(this,%20'jour',%20'J%20Am%20Soc%20Nephrol.');" title="Journal of the American Society of Nephrology : JASN.">J Am Soc Nephrol.<wbr></A> 2010 Jun;21(6):1052-61. <STRONG>Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease.<wbr></STRONG><A href="http://www.ncbi.nlm.nih.gov/pubmed?term=%22Hogan%20MC%22%5BAuthor%5D">Hogan MC</A>, <A href="http://www.ncbi.nlm.nih.gov/pubmed?term=%22Masyuk%20TV%22%5BAuthor%5D">Masyuk TV</A>, <A href="http://www.ncbi.nlm.nih.gov/pubmed?term=%22Page%20LJ%22%5BAuthor%5D">Page LJ</A>, <A href="http://www.ncbi.nlm.nih.gov/pubmed?term=%22Kubly%20VJ%22%5BAuthor%5D">Kubly VJ</A>, <A href="http://www.ncbi.nlm.nih.gov/pubmed?term=%22Bergstralh%20EJ%22%5BAuthor%5D">Bergstralh EJ</A>, <A href="http://www.ncbi.nlm.nih.gov/pubmed?term=%22Li%20X%22%5BAuthor%5D">Li X</A>, <A href="http://www.ncbi.nlm.nih.gov/pubmed?term=%22Kim%20B%22%5BAuthor%5D">Kim B</A>, <A href="http://www.ncbi.nlm.nih.gov/pubmed?term=%22King%20BF%22%5BAuthor%5D">King BF</A>, <A href="http://www.ncbi.nlm.nih.gov/pubmed?term=%22Glockner%20J%22%5BAuthor%5D">Glockner J</A>, <A href="http://www.ncbi.nlm.nih.gov/pubmed?term=%22Holmes%20DR%203rd%22%5BAuthor%5D">Holmes DR 3rd</A>, <A href="http://www.ncbi.nlm.nih.gov/pubmed?term=%22Rossetti%20S%22%5BAuthor%5D">Rossetti S</A>, <A href="http://www.ncbi.nlm.nih.gov/pubmed?term=%22Harris%20PC%22%5BAuthor%5D">Harris PC</A>, <A href="http://www.ncbi.nlm.nih.gov/pubmed?term=%22LaRusso%20NF%22%5BAuthor%5D">LaRusso NF</A>, <A href="http://www.ncbi.nlm.nih.gov/pubmed?term=%22Torres%20VE%22%5BAuthor%5D">Torres VE</A>.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120831&edate=20120501&rec=7024">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-07-13T12:32:58+02:00</dc:date><dc:creator>clm11175</dc:creator></item><item>
<title>Intelligence From The ADA Meeting In June - The Popularity Of The GLP-1 Analogues [Alert, class:GLP1, comp:NovoNordisk, dis:Diabetes]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7022</link>
<description>Intelligence From The ADA Meeting In June - The Popularity Of The GLP-1 Analogues [Alert, class:GLP1, comp:NovoNordisk, dis:Diabetes]</description><category>Alert</category><category>class:GLP1</category><category>comp:NovoNordisk</category><category>dis:Diabetes</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7022</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120831&edate=20120501&rec=7022">Intelligence From The ADA Meeting In June - The Popularity Of The GLP-1 Analogues</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=Alert"><font color="#e95e0b">:Endocrinology:Alert</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=class%3aGLP1"><font color="#e95e0b">:Endocrinology:class:GLP1</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=comp%3aNovoNordisk"><font color="#e95e0b">:Endocrinology:comp:NovoNordisk</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=dis%3aDiabetes"><font color="#e95e0b">:Endocrinology:dis:Diabetes</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7022">Endocrinology7022</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 13 July 2012 | 11:25</font><br><br><div style="margin-bottom: 10px;">Comment: Thanks to Pascal Birman (Drug Development Director), we have interesting feedback on development activities with the GLP-1 analogues, following his recent attendance at the US ADA meeting.<wbr> Importantly, he noted how <FONT color="#000000">a new treatment paradigm is emerging which includes the use of GLP-1 analogues at an earlier stage of the disease.<wbr></FONT> </div><div style="margin-bottom: 10px;"><STRONG>New Guidelines</STRONG> </div><div style="margin-bottom: 10px;">New hyperglycaemia treatment guidelines for type 2 diabetes were released by the EASD/<wbr>ADA in April 2012.<wbr> The key messages were:- </div><div style="margin-bottom: 10px;"><UL><LI>Adopt a patient centered approach with individualized decisions
</LI>
<LI>Target a HbA1c &lt;7% with key criteria for decision
</LI>
<LI>1st line medical treatment should be metformin
</LI>
<LI>2nd line medical treatment should include 1 of 5 option including a GLP-1 analogue.<wbr>
</LI>
<LI>The decision should be made with the patient focusing onn his/<wbr>her preferences needs and values
</LI>
</UL> </div><div style="margin-bottom: 10px;">The guidelines are published by Inzucchi et al in Diabetes Care 2012 </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7022/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><FONT color="#000000"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7022/2/ScreenCapture2.jpg?user-agent=rss"></FONT> </div><div style="margin-bottom: 10px;"><STRONG>GLP-1 Class Perception</STRONG> </div><div style="margin-bottom: 10px;">GLP-1 analogues are considered as the most potent antidiabetic drugs with a good safety profile offering an excellent improvement in HbA1c similar or greater than other drugs plus moderate weight loss which is a unique efficacy parameter amongst anti-hyperglycaemic drugs.<wbr> </div><div style="margin-bottom: 10px;"><UL><LI>Liraglutide is considered the most potent
</LI>
<LI>Exenatide bid provides the best effect on post prandial hyperglycamia
</LI>
<LI>Exenatide LAR (Bydureon is the best tolerated)
</LI>
<LI>Lixisenatide OD will come soon submitted to the EMA Q411 and to be submitted to the FDA Q412.<wbr> It is less potent than liraglutide but has been effectively combined with insulin.<wbr>
</LI>
</UL> </div><div style="margin-bottom: 10px;">The attached presentation Pascal has compiled highlights:- </div><div style="margin-bottom: 10px;"><OL><LI>Recent data on lixisenatide in combination with insulin the GETGOAL studies
</LI>
<LI>Data on Albiglutide (GSK) in combination with insuln
</LI>
<LI>Other new areas for GLP-1
</LI>
</OL> </div><div style="margin-bottom: 10px;">The last topic highlights:- </div><div style="margin-bottom: 10px;"><UL><LI>The development of a new oral formulation Zyogi by Zydus research;
</LI>
<LI>The development of a new weekly subcutaneous version of exenatide;
</LI>
<LI>Interest in the use of GLP-1 analogues in pre-diabetes stage (Novo Nordisk is conducting a study); and,
</LI>
<LI>The future development of small molecules to target G-protein receptors that may stimulate the endogenous secretion of hGLP1.<wbr>
</LI>
</UL> </div><div>Finally, there is a slide on some key developments with insulin and comments on some of the other new molecules in development such as the SGLT2 inhibitors.<wbr> </div><!-- Comment details --><a name="endocrinology7022attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7022/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(38,3 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7022/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(84,2 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7022/3/ADA%202012%20highlightsV2.pptx">ADA 2012 highlightsV2.pptx</a>&nbsp;&nbsp;(374,1 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120831&edate=20120501&rec=7022">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-07-13T11:25:10+02:00</dc:date><dc:creator>jac89886</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7022/1/ScreenCapture1.jpg" length="39186" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7022/2/ScreenCapture2.jpg" length="86254" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7022/3/ADA%202012%20highlightsV2.pptx" length="383127" type="application/vnd.openxmlformats-officedocument.presentationml.presentation"/></item><item>
<title>French HAS Plans to Introduce New HTA Index for P&amp;R [mkt:France, mkt:Europe, sub:Pricing]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld9976</link>
<description>French HAS Plans to Introduce New HTA Index for P&amp;R [mkt:France, mkt:Europe, sub:Pricing]</description><category>mkt:France</category><category>mkt:Europe</category><category>sub:Pricing</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld9976</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120831&edate=20120501&rec=9976">French HAS Plans to Introduce New HTA Index for P&R</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=mkt%3aEurope"><font color="#e95e0b">:PharmaWorld:mkt:Europe</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=mkt%3aFrance"><font color="#e95e0b">:PharmaWorld:mkt:France</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=sub%3aPricing"><font color="#e95e0b">:PharmaWorld:sub:Pricing</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld9976">PharmaWorld9976</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 12 July 2012 | 14:59</font><br><br><div style="margin-bottom: 10px;">Comment: France's Transparency Commission (Haute Autorité de Santé, HAS) on 6 July confirmed plans to introduce a new way of evaluating medicines in order to set their price and reimbursement status.<wbr> The commission is working on the elaboration of an index that would replace the SMR (Service Médical Rendu) and ASMR (Amélioration du Service Médical Rendu) ratings currently used to respectively inform the reimbursement rate and price of medicines in France.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Significance</FONT></STRONG> </div><div style="margin-bottom: 10px;">The new index, the Relative Therapeutic Index, could be introduced at the beginning of 2013 as part of the next Bill on Financing Social Security (LFSS).<wbr> More details will be provided towards the end of September 2012.<wbr> </div><div style="margin-bottom: 10px;">According to Jean-Luc Harousseau, president of the HAS, the new index would allow the French public insurance and its pricing committee, CEPS, to determine the reimbursement and price of pharmaceuticals based on a comparison versus alternatives that are currently available on the market (source: lepharmacien.<wbr>fr).<wbr> The LFSS 2013 could also include an amendment that would render systematic the delisting of drugs that are deemed to have an insufficient therapeutic value (SMR).<wbr> </div><div style="margin-bottom: 10px;">This confirms that the French pricing and reimbursement system is expected to become less generous in the near term, with drugs brining no improvement in terms of therapeutic value set to suffer the most from upcoming reforms.<wbr> </div><div>Source: Global Insight </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120831&edate=20120501&rec=9976">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-07-12T14:59:26+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>UK:  Doctors Banned from Remotely Prescribing Cosmetic Injectables [class:BotulinumToxins, sub:Aesthetics, :PharmaWorld:mkt:UK, comp:Allergan, prod:Botox]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology6503</link>
<description>UK:  Doctors Banned from Remotely Prescribing Cosmetic Injectables [class:BotulinumToxins, sub:Aesthetics, :PharmaWorld:mkt:UK, comp:Allergan, prod:Botox]</description><category>class:BotulinumToxins</category><category>sub:Aesthetics</category><category>mkt:UK</category><category>comp:Allergan</category><category>prod:Botox</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology6503</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120831&edate=20120501&rec=6503">UK:  Doctors Banned from Remotely Prescribing Cosmetic Injectables</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=class%3aBotulinumToxins"><font color="#e95e0b">:Neurology:class:BotulinumToxins</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=comp%3aAllergan"><font color="#e95e0b">:Neurology:comp:Allergan</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=prod%3aBotox"><font color="#e95e0b">:Neurology:prod:Botox</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=sub%3aAesthetics"><font color="#e95e0b">:Neurology:sub:Aesthetics</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=mkt%3aUK"><font color="#e95e0b">:PharmaWorld:mkt:UK</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology6503">Neurology6503</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/20">Alison Attard</a> | 12 July 2012 | 14:56</font><br><br><div style="margin-bottom: 10px;">Comment: New guidance has been issued by the General Medical Council (GMC) and comes into effect on 23 July 2012.<wbr> Doctors who continue to prescribe Botox or similar products remotely will be putting their registration at risk.<wbr> </div><div style="margin-bottom: 10px;">The change means that doctors must have face-to-face consultations with patients before prescribing Botox and other injectable cosmetics to ensure they fully understand the patient&rsquo;s medical history and reasons for wanting the treatment.<wbr> </div><div style="margin-bottom: 10px;">A copy of the new remote prescribing guidance is at:  <A href="http://www.gmc-uk.org/guidance/ethical_guidance/13594.asp">www.<wbr>gmc-uk.<wbr>org/<wbr>guidance/<wbr>ethical_guidance/<wbr>13594.<wbr>asp</A> </div><div>Source: GMC 12 July 2012 </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120831&edate=20120501&rec=6503">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-07-12T14:56:42+02:00</dc:date><dc:creator>ala97794</dc:creator></item><item>
<title>AstraZeneca To Invest Over $150 Mn in a Manufacturing Hub in Russia [mkt:Intercontinental, mkt:Russia, :Oncology:comp:AstraZeneca]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld9974</link>
<description>AstraZeneca To Invest Over $150 Mn in a Manufacturing Hub in Russia [mkt:Intercontinental, mkt:Russia, :Oncology:comp:AstraZeneca]</description><category>mkt:Intercontinental</category><category>mkt:Russia</category><category>comp:AstraZeneca</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld9974</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120831&edate=20120501&rec=9974">AstraZeneca To Invest Over $150 Mn in a Manufacturing Hub in Russia</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=comp%3aAstraZeneca"><font color="#e95e0b">:Oncology:comp:AstraZeneca</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=mkt%3aIntercontinental"><font color="#e95e0b">:PharmaWorld:mkt:Intercontinental</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=mkt%3aRussia"><font color="#e95e0b">:PharmaWorld:mkt:Russia</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld9974">PharmaWorld9974</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/14">Thi-Le-Xuan-Ann NGUYEN-LAIRAUD</a> | 12 July 2012 | 11:09</font><br><br><div style="margin-bottom: 10px;">Comment : AZ to join a group of other pharma companies on a hub that should starts producing before this year end.<wbr> </div><div style="margin-bottom: 10px;">The hub will start with six residents &mdash; Denmark&rsquo;s Novo Nordisk, British-Swedish <STRONG>AstraZeneca</STRONG>, Germany&rsquo;s Stada and Italy&rsquo;s Menarini, as well as domestic drugmakers &ndash;Nearmedic and SpheraPharm- that already have a presence in the region, having jointly invested more than $500 million in their production facilities, creating 1,500 new jobs.<wbr> </div><div style="margin-bottom: 10px;">AZ plant will encompass a full production cycle, from medicine component preparation to packaging and is understood to include AZ <STRONG>oncological</STRONG>, cardiological, <STRONG>gastroenterological,</STRONG> psychiatric product ranges.<wbr> </div><div style="margin-bottom: 10px;">The overall investment by foreign companies in Russia&rsquo;s pharmaceutical industry over the last three years has exceeded 800 Mln &euro; ($992 Mln), according to the head of the Industry and Trade Ministry.<wbr> This includes various types of investment, with foreign drugmakers setting up manufacturing, buying into local companies or establishing J-Vs with them.<wbr> </div><div style="margin-bottom: 10px;">The country&rsquo;s pharma industry grew 17 percent last year and is expected to maintain this growth rate in 2012,  and the industry&rsquo;s total revenue might reach $23 Bn this year.<wbr> </div><div>Source : The Moscow Times /<wbr> RT News Network </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120831&edate=20120501&rec=9974">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-07-12T11:09:13+02:00</dc:date><dc:creator>len82156</dc:creator></item><item>
<title>WW Regulatory Filing of GSK's Once-Weekly GLP-1 Planned Early 2013 [class:GLP1, dis:Diabetes, :PharmaWorld:sub:Regulatory]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7020</link>
<description>WW Regulatory Filing of GSK's Once-Weekly GLP-1 Planned Early 2013 [class:GLP1, dis:Diabetes, :PharmaWorld:sub:Regulatory]</description><category>class:GLP1</category><category>dis:Diabetes</category><category>sub:Regulatory</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7020</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120831&edate=20120501&rec=7020">WW Regulatory Filing of GSK's Once-Weekly GLP-1 Planned Early 2013</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=class%3aGLP1"><font color="#e95e0b">:Endocrinology:class:GLP1</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=dis%3aDiabetes"><font color="#e95e0b">:Endocrinology:dis:Diabetes</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=sub%3aRegulatory"><font color="#e95e0b">:PharmaWorld:sub:Regulatory</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7020">Endocrinology7020</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 12 July 2012 | 10:01</font><br><br><div style="margin-bottom: 10px;">Comment: Human Genome Sciences and partner GSK have reported positive data from the Ph3 Harmony 8 trial.<wbr> Results show albiglutide was superior to sitagliptin (Januvia) on the primary endpoint of reducing HbA1c from baseline to week 26.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Liraglutide Regulatory Plans</FONT></STRONG> </div><div style="margin-bottom: 10px;">The remaining 5 trials are expected to complete in early 2013.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Liraglutide Program</FONT></STRONG> </div><div style="margin-bottom: 10px;">Please see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120831&edate=20120501&rec=6902" class="defaultlink">Endocrinology6902: Ph3 Results of GSK's Albiglutide (Once-Weekly GLP-1) Support Progression to Regulatory Filing</a>.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">A Crowded GLP-1 Market</FONT></STRONG> </div><div>Albiglutide will compete with Novo's Victoza, AZN/<wbr>BMS' Bydureon/<wbr>Byetta, Sanofi's Lyxumia and Lilly's dulaglutide.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120831&edate=20120501&rec=7020">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-07-12T10:01:00+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Main Takeaways on Astellas' Oncology Day [comp:Astellas, :PharmaWorld:func:RnD, dis:Prostate]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology8380</link>
<description>Main Takeaways on Astellas' Oncology Day [comp:Astellas, :PharmaWorld:func:RnD, dis:Prostate]</description><category>comp:Astellas</category><category>func:RnD</category><category>dis:Prostate</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology8380</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8380">Main Takeaways on Astellas' Oncology Day</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=comp%3aAstellas"><font color="#e95e0b">:Oncology:comp:Astellas</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=func%3aRnD"><font color="#e95e0b">:PharmaWorld:func:RnD</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8380">Oncology8380</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 11 July 2012 | 15:13</font><br><br><div style="margin-bottom: 10px;">Comment: The presentation given by W.<wbr> Klohs (Sr VP Oncology) was centered on scientific data and reviewed the R&amp;D pipeline.<wbr> S-I Tsukamoto outlined Astellas' mission and strategy in Drug Discovery Research.<wbr> Whilst the majority of the data had already been disclosed, the meeting confirmed the company's strong commitment to the franchise.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">R&amp;D Pipeline</FONT></STRONG> </div><div style="margin-bottom: 10px;"><FONT size="1">Source: Morgan Stanley</FONT> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8380/6/ScreenCapture6.jpg?user-agent=rss"></FONT></STRONG> </div><div style="margin-bottom: 10px;"><STRONG>Enzalutamide - Development Progress</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8380/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG>Degarelix Status in Japan</STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>1M : approved (see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8361" class="defaultlink">Oncology8361: Gonax (Degarelix 1M) Approved in Japan</a>).<wbr></LI>
<LI>3M : Ph2 ongoing</LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG>ASG-5ME for Prostate Cancer</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8380/2/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Drug Discovery Research</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8380/3/ScreenCapture3.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">In the field of precision medicine, Astellas is currently developing 7 companion diagnostics, 4 of which it has concluded partnering agreements with diagnostic companies.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8380/4/ScreenCapture4.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG>Research Centers</STRONG> </div><div><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8380/5/ScreenCapture5.jpg?user-agent=rss"> </div><!-- Comment details --><a name="oncology8380attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8380/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(84,2 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8380/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(91,4 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8380/3/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(123,5 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8380/4/ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(95,3 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8380/5/ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(65,1 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8380/6/ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(55,2 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8380">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-07-11T15:13:28+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8380/1/ScreenCapture1.jpg" length="86191" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8380/2/ScreenCapture2.jpg" length="93568" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8380/3/ScreenCapture3.jpg" length="126497" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8380/4/ScreenCapture4.jpg" length="97607" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8380/5/ScreenCapture5.jpg" length="66658" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8380/6/ScreenCapture6.jpg" length="56520" type="image/jpeg"/></item><item>
<title>Study - Oral Octreotide Absorption in Human Subjects [class:SomatostatinAnalogue, comp:Novartis, dis:Acromegaly, prod:Octreotide]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7017</link>
<description>Study - Oral Octreotide Absorption in Human Subjects [class:SomatostatinAnalogue, comp:Novartis, dis:Acromegaly, prod:Octreotide]</description><comments>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7017</comments><category>class:SomatostatinAnalogue</category><category>comp:Novartis</category><category>dis:Acromegaly</category><category>prod:Octreotide</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7017</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120831&edate=20120501&rec=7017">Study - Oral Octreotide Absorption in Human Subjects</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=class%3aSomatostatinAnalogue"><font color="#e95e0b">:Endocrinology:class:SomatostatinAnalogue</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=comp%3aNovartis"><font color="#e95e0b">:Endocrinology:comp:Novartis</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=dis%3aAcromegaly"><font color="#e95e0b">:Endocrinology:dis:Acromegaly</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=prod%3aOctreotide"><font color="#e95e0b">:Endocrinology:prod:Octreotide</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7017">Endocrinology7017</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/199">clm11175</a> | 11 July 2012 | 15:11</font><br><br><div style="margin-bottom: 10px;">Comment : Already signalled in April as a preprint but now full pagination in <EM>JCEM</EM>.<wbr> The authors conclude that the results support an oral octreotide alternative to parenteral octreotide treatment for patients with acromegaly.<wbr> Please find the abstract below.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Oral Octreotide Absorption in Human Subjects : Comparable Pharmacokinetics to Parenteral Octreotide and Effective Growth Hormone Suppression</STRONG>.<wbr> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-GB" style="FONT-SIZE: 10pt; COLOR: black; FONT-FAMILY: Helvetica, sans-serif">Context:Oral administration of a novel octreotide formulation enabled its absorption to the systemic circulation, exhibiting blood concentrations comparable to those observed with injected octreotide and maintaining its biological activity.<wbr></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-GB" style="FONT-SIZE: 10pt; COLOR: black; FONT-FAMILY: Helvetica, sans-serif">Objectives:The aim of the study was to determine oral octreotide absorption and effects on pituitary GH secretion compared to sc octreotide injection.<wbr></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-GB" style="FONT-SIZE: 10pt; COLOR: black; FONT-FAMILY: Helvetica, sans-serif">Design:Four single-dose studies were conducted in 75 healthy volunteers.<wbr>Intervention:Oral doses of 3, 10, or 20 mg octreotide and a single sc injection of 100 </SPAN><SPAN style="FONT-SIZE: 10pt; COLOR: black; FONT-FAMILY: Helvetica, sans-serif">μ</SPAN><SPAN lang="EN-GB" style="FONT-SIZE: 10pt; COLOR: black; FONT-FAMILY: Helvetica, sans-serif"> g octreotide were administered.<wbr></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-GB" style="FONT-SIZE: 10pt; COLOR: black; FONT-FAMILY: Helvetica, sans-serif">Main Outcome Measure:We measured the pharmacokinetic profile of orally administrated octreotide and the effect of octreotide on basal and stimulated GH secretion.<wbr></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-GB" style="FONT-SIZE: 10pt; COLOR: black; FONT-FAMILY: Helvetica, sans-serif">Results:Both oral and sc treatments were well tolerated.<wbr> Oral octreotide absorption to the circulation was apparent within 1 h after dose administration.<wbr> Escalating oral octreotide doses resulted in dose-dependent increased plasma octreotide concentrations, with an observed rate of plasma decay similar to parenteral administration.<wbr><STRONG> Both 20 mg oral octreotide and injection of 0.<wbr>1 mg sc octreotide resulted in equivalent pharmacokinetic parameters</STRONG> [mean peak plasma concentration, 3.<wbr>77 ± 0.<wbr>25 vs.<wbr> 3.<wbr>97 ± 0.<wbr>19 ng/<wbr>ml; mean area under the curve, 16.<wbr>2 ± 1.<wbr>25 vs.<wbr> 12.<wbr>1 ± 0.<wbr>45 h×ng/<wbr>ml); and median time ≥0.<wbr>5 ng/<wbr>ml, 7.<wbr>67 vs.<wbr> 5.<wbr>88 h, respectively).<wbr> <STRONG>A single dose of 20 mg oral octreotide resulted in basal</STRONG> (P &lt; 0.<wbr>05) <STRONG>and GHRH-stimulated</STRONG> (P &lt; 0.<wbr>001)<STRONG> mean GH levels suppressed by 49 and 80%, respectively</STRONG>.<wbr></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-GB" style="FONT-SIZE: 10pt; COLOR: black; FONT-FAMILY: Helvetica, sans-serif">Conclusions:The results support an oral octreotide alternative to parenteral octreotide treatment for patients with acromegaly.<wbr></SPAN> </div><div style="margin-bottom: 10px;"><P style="MARGIN: 0cm 0cm 0pt; WORD-SPACING: 0px; FONT: 13px arial, sans-serif; VERTICAL-ALIGN: baseline; TEXT-TRANSFORM: none; COLOR: #222222; TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; BACKGROUND-COLOR: white; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">Authors: <SPAN style="BORDER-RIGHT: windowtext 1pt; PADDING-RIGHT: 0cm; BORDER-TOP: windowtext 1pt; PADDING-LEFT: 0cm; PADDING-BOTTOM: 0cm; BORDER-LEFT: windowtext 1pt; COLOR: #333333; PADDING-TOP: 0cm; BORDER-BOTTOM: windowtext 1pt">Tuvia S</SPAN><SPAN style="DISPLAY: inline! important; FLOAT: none; WORD-SPACING: 0px; FONT: 13px Helvetica, sans-serif; TEXT-TRANSFORM: none; COLOR: #000000; TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; BACKGROUND-COLOR: #ffffff; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">,</SPAN> <SPAN style="BORDER-RIGHT: windowtext 1pt; PADDING-RIGHT: 0cm; BORDER-TOP: windowtext 1pt; PADDING-LEFT: 0cm; PADDING-BOTTOM: 0cm; BORDER-LEFT: windowtext 1pt; COLOR: #333333; PADDING-TOP: 0cm; BORDER-BOTTOM: windowtext 1pt">Atsmon J</SPAN><SPAN style="DISPLAY: inline! important; FLOAT: none; WORD-SPACING: 0px; FONT: 13px Helvetica, sans-serif; TEXT-TRANSFORM: none; COLOR: #000000; TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; BACKGROUND-COLOR: #ffffff; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">,</SPAN> <SPAN style="BORDER-RIGHT: windowtext 1pt; PADDING-RIGHT: 0cm; BORDER-TOP: windowtext 1pt; PADDING-LEFT: 0cm; PADDING-BOTTOM: 0cm; BORDER-LEFT: windowtext 1pt; COLOR: #333333; PADDING-TOP: 0cm; BORDER-BOTTOM: windowtext 1pt">Teichman SL</SPAN><SPAN style="DISPLAY: inline! important; FLOAT: none; WORD-SPACING: 0px; FONT: 13px Helvetica, sans-serif; TEXT-TRANSFORM: none; COLOR: #000000; TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; BACKGROUND-COLOR: #ffffff; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">,</SPAN> <SPAN style="BORDER-RIGHT: windowtext 1pt; PADDING-RIGHT: 0cm; BORDER-TOP: windowtext 1pt; PADDING-LEFT: 0cm; PADDING-BOTTOM: 0cm; BORDER-LEFT: windowtext 1pt; COLOR: #333333; PADDING-TOP: 0cm; BORDER-BOTTOM: windowtext 1pt">Katz S</SPAN><SPAN style="DISPLAY: inline! important; FLOAT: none; WORD-SPACING: 0px; FONT: 13px Helvetica, sans-serif; TEXT-TRANSFORM: none; COLOR: #000000; TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; BACKGROUND-COLOR: #ffffff; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">,</SPAN> <SPAN style="BORDER-RIGHT: windowtext 1pt; PADDING-RIGHT: 0cm; BORDER-TOP: windowtext 1pt; PADDING-LEFT: 0cm; PADDING-BOTTOM: 0cm; BORDER-LEFT: windowtext 1pt; COLOR: #333333; PADDING-TOP: 0cm; BORDER-BOTTOM: windowtext 1pt">Salama P</SPAN><SPAN style="DISPLAY: inline! important; FLOAT: none; WORD-SPACING: 0px; FONT: 13px Helvetica, sans-serif; TEXT-TRANSFORM: none; COLOR: #000000; TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; BACKGROUND-COLOR: #ffffff; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">,</SPAN> <SPAN style="BORDER-RIGHT: windowtext 1pt; PADDING-RIGHT: 0cm; BORDER-TOP: windowtext 1pt; PADDING-LEFT: 0cm; PADDING-BOTTOM: 0cm; BORDER-LEFT: windowtext 1pt; COLOR: #333333; PADDING-TOP: 0cm; BORDER-BOTTOM: windowtext 1pt">Pelled D</SPAN><SPAN style="DISPLAY: inline! important; FLOAT: none; WORD-SPACING: 0px; FONT: 13px Helvetica, sans-serif; TEXT-TRANSFORM: none; COLOR: #000000; TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; BACKGROUND-COLOR: #ffffff; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">,</SPAN> <SPAN style="BORDER-RIGHT: windowtext 1pt; PADDING-RIGHT: 0cm; BORDER-TOP: windowtext 1pt; PADDING-LEFT: 0cm; PADDING-BOTTOM: 0cm; BORDER-LEFT: windowtext 1pt; COLOR: #333333; PADDING-TOP: 0cm; BORDER-BOTTOM: windowtext 1pt">Landau I</SPAN><SPAN style="DISPLAY: inline! important; FLOAT: none; WORD-SPACING: 0px; FONT: 13px Helvetica, sans-serif; TEXT-TRANSFORM: none; COLOR: #000000; TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; BACKGROUND-COLOR: #ffffff; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">,</SPAN> <SPAN style="BORDER-RIGHT: windowtext 1pt; PADDING-RIGHT: 0cm; BORDER-TOP: windowtext 1pt; PADDING-LEFT: 0cm; PADDING-BOTTOM: 0cm; BORDER-LEFT: windowtext 1pt; COLOR: #333333; PADDING-TOP: 0cm; BORDER-BOTTOM: windowtext 1pt">Karmeli I</SPAN><SPAN style="DISPLAY: inline! important; FLOAT: none; WORD-SPACING: 0px; FONT: 13px Helvetica, sans-serif; TEXT-TRANSFORM: none; COLOR: #000000; TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; BACKGROUND-COLOR: #ffffff; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">,</SPAN> <SPAN style="BORDER-RIGHT: windowtext 1pt; PADDING-RIGHT: 0cm; BORDER-TOP: windowtext 1pt; PADDING-LEFT: 0cm; PADDING-BOTTOM: 0cm; BORDER-LEFT: windowtext 1pt; COLOR: #333333; PADDING-TOP: 0cm; BORDER-BOTTOM: windowtext 1pt">Bidlingmaier M</SPAN><SPAN style="DISPLAY: inline! important; FLOAT: none; WORD-SPACING: 0px; FONT: 13px Helvetica, sans-serif; TEXT-TRANSFORM: none; COLOR: #000000; TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; BACKGROUND-COLOR: #ffffff; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">,</SPAN> <SPAN style="BORDER-RIGHT: windowtext 1pt; PADDING-RIGHT: 0cm; BORDER-TOP: windowtext 1pt; PADDING-LEFT: 0cm; PADDING-BOTTOM: 0cm; BORDER-LEFT: windowtext 1pt; COLOR: #333333; PADDING-TOP: 0cm; BORDER-BOTTOM: windowtext 1pt">Strasburger CJ</SPAN><SPAN style="DISPLAY: inline! important; FLOAT: none; WORD-SPACING: 0px; FONT: 13px Helvetica, sans-serif; TEXT-TRANSFORM: none; COLOR: #000000; TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; BACKGROUND-COLOR: #ffffff; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">,</SPAN> <SPAN style="BORDER-RIGHT: windowtext 1pt; PADDING-RIGHT: 0cm; BORDER-TOP: windowtext 1pt; PADDING-LEFT: 0cm; PADDING-BOTTOM: 0cm; BORDER-LEFT: windowtext 1pt; COLOR: #333333; PADDING-TOP: 0cm; BORDER-BOTTOM: windowtext 1pt">Kleinberg DL</SPAN><SPAN style="DISPLAY: inline! important; FLOAT: none; WORD-SPACING: 0px; FONT: 13px Helvetica, sans-serif; TEXT-TRANSFORM: none; COLOR: #000000; TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; BACKGROUND-COLOR: #ffffff; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">,</SPAN> <SPAN style="BORDER-RIGHT: windowtext 1pt; PADDING-RIGHT: 0cm; BORDER-TOP: windowtext 1pt; PADDING-LEFT: 0cm; PADDING-BOTTOM: 0cm; BORDER-LEFT: windowtext 1pt; COLOR: #333333; PADDING-TOP: 0cm; BORDER-BOTTOM: windowtext 1pt">Melmed S</SPAN><SPAN style="DISPLAY: inline! important; FLOAT: none; WORD-SPACING: 0px; FONT: 13px Helvetica, sans-serif; TEXT-TRANSFORM: none; COLOR: #000000; TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; BACKGROUND-COLOR: #ffffff; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">,</SPAN> <SPAN style="BORDER-RIGHT: windowtext 1pt; PADDING-RIGHT: 0cm; BORDER-TOP: windowtext 1pt; PADDING-LEFT: 0cm; PADDING-BOTTOM: 0cm; BORDER-LEFT: windowtext 1pt; COLOR: #333333; PADDING-TOP: 0cm; BORDER-BOTTOM: windowtext 1pt">Mamluk R</SPAN><SPAN style="DISPLAY: inline! important; FLOAT: none; WORD-SPACING: 0px; FONT: 13px Helvetica, sans-serif; TEXT-TRANSFORM: none; COLOR: #000000; TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; BACKGROUND-COLOR: #ffffff; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">.<wbr> </SPAN></P> </div><div><P style="MARGIN: 0cm 0cm 0pt; WORD-SPACING: 0px; FONT: 13px arial, sans-serif; VERTICAL-ALIGN: baseline; TEXT-TRANSFORM: none; COLOR: #222222; TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; BACKGROUND-COLOR: white; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><SPAN style="DISPLAY: inline! important; FLOAT: none; WORD-SPACING: 0px; FONT: 13px Helvetica, sans-serif; TEXT-TRANSFORM: none; COLOR: #000000; TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; BACKGROUND-COLOR: #ffffff; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">Source: </SPAN><SPAN lang="EN-US" style="FONT-SIZE: 11pt; COLOR: black; FONT-FAMILY: Helvetica, sans-serif"><SPAN style="DISPLAY: inline! important; FLOAT: none; WORD-SPACING: 0px; FONT: 13px arial, sans-serif; TEXT-TRANSFORM: none; COLOR: #222222; TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; BACKGROUND-COLOR: #ffffff; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">J Clin Endocrinol Metab 2012;97 2362-2369</SPAN></SPAN></P> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Endocrinology7027c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;"><SPAN style="background-color: #ffffff;">.<wbr>.<wbr>.<wbr>.<wbr>then ,it is possible to calculate  the absolute oral bioavailability of the proposed formulation  which is :  <SPAN style="text-decoration: underline;"><STRONG>0.<wbr>5%</STRONG></SPAN> (0.<wbr>1/<wbr>20) , and as a consequence , novartis  will probably need to build a new API plant to produce 100 times more peptide to treat the same volume of patients !!!.<wbr>.<wbr>.<wbr>.<wbr>.<wbr>.<wbr>.<wbr> and also have to  support a huge manufacturing price increase  !</SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="background-color: #ffffff;">it is simply not realistic !</SPAN> </div><div><SPAN style="background-color: #ffffff;">Bruno</SPAN> </div><font size="-1">Bruno TISSIER / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7027" class="commentpermalink">Endocrinology7027</a> / <span class="date">13 July 2012</span> /
<span class="time">17:21:18 o'clock CEST</span>
</font></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120831&edate=20120501&rec=7017">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-07-11T15:11:17+02:00</dc:date><dc:creator>clm11175</dc:creator></item><item>
<title>Slovak Health Minister Plans to Change the Country's International-Pricing System (IRP) [mkt:Europe, sub:Pricing]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld9971</link>
<description>Slovak Health Minister Plans to Change the Country's International-Pricing System (IRP) [mkt:Europe, sub:Pricing]</description><category>mkt:Europe</category><category>sub:Pricing</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld9971</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120831&edate=20120501&rec=9971">Slovak Health Minister Plans to Change the Country's International-Pricing System (IRP)</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=mkt%3aEurope"><font color="#e95e0b">:PharmaWorld:mkt:Europe</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=sub%3aPricing"><font color="#e95e0b">:PharmaWorld:sub:Pricing</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld9971">PharmaWorld9971</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 11 July 2012 | 13:58</font><br><br><div style="margin-bottom: 10px;">Comment: It is reported by Slovak newspaper SME that changes may be made to the IRP.<wbr> One possibility that has been discussed is for prices of drugs in Slovakia to be referenced to the average of the three lowest-priced markets in the EU.<wbr> This is because some problems have materialised with the supply of some drugs as a result of the very low prices in the country.<wbr> </div><div style="margin-bottom: 10px;"><P class="bodyHeading2"><STRONG><FONT size="3">Slovak Pharma Market Grows 6.<wbr>7% Y/<wbr>Y in 2011</FONT></STRONG></P> </div><div style="margin-bottom: 10px;">The value of the Slovak pharmaceutical market in 2011 reached EUR1.<wbr>193 billion (USD1.<wbr>465 billion) in 2011, according to information provided by the Slovak National Health Information Centre.<wbr> Based on the estimate of the market's value for 2010 given by the Statistical Office of the Slovak Republic (EUR1.<wbr>118 billion), the Slovak pharmaceutical market grew by 6.<wbr>71% year-on-year in 2011.<wbr> </div><div style="margin-bottom: 10px;">In volume terms, the total number of packages sold in 2011 is reported to have reached 126.<wbr>672 million, of which some 90.<wbr>631 million were prescription medicines.<wbr> Health insurance funds provided a reported EUR897.<wbr>525 million in reimbursement spending on these prescription medicines, while the total amount patients spent on them—in the form of co-payments—reached EUR175.<wbr>751 million.<wbr> The total value of the sales of non-prescription medicines reached EUR119.<wbr>839 million, or 36.<wbr>040 million packages in volume terms.<wbr> </div><div style="margin-bottom: 10px;"><P class="bodyHeading2"><STRONG><FONT size="3">Patient Participation in Healthcare Costs Up 5.<wbr>1% Y/<wbr>Y</FONT></STRONG></P> </div><div style="margin-bottom: 10px;">Meanwhile, according to data from the Healthcare Surveillance Authority (UDZS), there was an increase of 5.<wbr>1% y/<wbr>y in the amount of money spent by Slovaks on healthcare from their own pockets, with the total reportedly reaching EUR1.<wbr>203 billion.<wbr> The UDZS reports that in 2011, there was a 2.<wbr>1% y/<wbr>y increase in total healthcare expenditure to EUR4.<wbr>904 billion, with public spending reaching EUR3.<wbr>7 billion.<wbr> Healthcare's share of GDP in Slovakia is reported to have increased from 7.<wbr>3% in 2010 to 7.<wbr>4% in 2011.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Top 10 Pharma Companies in Slovakia</FONT></STRONG> </div><div style="margin-bottom: 10px;">Looking at the top 10 pharmaceutical companies in Slovakia during 2011, based on data from IMS Health quoted by the Slovak Association of Research-based Pharmaceutical Companies, French major Sanofi occupied the first place, with sales of EUR121.<wbr>71 million, bolstered by the strong position of its generic branch Zentiva on the Slovak market.<wbr> The Swiss duo of Novartis and Roche were in second and third places respectively, at some considerable distance behind the market leader.<wbr> </div><div><TABLE class="table100"><TBODY><TR><TD align="middle" class="tableTitleBold" colspan="3" style="VERTICAL-ALIGN: top">
<P align="center" class="tableTitleBold"><B>Top 10 Pharmaceutical Companies in Slovakia by Sales Value, 2011</B></P></TD>
</TR>
<TR><TD align="middle" class="tableHeading" style="VERTICAL-ALIGN: top">
<P align="center" class="tableHeading"><B>Company</B></P></TD>
<TD align="middle" class="tableHeading" style="VERTICAL-ALIGN: top">
<P align="center" class="tableHeading"><B>Sales (EUR Mil.<wbr>)</B></P></TD>
<TD align="middle" class="tableHeading" style="VERTICAL-ALIGN: top">
<P align="center" class="tableHeading"><B>Number of Packages Sold (Mil.<wbr>)</B></P></TD>
</TR>
<TR><TD class="tableContent" style="VERTICAL-ALIGN: top">
<P class="tableContent"><FONT color="#f90000">Sanofi (France)</FONT></P></TD>
<TD align="right" class="tableContent" style="VERTICAL-ALIGN: top">
<P align="right" class="tableContent">121.<wbr>71</P></TD>
<TD align="right" class="tableContent" style="VERTICAL-ALIGN: top">
<P align="right" class="tableContent">37.<wbr>63</P></TD>
</TR>
<TR><TD class="tableContent" style="VERTICAL-ALIGN: top">
<P class="tableContent">Novartis (Switzerland)</P></TD>
<TD align="right" class="tableContent" style="VERTICAL-ALIGN: top">
<P align="right" class="tableContent">93.<wbr>72</P></TD>
<TD align="right" class="tableContent" style="VERTICAL-ALIGN: top">
<P align="right" class="tableContent">6.<wbr>76</P></TD>
</TR>
<TR><TD class="tableContent" style="VERTICAL-ALIGN: top">
<P class="tableContent">Roche (Switzerland)</P></TD>
<TD align="right" class="tableContent" style="VERTICAL-ALIGN: top">
<P align="right" class="tableContent">64.<wbr>94</P></TD>
<TD align="right" class="tableContent" style="VERTICAL-ALIGN: top">
<P align="right" class="tableContent">N/<wbr>A</P></TD>
</TR>
<TR><TD class="tableContent" style="VERTICAL-ALIGN: top">
<P class="tableContent">Pfizer (United States) </P></TD>
<TD align="right" class="tableContent" style="VERTICAL-ALIGN: top">
<P align="right" class="tableContent">60.<wbr>15</P></TD>
<TD align="right" class="tableContent" style="VERTICAL-ALIGN: top">
<P align="right" class="tableContent">2.<wbr>89</P></TD>
</TR>
<TR><TD class="tableContent" style="VERTICAL-ALIGN: top">
<P class="tableContent">GlaxoSmithKline (United Kingdom)</P></TD>
<TD align="right" class="tableContent" style="VERTICAL-ALIGN: top">
<P align="right" class="tableContent">59.<wbr>54</P></TD>
<TD align="right" class="tableContent" style="VERTICAL-ALIGN: top">
<P align="right" class="tableContent">5.<wbr>78</P></TD>
</TR>
<TR><TD class="tableContent" style="VERTICAL-ALIGN: top">
<P class="tableContent">Teva (Israel)</P></TD>
<TD align="right" class="tableContent" style="VERTICAL-ALIGN: top">
<P align="right" class="tableContent">58.<wbr>88</P></TD>
<TD align="right" class="tableContent" style="VERTICAL-ALIGN: top">
<P align="right" class="tableContent">1.<wbr>60</P></TD>
</TR>
<TR><TD class="tableContent" style="VERTICAL-ALIGN: top">
<P class="tableContent">Servier (France)</P></TD>
<TD align="right" class="tableContent" style="VERTICAL-ALIGN: top">
<P align="right" class="tableContent">56.<wbr>90</P></TD>
<TD align="right" class="tableContent" style="VERTICAL-ALIGN: top">
<P align="right" class="tableContent">N/<wbr>A</P></TD>
</TR>
<TR><TD class="tableContent" style="VERTICAL-ALIGN: top">
<P class="tableContent">Abbott (United States)</P></TD>
<TD align="right" class="tableContent" style="VERTICAL-ALIGN: top">
<P align="right" class="tableContent">55.<wbr>47</P></TD>
<TD align="right" class="tableContent" style="VERTICAL-ALIGN: top">
<P align="right" class="tableContent">2.<wbr>83</P></TD>
</TR>
<TR><TD class="tableContent" style="VERTICAL-ALIGN: top">
<P class="tableContent">Merck &amp; Co.<wbr>(United States)</P></TD>
<TD align="right" class="tableContent" style="VERTICAL-ALIGN: top">
<P align="right" class="tableContent">27.<wbr>31</P></TD>
<TD align="right" class="tableContent" style="VERTICAL-ALIGN: top">
<P align="right" class="tableContent">N/<wbr>A</P></TD>
</TR>
<TR><TD class="tableContent" style="VERTICAL-ALIGN: top">
<P class="tableContent">Krka (Slovenia)</P></TD>
<TD align="right" class="tableContent" style="VERTICAL-ALIGN: top">
<P align="right" class="tableContent">27.<wbr>08</P></TD>
<TD align="right" class="tableContent" style="VERTICAL-ALIGN: top">
<P align="right" class="tableContent">6.<wbr>25</P></TD>
</TR>
<TR><TD class="tableNotes" colspan="3" style="VERTICAL-ALIGN: top">
<P class="tableNotes">Source: IMS Health, Slovak Association of Research-Based Pharmaceutical Companies </P>
<P class="tableNotes">Source: GlobalInsight</P></TD>
</TR>
</TBODY>
</TABLE> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120831&edate=20120501&rec=9971">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-07-11T13:58:02+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Ranbaxy to Enter the Biosimilar Space [:PharmaWorld:mkt:Intercontinental, :PharmaWorld:mkt:India, :PharmaWorld:mkt:Europe]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology8379</link>
<description>Ranbaxy to Enter the Biosimilar Space [:PharmaWorld:mkt:Intercontinental, :PharmaWorld:mkt:India, :PharmaWorld:mkt:Europe]</description><category>mkt:Intercontinental</category><category>mkt:India</category><category>mkt:Europe</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology8379</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8379">Ranbaxy to Enter the Biosimilar Space</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=mkt%3aEurope"><font color="#e95e0b">:PharmaWorld:mkt:Europe</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=mkt%3aIndia"><font color="#e95e0b">:PharmaWorld:mkt:India</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=mkt%3aIntercontinental"><font color="#e95e0b">:PharmaWorld:mkt:Intercontinental</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8379">Oncology8379</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 11 July 2012 | 09:56</font><br><br><div style="margin-bottom: 10px;">Comment: Ranbaxy's plans is to launch at least 3 biosimilars mostly to treat cancer, in Indi by 2015.<wbr> The company's strategy is to seek EU and US approvals 4 to 5 years after India launches.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Which Biosimilar(s) ?</FONT></STRONG> </div><div style="margin-bottom: 10px;">The (undisclosed) biosimilar the company plans to introduce in India next year has the potential for global annual sales in "the hundreds of millions of dollars".<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Cooperation with Daichi Sankyo (DS)</FONT></STRONG> </div><div style="margin-bottom: 10px;">In 2008, DS acquired a majority stake in Ranbaxy (See <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120831&edate=20120501&rec=6632" class="defaultlink">PharmaWorld6632: Japan's Daiichi Sankyo to acquire majority stake in Ranbaxy</a>).<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8379/2/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Ranbaxy Footprint</FONT></STRONG> </div><div><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8379/3/ScreenCapture3.jpg?user-agent=rss"> </div><!-- Comment details --><a name="oncology8379attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8379/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(106,4 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8379/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(67,7 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8379/3/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(63,1 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8379">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-07-11T09:56:51+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8379/1/ScreenCapture1.jpg" length="108928" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8379/2/ScreenCapture2.jpg" length="69335" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8379/3/ScreenCapture3.jpg" length="64611" type="image/jpeg"/></item><item>
<title>Corcept Raises $46.4m in Financing [dis:Cushing, news]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7016</link>
<description>Corcept Raises $46.4m in Financing [dis:Cushing, news]</description><category>dis:Cushing</category><category>news</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7016</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120831&edate=20120501&rec=7016">Corcept Raises $46.<wbr>4m in Financing</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=dis%3aCushing"><font color="#e95e0b">:Endocrinology:dis:Cushing</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=news"><font color="#e95e0b">:Endocrinology:news</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7016">Endocrinology7016</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 10 July 2012 | 14:44</font><br><br><div style="margin-bottom: 10px;">Comment: Corcept raised $46.<wbr>4m late Friday through the sale of 11 million 
shares at $4.<wbr>22 per share in a placement organised by Credit Suisse.<wbr> Corcept is 
marketing Korlym (mifepristone) in the US to treat Cushing's syndrome.<wbr> </div><div style="margin-bottom: 10px;">The money has been raised to support the group's ongoing R&amp;D activities 
with its progesterone and cortisol receptor anatagonist in pychotic depression 
and to support the group's working capital and general corporate purposes.<wbr> </div><div>source:www.<wbr>corcept.<wbr>com </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120831&edate=20120501&rec=7016">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-07-10T14:44:41+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>Acino Is Confident to Have the First &quot;Generic&quot; Goserelin Coming to the Market [Alert, comp:Acino, prod:Goserelin, prod:Leuprorelin]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/DKPHybrids162</link>
<description>Acino Is Confident to Have the First &quot;Generic&quot; Goserelin Coming to the Market [Alert, comp:Acino, prod:Goserelin, prod:Leuprorelin]</description><category>Alert</category><category>comp:Acino</category><category>prod:Goserelin</category><category>prod:Leuprorelin</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/DKPHybrids162</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=DKPHybrids&sdate=20120831&edate=20120501&rec=162">Acino Is Confident to Have the First "Generic" Goserelin Coming to the Market</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=DKPHybrids&sdate=20120831&edate=20120501&cat=Alert"><font color="#e95e0b">:DKPHybrids:Alert</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=DKPHybrids&sdate=20120831&edate=20120501&cat=comp%3aAcino"><font color="#e95e0b">:DKPHybrids:comp:Acino</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=DKPHybrids&sdate=20120831&edate=20120501&cat=prod%3aGoserelin"><font color="#e95e0b">:DKPHybrids:prod:Goserelin</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=DKPHybrids&sdate=20120831&edate=20120501&cat=prod%3aLeuprorelin"><font color="#e95e0b">:DKPHybrids:prod:Leuprorelin</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/DKPHybrids162">DKPHybrids162</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 10 July 2012 | 12:43</font><br><br><div style="margin-bottom: 10px;">Comment: In a trading statement announcing its half-year 2012 sales result, Acino has reported that the goserelin 1M and 3M implant are expected to be launched H2:12 in several Middle Eastern and African countries.<wbr> The company plans first EU approvals of goserelin and leuprorelin in late 2015.<wbr> As reported in the company PR, goserelin is called 'generic' and not 'hybrid'.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Filings of Goserelin and Leuprorelin</FONT></STRONG> </div><div style="margin-bottom: 10px;"><STRONG>In EU</STRONG> </div><div style="margin-bottom: 10px;">In support of the EU filing, additional studies will be conducted with both drugs.<wbr> With a delay of approx.<wbr> 18 months for submitting the additional study results, Acino expects first approvals in late 2015.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>In Japan</STRONG> </div><div style="margin-bottom: 10px;">Clinical trials (performed by the licensee ? see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=DKPHybrids&sdate=20120831&edate=20120501&rec=44" class="defaultlink">DKPHybrids44: Acino Concludes Japanese Oncology Licensing Deal</a>) expected to start by the end of 2012.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Sales Result for the First Six Months of 2012</FONT></STRONG> </div><div style="margin-bottom: 10px;">The company has announced total revenues grew by 98% to €128.<wbr>9M (including 4 and a half months trading of Mepha and Cephalon business).<wbr> </div><div style="margin-bottom: 10px;">(please see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=DKPHybrids&sdate=20120831&edate=20120501&rec=107" class="defaultlink">DKPHybrids107: Why the Mepha/<wbr>Cephalon Acquisition Represents a" Game Changer"</a>).<wbr> </div><div style="margin-bottom: 10px;">The half-year report 2012 will be published on August 2, 2012, accompanied by an investor conference call with webcast at 10.<wbr>00 hrs.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Outlook for 2012</FONT></STRONG> </div><div>Acino expects FY sales to reach €240 to 260M.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=DKPHybrids&sdate=20120831&edate=20120501&rec=162">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-07-10T12:43:05+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>The Best Update on Allergan's Activities Since Its R&amp;D Meeting in March 2012 [Alert, comp:Allergan, dis:Spasticity, dis:iOAB, sub:Aesthetics]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology6502</link>
<description>The Best Update on Allergan's Activities Since Its R&amp;D Meeting in March 2012 [Alert, comp:Allergan, dis:Spasticity, dis:iOAB, sub:Aesthetics]</description><category>Alert</category><category>comp:Allergan</category><category>dis:Spasticity</category><category>dis:iOAB</category><category>sub:Aesthetics</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology6502</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120831&edate=20120501&rec=6502">The Best Update on Allergan's Activities Since Its R&D Meeting in March 2012</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=Alert"><font color="#e95e0b">:Neurology:Alert</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=comp%3aAllergan"><font color="#e95e0b">:Neurology:comp:Allergan</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=dis%3aiOAB"><font color="#e95e0b">:Neurology:dis:iOAB</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=dis%3aSpasticity"><font color="#e95e0b">:Neurology:dis:Spasticity</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=sub%3aAesthetics"><font color="#e95e0b">:Neurology:sub:Aesthetics</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology6502">Neurology6502</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 10 July 2012 | 11:32</font><br><br><div style="margin-bottom: 10px;">Comment: Thanks to Julia Hofer (BU Director Neurology Germany), we have 
access to a very recent presentation given by David Pyott Chairman 
&amp; CEO of Allergan to a group of German Neurologists.<wbr> Reference is 
made to an expected approval of the new targeted toxin for pain and OAB in 
2014+ and the ongoing US/<wbr>EU phIII programme in adult lower limb 
spasticity.<wbr> Presented below are a selection of the more interesting 
slides.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/6502/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/6502/2/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/6502/3/ScreenCapture3.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/6502/4/ScreenCapture4.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/6502/5/ScreenCapture5.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/6502/6/ScreenCapture6.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/6502/7/ScreenCapture7.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/6502/8/ScreenCapture8.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/6502/9/ScreenCapture9.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/6502/10/ScreenCapture10.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/6502/11/ScreenCapture13.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/6502/12/ScreenCapture14.jpg?user-agent=rss"> </div><div><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/6502/13/ScreenCapture15.jpg?user-agent=rss"> </div><!-- Comment details --><a name="neurology6502attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/6502/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(199,9 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/6502/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(126,6 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/6502/3/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(111,7 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/6502/4/ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(127,8 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/6502/5/ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(134,3 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/6502/6/ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(92,8 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/6502/7/ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(176,4 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/6502/8/ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(146,2 KB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/6502/9/ScreenCapture9.jpg">ScreenCapture9.jpg</a>&nbsp;&nbsp;(136,8 KB)<br>&nbsp;&nbsp;10.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/6502/10/ScreenCapture10.jpg">ScreenCapture10.jpg</a>&nbsp;&nbsp;(152,7 KB)<br>&nbsp;&nbsp;11.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/6502/11/ScreenCapture13.jpg">ScreenCapture13.jpg</a>&nbsp;&nbsp;(150,1 KB)<br>&nbsp;&nbsp;12.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/6502/12/ScreenCapture14.jpg">ScreenCapture14.jpg</a>&nbsp;&nbsp;(149,7 KB)<br>&nbsp;&nbsp;13.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/6502/13/ScreenCapture15.jpg">ScreenCapture15.jpg</a>&nbsp;&nbsp;(108,1 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120831&edate=20120501&rec=6502">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-07-10T11:32:09+02:00</dc:date><dc:creator>jac89886</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/6502/1/ScreenCapture1.jpg" length="204688" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/6502/2/ScreenCapture2.jpg" length="129646" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/6502/3/ScreenCapture3.jpg" length="114424" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/6502/4/ScreenCapture4.jpg" length="130913" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/6502/5/ScreenCapture5.jpg" length="137544" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/6502/6/ScreenCapture6.jpg" length="95060" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/6502/7/ScreenCapture7.jpg" length="180652" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/6502/8/ScreenCapture8.jpg" length="149668" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/6502/9/ScreenCapture9.jpg" length="140070" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/6502/10/ScreenCapture10.jpg" length="156356" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/6502/11/ScreenCapture13.jpg" length="153717" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/6502/12/ScreenCapture14.jpg" length="153300" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/6502/13/ScreenCapture15.jpg" length="110737" type="image/jpeg"/></item><item>
<title>Trial to Assess Medical/Economic Impact of Urinary PCA3 Test in France [sub:Diagnostic, :PharmaWorld:mkt:France, :PharmaWorld:sub:ClinicalTrial]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology8377</link>
<description>Trial to Assess Medical/Economic Impact of Urinary PCA3 Test in France [sub:Diagnostic, :PharmaWorld:mkt:France, :PharmaWorld:sub:ClinicalTrial]</description><category>sub:Diagnostic</category><category>mkt:France</category><category>sub:ClinicalTrial</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology8377</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8377">Trial to Assess Medical/<wbr>Economic Impact of Urinary PCA3 Test in France</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=sub%3aDiagnostic"><font color="#e95e0b">:Oncology:sub:Diagnostic</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=mkt%3aFrance"><font color="#e95e0b">:PharmaWorld:mkt:France</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=sub%3aClinicalTrial"><font color="#e95e0b">:PharmaWorld:sub:ClinicalTrial</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8377">Oncology8377</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 09 July 2012 | 16:20</font><br><br><div style="margin-bottom: 10px;">Comment: Seven renowned French Professors will be assessing the medical and economic impact of Gen-Probe's Progensa introduction into medical practice in France.<wbr> Primary endpoints will measure proportion of patients who inappropriately underwent prostate biopsies at end point.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Rationale</FONT></STRONG> </div><div style="margin-bottom: 10px;">Proposed in clinical practice in France as a commercial kit, Progensa is expensive, and not covered by health insurance.<wbr> It is therefore essential to assess the medical and economic impact of its introduction into medical practice.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Study Details - <A href="http://clinicaltrials.gov/ct2/show/NCT01632930?term=NCT01632930&amp;rank=1">NCT01632930</A></FONT></STRONG> </div><div style="margin-bottom: 10px;"><STRONG>Condition</STRONG>: patients scheduled for prostate biopsy because of increased serum PSA and/<wbr>or abnormal DRE </div><div style="margin-bottom: 10px;"><STRONG>Recruitment</STRONG>: approx 650 </div><div style="margin-bottom: 10px;"><STRONG>Start date</STRONG>: June 2012 - Completion dates: June 2019 /<wbr> Dec.<wbr> 2019 </div><div style="margin-bottom: 10px;"><STRONG>Site /<wbr> Location/<wbr> PI</STRONG> </div><div><UL><LI>CHU Angers - Angers - (PI: Rahmene Azzouzi, Dr)</LI>
<LI>Hop.<wbr> de la Cavale Blanche - Brest - (PI: Antoine Valeri, Pr)</LI>
<LI>Hop.<wbr> du Bocage - Dijon - (PI: Luc Cormier, Pr)</LI>
<LI>Hop.<wbr> E Herriot - Lyon - (PI: Marc Colombel, Pr)</LI>
<LI>Hop.<wbr> Tenon - Paris - (PI: Olivier Cussenot, Pr)</LI>
<LI>Hop.<wbr> Pitié Salpétrière - Paris - (PI: Marc Olivier Bitker, Pr)</LI>
<LI>Centre Hosp Lyon Sud - Pierre Bénite - (PI: Alain Ruffion, Pr)</LI>
<LI>Hop.<wbr> de la Milétrie - Poitiers - (PI: Jacques Irani, Pr)</LI>
</UL> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8377">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-07-09T16:20:50+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>New Combination Trial of Novartis' BEZ235 and BKM120 for CRPC [dis:Prostate, :PharmaWorld:sub:ClinicalTrial]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology8376</link>
<description>New Combination Trial of Novartis' BEZ235 and BKM120 for CRPC [dis:Prostate, :PharmaWorld:sub:ClinicalTrial]</description><category>dis:Prostate</category><category>sub:ClinicalTrial</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology8376</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8376">New Combination Trial of Novartis' BEZ235 and BKM120 for CRPC</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=sub%3aClinicalTrial"><font color="#e95e0b">:PharmaWorld:sub:ClinicalTrial</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8376">Oncology8376</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 09 July 2012 | 15:34</font><br><br><div style="margin-bottom: 10px;">Comment: Recently listed in clinicaltrials.<wbr>gov, the Ph1b dose finding study is designed to assess combination of the drugs with abiraterone in CRPC patients with abiraterone failure.<wbr> Primary outcome measures will evaluate incidence of DLTs.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Trial Details - </FONT></STRONG><A href="http://clinicaltrials.gov/ct2/show/NCT01634061?recr=Open&amp;cond=botulinum+OR+prostate+OR+neuroendocrine+OR+acromegaly+OR+Cushing+OR+hemophilia+OR+haemophilia+OR+spasticity+OR+huntington&amp;rcv_s=05%2F10%2F2012&amp;rank=22"><STRONG><FONT size="3">NCT01634061</FONT></STRONG></A> </div><div style="margin-bottom: 10px;"><STRONG>Design</STRONG>: non-randomized; open label </div><div style="margin-bottom: 10px;"><STRONG>Recruitment</STRONG>: approx.<wbr> 122 participants </div><div style="margin-bottom: 10px;"><STRONG>Start date</STRONG>: Aug.<wbr> 2012 - Completion date: March 2015 </div><div style="margin-bottom: 10px;"><STRONG>Regimen</STRONG> </div><div style="margin-bottom: 10px;">1/<wbr> Dose-escalation-part: to determinethe MTD and/<wbr>or RDE of abiraterone in combination with BEZ235 and abiraterone in combination with BMK120 </div><div style="margin-bottom: 10px;">2/<wbr> the MTD and/<wbr>or RDE of each combination will be investigated in 2 expansion groups.<wbr> </div><div><STRONG>Location</STRONG>: US (1); Canada (1); Spain (2) </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8376">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-07-09T15:34:52+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>ENDO Intelligence - Part  Three - NET &amp; Octreolin [sub:Hybrids, :PharmaWorld:congress:ENDO, Alert, prod:Octreotide, prod:Pasireotide]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7012</link>
<description>ENDO Intelligence - Part  Three - NET &amp; Octreolin [sub:Hybrids, :PharmaWorld:congress:ENDO, Alert, prod:Octreotide, prod:Pasireotide]</description><category>sub:Hybrids</category><category>congress:ENDO</category><category>Alert</category><category>prod:Octreotide</category><category>prod:Pasireotide</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7012</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120831&edate=20120501&rec=7012">ENDO Intelligence - Part  Three - NET & Octreolin</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=Alert"><font color="#e95e0b">:Endocrinology:Alert</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=prod%3aOctreotide"><font color="#e95e0b">:Endocrinology:prod:Octreotide</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=prod%3aPasireotide"><font color="#e95e0b">:Endocrinology:prod:Pasireotide</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=sub%3aHybrids"><font color="#e95e0b">:Endocrinology:sub:Hybrids</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=congress%3aENDO"><font color="#e95e0b">:PharmaWorld:congress:ENDO</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7012">Endocrinology7012</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/774">bee75336</a> | 06 July 2012 | 18:51</font><br><br><div style="margin-bottom: 10px;">Comment: The majority of the data on Octeolin had previously been presented and confirmation that Octreolin phase III safety and efficacy study has just started enrolling with a target of 150 patients (20mg — 40mb BID).<wbr> Duration will be 7-9 months.<wbr> NET sessions of interest again have previously been presented at ENETS and repackaged by Pavel.<wbr> </div><div style="margin-bottom: 10px;">It is understood that Pfizer are aiming to develop a PFS device for PegV similar to their mini-Quick used for their rhGH (Gentropin).<wbr> They are currently in the process of obtaining feedback from their US advisors.<wbr> We are unclear of the status in EU and ROW.<wbr> </div><div style="margin-bottom: 10px;">A big thanks to Christine Massien for helping collect information during the pasireotide poster sessions and to Neven Pessa for intelligence on PegV device.<wbr> </div><div style="margin-bottom: 10px;">As mentioned earlier, data from Octreolin has previously been published but a review of safety data and GH suppression is found below </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7012/15/ScreenCapture15.jpg?user-agent=rss"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7012/16/ScreenCapture16.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">During the NET session, Marianne Pavel walked us through the evolution of therapy, therapeutic options, targets and novel agents, results from placebo controlled trials, impact of novel agents on current therapy (discussed everolimus and sunitinib ) of NET and future perspectives.<wbr> The content and slide set was a well presented but repackaged from previous congresses such as ENETS.<wbr> The majority of the slides/<wbr>data has been previously published on Traction.<wbr> </div><div style="margin-bottom: 10px;">Pavel only discussed publically known trials/<wbr>data and did not allude to any real details of ongoing studies (a part from RADIANT-4 and COOPERATE -2 when she showed the study schema only (previously published on Traction).<wbr> </div><div style="margin-bottom: 10px;">During the discussion, Pavel highlighted pathways of interest, followed by a slide depicting developmental and avaliable drugs respective to their MOA.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7012/5/ScreenCapture5.jpg?user-agent=rss"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7012/6/ScreenCapture6.jpg?user-agent=rss"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7012/7/ScreenCapture7.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">She concluded the talk with a review of where the therapy stands and her views on future perspectives.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7012/8/ScreenCapture8.jpg?user-agent=rss"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7012/9/ScreenCapture9.jpg?user-agent=rss"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7012/10/ScreenCapture10.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">During Steven Libutti’s talk on the role of aggressive surgery in GI NETs, he presented a new study taking place at his centre — Albert Einstein College of Medicine (and others) - E2212: A Randomised Double Blind Placebo Controlled Phase II Study Of Adjuvant Everolimus Following The Resection Of Metastatic Pancreatic Neuroendocrine Tumours To The Liver.<wbr> ECOG exec approval conditional was given in 2/<wbr>2012, MET TF review was scheduled for 5/<wbr>2012 and GISC submission goal is July 2012.<wbr> </div><div style="margin-bottom: 10px;">Background to the study followed by study schema and key eligibility criteria follows: </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7012/11/ScreenCapture11.jpg?user-agent=rss"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7012/12/ScreenCapture12.jpg?user-agent=rss"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7012/13/ScreenCapture13.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">Poster: Pasireotide and Octreotide LAR Was an Effective Combination in a Patient With Small Intestinal NET With Hypokalemia and a High Level of VIP <A href="http:///“,”http://novartis.medicalcongressposters.com/Default.aspx?doc=a84c5“,”">http:/<wbr>/<wbr>novartis.<wbr>medicalcongressposters.<wbr>com/<wbr>Default.<wbr>aspx?doc=a84c5</A> </div><div style="margin-bottom: 10px;">A case study with a 70yr old woman who underwent bowel and liver resection surgery for a small intestinal NET in 1991.<wbr> In between 1991 — 200, she underwent radiofrequency ablation of liver metastases 6 times.<wbr> </div><div style="margin-bottom: 10px;"><UL><LI>Interferon was initiated and then stopped in 2006 due to adverse events (depression and muscle pain)</LI>
<LI>Increasing bouts of diarrhea in 2007/<wbr>8 (10 per 24 hrs)</LI>
<LI>Sc octretoide and potassium substitution were initiated </LI>
<LI>2008, discontinued and started with pasireotide sc (1200 µg 2xdaily)</LI>
<LI>2008 liver mets were confirmed and high levels of circulating VIP were detected during this time</LI>
<LI>IM octreotide LAR(30mg every 4th week) was added to pasireotide</LI>
<LI>This combination decrease the bouts of diarrhea to 3-4 times a day and need for potassium substitution decreased</LI>
<LI>VIP level decreased from 788pmol/<wbr>L in October 2008 to the lowest level of 79pmol/<wbr>L in October 2010</LI>
<LI>Patient is still alive</LI>
</UL> </div><div><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7012/14/ScreenCapture14.jpg?user-agent=rss"> </div><!-- Comment details --><a name="endocrinology7012attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7012/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(46,7 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7012/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(64,6 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7012/3/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(58,7 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7012/4/ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(65,7 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7012/5/ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(55,4 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7012/6/ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(66,3 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7012/7/ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(56,8 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7012/8/ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(50 KB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7012/9/ScreenCapture9.jpg">ScreenCapture9.jpg</a>&nbsp;&nbsp;(43,1 KB)<br>&nbsp;&nbsp;10.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7012/10/ScreenCapture10.jpg">ScreenCapture10.jpg</a>&nbsp;&nbsp;(45,1 KB)<br>&nbsp;&nbsp;11.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7012/11/ScreenCapture11.jpg">ScreenCapture11.jpg</a>&nbsp;&nbsp;(51,3 KB)<br>&nbsp;&nbsp;12.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7012/12/ScreenCapture12.jpg">ScreenCapture12.jpg</a>&nbsp;&nbsp;(54 KB)<br>&nbsp;&nbsp;13.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7012/13/ScreenCapture13.jpg">ScreenCapture13.jpg</a>&nbsp;&nbsp;(63,9 KB)<br>&nbsp;&nbsp;14.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7012/14/ScreenCapture14.jpg">ScreenCapture14.jpg</a>&nbsp;&nbsp;(92,3 KB)<br>&nbsp;&nbsp;15.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7012/15/ScreenCapture15.jpg">ScreenCapture15.jpg</a>&nbsp;&nbsp;(69,3 KB)<br>&nbsp;&nbsp;16.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7012/16/ScreenCapture16.jpg">ScreenCapture16.jpg</a>&nbsp;&nbsp;(57,6 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120831&edate=20120501&rec=7012">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-07-06T18:51:14+02:00</dc:date><dc:creator>bee75336</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7012/1/ScreenCapture1.jpg" length="47818" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7012/2/ScreenCapture2.jpg" length="66128" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7012/3/ScreenCapture3.jpg" length="60096" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7012/4/ScreenCapture4.jpg" length="67305" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7012/5/ScreenCapture5.jpg" length="56717" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7012/6/ScreenCapture6.jpg" length="67859" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7012/7/ScreenCapture7.jpg" length="58136" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7012/8/ScreenCapture8.jpg" length="51251" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7012/9/ScreenCapture9.jpg" length="44114" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7012/10/ScreenCapture10.jpg" length="46150" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7012/11/ScreenCapture11.jpg" length="52528" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7012/12/ScreenCapture12.jpg" length="55283" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7012/13/ScreenCapture13.jpg" length="65390" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7012/14/ScreenCapture14.jpg" length="94546" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7012/15/ScreenCapture15.jpg" length="71001" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7012/16/ScreenCapture16.jpg" length="58970" type="image/jpeg"/></item><item>
<title>Alternative for the Future Development of Medy-Tox' MT10109 [comp:MediTox, headline, dis:Dystonia, sub:Aesthetics, :DKPHybrids:comp:Daewoong, :PharmaWorld:mkt:Korea, :PharmaWorld:mkt:Intercontinental, :PharmaWorld:mkt:Australia]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology6495</link>
<description>Alternative for the Future Development of Medy-Tox' MT10109 [comp:MediTox, headline, dis:Dystonia, sub:Aesthetics, :DKPHybrids:comp:Daewoong, :PharmaWorld:mkt:Korea, :PharmaWorld:mkt:Intercontinental, :PharmaWorld:mkt:Australia]</description><category>comp:MediTox</category><category>headline</category><category>dis:Dystonia</category><category>sub:Aesthetics</category><category>comp:Daewoong</category><category>mkt:Korea</category><category>mkt:Intercontinental</category><category>mkt:Australia</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology6495</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120831&edate=20120501&rec=6495">Alternative for the Future Development of Medy-Tox' MT10109</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=DKPHybrids&sdate=20120831&edate=20120501&cat=comp%3aDaewoong"><font color="#e95e0b">:DKPHybrids:comp:Daewoong</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=comp%3aMediTox"><font color="#e95e0b">:Neurology:comp:MediTox</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=dis%3aDystonia"><font color="#e95e0b">:Neurology:dis:Dystonia</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=headline"><font color="#e95e0b">:Neurology:headline</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=sub%3aAesthetics"><font color="#e95e0b">:Neurology:sub:Aesthetics</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=mkt%3aAustralia"><font color="#e95e0b">:PharmaWorld:mkt:Australia</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=mkt%3aIntercontinental"><font color="#e95e0b">:PharmaWorld:mkt:Intercontinental</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=mkt%3aKorea"><font color="#e95e0b">:PharmaWorld:mkt:Korea</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology6495">Neurology6495</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 06 July 2012 | 14:38</font><br><br><div style="margin-bottom: 10px;">Comment: Analysts @ Woori have reported that under completion of the POC trial (ongoing in Australia), Medy-Tox may plan to either pursue a licensing out deal with multinational pharmas based in the US and EU or opt to internally carry out the Ph3 trials.<wbr> On June 18, Medy-Tox was listed by Korea's Ministry of Health &amp; Welfare among the 43 innovative pharma firms.<wbr> Incentives for the selected companies include R&amp;D-related help and loan for drugs for export.<wbr> Interestingly, we have noted that Daewoong, which recently started a Ph3 with its toxin, is part of the selection.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Important Milestone</FONT></STRONG> </div><div style="margin-bottom: 10px;"><STRONG>List of Companies</STRONG> </div><div style="margin-bottom: 10px;">The government and pharmaceuticals industry participants will meet in July to discuss incentives, aiming to confirm details this year and put most benefits into effect from 2013.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/6495/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">On June 18, the company was selected as one of the 43 pharmas to participate in the Ministry of Health and Welfare's pharma program aimed at fostering innovative domestic pharmas.<wbr> </div><div style="margin-bottom: 10px;"><U>Benefits of the Program</U> </div><div style="margin-bottom: 10px;">These firms will be give several incentives (including tax support, favorable drug pricing, R&amp;D-related assistance, and financial loan support for drugs for export purposes).<wbr> </div><div style="margin-bottom: 10px;">Medytox is likely to receive extend loans (up to W100bn at an interest rate 0.<wbr>5%p lower market lending rates over the next 8 years), equivalent to 90% of Ph3 clinical trials costs for its next-generation Meditoxin.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/6495/2/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">About MedyTox' POC Studies Ongoing in Australia</FONT></STRONG> </div><div style="margin-bottom: 10px;">Indication: CD (Please see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120831&edate=20120501&rec=6371" class="defaultlink">Neurology6371: New POC Trial of Medy-Tox' MT10109 Versus Botox(R) for Cervical Dystonia</a>) </div><div style="margin-bottom: 10px;">Indication: Glabellar Line (Please see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120831&edate=20120501&rec=6149" class="defaultlink">Neurology6149: New Study of Medy-Tox' s New BTA Formulation Versus Botox(R) in Glabellar Frown Lines</a>) </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">About Daewoong's Ph3 Study</FONT></STRONG> </div><div style="margin-bottom: 10px;">Indication: Glabellar Line (Please see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120831&edate=20120501&rec=6487" class="defaultlink">Neurology6487: New Trial of Daewoong's Botulinum Toxin for Glabellar Line</a>).<wbr> </div><div>Of note, Daewoong is Peptron licensee for Luphere Depot (an hybrid of leuprorelin).<wbr> </div><!-- Comment details --><a name="neurology6495attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/6495/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(68,1 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/6495/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(154,9 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120831&edate=20120501&rec=6495">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-07-06T14:38:49+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/6495/1/ScreenCapture1.jpg" length="69686" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/6495/2/ScreenCapture2.jpg" length="158568" type="image/jpeg"/></item><item>
<title>Medical Treatment Of Huntington's Disease [dis:Huntington, news]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology6493</link>
<description>Medical Treatment Of Huntington's Disease [dis:Huntington, news]</description><category>dis:Huntington</category><category>news</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology6493</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120831&edate=20120501&rec=6493">Medical Treatment Of Huntington's Disease</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=dis%3aHuntington"><font color="#e95e0b">:Neurology:dis:Huntington</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=news"><font color="#e95e0b">:Neurology:news</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology6493">Neurology6493</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 06 July 2012 | 13:54</font><br><br><div style="margin-bottom: 10px;">Comment: Several presentations from the recent Huntington's Disease Society of America National Convention are now available on line.<wbr> Attached is a presentation given by Victor Sung UAB/<wbr>HDSA Centre of Excellence on the medical management of motor symptoms.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/6493/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/6493/2/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><A href="http://www.hdsa.org/national-convention/2012-convention-presentations.html">http:/<wbr>/<wbr>www.<wbr>hdsa.<wbr>org/<wbr>national-convention/<wbr>2012-convention-presentations.<wbr>html</A> </div><div style="margin-bottom: 10px;">One other sessions of interest, where the presentations have yet to be made available focused on "Potential New Therapies".<wbr> The panel included speakers from Vertex, Raptor Pharmaceuticals and ISIS.<wbr> We have previously feature ongoing developments at Raptor (see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120831&edate=20120501&rec=6458" class="defaultlink">Neurology6458: Raptor Files For Approval of RP103</a>).<wbr> Vertex is known to have a preclinical programme ongoing, whilst the ISIS drug candidate is unclear but seems likely to involve a preclinical antisense programme.<wbr> An evaluation undertaken by the CI Department in March this year pointed to the following industry sponsored development programmes.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/6493/3/ScreenCapture3.jpg?user-agent=rss"> </div><div><STRONG><FONT color="#ffffff" size="7"><FONT color="#ffffff" size="7">Symptoms</FONT></FONT></STRONG><FONT color="#ffffff" face="Arial,Arial" size="6"><FONT color="#ffffff" face="Arial,Arial" size="6"><FONT color="#ffffff" face="Arial,Arial" size="6">Victor Sung, MDUAB /<wbr> HDSA Center of Excellence</FONT></FONT></FONT><STRONG><FONT color="#ffffff" size="6"><FONT color="#ffffff" size="6">HDSA </FONT></FONT></STRONG> </div><!-- Comment details --><a name="neurology6493attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/6493/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(117,1 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/6493/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(103,8 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/6493/3/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(93,6 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/6493/4/HDSA%20Medical%20Management%20Motor%20Symptoms%202012%2d%20victor%20sung%5b2%5d.pdf">HDSA Medical Management Motor Symptoms 2012- victor sung[2].pdf</a>&nbsp;&nbsp;(512,5 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120831&edate=20120501&rec=6493">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-07-06T13:54:22+02:00</dc:date><dc:creator>jac89886</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/6493/1/ScreenCapture1.jpg" length="119885" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/6493/2/ScreenCapture2.jpg" length="106313" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/6493/3/ScreenCapture3.jpg" length="95855" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/6493/4/HDSA%20Medical%20Management%20Motor%20Symptoms%202012%2d%20victor%20sung%5b2%5d.pdf" length="524773" type="application/pdf"/></item><item>
<title>Ferring Collaboration with British Columbia Cancer Agency [dis:Prostate, prod:Firmagon, :PharmaWorld:sub:ClinicalTrial]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology8370</link>
<description>Ferring Collaboration with British Columbia Cancer Agency [dis:Prostate, prod:Firmagon, :PharmaWorld:sub:ClinicalTrial]</description><category>dis:Prostate</category><category>prod:Firmagon</category><category>sub:ClinicalTrial</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology8370</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8370">Ferring Collaboration with British Columbia Cancer Agency</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=prod%3aFirmagon"><font color="#e95e0b">:Oncology:prod:Firmagon</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=sub%3aClinicalTrial"><font color="#e95e0b">:PharmaWorld:sub:ClinicalTrial</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8370">Oncology8370</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 06 July 2012 | 13:52</font><br><br><div style="margin-bottom: 10px;">Comment: Clinicaltrials.<wbr>gov is listing a new Ph2 single arm study of degarelix aimed at determining the porportion of patients with CRPC who have a PSA declined of ≥50% from baseline PSA when switchd from an LHRH agonist to an antagonist.<wbr> P.<wbr> Cabri (Medical Director, Uro-Onco) has highlighted that "this trial<SPAN style="DISPLAY: inline! important; FLOAT: none; WORD-SPACING: 0px; FONT: 13px arial, sans-serif; TEXT-TRANSFORM: none; COLOR: rgb(34,34,34); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><FONT face="Verdana" size="2"> is based on the </FONT><A href="http://www.ncbi.nlm.nih.gov/pubmed/21788033?dopt=Abstract"><FONT face="Verdana" size="2">Crawford extension study</FONT></A><FONT face="Verdana" size="2">.<wbr> They found out that patients may be too quickly diagnosed as castration resistant but by switching to an antagonist the PSA is decreasing again.<wbr> The message behind is that if a patient does not respond anymore to a LHRH analogue switch first to another (agonist or antagonist) before going towards chemotherapy.<wbr> Here they are performing trials in this field in order to publish".<wbr></FONT></SPAN> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Trial Details </FONT></STRONG><A href="http://clinicaltrials.gov/ct2/show/NCT01630967?recr=Open&amp;fund=2&amp;rcv_s=06%2F20%2F2012&amp;rank=98"><STRONG><FONT size="3">NCT01630967</FONT></STRONG></A> </div><div style="margin-bottom: 10px;">- Start date: Aug.<wbr> 2012 - Completion date: Dec.<wbr> 2013 </div><div style="margin-bottom: 10px;">- Recruitment: approx.<wbr> 40 participants </div><div>- Location: Canada </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8370">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-07-06T13:52:34+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>PhI Safety &amp; Efficacy Data On The Combination of Pasireotide &amp; Afinitor [Alert, class:SomatostatinAnalogue, comp:Novartis, dis:MidGutNET, dis:pNET, prod:Pasireotide, :PharmaWorld:sub:ClinicalTrial]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7011</link>
<description>PhI Safety &amp; Efficacy Data On The Combination of Pasireotide &amp; Afinitor [Alert, class:SomatostatinAnalogue, comp:Novartis, dis:MidGutNET, dis:pNET, prod:Pasireotide, :PharmaWorld:sub:ClinicalTrial]</description><category>Alert</category><category>class:SomatostatinAnalogue</category><category>comp:Novartis</category><category>dis:MidGutNET</category><category>dis:pNET</category><category>prod:Pasireotide</category><category>sub:ClinicalTrial</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7011</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120831&edate=20120501&rec=7011">PhI Safety & Efficacy Data On The Combination of Pasireotide & Afinitor</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=Alert"><font color="#e95e0b">:Endocrinology:Alert</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=class%3aSomatostatinAnalogue"><font color="#e95e0b">:Endocrinology:class:SomatostatinAnalogue</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=comp%3aNovartis"><font color="#e95e0b">:Endocrinology:comp:Novartis</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=dis%3aMidGutNET"><font color="#e95e0b">:Endocrinology:dis:MidGutNET</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=dis%3apNET"><font color="#e95e0b">:Endocrinology:dis:pNET</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=prod%3aPasireotide"><font color="#e95e0b">:Endocrinology:prod:Pasireotide</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=sub%3aClinicalTrial"><font color="#e95e0b">:PharmaWorld:sub:ClinicalTrial</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7011">Endocrinology7011</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 06 July 2012 | 11:08</font><br><br><div style="margin-bottom: 10px;">Comment: PhI results from a combination study evaluating the safety 
and MTD of pasireotide and Afinitor (RAD-001) have been published 
in the journal of Endocrine Related Cancer.<wbr> We believe the outcome from this 
study is what has underpinned the development of the Novartis 
sponsored COOPERATE I &amp; II studies, recruitment for which is 
ongoing.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>PhI Study Design</STRONG> </div><div style="margin-bottom: 10px;">The study sponsored by the Dana Farber Cancer Institute (Jenifer Chan was the 
Primary Investigator) was initiated in 2008 and enrolled 21 patients 
with locally unresectable or metastatic neuroendocrine tumor.<wbr> The study 
originally planned to enroll 32 patients and was due to complete in November 
this year.<wbr> </div><div style="margin-bottom: 10px;">Patients had confirmed low-grade or intermediate-grade neuroendocrine 
carcinoma.<wbr> Patients with poorly differentiated neuroendocrine carcinoma, 
high-grade neuroendocrine carcinoma, adenocarcinoid, goblet cell carcinoid, and 
small cell carcinoma were not eligible.<wbr> </div><div style="margin-bottom: 10px;">Cohorts of patients were treated with escalating doses of pasireotide 
600-1200mg s.<wbr>c.<wbr> bd for 4 weeks followed by pasireotide LAR 40-60mg IM monthly 
and everolimus 5-10mg orally daily.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>PhI Study Results</STRONG> </div><div style="margin-bottom: 10px;">Dose limiting toxicities of grade 3 rash and diarrhoea were observerd but 12 
patients were safely treated with the maximum protocol-defined dose level of 
each drug.<wbr> Hyperglycaemia was a common feature, whilts other toxicities observed 
were consistent with the known safety profile of each drug.<wbr> </div><div style="margin-bottom: 10px;">From an efficacy standpoint, one patient had a partial response whilst 17 
(81%) experiences some tumour regression.<wbr> </div><div style="margin-bottom: 10px;">The investigators conclude that combination therapy is feasible and showed 
some preliminary evidence of anti-tumour activity which warrents further 
investigation.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>This is now underway in the shape of the COOPERATE I &amp; II 
studies.<wbr></STRONG> </div><div style="margin-bottom: 10px;"><STRONG>COOPERATE-I</STRONG> is a larger phI study sponsored by Novartis 
being undertaken in Germany in patients with a confirmed diagnosis of grade 1/<wbr>2 
advanced pulmonary or gastroenteropancreatic neuroendocrine tumor functioning 
and non-functioning patients.<wbr> Those with non-functioning disease are required to 
have progressive disease within last 12 months.<wbr> </div><div style="margin-bottom: 10px;">The study design includes six treatment arms as follows which will thoroughly 
evaluate all possible combinations in both pre-treated and treatment naive 
patients.<wbr> </div><div style="margin-bottom: 10px;"><UL><LI>Functional tumours, pre-treated - pasireotide followed by pasireotide 
  &amp; everolimus</LI>
<LI>Functional tumours, treatment naive (similar treatment schedule)</LI>
<LI>Nonfunctional tumours, pretreated 1 - pasireotide followed by pasireotide 
  and eveolimus</LI>
<LI>Nonfunctional tumours, pretreated 2 - everolimus followed by pasireotide 
  and everolimus</LI>
<LI>Nonfunctional tumours treatment naive 1 - pasireotide followed by 
  pasireotide and everolimus</LI>
<LI>Nonfunctional tumours treatment naive 2 - everolimus followed by 
  pasireotide and everolimus.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;">
The study started in November 2010 and is scheduled to complete in May 2014 
and the primary endpoint is safety and tolerability.<wbr> </div><div style="margin-bottom: 10px;">Key centres involved in the study include, Bad Berka, Berlin, Marburg, 
Muenster and Tumbingen.<wbr> </div><div style="margin-bottom: 10px;"><TABLE border="0" cellpadding="0" cellspacing="0" class="layout_table" style="MARGIN-TOP: 1ex"><TBODY><TR valign="top"><TD>ClinicalTrials.<wbr>gov Identifier:</TD>
<TD style="PADDING-LEFT: 1em"><A href="http://clinicaltrials.gov/ct2/show/NCT01263353" title="Current version of study NCT01263353 on ClinicalTrials.gov">NCT01263353</A></TD>
</TR>
</TBODY>
</TABLE> </div><div style="margin-bottom: 10px;"><STRONG>COOPERATE-2</STRONG> an openn-label phII study will evluate 
combination treatment in patients with progressive advanced pNET in 
150 patients.<wbr> It started in June 2011 and is estimated to complete in September 
2015.<wbr> Its primary endpoint is PFS using RECIST criteria.<wbr> This second study 
is a global study involving 59 centres across the US, Europe, Asia &amp; Latin 
Amerca.<wbr> </div><div style="margin-bottom: 10px;"><TABLE border="0" cellpadding="0" cellspacing="0" class="layout_table" style="MARGIN-TOP: 1ex"><TBODY><TR valign="top"><TD>ClinicalTrials.<wbr>gov Identifier:</TD>
<TD style="PADDING-LEFT: 1em"><A href="http://clinicaltrials.gov/ct2/show/NCT01374451" title="Current version of study NCT01374451 on ClinicalTrials.gov">NCT01374451</A></TD>
</TR>
</TBODY>
</TABLE> </div><div>source: <A href="http://erc.endocrinology-journals.org/content/early/2012/06/26/ERC-11-0382.abstract">http:/<wbr>/<wbr>erc.<wbr>endocrinology-journals.<wbr>org/<wbr>content/<wbr>early/<wbr>2012/<wbr>06/<wbr>26/<wbr>ERC-11-0382.<wbr>abstract</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120831&edate=20120501&rec=7011">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-07-06T11:08:46+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>Merck's EXPAND Trial Fails To Meet Primary Endpoint in Gastric Cancer Trial [news, class:MonoclonalAntibody]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology8369</link>
<description>Merck's EXPAND Trial Fails To Meet Primary Endpoint in Gastric Cancer Trial [news, class:MonoclonalAntibody]</description><category>news</category><category>class:MonoclonalAntibody</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology8369</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8369">Merck's EXPAND Trial Fails To Meet Primary Endpoint in Gastric Cancer Trial</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=class%3aMonoclonalAntibody"><font color="#e95e0b">:Oncology:class:MonoclonalAntibody</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=news"><font color="#e95e0b">:Oncology:news</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8369">Oncology8369</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 05 July 2012 | 15:19</font><br><br><div style="margin-bottom: 10px;">Comment: Erbitux in combination with cisplatin and capecitabine did not 
significantly increase progression-free survival in patients with advanced 
gastric cancer.<wbr> </div><div style="margin-bottom: 10px;">The combination was studied as a first-line treatment for patients with 
advanced gastric adenocarcinoma including adenocarcinoma of the 
gastro-oesophageal junction.<wbr> </div><div style="margin-bottom: 10px;">Patients with advanced gastric cancer currently have few treatment choices 
and a poor prognosis so the results are disappointing.<wbr> </div><div style="margin-bottom: 10px;">EXPAND was a multi-center, open-label, randomized, controlled trial in 904 
patients at 150 centers in 25 countries across Latin America, Europe, Asia 
Pacific and Japan.<wbr> Patients had unresectable advanced cancer and had received no 
prior treatment with chemotherapy or radiotherapy in this setting.<wbr> Usually, 
these patients would receive palliative chemotherapy only.<wbr> </div><div>Source: <a href="http://www.merckgroup.com" class="defaultlink" title="www.merckgroup.com">merckgroup.com</a> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8369">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-07-05T15:19:47+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>ENDO Intelligence - Part Two - Pasireotide in Acromegaly [dis:Acromegaly, prod:Pasireotide, :PharmaWorld:congress:ENDO, Alert]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7003</link>
<description>ENDO Intelligence - Part Two - Pasireotide in Acromegaly [dis:Acromegaly, prod:Pasireotide, :PharmaWorld:congress:ENDO, Alert]</description><category>dis:Acromegaly</category><category>prod:Pasireotide</category><category>congress:ENDO</category><category>Alert</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7003</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120831&edate=20120501&rec=7003">ENDO Intelligence - Part Two - Pasireotide in Acromegaly</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=Alert"><font color="#e95e0b">:Endocrinology:Alert</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=dis%3aAcromegaly"><font color="#e95e0b">:Endocrinology:dis:Acromegaly</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=prod%3aPasireotide"><font color="#e95e0b">:Endocrinology:prod:Pasireotide</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=congress%3aENDO"><font color="#e95e0b">:PharmaWorld:congress:ENDO</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7003">Endocrinology7003</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/774">bee75336</a> | 05 July 2012 | 11:24</font><br><br><div style="margin-bottom: 10px;"><FONT face="Arial">Comment: Five posters were presented on Acromegaly depicting the results from the core C2305 pasireotide LAR study and the extension study including HRQoL, switching data, a post-hoc analysis and a retrospective study in a large US claims database.<wbr> Filing for Acromegaly in the US will take place in December 2012 (no later than end January 2013) It is understood that pasireotide LAR in the US will be delivered in the same device as sandostatin LAR.<wbr> There was a suggestion of a "first line" label being sought (see comments below).<wbr></FONT> </div><div style="margin-bottom: 10px;"><FONT face="Arial">Various sources at NVS stated that pasireotide (in both indications Cushing's and acromegaly) will be eventually positioned as a first line treatment, but delegates were still unsure of where pasireotide will fit in the treatment arsenal.<wbr> One stood up in the oral session declaring &lsquo;<EM>there is no reason for us to use this product because of its side effect profile&rsquo;</EM> .<wbr></FONT> </div><div style="margin-bottom: 10px;"><FONT face="Arial">This topic was raised again during the poster session and when pushed to specifiy which patient pasireotide would be indicated for K Hermosillo (Novartis) pointed to the poster in front of him (SUN-739) referring to response versus tumour base-line which specifically states in the conclusion "<EM> Pasireotide LAR may become the first choice medical therapy for acromegaly either as first-line therapy when surgery is not an option or as the first medical therapy used post surgery" </EM>Although not filed this seems to reflect Novartis' s labelling intent.<wbr> Whether they obtain this from the regulators remains to be seen.<wbr></FONT> </div><div style="margin-bottom: 10px;"><FONT face="Arial">Ilan Shimon at the Novartis symposia at the ECE in May took a more cautious view of the actual label suggesting it was most likely to be similar to that for the recently approved Cushing's disease indication i.<wbr>e.<wbr> <EM>"for whom surgery is not an option or for whom surgery has failed".<wbr></EM></FONT> </div><div style="margin-bottom: 10px;"><FONT face="Arial">At the booth, hand-outs included details of the phase III multi-centre randomised, parallel group study to address the efficacy and safety of double blind pasireotide LAR 40mg and pasireotide LAR 60mg vs open label ocreotide LAR or lanreotide ATG in patients with inadequately controlled acromegaly This study is now enrolling.<wbr></FONT> </div><div style="margin-bottom: 10px;"><FONT face="Arial"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7003/1/ScreenCapture1.jpg?user-agent=rss"></FONT> </div><div style="margin-bottom: 10px;"><FONT face="Arial">In addition, a hand-out depicting key current clinical studies was available</FONT> </div><div style="margin-bottom: 10px;"><FONT face="Arial"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7003/2/ScreenCapture2.jpg?user-agent=rss"></FONT> </div><div style="margin-bottom: 10px;"><FONT face="Arial">All data (posters/<wbr>oral session) presented refers to the following study design</FONT> </div><div style="margin-bottom: 10px;"><FONT face="Arial"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7003/3/ScreenCapture3.jpg?user-agent=rss"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7003/4/ScreenCapture4.jpg?user-agent=rss"></FONT> </div><div style="margin-bottom: 10px;"><FONT face="Arial">The oral session was presented by Marcello Bronstein &mdash; titled Pasireotide LAR Is Significantly More Effective Than Ocrtreotide LAR at Inducing Biochemical Control in Pts With Acromegaly.<wbr> The content of his talk was similar to the data presented at the Novartis symposium at the ECE meeting in early May (see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120831&edate=20120501&rec=6923" class="defaultlink">Endocrinology6923: ECE Intelligence Part 1 - Key Data From The Novartis & Pfizer Satellite Symposium</a>).<wbr> Bronstein commenced the talk by highlighting data showing that medically na&iuml;ve patients experience suboptimal biochemical control with conventional SSAs (ocreotide/<wbr>lanreotide)</FONT> </div><div style="margin-bottom: 10px;"><FONT face="Arial"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7003/5/ScreenCapture5.jpg?user-agent=rss"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7003/6/ScreenCapture6.jpg?user-agent=rss"></FONT> </div><div style="margin-bottom: 10px;"><FONT face="Arial">He then introduced pasireotide LAR as a new medical therapy along side the C2305 phase III study (358 pts, 84 sites, 27 countries &mdash; the largest trial in acromegaly to date).<wbr> See study design above.<wbr> </FONT> </div><div style="margin-bottom: 10px;"><FONT face="Arial">The results slides shown below are identical to those presented previously but as the lighting and quality is superior we are republishing them.<wbr></FONT> </div><div style="margin-bottom: 10px;"><FONT face="Arial">Pasreotide LAR was significantly superior to octreotide LAR in providing biochemical control at month 12 (p=0.<wbr>007)</FONT> </div><div style="margin-bottom: 10px;"><FONT face="Arial">Patients on pasreotide LAR were 63% more likely to achieve GH&lt;2.<wbr>5&mu;g/<wbr>L and normal IGF-1.<wbr> This was driven by the significantly higher rate of IGF-1 normalisation seen with pasireotide LAR (p=0.<wbr>002).<wbr></FONT> </div><div style="margin-bottom: 10px;"><FONT face="Arial">35.<wbr>8% of pasireotide LAR and 20.<wbr>9% of octreotide LAR patients achieved full control &mdash; including patients with IGF-1&le;LLN (over responders)</FONT> </div><div style="margin-bottom: 10px;"><FONT face="Arial"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7003/7/ScreenCapture7.jpg?user-agent=rss"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7003/8/ScreenCapture8.jpg?user-agent=rss"></FONT> </div><div style="margin-bottom: 10px;"><FONT face="Arial">Significant tumour volume reduction was achieved in most patients receiving pasireotide LAR and octreotide LAR</FONT> </div><div style="margin-bottom: 10px;"><FONT face="Arial"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7003/9/ScreenCapture9.jpg?user-agent=rss"></FONT> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="font-size: 12pt; font-family: 'Arial','sans-serif'; mso-fareast-font-family: 'MS Mincho'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;"><FONT size="2">Similar adverse events profile to that of other SSA bar hyperglycemia</FONT></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="font-size: 12pt; font-family: 'Arial','sans-serif'; mso-fareast-font-family: 'MS Mincho'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;"><FONT size="2"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7003/10/ScreenCapture10.jpg?user-agent=rss"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7003/11/ScreenCapture11.jpg?user-agent=rss"></FONT></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="font-size: 12pt; font-family: 'Arial','sans-serif'; mso-fareast-font-family: 'MS Mincho'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;"><FONT size="2"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7003/12/ScreenCapture12.jpg?user-agent=rss"></FONT></SPAN> </div><div style="margin-bottom: 10px;"><FONT face="Arial">Posters (please see study design at top of page)</FONT> </div><div style="margin-bottom: 10px;"><FONT face="Arial">Switching Patients With Acromegaly From Octreotide LAR To Pasireotide LAR Improves Biochemical Control: Cross Over Extension</FONT> </div><div style="margin-bottom: 10px;"><UL type="disc"><LI>
<UL type="circle"><LI><FONT face="Arial">21.<wbr>0% of patients who were inadequately controlled on octreotide LAR achieved biochemical control after switching to pasireotide LAR</FONT>
</LI>
<LI><FONT face="Arial">2.<wbr>6% of patients who were patients who were inadequately controlled on pasireotide LAR achieved biochemical control after switching to octreotide LAR</FONT>
</LI>
</UL>

</LI>
</UL> </div><div style="margin-bottom: 10px;"><FONT face="Arial"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7003/17/ScreenCapture17.jpg?user-agent=rss"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7003/18/ScreenCapture18.jpg?user-agent=rss"></FONT> </div><div style="margin-bottom: 10px;"><FONT face="Arial">New in terms of presentation was data showing that Pasireotide Improves HRQoL and Signs and Symptoms in Pts With Acromegaly &mdash; results of a 12 month randomised, double blind multi-centre P3 study</FONT> </div><div style="margin-bottom: 10px;"><UL type="disc"><LI>
<UL type="circle"><LI><FONT face="Arial">Improvements in headache, fatigue perspiration, paresthesia, osteoarthralgia was seen across both arms (although ocretotide LAR fared better) &mdash; largest improvement was seen in perspiration (both arms)</FONT>
</LI>
<LI><FONT face="Arial">Safety &mdash; 57.<wbr>3% of patients had hyperglycemic events in the pasreotide LAR arm</FONT>
</LI>
<LI><FONT face="Arial">At month 12, mean AcroQoL scores had improved 7.<wbr>0&plusmn; 14.<wbr>5 points in the pasireotide LAR arm and by 4.<wbr>9&plusmn; 15.<wbr>5 points in the octreotide LAR arm &mdash; there was no statistical difference between the two treatment groups</FONT>
</LI>
</UL>

</LI>
</UL> </div><div style="margin-bottom: 10px;"><FONT face="Arial"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7003/13/ScreenCapture13.jpg?user-agent=rss"></FONT> </div><div style="margin-bottom: 10px;"><FONT face="Arial">Pasireotide LAR And Octreotide LAR Maintain Biochemical Control In Patients With Acromegaly: Extension Phase</FONT> </div><div style="margin-bottom: 10px;"><UL type="disc"><LI>
<UL type="circle"><LI><FONT face="Arial">Pasireotide LAR demonstrated superiority to octreotide LAR in providing biochemical control (GH&lt;2.<wbr>5&mu;g/<wbr>L and normal IGF-1) after 12 months of therapy and during the extension phase, GH and IGF-1 levels remained suppressed to 19 months in the pasreotide LAR and octreotide LAR arms.<wbr> This is longer term data than was presented at the ECE meeting.<wbr> </FONT>
</LI>
</UL>

</LI>
</UL> </div><div style="margin-bottom: 10px;"><FONT face="Arial"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7003/14/ScreenCapture14.jpg?user-agent=rss"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7003/15/ScreenCapture15.jpg?user-agent=rss"></FONT> </div><div style="margin-bottom: 10px;"><FONT face="Arial">New data was also highligthed demonstrating that Pasireotide LAR Achieves Greater Response Than Octreotide LAR In Pts With Acromegaly, Irrespective Of Baseline Tumour Volume: A Post-Hoc Analysis</FONT> </div><div style="margin-bottom: 10px;"><UL type="disc"><LI>
<UL type="circle"><LI><FONT face="Arial">Treatment with pasireotide LAR led to higher response rates than with ocretotide LAR in both the de novo and post-surgical patients</FONT>
</LI>
</UL>

</LI>
</UL> </div><div><FONT face="Arial"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7003/16/ScreenCapture16.jpg?user-agent=rss"></FONT> </div><!-- Comment details --><a name="endocrinology7003attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7003/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(46,6 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7003/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(74,6 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7003/3/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(52,3 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7003/4/ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(56,4 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7003/5/ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(58,2 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7003/6/ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(60,4 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7003/7/ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(61 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7003/8/ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(59,2 KB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7003/9/ScreenCapture9.jpg">ScreenCapture9.jpg</a>&nbsp;&nbsp;(57 KB)<br>&nbsp;&nbsp;10.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7003/10/ScreenCapture10.jpg">ScreenCapture10.jpg</a>&nbsp;&nbsp;(65,4 KB)<br>&nbsp;&nbsp;11.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7003/11/ScreenCapture11.jpg">ScreenCapture11.jpg</a>&nbsp;&nbsp;(69,5 KB)<br>&nbsp;&nbsp;12.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7003/12/ScreenCapture12.jpg">ScreenCapture12.jpg</a>&nbsp;&nbsp;(57,7 KB)<br>&nbsp;&nbsp;13.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7003/13/ScreenCapture13.jpg">ScreenCapture13.jpg</a>&nbsp;&nbsp;(51,6 KB)<br>&nbsp;&nbsp;14.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7003/14/ScreenCapture14.jpg">ScreenCapture14.jpg</a>&nbsp;&nbsp;(65,6 KB)<br>&nbsp;&nbsp;15.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7003/15/ScreenCapture15.jpg">ScreenCapture15.jpg</a>&nbsp;&nbsp;(62,2 KB)<br>&nbsp;&nbsp;16.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7003/16/ScreenCapture16.jpg">ScreenCapture16.jpg</a>&nbsp;&nbsp;(57,1 KB)<br>&nbsp;&nbsp;17.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7003/17/ScreenCapture17.jpg">ScreenCapture17.jpg</a>&nbsp;&nbsp;(69,9 KB)<br>&nbsp;&nbsp;18.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7003/18/ScreenCapture18.jpg">ScreenCapture18.jpg</a>&nbsp;&nbsp;(55 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120831&edate=20120501&rec=7003">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-07-05T11:24:15+02:00</dc:date><dc:creator>bee75336</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7003/1/ScreenCapture1.jpg" length="47752" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7003/2/ScreenCapture2.jpg" length="76370" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7003/3/ScreenCapture3.jpg" length="53506" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7003/4/ScreenCapture4.jpg" length="57799" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7003/5/ScreenCapture5.jpg" length="59599" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7003/6/ScreenCapture6.jpg" length="61860" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7003/7/ScreenCapture7.jpg" length="62481" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7003/8/ScreenCapture8.jpg" length="60587" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7003/9/ScreenCapture9.jpg" length="58333" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7003/10/ScreenCapture10.jpg" length="67003" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7003/11/ScreenCapture11.jpg" length="71121" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7003/12/ScreenCapture12.jpg" length="59097" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7003/13/ScreenCapture13.jpg" length="52821" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7003/14/ScreenCapture14.jpg" length="67203" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7003/15/ScreenCapture15.jpg" length="63740" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7003/16/ScreenCapture16.jpg" length="58470" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7003/17/ScreenCapture17.jpg" length="71627" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7003/18/ScreenCapture18.jpg" length="56340" type="image/jpeg"/></item><item>
<title>ENDO Intelligence - Part One - Pasireotide in Cushings Disease [comp:Novartis, dis:Cushing, :PharmaWorld:congress:ENDO, Alert]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7000</link>
<description>ENDO Intelligence - Part One - Pasireotide in Cushings Disease [comp:Novartis, dis:Cushing, :PharmaWorld:congress:ENDO, Alert]</description><category>comp:Novartis</category><category>dis:Cushing</category><category>congress:ENDO</category><category>Alert</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7000</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120831&edate=20120501&rec=7000">ENDO Intelligence - Part One - Pasireotide in Cushings Disease</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=Alert"><font color="#e95e0b">:Endocrinology:Alert</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=comp%3aNovartis"><font color="#e95e0b">:Endocrinology:comp:Novartis</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=dis%3aCushing"><font color="#e95e0b">:Endocrinology:dis:Cushing</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=congress%3aENDO"><font color="#e95e0b">:PharmaWorld:congress:ENDO</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7000">Endocrinology7000</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/774">bee75336</a> | 05 July 2012 | 11:08</font><br><br><div style="margin-bottom: 10px;">Comment: Although Novartis did not hold a sponsored symposia, pasireotide posters were in abundance.<wbr> Data from the B2305 core and extension study were presented with an oral session covering early response to treatment.<wbr> Pasireotide in Cushings will launch in the US in November 2012.<wbr> </div><div style="margin-bottom: 10px;">At the booth, hand-outs included: CSOM230B2406 (SEASCAPE) trial — an open label, multi-centre expanded access study of pasireotide sc in patients with CD - target enrollment of 300 patients.<wbr> Another hand-out was the phase III study to evaluate the efficacy and safety of pasireotide LAR in patients with CD.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7000/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">During the poster sessions, talk revolved around the side effect profile of pasireotide (hyperglycemia).<wbr> It is clear that NVS had briefed all the presenters in how to handle these challenges.<wbr> The message from NVS on this matter is focused on <EM>early detection followed by aggressive treatment.<wbr> </EM>When speaking with K.<wbr> Hermosillo, he declared that <EM>‘we made a big mistake in that NVS did not communicate to the centres quickly enough to treat the patients aggressively, rather we told the Investigators to adopt a wait and watch position, it was not a good idea and we are paying for it now’</EM> </div><div style="margin-bottom: 10px;">In order to address the hyperglycemia issue (which is more of a concern in CD patients), NVS are currently designing a trial in CD patients using incretins.<wbr> The trial is expected to be up and running before the end of the year.<wbr> </div><div style="margin-bottom: 10px;">Interestingly there was a poster by HA Schmid demonstrating the PK and PD effects of pasireotide IR and LAR in rats and mice that showed pasireotide LAR appears to be associated with smaller and more transient elevations in glucose levels than paireotide sc in both </div><div style="margin-bottom: 10px;">species.<wbr><A href="http://ci.beaufour-ipsen.com/“,”http://novartis.medicalcongressposters.com/Default.aspx?doc=6eb97“,”">http:/<wbr>/<wbr>novartis.<wbr>medicalcongressposters.<wbr>com/<wbr>Default.<wbr>aspx?doc=6eb97</A> </div><div style="margin-bottom: 10px;">Data from on initial response to pasireotide treatment was presented by Andre Lacroix - results are from the B2305 core study.<wbr> </div><div style="margin-bottom: 10px;">The overall message from the session was that patients who do not respond biochemically within the first two months are unlikely to respond at a later time point.<wbr> These patients who do have an early biochemical response, stay on treatment longer and approximately 50% continue to respond.<wbr> </div><div style="margin-bottom: 10px;">The results showed that pasireotide treatment leads to rapid and sustained decrease in mean UFC with a similar trend in ACTH and serum cortisol being observed.<wbr> Early responders tend to have greater improvements in weight, BMI, blood pressure and cholesterol to those who are uncontrolled.<wbr> </div><div style="margin-bottom: 10px;">A reminder of the study schema is below: </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7000/2/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">Results are as follows: </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7000/3/ScreenCapture3.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7000/4/ScreenCapture4.jpg?user-agent=rss"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7000/5/ScreenCapture5.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 12pt; FONT-FAMILY: 'Arial','sans-serif'; mso-fareast-font-family: 'MS Mincho'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7000/6/ScreenCapture6.jpg?user-agent=rss"></SPAN><SPAN lang="EN-US" style="FONT-SIZE: 12pt; FONT-FAMILY: 'Arial','sans-serif'; mso-fareast-font-family: 'MS Mincho'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"><SPAN lang="EN-US" style="FONT-SIZE: 12pt; FONT-FAMILY: 'Arial','sans-serif'; mso-fareast-font-family: 'MS Mincho'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7000/7/ScreenCapture7.jpg?user-agent=rss"></SPAN></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 12pt; FONT-FAMILY: 'Arial','sans-serif'; mso-fareast-font-family: 'MS Mincho'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7000/8/ScreenCapture8.jpg?user-agent=rss"></SPAN><SPAN lang="EN-US" style="FONT-SIZE: 12pt; FONT-FAMILY: 'Arial','sans-serif'; mso-fareast-font-family: 'MS Mincho'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7000/9/ScreenCapture9.jpg?user-agent=rss"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 12pt; FONT-FAMILY: 'Arial','sans-serif'; mso-fareast-font-family: 'MS Mincho'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7000/10/ScreenCapture10.jpg?user-agent=rss"></SPAN> </div><div style="margin-bottom: 10px;">Posters (see study design above) </div><div style="margin-bottom: 10px;">Pasireotide Treatment In CD Is Associated With Significant Improvements In Hypertension: 12 Months Results From A Large P3 Study - <A href="http://ci.beaufour-ipsen.com/“,”http://novartis.medicalcongressposters.com/Default.aspx?doc=8a5c0“,”">http:/<wbr>/<wbr>novartis.<wbr>medicalcongressposters.<wbr>com/<wbr>Default.<wbr>aspx?doc=8a5c0</A> </div><div style="margin-bottom: 10px;"><UL><LI>From baseline to month six, mean (±SE) SBP decreased from 133.<wbr>5± 1.<wbr>5mmHg to 125.<wbr>5± 1.<wbr>2mmHg (p=0.<wbr>001), and mean DBP decreased from 86.<wbr>3± 1.<wbr>0mmHg to 82.<wbr>8±1.<wbr>0mmHg (p=0.<wbr>0024).<wbr> These decreases were maintained to month 12 </LI>
<LI>Significant decrease in SBP and DBP were seen in the subset of patients whose UFC levels were controlled at month 6 </LI>
<LI>Significant improvements in SBP and DBP from baseline to month 12 were seen in patients with baseline hypertension </LI>
</UL> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 12pt; FONT-FAMILY: 'Arial','sans-serif'; mso-fareast-font-family: 'MS Mincho'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7000/11/ScreenCapture11.jpg?user-agent=rss"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 12pt; FONT-FAMILY: 'Arial','sans-serif'; mso-fareast-font-family: 'MS Mincho'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7000/12/ScreenCapture12.jpg?user-agent=rss"></SPAN> </div><div style="margin-bottom: 10px;">Pasireotide Treatment Is Associated With Clinically Meaningful Improvements in Health Related QoL In CD: Results From A Large P3 Study <A href="http://ci.beaufour-ipsen.com/“,”http://novartis.medicalcongressposters.com/Default.aspx?doc=25f92“,”">http:/<wbr>/<wbr>novartis.<wbr>medicalcongressposters.<wbr>com/<wbr>Default.<wbr>aspx?doc=25f92</A> </div><div style="margin-bottom: 10px;"><UL><LI>In both dose groups, HRQoL including weight improved from baseline to month 3 along with rapid and sustained decreases in UFC levels </LI>
<LI>By month 12, there was clinically meaningful improvement in HRQoL in patients whose UFC levels were controlled (n=29); mean improvement: 12.<wbr>8, 95% CI: 7:1, 18.<wbr>5) or partially controlled at month 6 (n=17); mean improvement: 10:7, 95% CI: 0.<wbr>8, 20.<wbr>5) </LI>
</UL> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 12pt; FONT-FAMILY: 'Arial','sans-serif'; mso-fareast-font-family: 'MS Mincho'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7000/13/ScreenCapture13.jpg?user-agent=rss"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7000/14/ScreenCapture14.jpg?user-agent=rss"></SPAN> </div><div style="margin-bottom: 10px;">Long-Term Pasireotide Use Leads To Significant And Sustained Improvements In The Signs And Symptoms Of CD: 24 Months Results From A Randomized P3 Study </div><div style="margin-bottom: 10px;"><A href="http://ci.beaufour-ipsen.com/“,”http://novartis.medicalcongressposters.com/Default.aspx?doc=39912“,”">http:/<wbr>/<wbr>novartis.<wbr>medicalcongressposters.<wbr>com/<wbr>Default.<wbr>aspx?doc=39912</A> </div><div style="margin-bottom: 10px;"><UL><LI>The mean percentage decrease in UFC that occurred during the core study(54.<wbr>7%[95% CI: 37.<wbr>6, 71.<wbr>8]) was sustained throughout the extension phase: mean percentage decrease from core baseline to month 24 was 59.<wbr>5% (95% CI: 50.<wbr>5,68.<wbr>6) for all patients who entered the extension (n=58) </LI>
<LI>Of the 58 patients, the proportion with UFC ≤ULN at 12,18,24 months was 38.<wbr>5%, 46.<wbr>2% and 30.<wbr>8% in the 600μg bid group and 59.<wbr>4%, 40.<wbr>6% and 37.<wbr>5% in the 900μg bid group respectively </LI>
<LI>Sustained mean reductions from baseline in serum cortisol and plasma ACTH levels were observed </LI>
<LI>Further improvements on SBP and DBP as well as weight decrease were observed </LI>
<LI>Mean change from baseline in total cholesterol levels was -8.<wbr>5% and -5.<wbr>8% at 12 and 24 months </LI>
</UL> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 12pt; FONT-FAMILY: 'Arial','sans-serif'; mso-fareast-font-family: 'MS Mincho'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7000/15/ScreenCapture15.jpg?user-agent=rss"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7000/16/ScreenCapture16.jpg?user-agent=rss"></SPAN> </div><div style="margin-bottom: 10px;">Pasireotide As A Long-Term Treatment For Patients With CD: 24 Months Safety Results From A Randomized P3 Study <A href="http://ci.beaufour-ipsen.com/“,”http://novartis.medicalcongressposters.com/Default.aspx?doc=8cd91“,”">http:/<wbr>/<wbr>novartis.<wbr>medicalcongressposters.<wbr>com/<wbr>Default.<wbr>aspx?doc=8cd91</A> </div><div style="margin-bottom: 10px;"><UL><LI>AEs include diarrhea (56%), nausea (48.<wbr>1%), hyperglycemia (38.<wbr>9%) and cholelithiasis (31.<wbr>5%) </LI>
<LI>Compared to the 12 months data cut-off - Mean increase in HbA1c increased from 5.<wbr>8% at core baseline to 7.<wbr>2 and 6.<wbr>8% at months 12 and 24 respectively </LI>
<LI>Mean fasting glucose icreased from 97.<wbr>8 mg/<wbr>dL at core baseline to 117.<wbr>7 and 119.<wbr>5 mg/<wbr>dL at months 12 and 24 respectively </LI>
</UL> </div><div><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7000/17/ScreenCapture17.jpg?user-agent=rss"> </div><!-- Comment details --><a name="endocrinology7000attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7000/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(51,4 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7000/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(66,2 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7000/3/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(60,3 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7000/4/ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(69,8 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7000/5/ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(68,1 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7000/6/ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(61,1 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7000/7/ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(69,2 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7000/8/ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(71,2 KB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7000/9/ScreenCapture9.jpg">ScreenCapture9.jpg</a>&nbsp;&nbsp;(66,3 KB)<br>&nbsp;&nbsp;10.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7000/10/ScreenCapture10.jpg">ScreenCapture10.jpg</a>&nbsp;&nbsp;(47,9 KB)<br>&nbsp;&nbsp;11.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7000/11/ScreenCapture11.jpg">ScreenCapture11.jpg</a>&nbsp;&nbsp;(122,8 KB)<br>&nbsp;&nbsp;12.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7000/12/ScreenCapture12.jpg">ScreenCapture12.jpg</a>&nbsp;&nbsp;(46,5 KB)<br>&nbsp;&nbsp;13.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7000/13/ScreenCapture13.jpg">ScreenCapture13.jpg</a>&nbsp;&nbsp;(41,3 KB)<br>&nbsp;&nbsp;14.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7000/14/ScreenCapture14.jpg">ScreenCapture14.jpg</a>&nbsp;&nbsp;(113,5 KB)<br>&nbsp;&nbsp;15.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7000/15/ScreenCapture15.jpg">ScreenCapture15.jpg</a>&nbsp;&nbsp;(79,4 KB)<br>&nbsp;&nbsp;16.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7000/16/ScreenCapture16.jpg">ScreenCapture16.jpg</a>&nbsp;&nbsp;(64,2 KB)<br>&nbsp;&nbsp;17.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7000/17/ScreenCapture17.jpg">ScreenCapture17.jpg</a>&nbsp;&nbsp;(133,1 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120831&edate=20120501&rec=7000">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-07-05T11:08:41+02:00</dc:date><dc:creator>bee75336</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7000/1/ScreenCapture1.jpg" length="52652" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7000/2/ScreenCapture2.jpg" length="67758" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7000/3/ScreenCapture3.jpg" length="61719" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7000/4/ScreenCapture4.jpg" length="71428" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7000/5/ScreenCapture5.jpg" length="69700" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7000/6/ScreenCapture6.jpg" length="62606" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7000/7/ScreenCapture7.jpg" length="70811" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7000/8/ScreenCapture8.jpg" length="72925" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7000/9/ScreenCapture9.jpg" length="67924" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7000/10/ScreenCapture10.jpg" length="49045" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7000/11/ScreenCapture11.jpg" length="125797" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7000/12/ScreenCapture12.jpg" length="47615" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7000/13/ScreenCapture13.jpg" length="42329" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7000/14/ScreenCapture14.jpg" length="116242" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7000/15/ScreenCapture15.jpg" length="81330" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7000/16/ScreenCapture16.jpg" length="65769" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7000/17/ScreenCapture17.jpg" length="136264" type="image/jpeg"/></item><item>
<title>Paper: Purified Botulinum Type A Neurotoxin in Patients with Urinary Incontinence and Prostatic Hyperplasia. [class:BotulinumToxins, dis:iOAB]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology6492</link>
<description>Paper: Purified Botulinum Type A Neurotoxin in Patients with Urinary Incontinence and Prostatic Hyperplasia. [class:BotulinumToxins, dis:iOAB]</description><category>class:BotulinumToxins</category><category>dis:iOAB</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology6492</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120831&edate=20120501&rec=6492">Paper: Purified Botulinum Type A Neurotoxin in Patients with Urinary Incontinence and Prostatic Hyperplasia.<wbr></a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=class%3aBotulinumToxins"><font color="#e95e0b">:Neurology:class:BotulinumToxins</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=dis%3aiOAB"><font color="#e95e0b">:Neurology:dis:iOAB</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology6492">Neurology6492</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/20">Alison Attard</a> | 03 July 2012 | 17:49</font><br><br><div style="margin-bottom: 10px;">Comment: The purified toxin was used to treat 49 patients with urinary incontinence, 36 patients showed significant improvement in symptoms.<wbr> These beneficial effects were also observed in cases of prostatic hyperplasia.<wbr> </div><div style="margin-bottom: 10px;">The authors suggest that the purified toxin has less immunoenhancing activity.<wbr> </div><div style="margin-bottom: 10px;">Full text (open access) is at: <A href="http://www.hindawi.com/journals/jt/2012/648384/">http:/<wbr>/<wbr>www.<wbr>hindawi.<wbr>com/<wbr>journals/<wbr>jt/<wbr>2012/<wbr>648384/<wbr></A> </div><div>Source: Journal of Toxicology epub 14 June 2012 </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120831&edate=20120501&rec=6492">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-07-03T17:49:10+02:00</dc:date><dc:creator>ala97794</dc:creator></item><item>
<title>Withdrawal of Co-Payment for 456 Drugs Expected to Increase Prices in Spain [mkt:Spain, mkt:Europe, sub:Pricing]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld9966</link>
<description>Withdrawal of Co-Payment for 456 Drugs Expected to Increase Prices in Spain [mkt:Spain, mkt:Europe, sub:Pricing]</description><category>mkt:Spain</category><category>mkt:Europe</category><category>sub:Pricing</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld9966</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120831&edate=20120501&rec=9966">Withdrawal of Co-Payment for 456 Drugs Expected to Increase Prices in Spain</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=mkt%3aEurope"><font color="#e95e0b">:PharmaWorld:mkt:Europe</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=mkt%3aSpain"><font color="#e95e0b">:PharmaWorld:mkt:Spain</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=sub%3aPricing"><font color="#e95e0b">:PharmaWorld:sub:Pricing</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld9966">PharmaWorld9966</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 03 July 2012 | 17:22</font><br><br><div style="margin-bottom: 10px;">Comment: The withdrawal of governmental co-payment for 456 low-intensity illness drugs that came into force on 1 July in Spain is expected to increase the price of such drugs in the short-to-medium term as they will no longer be regulated under the government's co-payment scheme.<wbr> The co-payment withdrawal is expected to save the government EUR440 million (USD 556 million).<wbr> </div><div style="margin-bottom: 10px;">According to <I>La Opinion de Zamora</I>, among those drugs to be affected are antacid tablets such as Almax (almagato); anti-haemorrhoidal treatments such as Synalar (fluocinolone acetonide); anti-inflammatory drugs such as Voltaren (diclofenac); mucolytics such as acetylcysteine; cough and cold mixtures; and artificial tears.<wbr> </div><div style="margin-bottom: 10px;">According to Jose Espinosa Navarro, president of the Zamora Pharmaceutical Association, cited by the source, with this move, the government plans to open up space for more innovative drugs to be inserted on the list of drug co-payments in the medium term.<wbr> According to the source, although 456 drugs are expected to be affected by the new decree in the medium-to-long term, 426 drugs have been affected already.<wbr> According to the source, the 456 drugs awaiting withdrawal cost the government EUR458 million in 2011, so the cuts are expected to save the government EUR440 million by end of 2012.<wbr> </div><div style="margin-bottom: 10px;"><P class="bodyHeading2"><STRONG><FONT size="3">Outlook and Implications</FONT></STRONG></P> </div><div style="margin-bottom: 10px;">The withdrawal of the drugs from the national co-payment list is aimed at lowering Spain's healthcare expenditure and boosting the national healthcare budget together with the announced price increase of chronic illness drugs as well as the one-euro-per-prescription measure which has been enforced in some regions.<wbr> </div><div style="margin-bottom: 10px;">Although these measures are expected to benefit the government's coffers, they will most likely have a long-term negative impact on the revenues of pharmacies across the country as patients are expected to purchase less drugs as a consequence of possible rising prices for those drugs that have been withdrawn from the co-payment scheme.<wbr> </div><div style="margin-bottom: 10px;">The new set of austerity measures, including co-payment withdrawal of over-the-counter drugs as part of Royal Decree 16/<wbr>2012, may be an effective relief to the strain on public healthcare in the short-to-medium term, but is not expected to be a sustainable option for the public in the long term as it will add a financial burden on the population as well as affecting pharmacy revenues.<wbr> </div><div>Source: GlobalInsight </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120831&edate=20120501&rec=9966">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-07-03T17:22:11+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Update on Alpharadin Status for Prostate Cancer [dis:Prostate]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology8367</link>
<description>Update on Alpharadin Status for Prostate Cancer [dis:Prostate]</description><category>dis:Prostate</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology8367</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8367">Update on Alpharadin Status for Prostate Cancer</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8367">Oncology8367</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 03 July 2012 | 16:04</font><br><br><div style="margin-bottom: 10px;">Comment: Algeta is about to file EMA and FDA in H2:12.<wbr> The drug, which is likely to extend the 'chemotherapy-free' window, is anticipated to be approved in H1:13 in EU and US.<wbr> Bayer expects the drug has potential to be a blockbuster.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Comparison of Ph3 Data in Advanced Prostate Cancer</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8367/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Bayer /<wbr> Algeta Agreement</FONT></STRONG> </div><div>Algeta will co-promote the drug (50/<wbr>50 profit/<wbr>loss sharing) in the US with bayer.<wbr> </div><!-- Comment details --><a name="oncology8367attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8367/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(134,7 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8367">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-07-03T16:04:38+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8367/1/ScreenCapture1.jpg" length="137977" type="image/jpeg"/></item><item>
<title>Ferring Acquires Licensing Rights for Albireo's GI Drug [dis:IBS, dis:Constipation, :Endocrinology:comp:Ferring]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology1845</link>
<description>Ferring Acquires Licensing Rights for Albireo's GI Drug [dis:IBS, dis:Constipation, :Endocrinology:comp:Ferring]</description><category>dis:IBS</category><category>dis:Constipation</category><category>comp:Ferring</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology1845</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20120831&edate=20120501&rec=1845">Ferring Acquires Licensing Rights for Albireo's GI Drug</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=comp%3aFerring"><font color="#e95e0b">:Endocrinology:comp:Ferring</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20120831&edate=20120501&cat=dis%3aConstipation"><font color="#e95e0b">:GastroEnterology:dis:Constipation</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20120831&edate=20120501&cat=dis%3aIBS"><font color="#e95e0b">:GastroEnterology:dis:IBS</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology1845">GastroEnterology1845</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 03 July 2012 | 12:10</font><br><br><div style="margin-bottom: 10px;">Comment: The agreement is one of the biggest investments made by Ferring for licensing rights of a product.<wbr> Albireo's elobixibat is due to enter Ph3 for the CIC indication and Ph2b for the IBS-C indication shortly.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Rationale for Ferring</FONT></STRONG> </div><div style="margin-bottom: 10px;">The company is looking to strengthen its position in the GI field.<wbr> </div><div style="margin-bottom: 10px;"><U>On the Market</U> </div><div style="margin-bottom: 10px;">Ferring's gastroenterology portfolio includes PENTASA® for IBD and PICOPREP® for bowel cleansing.<wbr> </div><div style="margin-bottom: 10px;"><U>In the pipeline</U> </div><div style="margin-bottom: 10px;">- Ferring has developed a 2-gram sachet of PENTASA® to facilitate intake for patients who require higher doses.<wbr> A new device for the enema presentaton is under investigating changes.<wbr> </div><div style="margin-bottom: 10px;">- FE301 a new recombinant protein inhibitor of the IL-6 pathway for inflammatory conditions such as IBD (and rheumatoid arthritis).<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Terms of the Agreement</FONT></STRONG> </div><div style="margin-bottom: 10px;"><STRONG>Indications</STRONG>: Ferring has rights to develop and commercialise elobixibat for chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C).<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Territories</STRONG>: The agreement gives Ferring rights to market the product WW with the exception of Japan and a small number of Asian markets.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Financial</STRONG>: Ferring will pay Albireo a significant upfront licensing fee, milestones and tiered double-digit royalties.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Development costs</STRONG>: Ferring will also be responsible for development costs in its territory.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Drug Mechanism of Action</FONT></STRONG> </div><div style="margin-bottom: 10px;">Acts locally in the gut with minimal systemic exposure and modulates the enterohepatic circulation of bile acids by a partial inhibition of the Ileal Bile Acid Transporter (IBAT).<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Albireo Pharm.<wbr> Snapshot</FONT></STRONG> </div><div style="margin-bottom: 10px;"><STRONG>Focus</STRONG>: GI indications </div><div style="margin-bottom: 10px;">Independent Swedish Biotech company based in Gothenburg </div><div style="margin-bottom: 10px;">Spun-out of AstraZeneca in February 2008.<wbr> </div><div style="margin-bottom: 10px;">Financed by Phase4 Ventures and supported by TVM Capital and Scottish Widows Investment Partnership.<wbr> </div><div>Source: Ferring; Albireo </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20120831&edate=20120501&rec=1845">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-07-03T12:10:15+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>BMS To Acquire Amylin For $7bn &amp; Then Integrate Products Into AZ Collaboration [Alert, class:GLP1, dis:Diabetes]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology6996</link>
<description>BMS To Acquire Amylin For $7bn &amp; Then Integrate Products Into AZ Collaboration [Alert, class:GLP1, dis:Diabetes]</description><comments>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology6996</comments><category>Alert</category><category>class:GLP1</category><category>dis:Diabetes</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology6996</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120831&edate=20120501&rec=6996">BMS To Acquire Amylin For $7bn & Then Integrate Products Into AZ Collaboration</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=Alert"><font color="#e95e0b">:Endocrinology:Alert</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=class%3aGLP1"><font color="#e95e0b">:Endocrinology:class:GLP1</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=dis%3aDiabetes"><font color="#e95e0b">:Endocrinology:dis:Diabetes</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology6996">Endocrinology6996</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 02 July 2012 | 15:22</font><br><br><div style="margin-bottom: 10px;">Comment: BMS has today announced the acquisition of Amylin.<wbr> Following the completion of the purchase, the company will then enter into a collaboration with AstraZeneca , based on their existing diabetes alliance, regarding the development and commercialisation of Amylin's portfolio of products.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6996/1/ScreenCapture3.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6996/2/ScreenCapture4.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6996/3/ScreenCapture5.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6996/4/ScreenCapture6.jpg?user-agent=rss"> </div><div><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6996/5/ScreenCapture7.jpg?user-agent=rss"> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Endocrinology7054c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;"><SPAN style="display: inline! important; float: none; word-spacing: 0px; font: 12px helvetica; text-transform: none; color: #000000; text-indent: 0px; white-space: normal; letter-spacing: normal; background-color: #ffffff; widows: 2; orphans: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">Bristol-Myers Squibb announced on 9 August 2012 that it has  completed its $5-billion purchase of Amylin and its diabetes franchise.<wbr></SPAN> </div><div style="margin-bottom: 10px;">AstraZeneca has also informed Bristol-Myers Squibb of its intention to exercise its option to <EM>acquire certain additional governance rights over key strategic and financial decisions regarding Amylin&rsquo;s portfolio</EM>.<wbr> The right to exercise this option will become effective once applicable anti-trust and competition approvals are received by AstraZeneca.<wbr> Upon the exercise of the option an additional payment of $135 million will be made to Bristol-Myers Squibb.<wbr> </div><div>Source: Pharmiweb 9 August 2012 </div><font size="-1">Alison Attard / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7054" class="commentpermalink">Endocrinology7054</a> / <span class="date">09 August 2012</span> /
<span class="time">16:04:24 o'clock CEST</span>
</font></div><a name="endocrinology6996attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6996/1/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(177,1 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6996/2/ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(222,5 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6996/3/ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(235,5 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6996/4/ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(144,9 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6996/5/ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(109,2 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120831&edate=20120501&rec=6996">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-07-02T15:22:17+02:00</dc:date><dc:creator>jac89886</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6996/1/ScreenCapture3.jpg" length="181320" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6996/2/ScreenCapture4.jpg" length="227831" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6996/3/ScreenCapture5.jpg" length="241140" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6996/4/ScreenCapture6.jpg" length="148339" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6996/5/ScreenCapture7.jpg" length="111858" type="image/jpeg"/></item><item>
<title>re: Astellas Boosts its Foothold in Urology</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology8366</link>
<description>re: Astellas Boosts its Foothold in Urology</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology8366</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8366">re: Astellas Boosts its Foothold in Urology</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8366">Oncology8366</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/20">Alison Attard</a> | 02 July 2012 | 10:55</font><br><br><div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Astellas Boosts its Foothold in Urology</span>&nbsp;<font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=comp%3aAstellas"><font color="#e95e0b">:Oncology:comp:Astellas</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=mkt%3aNorthAmerica"><font color="#e95e0b">:PharmaWorld:mkt:NorthAmerica</font></a>]</font></font><br><span style="font-size: 12px;">Comment: The FDA has approved Astellas' mirabegron (once-daily pill) for OAB.<wbr> The drug launch is set for Oct-Dec, and will be sold as Myrbetriq.<wbr> The company expects the drug to drive synergy with Vesicare (which has top brand market share at 23%).<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8362">...</a><br><font size="-1">Brigitte DESCHAMPS / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8362" class="commentpermalink">Oncology8362</a> / <span class="date">29 June 2012</span> /
<span class="time">11:20:48 o'clock CEST</span>
</font></div><div style="margin-bottom: 10px;">According to FirstWord global sales of Myrbetriq are anticipated to reach approximately $600 million in 2016.<wbr> The product is expected to be a key profit driver for Astellas, being both developed in-house and given the opportunity for it to be marketed in close conjunction with its other OAB treatment, Vesicare, and a number of other urology brands.<wbr>  US launch of the product is expected during the third quarter.<wbr> </div><div style="margin-bottom: 10px;">Analysts at JP Morgan had predicted a short delay prior to approval, due to concerns being raised about elevated heart rate at an FDA advisory panel meeting in April.<wbr> </div><div style="margin-bottom: 10px;">Approval of Myrbetriq is also notable given Astellas' relatively weak in house-R&amp;D pipeline, said analysts at Morgan Stanley.<wbr> </div><div>Source: FirstWord 29 June 2012 </div><!-- Comment details --><font size="-1">Alison Attard / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8366" class="commentpermalink">Oncology8366</a> / <span class="date">02 July 2012</span> /
<span class="time">10:55:41 o'clock CEST</span>
</font><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8366">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8362">View thread  Oncology8362: Astellas Boosts its Foothold in Urology</a>]]></content:encoded><dc:date>2012-07-02T10:55:41+02:00</dc:date><dc:creator>ala97794</dc:creator></item><item>
<title>Biogen-Idec &amp; Isis Form New Neuromuscular Disease Collaboration [headline, dis:MuscularDystrophy]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology6490</link>
<description>Biogen-Idec &amp; Isis Form New Neuromuscular Disease Collaboration [headline, dis:MuscularDystrophy]</description><comments>http://ci.beaufour-ipsen.com/traction/permalink/Neurology6490</comments><category>headline</category><category>dis:MuscularDystrophy</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology6490</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120831&edate=20120501&rec=6490">Biogen-Idec & Isis Form New Neuromuscular Disease Collaboration</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=dis%3aMuscularDystrophy"><font color="#e95e0b">:Neurology:dis:MuscularDystrophy</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=headline"><font color="#e95e0b">:Neurology:headline</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology6490">Neurology6490</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 02 July 2012 | 10:31</font><br><br><div style="margin-bottom: 10px;">Comment: Biogen-Idec and Isis have entered into an exclusive worldwide option 
and collaboration agreement to develop and commercialise an antisense 
programme targeting the neuromusucular disease mytonic dystrophy.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>How Does The Antisense Approach Work</STRONG> </div><div style="margin-bottom: 10px;">DM1, the most common form of muscular dystrophy is caused by a genetic defect 
in the dystrophia myotonic-protein kinase DMPK gene in which a sequence of three 
nucleotides repeats ectensively creatin an abnormally long toxic RNA.<wbr> This 
accumulates in cells and  prevents the production of proteins needed for 
normal cellular function.<wbr> Isis's DM1 antisense should block the production of 
this toxic RNA sequence thereby correcting the underlying disorder.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Deal Terms</STRONG> </div><div style="margin-bottom: 10px;">Isis will receive an upfront payment of $12m and will be responsible for the 
identification of a lead antisense target.<wbr> It is also eligible for up to $59m in 
milestone payments.<wbr> Biogen-Idec has an option to in-license the 
product up to completion of phase 2 at which point Isis would receive another 
$200m in a license fee and regulatory milestones plus royalties on sales.<wbr> If 
Biogen-Idex exercises its option it will take full responsibility for further 
development and commercialisation.<wbr> </div><div>Source: <a href="http://www.biogenidec.com" class="defaultlink" title="www.biogenidec.com">biogenidec.com</a> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Neurology6679c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">The companies have signed a third global collaboration agreement under which they will  discover and develop antisense drugs againt 3 undisclosed targets to treat neurological or neuromuscular disorders.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Terms of the Agreement</STRONG> </div><div style="margin-bottom: 10px;">Under the terms of the agreement, Isis will receive an upfront payment of $30M and is responsible for the discovery of a lead antisense drug for each of the 3 undisclosed drugs.<wbr> </div><div style="margin-bottom: 10px;">Isis is eligible to receive substantial development milestone payments to support R&amp;D of each program prior to the exercise by Biogen Idec of its option to license each program.<wbr> </div><div>Biogen Idec has the option to license a drug from each of the three programs through the completion of Phase 2 trials.<wbr> Isis could receive up to another $200 million in a license fee and regulatory milestone payments per program.<wbr> In addition, Isis will receive double-digit royalties on sales of drugs.<wbr> Isis will be responsible for development of the drugs through the completion of the initial Phase 2 clinical trial, with Biogen Idec providing advice and assistance on research and the clinical trial design and conduct and regulatory strategy for each program.<wbr> If Biogen Idec exercises its option, it will assume global development, regulatory and commercialization responsibilities.<wbr> </div><font size="-1">Brigitte DESCHAMPS / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology6679" class="commentpermalink">Neurology6679</a> / <span class="date">10 December 2012</span> /
<span class="time">18:16:32 o'clock CET</span>
</font></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120831&edate=20120501&rec=6490">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-07-02T10:31:59+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>PregLem's SSI Inhibitor Has Entered POC for Endometriosis [dis:Gynea, :PharmaWorld:sub:ClinicalTrial]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology8364</link>
<description>PregLem's SSI Inhibitor Has Entered POC for Endometriosis [dis:Gynea, :PharmaWorld:sub:ClinicalTrial]</description><category>dis:Gynea</category><category>sub:ClinicalTrial</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology8364</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8364">PregLem's SSI Inhibitor Has Entered POC for Endometriosis</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=dis%3aGynea"><font color="#e95e0b">:Oncology:dis:Gynea</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=sub%3aClinicalTrial"><font color="#e95e0b">:PharmaWorld:sub:ClinicalTrial</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8364">Oncology8364</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 29 June 2012 | 17:58</font><br><br><div style="margin-bottom: 10px;">Comment: The AMBER study has been designed to assess the efficacy, safety, PK and PD of PGL2001 with concomitant, continuous norethisterone acetate for the treatment of pain symptoms suggestive of endometriosis.<wbr> Primary outcome will measure non-menstrual pelvic pain.<wbr> </div><div style="margin-bottom: 10px;">Study Design - <A href="http://clinicaltrials.gov/ct2/show/NCT01631981?recr=Open&amp;fund=2&amp;rcv_s=06%2F15%2F2012&amp;rank=98">NCT01631981</A> </div><div style="margin-bottom: 10px;">Recuitment: approx.<wbr> 132 participants </div><div style="margin-bottom: 10px;">Start date: June 2012 - Completion dates: Oct 2013 /<wbr> May 2014 </div><div>Locations: Hungary (5 sites); Poland (10 sites); Romania (5 sites) </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8364">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-06-29T17:58:31+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>MDS Intelligence Part 2 - Parkinson's Disease - Hurdles, Solutions &amp; Pathology [dis:Parkinson, headline, sub:Biomarkers, sub:Diagnostic, :PharmaWorld:congress:MDS]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology6488</link>
<description>MDS Intelligence Part 2 - Parkinson's Disease - Hurdles, Solutions &amp; Pathology [dis:Parkinson, headline, sub:Biomarkers, sub:Diagnostic, :PharmaWorld:congress:MDS]</description><category>dis:Parkinson</category><category>headline</category><category>sub:Biomarkers</category><category>sub:Diagnostic</category><category>congress:MDS</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology6488</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120831&edate=20120501&rec=6488">MDS Intelligence Part 2 - Parkinson's Disease - Hurdles, Solutions & Pathology</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=dis%3aParkinson"><font color="#e95e0b">:Neurology:dis:Parkinson</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=headline"><font color="#e95e0b">:Neurology:headline</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=sub%3aBiomarkers"><font color="#e95e0b">:Neurology:sub:Biomarkers</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=sub%3aDiagnostic"><font color="#e95e0b">:Neurology:sub:Diagnostic</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=congress%3aMDS"><font color="#e95e0b">:PharmaWorld:congress:MDS</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology6488">Neurology6488</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 29 June 2012 | 17:41</font><br><br><div style="margin-bottom: 10px;"><FONT size="3"><FONT face="Calibri">Comment: Key developments in terms of Parkinson&rsquo;s disease therapeutics particularly from the perspective of control of motor fluctuations are reviewed.<wbr> Progress with cell and gene therapy approaches are also highlighted.<wbr> Whilst some tantalizing insight into the potential pathology of Alzheimer&rsquo;s disease and maybe Parkinson&rsquo;s disease featured in a provocative translational science symposium.<wbr></FONT></FONT> </div><div style="margin-bottom: 10px;"><FONT size="3"><FONT face="Calibri"><STRONG>Recent &amp; On-going Clinical Trials In Movement Disorders</STRONG></FONT></FONT> </div><div style="margin-bottom: 10px;"><FONT size="3"><FONT face="Calibri"><EM><STRONG>Parkinson&rsquo;s Disease</STRONG></EM></FONT></FONT> </div><div style="margin-bottom: 10px;"><FONT size="3"><FONT face="Calibri">Werner Poewe (Austria) gave a thorough overview of the current state of the art.<wbr> He noted that there are currently 66 on-going randomised trials in PD of which the largest amount of activity is focused on dopaminergic drugs or new ways of delivering them.<wbr></FONT></FONT> </div><div style="margin-bottom: 10px;"><FONT size="3"><FONT face="Calibri"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/6488/1/ScreenCapture1.jpg?user-agent=rss"></FONT></FONT> </div><div style="margin-bottom: 10px;"><FONT size="3"><FONT face="Calibri"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/6488/2/ScreenCapture2.jpg?user-agent=rss"></FONT></FONT> </div><div style="margin-bottom: 10px;"><FONT size="3"><FONT face="Calibri">He highlighted IPX066 as new way of delivering L-Dopa and noted that data has shown that this is successful in treating advanced PD demonstrating a significant improvement in off-time of 2 hour (data published one year ago in Movement Disorders Journal).<wbr> A new study is now underway comparing IPX066 with LD/<wbr>CD and entacapone after a single dose study demonstrated a longer duration of motor effects compared to CD-LD IR + entacapone in fluctuating PD patients (see abstract attached)</FONT></FONT> </div><div style="margin-bottom: 10px;"><FONT size="3"><FONT face="Calibri">Another interesting development highlighted was patch pumps.<wbr> These can be used for continuous drug delivery and have been used successfully in diabetic patients for the administration of insulin.<wbr> One company now has an active development programme in PD and a product that provides continuous subcutaneous delivery of L-Dopa (2-4ml/<wbr>day) via a patch.<wbr> A phase I study in healthy volunteers is underway.<wbr> Poewe suggested that this could be useful for treating patients with motor fluctuations on L-Dopa.<wbr></FONT></FONT> </div><div style="margin-bottom: 10px;"><FONT size="3"><FONT face="Calibri">He suggested that intrapulmonary delivery of apomorphine is also of interest and noted that a Phase 2 4 week double-blind study conducted in 55 patients found that 85% of off-periods successfully reverted upon treatment.<wbr> Moreover, peak apomorphine levels were reached within 1-3 minutes.<wbr> He stated his hope that this product would enter phIII development.<wbr></FONT></FONT> </div><div style="margin-bottom: 10px;"><FONT size="3"><FONT face="Calibri">The product highlighted, is in fact Vectura&rsquo;s VR040 and the study was completed in November 2010.<wbr> Vectura is currently looking to partner this product for phIII development as its development focus is concentrated on the development of respiratory products.<wbr></FONT></FONT> </div><div style="margin-bottom: 10px;"><FONT size="3"><FONT face="Calibri">Poewe drew attention to the results of the PD-Med study, a long-term simple study which is comparing treatment outcomes in both early and later PD looking at treatment with either a DA-agonist, L-DOPA or a COMT-inhibitor.<wbr> The 1<SUP>st</SUP> results reported last December demonstrated that at least in early PD L-Dopa treatment provides better control than a DA-agonist or a COMT inhibitor.<wbr></FONT></FONT> </div><div style="margin-bottom: 10px;"><FONT size="3"><FONT face="Calibri">From a non-dopaminergic perspective the range of ongoing developments is as shown below.<wbr> </FONT></FONT> </div><div style="margin-bottom: 10px;"><FONT size="3"><FONT face="Calibri"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/6488/3/ScreenCapture3.jpg?user-agent=rss"></FONT></FONT> </div><div style="margin-bottom: 10px;"><FONT size="3"><FONT face="Calibri">Interest in the A2A antagonists developed a few years ago but the first product istradefylline has produced inconsistent results.<wbr> However, a new study a Japanese trial is positive and supports the outcome from a similar US study.<wbr> Hence it was suggested that the drug could become the first A2A antagonist to reach the market.<wbr></FONT></FONT> </div><div style="margin-bottom: 10px;"><FONT size="3"><FONT face="Calibri">Merck published positive phII data on preladenant last year from a dose finding study demonstrating a dose-dependent decrease in off-time with both 5 and 10mg doses.<wbr> Data from a post-hoc responder analysis of the phII double-blind study was presented this year and is attached in abstract form.<wbr> The product is now in PhIII development with the programme close to being finished.<wbr></FONT></FONT> </div><div style="margin-bottom: 10px;"><FONT size="3"><FONT face="Calibri">mGLuR5 antagonism to treat L-Dopa induced dyskinesia in PD has also demonstrated some therapeutic efficacy.<wbr> PhII data on Mavoglurant AFQ056 was presented last year in Toronto with the drug having demonstrated a dose dependent effect on LID using the modified AIMS scale.<wbr> Data presented at MDS this year demonstrated the effectiveness of the drug in reducing off-time and opening the therapeutic window for L-Dopa (see abstract attached).<wbr> An on-going phIIb trial is testing two different formulations one an immediate release form and the other a modified release formulation to try and modify the drug&rsquo;s AE profile.<wbr> </FONT></FONT> </div><div style="margin-bottom: 10px;"><FONT size="3"><FONT face="Calibri">Included at the meeting was also a late-breaking abstract on Addex&rsquo;s mGLuR5 ADX48621 Dipraglurant which completed a PhIIa study a few weeks ago.<wbr> The study met its primary endpoint in demonstrating good safety and tolerability in PD patients.<wbr> Exploratory efficacy data showed the anti-dyskinetic effect both on observer and evaluated mAIMS and patient reported diary data (including an effect on motor fluctuations) (poster attached).<wbr></FONT></FONT> </div><div style="margin-bottom: 10px;"><FONT size="3"><FONT face="Calibri">In terms of fipamezole, a study headed by Peter De Witt is in press showing the results of s 4 week 4-arm trial that tested 3 different doses.<wbr> The total population did not show any significant benefit from treatment on the LID scale but a statistically positive finding was found in the US population.<wbr> Poewe&rsquo;s comment was &ldquo;fipamezole is still in the race of potential anti-dyskinetic agents&rdquo;.<wbr></FONT></FONT> </div><div style="margin-bottom: 10px;"><FONT size="3"><FONT face="Calibri">Turning to non-motor PD symptoms Poewe noted that there are two areas with new data, depression and orthostatic hypertension.<wbr> With respect to depression he referred to a trial undertaken by Richard and colleagues which compared the effects of paroxetine and venlaflexine.<wbr> Both antidepressants were found to be efficacious with both the SSRI and the SSNi approach being similarly effective.<wbr></FONT></FONT> </div><div style="margin-bottom: 10px;"><FONT size="3"><FONT face="Calibri">One small study in orthostatic hypertension with Chelsea&rsquo;s droxidopa witnessed a significant improvement in dizziness even though that was not the primary endpoint.<wbr> This formed the basis for a larger randomised study which observed a significant decrease in falls amongst treated patients.<wbr> Poewe suggested that this could be &ldquo;exciting if reproducible&rdquo;.<wbr></FONT></FONT> </div><div style="margin-bottom: 10px;"><FONT size="3"><FONT face="Calibri">Finally, he noted that there is activity in the disease modifying area but that trials are ongoing and that there is no new efficacy data as yet.<wbr></FONT></FONT> </div><div style="margin-bottom: 10px;"><FONT size="3"><FONT face="Calibri"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/6488/4/ScreenCapture4.jpg?user-agent=rss"></FONT></FONT> </div><div style="margin-bottom: 10px;"><FONT size="3"><FONT face="Calibri">Poewe was questioned subsequently about how many trials have or are including pharmacogenomics in their analysis.<wbr> Seemingly not many at the current juncture and that if applied it has been mostly on a post-hoc basis.<wbr> However, he did suggest he expected more to do so more in the future as a number of the regulatory agencies are now insisting that such data should be included in trials.<wbr> What to use for stratification purposes is still a matter of debate other than he suggested for the LRRK2 inhibitors.<wbr></FONT></FONT> </div><div style="margin-bottom: 10px;"><FONT size="3"><FONT face="Calibri">Joaquim Ferraira followed with an overview of non-PD studies largely focusing on the negative outcome in several large Huntington disease trials with Neurosearch&rsquo;s Huntexil and Pfizer/<wbr>Medivation&rsquo;s Dimebon.<wbr> He noted that there are many new trials planned with new compounds now entering clinical development.<wbr> He also highlighted the PREQUEL study which is testing coenzyme Q10 in pre-manifest Huntington disease and the Enroll HD study.<wbr> The latter is a prospective registry study in a global HD cohort, which has the overarching objective of to accelerate the development of therapies for HD by developing a better understanding of the natural history of HD and to expedite recruitment into global clinical trials of candidate therapeutics in the coming years.<wbr></FONT></FONT> </div><div style="margin-bottom: 10px;"><FONT size="3"><FONT face="Calibri">The final session of this plenary focused on clinical trials with DBS surgery amongst which there was some first time<STRONG> &ldquo;really exciting&rdquo; data presented on the earlier use of DBS treatment in Parkinson&rsquo;s disease.<wbr> The EARLYSTIM trial</STRONG> sponsored by the French government has tested the effects of DBS in patients whose PD is deteriorating in terms of the onset of dyskinesias and motor fluctuation but who are at a stage in the disease earlier than when DBS would normally be applied.<wbr> 250 patients were enrolled in the trial at 16 centres in France and Germany.<wbr> Entry criteria were PD&gt;4yrs, dyskinesia and motor fluctuation no longer than 3 yrs.<wbr> and age below 60.<wbr> In fact the patient cohort tested had a mean age of 55, a disease duration of 7.<wbr>3 yrs.<wbr>, dyskinesias for 1.<wbr>5 yrs.<wbr> and motor fluctuations for 1.<wbr>6yrs.<wbr> Patients were randomised to early surgery plus best medical therapy (BMT) or BMT alone.<wbr> The primary endpoint of the study was QOL.<wbr></FONT></FONT> </div><div style="margin-bottom: 10px;"><FONT size="3"><FONT face="Calibri">Interestingly the surgery group showed a dramatic improvement at 5 months in terms of QOL.<wbr> +27% relative to BMT.<wbr> Moreover, UPDRS II, III and IV all were significantly in favour of DBS treatment.<wbr> Gunther Deuschl who presented the data stated that what was surprising was that in all measurements undertaken there was not that much of an improvement with medical therapy.<wbr></FONT></FONT> </div><div style="margin-bottom: 10px;"><FONT size="3"><FONT face="Calibri"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/6488/5/ScreenCapture5.jpg?user-agent=rss"></FONT></FONT> </div><div style="margin-bottom: 10px;"><FONT size="3"><FONT face="Calibri">Serious AEs were not seen with more frequency in one group versus another.<wbr></FONT></FONT> </div><div style="margin-bottom: 10px;"><FONT size="3"><FONT face="Calibri">Interestingly, at its recent investor day Medtronics noted that its DBS business was now growing initial implants faster than it has for some years.<wbr></FONT></FONT> </div><div style="margin-bottom: 10px;"><FONT size="3"><FONT face="Calibri">In the Abbott symposium that followed, Hubert Ferandez presented the latest evidence on levodopa/<wbr>carbidopa intestinal gel (LCIG as it is now know).<wbr> Results from two studies were presented showing a substantial improvement in &ldquo;off time&rdquo; (circa 70%) and improvement in &ldquo;on time&rdquo; without troublesome dyskinesias relative to standard oral L-Dopa treatment.<wbr> The tendency to reverse dyskinesias and to open the therapeutic window does need confirmation in larger studies but in terms of motor fluctuations it was suggested that DBS and LCIG have similar effects.<wbr> A direct head-to-head trial is now planned by Abbott.<wbr></FONT></FONT> </div><div style="margin-bottom: 10px;"><FONT size="3"><FONT face="Calibri"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/6488/6/ScreenCapture6.jpg?user-agent=rss"></FONT></FONT> </div><div style="margin-bottom: 10px;"><FONT size="3"><FONT face="Calibri">The question raised by all advanced therapies is when to use them? </FONT></FONT> </div><div style="margin-bottom: 10px;"><FONT size="3"><FONT face="Calibri">Per Odin (Bremerhaven Germany) suggested that when deciding which CDS therapy to give to an individual many factors come into play.<wbr> The method of administration, effects on motor symptoms and non-motor symptoms, side-effects, complications and patient preference are key.<wbr> Other factors that are important are age, co-morbidities, presence of carer, psychological state and cognitive impairment.<wbr> Per Odin presented a very useful treatment algorithm which is shown below to indicate what tends to be suitable for which type of patient.<wbr></FONT></FONT> </div><div style="margin-bottom: 10px;"><FONT size="3"><FONT face="Calibri"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/6488/7/ScreenCapture7.jpg?user-agent=rss"></FONT></FONT> </div><div style="margin-bottom: 10px;"><FONT size="3"><FONT face="Calibri">Finally, Odin questioned when should advanced therapy be started? He advocated that pump therapies should probably be considered more frequently at an earlier stage in the disease process.<wbr> He claimed that earlier studies should be done as have been undertaken with DBS to see if a new paradigm of care is warranted.<wbr></FONT></FONT> </div><div style="margin-bottom: 10px;"><FONT size="3"><FONT face="Calibri">The last session of the symposium focused on the need for multidisciplinary care for advanced PD.<wbr> Professor Bastiaan stated &ldquo;PD cannot be managed by a neurologist alone a battery of help is needed but at the moment it is not done in an organised way&rdquo;.<wbr></FONT></FONT> </div><div style="margin-bottom: 10px;"><FONT size="3"><FONT face="Calibri">New multidisciplinary guidelines have apparently been released in Holland written by 19 different disciplines and there is growing evidence to support the merit of allied healthcare intervention.<wbr> Patients are demanding a multidisciplinary approach but at the moment there is little evidence to support it.<wbr> The trials are difficult to conduct and hard outcomes difficult to come by.<wbr> He advocated that patients do need to be more active members in the process and noted that Abbott is co-ordinating a shared decision making project whereby patient receive all of the information that doctors receive.<wbr> It is using a web-based approach to do this.<wbr> Finally, he mentioned PARKINSONNET as a new very good collaborative PD tool.<wbr></FONT></FONT> </div><div style="margin-bottom: 10px;"><FONT size="3"><FONT face="Calibri"><STRONG><EM>Cell &amp; Gene Therapy</EM></STRONG></FONT></FONT> </div><div style="margin-bottom: 10px;"><FONT size="3"><FONT face="Calibri">Lorenz Studer (Director of the Sloane Kettering Cell Therapy Unit) initiated the review focusing on progress with stem cell therapy.<wbr> He acknowledged that currently no stem cell therapy actually works but he hopes that such an approach will make a contribution to the treatment of Parkinson&rsquo;s in the future.<wbr> There are a number of different cell types that have been evaluated, options for which include:-</FONT></FONT> </div><div style="margin-bottom: 10px;"><SPAN style="mso-bidi-font-family: Calibri;"><SPAN style="mso-list: Ignore;"><FONT face="Calibri" size="3">i)</FONT> </SPAN></SPAN><FONT size="3"><FONT face="Calibri">Neuro stem cells (adult of fetal).<wbr> These are limited in their capacity to make dopamine cells</FONT></FONT> </div><div style="margin-bottom: 10px;"><SPAN style="mso-bidi-font-family: Calibri;"><SPAN style="mso-list: Ignore;"><FONT face="Calibri" size="3">ii)</FONT> </SPAN></SPAN><FONT size="3"><FONT face="Calibri">Mesenchymal cells (blood, placenta).<wbr> There is no good data to show these have an impact but a no of companies around who are fraudulently trying to sell the concept.<wbr></FONT></FONT> </div><div style="margin-bottom: 10px;"><SPAN style="mso-bidi-font-family: Calibri;"><SPAN style="mso-list: Ignore;"><FONT face="Calibri" size="3">iii)</FONT> </SPAN></SPAN><FONT size="3"><FONT face="Calibri">Pluripotent stem cells .<wbr> This area shows more promise.<wbr></FONT></FONT> </div><div style="margin-bottom: 10px;"><FONT size="3"><FONT face="Calibri">There are two major sources of pluripotent cells: those isolated at a very early stage from an embryo or alternatively those harvested from skin biopsies.<wbr> The latter can be re-programmed to transform them back to a stage which looks like an embryonic stem cell.<wbr> Generating a supply of cells that are developmentally correct from these cells, however, has been difficult until now.<wbr> Advanced Cell Technology appears to be succeeding in producing a reproducible GMP supply having been the first to report clinical data regarding the use of hESCs to treat the eye disease AMD earlier this year.<wbr> It is developing a protocol for clinical consideration for the treatment of PD but determining which patients to include remains a matter for debate.<wbr> </FONT></FONT> </div><div style="margin-bottom: 10px;"><FONT size="3"><FONT face="Calibri">Lorenz Studer noted that his group together with many collaborators (Sonia Kriks, Jae Won Shim) has now developed a method for the efficient generation of authentic midbrain dopamine neurones and that they are aiming to start the first clinical trials in 2016/<wbr>2017.<wbr></FONT></FONT> </div><div style="margin-bottom: 10px;"><FONT size="3"><FONT face="Calibri">William Marks &lsquo; (San Fransisco) presentation followed with an answer to the question &ldquo;Can gene therapies really help patients with Parkinson&rsquo;s disease? &ldquo;Yes probably&rdquo; was his reply.<wbr></FONT></FONT> </div><div style="margin-bottom: 10px;"><FONT size="3"><FONT face="Calibri">Essentially three viral vector approaches have been tried:-</FONT></FONT> </div><div style="margin-bottom: 10px;"><UL style="margin-top: 0cm;" type="disc"><LI style="margin: 0cm 0cm 10pt; mso-list: l0 level1 lfo2;"><FONT size="3"><FONT face="Calibri">STN glutamic acid decarboxylase (so called AAV2 GAD therapy)</FONT></FONT>
</LI>
<LI style="margin: 0cm 0cm 10pt; mso-list: l0 level1 lfo2;"><FONT size="3"><FONT face="Calibri">Putamenal aromatic acid decarboxylase (so called AAV2 AADC therapy)</FONT></FONT>
</LI>
<LI style="margin: 0cm 0cm 10pt; mso-list: l0 level1 lfo2;"><FONT size="3"><FONT face="Calibri">Niagral striatal pathway intervention using AAV2 as a viral vector for nurturin</FONT></FONT>
</LI>
</UL> </div><div style="margin-bottom: 10px;"><FONT size="3"><FONT face="Calibri">The latter he claims looks the most promising with a single treatment of AAV2- NTN (nurturin) offering long-term expression of a therapeutic protein.<wbr> Evidence for long-term safety is also accumulating (n=80pts).<wbr></FONT></FONT> </div><div style="margin-bottom: 10px;"><FONT size="3"><FONT face="Calibri">The first approach with AAV2 GAD therapy, has thus far been the only approach tested under controlled trial conditions.<wbr> The study produced a statistically significant improvement and met its endpoint.<wbr> However, the problem with this approach is you are never quite sure whether you are delivering the therapy to exactly the place that you want it.<wbr></FONT></FONT> </div><div style="margin-bottom: 10px;"><FONT size="3"><FONT face="Calibri">The second approach has also produced some positive data, enough to merit an upcoming study where higher doses will be tested.<wbr> Oxford Biomedica has a similar trial underway with its product ProSavin which has demonstrated a 20-30% improvement in on-time.<wbr></FONT></FONT> </div><div style="margin-bottom: 10px;"><FONT size="3"><FONT face="Calibri">Currently, in terms of AAV2 NTN a phI/<wbr>IIb trial is underway in 61 patients, the results of which should be available in Spring 2013.<wbr> Anecdotally, some nurturin patients have now been followed up for up to 8 yrs in an open-label trial format and some early very severe patients are continuing to do very well.<wbr></FONT></FONT> </div><div style="margin-bottom: 10px;"><FONT size="3"><FONT face="Calibri">Meanwhile, there is an upcoming study of AAV2-GDNF which will start soon and will be funded by the NIH.<wbr></FONT></FONT> </div><div style="margin-bottom: 10px;"><FONT size="3"><FONT face="Calibri">Finally, Thomas Foltynie addressed the million dollar question - whether cell or gene therapies can ever be expected to be competitive with DBS treatment? He suggested it depends on what you use as the comparison</FONT></FONT> </div><div style="margin-bottom: 10px;"><SPAN style="mso-bidi-font-family: Calibri;"><SPAN style="mso-list: Ignore;"><FONT face="Calibri" size="3">i)</FONT> </SPAN></SPAN><FONT size="3"><FONT face="Calibri">Symptomatic treatment &ndash; efficacy and safety</FONT></FONT> </div><div style="margin-bottom: 10px;"><SPAN style="mso-bidi-font-family: Calibri;"><SPAN style="mso-list: Ignore;"><FONT face="Calibri" size="3">ii)</FONT> </SPAN></SPAN><FONT size="3"><FONT face="Calibri">Disease modifying properties</FONT></FONT> </div><div style="margin-bottom: 10px;"><SPAN style="mso-bidi-font-family: Calibri;"><SPAN style="mso-list: Ignore;"><FONT face="Calibri" size="3">iii)</FONT> </SPAN></SPAN><FONT size="3"><FONT face="Calibri">Commercial issues &ndash; competing with the big boys.<wbr></FONT></FONT> </div><div style="margin-bottom: 10px;"><FONT size="3"><FONT face="Calibri">He noted that DBS produces very good resolution of L-Dopa induced dyskinesias.<wbr> However, there has been no double-blind component to any DBS trial.<wbr> In that sense comparisons with gene therapy are unfair as these have uncovered some of the functional changes that can be seen with placebo.<wbr></FONT></FONT> </div><div style="margin-bottom: 10px;"><FONT size="3"><FONT face="Calibri">He provided an interesting comparison of changes in UPDRS III scores, highlighting how with DBS you can observe a &gt;than 50% improvement which can be durable for up to 8 years, whereas with Prosavin (Oxford Biotech) so far only a 30% improvement has been seen and with GAD around 25%.<wbr> Hence, in his opinion the improvements seen so far do NOT compete in terms of symptomatic efficacy.<wbr> He suggests that as of today the bar for achieving superior efficacy is already high.<wbr> All technologies are trying to improve control but not necessarily achieving this.<wbr> However, he acknowledged that efficacy is not the only important factor with safety, ease of use and cost of therapy important considerations.<wbr></FONT></FONT> </div><div style="margin-bottom: 10px;"><FONT size="3"><FONT face="Calibri">From a safety perspective, DBS can be associated with speech impediment, verbal fluency issues and a risk of infection.<wbr> With cell therapy there may be a risk of graft induced dyskinesia, whereas gene therapy to date appears very safe.<wbr></FONT></FONT> </div><div style="margin-bottom: 10px;"><FONT size="3"><FONT face="Calibri">When it comes to disease modification, DBS may have shown some properties in animal studies but it was felt unlikely to demonstrate any effect in humans.<wbr> Little is currently known about the other two approaches.<wbr></FONT></FONT> </div><div style="margin-bottom: 10px;"><FONT size="3"><FONT face="Calibri"><STRONG><EM>So where next? </EM></STRONG></FONT></FONT> </div><div style="margin-bottom: 10px;"><FONT size="3"><FONT face="Calibri">In terms of Prosavin, higher doses will be tested to see if you can achieve better symptomatic control.<wbr> The nurturin approach, he suggested, may prove better in an earlier treatment setting.<wbr> Meanwhile, it was noted that the manufacturers of DBS are not standing still with PPN potentially helpful in terms of treating DA refractory gait problems and EARLYSTIM maybe heralding the treatment of earlier stage PD patients.<wbr></FONT></FONT> </div><div style="margin-bottom: 10px;"><FONT size="3"><FONT face="Calibri">Commercially, all gene therapy manufacturers face the issue of scalability and one, Neurologix, recently went into administration due to lack of financial resourced to take its programme forward.<wbr> </FONT></FONT> </div><div style="margin-bottom: 10px;"><FONT size="3"><FONT face="Calibri">Concluding the session, Foltynie&rsquo;s expressed his belief that neither cell or gene therapy will compete in the advanced disease treatment area but that they may offer more promise at an earlier stage of the disease.<wbr> Currently, he stated &ldquo;the same patients are suitable for all three approaches but the vast majority of patients are not suitable for any&rdquo;.<wbr> He noted that at Queen&rsquo;s Square the vast majority of his patients are young onset patients with severe motor problems who have had the disease for years.<wbr> They are not representative of the wider population.<wbr> Similarly, those with gene mutations such LRRK2 are overrepresented in his cohorts but treating them will not tell us what will be useful in the wider community.<wbr></FONT></FONT> </div><div style="margin-bottom: 10px;"><FONT size="3"><FONT face="Calibri"><STRONG><EM>Translational Science Breakthroughs</EM></STRONG></FONT></FONT> </div><div style="margin-bottom: 10px;"><FONT size="3"><FONT face="Calibri">One of the more fascinating sessions of the conference was John Tojanowski&rsquo;s presentation on re-engineering translational sciences: New approached to the development of diagnostics and therapeutics in neurodegenerative disorders.<wbr></FONT></FONT> </div><div style="margin-bottom: 10px;"><FONT size="3"><FONT face="Calibri">Tojanowski noted the &ldquo;stunning outcome&rdquo; of the ADNI-1 public private initiative which was launched in 2004 and then renewed in Oct 2010 in identifying potential early biomarkers of Alzheimer&rsquo;s disease, highlighting how we now face a new era in Alzheimer&rsquo;s diagnostics which is focused on CSF, TAU &amp; alpha-beta 1-42 and how the pathology plays out 10-15 years in the brain before clinical symptoms emerge.<wbr> First comes the Tau pathology followed by the alpha-beta pathology.<wbr></FONT></FONT> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/6488/8/ScreenCapture8.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><FONT size="3"><FONT face="Calibri">The same situation is now starting to play out now for Parkinson&rsquo;s disease under an initiative led by &hellip; and funded by Michael J Fox.<wbr> The same approach is being applied as was adopted by the ADNE projects involving 21 sites in the US &amp; EU.<wbr> The first data was presented at the meeting with the key data shown below.<wbr></FONT></FONT> </div><div style="margin-bottom: 10px;"><FONT size="3"><FONT face="Calibri"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/6488/9/ScreenCapture9.jpg?user-agent=rss"></FONT></FONT> </div><div style="margin-bottom: 10px;"><FONT size="3"><FONT face="Calibri"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/6488/10/ScreenCapture10.jpg?user-agent=rss"></FONT></FONT> </div><div style="margin-bottom: 10px;"><FONT size="3"><FONT face="Calibri">Returning to the Alzheimer situation, he noted that thinking about TAU would have generated laughter and mirth 10 years ago but as of today many companies now have TAU programmes.<wbr> He proceeded to outline a concept of pursuing restoration of Tau function through microtubule stabilisation; especially as axonal transport is impaired.<wbr> He described a series of experiments that have been undertaken and remarkably shown that by administering a microtubule stabiliser in mouse models of tauopathy you can increase microtubule nos.<wbr> Epotholone D has performed exceptionally well in this mouse model and moreover has good brain barrier penetration producing and effect Tojanowski described as &ldquo;an effect to die for&rdquo; On the basis of these fascinating results, BMS has launched a trial of its epotholone in Alzheimer&rsquo;s disease.<wbr> The expectation is that this approach could have a benefit in other neurodegenerative diseases even possibly in Parkinson&rsquo;s disease.<wbr></FONT></FONT> </div><div style="margin-bottom: 10px;"><FONT size="3"><FONT face="Calibri">In summary preclinical data has shown that EPO D </FONT></FONT> </div><div style="margin-bottom: 10px;"><UL><LI><FONT size="3"><FONT face="Calibri">Attenuates dystrophic axons in mouse model of tauopathy@12 months</FONT></FONT>
</LI>
<LI><FONT size="3"><FONT face="Calibri">Recovers MT density in PS19 mice</FONT></FONT>
</LI>
<LI><FONT size="3"><FONT face="Calibri">Reduces TAU pathology in PS19 mice at 12 months of age</FONT></FONT>
</LI>
<LI><FONT size="3"><FONT face="Calibri">Improves working and spatial learning in aged TAU mice</FONT></FONT>
</LI>
<LI><FONT size="3"><FONT face="Calibri">No detectable toxicity observed</FONT></FONT>
</LI>
</UL> </div><div style="margin-bottom: 10px;"><FONT size="3"><FONT face="Calibri"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/6488/11/ScreenCapture11.jpg?user-agent=rss"></FONT></FONT> </div><div style="margin-bottom: 10px;"><FONT size="3"><FONT face="Calibri"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/6488/12/ScreenCapture12.jpg?user-agent=rss"></FONT></FONT> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/6488/13/ScreenCapture13.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/6488/14/ScreenCapture14.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><FONT size="3"><FONT face="Calibri"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/6488/15/ScreenCapture15.jpg?user-agent=rss"></FONT></FONT> </div><div style="margin-bottom: 10px;"><FONT size="3"><FONT face="Calibri">Finally, Virginia Lee (Philadelphia) presented data on a working model of the spready of alpha-synuclein pathology demonstrating how cells that have lewy bodies may spread and how Tau spreads in PD as the disease progresses.<wbr></FONT></FONT> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/6488/16/ScreenCapture16.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/6488/17/ScreenCapture17.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/6488/18/ScreenCapture18.jpg?user-agent=rss"> </div><div><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/6488/19/ScreenCapture19.jpg?user-agent=rss"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/6488/20/ScreenCapture20.jpg?user-agent=rss"> </div><!-- Comment details --><a name="neurology6488attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/6488/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(32,5 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/6488/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(36,4 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/6488/3/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(34,3 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/6488/4/ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(26,7 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/6488/5/ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(24,1 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/6488/6/ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(134,2 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/6488/7/ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(56 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/6488/8/ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(49,2 KB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/6488/9/ScreenCapture9.jpg">ScreenCapture9.jpg</a>&nbsp;&nbsp;(38,9 KB)<br>&nbsp;&nbsp;10.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/6488/10/ScreenCapture10.jpg">ScreenCapture10.jpg</a>&nbsp;&nbsp;(57,9 KB)<br>&nbsp;&nbsp;11.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/6488/11/ScreenCapture11.jpg">ScreenCapture11.jpg</a>&nbsp;&nbsp;(59,8 KB)<br>&nbsp;&nbsp;12.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/6488/12/ScreenCapture12.jpg">ScreenCapture12.jpg</a>&nbsp;&nbsp;(49,1 KB)<br>&nbsp;&nbsp;13.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/6488/13/ScreenCapture13.jpg">ScreenCapture13.jpg</a>&nbsp;&nbsp;(62 KB)<br>&nbsp;&nbsp;14.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/6488/14/ScreenCapture14.jpg">ScreenCapture14.jpg</a>&nbsp;&nbsp;(59,7 KB)<br>&nbsp;&nbsp;15.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/6488/15/ScreenCapture15.jpg">ScreenCapture15.jpg</a>&nbsp;&nbsp;(61,8 KB)<br>&nbsp;&nbsp;16.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/6488/16/ScreenCapture16.jpg">ScreenCapture16.jpg</a>&nbsp;&nbsp;(59,2 KB)<br>&nbsp;&nbsp;17.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/6488/17/ScreenCapture17.jpg">ScreenCapture17.jpg</a>&nbsp;&nbsp;(69,7 KB)<br>&nbsp;&nbsp;18.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/6488/18/ScreenCapture18.jpg">ScreenCapture18.jpg</a>&nbsp;&nbsp;(61,5 KB)<br>&nbsp;&nbsp;19.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/6488/19/ScreenCapture19.jpg">ScreenCapture19.jpg</a>&nbsp;&nbsp;(65,9 KB)<br>&nbsp;&nbsp;20.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/6488/20/ScreenCapture20.jpg">ScreenCapture20.jpg</a>&nbsp;&nbsp;(65,9 KB)<br>&nbsp;&nbsp;21.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/6488/21/Efficacy%20of%20Novartis%27s%20mGLUR5%20in%20PD%20%2d%20June%202012.pdf">Efficacy of Novartis's mGLUR5 in PD - June 2012.pdf</a>&nbsp;&nbsp;(226,3 KB)<br>&nbsp;&nbsp;22.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/6488/22/Effect%20of%20IPX006%20on%20motor%20fluctuations%20%2d%20June%202012.pdf">Effect of IPX006 on motor fluctuations - June 2012.pdf</a>&nbsp;&nbsp;(167,4 KB)<br>&nbsp;&nbsp;23.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/6488/23/Efficacy%20of%20Merck%27s%20Preladenant%20%2d%20June%202012.pdf">Efficacy of Merck's Preladenant - June 2012.pdf</a>&nbsp;&nbsp;(177,2 KB)<br>&nbsp;&nbsp;24.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/6488/24/Efficacy%20of%20Addex%27s%20mGLuR5%20in%20LID%20%2d%20June%202012.pdf">Efficacy of Addex's mGLuR5 in LID - June 2012.pdf</a>&nbsp;&nbsp;(198,1 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120831&edate=20120501&rec=6488">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-06-29T17:41:48+02:00</dc:date><dc:creator>jac89886</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/6488/1/ScreenCapture1.jpg" length="33279" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/6488/2/ScreenCapture2.jpg" length="37243" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/6488/3/ScreenCapture3.jpg" length="35092" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/6488/4/ScreenCapture4.jpg" length="27373" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/6488/5/ScreenCapture5.jpg" length="24667" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/6488/6/ScreenCapture6.jpg" length="137423" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/6488/7/ScreenCapture7.jpg" length="57331" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/6488/8/ScreenCapture8.jpg" length="50399" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/6488/9/ScreenCapture9.jpg" length="39843" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/6488/10/ScreenCapture10.jpg" length="59303" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/6488/11/ScreenCapture11.jpg" length="61238" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/6488/12/ScreenCapture12.jpg" length="50274" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/6488/13/ScreenCapture13.jpg" length="63493" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/6488/14/ScreenCapture14.jpg" length="61170" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/6488/15/ScreenCapture15.jpg" length="63261" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/6488/16/ScreenCapture16.jpg" length="60661" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/6488/17/ScreenCapture17.jpg" length="71344" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/6488/18/ScreenCapture18.jpg" length="62947" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/6488/19/ScreenCapture19.jpg" length="67450" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/6488/20/ScreenCapture20.jpg" length="67486" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/6488/21/Efficacy%20of%20Novartis%27s%20mGLUR5%20in%20PD%20%2d%20June%202012.pdf" length="231759" type="application/pdf"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/6488/22/Effect%20of%20IPX006%20on%20motor%20fluctuations%20%2d%20June%202012.pdf" length="171389" type="application/pdf"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/6488/23/Efficacy%20of%20Merck%27s%20Preladenant%20%2d%20June%202012.pdf" length="181434" type="application/pdf"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/6488/24/Efficacy%20of%20Addex%27s%20mGLuR5%20in%20LID%20%2d%20June%202012.pdf" length="202905" type="application/pdf"/></item><item>
<title>New Trial of Daewoong's Botulinum Toxin for Glabellar Line [headline, sub:Aesthetics, class:BotulinumToxins, :PharmaWorld:sub:ClinicalTrial, :PharmaWorld:mkt:Korea, :PharmaWorld:mkt:Intercontinental, comp:Allergan, prod:Botox]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology6487</link>
<description>New Trial of Daewoong's Botulinum Toxin for Glabellar Line [headline, sub:Aesthetics, class:BotulinumToxins, :PharmaWorld:sub:ClinicalTrial, :PharmaWorld:mkt:Korea, :PharmaWorld:mkt:Intercontinental, comp:Allergan, prod:Botox]</description><comments>http://ci.beaufour-ipsen.com/traction/permalink/Neurology6487</comments><category>headline</category><category>sub:Aesthetics</category><category>class:BotulinumToxins</category><category>sub:ClinicalTrial</category><category>mkt:Korea</category><category>mkt:Intercontinental</category><category>comp:Allergan</category><category>prod:Botox</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology6487</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120831&edate=20120501&rec=6487">New Trial of Daewoong's Botulinum Toxin for Glabellar Line</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=class%3aBotulinumToxins"><font color="#e95e0b">:Neurology:class:BotulinumToxins</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=comp%3aAllergan"><font color="#e95e0b">:Neurology:comp:Allergan</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=headline"><font color="#e95e0b">:Neurology:headline</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=prod%3aBotox"><font color="#e95e0b">:Neurology:prod:Botox</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=sub%3aAesthetics"><font color="#e95e0b">:Neurology:sub:Aesthetics</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=mkt%3aIntercontinental"><font color="#e95e0b">:PharmaWorld:mkt:Intercontinental</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=mkt%3aKorea"><font color="#e95e0b">:PharmaWorld:mkt:Korea</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=sub%3aClinicalTrial"><font color="#e95e0b">:PharmaWorld:sub:ClinicalTrial</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology6487">Neurology6487</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 29 June 2012 | 17:17</font><br><br><div style="margin-bottom: 10px;">Comment: Just listed in clinicaltrials.<wbr>gov, the Ph3 study which started in March is designed to evaluate the efficacy and safety of Daewoong's DWP450 compared with Botox in patients with moderate to severe glabellar line.<wbr> Whilst highlighted in a recent report dated June 28 by Tongyang Securities as a "2013 catalyst" for the company, there has been no previous published reference to this toxin that may allow its identification.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Study Details - </FONT></STRONG><A href="http://clinicaltrials.gov/ct2/show/NCT01629875?term=toxin&amp;recr=Open&amp;fund=2&amp;rank=44"><STRONG><FONT size="3">NCT01629875</FONT></STRONG></A> </div><div style="margin-bottom: 10px;">Reference is made to the toxin being a generic equivalent of clostridium botulinum toxin A </div><div style="margin-bottom: 10px;">- Primary Outcome Measures: At 4 wks, glabellar line improvement rate at max.<wbr> frown confirmed with investigator's live severity assessment.<wbr> </div><div style="margin-bottom: 10px;">- Secondary Outcome Measure: At 8,12 &amp; 16 weeks glabellar line improvement rate at max.<wbr> frown confirmed with investigators's live severity assessment </div><div style="margin-bottom: 10px;">- Recruitment: approx.<wbr> 268 participants </div><div style="margin-bottom: 10px;">- Started in March 2012 - Completion date : Dec.<wbr> 2012 </div><div>Location: Rep of Korea (Chung-Ang U.<wbr> Hospital) </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Neurology6600c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">At CPhI (Oct.<wbr> 9th /<wbr> Madrid), we have learnt that the toxin was produced by Daewoong (in Korea).<wbr> DW BTX-A is expected to be registered by the Korean FDA in 2013 for GL.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Next Indications : </STRONG>Blepharospasm, sweating, CD, upper motor neuron syndrome and chronic migraine are part of the development program of the drug in a near future.<wbr> </div><div>When questionned if the toxin may come from a patnership/<wbr>technology transfer agreement with Medy-Tox, a representative of Daewoong denied, and accentuated that DW BTX-A is a proprietary product from its company.<wbr> </div><font size="-1">Brigitte DESCHAMPS / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology6600" class="commentpermalink">Neurology6600</a> / <span class="date">10 October 2012</span> /
<span class="time">17:44:19 o'clock CEST</span>
</font></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120831&edate=20120501&rec=6487">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-06-29T17:17:33+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>re: Intelligence From MDS Part 1 - Botulinum Toxin Company Activity</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology6483</link>
<description>re: Intelligence From MDS Part 1 - Botulinum Toxin Company Activity</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology6483</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120831&edate=20120501&rec=6483">re: Intelligence From MDS Part 1 - Botulinum Toxin Company Activity</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology6483">Neurology6483</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/861">siy15897</a> | 29 June 2012 | 16:31</font><br><br><div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Intelligence From MDS Part 1 - Botulinum Toxin Company Activity</span>&nbsp;<font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=Alert"><font color="#e95e0b">:Neurology:Alert</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=comp%3aAllergan"><font color="#e95e0b">:Neurology:comp:Allergan</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=comp%3aMerz"><font color="#e95e0b">:Neurology:comp:Merz</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=dis%3aDystonia"><font color="#e95e0b">:Neurology:dis:Dystonia</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=dis%3aSpasticity"><font color="#e95e0b">:Neurology:dis:Spasticity</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=prod%3aBotox"><font color="#e95e0b">:Neurology:prod:Botox</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=prod%3aXeomin"><font color="#e95e0b">:Neurology:prod:Xeomin</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=congress%3aMDS"><font color="#e95e0b">:PharmaWorld:congress:MDS</font></a>]</font></font><br><span style="font-size: 12px;"><FONT size="3"><FONT face="Calibri">Comment: MDS this year was well attended with no of attendees in excess of 5000.<wbr> All three major toxin companies were exhibiting but the oral presentations focused on toxin science were limited, with more activity/<wbr>interest centred around the corporate symposium and the poster presentations.<wbr> We did, however, learn that Merz is soon to file for approval of a label amendment to include data from its flexible dosing studies in CD and blepharospasm.<wbr> </FONT></FONT></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120831&edate=20120501&rec=6473">...</a><br><font size="-1">Jacquelyne CANTLE MEYRICK / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology6473" class="commentpermalink">Neurology6473</a> / <span class="date">26 June 2012</span> /
<span class="time">17:27:32 o'clock CEST</span>
</font></div><div style="margin-bottom: 10px;">Very helpful.<wbr> Nice job team.<wbr> We need to tackle the Marchetti paper Allergan keeps using.<wbr> Allergans position is paradoxical as we heard at their symposium in Dublin.<wbr> </div><div style="margin-bottom: 10px;">On one hand, they agree that there is no conversion ratio, on the other hand, they consistently show the Marchetti paper results in a way that implies that this is high quality clinical research (even though it is a retrospective review and that the dose conversion ratio is on average 4-5:1 or higher which is both dangerous for our patients and destroys our value proposition.<wbr> I was glad to see the Korean study demonstrating 2.<wbr>5:1 ratio with encouraging results in this meeting.<wbr> </div><div>Overall at the MDS I felt the star of Ipsen and Dysport was shining.<wbr> We had a full attendance to our symposia, best booth location and several posters from US affiliate with Anchor-CD study.<wbr> </div><!-- Comment details --><font size="-1">siy15897 / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology6483" class="commentpermalink">Neurology6483</a> / <span class="date">29 June 2012</span> /
<span class="time">16:31:07 o'clock CEST</span>
</font><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120831&edate=20120501&rec=6483">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology6473">View thread  Neurology6473: Intelligence From MDS Part 1 - Botulinum Toxin Company Activity</a>]]></content:encoded><dc:date>2012-06-29T16:31:07+02:00</dc:date><dc:creator>siy15897</dc:creator></item><item>
<title>Astellas Boosts its Foothold in Urology [comp:Astellas, :PharmaWorld:mkt:NorthAmerica]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology8362</link>
<description>Astellas Boosts its Foothold in Urology [comp:Astellas, :PharmaWorld:mkt:NorthAmerica]</description><comments>http://ci.beaufour-ipsen.com/traction/permalink/Oncology8362</comments><category>comp:Astellas</category><category>mkt:NorthAmerica</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology8362</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8362">Astellas Boosts its Foothold in Urology</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=comp%3aAstellas"><font color="#e95e0b">:Oncology:comp:Astellas</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=mkt%3aNorthAmerica"><font color="#e95e0b">:PharmaWorld:mkt:NorthAmerica</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8362">Oncology8362</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 29 June 2012 | 11:20</font><br><br><div style="margin-bottom: 10px;">Comment: The FDA has approved Astellas' mirabegron (once-daily pill) for OAB.<wbr> The drug launch is set for Oct-Dec, and will be sold as Myrbetriq.<wbr> The company expects the drug to drive synergy with Vesicare (which has top brand market share at 23%).<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Drug Status</FONT></STRONG> </div><div style="margin-bottom: 10px;">In Japan: launched on Sept.<wbr> 2011 as Betanis </div><div style="margin-bottom: 10px;">In EU: MAA filed on Aug.<wbr> 2011 </div><div style="margin-bottom: 10px;">Ph2 studies on combined use with Vesicare are ongoing (completion estimated this month) </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Next Approvals in Onco-Uro</FONT></STRONG> </div><div style="margin-bottom: 10px;">Enzalutamide/<wbr>MDV3100 (prostate cancer) : US filing on May 21 - EU filing on June 26 </div><div>Tivozanib (RCC): EU/<wbr>US filing expected in Q3:12 </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Oncology8366c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">According to FirstWord global sales of Myrbetriq are anticipated to reach approximately $600 million in 2016.<wbr> The product is expected to be a key profit driver for Astellas, being both developed in-house and given the opportunity for it to be marketed in close conjunction with its other OAB treatment, Vesicare, and a number of other urology brands.<wbr>  US launch of the product is expected during the third quarter.<wbr> </div><div style="margin-bottom: 10px;">Analysts at JP Morgan had predicted a short delay prior to approval, due to concerns being raised about elevated heart rate at an FDA advisory panel meeting in April.<wbr> </div><div style="margin-bottom: 10px;">Approval of Myrbetriq is also notable given Astellas' relatively weak in house-R&amp;D pipeline, said analysts at Morgan Stanley.<wbr> </div><div>Source: FirstWord 29 June 2012 </div><font size="-1">Alison Attard / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8366" class="commentpermalink">Oncology8366</a> / <span class="date">02 July 2012</span> /
<span class="time">10:55:41 o'clock CEST</span>
</font></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8362">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-06-29T11:20:48+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Gonax (Degarelix 1M) Approved in Japan [comp:Astellas, dis:Prostate, :PharmaWorld:mkt:Japan]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology8361</link>
<description>Gonax (Degarelix 1M) Approved in Japan [comp:Astellas, dis:Prostate, :PharmaWorld:mkt:Japan]</description><category>comp:Astellas</category><category>dis:Prostate</category><category>mkt:Japan</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology8361</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8361">Gonax (Degarelix 1M) Approved in Japan</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=comp%3aAstellas"><font color="#e95e0b">:Oncology:comp:Astellas</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=mkt%3aJapan"><font color="#e95e0b">:PharmaWorld:mkt:Japan</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8361">Oncology8361</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 29 June 2012 | 09:29</font><br><br><div style="margin-bottom: 10px;">Comment: Astellas' Gonax 80mg/<wbr>120mg (degarelix, sub; inj.<wbr>) was granted Japanese marketing approval for prostate cancer.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Regulatory Pathway</FONT></STRONG> </div><div style="margin-bottom: 10px;">End of 2010, Astellas submitted an application based on the results of Ph1 and Ph2 studies in Japan and abroad Ph3 data (skipping the Ph3 study in Japan).<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Business Development</FONT></STRONG> </div><div>Astellas holds exclusive rights to dev.<wbr> and market degarelix for the treatment of prostate cancer in Japan.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8361">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-06-29T09:29:33+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Civitas Therapeutics Initiates PhII Study For Parkinson Disease [dis:Parkinson, news]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology6481</link>
<description>Civitas Therapeutics Initiates PhII Study For Parkinson Disease [dis:Parkinson, news]</description><comments>http://ci.beaufour-ipsen.com/traction/permalink/Neurology6481</comments><category>dis:Parkinson</category><category>news</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology6481</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120831&edate=20120501&rec=6481">Civitas Therapeutics Initiates PhII Study For Parkinson Disease</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=dis%3aParkinson"><font color="#e95e0b">:Neurology:dis:Parkinson</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=news"><font color="#e95e0b">:Neurology:news</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology6481">Neurology6481</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 28 June 2012 | 17:43</font><br><br><div style="margin-bottom: 10px;">Comment: Civitas has announced the initiation of a phase 2 a clinical trial 
evaluating its pulmonary inhaled formulation of L-Dopa CVT-301 as an adjunctive 
treatment to oral L-Dopa.<wbr> Funding for the study is being  provided by the 
Michael J Fox Foundation.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Study Design</STRONG> </div><div style="margin-bottom: 10px;"><P align="left">The Phase 2a study is a randomized, placebo-controlled, single 
dose, cross-over design that will characterize the safety and tolerability of 
CVT-301 and evaluate pharmacodynamic effects and L-dopa pharmacokinetics in 
patients with Parkinson’s disease with motor fluctuations</P> </div><div style="margin-bottom: 10px;"><P align="left">It is designed to establish the dose for future clinical 
trials with CVT-301.<wbr> Patients will receive oral Sinemet®, inhaled placebo and 
CVT-301 which will be followed by serial evaluations of Ldopa pharmacokinetics, 
motor response and safety at each visit.<wbr> Twenty-four patients will be 
enrolled.<wbr></P> </div><div style="margin-bottom: 10px;"><P align="left"><STRONG>What Is Different About CVT-301</STRONG></P> </div><div style="margin-bottom: 10px;"><P align="left">it is an inhaled formulation of L-dopa designed to 
produce immediate relief from debilitating motor fluctuations associated with 
Parkinson’s disease.<wbr> For symptomatic relief, patients receive oral 
L-dopa to maintain dopamine levels in the brain above the therapeutic 
threshold.<wbr> However, the efficacy of oral L-dopa is significantly compromised by 
delayed absorption and excessive variability in the circulating plasma drug 
concentrations inherent to the oral delivery route.<wbr> </P> </div><div style="margin-bottom: 10px;"><P align="left">CVT-301 has been developed utilising Civitas proprietary 
ARCUS Technology which is capable of <FONT face="ArialMT" size="2"><FONT face="ArialMT" size="2">delivering a precise dose to the deep 
lung for rapid and predictable L-dopa absorption.<wbr> </FONT></FONT></P> </div><div style="margin-bottom: 10px;"><P align="left"><FONT face="ArialMT" size="2"><FONT face="ArialMT" size="2">In preclinical 
models, CVT-301 has demonstrated rapid, durable symptomatic relief,even when 
compared to larger doses of oral L-dopa.<wbr> A phase I study has also been 
completed demonstrating PK proof-of-concept.<wbr> Therapeutic plasma 
levels of L-dopa were achieved within five minutes of inhalation dosing 
and dose proportional pharmacokinetics were seen across all doses tested.<wbr> 
</FONT></FONT></P> </div><div style="margin-bottom: 10px;"><P align="left"><STRONG>Place In Treatment Paradigm</STRONG></P> </div><div style="margin-bottom: 10px;"><P align="left">As tomorrow's Traction review of PD therapeutics will 
demonstrate, there are many treatments trying to compete in the advanced disease 
PD space to improve control of motor fluctuations both oral treatments and more 
complex therapies such as DBS and LCIG.<wbr> Interestingly, the latter may start to 
move forward into an earlier treatment paradigm.<wbr> However, the beauty of the 
Civitas approach may be the simplicity with which it can be administered and the 
realiability of the response, something that not all oral therapies are capable 
of delivering.<wbr> </P> </div><div><P align="left">Source:www.<wbr>civitastherapeutics.<wbr>com</P> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Neurology7130c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">Civitas has initiated a Ph2b for CVT-301 in the USA and EU to test the efficacy, safety and tolerability of the drug in the treatment of intermittent OFF episodes.<wbr> </div><div style="margin-bottom: 10px;">Recruitment: approx 80 patients </div><div style="margin-bottom: 10px;">Preliminary data: H1 14 </div><div>Drug Characteristics: ease of use; simple ARCUS(R) inhaler; allows whenever and whereever use.<wbr> </div><font size="-1">Brigitte DESCHAMPS / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7130" class="commentpermalink">Neurology7130</a> / <span class="date">05 September 2013</span> /
<span class="time">16:57:33 o'clock CEST</span>
</font></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120831&edate=20120501&rec=6481">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-06-28T17:43:48+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>Sales of Microrelin Temporiraly Suspended in Iran [comp:PooyeshDarou, prod:Triptorelin, Alert, :PharmaWorld:mkt:Intercontinental, :PharmaWorld:func:Sales]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/DKPHybrids151</link>
<description>Sales of Microrelin Temporiraly Suspended in Iran [comp:PooyeshDarou, prod:Triptorelin, Alert, :PharmaWorld:mkt:Intercontinental, :PharmaWorld:func:Sales]</description><category>comp:PooyeshDarou</category><category>prod:Triptorelin</category><category>Alert</category><category>mkt:Intercontinental</category><category>func:Sales</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/DKPHybrids151</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=DKPHybrids&sdate=20120831&edate=20120501&rec=151">Sales of Microrelin Temporiraly Suspended in Iran</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=DKPHybrids&sdate=20120831&edate=20120501&cat=Alert"><font color="#e95e0b">:DKPHybrids:Alert</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=DKPHybrids&sdate=20120831&edate=20120501&cat=comp%3aPooyeshDarou"><font color="#e95e0b">:DKPHybrids:comp:PooyeshDarou</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=DKPHybrids&sdate=20120831&edate=20120501&cat=prod%3aTriptorelin"><font color="#e95e0b">:DKPHybrids:prod:Triptorelin</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=func%3aSales"><font color="#e95e0b">:PharmaWorld:func:Sales</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=mkt%3aIntercontinental"><font color="#e95e0b">:PharmaWorld:mkt:Intercontinental</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/DKPHybrids151">DKPHybrids151</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 28 June 2012 | 14:40</font><br><br><div style="margin-bottom: 10px;">Comment: Thanks to our partner in Iran and Matthieu Raimbault (Director, Turkey &amp; Iran Alliances) we have learnt that the Head of Drug Supervision and Evaluation of MOH has recently requested the recall of Microrelin 3.<wbr>75mg from the market for "quality problems".<wbr> Whilst the exact reasons have not been very well known yet, it is assumed that one possible might be the blocking of the needle during the injection.<wbr> An update will be provided as soon as we capture more information.<wbr> </div><div style="margin-bottom: 10px;">One box of Microrelin contains the same syringe (for reconstitution AND injection).<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/dkphybrids/151/1/ScreenCapture1.jpg?user-agent=rss"> </div><div>The recall affecting the batch N°BPD111, from which all the sales since December 2011 have come from, temporarily prevents Pooyesh Darou from selling Microrelin 3.<wbr>75mg.<wbr> </div><!-- Comment details --><a name="dkphybrids151attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/dkphybrids/151/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(29,1 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=DKPHybrids&sdate=20120831&edate=20120501&rec=151">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-06-28T14:40:08+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/dkphybrids/151/1/ScreenCapture1.jpg" length="29750" type="image/jpeg"/></item><item>
<title>re: NICE Reverses Opinion And Agrees To Fund Zytiga Under the NHS</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology8360</link>
<description>re: NICE Reverses Opinion And Agrees To Fund Zytiga Under the NHS</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology8360</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8360">re: NICE Reverses Opinion And Agrees To Fund Zytiga Under the NHS</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8360">Oncology8360</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 28 June 2012 | 12:49</font><br><br><div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">NICE Reverses Opinion And Agrees To Fund Zytiga Under the NHS</span>&nbsp;<font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=class%3aAntihormonals"><font color="#e95e0b">:Oncology:class:Antihormonals</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=news"><font color="#e95e0b">:Oncology:news</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=prod%3aZytiga"><font color="#e95e0b">:Oncology:prod:Zytiga</font></a>]</font></font><br><span style="font-size: 12px;">Comment: After further consultation between NICE and J&amp;J during which J&amp;J has agreed a revised patient access scheme with the Department of Health which makes abiraterone (Zytiga) available at a discount price, NICE has agreed to recommend the use of the drug for the treatment of post-docetaxel CRPC.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8279">...</a><br><font size="-1">Jacquelyne CANTLE MEYRICK / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8279" class="commentpermalink">Oncology8279</a> / <span class="date">16 May 2012</span> /
<span class="time">15:04:08 o'clock CEST</span>
</font></div><div style="margin-bottom: 10px;">On June 28th, NICE issued its final guidance recommending abiraterone (Zytiga, Janssen) in combination with prednisone for mCRPC post docetaxel.<wbr> </div><div>Information provided by Janssen enabled the committee to recommend the drug for use on the NHS.<wbr> </div><!-- Comment details --><font size="-1">Brigitte DESCHAMPS / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8360" class="commentpermalink">Oncology8360</a> / <span class="date">28 June 2012</span> /
<span class="time">12:49:08 o'clock CEST</span>
</font><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8360">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8279">View thread  Oncology8279: NICE Reverses Opinion And Agrees To Fund Zytiga Under the NHS</a>]]></content:encoded><dc:date>2012-06-28T12:49:08+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>M Zügel to Leave Merz Next Month [sub:People, :Neurology:comp:Merz]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld9962</link>
<description>M Zügel to Leave Merz Next Month [sub:People, :Neurology:comp:Merz]</description><category>sub:People</category><category>comp:Merz</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld9962</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120831&edate=20120501&rec=9962">M Zügel to Leave Merz Next Month</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=comp%3aMerz"><font color="#e95e0b">:Neurology:comp:Merz</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=sub%3aPeople"><font color="#e95e0b">:PharmaWorld:sub:People</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld9962">PharmaWorld9962</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 28 June 2012 | 12:38</font><br><br><div style="margin-bottom: 10px;">Comment: M Zügel will be replaced by Philip Buchard.<wbr> The transition will start on July 1, 2012.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Ph Buchard's Bio</FONT></STRONG> </div><div style="margin-bottom: 10px;">- Began his professional career in the U.<wbr>S.<wbr> at Hoechst.<wbr> </div><div style="margin-bottom: 10px;">- After several assignments in Germany and abroad, he became Managing Director for Germany in 2002 at AstraZeneca, where he held various international positions over the past ten years.<wbr> </div><div>He was responsible for marketing &amp; sales WW, and his most recent position was Vice President Western EU.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120831&edate=20120501&rec=9962">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-06-28T12:38:42+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>re: Esmya(R) Granted EMA for Uterine Fibroids</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology8359</link>
<description>re: Esmya(R) Granted EMA for Uterine Fibroids</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology8359</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8359">re: Esmya(R) Granted EMA for Uterine Fibroids</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8359">Oncology8359</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 27 June 2012 | 17:45</font><br><br><div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Esmya(R) Granted EMA for Uterine Fibroids</span>&nbsp;<font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=dis%3aGynea"><font color="#e95e0b">:Oncology:dis:Gynea</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=mkt%3aEurope"><font color="#e95e0b">:PharmaWorld:mkt:Europe</font></a>]</font></font><br><span style="font-size: 12px;">Comment: The EC has granted marketing authorization to Richter/<wbr>PregLem's Esmya(R) 5mg tablet for pre-operative treatment of moderate to severe symptoms of uterine fibroids.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8125">...</a><br><font size="-1">Brigitte DESCHAMPS / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8125" class="commentpermalink">Oncology8125</a> / <span class="date">28 February 2012</span> /
<span class="time">15:41:49 o'clock CET</span>
</font></div><div style="margin-bottom: 10px;"><SPAN style="background-color: #ffffff;">Clinicaltrials.<wbr>gov is listing a new Ph3 trial which is to evaluate the sustained efficacy and safety of long term on-off treatment with Esmya (5 or 10mg doses) on uterine bleeding, myoma size, pain and quality of life.<wbr></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="background-color: #ffffff;">Start date: June 2012 - Completion date: April 2015/<wbr>June 2015</SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="background-color: #ffffff;">Recruitment: Approx.<wbr> 600 pre-menopausal women with symptomatic uterine myoma(s) characterised by heavy bleeding</SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="background-color: #ffffff;">Locations: 13 EU countries</SPAN> </div><div><SPAN style="background-color: #ffffff;">Source: <a href="http://clinicaltrials.gov/ct2/show/NCT01629563?recr=Open&fund=2&rcv_s=06%2F13%2F2012&rank=71" class="defaultlink">NCT01629563</a></SPAN> </div><!-- Comment details --><font size="-1">Brigitte DESCHAMPS / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8359" class="commentpermalink">Oncology8359</a> / <span class="date">27 June 2012</span> /
<span class="time">17:45:16 o'clock CEST</span>
</font><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8359">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8125">View thread  Oncology8125: Esmya(R) Granted EMA for Uterine Fibroids</a>]]></content:encoded><dc:date>2012-06-27T17:45:16+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Third Ph2 Has Started with Kissei's GnRH Antagonist for Endometriosis [dis:Gynea, :PharmaWorld:mkt:Japan, :PharmaWorld:sub:ClinicalTrial]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology8358</link>
<description>Third Ph2 Has Started with Kissei's GnRH Antagonist for Endometriosis [dis:Gynea, :PharmaWorld:mkt:Japan, :PharmaWorld:sub:ClinicalTrial]</description><category>dis:Gynea</category><category>mkt:Japan</category><category>sub:ClinicalTrial</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology8358</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8358">Third Ph2 Has Started with Kissei's GnRH Antagonist for Endometriosis</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=dis%3aGynea"><font color="#e95e0b">:Oncology:dis:Gynea</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=mkt%3aJapan"><font color="#e95e0b">:PharmaWorld:mkt:Japan</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=sub%3aClinicalTrial"><font color="#e95e0b">:PharmaWorld:sub:ClinicalTrial</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8358">Oncology8358</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 27 June 2012 | 17:31</font><br><br><div style="margin-bottom: 10px;">Comment: Efficacy and safety will be evaluated in approx.<wbr> 20 Japanese participants.<wbr> Primary oucome measures will assess the severity score of the pelvic pain.<wbr> </div><div style="margin-bottom: 10px;">Source: <A href="http://clinicaltrials.gov/ct2/show/NCT01629420?recr=Open&amp;fund=2&amp;rcv_s=06%2F13%2F2012&amp;rank=29">NCT01629420</A> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Background in Traction</FONT></STRONG> </div><div style="margin-bottom: 10px;">The 1st Ph2 was initiated in July 2011, and the 2nde in February 2012.<wbr> </div><div>(Please see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8104" class="defaultlink">Oncology8104: Kissei Has Initiated a Second Ph2 Study with its In-House GnRH antagonist for Endometriosis</a>).<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8358">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-06-27T17:31:06+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Novartis to Start Head-to-Head Study Comparing BEZ2235 to Everolimus in mTORi Naive pNET [class:PI3KInhibitor, class:mTORInhibitor, comp:Novartis, dis:pNET, :PharmaWorld:mkt:NorthAmerica, :PharmaWorld:sub:ClinicalTrial]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology6991</link>
<description>Novartis to Start Head-to-Head Study Comparing BEZ2235 to Everolimus in mTORi Naive pNET [class:PI3KInhibitor, class:mTORInhibitor, comp:Novartis, dis:pNET, :PharmaWorld:mkt:NorthAmerica, :PharmaWorld:sub:ClinicalTrial]</description><category>class:PI3KInhibitor</category><category>class:mTORInhibitor</category><category>comp:Novartis</category><category>dis:pNET</category><category>mkt:NorthAmerica</category><category>sub:ClinicalTrial</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology6991</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120831&edate=20120501&rec=6991">Novartis to Start Head-to-Head Study Comparing BEZ2235 to Everolimus in mTORi Naive pNET</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=class%3amTORInhibitor"><font color="#e95e0b">:Endocrinology:class:mTORInhibitor</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=class%3aPI3KInhibitor"><font color="#e95e0b">:Endocrinology:class:PI3KInhibitor</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=comp%3aNovartis"><font color="#e95e0b">:Endocrinology:comp:Novartis</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=dis%3apNET"><font color="#e95e0b">:Endocrinology:dis:pNET</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=mkt%3aNorthAmerica"><font color="#e95e0b">:PharmaWorld:mkt:NorthAmerica</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=sub%3aClinicalTrial"><font color="#e95e0b">:PharmaWorld:sub:ClinicalTrial</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology6991">Endocrinology6991</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 27 June 2012 | 17:20</font><br><br><div style="margin-bottom: 10px;">Comment: The Ph2 study, designed to evaluate the dual inhibition of mTOR and PI3K, was discussed during ENETS and is now listed in clinicaltrials.<wbr>gov.<wbr> Primary outcome measures will assess PFS.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Study Design </FONT></STRONG><A href="http://clinicaltrials.gov/ct2/show/NCT01628913?recr=Open&amp;fund=2&amp;rcv_s=06%2F13%2F2012&amp;rank=23"><STRONG><FONT size="3">NCT01628913</FONT></STRONG></A> </div><div style="margin-bottom: 10px;">Recruitment: approx.<wbr> 140 </div><div style="margin-bottom: 10px;">Start date: Sept.<wbr> 2012 - Completion date: April 2015 </div><div>Locations: USA (8 states; 10 sites) </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120831&edate=20120501&rec=6991">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-06-27T17:20:10+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Roche to Cut Jobs and Close Site in the U.S to Free Up Resources [func:RnD, :Endocrinology:comp:Roche, mkt:Germany, mkt:NorthAmerica]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld9960</link>
<description>Roche to Cut Jobs and Close Site in the U.S to Free Up Resources [func:RnD, :Endocrinology:comp:Roche, mkt:Germany, mkt:NorthAmerica]</description><category>func:RnD</category><category>comp:Roche</category><category>mkt:Germany</category><category>mkt:NorthAmerica</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld9960</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120831&edate=20120501&rec=9960">Roche to Cut Jobs and Close Site in the U.<wbr>S to Free Up Resources</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=comp%3aRoche"><font color="#e95e0b">:Endocrinology:comp:Roche</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=func%3aRnD"><font color="#e95e0b">:PharmaWorld:func:RnD</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=mkt%3aGermany"><font color="#e95e0b">:PharmaWorld:mkt:Germany</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=mkt%3aNorthAmerica"><font color="#e95e0b">:PharmaWorld:mkt:NorthAmerica</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld9960">PharmaWorld9960</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 27 June 2012 | 15:32</font><br><br><div style="margin-bottom: 10px;">Comment: The closure of Roche's Pharma Research and Early Development Unit in Nutley (NJ) will result in the loss of approx.<wbr> 1000 positions.<wbr> The R&amp;D activities of the site will be consolidated in Basel (Switzerland), and Penzberg (Germany).<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Rationale</FONT></STRONG> </div><div style="margin-bottom: 10px;">The closure of the Nutley site is part of a planned site consolidation and the streamlining of research activities.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Research Activities in Switzerland and Germany</FONT></STRONG> </div><div style="margin-bottom: 10px;">According to the company, research activities will focus on oncology, virology, metabolism and neurology.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Roche Presence in the U.<wbr>S.<wbr></FONT></STRONG> </div><div style="margin-bottom: 10px;">In 2013, a new Pharmaceuticals Translational Clinical Research Center is slated to open on the US East coast.<wbr> </div><div>It is dedicated to support US-based clinial trials, early dev.<wbr> programs and employ approx.<wbr> 240 people.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120831&edate=20120501&rec=9960">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-06-27T15:32:03+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Pfizer's New Long-acting rHGH [comp:Pfizer, class:GrowthHormone, :PharmaWorld:sub:DrugDelivery]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology6990</link>
<description>Pfizer's New Long-acting rHGH [comp:Pfizer, class:GrowthHormone, :PharmaWorld:sub:DrugDelivery]</description><category>comp:Pfizer</category><category>class:GrowthHormone</category><category>sub:DrugDelivery</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology6990</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120831&edate=20120501&rec=6990">Pfizer's New Long-acting rHGH</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=class%3aGrowthHormone"><font color="#e95e0b">:Endocrinology:class:GrowthHormone</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=comp%3aPfizer"><font color="#e95e0b">:Endocrinology:comp:Pfizer</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=sub%3aDrugDelivery"><font color="#e95e0b">:PharmaWorld:sub:DrugDelivery</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology6990">Endocrinology6990</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 27 June 2012 | 14:27</font><br><br><div style="margin-bottom: 10px;">Comment: Pfizer has developed a new sustained-release formulation of growth hormone working with a resesarch group in China.<wbr> </div><div style="margin-bottom: 10px;">Detailed information on the formulation and a rat study undertaken to evaluate its PK, PD and safety profile are reported in the June 2nd issue of <EM>Journal of Molecular Pharmaceutics</EM>.<wbr> </div><div style="margin-bottom: 10px;">Its publication highlights a new rhGH-PEA microsphere system that has the potential to be clinically effective when administered once every two months.<wbr> In rat studies the new formulation extended the release of rhGH for up to 56 days and showed better phamacological efficacy than daily administration after 6 days.<wbr> </div><div>The PELA microspheres are apparently formulated using a combination of traditional and membrane emulsification methods.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120831&edate=20120501&rec=6990">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-06-27T14:27:51+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>re: Bid Speculation Circles Diabetes Company Amylin</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology6986</link>
<description>re: Bid Speculation Circles Diabetes Company Amylin</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology6986</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120831&edate=20120501&rec=6986">re: Bid Speculation Circles Diabetes Company Amylin</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology6986">Endocrinology6986</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 27 June 2012 | 11:20</font><br><br><div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Bid Speculation Circles Diabetes Company Amylin</span>&nbsp;<font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=class%3aGLP1"><font color="#e95e0b">:Endocrinology:class:GLP1</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=dis%3aDiabetes"><font color="#e95e0b">:Endocrinology:dis:Diabetes</font></a>]</font></font><br><span style="font-size: 12px;">Comment: Shares in Amylin have leapt by over 8% as a report on Bloomberg 
claimed that both Sanofi and Merck have made initial takeover bids for the 
diabetes drug specialist that markets and manufactures the GLP-1 analogues 
Byetta and Bydureon.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120831&edate=20120501&rec=6945">...</a><br><font size="-1">Jacquelyne CANTLE MEYRICK / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology6945" class="commentpermalink">Endocrinology6945</a> / <span class="date">28 May 2012</span> /
<span class="time">13:09:58 o'clock CEST</span>
</font></div><div style="margin-bottom: 10px;">As the auction for Amylin enters the last leg 5 companies are reported to be still interested in acquiring the company for a pirce tag of around $4.<wbr>5bn.<wbr> Interested parties reportedly include Novartis, Sanofi, BMS, Merck and AstraZeneca.<wbr> Final bids are expected by the weekend.<wbr> </div><div>Source: Rueters </div><!-- Comment details --><font size="-1">Jacquelyne CANTLE MEYRICK / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology6986" class="commentpermalink">Endocrinology6986</a> / <span class="date">27 June 2012</span> /
<span class="time">11:20:01 o'clock CEST</span>
</font><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120831&edate=20120501&rec=6986">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology6945">View thread  Endocrinology6945: Bid Speculation Circles Diabetes Company Amylin</a>]]></content:encoded><dc:date>2012-06-27T11:20:01+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>MAA Submitted for Enzalutamide (ex MDV-3100) in Post-Chemo Setting [comp:Astellas, prod:MDV3100, dis:Prostate, :PharmaWorld:mkt:Europe, :PharmaWorld:sub:Regulatory]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology8356</link>
<description>MAA Submitted for Enzalutamide (ex MDV-3100) in Post-Chemo Setting [comp:Astellas, prod:MDV3100, dis:Prostate, :PharmaWorld:mkt:Europe, :PharmaWorld:sub:Regulatory]</description><category>comp:Astellas</category><category>prod:MDV3100</category><category>dis:Prostate</category><category>mkt:Europe</category><category>sub:Regulatory</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology8356</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8356">MAA Submitted for Enzalutamide (ex MDV-3100) in Post-Chemo Setting</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=comp%3aAstellas"><font color="#e95e0b">:Oncology:comp:Astellas</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=prod%3aMDV3100"><font color="#e95e0b">:Oncology:prod:MDV3100</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=mkt%3aEurope"><font color="#e95e0b">:PharmaWorld:mkt:Europe</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=sub%3aRegulatory"><font color="#e95e0b">:PharmaWorld:sub:Regulatory</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8356">Oncology8356</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 27 June 2012 | 09:28</font><br><br><div style="margin-bottom: 10px;">Comment: Astellas and Medivation have announced that they have submitted a MAA to the EMA for the treatment of men with mCRPC who have been previously treated with docetaxel.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Base of the Submission</FONT></STRONG> </div><div style="margin-bottom: 10px;">The submissions (EU and US) are based on data from the late-stage AFFIRM trial, which was halted early.<wbr> </div><div style="margin-bottom: 10px;">Common side effects observed more frequently in enzalutamide as compared with placebo-treated patients included fatigue, diarrhea and hot flush.<wbr> </div><div style="margin-bottom: 10px;">In the AFFIRM trial, seizure was reported in less than 1% of enzalutamide-treated patients.<wbr> Serious adverse events, adverse events causing patients to stop treatment, and adverse events causing death all were lower in the enzalutamide group than in the placebo group.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Commercialisation Strategy</FONT></STRONG> </div><div>Astellas and Medivation will co-market the drug in the US, with Astellas having responsibility for commercialising the drug in all other markets.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8356">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-06-27T09:28:28+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>re: Intelligence From MDS Part 1 - Boutlinum Toxin Company Activity</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology6476</link>
<description>re: Intelligence From MDS Part 1 - Boutlinum Toxin Company Activity</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology6476</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120831&edate=20120501&rec=6476">re: Intelligence From MDS Part 1 - Boutlinum Toxin Company Activity</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology6476">Neurology6476</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/517">Robin KINGSWELL</a> | 27 June 2012 | 08:42</font><br><br><div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Intelligence From MDS Part 1 - Botulinum Toxin Company Activity</span>&nbsp;<font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=Alert"><font color="#e95e0b">:Neurology:Alert</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=comp%3aAllergan"><font color="#e95e0b">:Neurology:comp:Allergan</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=comp%3aMerz"><font color="#e95e0b">:Neurology:comp:Merz</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=dis%3aDystonia"><font color="#e95e0b">:Neurology:dis:Dystonia</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=dis%3aSpasticity"><font color="#e95e0b">:Neurology:dis:Spasticity</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=prod%3aBotox"><font color="#e95e0b">:Neurology:prod:Botox</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=prod%3aXeomin"><font color="#e95e0b">:Neurology:prod:Xeomin</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=congress%3aMDS"><font color="#e95e0b">:PharmaWorld:congress:MDS</font></a>]</font></font><br><span style="font-size: 12px;"><FONT size="3"><FONT face="Calibri">Comment: MDS this year was well attended with no of attendees in excess of 5000.<wbr> All three major toxin companies were exhibiting but the oral presentations focused on toxin science were limited, with more activity/<wbr>interest centred around the corporate symposium and the poster presentations.<wbr> We did, however, learn that Merz is soon to file for approval of a label amendment to include data from its flexible dosing studies in CD and blepharospasm.<wbr> </FONT></FONT></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120831&edate=20120501&rec=6473">...</a><br><font size="-1">Jacquelyne CANTLE MEYRICK / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology6473" class="commentpermalink">Neurology6473</a> / <span class="date">26 June 2012</span> /
<span class="time">17:27:32 o'clock CEST</span>
</font></div><div>Wonderful detailed information that will prove extremely useful in our promotion and defence of Dysport.<wbr>  Thank you </div><!-- Comment details --><font size="-1">Robin KINGSWELL / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology6476" class="commentpermalink">Neurology6476</a> / <span class="date">27 June 2012</span> /
<span class="time">08:42:54 o'clock CEST</span>
</font><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120831&edate=20120501&rec=6476">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology6473">View thread  Neurology6473: Intelligence From MDS Part 1 - Botulinum Toxin Company Activity</a>]]></content:encoded><dc:date>2012-06-27T08:42:54+02:00</dc:date><dc:creator>rok82893</dc:creator></item><item>
<title>re: Detailed Information On New Sandostatin LAR Device</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology6983</link>
<description>re: Detailed Information On New Sandostatin LAR Device</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology6983</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120831&edate=20120501&rec=6983">re: Detailed Information On New Sandostatin LAR Device</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology6983">Endocrinology6983</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 26 June 2012 | 17:35</font><br><br><div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Detailed Information On New Sandostatin LAR Device</span>&nbsp;<font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=Alert"><font color="#e95e0b">:Endocrinology:Alert</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=class%3aSomatostatinAnalogue"><font color="#e95e0b">:Endocrinology:class:SomatostatinAnalogue</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=comp%3aNovartis"><font color="#e95e0b">:Endocrinology:comp:Novartis</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=dis%3aAcromegaly"><font color="#e95e0b">:Endocrinology:dis:Acromegaly</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=dis%3aMidGutNET"><font color="#e95e0b">:Endocrinology:dis:MidGutNET</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=dis%3apNET"><font color="#e95e0b">:Endocrinology:dis:pNET</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=sub%3aDevices"><font color="#e95e0b">:PharmaWorld:sub:Devices</font></a>]</font></font><br><span style="font-size: 12px;">Comment: Thanks to Claudia Limberger (Endocrinology Marketing Manager 
Germany), we have more details about Novartis's new Sandostatin LAR device.<wbr> A 
copy of the visual aid is attached.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120831&edate=20120501&rec=6963">...</a><br><font size="-1">Jacquelyne CANTLE MEYRICK / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology6963" class="commentpermalink">Endocrinology6963</a> / <span class="date">12 June 2012</span> /
<span class="time">12:18:37 o'clock CEST</span>
</font></div><div style="margin-bottom: 10px;">Thanks to Susan Scott (Publications Director) at ENDO we have learnt that Novartis does not intend to launch new  LAR device in USA for a couple of years at least, due to changing requirements to US regulations and study requirements.<wbr> </div><div style="margin-bottom: 10px;">The local US sales team stated " We are very happy with our current syringe and expect Pasreotide to be the next big thing" - " why would we  launch a new device in USA when we have no competition in our biggest market NET.<wbr>" </div><div><DIV class="yj6qo ajU" style="padding-bottom: 10px; widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; margin: 2px 0px 0px; outline-style: none; outline-color: invert; padding-left: 0px; outline-width: medium; width: 22px; padding-right: 0px; font: 13px arial, sans-serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #222222; cursor: pointer; word-spacing: 0px; padding-top: 10px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">
<DIV class="ajR" id=":1b9" style="position: relative; line-height: 6px; background-color: #f1f1f1; outline-style: none; outline-color: invert; outline-width: medium; width: 20px; clear: both; border: #dddddd 1px solid;" tabindex="0"><IMG class="ajT" src="https://mail.google.com/mail/u/0/images/cleardot.gif" style="background-image: url('https://ssl.gstatic.com/ui/v1/icons/mail/ellipsis.png'); width: 20px; height: 8px; opacity: 0.3;"></DIV>
</DIV> </div><!-- Comment details --><font size="-1">Jacquelyne CANTLE MEYRICK / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology6983" class="commentpermalink">Endocrinology6983</a> / <span class="date">26 June 2012</span> /
<span class="time">17:35:42 o'clock CEST</span>
</font><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120831&edate=20120501&rec=6983">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology6963">View thread  Endocrinology6963: Detailed Information On New Sandostatin LAR Device</a>]]></content:encoded><dc:date>2012-06-26T17:35:42+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>Intelligence From MDS Part 1 - Botulinum Toxin Company Activity [Alert, comp:Allergan, comp:Merz, dis:Dystonia, dis:Spasticity, prod:Botox, prod:Xeomin, :PharmaWorld:congress:MDS]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology6473</link>
<description>Intelligence From MDS Part 1 - Botulinum Toxin Company Activity [Alert, comp:Allergan, comp:Merz, dis:Dystonia, dis:Spasticity, prod:Botox, prod:Xeomin, :PharmaWorld:congress:MDS]</description><comments>http://ci.beaufour-ipsen.com/traction/permalink/Neurology6473</comments><category>Alert</category><category>comp:Allergan</category><category>comp:Merz</category><category>dis:Dystonia</category><category>dis:Spasticity</category><category>prod:Botox</category><category>prod:Xeomin</category><category>congress:MDS</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology6473</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120831&edate=20120501&rec=6473">Intelligence From MDS Part 1 - Botulinum Toxin Company Activity</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=Alert"><font color="#e95e0b">:Neurology:Alert</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=comp%3aAllergan"><font color="#e95e0b">:Neurology:comp:Allergan</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=comp%3aMerz"><font color="#e95e0b">:Neurology:comp:Merz</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=dis%3aDystonia"><font color="#e95e0b">:Neurology:dis:Dystonia</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=dis%3aSpasticity"><font color="#e95e0b">:Neurology:dis:Spasticity</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=prod%3aBotox"><font color="#e95e0b">:Neurology:prod:Botox</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=prod%3aXeomin"><font color="#e95e0b">:Neurology:prod:Xeomin</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=congress%3aMDS"><font color="#e95e0b">:PharmaWorld:congress:MDS</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology6473">Neurology6473</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 26 June 2012 | 17:27</font><br><br><div style="margin-bottom: 10px;"><FONT size="3"><FONT face="Calibri">Comment: MDS this year was well attended with no of attendees in excess of 5000.<wbr> All three major toxin companies were exhibiting but the oral presentations focused on toxin science were limited, with more activity/<wbr>interest centred around the corporate symposium and the poster presentations.<wbr> We did, however, learn that Merz is soon to file for approval of a label amendment to include data from its flexible dosing studies in CD and blepharospasm.<wbr> </FONT></FONT> </div><div style="margin-bottom: 10px;"><FONT size="3"><FONT face="Calibri"><STRONG>Corporate Symposia</STRONG></FONT></FONT> </div><div style="margin-bottom: 10px;"><FONT size="3"><FONT face="Calibri">Ipsen symposia was very well attended with the room full to capacity (650) and 75 people waiting outside.<wbr> In Allergan’s meeting, by contrast, which did clash with a Parkinson's Disease symposia there were around 350 attendees (same hall).<wbr> </FONT></FONT> </div><div style="margin-bottom: 10px;"><FONT size="3"><FONT face="Calibri">The content of Allergan’s symposia was not as rich in terms of new data as might have been expected given the title “Great Debates &amp; Hot Topics In Cervical Dystonia” The first speaker Dr Markus Naumann highlighted the difference and similarities between botulinum toxins cleverly messaging some key promotional points regarding dose ratio relative to Dysport and duration of effect when it comes to Xeomin.<wbr></FONT></FONT> </div><div style="margin-bottom: 10px;"><FONT size="3"><FONT face="Calibri">Dr Naumann (Augsberg Academic Hospital) acknowledge the large amount of published literature on the different toxin products albeit highlighting the order of magnitude more papers on Botox than on its competitors but his main message was focused on the lack of interchangeablility of the currently available toxin products.<wbr> He noted how biologics are sensitive to differences in manufacturing and formulation and that this combined with different assays lead to products with different potencies and dose conversion factors.<wbr> He stated there is no clear dose ratio and that what one needs is an individualised patient approach to treatment.<wbr></FONT></FONT> </div><div style="margin-bottom: 10px;"><FONT size="3"><FONT face="Calibri"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/6473/1/ScreenCapture1.jpg?user-agent=rss"></FONT></FONT> </div><div style="margin-bottom: 10px;"><FONT size="3"><FONT face="Calibri"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/6473/2/ScreenCapture2.jpg?user-agent=rss"></FONT></FONT> </div><div style="margin-bottom: 10px;"><FONT size="3"><FONT face="Calibri">He also emphasised in terms of Xeomin how non-inferiority trials are not head-to-head trials and therefore care is needed in terms of the conclusions one may make.<wbr> It was noted that the mean injection interval in the CD Probe study was 14.<wbr>4weeks and that this is similar to Dsyport but not the same as that observed with Xeomin.<wbr></FONT></FONT> </div><div style="margin-bottom: 10px;"><FONT size="3"><FONT face="Calibri"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/6473/3/ScreenCapture3.jpg?user-agent=rss"></FONT></FONT> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/6473/4/ScreenCapture4.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><FONT size="3"><FONT face="Calibri">Finally, he commented on the low rates of immunogenicity observed with Botox referencing in particular a meta-analysis of 16 trials including more than 3000 patients treated with Botox for various indications and then proceeded to highlight the higher incidence reported with Dysport and the fact that neutralising antibodies have also been observed with Xeomin (despite sometimes claims to the contrary).<wbr></FONT></FONT> </div><div style="margin-bottom: 10px;"><FONT size="3"><FONT face="Calibri"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/6473/5/ScreenCapture5.jpg?user-agent=rss"></FONT></FONT> </div><div style="margin-bottom: 10px;"><FONT size="3"><FONT face="Calibri"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/6473/6/ScreenCapture6.jpg?user-agent=rss"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/6473/7/ScreenCapture7.jpg?user-agent=rss"></FONT></FONT> </div><div style="margin-bottom: 10px;"><FONT size="3"><FONT face="Calibri"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/6473/8/ScreenCapture8.jpg?user-agent=rss"></FONT></FONT> </div><div style="margin-bottom: 10px;"><FONT size="3"><FONT face="Calibri">In concluding, however, he did acknowledge that neutralising antibodies rarely cause lack of efficacy.<wbr></FONT></FONT> </div><div style="margin-bottom: 10px;"><FONT face="Calibri" size="3"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/6473/9/ScreenCapture9.jpg?user-agent=rss"></FONT> </div><div style="margin-bottom: 10px;"><FONT size="3"><FONT face="Calibri">Dr Giovanni Fabbrini (University of Rome) followed noting how difficult it is to assess the prevalence of CD and how it may be more prevalent than previously thought.<wbr></FONT></FONT> </div><div style="margin-bottom: 10px;"><FONT size="3"><FONT face="Calibri"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/6473/10/ScreenCapture10.jpg?user-agent=rss"></FONT></FONT> </div><div style="margin-bottom: 10px;"><FONT size="3"><FONT face="Calibri">His talk then focused on the disease burden associated with CD not just in terms of motor complications but non-motor complications as well and emphasised how more needs to be done in terms of understanding the non-motor consequences (parallels with the evolving treatment paradigm in Parkinson’s disease).<wbr> </FONT></FONT> </div><div style="margin-bottom: 10px;"><FONT size="3"><FONT face="Calibri">The challenge is frequently delayed diagnosis and the need for new diagnostic tools.<wbr> Giovannia presented the results of the COPE study which has evaluated the possible relationship between stress coping lifestyles and the presence of symptoms of CD comparing three groups, those with CD, those with hemiplegia associated with stroke and healthy volunteers.<wbr></FONT></FONT> </div><div style="margin-bottom: 10px;"><FONT size="3"><FONT face="Calibri"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/6473/11/ScreenCapture11.jpg?user-agent=rss"></FONT></FONT> </div><div style="margin-bottom: 10px;"><FONT size="3"><FONT face="Calibri"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/6473/12/ScreenCapture13.jpg?user-agent=rss"></FONT></FONT> </div><div style="margin-bottom: 10px;"><FONT size="3"><FONT face="Calibri"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/6473/13/ScreenCapture14.jpg?user-agent=rss"></FONT></FONT> </div><div style="margin-bottom: 10px;"><FONT size="3"><FONT face="Calibri"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/6473/14/ScreenCapture15.jpg?user-agent=rss"></FONT></FONT> </div><div style="margin-bottom: 10px;"><FONT size="3"><FONT face="Calibri"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/6473/15/ScreenCapture17.jpg?user-agent=rss"></FONT></FONT> </div><div style="margin-bottom: 10px;"><FONT size="3"><FONT face="Calibri"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/6473/16/ScreenCapture18.jpg?user-agent=rss"></FONT></FONT> </div><div style="margin-bottom: 10px;"><FONT size="3"><FONT face="Calibri">He stated that no other dystonias have a psychiatric burden compared to that seen in CD.<wbr> There is an increased frequency of mood disorders noted in 50% of patients prior to the onset of CD and in 50% post the development of CD and suggested that this is probably due to cellular loss and a decrease in grey matter volume.<wbr> Advanced neuroimaging techniques could it was proposed be useful as a CD diagnostic tool.<wbr></FONT></FONT> </div><div style="margin-bottom: 10px;"><FONT size="3"><FONT face="Calibri"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/6473/17/ScreenCapture19.jpg?user-agent=rss"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/6473/18/ScreenCapture20.jpg?user-agent=rss"></FONT></FONT> </div><div style="margin-bottom: 10px;"><FONT size="3"><FONT face="Calibri"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/6473/19/ScreenCapture21.jpg?user-agent=rss"></FONT></FONT> </div><div style="margin-bottom: 10px;"><FONT size="3"><FONT face="Calibri"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/6473/20/ScreenCapture22.jpg?user-agent=rss"></FONT></FONT> </div><div style="margin-bottom: 10px;"><FONT size="3"><FONT face="Calibri">Axel Schramm (University of Erlangen) concluded the symposium with a passionate review of the pros and cons of EMG guidance.<wbr> He is a strong advocate of EMG guidance usage.<wbr></FONT></FONT> </div><div style="margin-bottom: 10px;"><FONT size="3"><FONT face="Calibri"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/6473/21/ScreenCapture23.jpg?user-agent=rss"></FONT></FONT> </div><div style="margin-bottom: 10px;"><FONT size="3"><FONT face="Calibri"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/6473/22/ScreenCapture25.jpg?user-agent=rss"></FONT></FONT> </div><div style="margin-bottom: 10px;"><FONT face="Calibri" size="3"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/6473/23/ScreenCapture26.jpg?user-agent=rss"></FONT> </div><div style="margin-bottom: 10px;"><FONT size="3"><FONT face="Calibri">Most useful was a proposed schematic for suggestions on when and where to use EMG and ultrasound guidance.<wbr></FONT></FONT> </div><div style="margin-bottom: 10px;"><FONT size="3"><FONT face="Calibri"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/6473/24/ScreenCapture27.jpg?user-agent=rss">10328</FONT></FONT> </div><div style="margin-bottom: 10px;"><FONT size="3"><FONT face="Calibri"><STRONG>Exhibition Presence</STRONG></FONT></FONT> </div><div style="margin-bottom: 10px;"><FONT size="3"><FONT face="Calibri">As mentioned both Allergan and Merz had a significant presence at the exhibition.<wbr> The panelling on the Allergan Booth is as shown below with the focus on 2005 CD data, the history of Botox’s approvals and its new assay.<wbr></FONT></FONT> </div><div style="margin-bottom: 10px;"><FONT face="Calibri" size="3"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/6473/25/ScreenCapture28.jpg?user-agent=rss"> </FONT> </div><div style="margin-bottom: 10px;"><FONT size="3"><FONT face="Calibri"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/6473/26/ScreenCapture29.jpg?user-agent=rss"></FONT></FONT> </div><div style="margin-bottom: 10px;"><FONT face="Calibri" size="3"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/6473/27/ScreenCapture30.jpg?user-agent=rss"></FONT> </div><div style="margin-bottom: 10px;"><FONT size="3"><FONT face="Calibri">Merz had many recent publications available on its stand including and was asking a different question every day about the need and desirability of more frequent injections.<wbr> On the 1st day its questions was "If your patients could decide, which injection intervals they would prefer a) around 10 weeks, b) 3 months or c) more than 3 months.<wbr> The preference as indicated by physicians was b) followed by c).<wbr></FONT></FONT> </div><div style="margin-bottom: 10px;"><FONT size="3"><FONT face="Calibri">Interestingly in this context, Julie Hoffer (Business Unit Manager in Germany) reported that there are rumours that the German Botulinum Toxin Working Group is about to issue a statement supporting more frequent botulinum toxin dosing and will recommend injection intervals of 8 weeks for both the treatment of CD and Blepharospasm.<wbr></FONT></FONT> </div><div style="margin-bottom: 10px;"><EM><FONT size="3"><FONT face="Calibri">Merz Papers On The Stand</FONT></FONT></EM> </div><div style="margin-bottom: 10px;"><UL><LI><FONT size="3"><FONT face="Calibri">Efficacy and safety of incobotulinumtoxin A (NT201, Xeomin in the treatment of blepharospasm – a randomised trial.<wbr> Jankovic J et al Movement Disorders 2011 26: 1521 </FONT></FONT></LI>
<LI><FONT size="3"><FONT face="Calibri">Five year experience with incobotulinumtoxin A (Xeomin): the first botulinum toxin drug free of complexing proteins D Dressler EFNS Vol 19 No 3 March 2012</FONT></FONT> </LI>
<LI><FONT size="3"><FONT face="Calibri">Efficacy and safety of incobotulinumtoxin A (NT201, Xeomin, botulinum neurotoxin type A, without accessory proteins) in patients with cervical dystonia Comella CL et al J Neurol Sci 2011: 308 103</FONT></FONT> </LI>
<LI><FONT size="3"><FONT face="Calibri">Stability of botulinum neurotoxin type A, devoid of complexing proteins.<wbr> Grein S et al The Botulinum J 2011 2: 49</FONT></FONT> </LI>
<LI><FONT size="3"><FONT face="Calibri">Studies on the dissociation of botulinum neurotoxin type A complexes.<wbr> Eisele KH et al Toxicon 2011: 57:555</FONT></FONT> </LI>
</UL> </div><div style="margin-bottom: 10px;"><FONT size="3"><FONT face="Calibri"><STRONG>Poster Review.<wbr></STRONG></FONT></FONT> </div><div style="margin-bottom: 10px;"><FONT size="3"><FONT face="Calibri">In all instances the poster data was different or an extension of the poster data presented at the AAN meeting in April.<wbr></FONT></FONT> </div><div style="margin-bottom: 10px;"><FONT size="3"><FONT face="Calibri"><EM>Allergan Posters</EM></FONT></FONT> </div><div style="margin-bottom: 10px;"><FONT size="3"><FONT face="Calibri">Allergan had four significant posters at the MDS meeting all of which are attached for review.<wbr></FONT></FONT> </div><div style="margin-bottom: 10px;"><FONT size="3"><FONT face="Calibri">It presented a systematic review of the literature on the use of Botox for the treatment of spasticity since 1985.<wbr> When various attrition criteria were applied 74 publications were left for review including 28 randomised clinical trials, five non-randomised trials and 37 single-arm uncontrolled case series.<wbr> The majority reported treatments of the upper limb (n=33), 11 required treatment of both and 26 evaluated lower limb treatment.<wbr> The review concludes that Botox has been well studied and that in terms of upper limbs, the wrist elbow and finger flexors are the most frequently injected muscules, whereas in the lower limbs the ankle plantar flexor is the most commonly injected site.<wbr> Mean dosage information was wide ranging and is specified in more detail on the poster.<wbr></FONT></FONT> </div><div style="margin-bottom: 10px;"><FONT size="3"><FONT face="Calibri">One of the more interesting posters Allergan displayed was that highlighting the cost of cervical dysontia treatment in the United States.<wbr> Data has been extracted from the ongoing CD PROBE study and has evaluated the total cost for CD-related care over 6 months prior to toxin exposure based on severity and sub-type of CD.<wbr> Unit cost estimates per provider visit are shown as are the number of visits to various types of providers due to CD 6 months prior to baseline.<wbr></FONT></FONT> </div><div style="margin-bottom: 10px;"><FONT size="3"><FONT face="Calibri"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/6473/43/ScreenCapture46.jpg?user-agent=rss"></FONT></FONT> </div><div style="margin-bottom: 10px;"><FONT size="3"><FONT face="Calibri">Other data from the CD PROBE study focused on the different subtypes of CD and how CD presenting with predominant anterocollis or retrocollis is less common but often associated with increased disease burden, disease severity and disability.<wbr> The other poster highlighted the degree to which patients employment is impacted by the onset of CD.<wbr> Over two-thirds who were employed in the US at the point that there symptoms developed had to stop work.<wbr></FONT></FONT> </div><div style="margin-bottom: 10px;"><FONT size="3"><FONT face="Calibri"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/6473/44/ScreenCapture47.jpg?user-agent=rss"></FONT></FONT> </div><div style="margin-bottom: 10px;"><FONT size="3"><FONT face="Calibri"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/6473/42/ScreenCapture45.jpg?user-agent=rss"></FONT></FONT> </div><div style="margin-bottom: 10px;"><FONT size="3"><FONT face="Calibri"><EM><STRONG>Merz Posters</STRONG></EM></FONT></FONT> </div><div style="margin-bottom: 10px;"><FONT size="3"><FONT face="Calibri">Merz had six posters on display but no handouts.<wbr> Three featured the results from its phIV observational study XCiDaBle, one on dosing interval frequency, another on satisfaction with therapy in CD and the finally data from the SPACE (Spasticity In Practice) study interim data from which was presented at the recent ESPRM meeting in Greece where 48.<wbr>1% of participating physicians (26/<wbr>54) stated that they would like to inject higher doses of botulinum toxin type A than permitted by current product labelling.<wbr> Something Merz is now investigating in terms of safety profile in the recently initiated TOWER study (see attached SPACE poster) (see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120831&edate=20120501&rec=6441" class="defaultlink">Neurology6441: Focus on Merz & Allergan Spasticity Symposia @  the 18th ESPRM (Thessaloniki, Greece)</a>).<wbr></FONT></FONT> </div><div style="margin-bottom: 10px;"><FONT size="3"><FONT face="Calibri">In terms of the dosing frequency study the data appears to support the view that the safety profile of the drug remains consistent across dosing intervals of 6-20 weeks.<wbr> In terms of 821 repeat injections 29.<wbr>5% were administered within 6-9 weeks, 39.<wbr>3% within 10-13 weeks and 31.<wbr>2% in 14-2 20 weeks.<wbr></FONT></FONT> </div><div style="margin-bottom: 10px;"><FONT size="3"><FONT face="Calibri">The study investigators involved in the study are shown as are the results in patients previously treated with toxin.<wbr></FONT></FONT> </div><div style="margin-bottom: 10px;"><FONT size="3"><FONT face="Calibri"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/6473/28/ScreenCapture31.jpg?user-agent=rss"></FONT></FONT> </div><div style="margin-bottom: 10px;"><FONT size="3"><FONT face="Calibri"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/6473/29/ScreenCapture32.jpg?user-agent=rss"></FONT></FONT> </div><div style="margin-bottom: 10px;"><FONT size="3"><FONT face="Calibri">A further poster supporting the concept of earlier treatment was data presented from a structured patient survey undertaken in Germany, France, US &amp; Canada.<wbr> 136 patients were recruited but it is unclear whether they were all Xeomin users or being treated with other botulinum toxin therapy (possibly the former).<wbr></FONT></FONT> </div><div style="margin-bottom: 10px;"><FONT size="3"><FONT face="Calibri">The baseline characteristics are shown as is duration of peak effect and overall levels of satisfaction.<wbr> As the slide below shows, Merz concludes that many patients prefer an injection interval shorter than 12 weeks.<wbr></FONT></FONT> </div><div style="margin-bottom: 10px;"><FONT size="3"><FONT face="Calibri"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/6473/30/ScreenCapture33.jpg?user-agent=rss"></FONT></FONT> </div><div style="margin-bottom: 10px;"><FONT size="3"><FONT face="Calibri"><SPAN style="mso-spacerun: yes"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/6473/31/ScreenCapture34.jpg?user-agent=rss"></SPAN></FONT></FONT> </div><div style="margin-bottom: 10px;"><FONT face="Calibri" size="3"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/6473/32/ScreenCapture35.jpg?user-agent=rss"></FONT> </div><div style="margin-bottom: 10px;">In terms of the XCiDaBLE data some of the baseline findings both in CD and Blepharospasm are shown below.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/6473/33/ScreenCapture36.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/6473/34/ScreenCapture37.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/6473/35/ScreenCapture38.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/6473/36/ScreenCapture39.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/6473/37/ScreenCapture40.jpg?user-agent=rss"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/6473/38/ScreenCapture41.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/6473/39/ScreenCapture42.jpg?user-agent=rss"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/6473/40/ScreenCapture43.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">Finally one non-industry sponsored poster of interest worth highlighting is a small study that has evaluated the response to Xeomin in patients who were secondary non-responders to other toxins due to neutralising antibodies.<wbr> It found no benefit with Xeomin treatment.<wbr> </div><div><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/6473/41/ScreenCapture44.jpg?user-agent=rss"> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Neurology6476c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;"><span style="font-weight: bold;">re: Intelligence From MDS Part 1 - Boutlinum Toxin Company Activity</span> </div><div>Wonderful detailed information that will prove extremely useful in our promotion and defence of Dysport.<wbr>  Thank you </div><font size="-1">Robin KINGSWELL / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology6476" class="commentpermalink">Neurology6476</a> / <span class="date">27 June 2012</span> /
<span class="time">08:42:54 o'clock CEST</span>
</font></div><a name="Neurology6483c"></a><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">Very helpful.<wbr> Nice job team.<wbr> We need to tackle the Marchetti paper Allergan keeps using.<wbr> Allergans position is paradoxical as we heard at their symposium in Dublin.<wbr> </div><div style="margin-bottom: 10px;">On one hand, they agree that there is no conversion ratio, on the other hand, they consistently show the Marchetti paper results in a way that implies that this is high quality clinical research (even though it is a retrospective review and that the dose conversion ratio is on average 4-5:1 or higher which is both dangerous for our patients and destroys our value proposition.<wbr> I was glad to see the Korean study demonstrating 2.<wbr>5:1 ratio with encouraging results in this meeting.<wbr> </div><div>Overall at the MDS I felt the star of Ipsen and Dysport was shining.<wbr> We had a full attendance to our symposia, best booth location and several posters from US affiliate with Anchor-CD study.<wbr> </div><font size="-1">siy15897 / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology6483" class="commentpermalink">Neurology6483</a> / <span class="date">29 June 2012</span> /
<span class="time">16:31:07 o'clock CEST</span>
</font></div><a name="neurology6473attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/6473/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(56,4 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/6473/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(59 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/6473/3/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(58,8 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/6473/4/ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(61,6 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/6473/5/ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(66,6 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/6473/6/ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(53,7 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/6473/7/ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(60,8 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/6473/8/ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(56,3 KB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/6473/9/ScreenCapture9.jpg">ScreenCapture9.jpg</a>&nbsp;&nbsp;(57,1 KB)<br>&nbsp;&nbsp;10.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/6473/10/ScreenCapture10.jpg">ScreenCapture10.jpg</a>&nbsp;&nbsp;(57,7 KB)<br>&nbsp;&nbsp;11.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/6473/11/ScreenCapture11.jpg">ScreenCapture11.jpg</a>&nbsp;&nbsp;(50,5 KB)<br>&nbsp;&nbsp;12.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/6473/12/ScreenCapture13.jpg">ScreenCapture13.jpg</a>&nbsp;&nbsp;(51 KB)<br>&nbsp;&nbsp;13.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/6473/13/ScreenCapture14.jpg">ScreenCapture14.jpg</a>&nbsp;&nbsp;(48 KB)<br>&nbsp;&nbsp;14.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/6473/14/ScreenCapture15.jpg">ScreenCapture15.jpg</a>&nbsp;&nbsp;(63,8 KB)<br>&nbsp;&nbsp;15.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/6473/15/ScreenCapture17.jpg">ScreenCapture17.jpg</a>&nbsp;&nbsp;(62 KB)<br>&nbsp;&nbsp;16.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/6473/16/ScreenCapture18.jpg">ScreenCapture18.jpg</a>&nbsp;&nbsp;(58,7 KB)<br>&nbsp;&nbsp;17.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/6473/17/ScreenCapture19.jpg">ScreenCapture19.jpg</a>&nbsp;&nbsp;(55,1 KB)<br>&nbsp;&nbsp;18.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/6473/18/ScreenCapture20.jpg">ScreenCapture20.jpg</a>&nbsp;&nbsp;(59,2 KB)<br>&nbsp;&nbsp;19.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/6473/19/ScreenCapture21.jpg">ScreenCapture21.jpg</a>&nbsp;&nbsp;(58,8 KB)<br>&nbsp;&nbsp;20.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/6473/20/ScreenCapture22.jpg">ScreenCapture22.jpg</a>&nbsp;&nbsp;(60,7 KB)<br>&nbsp;&nbsp;21.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/6473/21/ScreenCapture23.jpg">ScreenCapture23.jpg</a>&nbsp;&nbsp;(57,8 KB)<br>&nbsp;&nbsp;22.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/6473/22/ScreenCapture25.jpg">ScreenCapture25.jpg</a>&nbsp;&nbsp;(68,2 KB)<br>&nbsp;&nbsp;23.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/6473/23/ScreenCapture26.jpg">ScreenCapture26.jpg</a>&nbsp;&nbsp;(57,4 KB)<br>&nbsp;&nbsp;24.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/6473/24/ScreenCapture27.jpg">ScreenCapture27.jpg</a>&nbsp;&nbsp;(68,1 KB)<br>&nbsp;&nbsp;25.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/6473/25/ScreenCapture28.jpg">ScreenCapture28.jpg</a>&nbsp;&nbsp;(31,3 KB)<br>&nbsp;&nbsp;26.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/6473/26/ScreenCapture29.jpg">ScreenCapture29.jpg</a>&nbsp;&nbsp;(53,3 KB)<br>&nbsp;&nbsp;27.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/6473/27/ScreenCapture30.jpg">ScreenCapture30.jpg</a>&nbsp;&nbsp;(60,8 KB)<br>&nbsp;&nbsp;28.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/6473/28/ScreenCapture31.jpg">ScreenCapture31.jpg</a>&nbsp;&nbsp;(56,2 KB)<br>&nbsp;&nbsp;29.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/6473/29/ScreenCapture32.jpg">ScreenCapture32.jpg</a>&nbsp;&nbsp;(30,5 KB)<br>&nbsp;&nbsp;30.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/6473/30/ScreenCapture33.jpg">ScreenCapture33.jpg</a>&nbsp;&nbsp;(68,2 KB)<br>&nbsp;&nbsp;31.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/6473/31/ScreenCapture34.jpg">ScreenCapture34.jpg</a>&nbsp;&nbsp;(76,8 KB)<br>&nbsp;&nbsp;32.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/6473/32/ScreenCapture35.jpg">ScreenCapture35.jpg</a>&nbsp;&nbsp;(32,5 KB)<br>&nbsp;&nbsp;33.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/6473/33/ScreenCapture36.jpg">ScreenCapture36.jpg</a>&nbsp;&nbsp;(88,6 KB)<br>&nbsp;&nbsp;34.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/6473/34/ScreenCapture37.jpg">ScreenCapture37.jpg</a>&nbsp;&nbsp;(58,2 KB)<br>&nbsp;&nbsp;35.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/6473/35/ScreenCapture38.jpg">ScreenCapture38.jpg</a>&nbsp;&nbsp;(58,6 KB)<br>&nbsp;&nbsp;36.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/6473/36/ScreenCapture39.jpg">ScreenCapture39.jpg</a>&nbsp;&nbsp;(31 KB)<br>&nbsp;&nbsp;37.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/6473/37/ScreenCapture40.jpg">ScreenCapture40.jpg</a>&nbsp;&nbsp;(639 B)<br>&nbsp;&nbsp;38.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/6473/38/ScreenCapture41.jpg">ScreenCapture41.jpg</a>&nbsp;&nbsp;(90,8 KB)<br>&nbsp;&nbsp;39.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/6473/39/ScreenCapture42.jpg">ScreenCapture42.jpg</a>&nbsp;&nbsp;(657 B)<br>&nbsp;&nbsp;40.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/6473/40/ScreenCapture43.jpg">ScreenCapture43.jpg</a>&nbsp;&nbsp;(74,4 KB)<br>&nbsp;&nbsp;41.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/6473/41/ScreenCapture44.jpg">ScreenCapture44.jpg</a>&nbsp;&nbsp;(68 KB)<br>&nbsp;&nbsp;42.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/6473/42/ScreenCapture45.jpg">ScreenCapture45.jpg</a>&nbsp;&nbsp;(102,3 KB)<br>&nbsp;&nbsp;43.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/6473/43/ScreenCapture46.jpg">ScreenCapture46.jpg</a>&nbsp;&nbsp;(104,4 KB)<br>&nbsp;&nbsp;44.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/6473/44/ScreenCapture47.jpg">ScreenCapture47.jpg</a>&nbsp;&nbsp;(84,7 KB)<br>&nbsp;&nbsp;45.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/6473/45/Cost%20of%20CD%20Burden%20In%20The%20US%20June%202012.pdf">Cost of CD Burden In The US June 2012.pdf</a>&nbsp;&nbsp;(218,4 KB)<br>&nbsp;&nbsp;46.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/6473/46/CDPROBE%20Employment%20Data%20June%202012.pdf">CDPROBE Employment Data June 2012.pdf</a>&nbsp;&nbsp;(161,4 KB)<br>&nbsp;&nbsp;47.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/6473/47/Botox%20For%20Adult%20Spasticity%20A%20Systematic%20Review%20Of%20The%20Literatrure%20June%202012.pdf">Botox For Adult Spasticity A Systematic Review Of The Literatrure June 2012.pdf</a>&nbsp;&nbsp;(237 KB)<br>&nbsp;&nbsp;48.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/6473/48/SPACE%20Merz%20Trial%20June%202012.pdf">SPACE Merz Trial June 2012.pdf</a>&nbsp;&nbsp;(238,1 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120831&edate=20120501&rec=6473">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-06-26T17:27:32+02:00</dc:date><dc:creator>jac89886</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/6473/1/ScreenCapture1.jpg" length="57796" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/6473/2/ScreenCapture2.jpg" length="60438" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/6473/3/ScreenCapture3.jpg" length="60217" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/6473/4/ScreenCapture4.jpg" length="63112" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/6473/5/ScreenCapture5.jpg" length="68239" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/6473/6/ScreenCapture6.jpg" length="55007" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/6473/7/ScreenCapture7.jpg" length="62308" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/6473/8/ScreenCapture8.jpg" length="57685" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/6473/9/ScreenCapture9.jpg" length="58518" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/6473/10/ScreenCapture10.jpg" length="59049" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/6473/11/ScreenCapture11.jpg" length="51661" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/6473/12/ScreenCapture13.jpg" length="52226" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/6473/13/ScreenCapture14.jpg" length="49122" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/6473/14/ScreenCapture15.jpg" length="65362" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/6473/15/ScreenCapture17.jpg" length="63514" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/6473/16/ScreenCapture18.jpg" length="60150" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/6473/17/ScreenCapture19.jpg" length="56415" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/6473/18/ScreenCapture20.jpg" length="60608" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/6473/19/ScreenCapture21.jpg" length="60170" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/6473/20/ScreenCapture22.jpg" length="62119" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/6473/21/ScreenCapture23.jpg" length="59149" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/6473/22/ScreenCapture25.jpg" length="69800" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/6473/23/ScreenCapture26.jpg" length="58806" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/6473/24/ScreenCapture27.jpg" length="69770" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/6473/25/ScreenCapture28.jpg" length="32093" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/6473/26/ScreenCapture29.jpg" length="54585" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/6473/27/ScreenCapture30.jpg" length="62222" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/6473/28/ScreenCapture31.jpg" length="57571" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/6473/29/ScreenCapture32.jpg" length="31272" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/6473/30/ScreenCapture33.jpg" length="69823" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/6473/31/ScreenCapture34.jpg" length="78621" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/6473/32/ScreenCapture35.jpg" length="33243" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/6473/33/ScreenCapture36.jpg" length="90733" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/6473/34/ScreenCapture37.jpg" length="59552" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/6473/35/ScreenCapture38.jpg" length="59965" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/6473/36/ScreenCapture39.jpg" length="31715" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/6473/37/ScreenCapture40.jpg" length="639" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/6473/38/ScreenCapture41.jpg" length="92928" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/6473/39/ScreenCapture42.jpg" length="657" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/6473/40/ScreenCapture43.jpg" length="76158" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/6473/41/ScreenCapture44.jpg" length="69653" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/6473/42/ScreenCapture45.jpg" length="104737" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/6473/43/ScreenCapture46.jpg" length="106910" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/6473/44/ScreenCapture47.jpg" length="86740" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/6473/45/Cost%20of%20CD%20Burden%20In%20The%20US%20June%202012.pdf" length="223688" type="application/pdf"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/6473/46/CDPROBE%20Employment%20Data%20June%202012.pdf" length="165256" type="application/pdf"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/6473/47/Botox%20For%20Adult%20Spasticity%20A%20Systematic%20Review%20Of%20The%20Literatrure%20June%202012.pdf" length="242716" type="application/pdf"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/6473/48/SPACE%20Merz%20Trial%20June%202012.pdf" length="243812" type="application/pdf"/></item><item>
<title>Positive Results from Ph1 of Versartis' Once-Monthly GH Presented @ ENDO 2012 [dis:GrowthHormoneDeficiency]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology6981</link>
<description>Positive Results from Ph1 of Versartis' Once-Monthly GH Presented @ ENDO 2012 [dis:GrowthHormoneDeficiency]</description><category>dis:GrowthHormoneDeficiency</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology6981</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120831&edate=20120501&rec=6981">Positive Results from Ph1 of Versartis' Once-Monthly GH Presented @ ENDO 2012</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=dis%3aGrowthHormoneDeficiency"><font color="#e95e0b">:Endocrinology:dis:GrowthHormoneDeficiency</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology6981">Endocrinology6981</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 26 June 2012 | 10:40</font><br><br><div style="margin-bottom: 10px;">Comment: During the oral discussion of the Ph1 results, G.<wbr> Bright, VP of Medical Affairs, stated that a single dose of VRS-317 was "very well tolerated" in GHD adult patients.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Top Line Findings</FONT></STRONG> </div><div style="margin-bottom: 10px;">AEs considered drug-related were primarily mild and transient.<wbr> </div><div style="margin-bottom: 10px;">No injection site lipoatrophy observed during the treatment.<wbr> </div><div style="margin-bottom: 10px;">More details @ <A href="http://www.versartis.com/content/newsandevents/releases/062512.htm">http:/<wbr>/<wbr>www.<wbr>versartis.<wbr>com/<wbr>content/<wbr>newsandevents/<wbr>releases/<wbr>062512.<wbr>htm</A> </div><div style="margin-bottom: 10px;"><A href="http://clinicaltrials.gov/ct2/show/NCT01359488?fund=2&amp;rcv_s=05%2F10%2F2011&amp;rank=158"><STRONG><FONT size="3">Phase 1 Details</FONT></STRONG></A> </div><div style="margin-bottom: 10px;"><UL><LI>Design: 60-day double-blind, randomized, placebo-controlled,single-ascending dose</LI>
<LI>Recruitment: 50 GHD adult patients</LI>
<LI>Locations: the US and EU</LI>
<LI>Primary outcome measures were to assess the safety and tolerability of a single sub (sc) dose of VRS-317</LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Recent Publication</FONT></STRONG> </div><div style="margin-bottom: 10px;"><DIV class="ii" id="endocrinology6953.07ii">PC safety and efficacy data were recently published in The Journal of Pharmaceutical Sciences (7 JUN 2012 | DOI: 10.<wbr><WBR>1002/<wbr></WBR><WBR>jps.<wbr></WBR><WBR>23229).<wbr></WBR></DIV> </div><div>Source: Versartis </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120831&edate=20120501&rec=6981">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-06-26T10:40:00+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Quintiles Offers Jobs to Merck Serono's Employees Affected by the Restructuring [:Endocrinology:comp:MerckSerono, sub:People]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld9959</link>
<description>Quintiles Offers Jobs to Merck Serono's Employees Affected by the Restructuring [:Endocrinology:comp:MerckSerono, sub:People]</description><category>comp:MerckSerono</category><category>sub:People</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld9959</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120831&edate=20120501&rec=9959">Quintiles Offers Jobs to Merck Serono's Employees Affected by the Restructuring</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=comp%3aMerckSerono"><font color="#e95e0b">:Endocrinology:comp:MerckSerono</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=sub%3aPeople"><font color="#e95e0b">:PharmaWorld:sub:People</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld9959">PharmaWorld9959</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 26 June 2012 | 10:23</font><br><br><div style="margin-bottom: 10px;">Comment: Quintiles has committed to offer approx.<wbr> 100 positions to Merck Serono's employees primarily working in the Global Development &amp; Medical Function in Geneva.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">About the Process</FONT></STRONG> </div><div style="margin-bottom: 10px;">Early July, Quintiles is to hold an information session for the employees and will conduct job interviews.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Positions Offered</FONT></STRONG> </div><div style="margin-bottom: 10px;">Primarily in clinical ops, biostatistics, clinical research, and drug safety.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Rationale for Quintiles</FONT></STRONG> </div><div>To benefit from Merck Serono's talents and expertise.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120831&edate=20120501&rec=9959">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-06-26T10:23:51+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Lexicon's Diabetes Drug Poised to Enter Ph3 in H1:13 [dis:Diabetes]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology6979</link>
<description>Lexicon's Diabetes Drug Poised to Enter Ph3 in H1:13 [dis:Diabetes]</description><category>dis:Diabetes</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology6979</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120831&edate=20120501&rec=6979">Lexicon's Diabetes Drug Poised to Enter Ph3 in H1:13</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=dis%3aDiabetes"><font color="#e95e0b">:Endocrinology:dis:Diabetes</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology6979">Endocrinology6979</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 25 June 2012 | 14:01</font><br><br><div style="margin-bottom: 10px;">Comment: The company has announced positive results of LX-4211 Ph2b study for type 2 diabetes.<wbr> The drug has shown favorable safety profile, and was well tolerated.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Highlights of Main Results</FONT></STRONG> </div><div style="margin-bottom: 10px;">LX-4211 showed statistically-significant reductions in hemoglobin a1c in a Ph2 b trial.<wbr> </div><div>Side effects were mild to moderate, similar to placebo (4 adverse events were reported during the trial, and were not treatment related).<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120831&edate=20120501&rec=6979">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-06-25T14:01:06+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>New CRPC Treatments Are Likley To Prompt A Change In The Dynamic Equilbrium Between Urologists &amp; Oncologists [dis:Prostate, headline]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology8354</link>
<description>New CRPC Treatments Are Likley To Prompt A Change In The Dynamic Equilbrium Between Urologists &amp; Oncologists [dis:Prostate, headline]</description><category>dis:Prostate</category><category>headline</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology8354</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8354">New CRPC Treatments Are Likley To Prompt A Change In The Dynamic Equilbrium Between Urologists & Oncologists</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=headline"><font color="#e95e0b">:Oncology:headline</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8354">Oncology8354</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 25 June 2012 | 13:01</font><br><br><div style="margin-bottom: 10px;">Comment: The latest edition of the British Journal of Urology highlights how the relationship between urologists and oncologists is likely to change as a result of evolving new treatment paradigms for the treatment of CRPC.<wbr> </div><div style="margin-bottom: 10px;">The paper suggests a redefinition of the respective roles of oncologists and urologists will occur and that a multidisciplinary team or co-ordinated care approach will become a necessity.<wbr> </div><div style="margin-bottom: 10px;">For copies of the article please contact Helen Rendell (Scientific Information Services) </div><div><A href="http://www.ncbi.nlm.nih.gov/pubmed/22712568?dopt=Abstract" style="text-align: left; widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; margin: 0px; outline-style: none; outline-color: invert; outline-width: 0px; font: 11px/15px arial, helvetica, clean, sans-serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #660066; vertical-align: baseline; word-spacing: 0px; text-decoration: underline; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; border: 0px; padding: 0px;" title="BJU international.">BJU Int.<wbr></A><SPAN style="text-align: left; widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; display: inline !important; font: 11px/15px arial, helvetica, clean, sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;"> 2012 Jun 19.<wbr> doi: 10.<wbr>1111/<wbr>j.<wbr>1464-410X.<wbr>2011.<wbr>10818.<wbr>x.<wbr> [Epub ahead of print)</SPAN> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8354">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-06-25T13:01:29+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>CHMP Adopted A Positive Opinion On Label Expansion For Novartis's Afinitor [class:KinaseInhibitors, headline, :Endocrinology:dis:pNET]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology8353</link>
<description>CHMP Adopted A Positive Opinion On Label Expansion For Novartis's Afinitor [class:KinaseInhibitors, headline, :Endocrinology:dis:pNET]</description><comments>http://ci.beaufour-ipsen.com/traction/permalink/Oncology8353</comments><category>class:KinaseInhibitors</category><category>headline</category><category>dis:pNET</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology8353</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8353">CHMP Adopted A Positive Opinion On Label Expansion For Novartis's Afinitor</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=dis%3apNET"><font color="#e95e0b">:Endocrinology:dis:pNET</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=class%3aKinaseInhibitors"><font color="#e95e0b">:Oncology:class:KinaseInhibitors</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=headline"><font color="#e95e0b">:Oncology:headline</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8353">Oncology8353</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 25 June 2012 | 11:05</font><br><br><div style="margin-bottom: 10px;">Comment: On Friday the European CHMP recommended approval of Afinitor (everolimus) for the treatment of certain patients with breast cancer.<wbr> Specifically, for use in combination with Pfizer's exemestane (Aromasin) for the treatment of hormone receptor positive HER2/<wbr>neu- negative postmenopausal advanced breast cancer.<wbr> </div><div style="margin-bottom: 10px;">It recommended use in women without symptomatic visceral disease after recurrence or progression following a non-steroidal aromatase inhibitor.<wbr> </div><div style="margin-bottom: 10px;">The CHMP's decision was taken based on data from the late-stage BOLERO-2 trial which Novartis reported last year.<wbr> Novartis filed for approval of this indication in Q42011.<wbr> </div><div style="margin-bottom: 10px;">The BOLERO-2 study demonstrated that Afinitor plus Aromasin more than doubled median PFS to 7.<wbr>8 months compared to 3.<wbr>2 months iwth Aromasin alone.<wbr> </div><div style="margin-bottom: 10px;">Novartis noted that with this approval Afinitor will represnet the first major innovation in HR+/<wbr>HER2 negative disease disnce the aromatase inhibitors were first introduced more than 15 years ago.<wbr> </div><div style="margin-bottom: 10px;">For Afinitor this will represent the third major approval for its usage with the drug already recommended for the treatment of renal cell cancer and pancreatic neuroendocrine tumours.<wbr> </div><div>source: <A href="http://www.novartis.com/">www.<wbr>novartis.<wbr>com</A> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Oncology8389c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;"><span style="font-weight: bold;">re: CHMP Adopted A Postiive Opinion On Label Expansion For Novartis's Afinitor</span> </div><div style="margin-bottom: 10px;">On July 20th, the FDA expanded approval of Afinitor (everolimus) for postmenopausal women with advanced hormonr receptor-positive, HER2-negative breast cancer.<wbr> Novartis noted that the approval marks the &amp;st time the US agency has approved mTOR inhibitor for this indication.<wbr> </div><div style="margin-bottom: 10px;">The approval calls for the drug to be used in combination with Aromasin (exemestane), after failure with Femara (letrozole) or Arimidex (anastrozole).<wbr> </div><div>According to Evaluate Pharma this is an earlier than expected move from the FDA.<wbr> Analysts think that the approval will  deliver more than $1bn in additional sales by 2018, taking Afinitor firmly into blockbuster territory.<wbr> This promise in breast cancer has not only helped Afinitor to be the number one growth driver for Novartis, it also goes some way to helping to offset the revenue gap that will be left when Diovan loses patent protection in September 2012.<wbr> While approval in breast cancer is the biggest win for Novartis, there are studies in a number of other indications that could see sales forecasts grow further.<wbr> </div><font size="-1">Brigitte DESCHAMPS / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8389" class="commentpermalink">Oncology8389</a> / <span class="date">23 July 2012</span> /
<span class="time">09:40:00 o'clock CEST</span>
</font></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8353">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-06-25T11:05:11+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>ReNeuron's Stroke Drug Produces Early Evidence Of Functional Improvement [dis:Spasticity, headline]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology6470</link>
<description>ReNeuron's Stroke Drug Produces Early Evidence Of Functional Improvement [dis:Spasticity, headline]</description><category>dis:Spasticity</category><category>headline</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology6470</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120831&edate=20120501&rec=6470">ReNeuron's Stroke Drug Produces Early Evidence Of Functional Improvement</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=dis%3aSpasticity"><font color="#e95e0b">:Neurology:dis:Spasticity</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=headline"><font color="#e95e0b">:Neurology:headline</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology6470">Neurology6470</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 25 June 2012 | 10:41</font><br><br><div style="margin-bottom: 10px;"><P align="left">Comment:ReNeuron has reported further positive results from its dose-escalation PISCES trial in severe stroke patients with its neural stem cell therapy ReN001, including improvements in spasticity as measured by the Ashworth Scale</P> </div><div style="margin-bottom: 10px;"><P align="left"><STRONG>What is ReN001?</STRONG></P> </div><div style="margin-bottom: 10px;"><P align="left">It is a cell therapy consisting of neural stem cells derived from ReNeuron&rsquo;s c-mycER technology</P> </div><div style="margin-bottom: 10px;"><P align="left"><STRONG>What is PISCES?</STRONG></P> </div><div style="margin-bottom: 10px;"><P align="left">PISCES is <FONT color="#231f20" face="GillSans" size="2"><FONT color="#231f20" face="GillSans" size="2"><FONT color="#231f20" face="GillSans" size="2">designed to evaluate 2 million, 5 million, 10 million or 20 million cell doses of ReN001 given 6-24 months after a stroke in 12 patients (see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120831&edate=20120501&rec=5430" class="defaultlink">Neurology5430: ReNeuron Comments on Progress With Stem Cell Stroke Trial</a>).<wbr></FONT></FONT></FONT></P> </div><div style="margin-bottom: 10px;"><P align="left"><FONT color="#231f20" face="GillSans" size="2"><FONT color="#231f20" face="GillSans" size="2"><FONT color="#231f20" face="GillSans" size="2"><STRONG>Key Findings To Date</STRONG></FONT></FONT></FONT></P> </div><div style="margin-bottom: 10px;"><P align="left"><FONT color="#231f20" face="GillSans" size="2"><FONT color="#231f20" face="GillSans" size="2"><FONT color="#231f20" face="GillSans" size="2">Interim data were presented at the International Society for Stem Cell Research meeting in Yokohama </FONT></FONT></FONT>from 5 patients with moderate to severe functional neurological impairments resulting from stroke in the open-label, dose-escalation, U.<wbr>K.<wbr> Phase I PISCES trial showed that single doses of intracranial ReN001 led to no cell-related adverse events or adverse immune-related responses at 3 (n=2), 6 (n=1) or 12 months (n=2) posttreatment.<wbr></P> </div><div style="margin-bottom: 10px;"><P align="left">There were minor procedure-related adverse events, including asymptomatic bleeds and superficial scalp infections at the implantation site.<wbr></P> </div><div style="margin-bottom: 10px;"><P align="left">Additionally, ReN001 improved neurological deficits, as measured by a reduction in National Institutes of Health Stroke Scale (NIHSS) scores, with a median score of 4 points at 3 months posttreatment vs.<wbr> 8 points at baseline.<wbr> <STRONG>Furthermore, ReN001 improved spasticity, as measured by a reduction in Summated Ashworth Scale for affected upper and lower limbs scores, with a mean score of 21.<wbr>8 points at 3 months post-treatment vs.<wbr> 28.<wbr>6 points at baseline.<wbr> </STRONG></P> </div><div style="margin-bottom: 10px;"><P align="left"><FONT color="#231f20" face="GillSans" size="2"><FONT color="#231f20" face="GillSans" size="2"><FONT color="#231f20" face="GillSans" size="2">ReNeuron plans to complete dosing of the remaining higher-dose cohorts in PISCES in the next 12 months.<wbr></FONT></FONT></FONT></P> </div><div><P align="left"><FONT color="#231f20" face="GillSans" size="2"><FONT color="#231f20" face="GillSans" size="2"><FONT color="#231f20" face="GillSans" size="2">Source: <A href="http://www.reneuron.com/">www.<wbr>reneuron.<wbr>com</A></FONT></FONT></FONT></P> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120831&edate=20120501&rec=6470">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-06-25T10:41:55+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>Norgine Conducts Evaluation Study in Italy to Determine Patient's Acceptability of Bowel Cleansing Procedure [comp:Norgine, sub:CRCPrevention, :PharmaWorld:sub:ClinicalTrial, :PharmaWorld:mkt:Italy, :PharmaWorld:mkt:Europe]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology1842</link>
<description>Norgine Conducts Evaluation Study in Italy to Determine Patient's Acceptability of Bowel Cleansing Procedure [comp:Norgine, sub:CRCPrevention, :PharmaWorld:sub:ClinicalTrial, :PharmaWorld:mkt:Italy, :PharmaWorld:mkt:Europe]</description><category>comp:Norgine</category><category>sub:CRCPrevention</category><category>sub:ClinicalTrial</category><category>mkt:Italy</category><category>mkt:Europe</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology1842</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20120831&edate=20120501&rec=1842">Norgine Conducts Evaluation Study in Italy to Determine Patient's Acceptability of Bowel Cleansing Procedure</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20120831&edate=20120501&cat=comp%3aNorgine"><font color="#e95e0b">:GastroEnterology:comp:Norgine</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20120831&edate=20120501&cat=sub%3aCRCPrevention"><font color="#e95e0b">:GastroEnterology:sub:CRCPrevention</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=mkt%3aEurope"><font color="#e95e0b">:PharmaWorld:mkt:Europe</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=mkt%3aItaly"><font color="#e95e0b">:PharmaWorld:mkt:Italy</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=sub%3aClinicalTrial"><font color="#e95e0b">:PharmaWorld:sub:ClinicalTrial</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology1842">GastroEnterology1842</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 25 June 2012 | 10:02</font><br><br><div style="margin-bottom: 10px;">Comment: In this Italian 'real life' study, approx.<wbr> 600 patients will be recruited to measure the patients acceptability of the procedure.<wbr> The second measures will assess the time to reach the caecum, and the adenoma detection rate.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Study Details <A href="http://clinicaltrials.gov/ct2/show/NCT01626196?recr=Open&amp;fund=2&amp;rcv_s=06%2F11%2F2012&amp;rank=93">NCT01626196</A></FONT></STRONG> </div><div style="margin-bottom: 10px;">Start date: Feb.<wbr> 2012 - Completion date: June 2012 </div><div style="margin-bottom: 10px;">Recruitment: Male and female outpatients, aged ≥ 18, treated with bowel cleansing preparation the day before undergoing routine colonoscopy at selected participating centres </div><div style="margin-bottom: 10px;">Location: IRCCS </div><div>Principal Investigator: Alessandro Repici, MD </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20120831&edate=20120501&rec=1842">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-06-25T10:02:09+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>re: AAA Reports Strong Growth In 2011 &amp; Appointment Of New Chairman</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology6978</link>
<description>re: AAA Reports Strong Growth In 2011 &amp; Appointment Of New Chairman</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology6978</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120831&edate=20120501&rec=6978">re: AAA Reports Strong Growth In 2011 & Appointment Of New Chairman</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology6978">Endocrinology6978</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/359">Philip HARRIS</a> | 23 June 2012 | 15:24</font><br><br><div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-size: 12px;">I am delighted to have Claudio serve as Chairman as AAA increases its 
development efforts and international expansion.<wbr> It is the next logical step for 
the company and will enable me to focus on the business at this important time 
of growth.<wbr> Claudio's investment and business expertise will be a huge asset to 
us as we leverage the many opportunities within the Molecular Nucleur Medicine 
Market and drive the company towards its next stage of evolution.<wbr></span>&nbsp;<br><font size="-1">Jacquelyne CANTLE MEYRICK / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology6973" class="commentpermalink">Endocrinology6973</a> / <span class="date">21 June 2012</span> /
<span class="time">16:06:44 o'clock CEST</span>
</font></div><div>The 60 mg comparator dose of LAR is surprising as it is off label.<wbr>  Quite a few patients are treated with high off-label doses, but it doesn't seem to be appropriate for a potential registration trial.<wbr> It would be really interesting to get some further information on the thinking behind this and the regulatory views.<wbr> </div><!-- Comment details --><font size="-1">Philip HARRIS / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology6978" class="commentpermalink">Endocrinology6978</a> / <span class="date">23 June 2012</span> /
<span class="time">15:24:29 o'clock CEST</span>
</font><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120831&edate=20120501&rec=6978">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology6973">View thread  Endocrinology6973: AAA Reports Strong Growth In 2011 & Appointment Of New Chairman</a>]]></content:encoded><dc:date>2012-06-23T15:24:29+02:00</dc:date><dc:creator>phh74924</dc:creator></item><item>
<title>Regional Debt to Pharma Companies in Spain Hits USD1.8 Bil. in June [mkt:Spain, mkt:Europe]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld9955</link>
<description>Regional Debt to Pharma Companies in Spain Hits USD1.8 Bil. in June [mkt:Spain, mkt:Europe]</description><category>mkt:Spain</category><category>mkt:Europe</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld9955</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120831&edate=20120501&rec=9955">Regional Debt to Pharma Companies in Spain Hits USD1.<wbr>8 Bil.<wbr> in June</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=mkt%3aEurope"><font color="#e95e0b">:PharmaWorld:mkt:Europe</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=mkt%3aSpain"><font color="#e95e0b">:PharmaWorld:mkt:Spain</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld9955">PharmaWorld9955</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 22 June 2012 | 15:24</font><br><br><div style="margin-bottom: 10px;">Comment: A repayment plan has been set by the Spanish central government for domestic and international pharmaceutical companies that are being affected by the wave of payment delays, but it has not yet become effective, and Spanish regions owe pharmaceutical companies a total of EUR 1.<wbr>5 billion (USD1.<wbr>8 billion) as of June.<wbr> </div><div style="margin-bottom: 10px;">- According to Reuters, the debt increased throughout the first months of 2011 with the figure standing at EUR6.<wbr>3 billion by the end of the year.<wbr> </div><div style="margin-bottom: 10px;">- According to the source, the government repayment plan envisaged repayment beginning at the end of 2011, but this has not come into force.<wbr> </div><div style="margin-bottom: 10px;">- According to Spanish pharmaceutical association Farmaindustria's president Humberto Arnes, cited by the source, the 2012 debt is growing at a faster rate than in 2011.<wbr> According to Arnes, the debt rate in 2012 has increased by 10 days of delayed payments per month.<wbr> </div><div style="margin-bottom: 10px;"><P class="bodyHeading2"><STRONG><FONT size="3">Significance</FONT></STRONG></P> </div><div style="margin-bottom: 10px;">Despite the government's repayment plan which was promised to domestic and international pharmacies operating in the country, the short-to-medium-term outlook on the situation will see most pharma companies cutting their medicinal supplies or setting credit limits to avoid further payment delays.<wbr> </div><div style="margin-bottom: 10px;">In the case of Swiss firm Roche, the company decided in May to set a payment credit limit for 12 Spanish hospitals in order to avoid further delays.<wbr> Despite the recent reforms announced by the Spanish government to tackle healthcare debt and reduce the debt in order to be able to review the situation and keep up to date with payments, Spain needs to engage in a stricter repayment plan with the regional councils in order to be able to cope.<wbr> Although a new financial mechanism to avoid systemic breakdown has recently been announced, this is still too recent to be able to assess its effects in the short-to-medium term.<wbr> </div><div style="margin-bottom: 10px;">Accruing EUR1.<wbr>5 billion in debt to pharma companies may lead to further lack in pharmaceutical stock in pharmacies and hospitals across the country, especially with critical life-saving treatments, such as oncology or diabetes drugs.<wbr> In order to avoid more financial strain on the overall national healthcare budget, the government recently proposed to withdraw the co-payment of over-the-counter drugs.<wbr> </div><div>Source: GlobalInsight </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120831&edate=20120501&rec=9955">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-06-22T15:24:56+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Pioneering Antisense Approach May Offer Hope For Huntington's Disease Patients [dis:Huntington, headline]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology6468</link>
<description>Pioneering Antisense Approach May Offer Hope For Huntington's Disease Patients [dis:Huntington, headline]</description><category>dis:Huntington</category><category>headline</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology6468</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120831&edate=20120501&rec=6468">Pioneering Antisense Approach May Offer Hope For Huntington's Disease Patients</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=dis%3aHuntington"><font color="#e95e0b">:Neurology:dis:Huntington</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=headline"><font color="#e95e0b">:Neurology:headline</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology6468">Neurology6468</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 22 June 2012 | 11:48</font><br><br><div style="margin-bottom: 10px;">Comment: Scientists at the University of California have reported in the journal Neuron a potentially effective therapeutic strategy to combat Huntington's disease involving a DNA-based antisense drug.<wbr> </div><div style="margin-bottom: 10px;">A single injection of the drug slowed and partially reversed progression of the disease in mice and monkeys affected with the disease.<wbr> Treated animals began moving better within a month and were physically back to normal within 2 months.<wbr>The benefits, it is claimed persisted for nine months after treatment long after levels of the Huntingtin protein began to build again.<wbr> </div><div style="margin-bottom: 10px;">The lead researcher Professor Don Cleveland is quoted in the UK press as saying "Our approach is feasible for development now into a therapy for Huntington's disease in man" </div><div>Source: Neron , Vol 74 Issue 6 964-966 21 June 2012 </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120831&edate=20120501&rec=6468">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-06-22T11:48:42+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>OXiGENE In-Licenses Angiogene Pharm's IP to Support Carcinoid Syndrome Studies [headline, :PharmaWorld:sub:xLicensing]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology6976</link>
<description>OXiGENE In-Licenses Angiogene Pharm's IP to Support Carcinoid Syndrome Studies [headline, :PharmaWorld:sub:xLicensing]</description><category>headline</category><category>sub:xLicensing</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology6976</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120831&edate=20120501&rec=6976">OXiGENE In-Licenses Angiogene Pharm's IP to Support Carcinoid Syndrome Studies</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=headline"><font color="#e95e0b">:Endocrinology:headline</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=sub%3axLicensing"><font color="#e95e0b">:PharmaWorld:sub:xLicensing</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology6976">Endocrinology6976</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 22 June 2012 | 11:29</font><br><br><div style="margin-bottom: 10px;">Comment: OXiGENE management reported that the in-licensing of IP and other assets from Angiogene is strategically important as it provides potential to significantly expand the commercial opportunity and patent protection for ZYBRESTAT, its lead vascular disrupting agent.<wbr> OXiGENE believes the drug may provide clinical benefit in reducing circulating levels of serotonin or 5-HIAA, either by itself or in conjunction with drugs like Sandostatin(R).<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Rationale for OXiGENE</FONT></STRONG> </div><div style="margin-bottom: 10px;">OXiGENE believes that these in-licensed assets will provide a compelling therapeutic rationale to conduct a Ph2 clinical study in persistent carcinoid syndrome, potentially to be followed by advancing to a registration clinical program.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Angiogene Pharm SnapShot</FONT></STRONG> </div><div style="margin-bottom: 10px;">- Virtual" company with staff in both Europe and North America.<wbr> </div><div style="margin-bottom: 10px;">- Privately-held company owned entirely by its Directors.<wbr> </div><div style="margin-bottom: 10px;">- Technology <A href="http://www.angiogene.co.uk/technologies.html">http:/<wbr>/<wbr>www.<wbr>angiogene.<wbr>co.<wbr>uk/<wbr>technologies.<wbr>html</A> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6976/1/ScreenCapture1.jpg?user-agent=rss"> </div><div>Source: OXiGENE; Angiogene Pharm.<wbr> </div><!-- Comment details --><a name="endocrinology6976attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6976/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(16,6 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120831&edate=20120501&rec=6976">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-06-22T11:29:49+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6976/1/ScreenCapture1.jpg" length="17004" type="image/jpeg"/></item><item>
<title>Novo Stops Once-Weekly Liraglutide to Focus on Once-Weekly Semaglutide [comp:NovoNordisk, class:GLP1, dis:Diabetes]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology6974</link>
<description>Novo Stops Once-Weekly Liraglutide to Focus on Once-Weekly Semaglutide [comp:NovoNordisk, class:GLP1, dis:Diabetes]</description><category>comp:NovoNordisk</category><category>class:GLP1</category><category>dis:Diabetes</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology6974</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120831&edate=20120501&rec=6974">Novo Stops Once-Weekly Liraglutide to Focus on Once-Weekly Semaglutide</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=class%3aGLP1"><font color="#e95e0b">:Endocrinology:class:GLP1</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=comp%3aNovoNordisk"><font color="#e95e0b">:Endocrinology:comp:NovoNordisk</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=dis%3aDiabetes"><font color="#e95e0b">:Endocrinology:dis:Diabetes</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology6974">Endocrinology6974</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 22 June 2012 | 08:46</font><br><br><div style="margin-bottom: 10px;">Comment: The strategic decision to pursue the once-weekly GLP-1 either with semaglutide or liraglutide depot was announced last year during the company 'Market Capital Day'.<wbr> Semaglutide is slated to enter Ph3 for type 2 diabetes in H1:13.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Rationale</FONT></STRONG> </div><div style="margin-bottom: 10px;">Novo reported semaglutide has a better safety profile for once-weekly dosing compared to the once-weekly liraglutide formulation (which was in Ph1).<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Semaglutide Ph3 Program</FONT></STRONG> </div><div style="margin-bottom: 10px;">Novo plans to initiate the 1st Ph3 in the SUSTAIN™ programme.<wbr> </div><div>The global clinical development programme is expected to include &gt; 8,000 patients.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120831&edate=20120501&rec=6974">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-06-22T08:46:31+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>EMA Reports on Roche Pharmacovigilance Deficiencies [mkt:Europe, :Endocrinology:comp:Roche]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld9953</link>
<description>EMA Reports on Roche Pharmacovigilance Deficiencies [mkt:Europe, :Endocrinology:comp:Roche]</description><category>mkt:Europe</category><category>comp:Roche</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld9953</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120831&edate=20120501&rec=9953">EMA Reports on Roche Pharmacovigilance Deficiencies</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=comp%3aRoche"><font color="#e95e0b">:Endocrinology:comp:Roche</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=mkt%3aEurope"><font color="#e95e0b">:PharmaWorld:mkt:Europe</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld9953">PharmaWorld9953</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 22 June 2012 | 08:20</font><br><br><div style="margin-bottom: 10px;">Comment: An inspection by the MHRA found that Roche did not assess approx.<wbr> 80,000 safety reports collected for its drugs, and did not report them to health authorities.<wbr> EMA is requiring the company to submit a revised comprehensive action plan by June 27.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Roche's Position</FONT></STRONG> </div><div>The company agreed that it did not fully comply with pharmacovigilance regulations, and reported it is working with health authorities to correct the issue.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120831&edate=20120501&rec=9953">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-06-22T08:20:09+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>AAA Reports Strong Growth In 2011 &amp; Appointment Of New Chairman [headline, dis:MidGutNET, :PharmaWorld:sub:ClinicalTrial]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology6973</link>
<description>AAA Reports Strong Growth In 2011 &amp; Appointment Of New Chairman [headline, dis:MidGutNET, :PharmaWorld:sub:ClinicalTrial]</description><comments>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology6973</comments><category>headline</category><category>dis:MidGutNET</category><category>sub:ClinicalTrial</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology6973</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120831&edate=20120501&rec=6973">AAA Reports Strong Growth In 2011 & Appointment Of New Chairman</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=dis%3aMidGutNET"><font color="#e95e0b">:Endocrinology:dis:MidGutNET</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=headline"><font color="#e95e0b">:Endocrinology:headline</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=sub%3aClinicalTrial"><font color="#e95e0b">:PharmaWorld:sub:ClinicalTrial</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology6973">Endocrinology6973</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 21 June 2012 | 16:06</font><br><br><div style="margin-bottom: 10px;">Comment: The Nucleur Medicine Company AAA reported strong growth in the year 
to </div><div style="margin-bottom: 10px;">Sales for the year increased by 21.<wbr>8% to Euro 33.<wbr>4m, whilst the group spent 
Euro 13m on R&amp;D.<wbr> Net cash currently stands at Euro 29.<wbr>8m.<wbr> </div><div style="margin-bottom: 10px;">2011 was a year of significant investment in manufacturing with the opening 
to two new sites in Spain and Italy.<wbr> In April the group raised  Euro 40m 
from existing and new investors to strengthen the company's growth potential.<wbr> </div><div style="margin-bottom: 10px;">Yesterday the group appointed Claudio Costamagna as Chairman of the board.<wbr> He 
has been on the board since January 2010 and was previously Chairman of Goldman 
Sachs Investment Banking Division for Europe, Middle Ease and Africa.<wbr> </div><div style="margin-bottom: 10px;">Commenting on the appointment Stefano Buono Founder and CEO of AAA, 
commented </div><div style="margin-bottom: 10px;">I am delighted to have Claudio serve as Chairman as AAA increases its 
development efforts and international expansion.<wbr> It is the next logical step for 
the company and will enable me to focus on the business at this important time 
of growth.<wbr> Claudio's investment and business expertise will be a huge asset to 
us as we leverage the many opportunities within the Molecular Nucleur Medicine 
Market and drive the company towards its next stage of evolution.<wbr> <a name="Endocrinology6978c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div>The 60 mg comparator dose of LAR is surprising as it is off label.<wbr>  Quite a few patients are treated with high off-label doses, but it doesn't seem to be appropriate for a potential registration trial.<wbr> It would be really interesting to get some further information on the thinking behind this and the regulatory views.<wbr> </div><font size="-1">Philip HARRIS / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology6978" class="commentpermalink">Endocrinology6978</a> / <span class="date">23 June 2012</span> /
<span class="time">15:24:29 o'clock CEST</span>
</font></div></div><div style="margin-bottom: 10px;"><STRONG>Next Steps With Carcinoid Trial</STRONG> </div><div style="margin-bottom: 10px;">AAA is poised to start recruitment its phIII trial  which will compare 
PFS after treatment with 177Lu-DOTA0-Tyr3-Octreotate 
plus best supportive care (30 mg Octreotide LAR) to treatment with high dose (60 
mg) Octreotide LAR in patients with inoperable, progressive (as determined by 
RECIST Criteria), somatostatin receptor positive, well-differentiated 
neuroendocrine tumours of the small bowel (midgut carcinoid tumours).<wbr> </div><div style="margin-bottom: 10px;"><STRONG>41 sites across Europe and the US are listed as participants</STRONG> 
in the trial which is being co-ordinated by the CRO Pierrel Research Europe 
GmbH.<wbr> The study which will enroll 200 patients is scheduled to complete in terms 
of primary endpoint (PFS) by Dec 2014.<wbr><BR> </div><div style="margin-bottom: 10px;">ClinicalTrials.<wbr>gov identifier: NCT01578239 </div><div style="margin-bottom: 10px;"><A href="http://clinicaltrials.gov/ct2/show/NCT01578239?term=Lu-dota&amp;rank=1">http:/<wbr>/<wbr>clinicaltrials.<wbr>gov/<wbr>ct2/<wbr>show/<wbr>NCT01578239?term=Lu-dota&amp;rank=1</A> </div><div>Source: <A href="http://www.adacap.com">www.<wbr>adacap.<wbr>com</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120831&edate=20120501&rec=6973">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-06-21T16:06:44+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>The Industry Combines Forces To Enhance Neuroscience R&amp;D [:PharmaWorld:sub:Finance, :PharmaWorld:func:RnD, news]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology6466</link>
<description>The Industry Combines Forces To Enhance Neuroscience R&amp;D [:PharmaWorld:sub:Finance, :PharmaWorld:func:RnD, news]</description><category>sub:Finance</category><category>func:RnD</category><category>news</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology6466</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120831&edate=20120501&rec=6466">The Industry Combines Forces To Enhance Neuroscience R&D</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=news"><font color="#e95e0b">:Neurology:news</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=func%3aRnD"><font color="#e95e0b">:PharmaWorld:func:RnD</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=sub%3aFinance"><font color="#e95e0b">:PharmaWorld:sub:Finance</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology6466">Neurology6466</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 21 June 2012 | 12:52</font><br><br><div style="margin-bottom: 10px;">Comment: Announced today at the 2012 BIO International Convention, seven 
companies have joined forces to create the Masachusetts Neuroscience Consortium, 
an institution designed to fund preclinical neuroscience programmes at 
Masachusetts academic and research institutions.<wbr> </div><div style="margin-bottom: 10px;">The companies involved are Abbott, Biogen-Idec, EMD Serono, Janssen, Merck, 
Pfizer and Sunovion.<wbr> Each has pledged $250,000 to create an initial fund of 
$1.<wbr>75m.<wbr> </div><div>The outcome of any research undertaken will be shared with all 
participants.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120831&edate=20120501&rec=6466">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-06-21T12:52:22+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>Main Takeaways from Forest's Analyst Day [:GastroEnterology:dis:IBS, :GastroEnterology:dis:Constipation, :Neurology:comp:Merz, :Ginkgo:dis:Alzheimer, mkt:Brazil, mkt:Intercontinental]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld9951</link>
<description>Main Takeaways from Forest's Analyst Day [:GastroEnterology:dis:IBS, :GastroEnterology:dis:Constipation, :Neurology:comp:Merz, :Ginkgo:dis:Alzheimer, mkt:Brazil, mkt:Intercontinental]</description><category>dis:IBS</category><category>dis:Constipation</category><category>comp:Merz</category><category>dis:Alzheimer</category><category>mkt:Brazil</category><category>mkt:Intercontinental</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld9951</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120831&edate=20120501&rec=9951">Main Takeaways from Forest's Analyst Day</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20120831&edate=20120501&cat=dis%3aConstipation"><font color="#e95e0b">:GastroEnterology:dis:Constipation</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20120831&edate=20120501&cat=dis%3aIBS"><font color="#e95e0b">:GastroEnterology:dis:IBS</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Ginkgo&sdate=20120831&edate=20120501&cat=dis%3aAlzheimer"><font color="#e95e0b">:Ginkgo:dis:Alzheimer</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=comp%3aMerz"><font color="#e95e0b">:Neurology:comp:Merz</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=mkt%3aBrazil"><font color="#e95e0b">:PharmaWorld:mkt:Brazil</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=mkt%3aIntercontinental"><font color="#e95e0b">:PharmaWorld:mkt:Intercontinental</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld9951">PharmaWorld9951</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 21 June 2012 | 09:44</font><br><br><div style="margin-bottom: 10px;">Comment: Already well established in the U.<wbr>S and Canada, the company is poised to expand significantly in Europe and has expressed a particular interest in Brazil/<wbr>Latin America.<wbr> Management expects approval of linaclotide (for IBS-c) in September this year.<wbr> The launch of Namenda XR (early 2013) is perceived as the preservation of the Namenda franchise post genericization.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">R&amp;D Facts and Figures</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/9951/5/ScreenCapture5.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Forest Geo Footprint</FONT></STRONG> </div><div style="margin-bottom: 10px;"><U>Europe </U> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/9951/6/ScreenCapture6.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/9951/7/ScreenCapture7.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Forest Pipeline</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/9951/3/ScreenCapture3.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Focus on Linaclotide</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/9951/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/9951/2/ScreenCapture2.jpg?user-agent=rss"> </div><div><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/9951/4/ScreenCapture4.jpg?user-agent=rss"> </div><!-- Comment details --><a name="pharmaworld9951attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/9951/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(47,7 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/9951/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(42,9 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/9951/3/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(46 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/9951/4/ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(36,1 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/9951/5/ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(57,1 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/9951/6/ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(23 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/9951/7/ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(28,4 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120831&edate=20120501&rec=9951">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-06-21T09:44:20+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/9951/1/ScreenCapture1.jpg" length="48864" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/9951/2/ScreenCapture2.jpg" length="43980" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/9951/3/ScreenCapture3.jpg" length="47133" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/9951/4/ScreenCapture4.jpg" length="36926" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/9951/5/ScreenCapture5.jpg" length="58480" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/9951/6/ScreenCapture6.jpg" length="23578" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/9951/7/ScreenCapture7.jpg" length="29078" type="image/jpeg"/></item><item>
<title>Medy-Tox and Pacific Pharma Have Signed Joint Marketing Agreement [comp:MediTox, :PharmaWorld:func:Sales, :PharmaWorld:mkt:Korea, :PharmaWorld:mkt:Intercontinental, :PharmaWorld:func:Marketing, sub:Aesthetics]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology6464</link>
<description>Medy-Tox and Pacific Pharma Have Signed Joint Marketing Agreement [comp:MediTox, :PharmaWorld:func:Sales, :PharmaWorld:mkt:Korea, :PharmaWorld:mkt:Intercontinental, :PharmaWorld:func:Marketing, sub:Aesthetics]</description><category>comp:MediTox</category><category>func:Sales</category><category>mkt:Korea</category><category>mkt:Intercontinental</category><category>func:Marketing</category><category>sub:Aesthetics</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology6464</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120831&edate=20120501&rec=6464">Medy-Tox and Pacific Pharma Have Signed Joint Marketing Agreement</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=comp%3aMediTox"><font color="#e95e0b">:Neurology:comp:MediTox</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=sub%3aAesthetics"><font color="#e95e0b">:Neurology:sub:Aesthetics</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=func%3aMarketing"><font color="#e95e0b">:PharmaWorld:func:Marketing</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=func%3aSales"><font color="#e95e0b">:PharmaWorld:func:Sales</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=mkt%3aIntercontinental"><font color="#e95e0b">:PharmaWorld:mkt:Intercontinental</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=mkt%3aKorea"><font color="#e95e0b">:PharmaWorld:mkt:Korea</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology6464">Neurology6464</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 20 June 2012 | 16:12</font><br><br><div style="margin-bottom: 10px;">Comment: The purpose of the agreement is to jointly sell Meditoxin (for cosmetic use) in the Korean market.<wbr> Medy-Tox expects a boost from Q3:12 as a result.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Situation to Date</FONT></STRONG> </div><div style="margin-bottom: 10px;">To date, Meditoxin (cosmetic) has been exclusively sold by Pacific Pharma.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Medy-Tox' 2012 Sales Projection</FONT></STRONG> </div><div style="margin-bottom: 10px;">The company expects sales to reach W1.<wbr>8bn, while SG&amp;A to rise to W1.<wbr>3bn on the recruitment of a new sale force.<wbr> </div><div><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/6464/1/ScreenCapture1.jpg?user-agent=rss"> </div><!-- Comment details --><a name="neurology6464attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/6464/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(89 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120831&edate=20120501&rec=6464">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-06-20T16:12:07+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/6464/1/ScreenCapture1.jpg" length="91151" type="image/jpeg"/></item><item>
<title>re: Raptor Files For Approval of RP103</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology6462</link>
<description>re: Raptor Files For Approval of RP103</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology6462</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120831&edate=20120501&rec=6462">re: Raptor Files For Approval of RP103</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology6462">Neurology6462</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 20 June 2012 | 14:42</font><br><br><div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-size: 12px;"><SPAN style="DISPLAY: inline! important; FLOAT: none; WORD-SPACING: 0px; FONT: 13px arial, sans-serif; TEXT-TRANSFORM: none; COLOR: rgb(34,34,34); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; WIDOWS: 2; ORPHANS: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">Comment: FDA has accepted for review an NDA from Raptor Pharmaceuticals for RP103</SPAN><SPAN style="DISPLAY: inline! important; FLOAT: none; WORD-SPACING: 0px; FONT: 13px arial, sans-serif; TEXT-TRANSFORM: none; COLOR: rgb(34,34,34); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; WIDOWS: 2; ORPHANS: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"> to treat nephropathic cystinosis.<wbr> The company had requested Priority Review, but FDA assigned the product a standard review.<wbr> Interestingly the same drug is also being developed by Raptor in a phII trial for Huntington's disease.<wbr></SPAN></span>&nbsp;<br><font size="-1">Jacquelyne CANTLE MEYRICK / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology6458" class="commentpermalink">Neurology6458</a> / <span class="date">14 June 2012</span> /
<span class="time">11:41:21 o'clock CEST</span>
</font></div><div>Alongside the announcement of the acquisition of exclusve rights to IP related to cysteamine and related compounds in the potential treatment of PD from Universite Laval, Dr Patrice Rioux, Raptor's CMO, outlined that the company is currently conducting a Ph2/<wbr>3 trial with RP103 in France for the treatment of HD.<wbr> </div><!-- Comment details --><font size="-1">Brigitte DESCHAMPS / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology6462" class="commentpermalink">Neurology6462</a> / <span class="date">20 June 2012</span> /
<span class="time">14:42:52 o'clock CEST</span>
</font><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120831&edate=20120501&rec=6462">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology6458">View thread  Neurology6458: Raptor Files For Approval of RP103</a>]]></content:encoded><dc:date>2012-06-20T14:42:52+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Swedish Agency Refuses to Grant Reimbursement to Zytiga [prod:Zytiga, :PharmaWorld:mkt:Europe, :PharmaWorld:sub:Pricing, comp:JnJ, dis:Prostate]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology8347</link>
<description>Swedish Agency Refuses to Grant Reimbursement to Zytiga [prod:Zytiga, :PharmaWorld:mkt:Europe, :PharmaWorld:sub:Pricing, comp:JnJ, dis:Prostate]</description><category>prod:Zytiga</category><category>mkt:Europe</category><category>sub:Pricing</category><category>comp:JnJ</category><category>dis:Prostate</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology8347</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8347">Swedish Agency Refuses to Grant Reimbursement to Zytiga</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=comp%3aJnJ"><font color="#e95e0b">:Oncology:comp:JnJ</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=prod%3aZytiga"><font color="#e95e0b">:Oncology:prod:Zytiga</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=mkt%3aEurope"><font color="#e95e0b">:PharmaWorld:mkt:Europe</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=sub%3aPricing"><font color="#e95e0b">:PharmaWorld:sub:Pricing</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8347">Oncology8347</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 20 June 2012 | 14:02</font><br><br><div style="margin-bottom: 10px;">Comment: The TLV considers that the price of Zytiga is far too high when compared to the benefits it brings to patients.<wbr> Thanks to Tommy Söderman (General Manager Ipsen AB) we have more details about the price.<wbr> Janssen-Cilag have asked for a price of 30 000 SEK/<wbr>month (approx.<wbr> 3400€).<wbr> The cost per QALY was calculated to 1,135M SEK (approx.<wbr> 125K€).<wbr> The agency normally accept if this cost is around 600K SEK.<wbr> </div><div style="margin-bottom: 10px;"><B>Significance</B> </div><div style="margin-bottom: 10px;">The TLV acknowledged the slight overall survival benefit shown in patients with metastatic prostate cancer with Zytiga, but denied reimbursement to the medicine despite the need for novel prostate cancer treatments.<wbr> </div><div style="margin-bottom: 10px;">Overall, Janssen has been successful in securing positive reimbursement status for Zytiga in Europe.<wbr> Even the UK's NICE approved its funding under the National Health Service (See <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8279" class="defaultlink">Oncology8279: NICE Reverses Opinion And Agrees To Fund Zytiga Under the NHS</a>).<wbr> </div><div>Additional Source: GlobalInsight </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8347">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-06-20T14:02:06+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>New Trial with Bayer's Alpharadin for CRPC [comp:BayerSchering, dis:Prostate, :PharmaWorld:sub:ClinicalTrial]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology8345</link>
<description>New Trial with Bayer's Alpharadin for CRPC [comp:BayerSchering, dis:Prostate, :PharmaWorld:sub:ClinicalTrial]</description><category>comp:BayerSchering</category><category>dis:Prostate</category><category>sub:ClinicalTrial</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology8345</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8345">New Trial with Bayer's Alpharadin for CRPC</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=comp%3aBayerSchering"><font color="#e95e0b">:Oncology:comp:BayerSchering</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=sub%3aClinicalTrial"><font color="#e95e0b">:PharmaWorld:sub:ClinicalTrial</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8345">Oncology8345</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 20 June 2012 | 08:50</font><br><br><div style="margin-bottom: 10px;">Comment: Clinicaltrials.<wbr>gov is listing a new Ph3 multi-center early access program for the use of Alpharadin in CRPC patients diagnosed with bone metastasis.<wbr> The fact that most of the selected sites are located in EU may lead us to believe that one of the purpose of this trial is for filing the drug in this zone.<wbr> Primary outcomes measures will assess safety.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Trial Details </FONT></STRONG><A href="http://clinicaltrials.gov/ct2/show/NCT01618370?recr=Open&amp;cond=botulinum+OR+spasticity+OR+blepharospasm+OR+prostate+OR+neuroendocrine+OR+acromegaly&amp;fund=2&amp;rcv_s=04%2F21%2F2012&amp;rank=10"><STRONG><FONT size="3">NCT01618370</FONT></STRONG></A> </div><div style="margin-bottom: 10px;">Recruitment: Approx.<wbr> 2000 </div><div style="margin-bottom: 10px;">Start date: June 2012 - Completion dates: Feb.<wbr> 2015 </div><div style="margin-bottom: 10px;">Location: 94 sites, mostly in EU </div><div>Protocol: One injection to be administered every 4 weeks </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8345">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-06-20T08:50:36+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Final Measures of Merck Serono's Efficiency Plan [:Endocrinology:comp:MerckSerono]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld9940</link>
<description>Final Measures of Merck Serono's Efficiency Plan [:Endocrinology:comp:MerckSerono]</description><category>comp:MerckSerono</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld9940</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120831&edate=20120501&rec=9940">Final Measures of Merck Serono's Efficiency Plan</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=comp%3aMerckSerono"><font color="#e95e0b">:Endocrinology:comp:MerckSerono</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld9940">PharmaWorld9940</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 19 June 2012 | 14:59</font><br><br><div style="margin-bottom: 10px;">Comment: Merck Serono has confirmed it will close the Geneva sites (mid-2013) and the Coinsins site (2014).<wbr> The company has reported it will support potential start-ups by its employees through &gt; to €30M financing fund.<wbr> Additional measures are provided below.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">HQ Functions</FONT></STRONG> </div><div style="margin-bottom: 10px;">Merck Serono will consolidate all headquarter functions on a Merck Serono campus in Darmstadt, Germany.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">R&amp;D Resources</FONT></STRONG> </div><div style="margin-bottom: 10px;">Focused in 3 hubs located in Europe (Darmstadt), the USA (Boston) and Asia (Beijing).<wbr> </div><div style="margin-bottom: 10px;">Out of the 1,250 positions currently located in Geneva, approximately 750 will be transferred to other sites (including 130 to the Canton of Vaud) and around 500 will be reduced to eliminate duplications and create a leaner, more agile organization.<wbr> Approximately 80 positions will be made redundant in the sites located in the Canton of Vaud (Aubonne, Coinsins and Corsier-sur-Vevey).<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Manufacturing Operations</FONT></STRONG> </div><div style="margin-bottom: 10px;">Currently based in Coinsins, they will be relocated to Aubonne.<wbr> </div><div style="margin-bottom: 10px;">The biotech production sites located in Aubonne and Corsier-sur-Vevey will continue to manufacture leading medicines for the entire world.<wbr> </div><div style="margin-bottom: 10px;">Merck Serono’s new unit dedicated to biosimilars, a novel activity crucial for the future, will also be based in the Canton of Vaud.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Commercial Operations</FONT></STRONG> </div><div>The commercial operations based in Zug will continue to serve physicians and patients in Switzerland.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120831&edate=20120501&rec=9940">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-06-19T14:59:40+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Second Deal Validates Protagonist's Peptide Technology Platform</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology6972</link>
<description>Second Deal Validates Protagonist's Peptide Technology Platform</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology6972</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120831&edate=20120501&rec=6972">Second Deal Validates Protagonist's Peptide Technology Platform</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology6972">Endocrinology6972</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 19 June 2012 | 08:26</font><br><br><div style="margin-bottom: 10px;">Comment: Zealand Pharma has entered into collaboration with Protagonist Therapeutics, which develops a validated and proprietary technology platform for the discovery and optimization of novel disulfide-rich peptides (DRPs).<wbr> Those peptides are characterized by inherent stabilizing properties, which lead to improved PK profiles.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Terms of the Agreement</FONT></STRONG> </div><div style="margin-bottom: 10px;">Zealand has identified the disease targets for the peptide drug discovery activities covered by the collaboration, and will be responsible for PC and clinical drug development of DRPs, discovered under the collaboration.<wbr> </div><div style="margin-bottom: 10px;">Zealand will fund the deal.<wbr> </div><div style="margin-bottom: 10px;">Protagonist will receive an upfront payment, and is eligible for milestones.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Protagonist Snapshot</FONT></STRONG> </div><div style="margin-bottom: 10px;">- Private </div><div style="margin-bottom: 10px;">- Corporate HQ: Menlo Park, CA (USA) </div><div style="margin-bottom: 10px;">- About the Platform: <A href="http://www.protagonist-inc.com/tech_main.html">http:/<wbr>/<wbr>www.<wbr>protagonist-inc.<wbr>com/<wbr>tech_main.<wbr>html</A> </div><div style="margin-bottom: 10px;">- Business Dev: At the beginning of 2011, the company entered into a collaboration to discover novel peptides for potential development by Ironwood (<A href="http://www.protagonist-inc.com/news/2011/pr_011811.html">http:/<wbr>/<wbr>www.<wbr>protagonist-inc.<wbr>com/<wbr>news/<wbr>2011/<wbr>pr_011811.<wbr>html</A>) </div><div>- Investors: Lilly Ventures; qbf; Starfish Ventures; IMBcom </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120831&edate=20120501&rec=6972">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-06-19T08:26:22+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Debiopharm to Develop Ascepion's Multikinase Inhibitor [comp:Debiopharm, :PharmaWorld:sub:xLicensing]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology8343</link>
<description>Debiopharm to Develop Ascepion's Multikinase Inhibitor [comp:Debiopharm, :PharmaWorld:sub:xLicensing]</description><category>comp:Debiopharm</category><category>sub:xLicensing</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology8343</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8343">Debiopharm to Develop Ascepion's Multikinase Inhibitor</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=comp%3aDebiopharm"><font color="#e95e0b">:Oncology:comp:Debiopharm</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=sub%3axLicensing"><font color="#e95e0b">:PharmaWorld:sub:xLicensing</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8343">Oncology8343</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 18 June 2012 | 16:03</font><br><br><div style="margin-bottom: 10px;">Comment: The drug (ASP-08126, called Debio 1144), in PC development, is expected to be effective in the treatment of various solid tumours as a mono agent or in combination with other anti-cancer therapies.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Drug Characteristics</FONT></STRONG> </div><div style="margin-bottom: 10px;">The drug is designed to inhibit specific signal pathway targets (tyrosine kinases), and has combined functions of bocking blood supply in solid tumours, and inhibiting tumour growth and stopping tumour spreading and metastasis.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Terms of the Licensing Agreement</FONT></STRONG> </div><div style="margin-bottom: 10px;">Exclusive WW agreement.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Ascepion SnapShot</FONT></STRONG> </div><div style="margin-bottom: 10px;">Based in Suzhou, China.<wbr> </div><div style="margin-bottom: 10px;">Focus to the discovery and development of breakthrough small molecule drugs.<wbr> </div><div style="margin-bottom: 10px;">Pipeline <A href="http://www.ascepion.com/EN/zaiyanchanpin.html">http:/<wbr>/<wbr>www.<wbr>ascepion.<wbr>com/<wbr>EN/<wbr>zaiyanchanpin.<wbr>html</A> </div><div style="margin-bottom: 10px;">Platform <A href="http://www.ascepion.com/EN/keyanziyuan.html">http:/<wbr>/<wbr>www.<wbr>ascepion.<wbr>com/<wbr>EN/<wbr>keyanziyuan.<wbr>html</A> </div><div>Sources: Debiopharm; Ascepion </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8343">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-06-18T16:03:25+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Denmark Accelerates Drug Development [func:RnD, mkt:Europe]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld9937</link>
<description>Denmark Accelerates Drug Development [func:RnD, mkt:Europe]</description><category>func:RnD</category><category>mkt:Europe</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld9937</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120831&edate=20120501&rec=9937">Denmark Accelerates Drug Development</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=func%3aRnD"><font color="#e95e0b">:PharmaWorld:func:RnD</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=mkt%3aEurope"><font color="#e95e0b">:PharmaWorld:mkt:Europe</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld9937">PharmaWorld9937</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 18 June 2012 | 13:47</font><br><br><div style="margin-bottom: 10px;">Comment: On June 19th, 'Invest in Denmark' will be organizing a roundtable @ BIO 2012 Conference to outline the Danish success of using translational medicine to bring new drugs faster to market.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Program of the Roundtable</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/9937/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">The roundtable will be lead by Liselotte Hojgaard and moderated by Steven Burrill.<wbr> </div><div style="margin-bottom: 10px;">The focus will be on proven models of collaboration and infrastrcuture to improve R&amp;D.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Rationale for Investing in Denmark</FONT></STRONG> </div><div style="margin-bottom: 10px;">- Improve R&amp;D: The country is among the top ones in the world producing biomedical research per capita.<wbr> </div><div style="margin-bottom: 10px;">- Opportunities for R&amp;D: a National Biobank was just launched with &gt; 15 million biologic samples/<wbr>specimens </div><div style="margin-bottom: 10px;">- Accelerate R&amp;D: the country has the world's oldest cancer registry.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Examples of Major US Life Sciences Companies Interested in Denmark</FONT></STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>Agilent (which just acquired Dako)</LI>
<LI>Abbott (which bought a compound from Action Pharma)</LI>
<LI>Pfizer Consumer HC (which acquired Ferrosan)</LI>
</UL> </div><div>
Please see more @ <A href="http://www.investindk.com/News-and-events/Events/2012/BIO-International-Convention">http:/<wbr>/<wbr>www.<wbr>investindk.<wbr>com/<wbr>News-and-events/<wbr>Events/<wbr>2012/<wbr>BIO-International-Convention</A> </div><!-- Comment details --><a name="pharmaworld9937attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/9937/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(7,5 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120831&edate=20120501&rec=9937">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-06-18T13:47:12+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/9937/1/ScreenCapture1.jpg" length="7651" type="image/jpeg"/></item><item>
<title>Biotest to Officially Exit Greece [mkt:Europe]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld9935</link>
<description>Biotest to Officially Exit Greece [mkt:Europe]</description><category>mkt:Europe</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld9935</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120831&edate=20120501&rec=9935">Biotest to Officially Exit Greece</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=mkt%3aEurope"><font color="#e95e0b">:PharmaWorld:mkt:Europe</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld9935">PharmaWorld9935</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 18 June 2012 | 08:33</font><br><br><div style="margin-bottom: 10px;">Comment: The German company has reported that it would halt shipments to Greece next month, becoming the first drugmaker to announce it would leave the country because unpaid bills.<wbr> As a medium-sized pharmaceutical company, Biotest is exactly the type of firm which may feel that it is unable to withstand the financial pressures which it is under in Greece, not able—unlike larger companies—to absorb the losses sufficiently.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Company Situation in Other EU Countries</FONT></STRONG> </div><div style="margin-bottom: 10px;">According to management, in Italy customers are not taking any longer to pay their bills than they used to.<wbr> In Spain, where the company's exposure is limited, Biotest does not participate in public hospital tenders because it could take 2 years to receive any payment.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Implications</FONT></STRONG> </div><div style="margin-bottom: 10px;">Biotest, as a medium-sized pharmaceutical company with annual revenues of just over EUR400 million, may be a good example of the type of company which could see its position in Greece as untenable in the coming months, and, although in itself the withdrawal of the company is not majorly significant, its symbolic significance is much greater.<wbr> This is because in all previous standoffs between the Greek authorities and pharmaceutical companies, such as Novo Nordisk and LEO Pharma (both Denmark) in 2010, and later ones involving Roche (Switzerland), Bayer (Germany) and others, there was never the suggestion that the company intended to withdraw all supplies from the market, and indeed, this possibility was studiously played down, considering the potential adverse publicity which could result from such a move.<wbr> </div><div style="margin-bottom: 10px;">However, once one company has made this move, it becomes easier for others—and it is more probable that this would be the medium-sized or smaller pharmaceutical companies, for whom a loss of several million euro in Greece is an important issue, rather than the pharma majors, which are more capable of absorbing such losses.<wbr> </div><div style="margin-bottom: 10px;">Meanwhile, the respite for Greeks seeking medicines in pharmacies will be limited in terms of its geographic scope, and if the Pharmaceutical Association of Attica opts to continue the protest, as predicted, then in Greece's most populous region, the protest will persist.<wbr> Although there is a small glimmer of hope here, with promises of payments in order to get the pharmaceutical care system flowing again, the prospect of major protests by doctors puts any optimism on hold.<wbr> </div><div style="margin-bottom: 10px;">More broadly, the success of the pro-bailout New Democracy party in yesterday (June 17)'s parliamentary election means that at least there is some sense of stability restored to Greece, which may have a positive influence on the healthcare sector, especially if—as is widely predicted—there is a relative easing of the severity of the austerity measures the country is undergoing.<wbr> </div><div>Sources: PRs; GlobalInsight </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120831&edate=20120501&rec=9935">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-06-18T08:33:19+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>J&amp;J Intends to Extend the Use of Zytiga Earlier in the Course of Prostate Cancer [comp:JnJ, dis:Prostate, prod:Zytiga, :PharmaWorld:sub:Regulatory, :PharmaWorld:mkt:NorthAmerica, :PharmaWorld:mkt:Europe]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology8342</link>
<description>J&amp;J Intends to Extend the Use of Zytiga Earlier in the Course of Prostate Cancer [comp:JnJ, dis:Prostate, prod:Zytiga, :PharmaWorld:sub:Regulatory, :PharmaWorld:mkt:NorthAmerica, :PharmaWorld:mkt:Europe]</description><category>comp:JnJ</category><category>dis:Prostate</category><category>prod:Zytiga</category><category>sub:Regulatory</category><category>mkt:NorthAmerica</category><category>mkt:Europe</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology8342</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8342">J&J Intends to Extend the Use of Zytiga Earlier in the Course of Prostate Cancer</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=comp%3aJnJ"><font color="#e95e0b">:Oncology:comp:JnJ</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=prod%3aZytiga"><font color="#e95e0b">:Oncology:prod:Zytiga</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=mkt%3aEurope"><font color="#e95e0b">:PharmaWorld:mkt:Europe</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=mkt%3aNorthAmerica"><font color="#e95e0b">:PharmaWorld:mkt:NorthAmerica</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=sub%3aRegulatory"><font color="#e95e0b">:PharmaWorld:sub:Regulatory</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8342">Oncology8342</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 15 June 2012 | 16:58</font><br><br><div style="margin-bottom: 10px;">Comment: The company has simultaneously submitted a type II variation to the EMA and a supplemental sNDA to the FDA.<wbr> Both applications are intended to extend the use of the drug administered with prednisone for the treatment of patients with mCRPC who are asymptomatic or midly symptomatic after failure of ADT and before chemotherapy.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Approved Status</FONT></STRONG> </div><div>ZYTIGA in combination with prednisone was approved by the FDA in April 2011 and by the European Commission in September 2011 for the treatment of men with mCRPC who have received prior chemotherapy containing docetaxel.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8342">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-06-15T16:58:32+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Study: Fluorescent Cystoscopy Beats White Light in Bladder Cancer Surgery [dis:Bladder]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology8334</link>
<description>Study: Fluorescent Cystoscopy Beats White Light in Bladder Cancer Surgery [dis:Bladder]</description><category>dis:Bladder</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology8334</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8334">Study: Fluorescent Cystoscopy Beats White Light in Bladder Cancer Surgery</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=dis%3aBladder"><font color="#e95e0b">:Oncology:dis:Bladder</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8334">Oncology8334</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 15 June 2012 | 15:31</font><br><br><div style="margin-bottom: 10px;">Comment: Forwarded by Anne Kornowski (Global Medical Director, Uro-Onco), this article outlines the findings of a controlled, prospective and randomized trial.<wbr> Grossman and al reported "that fluorescent cytoscopy compared to standard white light cytoscopy detected more tumours, resulted in lower tumour recurrence rates and longer disease free intervals, and showed a trend toward increased bladder preservation".<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Study Details</FONT></STRONG> </div><div style="margin-bottom: 10px;">551 patients were tracked for &gt;9 months after surgery for bladder cancer; follow-up to a median of about 4.<wbr>5 years in 516 patients.<wbr> </div><div style="margin-bottom: 10px;"><U>Key Outcomes</U> </div><div style="margin-bottom: 10px;"><UL><LI>Time to recurrence: longer in the fluorescence group (16.<wbr>4 vs 9.<wbr>4 months, p=0.<wbr>04).<wbr></LI>
<LI>T2-T4 recurrences: fewer in the fluorescence group (3.<wbr>1% vs 6.<wbr>1%, p=0.<wbr>066).<wbr></LI>
<LI>Tumour free: <SPAN style="DISPLAY: inline! important; FLOAT: none; WORD-SPACING: 0px; FONT: 13px/18px arial, sans-serif; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); TEXT-ALIGN: left; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><FONT face="Verdana" size="2">31.<wbr>8% of white light patients remained tumor free, compared to 38.<wbr>0% in the fluorescence group, a nonsignificant difference.<wbr></FONT></SPAN></LI>
</UL> </div><div style="margin-bottom: 10px;"><SPAN style="DISPLAY: inline! important; FLOAT: none; WORD-SPACING: 0px; FONT: 13px/18px arial, sans-serif; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); TEXT-ALIGN: left; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><FONT face="Verdana" size="3"><STRONG>Comment and Conclusions</STRONG></FONT></SPAN> </div><div style="margin-bottom: 10px;"><P style="PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; MARGIN: 5px 0px 15px; WORD-SPACING: 0px; FONT: 13px/18px arial, sans-serif; OVERFLOW: visible; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); TEXT-INDENT: 0px; PADDING-TOP: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; TEXT-ALIGN: left; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><FONT face="Verdana" size="2">The authors write, "While it is reasonable to hypothesize that better bladder cancer visualization results in more complete resection and an improved disease-free interval, conflicting data from different studies make this conclusion controversial.<wbr>" T</FONT><FONT face="Verdana" size="2">hey conclude, "Experienced urologists can quickly become competent in fluorescence cystoscopy.<wbr>"</FONT></P> </div><div style="margin-bottom: 10px;"><P style="PADDING-RIGHT: 0px; PADDING-LEFT: 0px; PADDING-BOTTOM: 0px; MARGIN: 5px 0px 15px; WORD-SPACING: 0px; FONT: 13px/18px arial, sans-serif; OVERFLOW: visible; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); TEXT-INDENT: 0px; PADDING-TOP: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; TEXT-ALIGN: left; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><FONT face="Verdana" size="2">Dr.<wbr> Grossman added, "This easily learned technique can improve patient outcomes.<wbr>"</FONT></P> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Source</FONT></STRONG> </div><div><EM>H.<wbr> Barton Grossman - </EM>"Long-Term Decrease in Bladder Cancer Recurrence with Hexaminolevulinate Enabled Fluorescence Cystoscopy" - </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8334">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-06-15T15:31:54+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Key Takeaways from AstraZeneca R&amp;D Day [func:RnD, :Oncology:comp:AstraZeneca]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld9931</link>
<description>Key Takeaways from AstraZeneca R&amp;D Day [func:RnD, :Oncology:comp:AstraZeneca]</description><category>func:RnD</category><category>comp:AstraZeneca</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld9931</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120831&edate=20120501&rec=9931">Key Takeaways from AstraZeneca R&D Day</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=comp%3aAstraZeneca"><font color="#e95e0b">:Oncology:comp:AstraZeneca</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=func%3aRnD"><font color="#e95e0b">:PharmaWorld:func:RnD</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld9931">PharmaWorld9931</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 15 June 2012 | 14:56</font><br><br><div style="margin-bottom: 10px;">Comment: The company highlighted the significant changes since 2010 with respect to its R&amp;D (60% of top 50 managers are new hires, &gt;40% of pipeline is sourced externally, biologics are 45% of portfolio).<wbr> Below is a selection of key slides from the presentation.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Transforming R&amp;D (2010-2012)</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/9931/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/9931/2/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">Using the 5 Rs (“Right” – target, tissue, safety, patients, and commercial opportunity), and making better Ph3 go/<wbr>no-go decisions than in the past based on efficacy/<wbr>safety “assurance mapping”<img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/9931/3/ScreenCapture3.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">R&amp;D Priorities</FONT></STRONG> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/9931/4/ScreenCapture4.jpg?user-agent=rss"></FONT></STRONG> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Accountability @ Every Stage</FONT></STRONG> </div><div><STRONG><FONT size="3"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/9931/5/ScreenCapture5.jpg?user-agent=rss"></FONT></STRONG> </div><!-- Comment details --><a name="pharmaworld9931attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/9931/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(66,8 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/9931/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(42,2 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/9931/3/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(28,5 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/9931/4/ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(59 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/9931/5/ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(53,6 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120831&edate=20120501&rec=9931">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-06-15T14:56:57+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/9931/1/ScreenCapture1.jpg" length="68402" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/9931/2/ScreenCapture2.jpg" length="43212" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/9931/3/ScreenCapture3.jpg" length="29200" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/9931/4/ScreenCapture4.jpg" length="60410" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/9931/5/ScreenCapture5.jpg" length="54902" type="image/jpeg"/></item><item>
<title>Lundbeck Restructuring EU Commercial Organization [mkt:Europe]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld9930</link>
<description>Lundbeck Restructuring EU Commercial Organization [mkt:Europe]</description><category>mkt:Europe</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld9930</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120831&edate=20120501&rec=9930">Lundbeck Restructuring EU Commercial Organization</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=mkt%3aEurope"><font color="#e95e0b">:PharmaWorld:mkt:Europe</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld9930">PharmaWorld9930</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 15 June 2012 | 09:46</font><br><br><div style="margin-bottom: 10px;">Comment: The company has cited increased pressure from healthcare reforms, generic competition and uncertainty regarding price and reimbursement in EU as the reasons of the restructuring, which will primarily affect sales reps who target GPs.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Details of the Restructuring</FONT></STRONG> </div><div style="margin-bottom: 10px;">Lundbeck will reduce its EU commercial organization by approx.<wbr> 600 (30%) to about 1,200.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Timelines</FONT></STRONG> </div><div><SPAN style="DISPLAY: inline! important; FLOAT: none; WORD-SPACING: 0px; FONT: 13px arial, sans-serif; TEXT-TRANSFORM: none; COLOR: rgb(34,34,34); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><FONT face="Verdana" size="2">Lundbeck expects to complete the restructuring this year.<wbr></FONT></SPAN> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120831&edate=20120501&rec=9930">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-06-15T09:46:57+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Ipsen Shortcuts</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld9928</link>
<description>Ipsen Shortcuts</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld9928</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120831&edate=20120501&rec=9928">Ipsen Shortcuts</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld9928">PharmaWorld9928</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/254">Vivien SORET</a> | 14 June 2012 | 13:57</font><br><br><div style="margin-bottom: 10px;"><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120831&edate=20120501&rec=7400&brief=n&rsin=/link%20PharmaWorld7400%20%27Congresses%27&title=Congresses" class="defaultlink">Congresses</a><BR><a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=*&sdate=20120831&edate=All&cat=%3aPharmaWorld%3asub%3aUSwatch&rsin=/link%20%3a%3aPharmaWorld%3asub%3aUSwatch%20all%20%27US%20Watch%27%20()&title=US%20Watch" class="defaultlink">US Watch</a> <BR><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120831&edate=20120501&rec=0&brief=n&rsin=/link%20PharmaWorld0%20%27Competitors%27%20()&title=Competitors" class="defaultlink">Competitors</a> <BR><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120831&edate=20120501&rec=10099&brief=n&rsin=/link%20PharmaWorld10099%20%27%7c%27" class="defaultlink">Therapy Area Landscapes (TALs)</a> </div><div style="margin-bottom: 10px;"><SPAN style="font-size: small; color: #333333;"><STRONG>Get involved!</STRONG></SPAN><BR><a href="http://ci.beaufour-ipsen.com/traction?type=ipsentipform&proj=*&sdate=20120831&edate=20120501&rsin=/link%20type%20ipsentipform%20%27Give%20a%20CI%20Lead%27&title=Give%20a%20CI%20Lead" class="defaultlink">Give a CI Lead</a> </div><div><a href="/db/share/pharmaworld/EndUserTraining_Proteus.pptx" target="_blank" class="defaultlink">End User Training Guide</a> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120831&edate=20120501&rec=9928">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-06-14T13:57:52+02:00</dc:date><dc:creator>vis24524</dc:creator></item><item>
<title>Afinitor Approved for Full Reimbursement in Finland [dis:pNET, :PharmaWorld:mkt:Europe, :PharmaWorld:sub:Pricing, comp:Novartis]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology6971</link>
<description>Afinitor Approved for Full Reimbursement in Finland [dis:pNET, :PharmaWorld:mkt:Europe, :PharmaWorld:sub:Pricing, comp:Novartis]</description><category>dis:pNET</category><category>mkt:Europe</category><category>sub:Pricing</category><category>comp:Novartis</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology6971</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120831&edate=20120501&rec=6971">Afinitor Approved for Full Reimbursement in Finland</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=comp%3aNovartis"><font color="#e95e0b">:Endocrinology:comp:Novartis</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=dis%3apNET"><font color="#e95e0b">:Endocrinology:dis:pNET</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=mkt%3aEurope"><font color="#e95e0b">:PharmaWorld:mkt:Europe</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=sub%3aPricing"><font color="#e95e0b">:PharmaWorld:sub:Pricing</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology6971">Endocrinology6971</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 14 June 2012 | 13:34</font><br><br><div style="margin-bottom: 10px;">Comment: On June 6, Finland's Pharmaceuticals Pricing Board granted limited special reimbursement status to Novartis' Afinitor (everolimus).<wbr> Afinitor will as of 1 September 2012 be reimbursed at 100% for advanced renal cell carcinoma, and for the treatment of advanced pancreatic neuroendocrine tumours when the cancer cells are well- or moderately differentiated and the cancer is getting worse.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Significance</FONT></STRONG> </div><div style="margin-bottom: 10px;">The reimbursement verdict is good news for Novartis.<wbr> </div><div style="margin-bottom: 10px;">The drug is reimbursed at 42% since it entered the Basic Refund category in June 2010.<wbr> Novartis has fixed the price of 30 doses of Afinitor in its 5mg formulation at EUR3,006.<wbr>06 (USD3,766.<wbr>86).<wbr> </div><div style="margin-bottom: 10px;">Last year, the health insurers spent a total of EUR1.<wbr>3 million on Afinitor.<wbr> The new reimbursement status of the drug should increase public expenditure by about EUR80,000 per year.<wbr> </div><div>Source: Global Insight </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120831&edate=20120501&rec=6971">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-06-14T13:34:01+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Raptor Files For Approval of RP103 [dis:Huntington, news]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology6458</link>
<description>Raptor Files For Approval of RP103 [dis:Huntington, news]</description><comments>http://ci.beaufour-ipsen.com/traction/permalink/Neurology6458</comments><category>dis:Huntington</category><category>news</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology6458</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120831&edate=20120501&rec=6458">Raptor Files For Approval of RP103</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=dis%3aHuntington"><font color="#e95e0b">:Neurology:dis:Huntington</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=news"><font color="#e95e0b">:Neurology:news</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology6458">Neurology6458</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 14 June 2012 | 11:41</font><br><br><div style="margin-bottom: 10px;"><SPAN style="DISPLAY: inline! important; FLOAT: none; WORD-SPACING: 0px; FONT: 13px arial, sans-serif; TEXT-TRANSFORM: none; COLOR: rgb(34,34,34); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; WIDOWS: 2; ORPHANS: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">Comment: FDA has accepted for review an NDA from Raptor Pharmaceuticals for RP103</SPAN><SPAN style="DISPLAY: inline! important; FLOAT: none; WORD-SPACING: 0px; FONT: 13px arial, sans-serif; TEXT-TRANSFORM: none; COLOR: rgb(34,34,34); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; WIDOWS: 2; ORPHANS: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"> to treat nephropathic cystinosis.<wbr> The company had requested Priority Review, but FDA assigned the product a standard review.<wbr> Interestingly the same drug is also being developed by Raptor in a phII trial for Huntington's disease.<wbr></SPAN> <a name="Neurology6462c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div>Alongside the announcement of the acquisition of exclusve rights to IP related to cysteamine and related compounds in the potential treatment of PD from Universite Laval, Dr Patrice Rioux, Raptor's CMO, outlined that the company is currently conducting a Ph2/<wbr>3 trial with RP103 in France for the treatment of HD.<wbr> </div><font size="-1">Brigitte DESCHAMPS / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology6462" class="commentpermalink">Neurology6462</a> / <span class="date">20 June 2012</span> /
<span class="time">14:42:52 o'clock CEST</span>
</font></div></div><div style="margin-bottom: 10px;"><SPAN style="DISPLAY: inline! important; FLOAT: none; WORD-SPACING: 0px; FONT: 13px arial, sans-serif; TEXT-TRANSFORM: none; COLOR: rgb(34,34,34); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; WIDOWS: 2; ORPHANS: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><STRONG>What is RP103 &amp; What Has Been Demonstrated So Far</STRONG></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="DISPLAY: inline! important; FLOAT: none; WORD-SPACING: 0px; FONT: 13px arial, sans-serif; TEXT-TRANSFORM: none; COLOR: rgb(34,34,34); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; WIDOWS: 2; ORPHANS: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">RP103 is a delayed-release formulation of the degradation product of the amino acid cysteine.<wbr> The existing formulation on the market has signficant compliance issues because it has to be taken every 6 hours through the night</SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="DISPLAY: inline! important; FLOAT: none; WORD-SPACING: 0px; FONT: 13px arial, sans-serif; TEXT-TRANSFORM: none; COLOR: rgb(34,34,34); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; WIDOWS: 2; ORPHANS: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><FONT color="#000000">Raptor’s </FONT>Phase 3 trial<FONT color="#000000"> of Delayed-Release or DR Cysteamine, (RP103), for the treatment of nephropathic cystinosis, met the primary endpoint of non-inferiority compared to currently marketed immediate-release cysteamine bitartrate</FONT></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="DISPLAY: inline! important; FLOAT: none; WORD-SPACING: 0px; FONT: 13px arial, sans-serif; TEXT-TRANSFORM: none; COLOR: rgb(34,34,34); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; WIDOWS: 2; ORPHANS: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">The PDUFA date is not disclosed but should be around January 2013.<wbr> The product is also under review in the EU for the indication, with a decision expected in 1H13.<wbr> </SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="DISPLAY: inline! important; FLOAT: none; WORD-SPACING: 0px; FONT: 13px arial, sans-serif; TEXT-TRANSFORM: none; COLOR: rgb(34,34,34); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; WIDOWS: 2; ORPHANS: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><STRONG>Development Status For Huntington's Disease</STRONG></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="DISPLAY: inline! important; FLOAT: none; WORD-SPACING: 0px; FONT: 13px arial, sans-serif; TEXT-TRANSFORM: none; COLOR: rgb(34,34,34); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; WIDOWS: 2; ORPHANS: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/6458/1/ScreenCapture1.jpg?user-agent=rss"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="DISPLAY: inline! important; FLOAT: none; WORD-SPACING: 0px; FONT: 13px arial, sans-serif; TEXT-TRANSFORM: none; COLOR: rgb(34,34,34); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; WIDOWS: 2; ORPHANS: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">As a company Raptor is focused on improving the lives of patients with severe rare diseases.<wbr></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="DISPLAY: inline! important; FLOAT: none; WORD-SPACING: 0px; FONT: 13px arial, sans-serif; TEXT-TRANSFORM: none; COLOR: rgb(34,34,34); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; WIDOWS: 2; ORPHANS: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/6458/2/ScreenCapture2.jpg?user-agent=rss"></SPAN> </div><div><SPAN style="DISPLAY: inline! important; FLOAT: none; WORD-SPACING: 0px; FONT: 13px arial, sans-serif; TEXT-TRANSFORM: none; COLOR: rgb(34,34,34); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; WIDOWS: 2; ORPHANS: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">Source:www.<wbr>raptor.<wbr>com</SPAN> </div><!-- Comment details --><a name="neurology6458attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/6458/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(81,6 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/6458/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(96,7 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120831&edate=20120501&rec=6458">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-06-14T11:41:21+02:00</dc:date><dc:creator>jac89886</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/6458/1/ScreenCapture1.jpg" length="83535" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/6458/2/ScreenCapture2.jpg" length="99070" type="image/jpeg"/></item><item>
<title>Study: Long-Term Outcome of Botox for Idiopathic and Neurogenic Detrusor Overactivity [comp:Allergan, prod:Botox, dis:iOAB]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology6457</link>
<description>Study: Long-Term Outcome of Botox for Idiopathic and Neurogenic Detrusor Overactivity [comp:Allergan, prod:Botox, dis:iOAB]</description><category>comp:Allergan</category><category>prod:Botox</category><category>dis:iOAB</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology6457</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120831&edate=20120501&rec=6457">Study: Long-Term Outcome of Botox for Idiopathic and Neurogenic Detrusor Overactivity</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=comp%3aAllergan"><font color="#e95e0b">:Neurology:comp:Allergan</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=dis%3aiOAB"><font color="#e95e0b">:Neurology:dis:iOAB</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=prod%3aBotox"><font color="#e95e0b">:Neurology:prod:Botox</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology6457">Neurology6457</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/20">Alison Attard</a> | 13 June 2012 | 18:26</font><br><br><div style="margin-bottom: 10px;">Comment:  An article in BJU International note that at 3 years only one third of patients were still using Botox.<wbr> The accompanying editorial notes the shortcomings of this retrospective study.<wbr> </div><div style="margin-bottom: 10px;"><DIV class="para">
<P>The authors of the study say that it has the merit of reporting a &lsquo;real-life&rsquo; experience in a large teaching hospital in the UK National Health Service.<wbr> The retrospective study is based largely on patient choice and results show that shows that most patients fail to persist with intravesical BT treatment, mainly due to tolerability issues.<wbr></P>
<P><SPAN style="text-decoration: underline;">Study Details</SPAN></P>
</DIV> </div><div style="margin-bottom: 10px;"><DIV class="para">
<UL class="custom"><LI>
Over a period of 7 years, 268 patients were initiated on intravesical BT treatment for overactive bladder, with 137 followed up for &ge;36 months, with 80 patients having &ge;60 months follow-up after their first injection.<wbr>

</LI>
</UL>
</DIV> </div><div style="margin-bottom: 10px;"><DIV class="section">
<UL><LI>Almost two-thirds of patients (61.<wbr>3%) had discontinued intravesical BT therapy at 36 months, with a 63.<wbr>8% discontinuation rate at 60 months.<wbr>
</LI>
<LI>
The main reasons for discontinuation were tolerability issues, mainly urinary tract infections and the need for clean intermittent self-catheterisation.<wbr> Primary and secondary losses of efficacy were of secondary importance.<wbr>

</LI>
</UL>
</DIV> </div><div style="margin-bottom: 10px;"><P class="text">The study authors conclude that intravesical BY therapy is only effectve as a short-term treatment for OAB.<wbr></P> </div><div style="margin-bottom: 10px;"><P class="text">The authors acknowledge that shortcomings of the study: the use of an unlicensed treatment, the retrospective nature - with success being reported by patients rather than using a urological tool or questionnaire, all patients were in a single centre under the care of a single surgeon.<wbr>  Technical issues may have biased the results - lack of antibiotic prophylaxis and the use of relatively high doses in the early years.<wbr></P> </div><div style="margin-bottom: 10px;"><P class="text">The editorial notes thsese shortcomings and adds that if the 27% of patients who never had efficacy from their first treatment are removed from the calculations then the 'success rate' would be higher.<wbr></P> </div><div><P class="text">Source: BJU International published online: 6 JUN 2012</P> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120831&edate=20120501&rec=6457">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-06-13T18:26:06+02:00</dc:date><dc:creator>ala97794</dc:creator></item><item>
<title>Nymox Initiates Localised Prostate Cancer Study With NX-1207 [dis:Prostate, news]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology8330</link>
<description>Nymox Initiates Localised Prostate Cancer Study With NX-1207 [dis:Prostate, news]</description><category>dis:Prostate</category><category>news</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology8330</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8330">Nymox Initiates Localised Prostate Cancer Study With NX-1207</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=news"><font color="#e95e0b">:Oncology:news</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8330">Oncology8330</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 13 June 2012 | 15:34</font><br><br><div style="margin-bottom: 10px;">Comment: Nymox has enrolled the first patient in its phII study of NX-1207 for localised low risk prostate cancer.<wbr> NX-1207 is currently in phIII development in the US and Europe for BPH and is licensed to Recordatti for development &amp; commercialisation in Europe.<wbr> </div><div style="margin-bottom: 10px;">Preclinical studies with NX-1207 have shown activity against prostate cancer at higher dosage levels that are being studied for BPH.<wbr> </div><div style="margin-bottom: 10px;">The new study will test both high and low doses of NX-1207 and will have an efficacy readout at 6 weeks (see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8140" class="defaultlink">Oncology8140: New Prostate Cancer Indication for Nymox' NX-1207 Enters Ph2</a>).<wbr> </div><div style="margin-bottom: 10px;">NX-1207 is administered directly into the prostate by a urologist in an office setting that does not require aneasthesia, sedation or catheterization.<wbr> It takes only a few minutes to administer and in the BPH setting thus far has demonstrated none of the adverse sexual side-effects associated with some other medical therapies.<wbr> </div><div>Source: <a href="http://www.nymox.com" class="defaultlink" title="http://www.nymox.com">nymox.com</a> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8330">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-06-13T15:34:26+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>ASCO Intelligence Update - Part V - HCC [:PharmaWorld:congress:ASCO, :PharmaWorld:sub:ClinicalTrial]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology8329</link>
<description>ASCO Intelligence Update - Part V - HCC [:PharmaWorld:congress:ASCO, :PharmaWorld:sub:ClinicalTrial]</description><category>congress:ASCO</category><category>sub:ClinicalTrial</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology8329</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8329">ASCO Intelligence Update - Part V - HCC</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=congress%3aASCO"><font color="#e95e0b">:PharmaWorld:congress:ASCO</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=sub%3aClinicalTrial"><font color="#e95e0b">:PharmaWorld:sub:ClinicalTrial</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8329">Oncology8329</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/774">bee75336</a> | 13 June 2012 | 14:02</font><br><br><div style="margin-bottom: 10px;">Comment: Progress in HCC has been less dynamic although this not through lack of trying.<wbr> There have been a number of high profile trial failures described in Andrews Zhu’s talk including AZ’s cediranib which has been terminated.<wbr> The tivantinib study against this gloomy backdrop was considered a ray of sunshine, showing for the first time an OS advantage by inhibiting MET in HCC.<wbr> </div><div style="margin-bottom: 10px;">GSK’s foretinib showed promise in Phase II, and AG’s resminostat, generated some interest at the conference with the results of its Phase II Shelter study presented at ASCO as a poster.<wbr> There was also some activity seen in the <B>final clinical results of a single-arm phase II study of bevacizumab and everolimus which showed </B>combination treatment of RAD001 and bevazicumab is tolerated acceptably.<wbr> TTP and OS in the 1°/<wbr>2°-line HCC patients on treatment is comparable to sorafenib monotherapy in the SHARP trial (1° line only).<wbr> </div><div style="margin-bottom: 10px;">In addition, a number of HCC studies were “scientifically advertising” themselves in poster format, abstracts reiterating their protocols and recruitment status.<wbr> These can be found on clinicaltrials.<wbr>gov.<wbr> </div><div style="margin-bottom: 10px;"><B>A review of the Management of Hepatocellular Carcinoma (HCC): Standard Therapy and a Look to New Targets.<wbr></B> Zhu’s discussed staging and general principles of the management of HCC, management of early and intermediate stage of HCC, sorafenib use in HCC and new targets and regimens under development.<wbr> </div><div style="margin-bottom: 10px;">Less than 30% of HCC patients are suitable for surgical resection with a medium survival of 30%.<wbr> Currently there is no established adjuvant therapy with sorafenib currently being investigated in this context.<wbr> Transplantation is considered to be a highly successful with overall survival and recurrence-free survival in the 80-90% range.<wbr> </div><div style="margin-bottom: 10px;">In addition to RFA and TACE novel local treatment modalities are evolving.<wbr> DEB treatment with doxorubicin was specifically highlighted.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8329/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">Many questions are still needing to be answered regarding TACE and other treatments for unresectable disease including, patient selection, optimal chemotherapy agents and how to incorporate sorafenib.<wbr> A Phase III trial combining sorafenib with TACE unfortunately failed to meet its primary endpoint despite encouraging Phase I data.<wbr> A Phase II trial combining DEB-TACE with sorafenib also failed to meet its primary endpoint.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8329/2/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><SPAN style="FONT-SIZE: 11pt; FONT-FAMILY: 'Arial','sans-serif'; mso-fareast-font-family: Calibri; mso-ansi-language: EN-GB; mso-fareast-language: JA; mso-bidi-language: AR-SA">Sorafenib is the only agent approved to treat HCC a situation that hasn’t change over the past 5 years.<wbr> <img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8329/3/ScreenCapture3.jpg?user-agent=rss"></SPAN> </div><div style="margin-bottom: 10px;">Additional regimens are being trialled with existing and new agents but sadly, there has been a high risk of failure in both first and second line.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8329/4/ScreenCapture4.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">Next steps being considered for HCC </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8329/5/ScreenCapture5.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8329/6/ScreenCapture6.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><SPAN style="FONT-SIZE: 11pt; FONT-FAMILY: 'Arial','sans-serif'; mso-fareast-font-family: Calibri; mso-ansi-language: EN-GB; mso-fareast-language: JA; mso-bidi-language: AR-SA">Silencing the expression of c-Met is generating exciting Phase II data with tivantinib being highlighted.<wbr><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8329/7/ScreenCapture7.jpg?user-agent=rss"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="FONT-SIZE: 11pt; FONT-FAMILY: 'Arial','sans-serif'; mso-fareast-font-family: Calibri; mso-ansi-language: EN-GB; mso-fareast-language: JA; mso-bidi-language: AR-SA"><SPAN style="FONT-SIZE: 11pt; FONT-FAMILY: 'Arial','sans-serif'; mso-fareast-font-family: Calibri; mso-ansi-language: EN-GB; mso-fareast-language: JA; mso-bidi-language: AR-SA">Combining molecule target agents such as VEGF + EGRF pathway inhibitors has been explored with some success.<wbr> Dr Zhu pointed out the importance of patient selection with regard to single arm trials given the wide discrepancy of observed results</SPAN></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="FONT-SIZE: 11pt; FONT-FAMILY: 'Arial','sans-serif'; mso-fareast-font-family: Calibri; mso-ansi-language: EN-GB; mso-fareast-language: JA; mso-bidi-language: AR-SA"><SPAN style="FONT-SIZE: 11pt; FONT-FAMILY: 'Arial','sans-serif'; mso-fareast-font-family: Calibri; mso-ansi-language: EN-GB; mso-fareast-language: JA; mso-bidi-language: AR-SA"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8329/8/ScreenCapture8.jpg?user-agent=rss"></SPAN></SPAN> </div><div style="margin-bottom: 10px;">Dr Zhu concluded that biomarker lead tumour signatures will play an increasing role in guiding HCC treatment regimes and was very encouraged by tivantinib results.<wbr> </div><div style="margin-bottom: 10px;"><B>Oral Abstracts of Interest</B> </div><div style="margin-bottom: 10px;">• <B>Activity of Cabozantinib in HCC: Results from a phase II randomised discontinuation trial presented by Dr.<wbr>Chris Verslype.<wbr> </B>Study design below.<wbr> 41 advanced HCC patients , treated 12 weeks open label w/<wbr> cabozantinib, stratified in 3 groups </div><div style="margin-bottom: 10px;">◦ PR or CR : extension open label ( 17%) </div><div style="margin-bottom: 10px;">◦ SD : blinded &amp; randomized placebo vs cabozantinib ( 54%) </div><div style="margin-bottom: 10px;">◦ PD : discontinued (22%) </div><div style="margin-bottom: 10px;">◦ population characteristics : 61 median age, 37% asian - 63% non asian, 73% extrahepatic spread </div><div style="margin-bottom: 10px;">◦ Results : </div><div style="margin-bottom: 10px;">▪ 4.<wbr>4 months PFS regardless of prior treatment w/<wbr> sorfenib &amp; 15.<wbr>1 month median OS </div><div style="margin-bottom: 10px;">▪ 35% AFP response in patients randomized </div><div style="margin-bottom: 10px;">▪ 78% regression per RECIST </div><div style="margin-bottom: 10px;">▪ increase in hemoglobin ( 3g/<wbr>dl) over time </div><div style="margin-bottom: 10px;">▪ 29% discontinued prior week 12 </div><div style="margin-bottom: 10px;">▪ AEs : fatigue grade 3+ : 10% &amp; diarrhea grade 3+ : 20% </div><div style="margin-bottom: 10px;">Discussion </div><div style="margin-bottom: 10px;">• c-MET has some rationale , it does bad things as well ie proliferation.<wbr>.<wbr>.<wbr> </div><div style="margin-bottom: 10px;">• HCC is difficult population : frequent SD, heterogeneous etiologies </div><div style="margin-bottom: 10px;">• vs tivantinib, cabozantinib has a second pathway ie VEGFR2 besides c-MET &amp; a novel trial design ( randomized discontinuation) </div><div style="margin-bottom: 10px;">• an issue was the high amounts of discontinuation </div><div style="margin-bottom: 10px;">• PFS over 4 month suggests some effect while 15 month survival is encouraging.<wbr> </div><div style="margin-bottom: 10px;">• This is a highly selected patient group in a small study </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8329/9/ScreenCapture9.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8329/10/ScreenCapture10.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">A phenomena that happened during this trial is increases in haemoglobin but it is not yet known if this is a class or drug effect.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8329/11/ScreenCapture11.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">There is a randomised in depth phase II study at a lower dose of 60mg in 2<SUP>nd</SUP> line HCC is planned </div><div style="margin-bottom: 10px;"><B>Tivantinib (ARQ197) vs Placebo in Patients (Pts) with Hepatocellular Carcinoma (HCC) Who failed One Systemic Therapy: Results of a Randomized Controlled Phase 2 Trial (Sponsored by ArQule Inc.<wbr> and Daiichi Sankyo Co)</B> </div><div style="margin-bottom: 10px;">This study is the first randomized study to show overall survival advantage in MET HCC patients </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8329/12/ScreenCapture12.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">107 patients enrolled in 23 sites in Europe and North America participated in the study from October 2009 — August 2011.<wbr> Time to progression (TTP) was the primary study endpoint.<wbr> The primary endpoint was met with a 56% improvement of patients receiving tivantinib verses placebo.<wbr> OS, a secondary endpoint did not meet statistical significance.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8329/13/ScreenCapture13.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">MET High patients on placebo had twice the risk of dying verses those patients with MET low characteristics.<wbr> Whereas, <SPAN style="FONT-SIZE: 11pt; FONT-FAMILY: 'Arial','sans-serif'; mso-fareast-font-family: Calibri; mso-ansi-language: EN-GB; mso-fareast-language: JA; mso-bidi-language: AR-SA">MET high patients (a pre-specified sub-group for statistical analysis) on tivantinib experienced 133% improvement in TTP verses placebo </SPAN> </div><div style="margin-bottom: 10px;">The most impressive result of this trial was a 163% improvement in the overall survival of MET High patients receiving tivantinib verses placebo.<wbr> For MET low patients receiving tivantinib both TPP and OS were statistical similar to placebo.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8329/14/ScreenCapture14.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">The higher dose of tivantinib resulted in higher haematologic event (neutropenia).<wbr> This decreased when the dose was adjusted.<wbr> A comparable clinical benefit was observed for both doses.<wbr> A Phase III study in the MET Dx High HCC population is being planned.<wbr> </div><div style="margin-bottom: 10px;"><B>Questions </B> </div><div style="margin-bottom: 10px;">The speaker was asked a question about the apparent increased in benefit of tivantinib in HCV + /<wbr>HBV- patients.<wbr> Dr Rimassa confirmed the analytical observation however commented that no statistical relationship could be found between MET status and viral status.<wbr> </div><div style="margin-bottom: 10px;">Dr Rimassa then answered the question “no” to additional unspecified factors influencing the outcome of the study as everything had been analysed that had the potential to unbalance the study.<wbr> </div><div style="margin-bottom: 10px;">In response to the significance of MET in the design of future trials Dr Rimassa stated that it was clear prognostic factor.<wbr> She went onto to say the MET status should be assessed in all HCC studies where second line treatments were being studied.<wbr> </div><div style="margin-bottom: 10px;"><B>Posters of Interest: </B> </div><div style="margin-bottom: 10px;"><B>Safety and efficacy of MET inhibitor tivantinib (ARQ 197) combined with sorafenib in patients (pts) with hepatocellular carcinoma (HCC) from a phase I study.<wbr></B> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8329/15/ScreenCapture15.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><B>A phase II trial of MEK inhibitor BAY 86-9766 in combination with sorafenib as first-line systemic treatment for patients with unresectable hepatocellular carcinoma (HCC) </B>was also presented<B> h</B>owever, frequent dose modifications due to AEs might have limited the treatment effect of this combination.<wbr> </div><div style="margin-bottom: 10px;"><B>Randomized phase II study of the x-linked inhibitor of apoptosis (XIAP) antisense AEG35156 in combination with sorafenib in patients with advanced hepatocellular carcinoma (HCC).<wbr> </B>AEG35156 is a 2nd generation antisense oligonucleotide which targets XIAP; it is designed to lower the apoptotic threshold of cancer cells, enhancing their sensitivity to intrinsic death and chemotherapy, without harming healthy cells.<wbr> The Phase II results presented were not very impressive </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8329/17/ScreenCapture17.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8329/18/ScreenCapture18.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8329/19/ScreenCapture19.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8329/20/ScreenCapture20.jpg?user-agent=rss"> </div><div><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8329/21/ScreenCapture21.jpg?user-agent=rss"> </div><!-- Comment details --><a name="oncology8329attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8329/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(22,3 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8329/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(62,3 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8329/3/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(46,5 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8329/4/ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(51,3 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8329/5/ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(60,9 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8329/6/ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(59 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8329/7/ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(51,7 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8329/8/ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(46,8 KB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8329/9/ScreenCapture9.jpg">ScreenCapture9.jpg</a>&nbsp;&nbsp;(58,7 KB)<br>&nbsp;&nbsp;10.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8329/10/ScreenCapture10.jpg">ScreenCapture10.jpg</a>&nbsp;&nbsp;(54,4 KB)<br>&nbsp;&nbsp;11.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8329/11/ScreenCapture11.jpg">ScreenCapture11.jpg</a>&nbsp;&nbsp;(45,6 KB)<br>&nbsp;&nbsp;12.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8329/12/ScreenCapture12.jpg">ScreenCapture12.jpg</a>&nbsp;&nbsp;(61,2 KB)<br>&nbsp;&nbsp;13.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8329/13/ScreenCapture13.jpg">ScreenCapture13.jpg</a>&nbsp;&nbsp;(59,6 KB)<br>&nbsp;&nbsp;14.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8329/14/ScreenCapture14.jpg">ScreenCapture14.jpg</a>&nbsp;&nbsp;(43,7 KB)<br>&nbsp;&nbsp;15.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8329/15/ScreenCapture15.jpg">ScreenCapture15.jpg</a>&nbsp;&nbsp;(61,2 KB)<br>&nbsp;&nbsp;16.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8329/16/ScreenCapture16.jpg">ScreenCapture16.jpg</a>&nbsp;&nbsp;(47,3 KB)<br>&nbsp;&nbsp;17.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8329/17/ScreenCapture17.jpg">ScreenCapture17.jpg</a>&nbsp;&nbsp;(46,7 KB)<br>&nbsp;&nbsp;18.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8329/18/ScreenCapture18.jpg">ScreenCapture18.jpg</a>&nbsp;&nbsp;(64,8 KB)<br>&nbsp;&nbsp;19.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8329/19/ScreenCapture19.jpg">ScreenCapture19.jpg</a>&nbsp;&nbsp;(132,1 KB)<br>&nbsp;&nbsp;20.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8329/20/ScreenCapture20.jpg">ScreenCapture20.jpg</a>&nbsp;&nbsp;(61,7 KB)<br>&nbsp;&nbsp;21.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8329/21/ScreenCapture21.jpg">ScreenCapture21.jpg</a>&nbsp;&nbsp;(72,8 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8329">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-06-13T14:02:43+02:00</dc:date><dc:creator>bee75336</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8329/1/ScreenCapture1.jpg" length="22873" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8329/2/ScreenCapture2.jpg" length="63818" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8329/3/ScreenCapture3.jpg" length="47663" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8329/4/ScreenCapture4.jpg" length="52564" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8329/5/ScreenCapture5.jpg" length="62392" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8329/6/ScreenCapture6.jpg" length="60461" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8329/7/ScreenCapture7.jpg" length="52964" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8329/8/ScreenCapture8.jpg" length="47914" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8329/9/ScreenCapture9.jpg" length="60112" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8329/10/ScreenCapture10.jpg" length="55713" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8329/11/ScreenCapture11.jpg" length="46651" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8329/12/ScreenCapture12.jpg" length="62636" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8329/13/ScreenCapture13.jpg" length="60987" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8329/14/ScreenCapture14.jpg" length="44716" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8329/15/ScreenCapture15.jpg" length="62699" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8329/16/ScreenCapture16.jpg" length="48471" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8329/17/ScreenCapture17.jpg" length="47832" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8329/18/ScreenCapture18.jpg" length="66371" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8329/19/ScreenCapture19.jpg" length="135320" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8329/20/ScreenCapture20.jpg" length="63219" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8329/21/ScreenCapture21.jpg" length="74594" type="image/jpeg"/></item><item>
<title>ASCO Intelligence Update Part IV - NET/pNET [comp:Novartis, dis:pNET, :PharmaWorld:congress:ASCO]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology6967</link>
<description>ASCO Intelligence Update Part IV - NET/pNET [comp:Novartis, dis:pNET, :PharmaWorld:congress:ASCO]</description><category>comp:Novartis</category><category>dis:pNET</category><category>congress:ASCO</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology6967</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120831&edate=20120501&rec=6967">ASCO Intelligence Update Part IV - NET/<wbr>pNET</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=comp%3aNovartis"><font color="#e95e0b">:Endocrinology:comp:Novartis</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=dis%3apNET"><font color="#e95e0b">:Endocrinology:dis:pNET</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=congress%3aASCO"><font color="#e95e0b">:PharmaWorld:congress:ASCO</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology6967">Endocrinology6967</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/774">bee75336</a> | 13 June 2012 | 12:34</font><br><br><div style="margin-bottom: 10px;">Comment: New data was presented at ASCO although nothing earthshattering.<wbr>  Amgen’s AMG 479 did not fare so well in pNETs and doubts surround its use.<wbr>  Data from the RADIANT-2, RAMSETE, PAZONET, UKINETS and NCRI trials all are discussed.<wbr> </div><div style="margin-bottom: 10px;">Novartis presented a poster on multivariate analysis including biomarkers in the phase III RADIANT-2 study of octreotide LAR plus everolimus  or placebo among patients with advanced neuroendocrine tumors (NET).<wbr>  This information has been previously reported.<wbr>  Dr Andrea Wang-Gilliam discussed this poster in a session and agreed with the authors conclusion that baseline CgA (Chromogranin A) is a strong prognostic factor for beneficial everolimus therapy.<wbr> Given this data, she then posed the question should 24 hour urine samples to measure 5-HIAA still be collected and declared that RADIANT-3 should answer this question.<wbr> </div><div style="margin-bottom: 10px;">Amgen’s AMG 479 (a human monocolonal antibody against IGF1-R ) open label Phase II trial showed AMG479 was well tolerated however lacked efficacy in pNETs.<wbr> Subgroup analysis to identify characteristics of patients who may have benefited from therapy with AMG 479 is ongoing.<wbr> </div><div style="margin-bottom: 10px;"><B>RAMSETE</B>:  A single-arm, multicenter, single-stage phase II trial of RAD001 in advanced and metastatic silent neuro-endocrine tumours in Europe which evaluated<B> </B>the safety and efficacy of everolimus monotherapy was evaluated in pts with advanced nonsyndromic, nonpancreatic NET was presented.<wbr> </div><div style="margin-bottom: 10px;">82 patients were screened in 16 EU clinics, 73 were treated with everolimus monotherapy.<wbr>  18 completed the study and 55 discontinued mainly due to disease progression and adverse events (31% respectively).<wbr>  Data showed that everolimus demonstrated a high rate of disease stablisation after primary tumor progression with favourable median PFS in this group of patients.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6967/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">Updated results from a phase III trial of sunitinib vs placebo in patients with progressive, unresectable, well-differentiated PNETs — a retrospective analysis of PFS by Blinded Independent Central Review (BICR) along with 2 year updated OS results.<wbr>  The objective of the study was to determine whether BICR confirmed the investigator assessed PFS advantage for sunitinib and whether OS is prolonged in the sunitinib treatment arm compared with the placebo arm despite patient cross over.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6967/2/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6967/3/ScreenCapture3.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">BICR analysis of PFS showed a 6.<wbr>8 month improvement in median PFS with sunitinib confirming the treatment effect reported with investigator assessment.<wbr>  At 2 years after study closure, OS based on the ITT population continued to favour sunitinib although this result was not statistically significant (treatment cross over and limited statistical power) </div><div style="margin-bottom: 10px;"><B>PAZONET: </B>Results of a phase II trial of pazopanib as a sequencing treatment in progressive metastatic neuroendocrine tumors (NETs) patients (pts), on behalf of the Spanish task force for NETs  was presented.<wbr> </div><div style="margin-bottom: 10px;">Patients with locally advanced or metastatic NETs derived either from digestive tract, bronchial, thymic, or pancreatic islet cell origin will recieve pazopanib 800mg/<wbr>day until disease progression or intolerance.<wbr>  Patients could have previously received treatment with SSA, chemo, anti VEGF or mTOR inhibitors.<wbr>  44 patients were enrolled between Jan 2011 and March 2012.<wbr> Data cut off was in December 2011 with 33 patients evaluable for response per protocol.<wbr>  Primary endpoint was Clinical Benefit Rate.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6967/5/ScreenCapture5.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">This data showed: </div><div style="margin-bottom: 10px;"><UL><LI>Pazopanib either as a single agent or in combination with somatostatin analogue is an active option in patients with NETs</LI>
<LI>Pazopanib has shown activity in patients with NETs who have failed at least one previous systemic treatment based on mTOR or other multitarget agents</LI>
<LI>Pazopanib toxicity profile was similar to that reported with other types of solid tumors</LI>
<LI>Biomarker analysis using circulating tumour cells (CTC’s), circulating endothelial cells (CECs), circulating endothelial progenitor cells (CEPC’s), Tumor markers,metabolic polymorphisms and soluble angiogenic markers are ongoing.<wbr></LI>
<LI>Pazopanib derserves further studies in the sequencing strategy for those patients</LI>
</UL> </div><div style="margin-bottom: 10px;"><B>UKINETS:</B> Treatment of advanced neuroendocrine tumors: Results of the UKINETS and NCRI randomized phase II NET01 trial was presented, showing the novel Cap-strep ± cisplatin regimens were associated with overall disease control and survival durations consistent with published studies.<wbr> Cap-strep was better tolerated than Cap-cist.<wbr> Further prospective randomised studies are required to determine optimal NET chemotherapy.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6967/7/ScreenCapture7.jpg?user-agent=rss"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6967/8/ScreenCapture8.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">A phase II study of bevacizumab, pertuzumab and sandostation for patients with Advanced NETS from the Sarah Cannon Institute was presented.<wbr>  The primary endpoint was to determine the OOR of patients with low grade neuroendocrine cancer when treated with the combination of of bevacizumab, pertuzumab and sandostation LAR.<wbr>  Secondary endpoints were looking at the DCR, TTP PFS and OS.<wbr>   The study showed that OOR of the combination was similar to previously described results with the response rates in carcinoid patients encouraging.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6967/10/ScreenCapture10.jpg?user-agent=rss"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6967/11/ScreenCapture11.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">A discussion on the Current Therapeutic Approach for Pancreatic Neuroendocrine Tumours: Current and Future Directions is described below </div><div style="margin-bottom: 10px;"><B>Summary</B> </div><div style="margin-bottom: 10px;"><UL type="square"><LI>Classification of pNETs is still and on going issue and not fully resolved.<wbr> Evidence is emerging that AJCC pNET staging model included in the 7<SUP>th</SUP> edition of AJCC can be linked to prognosis.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><UL type="square"><LI>A well-defined patient selection algorithm exists with the clinical focus being on metastatic progressive patients</LI>
</UL> </div><div style="margin-bottom: 10px;"><UL type="square"><LI>Trials to answer the questions of whether biologic agent combinations improve outcomes as well as if somatostatin analogues have antitumor activity will soon report.<wbr> Ipsen’s CLARINET was mentioned in this context.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><UL type="square"><LI>A trial to help define a standard cytotoxic therapy is about to start evaluating temozolomoide and temozolomoide/<wbr>capecitabine</LI>
</UL> </div><div style="margin-bottom: 10px;"><UL type="square"><LI>Key recommendations from a 2009 NET clinical trials planning meeting have been realised over the past 3 years</LI>
</UL> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6967/13/ScreenCapture13.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6967/14/ScreenCapture14.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">Full consensus of how pancreatic NETS should be classified is still evolving with discrepancies between NANETS, WHO, ENETS and the AJCC.<wbr> The AJCC has now included pancreatic NETs staging into its 7<SUP>th</SUP> Edition which was closely modelled on the pancreatic adenocarcinoma system.<wbr> This has subsequently been validated with the staging being linked to disease prognosis.<wbr> </div><div style="margin-bottom: 10px;">The presenter followed on with the ideal sequencing of therapies is not yet known and went on to discuss chemotherapies and biologic agents.<wbr> Stating overall survival for Everolimus has not yet been reached and with sunitinib, median overall survival has been reached although not statistically significant.<wbr>  Finally, alkylating agents such as temozolomide have demonstrated 18 month PFS with a 70% response rate in treating pNETS.<wbr>  The speaker then posed the question <I>do biologic combinations improve outcome?  </I>An outline of the CALGB 80701 Phase II was described combining everolimus and octreotide.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6967/17/ScreenCapture17.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">Somatostatin analogues are known to have activity in mid gut NET however this has not yet been prospectively proven in pNETS.<wbr> Two trials, Ipsen’s CLARINET and Novartis COOPERATE are poised to answer this question </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6967/18/ScreenCapture18.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">An ECOG trial to help define a standard cytotoxic therapy is about to start evaluating temozolomoide and temozolomoide/<wbr>capecitabine </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6967/19/ScreenCapture19.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">Prognostic biomarkers have now been associated with longer survival </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6967/20/ScreenCapture20.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">Whereas chromogranin A and neuron specific enolase (NSE) are associated with shorter PFS/<wbr>OS.<wbr> Data showing that MGMT deficiency is associated with a response to temozolomide in pNETS although patient numbers were small </div><div><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6967/21/ScreenCapture21.jpg?user-agent=rss"> </div><!-- Comment details --><a name="endocrinology6967attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6967/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(192,2 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6967/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(57,7 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6967/3/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(56,6 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6967/4/ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(100,6 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6967/5/ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(100,7 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6967/6/ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(45,9 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6967/7/ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(88,4 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6967/8/ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(46,7 KB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6967/9/ScreenCapture9.jpg">ScreenCapture9.jpg</a>&nbsp;&nbsp;(76,3 KB)<br>&nbsp;&nbsp;10.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6967/10/ScreenCapture10.jpg">ScreenCapture10.jpg</a>&nbsp;&nbsp;(74,5 KB)<br>&nbsp;&nbsp;11.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6967/11/ScreenCapture11.jpg">ScreenCapture11.jpg</a>&nbsp;&nbsp;(98,6 KB)<br>&nbsp;&nbsp;12.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6967/12/ScreenCapture12.jpg">ScreenCapture12.jpg</a>&nbsp;&nbsp;(77,1 KB)<br>&nbsp;&nbsp;13.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6967/13/ScreenCapture13.jpg">ScreenCapture13.jpg</a>&nbsp;&nbsp;(73,7 KB)<br>&nbsp;&nbsp;14.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6967/14/ScreenCapture14.jpg">ScreenCapture14.jpg</a>&nbsp;&nbsp;(60,5 KB)<br>&nbsp;&nbsp;15.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6967/15/ScreenCapture15.jpg">ScreenCapture15.jpg</a>&nbsp;&nbsp;(30,3 KB)<br>&nbsp;&nbsp;16.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6967/16/ScreenCapture16.jpg">ScreenCapture16.jpg</a>&nbsp;&nbsp;(34,4 KB)<br>&nbsp;&nbsp;17.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6967/17/ScreenCapture17.jpg">ScreenCapture17.jpg</a>&nbsp;&nbsp;(34,5 KB)<br>&nbsp;&nbsp;18.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6967/18/ScreenCapture18.jpg">ScreenCapture18.jpg</a>&nbsp;&nbsp;(49 KB)<br>&nbsp;&nbsp;19.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6967/19/ScreenCapture19.jpg">ScreenCapture19.jpg</a>&nbsp;&nbsp;(38,1 KB)<br>&nbsp;&nbsp;20.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6967/20/ScreenCapture20.jpg">ScreenCapture20.jpg</a>&nbsp;&nbsp;(53,4 KB)<br>&nbsp;&nbsp;21.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6967/21/ScreenCapture21.jpg">ScreenCapture21.jpg</a>&nbsp;&nbsp;(67,4 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120831&edate=20120501&rec=6967">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-06-13T12:34:30+02:00</dc:date><dc:creator>bee75336</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6967/1/ScreenCapture1.jpg" length="196815" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6967/2/ScreenCapture2.jpg" length="59094" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6967/3/ScreenCapture3.jpg" length="57914" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6967/4/ScreenCapture4.jpg" length="102995" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6967/5/ScreenCapture5.jpg" length="103099" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6967/6/ScreenCapture6.jpg" length="47011" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6967/7/ScreenCapture7.jpg" length="90531" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6967/8/ScreenCapture8.jpg" length="47802" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6967/9/ScreenCapture9.jpg" length="78134" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6967/10/ScreenCapture10.jpg" length="76283" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6967/11/ScreenCapture11.jpg" length="100919" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6967/12/ScreenCapture12.jpg" length="78919" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6967/13/ScreenCapture13.jpg" length="75434" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6967/14/ScreenCapture14.jpg" length="61973" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6967/15/ScreenCapture15.jpg" length="31072" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6967/16/ScreenCapture16.jpg" length="35193" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6967/17/ScreenCapture17.jpg" length="35344" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6967/18/ScreenCapture18.jpg" length="50195" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6967/19/ScreenCapture19.jpg" length="38999" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6967/20/ScreenCapture20.jpg" length="54681" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6967/21/ScreenCapture21.jpg" length="69056" type="image/jpeg"/></item><item>
<title>re: Detailed Information On New Sandostatin LAR Device</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology6966</link>
<description>re: Detailed Information On New Sandostatin LAR Device</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology6966</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120831&edate=20120501&rec=6966">re: Detailed Information On New Sandostatin LAR Device</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology6966">Endocrinology6966</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/789">faj69866</a> | 13 June 2012 | 11:44</font><br><br><div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-size: 12px;">
The key messages are mentioned are:</span>&nbsp;<br><font size="-1">Jacquelyne CANTLE MEYRICK / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology6963" class="commentpermalink">Endocrinology6963</a> / <span class="date">12 June 2012</span> /
<span class="time">12:18:37 o'clock CEST</span>
</font></div><div>With a reduced filled volume this will have a direct impact on their CoG.<wbr> Lower i suppose ! </div><!-- Comment details --><font size="-1">faj69866 / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology6966" class="commentpermalink">Endocrinology6966</a> / <span class="date">13 June 2012</span> /
<span class="time">11:44:14 o'clock CEST</span>
</font><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120831&edate=20120501&rec=6966">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology6963">View thread  Endocrinology6963: Detailed Information On New Sandostatin LAR Device</a>]]></content:encoded><dc:date>2012-06-13T11:44:14+02:00</dc:date><dc:creator>faj69866</dc:creator></item><item>
<title>EMA Draft Position Paper on Possible Medication Errors When Developing New Forms and Indications [mkt:Europe, sub:AdverseEvents, sub:Regulatory]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld9920</link>
<description>EMA Draft Position Paper on Possible Medication Errors When Developing New Forms and Indications [mkt:Europe, sub:AdverseEvents, sub:Regulatory]</description><category>mkt:Europe</category><category>sub:AdverseEvents</category><category>sub:Regulatory</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld9920</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120831&edate=20120501&rec=9920">EMA Draft Position Paper on Possible Medication Errors When Developing New Forms and Indications</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=mkt%3aEurope"><font color="#e95e0b">:PharmaWorld:mkt:Europe</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=sub%3aAdverseEvents"><font color="#e95e0b">:PharmaWorld:sub:AdverseEvents</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=sub%3aRegulatory"><font color="#e95e0b">:PharmaWorld:sub:Regulatory</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld9920">PharmaWorld9920</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/20">Alison Attard</a> | 13 June 2012 | 11:37</font><br><br><div style="margin-bottom: 10px;">Comment: The position paper is intended to provide guidance on how potential medication errors should be addressed caused by confusion of a newly introduced medicinal product with an existing one, similar in active substance but different in some aspects.<wbr> </div><div style="margin-bottom: 10px;">The Agency says that changes introduced during the lifecycle of a medicine – such as a new indication, formulation, strength, or pack design – can have an impact on the product's use in clinical practice.<wbr> The same applies when a competing product a generic or biosimilar) that refers to the originator product but differs in certain respects is marketed.<wbr> </div><div style="margin-bottom: 10px;">The EMA says that that in many cases, the benefits of the new product may outweigh the risk of errors.<wbr> Examples of such benefits include improved stability, a reduction in excipients that can cause side-effects in some people, a different formulation not requiring dilution or liposomal forms that improve compliance.<wbr> </div><div style="margin-bottom: 10px;">The draft position paper is out for consultation until 30 November 2012 <a href="http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/06/WC500128054.pdf" class="defaultlink" title="http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/06/WC500128054.pdf">ema.europa.eu/<wbr>doc&hellip;</a> </div><div>Source: EMA/<wbr>Scrip </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120831&edate=20120501&rec=9920">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-06-13T11:37:12+02:00</dc:date><dc:creator>ala97794</dc:creator></item><item>
<title>Biogen Idec Analyst Day Takeaways [:Biologics:comp:BiogenIdec, :Biologics:dis:HaemophiliaA, :Biologics:dis:HaemophiliaB, :Biologics:news]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld9919</link>
<description>Biogen Idec Analyst Day Takeaways [:Biologics:comp:BiogenIdec, :Biologics:dis:HaemophiliaA, :Biologics:dis:HaemophiliaB, :Biologics:news]</description><category>comp:BiogenIdec</category><category>dis:HaemophiliaA</category><category>dis:HaemophiliaB</category><category>news</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld9919</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120831&edate=20120501&rec=9919">Biogen Idec Analyst Day Takeaways</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Biologics&sdate=20120831&edate=20120501&cat=comp%3aBiogenIdec"><font color="#e95e0b">:Biologics:comp:BiogenIdec</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Biologics&sdate=20120831&edate=20120501&cat=dis%3aHaemophiliaA"><font color="#e95e0b">:Biologics:dis:HaemophiliaA</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Biologics&sdate=20120831&edate=20120501&cat=dis%3aHaemophiliaB"><font color="#e95e0b">:Biologics:dis:HaemophiliaB</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Biologics&sdate=20120831&edate=20120501&cat=news"><font color="#e95e0b">:Biologics:news</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld9919">PharmaWorld9919</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 13 June 2012 | 11:31</font><br><br><div style="margin-bottom: 10px;">Comment: On June 12th, Biogen Idec hosted an Analyst Day to provide an update on the company’s commercial strategy, select late and early-stage clinical development programs, as well as the revitalization of its R&amp;D.<wbr> Management provided greater visibility into the early pipeline, which consists almost entirely of agents discovered by the company scientists.<wbr> Significant restructuring of R&amp;D is underway, with the elimination of 'cardiology' and 'oncology' to focus on 'neurology', 'immunology' and 'hemophilia'.<wbr> It was confirmed that both Ph3 hemophilia studies (A-LONG, B-LONG) are on-track for data in H2:12 (with no updates on timing).<wbr> Interesting slides on the 'success factors' for their 'successful launch' are provided below.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Key Messages - R&amp;D</FONT></STRONG> </div><div style="margin-bottom: 10px;"><U>Early stage Pipeline</U> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/9919/3/ScreenCapture3.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><U>Pipeline today</U> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/9919/2/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Focus on Hemophilia</FONT></STRONG> </div><div style="margin-bottom: 10px;"><U>Objectives of the Ph3</U> </div><div style="margin-bottom: 10px;"><U><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/9919/7/ScreenCapture7.jpg?user-agent=rss"></U> </div><div style="margin-bottom: 10px;"><U>US and EU Regulatory Status and Requirements</U> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/9919/8/ScreenCapture8.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><U>Potential Growth Opportunity in Prophylaxis Use</U> </div><div style="margin-bottom: 10px;">(sources: 1)UDC Jan.<wbr>2012 - 2)Internal company forecast) </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/9919/4/ScreenCapture4.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><U>Program Status &amp; Upcoming Milestones</U> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/9919/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><U>Commercial Launch Plans</U> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/9919/5/ScreenCapture5.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><U>Sucess factors</U> </div><div><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/9919/6/ScreenCapture6.jpg?user-agent=rss"> </div><!-- Comment details --><a name="pharmaworld9919attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/9919/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(30,4 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/9919/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(52,1 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/9919/3/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(46,2 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/9919/4/ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(58,9 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/9919/5/ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(46,9 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/9919/6/ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(97,1 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/9919/7/ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(31,9 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/9919/8/ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(80,9 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120831&edate=20120501&rec=9919">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-06-13T11:31:54+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/9919/1/ScreenCapture1.jpg" length="31161" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/9919/2/ScreenCapture2.jpg" length="53348" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/9919/3/ScreenCapture3.jpg" length="47268" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/9919/4/ScreenCapture4.jpg" length="60269" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/9919/5/ScreenCapture5.jpg" length="48038" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/9919/6/ScreenCapture6.jpg" length="99430" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/9919/7/ScreenCapture7.jpg" length="32708" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/9919/8/ScreenCapture8.jpg" length="82892" type="image/jpeg"/></item><item>
<title>Lilly Expands Stake In Chinese Manufacturer - Marketing Of Biosimilar Insulin In China Could Be Planned [class:GLP1, comp:EliLilly, dis:Diabetes, :PharmaWorld:mkt:China, :PharmaWorld:mkt:Intercontinental]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology6964</link>
<description>Lilly Expands Stake In Chinese Manufacturer - Marketing Of Biosimilar Insulin In China Could Be Planned [class:GLP1, comp:EliLilly, dis:Diabetes, :PharmaWorld:mkt:China, :PharmaWorld:mkt:Intercontinental]</description><category>class:GLP1</category><category>comp:EliLilly</category><category>dis:Diabetes</category><category>mkt:China</category><category>mkt:Intercontinental</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology6964</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120831&edate=20120501&rec=6964">Lilly Expands Stake In Chinese Manufacturer - Marketing Of Biosimilar Insulin In China Could Be Planned</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=class%3aGLP1"><font color="#e95e0b">:Endocrinology:class:GLP1</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=comp%3aEliLilly"><font color="#e95e0b">:Endocrinology:comp:EliLilly</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=dis%3aDiabetes"><font color="#e95e0b">:Endocrinology:dis:Diabetes</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=mkt%3aChina"><font color="#e95e0b">:PharmaWorld:mkt:China</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=mkt%3aIntercontinental"><font color="#e95e0b">:PharmaWorld:mkt:Intercontinental</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology6964">Endocrinology6964</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 13 June 2012 | 10:44</font><br><br><div style="margin-bottom: 10px;">Comment: Having unveiled robust Phase II data for its new insulin treatment 
LY2605541, which unusually is associated with weight loss, Eli Lilly also 
announced on Tuesday that it had boosted its equity position in Chinese player 
Novast Laboratories.<wbr> Lilly Could be the only established insulin 
manufacturer that pursues both branded and biosimilar 
insulins with potentially the commercialisation of biosimilar insulin 
focused on the emerging markets, notably China.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Lilly's Strategic Focus</STRONG> </div><div style="margin-bottom: 10px;">According to Morgan Stanley analysts, Diabetes remains an integral area of 
investment to Eli Lilly in terms of revenue expansion via its R&amp;D pipeline.<wbr> 
It forecasts that one third of the company's 2020 pipeline revenue projection 
will be derived from this disease area.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Competitive Forces In The Insulin Market</STRONG> </div><div style="margin-bottom: 10px;">Eli Lilly is gunning for Sanofi's Lantus, both in terms of trying to 
improve upon the drug's profile with LY2605541 and to produce a biosimilar 
equivalent phIII data for which will be available next 
year.<wbr> Sanofi is current market leader in the long-acting insulin 
space.<wbr> By the time Eli Lilly secures approval for its product, Novo Nordisk is 
also likely to have launched degludec.<wbr> A clearer understanding of the commercial 
profile of LY '541 will emerge in 2014, when pivotal-stage results become 
available.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Chinese Focus </STRONG> </div><div>Assuming both make it to the market, exactly how Lilly's plans to 
strategise the commercialisation of competing products remains unclear but 
the biosimilar focus could be more geared towards emerging markets including 
China.<wbr> Eli Lilly has stated that it believes a third of the global 
market could fall to biosimilars; an assertion that Sanofi management has 
dismissed.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120831&edate=20120501&rec=6964">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-06-13T10:44:52+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>ASCO Intelligence Update - Part III - Prostate Cancer [dis:Prostate, :PharmaWorld:congress:ASCO]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology8326</link>
<description>ASCO Intelligence Update - Part III - Prostate Cancer [dis:Prostate, :PharmaWorld:congress:ASCO]</description><category>dis:Prostate</category><category>congress:ASCO</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology8326</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8326">ASCO Intelligence Update - Part III - Prostate Cancer</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=congress%3aASCO"><font color="#e95e0b">:PharmaWorld:congress:ASCO</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8326">Oncology8326</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/774">bee75336</a> | 12 June 2012 | 16:54</font><br><br><div style="margin-bottom: 10px;"><FONT face="Arial">Comment:  Earlier stage compounds were gaining interest at ASCO, a selection are presented below with cabozantinib and TOK-001 receiving the most attention.<wbr>  </FONT> </div><div style="margin-bottom: 10px;"><FONT face="Arial">Dr.<wbr> Matthew Smith presented a phase II study with cabozantinib in mCRPC — this study is the non-randomised expansion cohort added to the Phase II randomised discontinuation study.<wbr> Key features of the study are represented below.<wbr>   Results are of the 100mg cohort.<wbr> </FONT> </div><div style="margin-bottom: 10px;"><FONT face="Arial"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8326/2/ScreenCapture2.jpg?user-agent=rss"></FONT> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 12pt; FONT-FAMILY: 'Cambria','serif'; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: 'MS Mincho'; mso-fareast-theme-font: minor-fareast; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"><FONT face="Arial" size="2">This group are a very treatment refractory group </FONT></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 12pt; FONT-FAMILY: 'Cambria','serif'; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: 'MS Mincho'; mso-fareast-theme-font: minor-fareast; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"><FONT face="Arial" size="2"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8326/3/ScreenCapture3.jpg?user-agent=rss"></FONT></SPAN> </div><div style="margin-bottom: 10px;"><FONT face="Arial" size="2">The last patient was accrued in November 2011 and data cut off was Feb 2012.<wbr>  Primary reason for discontinuation was progressive disease.<wbr></FONT> </div><div style="margin-bottom: 10px;"><FONT face="Arial" size="2">Safety profile of cabozantinib is similar to that other TKIs.<wbr>   84% of patients experienced at least one dose reduction due to AE (on the 100mg) </FONT> </div><div style="margin-bottom: 10px;"><FONT face="Arial" size="2"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8326/5/ScreenCapture5.jpg?user-agent=rss"></FONT> </div><div style="margin-bottom: 10px;"><FONT face="Arial" size="2">Primary endpoint was Bone Scan Response.<wbr> </FONT><FONT face="Arial" size="2">Results are as follows — cabozantinib has a high rate of bone scan response.<wbr> </FONT> </div><div style="margin-bottom: 10px;"><FONT face="Arial" size="2"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8326/7/ScreenCapture7.jpg?user-agent=rss"></FONT> </div><div style="margin-bottom: 10px;"><FONT face="Arial" size="2"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8326/8/ScreenCapture8.jpg?user-agent=rss"></FONT> </div><div style="margin-bottom: 10px;"><FONT face="Arial" size="2"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8326/9/ScreenCapture9.jpg?user-agent=rss"></FONT> </div><div style="margin-bottom: 10px;"><FONT face="Arial" size="2"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8326/11/ScreenCapture11.jpg?user-agent=rss"></FONT> </div><div style="margin-bottom: 10px;"><FONT face="Arial" size="2">In the general poster session, Activity of Cabozantinib at 40mg in Men with mCRPC showed cabozantinib 40mg was associated with:</FONT> </div><div style="margin-bottom: 10px;"><UL><LI><FONT face="Arial" size="2">High bone scan response rate (67% at Week 6)</FONT></LI>
<LI><FONT face="Arial" size="2">Substantial reductions in CTCs (58% converted to &lt;5)</FONT></LI>
<LI><FONT face="Arial" size="2">Improved tolerability compared to higher doses of cabozantinib</FONT></LI>
<LI><FONT face="Arial" size="2">No dose reductions were required</FONT></LI>
<LI><FONT face="Arial" size="2">Correlative studies are ongoing </FONT></LI>
</UL> </div><div style="margin-bottom: 10px;"><FONT face="Arial" size="2">Based on these observations, the non-randomised study has been amended to include additional patients treated on a lower starting dose (40mg) and the results of the  additional 51 patients accrued to that cohort will be presented at a future meeting.<wbr></FONT> </div><div style="margin-bottom: 10px;"><FONT face="Arial" size="2">Study schema for COMET 1 &amp; 2 is found below, it will be interesting to see if they amend these trials to incorporate a lower starting dose as well.<wbr> </FONT> </div><div style="margin-bottom: 10px;"><FONT face="Arial" size="2"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8326/13/ScreenCapture13.jpg?user-agent=rss"></FONT> </div><div style="margin-bottom: 10px;"><FONT face="Arial" size="2">In Dr.<wbr> Fizazi’s discussion, he highlighted the pros and cons for cabozantinib are found below</FONT> </div><div style="margin-bottom: 10px;"><FONT face="Arial" size="2"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8326/14/ScreenCapture14.jpg?user-agent=rss"></FONT> </div><div style="margin-bottom: 10px;"><FONT face="Arial" size="2">The phase I data for TOK-001 was presented.<wbr> The study aim was to find the optimal dose.<wbr>  There was heavy interest from Janssen around this poster and it is understood that they had several closed door meetings during ASCO.<wbr>  The PI described the drug as a better version of both abiraterone and MDV3100 with no need for steroids.<wbr>  A phase II study is planned for mid-2012 and will assess long term safety and efficacy.<wbr>  This trial will also feature a new formulation (which is meant to help optimize dosing).<wbr>  </FONT> </div><div style="margin-bottom: 10px;"><FONT face="Arial" size="2"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8326/15/ScreenCapture15.jpg?user-agent=rss"></FONT> </div><div style="margin-bottom: 10px;"><FONT face="Arial" size="2"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8326/16/ScreenCapture16.jpg?user-agent=rss"></FONT> </div><div style="margin-bottom: 10px;"><FONT face="Arial" size="2">Dr.<wbr> Kim Chi provided background on OGX-427 followed by the results from a randomized PII study of OGX-427 plus Prednisone vs Prednisone alone in patients with mCRPC</FONT> </div><div style="margin-bottom: 10px;"><FONT face="Arial" size="2">Study schema is found below.<wbr>  Because of the frequent use of corticosteroids to manage infusion reactions, they thought it was necessary to have a control arm to isolate the effect of OGX 427 </FONT> </div><div style="margin-bottom: 10px;"><FONT face="Arial" size="2"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8326/18/ScreenCapture18.jpg?user-agent=rss"></FONT> </div><div style="margin-bottom: 10px;"><FONT face="Arial" size="2"> Trial accrual is closed and stage 1 accrual is presented below.<wbr> </FONT><FONT face="Arial" size="2">Study arms were well balanced although there were more patients with lung mets, elevated LDH and ALP in the 427 arm.<wbr></FONT> </div><div style="margin-bottom: 10px;"><FONT face="Arial" size="2"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8326/23/ScreenCapture23.jpg?user-agent=rss"></FONT> </div><div style="margin-bottom: 10px;"><FONT face="Arial" size="2"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8326/24/ScreenCapture24.jpg?user-agent=rss"></FONT> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 12pt; FONT-FAMILY: 'Cambria','serif'; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: 'MS Mincho'; mso-fareast-theme-font: minor-fareast; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"><FONT face="Arial" size="2">Adverse events have been predominantly infusion related (similar to flu and happens in the first few infusions then the patients build up tolerance).<wbr> </FONT></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 12pt; FONT-FAMILY: 'Cambria','serif'; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: 'MS Mincho'; mso-fareast-theme-font: minor-fareast; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"><FONT face="Arial" size="2">Dr.<wbr> Fizazi highlighted the pros and cons of this drug during his discussion</FONT></SPAN> </div><div><FONT face="Arial" size="2"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8326/27/ScreenCapture27.jpg?user-agent=rss"></FONT> </div><!-- Comment details --><a name="oncology8326attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8326/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(92,9 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8326/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(40 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8326/3/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(42,2 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8326/4/ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(26,8 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8326/5/ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(42,8 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8326/6/ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(49,6 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8326/7/ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(42,8 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8326/8/ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(93,7 KB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8326/9/ScreenCapture9.jpg">ScreenCapture9.jpg</a>&nbsp;&nbsp;(88,4 KB)<br>&nbsp;&nbsp;10.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8326/10/ScreenCapture10.jpg">ScreenCapture10.jpg</a>&nbsp;&nbsp;(72,6 KB)<br>&nbsp;&nbsp;11.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8326/11/ScreenCapture11.jpg">ScreenCapture11.jpg</a>&nbsp;&nbsp;(63,4 KB)<br>&nbsp;&nbsp;12.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8326/12/ScreenCapture12.jpg">ScreenCapture12.jpg</a>&nbsp;&nbsp;(40,4 KB)<br>&nbsp;&nbsp;13.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8326/13/ScreenCapture13.jpg">ScreenCapture13.jpg</a>&nbsp;&nbsp;(41,1 KB)<br>&nbsp;&nbsp;14.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8326/14/ScreenCapture14.jpg">ScreenCapture14.jpg</a>&nbsp;&nbsp;(67,6 KB)<br>&nbsp;&nbsp;15.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8326/15/ScreenCapture15.jpg">ScreenCapture15.jpg</a>&nbsp;&nbsp;(146,7 KB)<br>&nbsp;&nbsp;16.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8326/16/ScreenCapture16.jpg">ScreenCapture16.jpg</a>&nbsp;&nbsp;(46,1 KB)<br>&nbsp;&nbsp;17.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8326/17/ScreenCapture17.jpg">ScreenCapture17.jpg</a>&nbsp;&nbsp;(57,6 KB)<br>&nbsp;&nbsp;18.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8326/18/ScreenCapture18.jpg">ScreenCapture18.jpg</a>&nbsp;&nbsp;(109,5 KB)<br>&nbsp;&nbsp;19.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8326/19/ScreenCapture19.jpg">ScreenCapture19.jpg</a>&nbsp;&nbsp;(46,2 KB)<br>&nbsp;&nbsp;20.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8326/20/ScreenCapture20.jpg">ScreenCapture20.jpg</a>&nbsp;&nbsp;(46,1 KB)<br>&nbsp;&nbsp;21.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8326/21/ScreenCapture21.jpg">ScreenCapture21.jpg</a>&nbsp;&nbsp;(56,3 KB)<br>&nbsp;&nbsp;22.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8326/22/ScreenCapture22.jpg">ScreenCapture22.jpg</a>&nbsp;&nbsp;(106 KB)<br>&nbsp;&nbsp;23.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8326/23/ScreenCapture23.jpg">ScreenCapture23.jpg</a>&nbsp;&nbsp;(74,3 KB)<br>&nbsp;&nbsp;24.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8326/24/ScreenCapture24.jpg">ScreenCapture24.jpg</a>&nbsp;&nbsp;(71,3 KB)<br>&nbsp;&nbsp;25.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8326/25/ScreenCapture25.jpg">ScreenCapture25.jpg</a>&nbsp;&nbsp;(32,1 KB)<br>&nbsp;&nbsp;26.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8326/26/ScreenCapture26.jpg">ScreenCapture26.jpg</a>&nbsp;&nbsp;(39,8 KB)<br>&nbsp;&nbsp;27.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8326/27/ScreenCapture27.jpg">ScreenCapture27.jpg</a>&nbsp;&nbsp;(54 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8326">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-06-12T16:54:20+02:00</dc:date><dc:creator>bee75336</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8326/1/ScreenCapture1.jpg" length="95125" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8326/2/ScreenCapture2.jpg" length="40922" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8326/3/ScreenCapture3.jpg" length="43236" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8326/4/ScreenCapture4.jpg" length="27420" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8326/5/ScreenCapture5.jpg" length="43853" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8326/6/ScreenCapture6.jpg" length="50750" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8326/7/ScreenCapture7.jpg" length="43777" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8326/8/ScreenCapture8.jpg" length="95941" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8326/9/ScreenCapture9.jpg" length="90482" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8326/10/ScreenCapture10.jpg" length="74360" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8326/11/ScreenCapture11.jpg" length="64910" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8326/12/ScreenCapture12.jpg" length="41362" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8326/13/ScreenCapture13.jpg" length="42121" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8326/14/ScreenCapture14.jpg" length="69238" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8326/15/ScreenCapture15.jpg" length="150221" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8326/16/ScreenCapture16.jpg" length="47194" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8326/17/ScreenCapture17.jpg" length="59005" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8326/18/ScreenCapture18.jpg" length="112144" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8326/19/ScreenCapture19.jpg" length="47266" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8326/20/ScreenCapture20.jpg" length="47254" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8326/21/ScreenCapture21.jpg" length="57624" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8326/22/ScreenCapture22.jpg" length="108572" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8326/23/ScreenCapture23.jpg" length="76070" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8326/24/ScreenCapture24.jpg" length="72974" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8326/25/ScreenCapture25.jpg" length="32836" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8326/26/ScreenCapture26.jpg" length="40790" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8326/27/ScreenCapture27.jpg" length="55259" type="image/jpeg"/></item><item>
<title>ASCO Intelligence Update - Part II - Prostate Cancer [dis:Prostate, :PharmaWorld:congress:ASCO, :PharmaWorld:mkt:Korea, :PharmaWorld:mkt:Intercontinental]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology8325</link>
<description>ASCO Intelligence Update - Part II - Prostate Cancer [dis:Prostate, :PharmaWorld:congress:ASCO, :PharmaWorld:mkt:Korea, :PharmaWorld:mkt:Intercontinental]</description><category>dis:Prostate</category><category>congress:ASCO</category><category>mkt:Korea</category><category>mkt:Intercontinental</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology8325</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8325">ASCO Intelligence Update - Part II - Prostate Cancer</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=congress%3aASCO"><font color="#e95e0b">:PharmaWorld:congress:ASCO</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=mkt%3aIntercontinental"><font color="#e95e0b">:PharmaWorld:mkt:Intercontinental</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=mkt%3aKorea"><font color="#e95e0b">:PharmaWorld:mkt:Korea</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8325">Oncology8325</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/774">bee75336</a> | 12 June 2012 | 15:53</font><br><br><div style="margin-bottom: 10px;">Comment: Enzalutatimde, Abiraterone, Radium-223 and Orteronel all had a number of posters displayed during ASCO.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Janssen - Abiraterone Poster Discussions</STRONG> </div><div style="margin-bottom: 10px;">Dr.<wbr> Goodman presented an Exploratory Analysis of Survial Benefit and Prior Docetaxel Treatment in COU-AA-301, a phase II study of AA plus prednisone in mCRPC highlighting that the survial benefit with AA was maintained regardless of prior docetaxel timing, duration and reason for discontinuation.<wbr>   However, survival benefit for patients in the AA arm was signifcatntly less in patients who discontiued docetaxel treatment due to progressive disease versus all other reasons.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8325/2/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">Janssen also held an invite only dinner where they basically detailed the summary of product characteristics of abiraterone, phase III post-chemo data,how to take the product and explained in detail why there is the need for steriods with this drug.<wbr> There were about 55 delegates in attendence at the dinner.<wbr> </div><div style="margin-bottom: 10px;"><B>Bayer — Radium 223 Oral Poster Discussions</B> </div><div style="margin-bottom: 10px;">Dr.<wbr> Chris Parker discussed the updated analysis of the phase III ALSYMPCA trial.<wbr>   This update is after 528 events and was conducted before the cut-off in July 2011.<wbr> It is understood that Bayer has filed Radium-223 and are expecting a first response from the FDA in the Autumn of this year.<wbr> The source could not provide details on a filing in the EU.<wbr> Due to the inclusion criteria, the label could be unusual in that it includes patients which are unfit for docetaxel.<wbr>  At least 45% of the patients on the trial ‘were considered unfit’.<wbr>    A reminder of the study schema is found below.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8325/3/ScreenCapture3.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">Primary endpoint is OS.<wbr>  Secondary endpoints include time to first SRE, time to total ALP progression, total ALP response, total ALP normalization, time to PSA progression, Safety and QOL  (not presented at this meeting) </div><div style="margin-bottom: 10px;">Results are as follows: </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8325/4/ScreenCapture4.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8325/5/ScreenCapture5.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">Off the back of this data, Dr.<wbr> Parker stated that he was tempted to speculate that radium 223 might be more effective in this high alkaline phosphatase group </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8325/7/ScreenCapture7.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8325/8/ScreenCapture8.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">There was a modest increase in grades 3 and 4 thrombocytopenia and an increase in grade 1 and 2 diarrhea and vomiting.<wbr>  He concluded with radium 223 is the first alpha-emitter to be investigated and may also be studied in other cancers with bone metastasis.<wbr> </div><div style="margin-bottom: 10px;">In a discussion by Dr.<wbr> Fizazi, he listed the pros and cons of Radium-223 and highlighted cost, lack of activity against non-bone metastases and disconnect between PSA/<wbr>OS as the most pressing unanswered questions.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8325/9/ScreenCapture9.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><B>Medivation/<wbr>Astellas — MDV3100 Posters</B> </div><div style="margin-bottom: 10px;">Medivation/<wbr>Astellas have opened a new Phase II trial, a randomised open label study of MDV3100 alone or in combination with Leuprolide and Dutasteride as neoadjuvant therapy to PT in intermediate and high risk pCa.<wbr>  The study opened in May 2012 and is enrolling 40-50 patients at 2 sites each in the USA and Canada.<wbr>  Study design and endpoints are found below </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8325/10/ScreenCapture10.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8325/11/ScreenCapture11.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">A poster of the on-going TERRAIN Study, a phase II randomised trial looking at MDV3100 vs bicalutamide in men with mCRPC was shown.<wbr> Planned enrolment of 370 patients in 90 sites across EU and USA.<wbr>   Study design is found below along with statistical methods for primary endpoint (PFS).<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8325/12/ScreenCapture12.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><B>Takada/<wbr>Millennium TAK-700 Posters</B> </div><div style="margin-bottom: 10px;">Takeda had three posters displayed at ASCO.<wbr> Currently, there are no trials  on-going in China and no plans as of yet to do so due to the difficulty of the regulatory environment.<wbr>  Trials are on-going in Taiwan, Korea, and Japan.<wbr>  The Japanese trial has about 25 — 26 patients currently and a lower dose is being investigated due to absorption differences in these patients.<wbr>  Takeda is now accepting TAK-700 in their IISR (Investigator Initiated Sponsored Research Study) Clinical Request System.<wbr>  Millennium have established an internal review committee to evaluate IISR proposals and are keen to receive submission for TAK-700 and Alisertib.<wbr>  See more on <a href="https://millennium.envisionpharma.com/vt_millennium/" class="defaultlink" title="https://millennium.envisionpharma.com/vt_millennium/">millennium.envisi&hellip;</a> </div><div style="margin-bottom: 10px;">1)Trial C21005 (post chemo) began in September and planned enrollment is 1,083 patients.<wbr>  Recruitment is at 85% and is expected to complete in October.<wbr>  It is understood C21004 (pre chemo) has completed enrollment.<wbr> </div><div style="margin-bottom: 10px;">2)Safety and activity of the investigational agent TAK-700 (orteronel) without prednisone in men with nonmetastatic castration-resistant prostate cancer (nmCRPC) and rising prostate-specific antigen (PSA): Updated results of a phase 2 study </div><div style="margin-bottom: 10px;">The primary objective of this study was to determine the percentage of patients achieving a PSA reduction to ≤ 0.<wbr>2 ng/<wbr>mL (undetectable levels).<wbr> Patients with PSA values of 0.<wbr>2ng/<wbr>mL or less have been shown to have a greater survival advantage.<wbr> Secondary objectives were to determine the safety of orteronel, PSA response rates at 3 months and 6 months (decline in PSA of ≥ 90 percent, ≥ 50 percent and/<wbr>or ≥ 30 percent), the percentage of patients achieving a PSA reduction to ≤ 0.<wbr>2 ng/<wbr>mL after 6 months, time to PSA progression, time to metastases, duration of progression-free survival, and changes in endocrine markers.<wbr> </div><div style="margin-bottom: 10px;">Results from the study of 39 patients, which were presented by Dr.<wbr> George, showed: </div><div style="margin-bottom: 10px;"><UL type="square"><LI>16 percent of patients experienced PSA ≤ 0.<wbr>2 ng/<wbr>mL at three months, and 12 (32%) experienced PSA ≤ 0.<wbr>2 ng/<wbr>mL as their best response </LI>
<LI>32 percent experienced a decline in PSA of ≥ 90 percent at 3 months 23 (61%) experienced a decline in PSA of ≥ 90 percent as their best response </LI>
<LI>76 percent experienced a decline in PSA of ≥ 50 percent at 3 months, and 84 percent experienced a decline in PSA of ≥ 50 percent as their best response </LI>
<LI>Median time to PSA progression was 14.<wbr>8 months </LI>
<LI>With a median follow-up of 7 cycles (8.<wbr>3 months), only three patients developed metastatic disease; freedom from metastases was 97 percent at 6 and 12 months, and median time to metastases was not reached </LI>
<LI>Orteronel dosed without prednisone suppressed testosterone by 87-89 percent and the adrenal androgen DHEA by 85-89 percent </LI>
<LI>The most common adverse events were fatigue (62 percent), diarrhea (38 percent); and hypertension (38 percent) </LI>
<LI>The most common adverse events of grade 3 or higher were hypertension (15 percent); dyspnea (8 percent); and fatigue, hypokalemia and pneumonitis (each 5 percent) </LI>
</UL> </div><div style="margin-bottom: 10px;">
3)Phase I results from a phase 1/<wbr>2 study of TAK-700 with docetaxel and prednisone in mCPRC.<wbr>  Study design presented below </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8325/14/ScreenCapture14.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">Results as follows: </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8325/15/ScreenCapture15.jpg?user-agent=rss"> </div><div><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8325/16/ScreenCapture16.jpg?user-agent=rss"> </div><!-- Comment details --><a name="oncology8325attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8325/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(108,3 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8325/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(115,5 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8325/3/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(49,6 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8325/4/ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(87,6 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8325/5/ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(111,2 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8325/6/ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(91,5 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8325/7/ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(97,8 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8325/8/ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(45,7 KB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8325/9/ScreenCapture9.jpg">ScreenCapture9.jpg</a>&nbsp;&nbsp;(56,5 KB)<br>&nbsp;&nbsp;10.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8325/10/ScreenCapture10.jpg">ScreenCapture10.jpg</a>&nbsp;&nbsp;(85,9 KB)<br>&nbsp;&nbsp;11.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8325/11/ScreenCapture11.jpg">ScreenCapture11.jpg</a>&nbsp;&nbsp;(277,2 KB)<br>&nbsp;&nbsp;12.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8325/12/ScreenCapture12.jpg">ScreenCapture12.jpg</a>&nbsp;&nbsp;(197 KB)<br>&nbsp;&nbsp;13.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8325/13/ScreenCapture13.jpg">ScreenCapture13.jpg</a>&nbsp;&nbsp;(68,3 KB)<br>&nbsp;&nbsp;14.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8325/14/ScreenCapture14.jpg">ScreenCapture14.jpg</a>&nbsp;&nbsp;(68,2 KB)<br>&nbsp;&nbsp;15.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8325/15/ScreenCapture15.jpg">ScreenCapture15.jpg</a>&nbsp;&nbsp;(72,7 KB)<br>&nbsp;&nbsp;16.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8325/16/ScreenCapture16.jpg">ScreenCapture16.jpg</a>&nbsp;&nbsp;(53,6 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8325">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-06-12T15:53:41+02:00</dc:date><dc:creator>bee75336</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8325/1/ScreenCapture1.jpg" length="110860" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8325/2/ScreenCapture2.jpg" length="118302" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8325/3/ScreenCapture3.jpg" length="50771" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8325/4/ScreenCapture4.jpg" length="89681" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8325/5/ScreenCapture5.jpg" length="113867" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8325/6/ScreenCapture6.jpg" length="93657" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8325/7/ScreenCapture7.jpg" length="100191" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8325/8/ScreenCapture8.jpg" length="46803" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8325/9/ScreenCapture9.jpg" length="57881" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8325/10/ScreenCapture10.jpg" length="87925" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8325/11/ScreenCapture11.jpg" length="283850" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8325/12/ScreenCapture12.jpg" length="201690" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8325/13/ScreenCapture13.jpg" length="69930" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8325/14/ScreenCapture14.jpg" length="69883" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8325/15/ScreenCapture15.jpg" length="74492" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8325/16/ScreenCapture16.jpg" length="54870" type="image/jpeg"/></item><item>
<title>PsychoGenics Is Seeking Partners for its Internal Neuro Program [dis:Dyskinesia, dis:Parkinson, :PharmaWorld:func:BusDev]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology6452</link>
<description>PsychoGenics Is Seeking Partners for its Internal Neuro Program [dis:Dyskinesia, dis:Parkinson, :PharmaWorld:func:BusDev]</description><category>dis:Dyskinesia</category><category>dis:Parkinson</category><category>func:BusDev</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology6452</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120831&edate=20120501&rec=6452">PsychoGenics Is Seeking Partners for its Internal Neuro Program</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=dis%3aDyskinesia"><font color="#e95e0b">:Neurology:dis:Dyskinesia</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=dis%3aParkinson"><font color="#e95e0b">:Neurology:dis:Parkinson</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=func%3aBusDev"><font color="#e95e0b">:PharmaWorld:func:BusDev</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology6452">Neurology6452</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 12 June 2012 | 14:44</font><br><br><div style="margin-bottom: 10px;">Comment: The preclinical CRO combines expertise in behavioral neurobiology with bioinformatics to discover treatments for major neuro/<wbr>psychiatric disorders.<wbr> Internal candidates include eltoprazine, a drug in Ph2 for Levodopa-Induced Dyskinesia (LID).<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Drug's Snapshot</FONT></STRONG> </div><div style="margin-bottom: 10px;">MOA: Eltoprazine is a selective 5-HT<SUB>1A</SUB>/<wbr><SUB>1B</SUB> partial agonist.<wbr> </div><div style="margin-bottom: 10px;">PC Data: eltoprazine effectively reduces LID at relatively low doses.<wbr> Chronic administration of eltoprazine for 45 days shows not only suppression of LID and no tolerance but also protection from development of dyskinesias.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Dose-finding study</FONT></STRONG> </div><div style="margin-bottom: 10px;"><STRONG>Study Results</STRONG> </div><div style="margin-bottom: 10px;">Eltoprazine met the primary objective of the study by exhibiting a statistically significant reduction in LID at the 5 mg dose (p = 0.<wbr>0007) and the 7.<wbr>5 mg dose (p = 0.<wbr>0467), without adversely affecting levodopa efficacy.<wbr> </div><div style="margin-bottom: 10px;">Eltoprazine was also well tolerated in this study and there were no serious AEs.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Study Design</STRONG> </div><div style="margin-bottom: 10px;">Location: Conducted at 2 sites in Sweden </div><div style="margin-bottom: 10px;">Recruitment: 22 patients </div><div style="margin-bottom: 10px;">Protocol: single doses of eltoprazine and placebo along with a challenge dose of levodopa at each of the 5 treatment visits and assessed for parkinsonian and dyskinesia symptoms over a period of 3 hours post-treatment.<wbr> The assessments were video-taped and scored by two independent blinded raters.<wbr> </div><div style="margin-bottom: 10px;">Primary efficacy: measured using the Clinical Dyskinesia Rating Scale (CDRS) and the Unified Parkinson's Disease Rating Scale (UPDRS).<wbr> </div><div style="margin-bottom: 10px;">Secondary endpoints: included the Rush Dyskinesia Rating Scale and evaluation of the patients' mood using the Hospital Anxiety &amp; Depression Score (HADS) and Montgomery-Asberg Depression Rating Scale (MADRS).<wbr> </div><div style="margin-bottom: 10px;">Support: The trial was partially supported by a grant from The Michael J.<wbr> Fox Foundation for Parkinson's Research.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Internal Candidates</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/6452/1/ScreenCapture1.jpg?user-agent=rss"> </div><div>Source: <A href="http://www.psychogenics.com/developmentpipeline.html">PsychoGenics</A> </div><!-- Comment details --><a name="neurology6452attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/6452/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(28,5 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120831&edate=20120501&rec=6452">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-06-12T14:44:08+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/6452/1/ScreenCapture1.jpg" length="29197" type="image/jpeg"/></item><item>
<title>Tokai's Galeterone Has Received Fast Track Designation for mCRPC [dis:Prostate, :PharmaWorld:mkt:NorthAmerica]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology8323</link>
<description>Tokai's Galeterone Has Received Fast Track Designation for mCRPC [dis:Prostate, :PharmaWorld:mkt:NorthAmerica]</description><category>dis:Prostate</category><category>mkt:NorthAmerica</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology8323</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8323">Tokai's Galeterone Has Received Fast Track Designation for mCRPC</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=mkt%3aNorthAmerica"><font color="#e95e0b">:PharmaWorld:mkt:NorthAmerica</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8323">Oncology8323</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 12 June 2012 | 14:21</font><br><br><div style="margin-bottom: 10px;">Comment: The drug is expected to enter Ph2 in H2:12.<wbr> The company believes that galeterone’s unique triple mechanism of action may offer an important therapeutic advance as CRPC often becomes resistant to androgen deprivation therapy.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Drug Status</FONT></STRONG> </div><div style="margin-bottom: 10px;">The Ph1 proof of concept study (ARMOR1), part of the ARMOR clinical dev.<wbr> programme, was recently completed.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">ARMOR1 Results</FONT></STRONG> </div><div>Presented recently at the American Association for Cancer Research (AACR) Annual Meeting 2012 and the 2012 Annual Meeting of the American Society of Clinical Oncology (ASCO) the results show that galeterone demonstrated efficacy and was well-tolerated in patients with CRPC.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8323">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-06-12T14:21:02+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Astellas and Drais Set Up Second Virtual Company for Accelerating Drug Development [func:RnD, sub:Partnership, :GastroEnterology:dis:IBS, :GastroEnterology:dis:Diarrhoea, :Oncology:comp:Astellas, func:BusDev]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld9911</link>
<description>Astellas and Drais Set Up Second Virtual Company for Accelerating Drug Development [func:RnD, sub:Partnership, :GastroEnterology:dis:IBS, :GastroEnterology:dis:Diarrhoea, :Oncology:comp:Astellas, func:BusDev]</description><category>func:RnD</category><category>sub:Partnership</category><category>dis:IBS</category><category>dis:Diarrhoea</category><category>comp:Astellas</category><category>func:BusDev</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld9911</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120831&edate=20120501&rec=9911">Astellas and Drais Set Up Second Virtual Company for Accelerating Drug Development</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20120831&edate=20120501&cat=dis%3aDiarrhoea"><font color="#e95e0b">:GastroEnterology:dis:Diarrhoea</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20120831&edate=20120501&cat=dis%3aIBS"><font color="#e95e0b">:GastroEnterology:dis:IBS</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=comp%3aAstellas"><font color="#e95e0b">:Oncology:comp:Astellas</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=func%3aBusDev"><font color="#e95e0b">:PharmaWorld:func:BusDev</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=func%3aRnD"><font color="#e95e0b">:PharmaWorld:func:RnD</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=sub%3aPartnership"><font color="#e95e0b">:PharmaWorld:sub:Partnership</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld9911">PharmaWorld9911</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 12 June 2012 | 13:30</font><br><br><div style="margin-bottom: 10px;">Comment: This partnership is similar to the one Astellas and Drais entered into in April 2012 to transfer another Astellas compound (for UC).<wbr> Those deals are part of Astellas' new 'Multi-Track R&amp;D' approach, a strategy that enables to optimize costs and control risks.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Terms of the Agreement</FONT></STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>Astellas to transfer to Seldar all rights and assets related to ASP147 (ready for an early-stage dosing trial)</LI>
<LI>Seldar to be responsible for all dev.<wbr>, manufacturing, and commercialization activies and their associated costs.<wbr></LI>
<LI>Astellas is entitled to receive milestone payment and royalties on future sales of the drug, and also has the right of first-exclusive negotiation for future partnering activities and the right for refusal for the Japanese market.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Seldar and Telsar</FONT></STRONG> </div><div style="margin-bottom: 10px;">Both virutal companies were set up by the lead investors in Drais along with Astellas Management.<wbr> </div><div><UL><LI>$13M will be invested into Seldar, which will provide a runway to further dev.<wbr> the compound</LI>
<LI>Telsar is receiving $14M to fund the dev.<wbr> of Astellas' ASP3291, a melanocortin receptor agonist in <A href="http://clinicaltrials.gov/ct2/show/NCT01612039?recr=Open&amp;fund=2&amp;rcv_s=05%2F29%2F2012&amp;rank=43">Ph2a for ulcerative colitis</A></LI>
</UL> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120831&edate=20120501&rec=9911">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-06-12T13:30:13+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Allergan Investors Can Proceed with BOTOX(R) Suit [comp:Allergan, prod:Botox]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology6450</link>
<description>Allergan Investors Can Proceed with BOTOX(R) Suit [comp:Allergan, prod:Botox]</description><category>comp:Allergan</category><category>prod:Botox</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology6450</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120831&edate=20120501&rec=6450">Allergan Investors Can Proceed with BOTOX(R) Suit</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=comp%3aAllergan"><font color="#e95e0b">:Neurology:comp:Allergan</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=prod%3aBotox"><font color="#e95e0b">:Neurology:prod:Botox</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology6450">Neurology6450</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 12 June 2012 | 12:24</font><br><br><div style="margin-bottom: 10px;">Comment: Two pension funds have claimed that Allergan's board failed to properly watch over executives who marketed the drug for unapproved indications, and gathered enough evidence to proceed with their demands.<wbr> On June 11th, a judge ruled that investors can seek to hold Allergan's directors responsible for criminal sanctions and a $600M penalty that the company was ordered to pay in 2010.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Derivative Suit Filed in 2010</FONT></STRONG> </div><div style="margin-bottom: 10px;">In 2010, the Louisiana Municipal Police Employees Retirement System, which invested in Allergan’s shares, filed a so-called derivative suit against the company’s board over the BOTOX(R) marketing campaign.<wbr> It later was joined in the suit by a Pennsylvania-based pension fund for restaurant workers.<wbr> </div><div style="margin-bottom: 10px;">Under such suits, any recovery from individual directors or insurance covering them would go to the company’s coffers rather than to individual shareholders.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Background in Traction</FONT></STRONG> </div><div style="margin-bottom: 10px;">Allergan agreed in Sept.<wbr> 2010 to plead guilty by promoting BOTOX(R) for unapproved uses and to pay a total of $600M in fines and damages, and approved a payment of $375M in criminal fines and $225M to resolve civil claims (Please see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120831&edate=20120501&rec=5177" class="defaultlink">Neurology5177: Allergan to Pay Fine to US Gov to Resolve Issues on BOTOX(R) Past Sales and Marketing Practices</a>).<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Source</FONT></STRONG> </div><div><P class="">The case is Louisiana Municipal Police Employees Retirement System and UFCW Local 1776 &amp; Participating Employers Pension Fund v.<wbr> Pyott, 5795, Delaware Chancery Court (Wilmington).<wbr></P> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120831&edate=20120501&rec=6450">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-06-12T12:24:39+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Detailed Information On New Sandostatin LAR Device [Alert, class:SomatostatinAnalogue, comp:Novartis, dis:Acromegaly, dis:pNET, dis:MidGutNET, :PharmaWorld:sub:Devices]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology6963</link>
<description>Detailed Information On New Sandostatin LAR Device [Alert, class:SomatostatinAnalogue, comp:Novartis, dis:Acromegaly, dis:pNET, dis:MidGutNET, :PharmaWorld:sub:Devices]</description><comments>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology6963</comments><category>Alert</category><category>class:SomatostatinAnalogue</category><category>comp:Novartis</category><category>dis:Acromegaly</category><category>dis:pNET</category><category>dis:MidGutNET</category><category>sub:Devices</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology6963</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120831&edate=20120501&rec=6963">Detailed Information On New Sandostatin LAR Device</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=Alert"><font color="#e95e0b">:Endocrinology:Alert</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=class%3aSomatostatinAnalogue"><font color="#e95e0b">:Endocrinology:class:SomatostatinAnalogue</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=comp%3aNovartis"><font color="#e95e0b">:Endocrinology:comp:Novartis</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=dis%3aAcromegaly"><font color="#e95e0b">:Endocrinology:dis:Acromegaly</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=dis%3aMidGutNET"><font color="#e95e0b">:Endocrinology:dis:MidGutNET</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=dis%3apNET"><font color="#e95e0b">:Endocrinology:dis:pNET</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=sub%3aDevices"><font color="#e95e0b">:PharmaWorld:sub:Devices</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology6963">Endocrinology6963</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 12 June 2012 | 12:18</font><br><br><div style="margin-bottom: 10px;">Comment: Thanks to Claudia Limberger (Endocrinology Marketing Manager 
Germany), we have more details about Novartis's new Sandostatin LAR device.<wbr> A 
copy of the visual aid is attached.<wbr> </div><div style="margin-bottom: 10px;">The changes are mostly in line with what was previously reported (see 
<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120831&edate=20120501&rec=6942" class="defaultlink">Endocrinology6942: ECE Intelligence Part 2 - Cushing's & NET & Pituitary Adenoma Data</a>) with the key features of the device as follows:- </div><div style="margin-bottom: 10px;"><UL><LI>easy: Quick-Link (Trademark) vial adapter makes the preparation of the 
  suspension easier and offers the possibility to mix the suspension while the 
  syringe is docked to the valve</LI>
<LI>safe: safety injection needle protects nurses against injuries </LI>
<LI>comfortable: 20% less injection volume (now 2 ml instead of 2,5 ml) for 
  more patient comfort </LI>
<LI>efficient: improved suspension characteristics for the convenient usage of 
  the application system</LI>
<LI>less pain: thinner injection needle (20 G instead of 19 G) for more 
  patient comfort" </LI>
</UL> </div><div style="margin-bottom: 10px;">
The key messages are mentioned are: <a name="Endocrinology6966c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div>With a reduced filled volume this will have a direct impact on their CoG.<wbr> Lower i suppose ! </div><font size="-1">faj69866 / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology6966" class="commentpermalink">Endocrinology6966</a> / <span class="date">13 June 2012</span> /
<span class="time">11:44:14 o'clock CEST</span>
</font></div></div><div style="margin-bottom: 10px;"><UL><LI>safe, due to new thinner safety needle (20G) </LI>
<LI>controlled, because it is injected by qualified personal </LI>
<LI>simple, thanks to easier and faster preparation </LI>
</UL> </div><div>
The new formulation is approved for both the treatment 
of Acromegaly and NET </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Endocrinology6983c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">Thanks to Susan Scott (Publications Director) at ENDO we have learnt that Novartis does not intend to launch new  LAR device in USA for a couple of years at least, due to changing requirements to US regulations and study requirements.<wbr> </div><div style="margin-bottom: 10px;">The local US sales team stated " We are very happy with our current syringe and expect Pasreotide to be the next big thing" - " why would we  launch a new device in USA when we have no competition in our biggest market NET.<wbr>" </div><div><DIV class="yj6qo ajU" style="padding-bottom: 10px; widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; margin: 2px 0px 0px; outline-style: none; outline-color: invert; padding-left: 0px; outline-width: medium; width: 22px; padding-right: 0px; font: 13px arial, sans-serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #222222; cursor: pointer; word-spacing: 0px; padding-top: 10px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">
<DIV class="ajR" id=":1b9" style="position: relative; line-height: 6px; background-color: #f1f1f1; outline-style: none; outline-color: invert; outline-width: medium; width: 20px; clear: both; border: #dddddd 1px solid;" tabindex="0"><IMG class="ajT" src="https://mail.google.com/mail/u/0/images/cleardot.gif" style="background-image: url('https://ssl.gstatic.com/ui/v1/icons/mail/ellipsis.png'); width: 20px; height: 8px; opacity: 0.3;"></DIV>
</DIV> </div><font size="-1">Jacquelyne CANTLE MEYRICK / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology6983" class="commentpermalink">Endocrinology6983</a> / <span class="date">26 June 2012</span> /
<span class="time">17:35:42 o'clock CEST</span>
</font></div><a name="endocrinology6963attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6963/1/New%20Sandostatin%20LAR%20Injection%20Device%20Promotion.pdf">New Sandostatin LAR Injection Device Promotion.pdf</a>&nbsp;&nbsp;(105,7 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120831&edate=20120501&rec=6963">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-06-12T12:18:37+02:00</dc:date><dc:creator>jac89886</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6963/1/New%20Sandostatin%20LAR%20Injection%20Device%20Promotion.pdf" length="108224" type="application/pdf"/></item><item>
<title>Japanese Filing For Sanofi's New GLP-1 Analogue [class:GLP1, headline, dis:Diabetes]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology6962</link>
<description>Japanese Filing For Sanofi's New GLP-1 Analogue [class:GLP1, headline, dis:Diabetes]</description><category>class:GLP1</category><category>headline</category><category>dis:Diabetes</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology6962</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120831&edate=20120501&rec=6962">Japanese Filing For Sanofi's New GLP-1 Analogue</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=class%3aGLP1"><font color="#e95e0b">:Endocrinology:class:GLP1</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=dis%3aDiabetes"><font color="#e95e0b">:Endocrinology:dis:Diabetes</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=headline"><font color="#e95e0b">:Endocrinology:headline</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology6962">Endocrinology6962</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 12 June 2012 | 12:06</font><br><br><div style="margin-bottom: 10px;">Comment: Sanofi has filed for regulatory approval in 
Japan of its GLP-1 analogue Lyxumia (lixisenatide) for the treatment 
of adults with type 2 diabetes.<wbr> </div><div style="margin-bottom: 10px;">The company said that the submission to the Japanese MHLW is supported by 
data from its GetGoal Phase III programme which included a GetGoal-L Asian study.<wbr> </div><div style="margin-bottom: 10px;">Lyxumia, which is being developed under a licence from Zealand Pharma, 
has already been filed for regulatory approval in the EU, and was 
accepted by the agency in November.<wbr> A submission in the US is expected in 
the fourth-quarter.<wbr> </div><div>Source: <A href="http://www.sanofi.com">www.<wbr>sanofi.<wbr>com</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120831&edate=20120501&rec=6962">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-06-12T12:06:02+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>NICE Revises Amgen's Xgeva Guidance [comp:Amgen, dis:Prostate, :PharmaWorld:mkt:UK]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology8322</link>
<description>NICE Revises Amgen's Xgeva Guidance [comp:Amgen, dis:Prostate, :PharmaWorld:mkt:UK]</description><comments>http://ci.beaufour-ipsen.com/traction/permalink/Oncology8322</comments><category>comp:Amgen</category><category>dis:Prostate</category><category>mkt:UK</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology8322</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8322">NICE Revises Amgen's Xgeva Guidance</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=comp%3aAmgen"><font color="#e95e0b">:Oncology:comp:Amgen</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=mkt%3aUK"><font color="#e95e0b">:PharmaWorld:mkt:UK</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8322">Oncology8322</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 12 June 2012 | 10:11</font><br><br><div style="margin-bottom: 10px;">Comment: Last March, NICE recommended the drug for breast and prostate cancer patients whose disease has spread to the bone.<wbr> But in light of new information from clinical experts, the agency has reported it no longer believed the drug represented a cost-effective treatment.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Background in Traction</FONT></STRONG> </div><div style="margin-bottom: 10px;">Please see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8195" class="defaultlink">Oncology8195: Amgen's Success With UK NICE</a>.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Rationale</FONT></STRONG> </div><div>The decision is due to revised thinking on the appropriate comparator treatments for the drug (which is an alternative to bisphosphonate drugs).<wbr> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Oncology8435c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;"><P align="left">The U.<wbr>K.<wbr>&rsquo;s NICE issued a final appraisal determination (FAD) recommending the use of Xgeva denosumab from Amgen to prevent skeletal-related events (SREs) in patients with bone metastases from breast cancer; and in patients with bone metastases from solid tumors other than breast and prostate cancer for whom zoledronic acid would be indicated.<wbr> The recommendation, which is contingent on Amgen providing Xgeva at an undisclosed discount under a patient access scheme, does not recommend Xgeva to prevent SREs in patients with bone metastases from hormone-refractory prostate cancer (HRPC).<wbr> Final guidance is expected next month.<wbr></P> </div><div>Source : BioCentury for the week of August 27, 2012 </div><font size="-1">fab42334 / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8435" class="commentpermalink">Oncology8435</a> / <span class="date">27 August 2012</span> /
<span class="time">17:54:02 o'clock CEST</span>
</font></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8322">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-06-12T10:11:42+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Exelixis Reports Highly Significant Improvement in PFS in Medullary Thyroid Cancer [headline, :Oncology:dis:Prostate]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology6959</link>
<description>Exelixis Reports Highly Significant Improvement in PFS in Medullary Thyroid Cancer [headline, :Oncology:dis:Prostate]</description><comments>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology6959</comments><category>headline</category><category>dis:Prostate</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology6959</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120831&edate=20120501&rec=6959">Exelixis Reports Highly Significant Improvement in PFS in Medullary Thyroid Cancer</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=headline"><font color="#e95e0b">:Endocrinology:headline</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology6959">Endocrinology6959</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 11 June 2012 | 11:45</font><br><br><div style="margin-bottom: 10px;">Comment: At ASCO last week, Exelexis reported additional data from its 
international PhIII EXAM trial in 330 patients with locally advanced or 
metastatic medullary thyroid cancer with once daily oral cabozantinib 
demonstrating a 1 -year PFS rate of 47.<wbr>3% vs 7.<wbr>2% for placebo.<wbr> </div><div style="margin-bottom: 10px;">Last month Exelixis completed a rolling NDA submission to the FDA for the 
treatment of MTC, requesting a priority review.<wbr> If approved it will market the 
product in the US.<wbr> Its thoughts on commercialisation are noted below.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Results of the EXAM Trial</STRONG> </div><div style="margin-bottom: 10px;">The EXAM study demonstrated a median duration of response of 14.<wbr>6 months but 
at this point is not mature enought to demonstrate an improvement in overall 
survival.<wbr> </div><div style="margin-bottom: 10px;">Cabozantinib did significantly improve ORR, a secondary endpoint vs.<wbr> placebo 
(28% vs.<wbr> 0% p&lt;0.<wbr>0001).<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6959/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6959/2/ScreenCapture3.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6959/3/ScreenCapture4.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6959/4/ScreenCapture5.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">When questioned about the commercial opportunity for a medullary thyoid 
cancer drug at the Goldman Sachs Conference Michael Morrissey CEO stated:- </div><div style="margin-bottom: 10px;">"So our view on MTC is relatively simple.<wbr> It's a small micro niche 
population.<wbr> There is approximately 1000 or so patients in North America, about 
1000 or so patients in Europe.<wbr> A fraction of those patients have what's arguably 
advanced stage metastatic, really aggressive disease.<wbr> Our clinical trial EXAM 
was designed to really ask the key question in that population.<wbr> We had a IRF 
based inclusion criteria for active aggressive progressing disease.<wbr> So we asked 
I think the right population – we asked the right question in the right 
population to really focus on the sub-population with the most clinical need 
versus the others who have relatively indolent disease for years or even a 
decade or more.<wbr>" </div><div style="margin-bottom: 10px;">"So how that plays out commercially? We're going through that right now.<wbr> We 
don't see this as a – as one that we'll invest heavily in.<wbr> We certainly are 
interested in being able to use this to build up some level of infrastructure, 
get our kind of all of our ducks lined up in terms of what we need to do to be 
able to commercialize the compound, but it will not be a large spend from the 
standpoint of building out for MTC because that indication just doesn't warrant 
that.<wbr>" </div><div style="margin-bottom: 10px;">"But that being said that, it's a great opportunity to get the compound 
potentially approved, which is no small feat for a company of our size and 
stature and to execute that across all the different components of what's 
involved is a very important point and with prostate, not too far behind.<wbr> So 
it's one area that we're looking at very closely, but doing it in a very careful 
way and with an investment that matches the potential upside.<wbr>" </div><div>source: <a href="http://www.exelixis.com" class="defaultlink" title="www.exelixis.com">exelixis.com</a> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Endocrinology7043c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div>Exelixis has been granted a priority review for cabozantinib for the treatment of medullary thyroid cancer.<wbr> The FDA has set a review date of November 29th.<wbr> </div><font size="-1">Jacquelyne CANTLE MEYRICK / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7043" class="commentpermalink">Endocrinology7043</a> / <span class="date">30 July 2012</span> /
<span class="time">15:52:03 o'clock CEST</span>
</font></div><a name="endocrinology6959attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6959/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(169,9 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6959/2/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(194,6 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6959/3/ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(176,5 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6959/4/ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(382,7 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120831&edate=20120501&rec=6959">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-06-11T11:45:10+02:00</dc:date><dc:creator>jac89886</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6959/1/ScreenCapture1.jpg" length="174002" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6959/2/ScreenCapture3.jpg" length="199233" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6959/3/ScreenCapture4.jpg" length="180735" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6959/4/ScreenCapture5.jpg" length="391835" type="image/jpeg"/></item><item>
<title>Monthly Administration of A GLP-1 Analogue Is Starting To Look Feasible [class:GLP1, dis:Diabetes, headline]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology6957</link>
<description>Monthly Administration of A GLP-1 Analogue Is Starting To Look Feasible [class:GLP1, dis:Diabetes, headline]</description><category>class:GLP1</category><category>dis:Diabetes</category><category>headline</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology6957</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120831&edate=20120501&rec=6957">Monthly Administration of A GLP-1 Analogue Is Starting To Look Feasible</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=class%3aGLP1"><font color="#e95e0b">:Endocrinology:class:GLP1</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=dis%3aDiabetes"><font color="#e95e0b">:Endocrinology:dis:Diabetes</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=headline"><font color="#e95e0b">:Endocrinology:headline</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology6957">Endocrinology6957</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 11 June 2012 | 10:42</font><br><br><div style="margin-bottom: 10px;">Comment At the ADA meeting this weekend, Diartis Pharmaceuticals presented positive data from its recently completed Phase 1 multicenter clinical trial of VRS-859 (exenatide-XTEN).<wbr> VRS-859, is a long-acting GLP-1 analog, that is being developed as a once monthly treatment for patients with type 2 diabetes mellitus.<wbr> </div><div style="margin-bottom: 10px;">The Diartis poster -- <STRONG>"Safety, Pharmacokinetics, and Pharmacodynamics of a Single Subcutaneous Administration of VRS-859 in Patients with Type 2 Diabetes"</STRONG> highlighted how in the Phase 1 multicenter, blinded, placebo-controlled, single-ascending dose study statistically significant reductions in HbA1c levels were noted at 30 days after only a single 200 mg dose of VRS-859.<wbr> A dose-proportional decreases in body weight was also observed within 30 days after a single treatment.<wbr> </div><div style="margin-bottom: 10px;">The study demonstrated that all doses administered (up to 200 mg) were well tolerated and no unexpected adverse events were noted.<wbr> Furthermore, the PK of VRS-859 in these patients was dose linear and comparable to the profile predicted from preclinical studies, validating the half-life extension capability of the XTEN technology and supporting a once monthly dosing regimen for VRS-859.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Trial Design</STRONG> </div><div style="margin-bottom: 10px;">The primary objective of the study was to determine the safety and tolerability of a single subcutaneous dose of VRS-859 in patients with T2DM.<wbr> Secondary objectives included single dose pharmacokinetics, assessment to evaluate evidence of VRS-859 activity by measurement of fasting plasma glucose and response to oral glucose tolerance tests at selected times post-dose, as well as to evaluate post-challenge glucose excursions.<wbr> Seventy T2DM patients concurrently on metformin were enrolled in the study: 18 patients received placebo and 52 patients received one of six dose levels: 12.<wbr>5, 25, 50, 100, 150 and 200 mg.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Next Steps</STRONG> </div><div style="margin-bottom: 10px;">The results support the company's plan to conduct a 6-month repeat dose study to determine a safe and efficacious subcutaneous dose of VRS-859 in patients with T2DM.<wbr> </div><div>Source: <A href="http://www.diartispharma.com">www.<wbr>diartispharma.<wbr>com</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120831&edate=20120501&rec=6957">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-06-11T10:42:41+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>Lexicon's Presentation @ Jefferies 2012 [dis:Diabetes, :GastroEnterology:dis:IBS, :GastroEnterology:dis:Diarrhoea]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology6955</link>
<description>Lexicon's Presentation @ Jefferies 2012 [dis:Diabetes, :GastroEnterology:dis:IBS, :GastroEnterology:dis:Diarrhoea]</description><category>dis:Diabetes</category><category>dis:IBS</category><category>dis:Diarrhoea</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology6955</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120831&edate=20120501&rec=6955">Lexicon's Presentation @ Jefferies 2012</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=dis%3aDiabetes"><font color="#e95e0b">:Endocrinology:dis:Diabetes</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20120831&edate=20120501&cat=dis%3aDiarrhoea"><font color="#e95e0b">:GastroEnterology:dis:Diarrhoea</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20120831&edate=20120501&cat=dis%3aIBS"><font color="#e95e0b">:GastroEnterology:dis:IBS</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology6955">Endocrinology6955</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 11 June 2012 | 10:16</font><br><br><div style="margin-bottom: 10px;">Comment: Lexicon provided some detailed data on LX4211, the only dual inhibitor of SGLT1 and SGLT2 in clinical development for diabetes.<wbr> Management also confirmed that regulatory interactions with EMA and FDA are ongoing for the Ph3 preparation of LX1032 (for carcinoid syndrome), and that the Ph2 trial of LX1033 for IBS-d is expected to complete enrollment around year end (data expected Q1:2013).<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Key Messages from the LX1033 Presentation</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6955/6/ScreenCapture6.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Key Messages from the LX1032 Presentation</FONT></STRONG> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6955/5/ScreenCapture5.jpg?user-agent=rss"></FONT></STRONG> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Key Messages from the LX4211 Presentation</FONT></STRONG> </div><div style="margin-bottom: 10px;"><U>Competition</U> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6955/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><U>Development Strategy</U> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6955/2/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6955/3/ScreenCapture3.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6955/4/ScreenCapture4.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Wedbush Estimates</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6955/7/ScreenCapture7.jpg?user-agent=rss"> </div><div><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6955/8/ScreenCapture8.jpg?user-agent=rss"> </div><!-- Comment details --><a name="endocrinology6955attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6955/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(38,1 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6955/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(26,3 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6955/3/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(24,3 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6955/4/ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(42,8 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6955/5/ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(56,1 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6955/6/ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(45,2 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6955/7/ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(103,3 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6955/8/ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(26,7 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120831&edate=20120501&rec=6955">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-06-11T10:16:49+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6955/1/ScreenCapture1.jpg" length="39035" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6955/2/ScreenCapture2.jpg" length="26911" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6955/3/ScreenCapture3.jpg" length="24915" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6955/4/ScreenCapture4.jpg" length="43835" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6955/5/ScreenCapture5.jpg" length="57417" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6955/6/ScreenCapture6.jpg" length="46241" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6955/7/ScreenCapture7.jpg" length="105783" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6955/8/ScreenCapture8.jpg" length="27311" type="image/jpeg"/></item><item>
<title>Xeomin to be Evaluated in a Small Pilot Study for the Treatment of Rosacea [prod:Xeomin, sub:Aesthetics, :PharmaWorld:sub:ClinicalTrial, :PharmaWorld:mkt:NorthAmerica, comp:Merz]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology6449</link>
<description>Xeomin to be Evaluated in a Small Pilot Study for the Treatment of Rosacea [prod:Xeomin, sub:Aesthetics, :PharmaWorld:sub:ClinicalTrial, :PharmaWorld:mkt:NorthAmerica, comp:Merz]</description><category>prod:Xeomin</category><category>sub:Aesthetics</category><category>sub:ClinicalTrial</category><category>mkt:NorthAmerica</category><category>comp:Merz</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology6449</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120831&edate=20120501&rec=6449">Xeomin to be Evaluated in a Small Pilot Study for the Treatment of Rosacea</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=comp%3aMerz"><font color="#e95e0b">:Neurology:comp:Merz</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=prod%3aXeomin"><font color="#e95e0b">:Neurology:prod:Xeomin</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=sub%3aAesthetics"><font color="#e95e0b">:Neurology:sub:Aesthetics</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=mkt%3aNorthAmerica"><font color="#e95e0b">:PharmaWorld:mkt:NorthAmerica</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=sub%3aClinicalTrial"><font color="#e95e0b">:PharmaWorld:sub:ClinicalTrial</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology6449">Neurology6449</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 08 June 2012 | 17:54</font><br><br><div style="margin-bottom: 10px;">Comment: In collaboration with Merz Pharm.<wbr> LLC, the Ph2 will assess the safety and the change in rosacea as primary outcome measures.<wbr> The pilot study will be conducted at DeNova Research Centre in Chicago (USA), which is specialized in aesthetic medicine, plastic surgery and dermatology.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Trial Details </FONT></STRONG><A href="http://clinicaltrials.gov/ct2/show/NCT01614743?recr=Open&amp;fund=2&amp;rcv_s=05%2F25%2F2012&amp;rank=115"><STRONG><FONT size="3">NCT01614743</FONT></STRONG></A> </div><div style="margin-bottom: 10px;">Recruitment: approx.<wbr> 10 subjects with rosacea of the cheek area.<wbr> </div><div style="margin-bottom: 10px;">Protocol: Upon entry, subjects will be randomized to receive either Xeomin or bacteriostatic saline to the cheek area.<wbr> </div><div style="margin-bottom: 10px;">At the 16 week visit, control subjects will enter the rescue arm portion of the study and all study subjects will receive treatment with incobotulinumtoxinA to the cheek areas.<wbr> </div><div style="margin-bottom: 10px;">Start date: June 2012 - Completion date: Dec 2012 /<wbr> Feb 2013 </div><div>Investigator: Steven H.<wbr> Dayan, Medical Director (DeNova Research) </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120831&edate=20120501&rec=6449">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-06-08T17:54:30+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>ASCO Intelligence Part 1 – New Treatment Paradigms For Hormone Therapy in Prostate Cancer [dis:Prostate, :PharmaWorld:congress:ASCO, :PharmaWorld:mkt:Australia, :PharmaWorld:mkt:Intercontinental]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology8315</link>
<description>ASCO Intelligence Part 1 – New Treatment Paradigms For Hormone Therapy in Prostate Cancer [dis:Prostate, :PharmaWorld:congress:ASCO, :PharmaWorld:mkt:Australia, :PharmaWorld:mkt:Intercontinental]</description><category>dis:Prostate</category><category>congress:ASCO</category><category>mkt:Australia</category><category>mkt:Intercontinental</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology8315</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8315">ASCO Intelligence Part 1 – New Treatment Paradigms For Hormone Therapy in Prostate Cancer</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=congress%3aASCO"><font color="#e95e0b">:PharmaWorld:congress:ASCO</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=mkt%3aAustralia"><font color="#e95e0b">:PharmaWorld:mkt:Australia</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=mkt%3aIntercontinental"><font color="#e95e0b">:PharmaWorld:mkt:Intercontinental</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8315">Oncology8315</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/774">bee75336</a> | 08 June 2012 | 16:01</font><br><br><div style="margin-bottom: 10px;"><FONT face="Arial">Comment: In this session, pivotal trial results for abiraterone (chemo naive and neoadjuvant) and results from MDV3100’s (Enzalutimide) AFFIRM trial were shown.<wbr> It is understood that the MDV3100 PREVAIL (pre-chemo study) will read out in the next 18 months and the Expanded Access Programme has started in the USA.<wbr> At this meeting and through their data, signs of marketing and counter marketing messages coming to the fore-front from Astellas/<wbr>Medivation were evident.<wbr></FONT> </div><div style="margin-bottom: 10px;"><FONT face="Arial">Following on from recent feedback on the Zytiga chemoniave data (see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8306" class="defaultlink">Oncology8306: Highlights from the Abiraterone Ph3 Pre-Docetaxel Data - Feedback from ASCO</a>) highlights from the ph3 pre-docetaxel trial data provide more details of the study as well as the slides presented.<wbr></FONT> </div><div style="margin-bottom: 10px;"><FONT face="Arial">Charles Ryan detailed the results of an interim analysis in chemo naïve patients (302 study) which took place in 151 sites and 12 countries worldwide including EU, USA, Australia and Canada.<wbr> The co-primary endpoints are OS and rPFS including a number of secondary endpoints seen below in the study design schema</FONT> </div><div style="margin-bottom: 10px;"><FONT face="Arial"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8315/1/ScreenCapture1.jpg?user-agent=rss"></FONT> </div><div style="margin-bottom: 10px;"><FONT face="Arial">rPFS was rigorously defined</FONT> </div><div style="margin-bottom: 10px;"><FONT face="Arial"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8315/2/ScreenCapture2.jpg?user-agent=rss"></FONT> </div><div style="margin-bottom: 10px;"><FONT face="Arial">There are three planned interim analysis on an event driven basis.<wbr> The second interim at 40% of events is actually taking place after 43% of events therefore, the actual observed analysis alpha value required for significance is 0.<wbr>0008.<wbr> Final analysis is planned after 773 events.<wbr></FONT> </div><div style="margin-bottom: 10px;"><FONT face="Arial"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8315/3/ScreenCapture3.jpg?user-agent=rss"></FONT> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 12pt; FONT-FAMILY: 'Cambria','serif'; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: 'MS Mincho'; mso-fareast-theme-font: minor-fareast; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"><FONT face="Arial" size="2">Treatment arms were well balanced.<wbr> In patients with mild symptoms, 2/<wbr>3rds had pain that required no analgesics and thus scored a 0-1 on the pain inventory.<wbr></FONT></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 12pt; FONT-FAMILY: 'Cambria','serif'; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: 'MS Mincho'; mso-fareast-theme-font: minor-fareast; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"><FONT face="Arial" size="2"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8315/4/ScreenCapture4.jpg?user-agent=rss"></FONT></SPAN> </div><div style="margin-bottom: 10px;"><FONT face="Arial">At the time of this analysis, 69% in the AA and 84% in the placebo arm discontinued therapy.<wbr> Of note, very few patients discontinued due to adverse events</FONT> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 12pt; FONT-FAMILY: 'Cambria','serif'; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: 'MS Mincho'; mso-fareast-theme-font: minor-fareast; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"><FONT face="Arial" size="2"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8315/5/ScreenCapture5.jpg?user-agent=rss"></FONT></SPAN> </div><div style="margin-bottom: 10px;"><FONT face="Arial">rPFS has not yet been reached in the AA arm with the prednisone control arm being 8.<wbr>3 months, this is associated with a HR of 0.<wbr>43 and a P value of &lt;0.<wbr>0001, this represents an approximate doubling of the rPFS.<wbr></FONT> </div><div style="margin-bottom: 10px;"><FONT face="Arial"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8315/6/ScreenCapture6.jpg?user-agent=rss"></FONT> </div><div style="margin-bottom: 10px;"><FONT face="Arial">All HRs significantly favoured abiraterone over the prednisone control group.<wbr></FONT> </div><div style="margin-bottom: 10px;"><FONT face="Arial"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8315/7/ScreenCapture7.jpg?user-agent=rss"></FONT> </div><div style="margin-bottom: 10px;"><FONT face="Arial">Median survival in the prednisone control arm is 27.<wbr>2 months, while the median survival has not yet been reached in the abiraterone arm.<wbr> This conforms to a HR of 0.<wbr>75 and a p value of 0 .<wbr>0097 showing a strong trend for OS with abiraterone.<wbr></FONT> </div><div style="margin-bottom: 10px;"><FONT face="Arial"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8315/8/ScreenCapture8.jpg?user-agent=rss"></FONT> </div><div style="margin-bottom: 10px;"><FONT face="Arial">There is no subgroup driving the overall OS benefit nor is there a patient group that is identified as having an unfavourable outcome with treatment of abiraterone.<wbr></FONT> </div><div style="margin-bottom: 10px;"><FONT face="Arial"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8315/9/ScreenCapture9.jpg?user-agent=rss"></FONT> </div><div style="margin-bottom: 10px;"><FONT face="Arial">Most common subsequent therapy was docetaxel.<wbr></FONT> </div><div style="margin-bottom: 10px;"><FONT face="Arial"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8315/10/ScreenCapture10.jpg?user-agent=rss"></FONT> </div><div style="margin-bottom: 10px;"><FONT face="Arial"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8315/11/ScreenCapture11.jpg?user-agent=rss"></FONT> </div><div style="margin-bottom: 10px;"><FONT face="Arial"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8315/13/ScreenCapture13.jpg?user-agent=rss"></FONT> </div><div style="margin-bottom: 10px;"><FONT face="Arial">The most common AEs in both arms was fatigue.<wbr> Most ALT and AST increases occurred during the first 3 months of treatment and no new safety concerns were highlighted even with the longer duration of treatment.<wbr></FONT> </div><div style="margin-bottom: 10px;"><FONT face="Arial"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8315/14/ScreenCapture14.jpg?user-agent=rss"></FONT> </div><div style="margin-bottom: 10px;"><FONT face="Arial">The IDMC has unblinded this study at the 2<SUP>nd</SUP> interim analysis although investigators and sponsors remain blinded.<wbr> They concluded that OS, rPFS and secondary endpoints all favoured abiraterone and therefore recommended unblinding and all placebo patients to be offered treatment with AA.<wbr> There has been criticism with this decision, with many feeling that the data was unblinded far too early before reaching the predetermined statistical assumption (see </FONT><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8306" class="defaultlink">Oncology8306: Highlights from the Abiraterone Ph3 Pre-Docetaxel Data - Feedback from ASCO</a><FONT face="Arial">).<wbr></FONT> </div><div style="margin-bottom: 10px;"><B><FONT face="Arial">Primary, secondary and QOL endpoint results from the P3 AFFIRM study of MDV3100 was presented by Johann Sebastian De Bono</FONT></B> </div><div style="margin-bottom: 10px;"><FONT face="Arial">Study schema for AFFIRM is found below and it is important to note that PCWG2 was used whereby therapy was continued despite minor rises in PSA.<wbr> Recruitment was in 156 centres from 15 countries on 5 continents— a truly a global trial.<wbr> Enrollment was between September 2009 — November 2011.<wbr> Detailed Pain, QOL and SRE data will be presented at ESMO by Dr.<wbr>Fizazi.<wbr></FONT> </div><div style="margin-bottom: 10px;"><FONT face="Arial"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8315/15/ScreenCapture15.jpg?user-agent=rss"></FONT> </div><div style="margin-bottom: 10px;"><FONT face="Arial"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8315/16/ScreenCapture16.jpg?user-agent=rss"></FONT> </div><div style="margin-bottom: 10px;"><FONT face="Arial">Only those in bold were presented during this meeting.<wbr></FONT> </div><div style="margin-bottom: 10px;"><FONT face="Arial"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8315/17/ScreenCapture17.jpg?user-agent=rss"></FONT> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 12pt; FONT-FAMILY: 'Cambria','serif'; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: 'MS Mincho'; mso-fareast-theme-font: minor-fareast; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"><FONT face="Arial" size="2">The HR of 0.<wbr>63 equates to a 37% reduction in risk of death with OS being 18.<wbr>4 months.<wbr> The placebo group registered a 11.<wbr>3 months OS.<wbr> Dr.<wbr> De Bono stated that this is the best survival data seen in the post-chemo setting.<wbr></FONT></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 12pt; FONT-FAMILY: 'Cambria','serif'; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: 'MS Mincho'; mso-fareast-theme-font: minor-fareast; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"><FONT face="Arial" size="2"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8315/18/ScreenCapture18.jpg?user-agent=rss"></FONT></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 12pt; FONT-FAMILY: 'Cambria','serif'; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: 'MS Mincho'; mso-fareast-theme-font: minor-fareast; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"><FONT face="Arial" size="2"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8315/19/ScreenCapture19.jpg?user-agent=rss"></FONT></SPAN> </div><div style="margin-bottom: 10px;"><FONT face="Arial">30% of the patient population in each arm received steroids (optional) and data presented at ESMO 2012 will detail the impact of steroids on outcomes.<wbr> Dr.<wbr> De Bono sees steroid usage as a double edge sword; one side giving benefit and one side impacting disease progression adversely in this patient population.<wbr></FONT> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 12pt; FONT-FAMILY: 'Cambria','serif'; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: 'MS Mincho'; mso-fareast-theme-font: minor-fareast; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"><FONT face="Arial" size="2"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8315/20/ScreenCapture20.jpg?user-agent=rss"></FONT></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 12pt; FONT-FAMILY: 'Cambria','serif'; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: 'MS Mincho'; mso-fareast-theme-font: minor-fareast; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"><FONT face="Arial" size="2"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8315/21/ScreenCapture21.jpg?user-agent=rss"></FONT></SPAN> </div><div style="margin-bottom: 10px;"><FONT face="Arial">All secondary endpoints favoured Enzalutamide.<wbr></FONT> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 12pt; FONT-FAMILY: 'Cambria','serif'; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: 'MS Mincho'; mso-fareast-theme-font: minor-fareast; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"><FONT face="Arial" size="2"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8315/22/ScreenCapture22.jpg?user-agent=rss"></FONT></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 12pt; FONT-FAMILY: 'Cambria','serif'; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: 'MS Mincho'; mso-fareast-theme-font: minor-fareast; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"><FONT face="Arial" size="2"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8315/23/ScreenCapture23.jpg?user-agent=rss"></FONT></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 12pt; FONT-FAMILY: 'Cambria','serif'; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: 'MS Mincho'; mso-fareast-theme-font: minor-fareast; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"><FONT face="Arial" size="2"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8315/24/ScreenCapture24.jpg?user-agent=rss"></FONT></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 12pt; FONT-FAMILY: 'Cambria','serif'; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: 'MS Mincho'; mso-fareast-theme-font: minor-fareast; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"><FONT face="Arial" size="2"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8315/25/ScreenCapture25.jpg?user-agent=rss"></FONT></SPAN> </div><div style="margin-bottom: 10px;"><FONT face="Arial">Enzalutamide is generally well tolerated but does cause a higher risk of fatigue which was not considered significant and there is a small risk of seizures.<wbr></FONT> </div><div style="margin-bottom: 10px;"><FONT face="Arial"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8315/26/ScreenCapture26.jpg?user-agent=rss"></FONT> </div><div style="margin-bottom: 10px;"><FONT face="Arial">Dr.<wbr> De Bono walked us through the breakdown of the seizures on a per case basis (there were only five).<wbr> Two of the five had significant intracerebral disease, one had a number of CNS metastasis and had a seizure directly after lidocaine administration with the last seizure patient listed as having accesses of alcohol throughout treatment and was on another sodium channel modulator and 7 days after taking haloperidol, the patient had a non-witnessed seizure.<wbr> Dr.<wbr> De Bono highlighted that although there were no cases of seizures in the placebo arm, there were confounding factors concerning the patients in the active arm.<wbr></FONT> </div><div style="margin-bottom: 10px;"><FONT face="Arial"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8315/27/ScreenCapture27.jpg?user-agent=rss"></FONT> </div><div style="margin-bottom: 10px;"><FONT face="Arial">Dr.<wbr>De Bono flashed the below slide demonstrating the OS and HR of all the recent trials with Enzalutamide showing the most impressive data.<wbr></FONT> </div><div style="margin-bottom: 10px;"><FONT face="Arial"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8315/28/ScreenCapture28.jpg?user-agent=rss"></FONT> </div><div style="margin-bottom: 10px;"><FONT face="Arial">Due to these results, the IDMC has asked to unblind the study with patients on placebo to be offered the active drug.<wbr></FONT> </div><div style="margin-bottom: 10px;"><FONT face="Arial">The subsequent discussion was focused on whether or not MDV3100 was a new class of drug or a better AR? During this talk, Dr.<wbr> William Kelley compared the OS data with abiraterone and also stated that a subgroup which may benefit from Enzalutamide over abiraterone or cabazitaxel are those with a poor performance status of 2.<wbr> In addition, another AR antagonist being trialed, BMS-641988 has shown incidences of seizures.<wbr></FONT> </div><div style="margin-bottom: 10px;"><FONT face="Arial"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8315/29/ScreenCapture29.jpg?user-agent=rss"></FONT> </div><div style="margin-bottom: 10px;"><B><FONT face="Arial">Effect of neoadjuvant AA plus Leuprolide on PSA, pCR and near pCR in LHRPC —results of the phase II study presented by Mary-Ellen Taplin</FONT></B> </div><div style="margin-bottom: 10px;"><FONT face="Arial">Patients in this cohort had unfavorable high-risk disease and lymph node enlargement was not excluded.<wbr></FONT> </div><div style="margin-bottom: 10px;"><FONT face="Arial"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8315/30/ScreenCapture30.jpg?user-agent=rss"></FONT> </div><div style="margin-bottom: 10px;"><FONT face="Arial">Study schema found below.<wbr> A key aspect of this trial was to demonstrate the effect of abriaterone on tissue androgens which had not yet been done in other trials.<wbr> In the abiraterone/<wbr>LHRHa/<wbr>prednisone (AA/<wbr>LHRHa/<wbr>pred) arm, prednisone was used at a dose of 5mg once daily.<wbr> After 3 months, both arms underwent a prostate biopsy for measurement of tissue androgens— these measurement was the primary endpoint.<wbr> All participants then carried on for another 3 months on AA/<wbr>LHRHa/<wbr>pred followed by RP.<wbr> Secondary endpoints include pathologic staging and PSA response rates.<wbr> Additional, secondary endpoints that were not discussed in this presentation include serum androgens, molecular profiling of the AR including amplification, mutation, splice variant analysis and gene expression profiling.<wbr></FONT> </div><div style="margin-bottom: 10px;"><FONT face="Arial"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8315/31/ScreenCapture31.jpg?user-agent=rss"></FONT> </div><div style="margin-bottom: 10px;"><FONT face="Arial"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8315/32/ScreenCapture32.jpg?user-agent=rss"></FONT> </div><div style="margin-bottom: 10px;"><FONT face="Arial"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8315/33/ScreenCapture33.jpg?user-agent=rss"></FONT> </div><div style="margin-bottom: 10px;"><FONT face="Arial">Lower PSA at 12 weeks on AA, however at 24 weeks, both groups were low.<wbr></FONT> </div><div style="margin-bottom: 10px;"><FONT face="Arial"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8315/34/ScreenCapture34.jpg?user-agent=rss"></FONT> </div><div style="margin-bottom: 10px;"><FONT face="Arial"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8315/35/ScreenCapture35.jpg?user-agent=rss"></FONT> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 12pt; FONT-FAMILY: 'Cambria','serif'; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: 'MS Mincho'; mso-fareast-theme-font: minor-fareast; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"><FONT face="Arial" size="2">Primary endpoint results are as follows.<wbr> This is the first time data in tissue has been shown.<wbr></FONT></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 12pt; FONT-FAMILY: 'Cambria','serif'; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: 'MS Mincho'; mso-fareast-theme-font: minor-fareast; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"><FONT face="Arial" size="2"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8315/37/ScreenCapture37.jpg?user-agent=rss"></FONT></SPAN> </div><div style="margin-bottom: 10px;"><FONT face="Arial">Additional hormones have been measured in the pathway.<wbr></FONT> </div><div style="margin-bottom: 10px;"><FONT face="Arial"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8315/38/ScreenCapture38.jpg?user-agent=rss"></FONT> </div><div style="margin-bottom: 10px;"><FONT face="Arial">Well tolerated although patients need to be monitored for hypokalemia.<wbr></FONT> </div><div style="margin-bottom: 10px;"><FONT face="Arial"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8315/39/ScreenCapture39.jpg?user-agent=rss"></FONT> </div><div style="margin-bottom: 10px;"><FONT face="Arial"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8315/40/ScreenCapture40.jpg?user-agent=rss"></FONT> </div><div style="margin-bottom: 10px;"><FONT face="Arial"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8315/41/ScreenCapture41.jpg?user-agent=rss"></FONT> </div><div style="margin-bottom: 10px;"><FONT face="Arial">Ongoing analysis with Taplin et al is listed as well as future clinical trials, including a phase II trial of neoadjuvant AA/<wbr>leuprolide/<wbr>pred/<wbr>ARN509 and an MDV3100 phase II trial of MDV3100 alone versus MDV3100/<wbr>LHRHa/<wbr>dutasteride which has just opened some sites including hospitals in Seattle and Canada as well as the Dana Farber Institute</FONT> </div><div><FONT face="Arial"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8315/42/ScreenCapture42.jpg?user-agent=rss"></FONT> </div><!-- Comment details --><a name="oncology8315attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8315/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(58,6 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8315/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(45,2 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8315/3/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(49,6 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8315/4/ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(65,8 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8315/5/ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(68,4 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8315/6/ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(50,2 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8315/7/ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(60,1 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8315/8/ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(50 KB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8315/9/ScreenCapture9.jpg">ScreenCapture9.jpg</a>&nbsp;&nbsp;(56,7 KB)<br>&nbsp;&nbsp;10.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8315/10/ScreenCapture10.jpg">ScreenCapture10.jpg</a>&nbsp;&nbsp;(54,7 KB)<br>&nbsp;&nbsp;11.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8315/11/ScreenCapture11.jpg">ScreenCapture11.jpg</a>&nbsp;&nbsp;(52,4 KB)<br>&nbsp;&nbsp;12.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8315/12/ScreenCapture12.jpg">ScreenCapture12.jpg</a>&nbsp;&nbsp;(50,1 KB)<br>&nbsp;&nbsp;13.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8315/13/ScreenCapture13.jpg">ScreenCapture13.jpg</a>&nbsp;&nbsp;(76,4 KB)<br>&nbsp;&nbsp;14.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8315/14/ScreenCapture14.jpg">ScreenCapture14.jpg</a>&nbsp;&nbsp;(70 KB)<br>&nbsp;&nbsp;15.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8315/15/ScreenCapture15.jpg">ScreenCapture15.jpg</a>&nbsp;&nbsp;(62,7 KB)<br>&nbsp;&nbsp;16.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8315/16/ScreenCapture16.jpg">ScreenCapture16.jpg</a>&nbsp;&nbsp;(51,4 KB)<br>&nbsp;&nbsp;17.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8315/17/ScreenCapture17.jpg">ScreenCapture17.jpg</a>&nbsp;&nbsp;(52 KB)<br>&nbsp;&nbsp;18.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8315/18/ScreenCapture18.jpg">ScreenCapture18.jpg</a>&nbsp;&nbsp;(66,4 KB)<br>&nbsp;&nbsp;19.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8315/19/ScreenCapture19.jpg">ScreenCapture19.jpg</a>&nbsp;&nbsp;(66,3 KB)<br>&nbsp;&nbsp;20.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8315/20/ScreenCapture20.jpg">ScreenCapture20.jpg</a>&nbsp;&nbsp;(53,4 KB)<br>&nbsp;&nbsp;21.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8315/21/ScreenCapture21.jpg">ScreenCapture21.jpg</a>&nbsp;&nbsp;(54,6 KB)<br>&nbsp;&nbsp;22.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8315/22/ScreenCapture22.jpg">ScreenCapture22.jpg</a>&nbsp;&nbsp;(56,4 KB)<br>&nbsp;&nbsp;23.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8315/23/ScreenCapture23.jpg">ScreenCapture23.jpg</a>&nbsp;&nbsp;(54,2 KB)<br>&nbsp;&nbsp;24.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8315/24/ScreenCapture24.jpg">ScreenCapture24.jpg</a>&nbsp;&nbsp;(61,3 KB)<br>&nbsp;&nbsp;25.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8315/25/ScreenCapture25.jpg">ScreenCapture25.jpg</a>&nbsp;&nbsp;(56,1 KB)<br>&nbsp;&nbsp;26.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8315/26/ScreenCapture26.jpg">ScreenCapture26.jpg</a>&nbsp;&nbsp;(64,5 KB)<br>&nbsp;&nbsp;27.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8315/27/ScreenCapture27.jpg">ScreenCapture27.jpg</a>&nbsp;&nbsp;(53,2 KB)<br>&nbsp;&nbsp;28.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8315/28/ScreenCapture28.jpg">ScreenCapture28.jpg</a>&nbsp;&nbsp;(69,4 KB)<br>&nbsp;&nbsp;29.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8315/29/ScreenCapture29.jpg">ScreenCapture29.jpg</a>&nbsp;&nbsp;(77,4 KB)<br>&nbsp;&nbsp;30.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8315/30/ScreenCapture30.jpg">ScreenCapture30.jpg</a>&nbsp;&nbsp;(46,6 KB)<br>&nbsp;&nbsp;31.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8315/31/ScreenCapture31.jpg">ScreenCapture31.jpg</a>&nbsp;&nbsp;(60 KB)<br>&nbsp;&nbsp;32.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8315/32/ScreenCapture32.jpg">ScreenCapture32.jpg</a>&nbsp;&nbsp;(61,5 KB)<br>&nbsp;&nbsp;33.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8315/33/ScreenCapture33.jpg">ScreenCapture33.jpg</a>&nbsp;&nbsp;(55,5 KB)<br>&nbsp;&nbsp;34.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8315/34/ScreenCapture34.jpg">ScreenCapture34.jpg</a>&nbsp;&nbsp;(46,8 KB)<br>&nbsp;&nbsp;35.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8315/35/ScreenCapture35.jpg">ScreenCapture35.jpg</a>&nbsp;&nbsp;(50,9 KB)<br>&nbsp;&nbsp;36.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8315/36/ScreenCapture36.jpg">ScreenCapture36.jpg</a>&nbsp;&nbsp;(54,3 KB)<br>&nbsp;&nbsp;37.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8315/37/ScreenCapture37.jpg">ScreenCapture37.jpg</a>&nbsp;&nbsp;(54,2 KB)<br>&nbsp;&nbsp;38.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8315/38/ScreenCapture38.jpg">ScreenCapture38.jpg</a>&nbsp;&nbsp;(48 KB)<br>&nbsp;&nbsp;39.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8315/39/ScreenCapture39.jpg">ScreenCapture39.jpg</a>&nbsp;&nbsp;(53,3 KB)<br>&nbsp;&nbsp;40.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8315/40/ScreenCapture40.jpg">ScreenCapture40.jpg</a>&nbsp;&nbsp;(52,5 KB)<br>&nbsp;&nbsp;41.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8315/41/ScreenCapture41.jpg">ScreenCapture41.jpg</a>&nbsp;&nbsp;(69,6 KB)<br>&nbsp;&nbsp;42.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8315/42/ScreenCapture42.jpg">ScreenCapture42.jpg</a>&nbsp;&nbsp;(78 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8315">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-06-08T16:01:23+02:00</dc:date><dc:creator>bee75336</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8315/1/ScreenCapture1.jpg" length="59981" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8315/2/ScreenCapture2.jpg" length="46283" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8315/3/ScreenCapture3.jpg" length="50754" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8315/4/ScreenCapture4.jpg" length="67373" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8315/5/ScreenCapture5.jpg" length="70009" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8315/6/ScreenCapture6.jpg" length="51416" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8315/7/ScreenCapture7.jpg" length="61562" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8315/8/ScreenCapture8.jpg" length="51190" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8315/9/ScreenCapture9.jpg" length="58060" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8315/10/ScreenCapture10.jpg" length="55997" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8315/11/ScreenCapture11.jpg" length="53703" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8315/12/ScreenCapture12.jpg" length="51287" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8315/13/ScreenCapture13.jpg" length="78188" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8315/14/ScreenCapture14.jpg" length="71728" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8315/15/ScreenCapture15.jpg" length="64212" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8315/16/ScreenCapture16.jpg" length="52594" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8315/17/ScreenCapture17.jpg" length="53277" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8315/18/ScreenCapture18.jpg" length="68037" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8315/19/ScreenCapture19.jpg" length="67936" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8315/20/ScreenCapture20.jpg" length="54673" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8315/21/ScreenCapture21.jpg" length="55906" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8315/22/ScreenCapture22.jpg" length="57793" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8315/23/ScreenCapture23.jpg" length="55489" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8315/24/ScreenCapture24.jpg" length="62812" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8315/25/ScreenCapture25.jpg" length="57419" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8315/26/ScreenCapture26.jpg" length="66010" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8315/27/ScreenCapture27.jpg" length="54528" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8315/28/ScreenCapture28.jpg" length="71112" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8315/29/ScreenCapture29.jpg" length="79262" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8315/30/ScreenCapture30.jpg" length="47712" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8315/31/ScreenCapture31.jpg" length="61420" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8315/32/ScreenCapture32.jpg" length="62991" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8315/33/ScreenCapture33.jpg" length="56788" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8315/34/ScreenCapture34.jpg" length="47876" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8315/35/ScreenCapture35.jpg" length="52086" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8315/36/ScreenCapture36.jpg" length="55607" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8315/37/ScreenCapture37.jpg" length="55535" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8315/38/ScreenCapture38.jpg" length="49142" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8315/39/ScreenCapture39.jpg" length="54548" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8315/40/ScreenCapture40.jpg" length="53714" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8315/41/ScreenCapture41.jpg" length="71279" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8315/42/ScreenCapture42.jpg" length="79901" type="image/jpeg"/></item><item>
<title>PROLOR's Presentation @ Jefferies 2012 - Focus on hGH and FVIIa [class:GrowthHormone, dis:GrowthHormoneDeficiency, :Biologics:news]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology6954</link>
<description>PROLOR's Presentation @ Jefferies 2012 - Focus on hGH and FVIIa [class:GrowthHormone, dis:GrowthHormoneDeficiency, :Biologics:news]</description><category>class:GrowthHormone</category><category>dis:GrowthHormoneDeficiency</category><category>news</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology6954</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120831&edate=20120501&rec=6954">PROLOR's Presentation @ Jefferies 2012 - Focus on hGH and FVIIa</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Biologics&sdate=20120831&edate=20120501&cat=news"><font color="#e95e0b">:Biologics:news</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=class%3aGrowthHormone"><font color="#e95e0b">:Endocrinology:class:GrowthHormone</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=dis%3aGrowthHormoneDeficiency"><font color="#e95e0b">:Endocrinology:dis:GrowthHormoneDeficiency</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology6954">Endocrinology6954</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 08 June 2012 | 13:33</font><br><br><div style="margin-bottom: 10px;">Comment: PROLOR successfully completed 4 clinical studies of its hGH-CTP in adults (I; II; IIa; 4 months IIb).<wbr> The PhIII initiation in this setting is expected later in 2012 (EU; USA).<wbr> When it comes to FVIIa-CTP (for haemophilia), the company indicated that a PhII is planned for 2013.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Take Home Messages from the Presentation</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6954/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">PhIII Planning</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6954/2/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6954/3/ScreenCapture3.jpg?user-agent=rss"> </div><div><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6954/4/ScreenCapture4.jpg?user-agent=rss"> </div><!-- Comment details --><a name="endocrinology6954attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6954/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(124,5 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6954/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(31,1 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6954/3/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(111,3 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6954/4/ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(47,5 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120831&edate=20120501&rec=6954">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-06-08T13:33:20+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6954/1/ScreenCapture1.jpg" length="127447" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6954/2/ScreenCapture2.jpg" length="31841" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6954/3/ScreenCapture3.jpg" length="114006" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6954/4/ScreenCapture4.jpg" length="48623" type="image/jpeg"/></item><item>
<title>Publication of Versartis' Once Monthly rhGH Preclinical Data [class:GrowthHormone, dis:GrowthHormoneDeficiency]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology6953</link>
<description>Publication of Versartis' Once Monthly rhGH Preclinical Data [class:GrowthHormone, dis:GrowthHormoneDeficiency]</description><category>class:GrowthHormone</category><category>dis:GrowthHormoneDeficiency</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology6953</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120831&edate=20120501&rec=6953">Publication of Versartis' Once Monthly rhGH Preclinical Data</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=class%3aGrowthHormone"><font color="#e95e0b">:Endocrinology:class:GrowthHormone</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=dis%3aGrowthHormoneDeficiency"><font color="#e95e0b">:Endocrinology:dis:GrowthHormoneDeficiency</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology6953">Endocrinology6953</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 08 June 2012 | 10:01</font><br><br><div style="margin-bottom: 10px;">Comment: The data published along with PC results previously presented @ ENDO last year demonstrate that VRS-317 provides comparable biologic activity and safety to daily rhGH with a lower total monthly dose of rhGH.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Background in Traction</FONT></STRONG> </div><div style="margin-bottom: 10px;"><STRONG>TechOp</STRONG> </div><div style="margin-bottom: 10px;">SynCo will scale-up a second manufacturing process for VRS-317 on behalf of Versartis.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Regulatory Status</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6953/1/ScreenCapture1.jpg?user-agent=rss"> </div><div>Source: The Journal of Pharmaceutical Sciences (7 JUN 2012 | DOI: 10.<wbr>1002/<wbr>jps.<wbr>23229) </div><!-- Comment details --><a name="endocrinology6953attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6953/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(17,7 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120831&edate=20120501&rec=6953">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-06-08T10:01:16+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6953/1/ScreenCapture1.jpg" length="18089" type="image/jpeg"/></item><item>
<title>Joint Agreement Between Allergan and Endo for the Delivery of BOTOX® [comp:Allergan, prod:Botox, :PharmaWorld:sub:DrugDelivery, headline]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology6447</link>
<description>Joint Agreement Between Allergan and Endo for the Delivery of BOTOX® [comp:Allergan, prod:Botox, :PharmaWorld:sub:DrugDelivery, headline]</description><category>comp:Allergan</category><category>prod:Botox</category><category>sub:DrugDelivery</category><category>headline</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology6447</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120831&edate=20120501&rec=6447">Joint Agreement Between Allergan and Endo for the Delivery of BOTOX®</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=comp%3aAllergan"><font color="#e95e0b">:Neurology:comp:Allergan</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=headline"><font color="#e95e0b">:Neurology:headline</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=prod%3aBotox"><font color="#e95e0b">:Neurology:prod:Botox</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=sub%3aDrugDelivery"><font color="#e95e0b">:PharmaWorld:sub:DrugDelivery</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology6447">Neurology6447</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 07 June 2012 | 17:34</font><br><br><div style="margin-bottom: 10px;">Comment: American Medical Systems (AMS), an Endo company, and Allergan signed a co-development agreement to develop and seek regulatory approval for the delivery of BOTOX&reg; using the JetTouch system(TM), a needle-free injection system, for the treatment of OAB.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">About the JetTouch(TM) System</FONT></STRONG> </div><div style="margin-bottom: 10px;">Has the potential to enable needle-free injection into any area of the body reachable by endoscopic or percutaneous access.<wbr> </div><div style="margin-bottom: 10px;">The description provided to the USPTO is: Needle-less injection systems comprised of an injector tip, a fluid delivery lumen and user-console for controlling fluid quantity and pressure.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Deal Terms</FONT></STRONG> </div><div style="margin-bottom: 10px;">AMS will first develop JetTouch&trade; for general use in the bladder.<wbr> Subject to the FDA approval of BOTOX&reg; for injection by needle as a treatment for OAB, AMS, in collaboration with Allergan, will seek to add BOTOX&reg;to the JetTouch&trade; label, and Allergan plans to seek regulatory advice to add the delivery of BOTOX&reg; with JetTouch&trade; to the BOTOX&reg; label.<wbr> </div><div>Source: ENDO Pharm.<wbr>; </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120831&edate=20120501&rec=6447">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-06-07T17:34:57+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>EMA Biosimilar Guidance To Allow More Dosage Form Flexibility [Alert, :Endocrinology:sub:Hybrids, :Endocrinology:sub:Biosimilars]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld9903</link>
<description>EMA Biosimilar Guidance To Allow More Dosage Form Flexibility [Alert, :Endocrinology:sub:Hybrids, :Endocrinology:sub:Biosimilars]</description><category>Alert</category><category>sub:Hybrids</category><category>sub:Biosimilars</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld9903</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120831&edate=20120501&rec=9903">EMA Biosimilar Guidance To Allow More Dosage Form Flexibility</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=sub%3aBiosimilars"><font color="#e95e0b">:Endocrinology:sub:Biosimilars</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=sub%3aHybrids"><font color="#e95e0b">:Endocrinology:sub:Hybrids</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=Alert"><font color="#e95e0b">:PharmaWorld:Alert</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld9903">PharmaWorld9903</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 07 June 2012 | 15:04</font><br><br><div style="margin-bottom: 10px;">Comment: The EMA has joined the FDA in proposing to accept different biosimilar formulations anhd closures in revised draft guidance.<wbr> </div><div style="margin-bottom: 10px;">It has reworked sections of the 6-yr old EMA guidelines clarifying the level of flexibility biosimilar manufacturers have when choosing formulations for their drugs.<wbr> </div><div style="margin-bottom: 10px;">It has stated that:- </div><div style="margin-bottom: 10px;">"The formulation of the bioisimilar does not need to be identifcal.<wbr> If a different formulation and or container/<wbr>closure system to the reference medicinal product is sellected its potential impact on the safety and efficacy should be appropriately justified" </div><div style="margin-bottom: 10px;">This new wording is more in line with draft guidance issued by the FDA in February (see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120831&edate=20120501&rec=9862" class="defaultlink">PharmaWorld9862: PhRMA Raises Concerns About FDA Biosimilar Flexibility</a>) </div><div style="margin-bottom: 10px;">Innovators have until November 30th to send comments to the EMA </div><div>A copy of the new draft guidance is attached to this article </div><!-- Comment details --><a name="pharmaworld9903attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/9903/1/New%20EMA%20Draft%20Biosimilar%20Guidance.pdf">New EMA Draft Biosimilar Guidance.pdf</a>&nbsp;&nbsp;(160,3 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120831&edate=20120501&rec=9903">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-06-07T15:04:57+02:00</dc:date><dc:creator>jac89886</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/9903/1/New%20EMA%20Draft%20Biosimilar%20Guidance.pdf" length="164107" type="application/pdf"/></item><item>
<title>Greece - Most Companies in Top 10 See Sales Decline in Q1:12 [mkt:Europe, news]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld9902</link>
<description>Greece - Most Companies in Top 10 See Sales Decline in Q1:12 [mkt:Europe, news]</description><category>mkt:Europe</category><category>news</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld9902</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120831&edate=20120501&rec=9902">Greece - Most Companies in Top 10 See Sales Decline in Q1:12</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=mkt%3aEurope"><font color="#e95e0b">:PharmaWorld:mkt:Europe</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=news"><font color="#e95e0b">:PharmaWorld:news</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld9902">PharmaWorld9902</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 07 June 2012 | 13:36</font><br><br><div style="margin-bottom: 10px;">Comment: Sales of pharmaceuticals in Greece declined by a reported 6.<wbr>7% year-on-year in the first quarter of 2012, while the problem of access to reimbursed medicines has become worse, as pharmacies continue to demand upfront payment.<wbr>
 </div><div style="margin-bottom: 10px;"><P class="bodyHeading2"><B>Decline in Value, Volume of Greek Market in Q1</B></P> </div><div style="margin-bottom: 10px;">Pharmaceutical sales in Greece, excluding the hospital sector, declined by a reported 6.<wbr>7% year-on-year (y/<wbr>y) in the first quarter, amounting to EUR898.<wbr>4 million (USD1.<wbr>123 billion), according to data from IMS Health, based on sales from pharmaceutical companies to wholesalers and pharmacies, quoted by Greek newspaper <I>Imerisia.<wbr> </I>The volume of the market fell slightly more steeply, by 8% y/<wbr>y, to 97.<wbr>7 million packages, the source reports.<wbr> </div><div style="margin-bottom: 10px;"><P class="bodyHeading2"><B>Most Firms in Top 10 See Sales Decline</B></P> </div><div style="margin-bottom: 10px;">In terms of the top 10 pharmaceutical companies in Greece during this period, the first position was occupied by Swiss major Novartis, although the company's sales tumbled y/<wbr>y in the period, to EUR76.<wbr>6 million.<wbr> In second place was United States major Pfizer, with an even larger sales slump of 17.<wbr>4% y/<wbr>y, to EUR71.<wbr>9 million.<wbr> The majority of the companies in the top 10 recorded falling sales during the period, although a number—including United Kingdom major GlaxoSmithKline (GSK) and German firm Boehringer Ingelheim—bucked this trend.<wbr> </div><div style="margin-bottom: 10px;"><TABLE class="table100"><TBODY><TR><TD align="middle" class="tableTitleBold" colspan="4" style="VERTICAL-ALIGN: top">
<P align="left" class="tableTitleBold"><B>Greek Pharmaceutical Market by Value, Excluding Hospital Sector, Q1</B></P>
</TD>
</TR>
<TR><TD align="middle" class="tableHeading" style="VERTICAL-ALIGN: top">
<P align="left" class="tableHeading"><B>Company</B></P></TD>
<TD align="middle" class="tableHeading" style="VERTICAL-ALIGN: top">
<P align="center" class="tableHeading"><B>Revenue (EUR Mil.<wbr>)</B></P></TD>
<TD align="middle" class="tableHeading" style="VERTICAL-ALIGN: top">
<P align="center" class="tableHeading"><B>% Change Y/<wbr>Y</B></P></TD>
<TD align="middle" class="tableHeading" style="VERTICAL-ALIGN: top">
<P align="right" class="tableHeading"><B>Market Share</B></P></TD>
</TR>
<TR><TD class="tableHeading" style="VERTICAL-ALIGN: top">
<P class="tableHeading"><B>Novartis (Switzerland)</B></P></TD>
<TD align="right" class="tableContent" style="VERTICAL-ALIGN: top">
<P align="right" class="tableContent">76.<wbr>6</P></TD>
<TD align="right" class="tableContent" style="VERTICAL-ALIGN: top">
<P align="right" class="tableContent">-11.<wbr>3</P></TD>
<TD align="right" class="tableContent" style="VERTICAL-ALIGN: top">
<P align="right" class="tableContent">8.<wbr>5</P></TD>
</TR>
<TR><TD class="tableHeading" style="VERTICAL-ALIGN: top">
<P class="tableHeading"><B>Pfizer (US)</B></P></TD>
<TD align="right" class="tableContent" style="VERTICAL-ALIGN: top">
<P align="right" class="tableContent">71.<wbr>9 </P></TD>
<TD align="right" class="tableContent" style="VERTICAL-ALIGN: top">
<P align="right" class="tableContent">-17.<wbr>4</P></TD>
<TD align="right" class="tableContent" style="VERTICAL-ALIGN: top">
<P align="right" class="tableContent">8.<wbr>0</P></TD>
</TR>
<TR><TD class="tableHeading" style="VERTICAL-ALIGN: top">
<P class="tableHeading"><B>Sanofi (France)</B></P></TD>
<TD align="right" class="tableContent" style="VERTICAL-ALIGN: top">
<P align="right" class="tableContent">61.<wbr>4</P></TD>
<TD align="right" class="tableContent" style="VERTICAL-ALIGN: top">
<P align="right" class="tableContent">-9.<wbr>4</P></TD>
<TD align="right" class="tableContent" style="VERTICAL-ALIGN: top">
<P align="right" class="tableContent">6.<wbr>8</P></TD>
</TR>
<TR><TD class="tableHeading" style="VERTICAL-ALIGN: top">
<P class="tableHeading"><B>AstraZeneca (UK)</B></P></TD>
<TD align="right" class="tableContent" style="VERTICAL-ALIGN: top">
<P align="right" class="tableContent">49.<wbr>6</P></TD>
<TD align="right" class="tableContent" style="VERTICAL-ALIGN: top">
<P align="right" class="tableContent">-7.<wbr>8</P></TD>
<TD align="right" class="tableContent" style="VERTICAL-ALIGN: top">
<P align="right" class="tableContent">5.<wbr>5</P></TD>
</TR>
<TR><TD class="tableHeading" style="VERTICAL-ALIGN: top">
<P class="tableHeading"><B>GSK (UK)</B></P></TD>
<TD align="right" class="tableContent" style="VERTICAL-ALIGN: top">
<P align="right" class="tableContent">47.<wbr>6</P></TD>
<TD align="right" class="tableContent" style="VERTICAL-ALIGN: top">
<P align="right" class="tableContent">2.<wbr>6</P></TD>
<TD align="right" class="tableContent" style="VERTICAL-ALIGN: top">
<P align="right" class="tableContent">5.<wbr>3</P></TD>
</TR>
<TR><TD class="tableHeading" style="VERTICAL-ALIGN: top">
<P class="tableHeading"><B>Vianex (Greece)</B></P></TD>
<TD align="right" class="tableContent" style="VERTICAL-ALIGN: top">
<P align="right" class="tableContent">45.<wbr>7</P></TD>
<TD align="right" class="tableContent" style="VERTICAL-ALIGN: top">
<P align="right" class="tableContent">4.<wbr>7</P></TD>
<TD align="right" class="tableContent" style="VERTICAL-ALIGN: top">
<P align="right" class="tableContent">5.<wbr>1</P></TD>
</TR>
<TR><TD class="tableHeading" style="VERTICAL-ALIGN: top">
<P class="tableHeading"><B>Elpen (Greece)</B></P></TD>
<TD align="right" class="tableContent" style="VERTICAL-ALIGN: top">
<P align="right" class="tableContent">36.<wbr>2</P></TD>
<TD align="right" class="tableContent" style="VERTICAL-ALIGN: top">
<P align="right" class="tableContent">8.<wbr>6</P></TD>
<TD align="right" class="tableContent" style="VERTICAL-ALIGN: top">
<P align="right" class="tableContent">4.<wbr>0</P></TD>
</TR>
<TR><TD class="tableHeading" style="VERTICAL-ALIGN: top">
<P class="tableHeading"><B>Pharmaserve (Greece)</B></P></TD>
<TD align="right" class="tableContent" style="VERTICAL-ALIGN: top">
<P align="right" class="tableContent">32.<wbr>5</P></TD>
<TD align="right" class="tableContent" style="VERTICAL-ALIGN: top">
<P align="right" class="tableContent">-12.<wbr>6</P></TD>
<TD align="right" class="tableContent" style="VERTICAL-ALIGN: top">
<P align="right" class="tableContent">3.<wbr>6</P></TD>
</TR>
<TR><TD class="tableHeading" style="VERTICAL-ALIGN: top">
<P class="tableHeading"><B>Boehringer Ingelheim (Germany)</B></P></TD>
<TD align="right" class="tableContent" style="VERTICAL-ALIGN: top">
<P align="right" class="tableContent">29.<wbr>7</P></TD>
<TD align="right" class="tableContent" style="VERTICAL-ALIGN: top">
<P align="right" class="tableContent">12.<wbr>9</P></TD>
<TD align="right" class="tableContent" style="VERTICAL-ALIGN: top">
<P align="right" class="tableContent">3.<wbr>3</P></TD>
</TR>
<TR><TD class="tableHeading" style="VERTICAL-ALIGN: top">
<P class="tableHeading"><B>Merck, Sharp &amp; Dohme (US)</B></P></TD>
<TD align="right" class="tableContent" style="VERTICAL-ALIGN: top">
<P align="right" class="tableContent">28.<wbr>0</P></TD>
<TD align="right" class="tableContent" style="VERTICAL-ALIGN: top">
<P align="right" class="tableContent">-11.<wbr>3</P></TD>
<TD align="right" class="tableContent" style="VERTICAL-ALIGN: top">
<P align="right" class="tableContent">3.<wbr>1</P></TD>
</TR>
<TR><TD class="tableNotes" colspan="4" style="VERTICAL-ALIGN: top">
<P class="tableNotes">Source: IMS Health, <I>Imerisia</I></P></TD>
</TR>
</TBODY>
</TABLE> </div><div style="margin-bottom: 10px;">In volume terms, Pfizer was the market leader in the period under review, although the number of packages it sold was down by 7.<wbr>8% y/<wbr>y to 7.<wbr>99 million in the period, followed by GSK, which recorded a 0.<wbr>9% y/<wbr>y decline in volume terms to 7.<wbr>50 million packages, and Sanofi, with a decline of 6.<wbr>3% y/<wbr>y to 6.<wbr>90 million packages.<wbr> In fourth and fifth position were Novartis, with a decline of 7.<wbr>6% y/<wbr>y to 6.<wbr>65 million packages, and Bristol-Myers Squibb (BMS, US), with a reduction of 4.<wbr>3% y/<wbr>y to 5.<wbr>87 million packages.<wbr> </div><div style="margin-bottom: 10px;">Additionally, the source reports that there was a decline in the volume of production of the domestic pharmaceutical industry in the first quarter, for the first time in some years, falling by a reported 0.<wbr>6% y/<wbr>y in the period under review.<wbr> </div><div style="margin-bottom: 10px;"><P class="bodyHeading2"><B>Situation of Drug Supplies to Patients Deteriorates</B></P> </div><div style="margin-bottom: 10px;">Meanwhile, UK newspaper <I>The Independent </I>reports on the chaotic situation at pharmacies in Greece, with long queues outside pharmacies as patients seek to obtain lifesaving cancer drugs.<wbr> Pharmacies continue to require upfront payment for reimbursed medicines, in protest against the substantial debts owed to them for reimbursed medicines supplied to patients insured under the National Organisation for Healthcare Provision (EOPYY).<wbr> The source reports that Greece's prime minister, Panayotis Pikrammenos, has stated this week that the caretaker government cannot start to pay debts to pharmacies until the next loan is received from the country's international creditors.<wbr> </div><div style="margin-bottom: 10px;">Greek newspaper <I>Ta Nea </I>reports that after a meeting between the caretaker health minister Christos Kittas and the leader of the caretaker government, Alexis Tsipras, the situation with the supply of cancer medicine will "normalise".<wbr> As the source reports, the Greek Ministry of Health has been in contact with pharmaceutical companies, which have agreed to a system under which they will be paid on delivery, and this solution will remain in place until the new government is elected.<wbr> </div><div style="margin-bottom: 10px;">Greek healthcare news provider Iatronet reports that Kittas is calling for 100 private pharmacies across Greece to co-operate with the EOPYY, admitting that with only four pharmacies in the Attica region supplying reimbursed medicines, the problem was serious.<wbr> Understandably, representatives of pharmacists in Greece are opposed to such plans, with the head of the National Pharmaceutical Association quoted as saying that the solution should not involve a limited number of pharmacies, but all of them.<wbr> </div><div style="margin-bottom: 10px;"><P class="bodyHeading2"><STRONG><FONT size="3">Outlook and Implications</FONT></STRONG></P> </div><div style="margin-bottom: 10px;">The decline in pharmaceutical sales in the outpatient sector is quite a lot less drastic than might be expected in Greece, considering the very difficult situation the country and its people are facing in economic terms.<wbr> This reflects the fact that it appears to be an uphill struggle to combat the prescribing of "uneconomical" medicines—i.<wbr>e.<wbr>, those more expensive than necessary—as has been shown by the fact that public spending on pharmaceuticals is still exceeding the levels set out in Greece's agreement with its creditors.<wbr> With the much vaunted electronic prescription system not working in the way it was hoped, there are ongoing threats to the spending targets.<wbr> </div><div style="margin-bottom: 10px;">Meanwhile, the situation in pharmacies becomes more urgent by the day, and it appears the pharmacists are determined to hold out, in spite of the chaos.<wbr> It should be emphasised that patients are able to obtain reimbursement once they have bought the medicines, but obviously, there are many people who are unable to afford to pay such sums of money upfront.<wbr> Having only four pharmacies to be open in Attica supplying reimbursed medicines to those insured under the EOPYY is obviously hopelessly inadequate, and this also means significant downturns in drug sales.<wbr> </div><div>From: Global Insight </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120831&edate=20120501&rec=9902">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-06-07T13:36:22+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>re: Astellas - FY2011 Results - Key Takeaways</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology8314</link>
<description>re: Astellas - FY2011 Results - Key Takeaways</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology8314</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8314">re: Astellas - FY2011 Results - Key Takeaways</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8314">Oncology8314</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 06 June 2012 | 18:52</font><br><br><div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-size: 12px;">Enrollment in the PREVAIL pre-chemotherapy trial should complete this month apart from in a few select Asian centres.<wbr> Whether the study will report out at the interim stage remains to be seen as it has a co-primary endpoint of PFS and OS, the event rate for which is being independently monitored.<wbr></span>&nbsp;<br><font size="-1">Jacquelyne CANTLE MEYRICK / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8271" class="commentpermalink">Oncology8271</a> / <span class="date">14 May 2012</span> /
<span class="time">10:21:47 o'clock CEST</span>
</font></div><div>On June 6th, Medivation and Astellas announced the completion of 1,680 patients in the PREVAIL (pre-chemo) trial apart in a few Asian centres, to gain additional information on this specific population.<wbr> </div><!-- Comment details --><font size="-1">Brigitte DESCHAMPS / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8314" class="commentpermalink">Oncology8314</a> / <span class="date">06 June 2012</span> /
<span class="time">18:52:44 o'clock CEST</span>
</font><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8314">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8271">View thread  Oncology8271: Astellas - FY2011 Results - Key Takeaways</a>]]></content:encoded><dc:date>2012-06-06T18:52:44+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Key Takeaways From Pfizer ASCO Presentation [headline, class:KinaseInhibitors]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology8313</link>
<description>Key Takeaways From Pfizer ASCO Presentation [headline, class:KinaseInhibitors]</description><category>headline</category><category>class:KinaseInhibitors</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology8313</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8313">Key Takeaways From Pfizer ASCO Presentation</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=class%3aKinaseInhibitors"><font color="#e95e0b">:Oncology:class:KinaseInhibitors</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=headline"><font color="#e95e0b">:Oncology:headline</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8313">Oncology8313</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 06 June 2012 | 17:12</font><br><br><div style="margin-bottom: 10px;">Comment: Alongside ASCO, Pfizer hosted an investor event to review the 
content and progress with its oncology pipeline, emphasising in particular how 
is at the forefront of developments in renal cancer and in early development 
(PhII) some novel PI3K/<wbr>mTOR programmes.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8313/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8313/2/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8313/3/ScreenCapture3.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8313/4/ScreenCapture4.jpg?user-agent=rss"> </div><div><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8313/5/ScreenCapture5.jpg?user-agent=rss"> </div><!-- Comment details --><a name="oncology8313attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8313/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(150,3 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8313/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(159,6 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8313/3/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(104,5 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8313/4/ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(154,5 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8313/5/ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(136,9 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8313">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-06-06T17:12:25+02:00</dc:date><dc:creator>jac89886</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8313/1/ScreenCapture1.jpg" length="153859" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8313/2/ScreenCapture2.jpg" length="163443" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8313/3/ScreenCapture3.jpg" length="106986" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8313/4/ScreenCapture4.jpg" length="158218" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8313/5/ScreenCapture5.jpg" length="140135" type="image/jpeg"/></item><item>
<title>Zytiga - Poised To Be The Second Most Succesful Oncology Launch [Alert, class:Antihormonals, comp:JnJ, dis:Prostate, prod:Zytiga]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology8310</link>
<description>Zytiga - Poised To Be The Second Most Succesful Oncology Launch [Alert, class:Antihormonals, comp:JnJ, dis:Prostate, prod:Zytiga]</description><category>Alert</category><category>class:Antihormonals</category><category>comp:JnJ</category><category>dis:Prostate</category><category>prod:Zytiga</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology8310</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8310">Zytiga - Poised To Be The Second Most Succesful Oncology Launch</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=Alert"><font color="#e95e0b">:Oncology:Alert</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=class%3aAntihormonals"><font color="#e95e0b">:Oncology:class:Antihormonals</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=comp%3aJnJ"><font color="#e95e0b">:Oncology:comp:JnJ</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=prod%3aZytiga"><font color="#e95e0b">:Oncology:prod:Zytiga</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8310">Oncology8310</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 06 June 2012 | 15:25</font><br><br><div style="margin-bottom: 10px;">Comment: Alongside ASCO, J&amp;J hosted and investor event to review both the COU-AAA-302 data and to provide a global overview of market access issues, reimbursement and sales uptake of Zytiga.<wbr> The latter is highlighted below, the data having been reviewed previously </div><div style="margin-bottom: 10px;">With 2011 global sales of $200m divided equally between the US and Europe, Zytiga uptake has got off to an impressive start.<wbr>.<wbr><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8310/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8310/2/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8310/3/ScreenCapture3.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8310/4/ScreenCapture4.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8310/5/ScreenCapture5.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8310/6/ScreenCapture6.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8310/7/ScreenCapture7.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8310/8/ScreenCapture8.jpg?user-agent=rss"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8310/9/ScreenCapture9.jpg?user-agent=rss"> </div><div>A full copy of the presentation including the data from the COU-AAA-302 is attached.<wbr> </div><!-- Comment details --><a name="oncology8310attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8310/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(73,6 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8310/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(124,5 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8310/3/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(98,6 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8310/4/ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(81,6 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8310/5/ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(110,8 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8310/6/ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(68,9 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8310/7/ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(73 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8310/8/ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(97,6 KB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8310/9/ScreenCapture9.jpg">ScreenCapture9.jpg</a>&nbsp;&nbsp;(75,1 KB)<br>&nbsp;&nbsp;10.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8310/10/FINAL%5fZYTIGA%5fWebcast%5fUpdate%5f6%2d4%2d2012%5b1%5d.pdf">FINAL_ZYTIGA_Webcast_Update_6-4-2012[1].pdf</a>&nbsp;&nbsp;(2 MB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8310">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-06-06T15:25:41+02:00</dc:date><dc:creator>jac89886</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8310/1/ScreenCapture1.jpg" length="75406" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8310/2/ScreenCapture2.jpg" length="127499" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8310/3/ScreenCapture3.jpg" length="100974" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8310/4/ScreenCapture4.jpg" length="83577" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8310/5/ScreenCapture5.jpg" length="113469" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8310/6/ScreenCapture6.jpg" length="70565" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8310/7/ScreenCapture7.jpg" length="74719" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8310/8/ScreenCapture8.jpg" length="99977" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8310/9/ScreenCapture9.jpg" length="76912" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8310/10/FINAL%5fZYTIGA%5fWebcast%5fUpdate%5f6%2d4%2d2012%5b1%5d.pdf" length="2045475" type="application/pdf"/></item><item>
<title>Amylin Data Highlights Impact Of Bydreon On The Diabetes Market [class:GLP1, headline, dis:Diabetes]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology6952</link>
<description>Amylin Data Highlights Impact Of Bydreon On The Diabetes Market [class:GLP1, headline, dis:Diabetes]</description><category>class:GLP1</category><category>headline</category><category>dis:Diabetes</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology6952</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120831&edate=20120501&rec=6952">Amylin Data Highlights Impact Of Bydreon On The Diabetes Market</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=class%3aGLP1"><font color="#e95e0b">:Endocrinology:class:GLP1</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=dis%3aDiabetes"><font color="#e95e0b">:Endocrinology:dis:Diabetes</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=headline"><font color="#e95e0b">:Endocrinology:headline</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology6952">Endocrinology6952</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 06 June 2012 | 13:03</font><br><br><div style="margin-bottom: 10px;">Comment: Yesterday at the Jefferies H/<wbr>C conference, Amylin presented some 
interesting data on the positive impact its weekly GLP-1 analogue Bydureon 
is having on the diabetes market and POC data for a monthly suspension 
formulation.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6952/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6952/2/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6952/3/ScreenCapture3.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6952/4/ScreenCapture4.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG>Monthly GLP-1 POC Data</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6952/5/ScreenCapture5.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6952/6/ScreenCapture6.jpg?user-agent=rss"> </div><div><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6952/7/ScreenCapture7.jpg?user-agent=rss"> </div><!-- Comment details --><a name="endocrinology6952attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6952/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(59 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6952/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(53,2 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6952/3/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(88,4 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6952/4/ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(53,4 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6952/5/ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(91,5 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6952/6/ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(87 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6952/7/ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(64,2 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120831&edate=20120501&rec=6952">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-06-06T13:03:07+02:00</dc:date><dc:creator>jac89886</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6952/1/ScreenCapture1.jpg" length="60368" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6952/2/ScreenCapture2.jpg" length="54428" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6952/3/ScreenCapture3.jpg" length="90567" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6952/4/ScreenCapture4.jpg" length="54667" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6952/5/ScreenCapture5.jpg" length="93657" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6952/6/ScreenCapture6.jpg" length="89072" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6952/7/ScreenCapture7.jpg" length="65764" type="image/jpeg"/></item><item>
<title>re: Focus on Merz &amp; Allergan Spasticity Symposia @  the 18th ESPRM (Thessaloniki, Greece)</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology6444</link>
<description>re: Focus on Merz &amp; Allergan Spasticity Symposia @  the 18th ESPRM (Thessaloniki, Greece)</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology6444</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120831&edate=20120501&rec=6444">re: Focus on Merz & Allergan Spasticity Symposia @  the 18th ESPRM (Thessaloniki, Greece)</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology6444">Neurology6444</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/68">Patrizia Caglioni</a> | 06 June 2012 | 12:20</font><br><br><div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Focus on Merz & Allergan Spasticity Symposia @  the 18th ESPRM (Thessaloniki, Greece)</span>&nbsp;<font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=comp%3aAllergan"><font color="#e95e0b">:Neurology:comp:Allergan</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=comp%3aMerz"><font color="#e95e0b">:Neurology:comp:Merz</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=dis%3aSpasticity"><font color="#e95e0b">:Neurology:dis:Spasticity</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=headline"><font color="#e95e0b">:Neurology:headline</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=prod%3aBotox"><font color="#e95e0b">:Neurology:prod:Botox</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=prod%3aXeomin"><font color="#e95e0b">:Neurology:prod:Xeomin</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=congress%3aISPRM"><font color="#e95e0b">:PharmaWorld:congress:ISPRM</font></a>]</font></font><br><span style="font-size: 12px;">Comment: Thanks to Eleni Bozika (Product Manager) key messages and comments on Allergan symposia are provided below, and most importantly the preliminary results of the Merz' SPACE study, which highlight a need for more research into the use of high-dose BoNT/<wbr>A.<wbr> Details of the TOWER study, which is currently investigating the safety of high doses of Xeomin, are outlined as well.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120831&edate=20120501&rec=6441">...</a><br><font size="-1">Brigitte DESCHAMPS / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology6441" class="commentpermalink">Neurology6441</a> / <span class="date">05 June 2012</span> /
<span class="time">15:20:00 o'clock CEST</span>
</font></div><div style="margin-bottom: 10px;">Tower study - In Italy, Principal Investigator is Dr.<wbr> F.<wbr> Molteni Costamasnaga Lecco.<wbr> </div><div style="margin-bottom: 10px;"><U>Other Centers</U> </div><div style="margin-bottom: 10px;">Hospital Casa Solievo della Sofferenza San Giovanni Rotondo (Bari) Dr.<wbr> M.<wbr> Basciani </div><div style="margin-bottom: 10px;">Hospital Passignano (Perugia) Dr.<wbr> F.<wbr> Sciarrini </div><div>Up to date: Received EC approvals.<wbr> Planned initiation visits.<wbr> </div><!-- Comment details --><font size="-1">Patrizia Caglioni / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology6444" class="commentpermalink">Neurology6444</a> / <span class="date">06 June 2012</span> /
<span class="time">12:20:38 o'clock CEST</span>
</font><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120831&edate=20120501&rec=6444">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology6441">View thread  Neurology6441: Focus on Merz & Allergan Spasticity Symposia @  the 18th ESPRM (Thessaloniki, Greece)</a>]]></content:encoded><dc:date>2012-06-06T12:20:38+02:00</dc:date><dc:creator>pac66703</dc:creator></item><item>
<title>re: Esmya(R) Granted EMA for Uterine Fibroids</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology8309</link>
<description>re: Esmya(R) Granted EMA for Uterine Fibroids</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology8309</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8309">re: Esmya(R) Granted EMA for Uterine Fibroids</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8309">Oncology8309</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 06 June 2012 | 11:58</font><br><br><div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-size: 12px;">This decision follows positive opinion from the CHMP for the EMA on December 2011 (see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=7967" class="defaultlink">Oncology7967: Richter/<wbr>PregLem's Esmya® Receives Positive Opinion from the EMA/<wbr>CHMP</a>).<wbr></span>&nbsp;<br><font size="-1">Brigitte DESCHAMPS / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8125" class="commentpermalink">Oncology8125</a> / <span class="date">28 February 2012</span> /
<span class="time">15:41:49 o'clock CET</span>
</font></div><div>Esmya is now commercially available in the UK from Preglem at a price of &pound;114.<wbr>13 for 28 5mg tablets.<wbr> </div><!-- Comment details --><font size="-1">Jacquelyne CANTLE MEYRICK / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8309" class="commentpermalink">Oncology8309</a> / <span class="date">06 June 2012</span> /
<span class="time">11:58:24 o'clock CEST</span>
</font><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8309">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8125">View thread  Oncology8125: Esmya(R) Granted EMA for Uterine Fibroids</a>]]></content:encoded><dc:date>2012-06-06T11:58:24+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>Ph3 Trial of Elagolix for Endometriosis-Associated Pain Has Begun Screening for Enrollment [dis:Gynea, :PharmaWorld:sub:ClinicalTrial]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology8308</link>
<description>Ph3 Trial of Elagolix for Endometriosis-Associated Pain Has Begun Screening for Enrollment [dis:Gynea, :PharmaWorld:sub:ClinicalTrial]</description><category>dis:Gynea</category><category>sub:ClinicalTrial</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology8308</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8308">Ph3 Trial of Elagolix for Endometriosis-Associated Pain Has Begun Screening for Enrollment</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=dis%3aGynea"><font color="#e95e0b">:Oncology:dis:Gynea</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=sub%3aClinicalTrial"><font color="#e95e0b">:PharmaWorld:sub:ClinicalTrial</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8308">Oncology8308</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 05 June 2012 | 17:20</font><br><br><div style="margin-bottom: 10px;">Comment: In line with the forecasts, Neurocrine and Abbott have announced the initiation of the first pivotal trial, designed to assess the safety and efficacy of the GnRH antagonist in female patients with endometriosis.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Trial Details - M12-665</FONT></STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>Design: multinational, randomized, double-blind, placebo-controlled study.<wbr></LI>
<LI>Recruitment: approx.<wbr> 875 women (age 18 to 49) with moderate-to-severe endometriosis associated pain.<wbr></LI>
<LI>Location: 160 sites (U.<wbr>S; Puerto Rico; Canada).<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Next Step</FONT></STRONG> </div><div>A 2nde Ph3 is planned with an NDA filing targeted in 2016.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8308">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-06-05T17:20:45+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>re: AFFiRiS Starts Preclinical Development Of Its Parkinson's Vaccine</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology6442</link>
<description>re: AFFiRiS Starts Preclinical Development Of Its Parkinson's Vaccine</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology6442</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120831&edate=20120501&rec=6442">re: AFFiRiS Starts Preclinical Development Of Its Parkinson's Vaccine</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology6442">Neurology6442</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 05 June 2012 | 16:59</font><br><br><div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">AFFiRiS Starts Preclinical Development Of Its Parkinson's Vaccine</span>&nbsp;<font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=dis%3aParkinson"><font color="#e95e0b">:Neurology:dis:Parkinson</font></a>]</font></font><br><span style="font-size: 12px;">Comment: On successful conclusion of this preclinical evaluation, initial clinical testing could start in 2010/<wbr>11.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120831&edate=20120501&rec=4053">...</a><br><font size="-1">Brigitte DESCHAMPS / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology4053" class="commentpermalink">Neurology4053</a> / <span class="date">11 December 2008</span> /
<span class="time">17:18:13 o'clock CET</span>
</font></div><div style="margin-bottom: 10px;">The WW 1st clinical trial has now been started by AFFiRiS AG.<wbr> The trial will be conducted at the Confraternit&auml;t Privatklinik Josefstadt (Vienna), and will involve &gt; 32 patients.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Mechanism of Action</STRONG> </div><div style="margin-bottom: 10px;">PD01A targets a protein called alpha-Synuclein (alpha-syn) which plays a key role in the onset and progression of Parkinson&acute;s.<wbr> The vaccination aims to educate the immune system to generate antibodies directed against alpha-syn </div><div style="margin-bottom: 10px;"><STRONG>Partnership</STRONG> </div><div>Alzheimer's disease is the current lead indication.<wbr> In Oct.<wbr> 2008, GSK licensed the vaccine.<wbr> </div><!-- Comment details --><font size="-1">Brigitte DESCHAMPS / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology6442" class="commentpermalink">Neurology6442</a> / <span class="date">05 June 2012</span> /
<span class="time">16:59:49 o'clock CEST</span>
</font><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120831&edate=20120501&rec=6442">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology4053">View thread  Neurology4053: AFFiRiS Starts Preclinical Development Of Its Parkinson's Vaccine</a>]]></content:encoded><dc:date>2012-06-05T16:59:49+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Focus on Merz &amp; Allergan Spasticity Symposia @  the 18th ESPRM (Thessaloniki, Greece) [comp:Merz, comp:Allergan, dis:Spasticity, prod:Xeomin, prod:Botox, :PharmaWorld:congress:ISPRM, headline]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology6441</link>
<description>Focus on Merz &amp; Allergan Spasticity Symposia @  the 18th ESPRM (Thessaloniki, Greece) [comp:Merz, comp:Allergan, dis:Spasticity, prod:Xeomin, prod:Botox, :PharmaWorld:congress:ISPRM, headline]</description><comments>http://ci.beaufour-ipsen.com/traction/permalink/Neurology6441</comments><category>comp:Merz</category><category>comp:Allergan</category><category>dis:Spasticity</category><category>prod:Xeomin</category><category>prod:Botox</category><category>congress:ISPRM</category><category>headline</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology6441</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120831&edate=20120501&rec=6441">Focus on Merz & Allergan Spasticity Symposia @  the 18th ESPRM (Thessaloniki, Greece)</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=comp%3aAllergan"><font color="#e95e0b">:Neurology:comp:Allergan</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=comp%3aMerz"><font color="#e95e0b">:Neurology:comp:Merz</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=dis%3aSpasticity"><font color="#e95e0b">:Neurology:dis:Spasticity</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=headline"><font color="#e95e0b">:Neurology:headline</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=prod%3aBotox"><font color="#e95e0b">:Neurology:prod:Botox</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=prod%3aXeomin"><font color="#e95e0b">:Neurology:prod:Xeomin</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=congress%3aISPRM"><font color="#e95e0b">:PharmaWorld:congress:ISPRM</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology6441">Neurology6441</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 05 June 2012 | 15:20</font><br><br><div style="margin-bottom: 10px;">Comment: Thanks to Eleni Bozika (Product Manager) key messages and comments on Allergan symposia are provided below, and most importantly the preliminary results of the Merz' SPACE study, which highlight a need for more research into the use of high-dose BoNT/<wbr>A.<wbr> Details of the TOWER study, which is currently investigating the safety of high doses of Xeomin, are outlined as well.<wbr> </div><div style="margin-bottom: 10px;"><U>Note</U>: The SPACE study was highlighted last year by Andrea Reissig (Scientific Manager) ahead of its posting on the clinical trial databases.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">ALLERGAN - Post-stroke spasticity: Action for the long-term journey</FONT></STRONG> </div><div style="margin-bottom: 10px;">The symposium was based on the importance of therapeutic goals when managing patients with stroke and treated with BTX-A.<wbr> At the center of the presentation was a video with a patient who had stroke and who described the problems, the management and the benefit of the therapy.<wbr> </div><div style="margin-bottom: 10px;">Some aspects of the BEST trial were presented, and in particular the GAS scale and how it is used.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">MERZ - Optimizing of BTX treatment in patients with spasticity</FONT></STRONG> </div><div style="margin-bottom: 10px;">Core message of the symposium was the need to use high doses of BTX (over the SPC recommendations).<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Dr Julian P.<wbr> Harriss</STRONG> (King's College Hospital - London, UK) presented an interim analysis of the <STRONG>SPACE</STRONG>, non-interventional study, which shows the need to treat with higher doses.<wbr> </div><div style="margin-bottom: 10px;"><UL><LI>Objective of the study: 1/<wbr>to improve knowledge of the actual use of BONT/<wbr>A in daily clinical practice 2/<wbr> to collect data from daily clinical practice.<wbr></LI>
<LI>Design: WW, non-interventional study</LI>
<LI>Recruitment: aim 930 (current 505)</LI>
<LI>Inclusion criteria: patients with spasticity naïve to BoNT/<wbr>A </LI>
<LI>Duration: Follow-up 2 years</LI>
<LI>Sites: 9 countries (115 centres)</LI>
</UL> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/6441/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG>Preliminary results</STRONG> </div><div style="margin-bottom: 10px;"><STRONG>205</STRONG> patients (57% male gender; mean age: 53.<wbr>7 years) assessed for baseline data to date.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/6441/2/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">Clinical need for high doses </div><div style="margin-bottom: 10px;">- many patients require treatment for multi-focal spasticity &gt; 51.<wbr>2% of patients have 4 or more locations; 44.<wbr>4% of patients have upper and lower limb spasticity and 49.<wbr>3% of patients have a spasticity in the elbow, wrist and fingers.<wbr> </div><div style="margin-bottom: 10px;">- up to 420U injected per pattern </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/6441/3/ScreenCapture3.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">Guideline Recommendations Vs Clinical Practices </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/6441/5/ScreenCapture5.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">SPACE Study Investigators</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/6441/6/ScreenCapture6.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">The TOWER study - <A href="http://clinicaltrials.gov/ct2/show/NCT01603459?recr=Open&amp;cond=Glabellar+OR+Canthal+OR+spasticity+OR+blepharospasm+OR+prostate+OR+neuroendocrine+OR+acromegaly&amp;fund=2&amp;rcv_s=03%2F23%2F2012&amp;rank=4">NCT1603549</A></FONT></STRONG> </div><div style="margin-bottom: 10px;">Additional information to the article published in Traction on May 22, 2012 (Please see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120831&edate=20120501&rec=6414" class="defaultlink">Neurology6414: Dose-Titration Trial of Xeomin for Spasticity in the Leg and Arm</a>).<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Protocol</STRONG> </div><div style="margin-bottom: 10px;">150 subjects (naïve or pre-treated with BoNT/<wbr>A or BoNT/<wbr>B) to be recruited across in 35 sites WW across 8 countries: </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/6441/7/ScreenCapture7.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG>Design</STRONG> </div><div><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/6441/8/ScreenCapture8.jpg?user-agent=rss"> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Neurology6444c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">Tower study - In Italy, Principal Investigator is Dr.<wbr> F.<wbr> Molteni Costamasnaga Lecco.<wbr> </div><div style="margin-bottom: 10px;"><U>Other Centers</U> </div><div style="margin-bottom: 10px;">Hospital Casa Solievo della Sofferenza San Giovanni Rotondo (Bari) Dr.<wbr> M.<wbr> Basciani </div><div style="margin-bottom: 10px;">Hospital Passignano (Perugia) Dr.<wbr> F.<wbr> Sciarrini </div><div>Up to date: Received EC approvals.<wbr> Planned initiation visits.<wbr> </div><font size="-1">Patrizia Caglioni / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology6444" class="commentpermalink">Neurology6444</a> / <span class="date">06 June 2012</span> /
<span class="time">12:20:38 o'clock CEST</span>
</font></div><a name="neurology6441attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/6441/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(52,6 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/6441/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(25,3 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/6441/3/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(55,1 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/6441/4/ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(639 B)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/6441/5/ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(86,4 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/6441/6/ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(110,2 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/6441/7/ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(35,3 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/6441/8/ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(39,7 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120831&edate=20120501&rec=6441">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-06-05T15:20:00+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/6441/1/ScreenCapture1.jpg" length="53821" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/6441/2/ScreenCapture2.jpg" length="25872" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/6441/3/ScreenCapture3.jpg" length="56373" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/6441/4/ScreenCapture4.jpg" length="639" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/6441/5/ScreenCapture5.jpg" length="88449" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/6441/6/ScreenCapture6.jpg" length="112823" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/6441/7/ScreenCapture7.jpg" length="36134" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/6441/8/ScreenCapture8.jpg" length="40631" type="image/jpeg"/></item><item>
<title>US District Court in Virginia Grants Allergan's Motion for a New Trial [comp:Allergan, :PharmaWorld:mkt:NorthAmerica, prod:Botox]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology6440</link>
<description>US District Court in Virginia Grants Allergan's Motion for a New Trial [comp:Allergan, :PharmaWorld:mkt:NorthAmerica, prod:Botox]</description><category>comp:Allergan</category><category>mkt:NorthAmerica</category><category>prod:Botox</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology6440</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120831&edate=20120501&rec=6440">US District Court in Virginia Grants Allergan's Motion for a New Trial</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=comp%3aAllergan"><font color="#e95e0b">:Neurology:comp:Allergan</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=prod%3aBotox"><font color="#e95e0b">:Neurology:prod:Botox</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=mkt%3aNorthAmerica"><font color="#e95e0b">:PharmaWorld:mkt:NorthAmerica</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology6440">Neurology6440</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 04 June 2012 | 13:10</font><br><br><div style="margin-bottom: 10px;">Comment: According to an article published in the <EM>Chicago Tribune</EM>, Allergan is granted a new trial, as Judge Robert Payne has ruled that the company could not include a boxed warning to BOTOX packing inserts regarding the potential health risks without obtaining prior FDA approval.<wbr> The hearing is expected for June 9.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Case Background</FONT></STRONG> </div><div style="margin-bottom: 10px;">In April 2011, a plaintiff won a $212M jury verdict after alleging the BOTOX injections he took to treat movement disorder in his right hand (an off-label-use of the drug) rendered him disabled.<wbr> </div><div style="margin-bottom: 10px;">Allergan was accused of failing to alert doctors that the drug injections could cacause autoimmune reactions that lead to brain damage.<wbr> </div><div style="margin-bottom: 10px;">Source: Chicago Tribune </div><div style="margin-bottom: 10px;"><UL><LI>Full PR @ <A href="http://articles.chicagotribune.com/2012-06-01/lifestyle/sns-rt-us-allergan-botox-trialbre85019y-20120601_1_juvenile-cerebral-palsy-kristen-spears-allergan">http:/<wbr>/<wbr>articles.<wbr>chicagotribune.<wbr>com/<wbr>2012-06-01/<wbr>lifestyle/<wbr>sns-rt-us-allergan-botox-trialbre85019y-20120601_1_juvenile-cerebral-palsy-kristen-spears-allergan</A></LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Background in Traction</FONT></STRONG> </div><div>Please see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120831&edate=20120501&rec=5177" class="defaultlink">Neurology5177: Allergan to Pay Fine to US Gov to Resolve Issues on BOTOX(R) Past Sales and Marketing Practices</a>.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120831&edate=20120501&rec=6440">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-06-04T13:10:13+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Lilly China Has Opened Diabetes-Focused R&amp;D [comp:EliLilly, dis:Diabetes, :PharmaWorld:mkt:China, :PharmaWorld:mkt:Intercontinental, :PharmaWorld:func:RnD]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology6951</link>
<description>Lilly China Has Opened Diabetes-Focused R&amp;D [comp:EliLilly, dis:Diabetes, :PharmaWorld:mkt:China, :PharmaWorld:mkt:Intercontinental, :PharmaWorld:func:RnD]</description><category>comp:EliLilly</category><category>dis:Diabetes</category><category>mkt:China</category><category>mkt:Intercontinental</category><category>func:RnD</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology6951</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120831&edate=20120501&rec=6951">Lilly China Has Opened Diabetes-Focused R&D</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=comp%3aEliLilly"><font color="#e95e0b">:Endocrinology:comp:EliLilly</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=dis%3aDiabetes"><font color="#e95e0b">:Endocrinology:dis:Diabetes</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=func%3aRnD"><font color="#e95e0b">:PharmaWorld:func:RnD</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=mkt%3aChina"><font color="#e95e0b">:PharmaWorld:mkt:China</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=mkt%3aIntercontinental"><font color="#e95e0b">:PharmaWorld:mkt:Intercontinental</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology6951">Endocrinology6951</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 04 June 2012 | 11:16</font><br><br><div style="margin-bottom: 10px;"><FONT face="Verdana" size="2">Comment: Located in Shanghai, the Lilly Research and Development Centre (LCRDC</FONT>) <FONT face="Verdana" size="2">will focus on the discovery of innovative diabetes treatments specific to the Chinese population.<wbr> </FONT> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">About the Centre</FONT></STRONG> </div><div style="margin-bottom: 10px;"><FONT face="Verdana" size="2">The LCRDC will employ approx.<wbr> 150 scientists (primarily Chinese) who wil focus on highly-selective targets for future clinical development.<wbr></FONT> </div><div style="margin-bottom: 10px;"><FONT face="Verdana" size="3"><STRONG>Focus on Genetics to Personalize Novel Treatments</STRONG></FONT> </div><div style="margin-bottom: 10px;"><FONT face="Verdana" size="2">Exploring the genetic profiles of Chinese people with diabetes is a key area of research being conducted at the LCRDC.<wbr></FONT> </div><div style="margin-bottom: 10px;"><FONT face="Verdana" size="2">Characteristics of the Chinese people with diabetes:</FONT> </div><div><UL><LI><FONT face="Verdana" size="2">have a significantly lower average body mass index (BMI) than do Americans with diabetes).<wbr> </FONT></LI>
<LI><FONT face="Verdana" size="2">tend to have a higher prevalence of abdominal obesity, fatty liver and insulin resistance than do non-Asians with diabetes.<wbr></FONT></LI>
</UL> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120831&edate=20120501&rec=6951">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-06-04T11:16:21+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Highlights from the Abiraterone Ph3 Pre-Docetaxel Data - Feedback from ASCO [comp:JnJ, prod:Zytiga, :PharmaWorld:congress:ASCO, dis:Prostate, headline]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology8306</link>
<description>Highlights from the Abiraterone Ph3 Pre-Docetaxel Data - Feedback from ASCO [comp:JnJ, prod:Zytiga, :PharmaWorld:congress:ASCO, dis:Prostate, headline]</description><category>comp:JnJ</category><category>prod:Zytiga</category><category>congress:ASCO</category><category>dis:Prostate</category><category>headline</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology8306</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8306">Highlights from the Abiraterone Ph3 Pre-Docetaxel Data - Feedback from ASCO</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=comp%3aJnJ"><font color="#e95e0b">:Oncology:comp:JnJ</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=headline"><font color="#e95e0b">:Oncology:headline</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=prod%3aZytiga"><font color="#e95e0b">:Oncology:prod:Zytiga</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=congress%3aASCO"><font color="#e95e0b">:PharmaWorld:congress:ASCO</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8306">Oncology8306</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 04 June 2012 | 10:56</font><br><br><div style="margin-bottom: 10px;">Comment: One of the more anticipated results at this year's ASCO was the final data of the <A href="http://clinicaltrials.gov/ct2/show/NCT00887198?term=abiraterone+302&amp;rank=1">COU-AA-302</A>, stopped early as independent monitors (DMC) reporting the drug was clearly effective.<wbr> Thanks to Eric Chetaille, who attended the presentation, key results of the co-primary endpoints (OS;PFS) are provided below, as well as highlights from a discussion which questionned the decision of the DMC.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">About the Results</FONT></STRONG> </div><div style="margin-bottom: 10px;">Presented by Dr Charles Ryan of UC San Francisco.<wbr> </div><div style="margin-bottom: 10px;"><U>PFS and OS as co-primary endpoints</U> </div><div style="margin-bottom: 10px;">- positive results both in OS (27.<wbr>2 months vs not reached yet estimated at 33 months i;e hazard ratio of 0.<wbr>75 (0.<wbr>61-0.<wbr>93) p=0.<wbr>0097 and PFS (8.<wbr>3 months vs not reached yet estimated at 13.<wbr>5 months i;e hazard ratio 0.<wbr>43.<wbr> </div><div style="margin-bottom: 10px;"><U>Safety</U> </div><div style="margin-bottom: 10px;">- no new safety signal with main relevant grade 3/<wbr>4 AE being cardiac toxicities (6 vs 3%).<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Discussion</FONT></STRONG> </div><div style="margin-bottom: 10px;"><FONT face="Verdana"><FONT size="2">Main criticism refered to the too early unbliding of the study before reaching the predetermined statistical assumption.<wbr></FONT></FONT> </div><div style="margin-bottom: 10px;"><DIV dir="ltr" style="WORD-SPACING: 0px; FONT: 13px arial, sans-serif; TEXT-TRANSFORM: none; COLOR: rgb(34,34,34); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><FONT face="Verdana"><FONT size="2"><U>Refer to slide on O'Brien-Fleming Boundary</U></FONT></FONT></DIV> </div><div style="margin-bottom: 10px;"><DIV dir="ltr" style="WORD-SPACING: 0px; FONT: 13px arial, sans-serif; TEXT-TRANSFORM: none; COLOR: rgb(34,34,34); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">
<P>Susan Halibi, associate professor of biostatistics and bioinformatics at Duke University, presented the COU-AA-302 OS data in the context of the O’Brien-Fleming boundary, that graphically represents a curve, one side of which the drug is judged to be “ineffective,” the other side “effective.<wbr>” </P>
<P>The slide below <FONT face="Verdana"><FONT size="2">shows that unblinding the study with only 0.<wbr>43 fraction of the trial information (i;e 333 deaths) can be questionned since the efficacy results are below the predefined curve.<wbr> </FONT></FONT></P></DIV> </div><div style="margin-bottom: 10px;"><DIV dir="ltr" style="WORD-SPACING: 0px; FONT: 13px arial, sans-serif; TEXT-TRANSFORM: none; COLOR: rgb(34,34,34); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><FONT face="Verdana"><FONT size="2"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8306/1/ScreenCapture1.jpg?user-agent=rss"></FONT></FONT></DIV> </div><div style="margin-bottom: 10px;"><DIV dir="ltr" style="WORD-SPACING: 0px; FONT: 13px arial, sans-serif; TEXT-TRANSFORM: none; COLOR: rgb(34,34,34); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px">
<P>In that case, why would the independent data monitoring committee (DMC) choose to unblind the study at the time it did the analysis, rather than wait a little longer until statistical significance might be reached?</P></DIV> </div><div style="margin-bottom: 10px;"><DIV dir="ltr" style="WORD-SPACING: 0px; FONT: 13px arial, sans-serif; TEXT-TRANSFORM: none; COLOR: rgb(34,34,34); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><FONT face="Verdana"><FONT size="2">The recommendation of Halabi, was that the study should have continued unblinded until the next planned analysis after 425 deaths (0.<wbr>55 fraction of trial information).<wbr> She said " follow-up data on OS wil be biaised due to confounding factors".<wbr></FONT></FONT></DIV> </div><div><DIV dir="ltr" style="WORD-SPACING: 0px; FONT: 13px arial, sans-serif; TEXT-TRANSFORM: none; COLOR: rgb(34,34,34); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><FONT face="Verdana" size="2">This could led to regulatory challenges during discussion with FDA.<wbr></FONT></DIV> </div><!-- Comment details --><a name="oncology8306attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8306/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(41,5 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8306">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-06-04T10:56:25+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8306/1/ScreenCapture1.jpg" length="42543" type="image/jpeg"/></item><item>
<title>Allergan's Sponsored Study Assesses Patient Satisfaction with BOTOX Cosmetic [comp:Allergan, sub:Aesthetics, :PharmaWorld:sub:ClinicalTrial, :PharmaWorld:mkt:NorthAmerica, :PharmaWorld:mkt:Canada, prod:Botox]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology6437</link>
<description>Allergan's Sponsored Study Assesses Patient Satisfaction with BOTOX Cosmetic [comp:Allergan, sub:Aesthetics, :PharmaWorld:sub:ClinicalTrial, :PharmaWorld:mkt:NorthAmerica, :PharmaWorld:mkt:Canada, prod:Botox]</description><category>comp:Allergan</category><category>sub:Aesthetics</category><category>sub:ClinicalTrial</category><category>mkt:NorthAmerica</category><category>mkt:Canada</category><category>prod:Botox</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology6437</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120831&edate=20120501&rec=6437">Allergan's Sponsored Study Assesses Patient Satisfaction with BOTOX Cosmetic</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=comp%3aAllergan"><font color="#e95e0b">:Neurology:comp:Allergan</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=prod%3aBotox"><font color="#e95e0b">:Neurology:prod:Botox</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=sub%3aAesthetics"><font color="#e95e0b">:Neurology:sub:Aesthetics</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=mkt%3aCanada"><font color="#e95e0b">:PharmaWorld:mkt:Canada</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=mkt%3aNorthAmerica"><font color="#e95e0b">:PharmaWorld:mkt:NorthAmerica</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=sub%3aClinicalTrial"><font color="#e95e0b">:PharmaWorld:sub:ClinicalTrial</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology6437">Neurology6437</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 01 June 2012 | 16:28</font><br><br><div style="margin-bottom: 10px;">Comment: On April 15, Allergan celebrated the 10-year anniversary of BOTOX Cosmetic, and announced it was likely to widely promote the concept in the U.<wbr>S.<wbr>.<wbr> Clinicaltrials.<wbr>gov is listing a new observational study assessing patient satisfaction with BOTOX treatment for Glabellar Lines (GL) as primary endpoint.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Trial Details - </FONT></STRONG><A href="http://clinicaltrials.gov/ct2/show/NCT01608672?recr=Open&amp;fund=2&amp;rcv_s=05%2F18%2F2012&amp;rank=76"><STRONG><FONT size="3">NCT01608672</FONT></STRONG></A> </div><div style="margin-bottom: 10px;">Recruitment: Approx.<wbr> 500 men and women (treated for at least 10 years for this indication) </div><div style="margin-bottom: 10px;">Startd date: April 2012 Completion date: September 2012 </div><div>Location: 1 site in Florida (U.<wbr>S); 1 site in Ontario (Canada).<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120831&edate=20120501&rec=6437">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-06-01T16:28:37+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>FIM of Novartis' Anti-Prolactin Receptor Ab in Japanese Patients with CRPC [comp:Novartis, dis:Prostate, :PharmaWorld:sub:ClinicalTrial, :PharmaWorld:mkt:Japan]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology8303</link>
<description>FIM of Novartis' Anti-Prolactin Receptor Ab in Japanese Patients with CRPC [comp:Novartis, dis:Prostate, :PharmaWorld:sub:ClinicalTrial, :PharmaWorld:mkt:Japan]</description><category>comp:Novartis</category><category>dis:Prostate</category><category>sub:ClinicalTrial</category><category>mkt:Japan</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology8303</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8303">FIM of Novartis' Anti-Prolactin Receptor Ab in Japanese Patients with CRPC</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=comp%3aNovartis"><font color="#e95e0b">:Oncology:comp:Novartis</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=mkt%3aJapan"><font color="#e95e0b">:PharmaWorld:mkt:Japan</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=sub%3aClinicalTrial"><font color="#e95e0b">:PharmaWorld:sub:ClinicalTrial</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8303">Oncology8303</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 01 June 2012 | 16:20</font><br><br><div style="margin-bottom: 10px;">Comment: The Phase 1 study will assess dose limiting toxicity as a primary outcome measure.<wbr> LFA102 is currently in Ph1 in the U.<wbr>S and EU (Belgium; Italy; Spain) in patients with prolactin receptor-positive CRPC or prolactin receptor-positive metastatic breast cancer.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Trial Details - </FONT></STRONG><A href="http://clinicaltrials.gov/ct2/show/NCT01610050?recr=Open&amp;fund=2&amp;rcv_s=05%2F18%2F2012&amp;rank=55"><STRONG><FONT size="3">NCT01610050</FONT></STRONG></A> </div><div style="margin-bottom: 10px;">Protocol: LFA102 will be administered intravenously once every 4 weeks during the study.<wbr> All patients will remain on treatment until they meet the criteria for study discontinuation.<wbr> </div><div style="margin-bottom: 10px;">Recruitment: approx.<wbr>2 4 </div><div style="margin-bottom: 10px;">Start date: June 2012 - Completion date: Aug 2014 </div><div style="margin-bottom: 10px;">Location: 2 sites in Nagoya and Kobe </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Ongoing Study with the drug</FONT></STRONG> </div><div>Please see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=7336" class="defaultlink">Oncology7336: Novartis' Anti-Prolactin Receptor Ab to Enter Phase 1</a> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8303">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-06-01T16:20:34+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>MHRA Says that 'EU Equivalence' Could Cause Drug Shortages [mkt:Europe, sub:Regulatory]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld9896</link>
<description>MHRA Says that 'EU Equivalence' Could Cause Drug Shortages [mkt:Europe, sub:Regulatory]</description><comments>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld9896</comments><category>mkt:Europe</category><category>sub:Regulatory</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld9896</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120831&edate=20120501&rec=9896">MHRA Says that 'EU Equivalence' Could Cause Drug Shortages</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=mkt%3aEurope"><font color="#e95e0b">:PharmaWorld:mkt:Europe</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=sub%3aRegulatory"><font color="#e95e0b">:PharmaWorld:sub:Regulatory</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld9896">PharmaWorld9896</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/20">Alison Attard</a> | 01 June 2012 | 13:03</font><br><br><div style="margin-bottom: 10px;">Comment: T<SPAN style="DISPLAY: inline! important; FLOAT: none; WORD-SPACING: 0px; FONT: 12px Arial, Helvetica, sans-serif; TEXT-TRANSFORM: none; COLOR: #000000; TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; BACKGROUND-COLOR: #ffffff; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><FONT face="Verdana" size="2">he European Commission's proposed approach towards ensuring 'EU equivalence' of active pharmaceutical ingredients being imported from third countries could lead to a shortage of medicines and the loss of manufacturing in the EU, the UK MHRA has said.<wbr></FONT></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="DISPLAY: inline! important; FLOAT: none; WORD-SPACING: 0px; FONT: 12px Arial, Helvetica, sans-serif; TEXT-TRANSFORM: none; COLOR: #000000; TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; BACKGROUND-COLOR: #ffffff; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><FONT face="Verdana"><FONT size="2">The European C<SPAN style="DISPLAY: inline! important; FLOAT: none; WORD-SPACING: 0px; FONT: 12px Arial, Helvetica, sans-serif; TEXT-TRANSFORM: none; COLOR: #000000; TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; BACKGROUND-COLOR: #ffffff; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><FONT face="Verdana" size="2">ommission has proposed that third country regulators should provide written statements to confirm that the APIs being manufactured and exported from their regions conform to EU standards</FONT>.<wbr> </SPAN></FONT></FONT></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="DISPLAY: inline! important; FLOAT: none; WORD-SPACING: 0px; FONT: 12px Arial, Helvetica, sans-serif; TEXT-TRANSFORM: none; COLOR: #000000; TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; BACKGROUND-COLOR: #ffffff; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><SPAN style="DISPLAY: inline! important; FLOAT: none; WORD-SPACING: 0px; FONT: 12px Arial, Helvetica, sans-serif; TEXT-TRANSFORM: none; COLOR: #000000; TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; BACKGROUND-COLOR: #ffffff; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><FONT face="Verdana"><FONT size="2">The MHRA, in its formal response to the Commission has expressed concerns that the <SPAN style="DISPLAY: inline! important; FLOAT: none; WORD-SPACING: 0px; FONT: 12px Arial, Helvetica, sans-serif; TEXT-TRANSFORM: none; COLOR: #000000; TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; BACKGROUND-COLOR: #ffffff; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><FONT face="Verdana" size="2">proposal could result in EU drug manufacturing companies moving</FONT> <FONT face="Verdana" size="2">all of</FONT> <FONT face="Verdana" size="2">their manufacturing activities to third countries because then they would not have to obtain a written confirmation before (importing and) using the APIs from third countries</FONT>.<wbr></SPAN></FONT></FONT></SPAN></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="DISPLAY: inline! important; FLOAT: none; WORD-SPACING: 0px; FONT: 12px Arial, Helvetica, sans-serif; TEXT-TRANSFORM: none; COLOR: #000000; TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; BACKGROUND-COLOR: #ffffff; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><SPAN style="DISPLAY: inline! important; FLOAT: none; WORD-SPACING: 0px; FONT: 12px Arial, Helvetica, sans-serif; TEXT-TRANSFORM: none; COLOR: #000000; TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; BACKGROUND-COLOR: #ffffff; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><SPAN style="DISPLAY: inline! important; FLOAT: none; WORD-SPACING: 0px; FONT: 12px Arial, Helvetica, sans-serif; TEXT-TRANSFORM: none; COLOR: #000000; TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; BACKGROUND-COLOR: #ffffff; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><SPAN style="DISPLAY: inline! important; FLOAT: none; WORD-SPACING: 0px; FONT: 12px Arial, Helvetica, sans-serif; TEXT-TRANSFORM: none; COLOR: #000000; TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; BACKGROUND-COLOR: #ffffff; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><FONT face="Verdana" size="2">In the UK, around 60% of authorised medicines use APIs sourced from third countries, with China and India being the largest suppliers.<wbr></FONT></SPAN></SPAN></SPAN></SPAN> </div><div><SPAN style="DISPLAY: inline! important; FLOAT: none; WORD-SPACING: 0px; FONT: 12px Arial, Helvetica, sans-serif; TEXT-TRANSFORM: none; COLOR: #000000; TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; BACKGROUND-COLOR: #ffffff; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><SPAN style="DISPLAY: inline! important; FLOAT: none; WORD-SPACING: 0px; FONT: 12px Arial, Helvetica, sans-serif; TEXT-TRANSFORM: none; COLOR: #000000; TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; BACKGROUND-COLOR: #ffffff; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><SPAN style="DISPLAY: inline! important; FLOAT: none; WORD-SPACING: 0px; FONT: 12px Arial, Helvetica, sans-serif; TEXT-TRANSFORM: none; COLOR: #000000; TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; BACKGROUND-COLOR: #ffffff; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><SPAN style="DISPLAY: inline! important; FLOAT: none; WORD-SPACING: 0px; FONT: 12px Arial, Helvetica, sans-serif; TEXT-TRANSFORM: none; COLOR: #000000; TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; BACKGROUND-COLOR: #ffffff; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><FONT face="Verdana" size="2">Source: Scrip 1 June 2012</FONT></SPAN></SPAN></SPAN></SPAN> <a name="PharmaWorld10199c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">Switzerland has become  the first country to receive an "equivalence" rating from the European Commission for its regulations on APIs,  however many of the biggest API manufacturing countries including India and China have still not even applied for an equivalence assessment.<wbr> </div><div style="margin-bottom: 10px;">Under the EU's falsified medicines Directive, whose provisions come into force on 2 January 2013, all APIs imported into the EU as of that date must have been manufactured to GMP standards that are at least equivalent to those of the EU.<wbr> Only four other countries have so far applied for an equivalence assessment: Israel, Australia, Singapore and Brazil.<wbr> </div><div style="margin-bottom: 10px;">The large API producers such as India, China, South Korea, Japan, Taiwan and Mexico have not yet applied.<wbr> </div><div>Source: Scrip 26 November 2012 </div><font size="-1">Alison Attard / <a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10199" class="commentpermalink">PharmaWorld10199</a> / <span class="date">26 November 2012</span> /
<span class="time">10:14:39 o'clock CET</span>
</font></div></div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120831&edate=20120501&rec=9896">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-06-01T13:03:36+02:00</dc:date><dc:creator>ala97794</dc:creator></item><item>
<title>Generic Prices in Europe: Evolving Trends and Their Impact on the Drug Industry [mkt:Europe, sub:Generics]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld9894</link>
<description>Generic Prices in Europe: Evolving Trends and Their Impact on the Drug Industry [mkt:Europe, sub:Generics]</description><category>mkt:Europe</category><category>sub:Generics</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld9894</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120831&edate=20120501&rec=9894">Generic Prices in Europe: Evolving Trends and Their Impact on the Drug Industry</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=mkt%3aEurope"><font color="#e95e0b">:PharmaWorld:mkt:Europe</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=sub%3aGenerics"><font color="#e95e0b">:PharmaWorld:sub:Generics</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld9894">PharmaWorld9894</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 01 June 2012 | 10:53</font><br><br><div style="margin-bottom: 10px;">Comment: In an attempt to generate savings, generics are increasingly being targeted by governments, which have found different ways to significantly lower their prices, as well as the prices of their originator counterparts.<wbr> This report aims to provide pharmaceutical companies with a better understanding of the cost-containment policies directly affecting prices once generics enter the market, as well as how pharmaceutical companies usually react to those policies.<wbr> </div><div style="margin-bottom: 10px;"><TABLE class="table100"><TBODY><TR><TD align="middle" class="tableTitleBold" style="VERTICAL-ALIGN: top">
<P align="left" class="tableTitleBold"><B>Key Findings</B></P></TD>
</TR>
<TR><TD class="tableContentLarge" style="VERTICAL-ALIGN: top">
<UL type="disc"><LI>Governments usually combine different cost-containment policies to ensure prices drop significantly once generics enter the market.<wbr> </LI>
<LI>Many governments are increasingly becoming suspicious that rather than being a source of cost saving compared with branded originator drugs, the prices of generics are actually higher than they should be, and their use is not generating as much in the way of savings as it should.<wbr> </LI>
<LI>An awareness of the main cost-containment policies affecting prices and how to react to them is critical.<wbr> </LI>
<LI>Several case studies demonstrate that a few competitors enter the pharmaceutical markets where conditions are too restrictive.<wbr> In those cases, generic companies will tend not to enter those markets and originator drugs are often withdrawn from the market.<wbr> </LI>
<LI>In Italy and Spain, generic prices are on average 16% and 13% below originator prices (in terms of retail prices), according to a selection of drugs from IHS Global Insight's international pricing data.<wbr> </LI>
<LI>In some countries, generic companies are dropping their prices significantly below the required levels.<wbr> For instance, our data show that the first generic of olanzapine has just entered the Austrian market (April 2012) and although only one company has entered the market so far, the price drop implemented is significantly larger compared with the minimum requested.<wbr> This will put new competitors in an extremely difficult position.<wbr></LI>
</UL></TD>
</TR>
</TBODY>
</TABLE> </div><div style="margin-bottom: 10px;">With universal healthcare coverage in place in almost all European countries, ageing populations, and costly treatments, healthcare expenditure is steadily rising in all developed countries, and as such, making savings has become one of the top priorities for governments, notably for drugs.<wbr> </div><div style="margin-bottom: 10px;">Governments are not only becoming increasingly stringent on funding new drugs, but also on drugs that are genericised (generics and biosimilars).<wbr> For the purpose of this report, and given the complexity of the biosimilars legislation, only generics will be studied.<wbr> Large savings are expected in this area, notably with the great number of molecules that are coming off-patent this year (including irbesartan, candesartan, donepezil, esomeprazole, and montelukast) and in the coming years.<wbr> Governments are increasingly becoming suspicious that rather than being a source of cost saving against branded originator drugs, the prices of generics are actually higher than they should be, and their use is not generating as much in the way of savings as it should.<wbr> </div><div style="margin-bottom: 10px;">Governments have found different ways to limit expenses: once generics enter the market, prices must drop significantly.<wbr> Most governments also set the maximum levels at which patients will be reimbursed.<wbr> Finally, in certain countries, exclusivity will be given to the pharmaceutical companies providing the lowest prices for a given genericised molecule.<wbr> Governments also combine some of these cost-containment policies to make sure significant savings are achieved.<wbr> On top of that, discounts are also largely granted, enabling prices to drop further.<wbr> In parallel, several policies also directly target pharmacists or physicians in an attempt to raise generic penetration.<wbr> Those policies will not be taken into account in this report, however.<wbr> </div><div style="margin-bottom: 10px;">The below table summarises the main policies used to lower prices in 24 EU countries.<wbr> Generic companies and pharmaceutical companies willing to face generic competition must assess the different criteria used in each pharmaceutical market before implementing their pricing strategy.<wbr> </div><div style="margin-bottom: 10px;"><TABLE class="table100"><TBODY><TR><TD align="middle" class="tableTitleBold" colspan="4" style="VERTICAL-ALIGN: top">
<P align="center" class="tableTitleBold"><B>Table 1: Generic Pricing Policies in 24 European Countries</B></P></TD>
</TR>
<TR><TD align="middle" class="tableHeadingLarge" style="VERTICAL-ALIGN: top">
<P align="center" class="tableHeadingLarge"><B>Country</B></P></TD>
<TD align="middle" class="tableHeadingLarge" style="VERTICAL-ALIGN: top">
<P align="center" class="tableHeadingLarge"><B>Generic Pricing Policy</B></P></TD>
<TD align="middle" class="tableHeadingLarge" style="VERTICAL-ALIGN: top">
<P align="center" class="tableHeadingLarge"><B>Reference Price for Reimbursement</B></P></TD>
<TD align="middle" class="tableHeadingLarge" style="VERTICAL-ALIGN: top">
<P align="center" class="tableHeadingLarge"><B>Market Exclusivity</B></P></TD>
</TR>
<TR><TD class="tableHeadingLarge" style="VERTICAL-ALIGN: top">
<P class="tableHeadingLarge"><B>Austria</B></P></TD>
<TD class="tableContentLarge" style="VERTICAL-ALIGN: top">
<P class="tableContentLarge"><B>Price capping:</B> a 48% price drop for the first generic, then 30% for the originator drug, 15% for the second generic, 10% for the third generic, then all prices must be brought into line with the price of the third generic.<wbr></P></TD>
<TD class="tableContentLarge" style="VERTICAL-ALIGN: top">
<P class="tableContentLarge">No</P></TD>
<TD class="tableContentLarge" style="VERTICAL-ALIGN: top">
<P class="tableContentLarge">No</P></TD>
</TR>
<TR><TD class="tableHeadingLarge" style="VERTICAL-ALIGN: top">
<P class="tableHeadingLarge"><B>Belgium</B></P></TD>
<TD class="tableContentLarge" style="VERTICAL-ALIGN: top">
<P class="tableContentLarge"><B>Price capping</B>: generic prices at least 44.<wbr>1% below the price of the originator before generics market entry.<wbr></P></TD>
<TD class="tableContentLarge" style="VERTICAL-ALIGN: top">
<P class="tableContentLarge">Yes</P></TD>
<TD class="tableContentLarge" style="VERTICAL-ALIGN: top">
<P class="tableContentLarge">No</P></TD>
</TR>
<TR><TD class="tableHeadingLarge" style="VERTICAL-ALIGN: top">
<P class="tableHeadingLarge"><B>Bulgaria</B></P></TD>
<TD class="tableContentLarge" style="VERTICAL-ALIGN: top">
<P class="tableContentLarge"><B>International reference pricing</B></P></TD>
<TD class="tableContentLarge" style="VERTICAL-ALIGN: top">
<P class="tableContentLarge">Yes</P></TD>
<TD class="tableContentLarge" style="VERTICAL-ALIGN: top">
<P class="tableContentLarge">No</P></TD>
</TR>
<TR><TD class="tableHeadingLarge" style="VERTICAL-ALIGN: top">
<P class="tableHeadingLarge"><B>Czech Republic</B></P></TD>
<TD class="tableContentLarge" style="VERTICAL-ALIGN: top">
<P class="tableContentLarge"><B>Price capping: </B>generic prices at least 32% below the price of the originator.<wbr></P></TD>
<TD class="tableContentLarge" style="VERTICAL-ALIGN: top">
<P class="tableContentLarge">Yes</P></TD>
<TD class="tableContentLarge" style="VERTICAL-ALIGN: top">
<P class="tableContentLarge">No</P></TD>
</TR>
<TR><TD class="tableHeadingLarge" style="VERTICAL-ALIGN: top">
<P class="tableHeadingLarge"><B>Denmark</B></P></TD>
<TD class="tableContentLarge" style="VERTICAL-ALIGN: top">
<P class="tableContentLarge">Free pricing</P></TD>
<TD class="tableContentLarge" style="VERTICAL-ALIGN: top">
<P class="tableContentLarge">Yes</P></TD>
<TD class="tableContentLarge" style="VERTICAL-ALIGN: top">
<P class="tableContentLarge">No</P></TD>
</TR>
<TR><TD class="tableHeadingLarge" style="VERTICAL-ALIGN: top">
<P class="tableHeadingLarge"><B>Estonia</B></P></TD>
<TD class="tableContentLarge" style="VERTICAL-ALIGN: top">
<P class="tableContentLarge"><B>Price capping:</B> generic prices at least 30% below the price of the originator.<wbr></P></TD>
<TD class="tableContentLarge" style="VERTICAL-ALIGN: top">
<P class="tableContentLarge">Yes</P></TD>
<TD class="tableContentLarge" style="VERTICAL-ALIGN: top">
<P class="tableContentLarge">No</P></TD>
</TR>
<TR><TD class="tableHeadingLarge" style="VERTICAL-ALIGN: top">
<P class="tableHeadingLarge"><B>Finland</B></P></TD>
<TD class="tableContentLarge" style="VERTICAL-ALIGN: top">
<P class="tableContentLarge">Fix percentage cut : Generic prices at 40% below the price of the originator drug (wholesale price).<wbr></P></TD>
<TD class="tableContentLarge" style="VERTICAL-ALIGN: top">
<P class="tableContentLarge">Yes</P></TD>
<TD class="tableContentLarge" style="VERTICAL-ALIGN: top">
<P class="tableContentLarge">No</P></TD>
</TR>
<TR><TD class="tableHeadingLarge" style="VERTICAL-ALIGN: top">
<P class="tableHeadingLarge"><B>France</B></P></TD>
<TD class="tableContentLarge" style="VERTICAL-ALIGN: top">
<P class="tableContentLarge"><B>Price capping:</B> generic prices at least 60% below the price of the originator, for which the price must decrease by 20%.<wbr></P></TD>
<TD class="tableContentLarge" style="VERTICAL-ALIGN: top">
<P class="tableContentLarge">Yes, for some genericised active ingredients only</P></TD>
<TD class="tableContentLarge" style="VERTICAL-ALIGN: top">
<P class="tableContentLarge">No</P></TD>
</TR>
<TR><TD class="tableHeadingLarge" style="VERTICAL-ALIGN: top">
<P class="tableHeadingLarge"><B>Germany</B></P></TD>
<TD class="tableContentLarge" style="VERTICAL-ALIGN: top">
<P class="tableContentLarge"><B>Free pricing</B></P></TD>
<TD class="tableContentLarge" style="VERTICAL-ALIGN: top">
<P class="tableContentLarge">Yes</P></TD>
<TD class="tableContentLarge" style="VERTICAL-ALIGN: top">
<P class="tableContentLarge">Yes</P></TD>
</TR>
<TR><TD class="tableHeadingLarge" style="VERTICAL-ALIGN: top">
<P class="tableHeadingLarge"><B>Greece</B></P></TD>
<TD class="tableContentLarge" style="VERTICAL-ALIGN: top">
<P class="tableContentLarge"><B>Price capping:</B> the price of the originator must first decrease 50%.<wbr> The first generic entering the market must decrease its price 60% below the originator's retail price (before the 50% price cut applies).<wbr> The following generics must drop their prices by 10%.<wbr></P></TD>
<TD class="tableContentLarge" style="VERTICAL-ALIGN: top">
<P class="tableContentLarge">No</P></TD>
<TD class="tableContentLarge" style="VERTICAL-ALIGN: top">
<P class="tableContentLarge">No</P></TD>
</TR>
<TR><TD class="tableHeadingLarge" style="VERTICAL-ALIGN: top">
<P class="tableHeadingLarge"><B>Hungary</B></P></TD>
<TD class="tableContentLarge" style="VERTICAL-ALIGN: top">
<P class="tableContentLarge"><B>Price capping:</B> the first generic is priced 35% below the originator drug, second generic priced 45% below the originator drug, third generic and subsequent ones priced 55% below the originator drug.<wbr></P></TD>
<TD class="tableContentLarge" style="VERTICAL-ALIGN: top">
<P class="tableContentLarge">No</P></TD>
<TD class="tableContentLarge" style="VERTICAL-ALIGN: top">
<P class="tableContentLarge">No</P></TD>
</TR>
<TR><TD class="tableHeadingLarge" style="VERTICAL-ALIGN: top">
<P class="tableHeadingLarge"><B>Ireland</B></P></TD>
<TD class="tableContentLarge" style="VERTICAL-ALIGN: top">
<P class="tableContentLarge"><B>Price capping</B></P></TD>
<TD class="tableContentLarge" style="VERTICAL-ALIGN: top">
<P class="tableContentLarge">No</P></TD>
<TD class="tableContentLarge" style="VERTICAL-ALIGN: top">
<P class="tableContentLarge">No</P></TD>
</TR>
<TR><TD class="tableHeadingLarge" style="VERTICAL-ALIGN: top">
<P class="tableHeadingLarge"><B>Italy</B></P></TD>
<TD class="tableContentLarge" style="VERTICAL-ALIGN: top">
<P class="tableContentLarge"><B>Price capping:</B> generic prices at least 20% below the originator price.<wbr></P></TD>
<TD class="tableContentLarge" style="VERTICAL-ALIGN: top">
<P class="tableContentLarge">Yes</P></TD>
<TD class="tableContentLarge" style="VERTICAL-ALIGN: top">
<P class="tableContentLarge">No</P></TD>
</TR>
<TR><TD class="tableHeadingLarge" style="VERTICAL-ALIGN: top">
<P class="tableHeadingLarge"><B>Latvia</B></P></TD>
<TD class="tableContentLarge" style="VERTICAL-ALIGN: top">
<P class="tableContentLarge"><B>Free pricing</B></P></TD>
<TD class="tableContentLarge" style="VERTICAL-ALIGN: top">
<P class="tableContentLarge">No</P></TD>
<TD class="tableContentLarge" style="VERTICAL-ALIGN: top">
<P class="tableContentLarge">No</P></TD>
</TR>
<TR><TD class="tableHeadingLarge" style="VERTICAL-ALIGN: top">
<P class="tableHeadingLarge"><B>Lithuania</B></P></TD>
<TD class="tableContentLarge" style="VERTICAL-ALIGN: top">
<P class="tableContentLarge"><B>Price capping:</B> generic prices at least 30% below the price of the originator.<wbr></P></TD>
<TD class="tableContentLarge" style="VERTICAL-ALIGN: top">
<P class="tableContentLarge">Yes</P></TD>
<TD class="tableContentLarge" style="VERTICAL-ALIGN: top">
<P class="tableContentLarge">No</P></TD>
</TR>
<TR><TD class="tableHeadingLarge" style="VERTICAL-ALIGN: top">
<P class="tableHeadingLarge"><B>Netherlands</B></P></TD>
<TD class="tableContentLarge" style="VERTICAL-ALIGN: top">
<P class="tableContentLarge"><B>International reference pricing</B></P></TD>
<TD class="tableContentLarge" style="VERTICAL-ALIGN: top">
<P class="tableContentLarge">Yes</P></TD>
<TD class="tableContentLarge" style="VERTICAL-ALIGN: top">
<P class="tableContentLarge">Yes</P></TD>
</TR>
<TR><TD class="tableHeadingLarge" style="VERTICAL-ALIGN: top">
<P class="tableHeadingLarge"><B>Poland</B></P></TD>
<TD class="tableContentLarge" style="VERTICAL-ALIGN: top">
<P class="tableContentLarge"><B>Same as innovative drugs:</B> class/<wbr>therapy reference pricing</P></TD>
<TD class="tableContentLarge" style="VERTICAL-ALIGN: top">
<P class="tableContentLarge">Yes</P></TD>
<TD class="tableContentLarge" style="VERTICAL-ALIGN: top">
<P class="tableContentLarge">No</P></TD>
</TR>
<TR><TD class="tableHeadingLarge" style="VERTICAL-ALIGN: top">
<P class="tableHeadingLarge"><B>Portugal</B></P></TD>
<TD class="tableContentLarge" style="VERTICAL-ALIGN: top">
<P class="tableContentLarge"><B>Price capping:</B> generic prices at least 50% below the price of the originator.<wbr></P></TD>
<TD class="tableContentLarge" style="VERTICAL-ALIGN: top">
<P class="tableContentLarge">No</P></TD>
<TD class="tableContentLarge" style="VERTICAL-ALIGN: top">
<P class="tableContentLarge">No</P></TD>
</TR>
<TR><TD class="tableHeadingLarge" style="VERTICAL-ALIGN: top">
<P class="tableHeadingLarge"><B>Romania</B></P></TD>
<TD class="tableContentLarge" style="VERTICAL-ALIGN: top">
<P class="tableContentLarge"><B>Price capping:</B> generic prices at least 70% below the price of the originator.<wbr></P></TD>
<TD class="tableContentLarge" style="VERTICAL-ALIGN: top">
<P class="tableContentLarge">No</P></TD>
<TD class="tableContentLarge" style="VERTICAL-ALIGN: top">
<P class="tableContentLarge">No</P></TD>
</TR>
<TR><TD class="tableHeadingLarge" style="VERTICAL-ALIGN: top">
<P class="tableHeadingLarge"><B>Slovakia</B></P></TD>
<TD class="tableContentLarge" style="VERTICAL-ALIGN: top">
<P class="tableContentLarge"><B>Price capping:</B> generic prices at least 30% below the price of the originator.<wbr></P></TD>
<TD class="tableContentLarge" style="VERTICAL-ALIGN: top">
<P class="tableContentLarge">Yes</P></TD>
<TD class="tableContentLarge" style="VERTICAL-ALIGN: top">
<P class="tableContentLarge">No</P></TD>
</TR>
<TR><TD class="tableHeadingLarge" style="VERTICAL-ALIGN: top">
<P class="tableHeadingLarge"><B>Slovenia</B></P></TD>
<TD class="tableContentLarge" style="VERTICAL-ALIGN: top">
<P class="tableContentLarge"><B>Price capping:</B> 15% price differential between a branded drug and its generic copies.<wbr></P></TD>
<TD class="tableContentLarge" style="VERTICAL-ALIGN: top">
<P class="tableContentLarge">Yes</P></TD>
<TD class="tableContentLarge" style="VERTICAL-ALIGN: top">
<P class="tableContentLarge">No</P></TD>
</TR>
<TR><TD class="tableHeadingLarge" style="VERTICAL-ALIGN: top">
<P class="tableHeadingLarge"><B>Spain</B></P></TD>
<TD class="tableContentLarge" style="VERTICAL-ALIGN: top">
<P class="tableContentLarge"><B>Price capping:</B> generic prices at least 30% below the price of the originator.<wbr></P></TD>
<TD class="tableContentLarge" style="VERTICAL-ALIGN: top">
<P class="tableContentLarge">Yes</P></TD>
<TD class="tableContentLarge" style="VERTICAL-ALIGN: top">
<P class="tableContentLarge">No</P></TD>
</TR>
<TR><TD class="tableHeadingLarge" style="VERTICAL-ALIGN: top">
<P class="tableHeadingLarge"><B>Sweden</B></P></TD>
<TD class="tableContentLarge" style="VERTICAL-ALIGN: top">
<P class="tableContentLarge"><B>Price negotiation:</B> cost-effectiveness review.<wbr></P></TD>
<TD class="tableContentLarge" style="VERTICAL-ALIGN: top">
<P class="tableContentLarge">No</P></TD>
<TD class="tableContentLarge" style="VERTICAL-ALIGN: top">
<P class="tableContentLarge">Yes</P></TD>
</TR>
<TR><TD class="tableHeadingLarge" style="VERTICAL-ALIGN: top">
<P class="tableHeadingLarge"><B>UK</B></P></TD>
<TD class="tableContentLarge" style="VERTICAL-ALIGN: top">
<P class="tableContentLarge"><B>Free pricing</B></P></TD>
<TD class="tableContentLarge" style="VERTICAL-ALIGN: top">
<P class="tableContentLarge">No</P></TD>
<TD class="tableContentLarge" style="VERTICAL-ALIGN: top">
<P class="tableContentLarge">No</P></TD>
</TR>
<TR><TD class="tableNotes" colspan="4" style="VERTICAL-ALIGN: top">
<P class="tableNotes">Source: IHS Global Insight, 2012</P></TD>
</TR>
</TBODY>
</TABLE> </div><div style="margin-bottom: 10px;"><P class="bodyHeading2"><B>Pricing Policies: First Tool Directly Lowering Prices</B></P> </div><div style="margin-bottom: 10px;">It is a well known fact that complex and usually time-consuming pricing procedures are in place for innovative drugs in all European countries.<wbr> In an attempt to generate savings quickly, governments have commonly implemented pricing procedures that differ from the ones used for new and innovative drugs and therefore speed up generic market entry.<wbr> Below are details of the different pricing policies used by governments in order to set generic prices.<wbr> </div><div style="margin-bottom: 10px;"><P class="bodyHeading3"><B>Price-Capping Policies</B></P> </div><div style="margin-bottom: 10px;">When it comes to generic pricing, most countries have now implemented a price-capping policy.<wbr> This is the case in 15 out of the 24 countries studied (more than 60%).<wbr> Prices of new generics coming onto these markets, as well as off-patent products, must decrease either by set percentages that pharmaceutical companies must strictly apply, or by percentages indicating the minimum price drop that must apply.<wbr> Those price cuts are in most cases directly linked to the price of the newly off-patent product.<wbr> In a few cases, the price of the first generic entering the market is linked to the price of the originator, while prices of the subsequent generics are linked to the price of other generics already on the market.<wbr> This is the case for instance in Austria.<wbr> </div><div style="margin-bottom: 10px;">These methods enable governments to speed up pricing procedures, and as such, generics quickly enter these markets.<wbr> In France, for instance, generic prices are set in advance of patent expiry.<wbr> Prices of the generics and off-patent medicines are published in the French Official Bulletin before the molecule loses its patent.<wbr> One example of this is olanzapine, for which generic were set in July 2011, but market entry occurred around two months later.<wbr> </div><div style="margin-bottom: 10px;"><P class="bodyHeading3"><B>Specific Percentage Price Drop</B></P> </div><div style="margin-bottom: 10px;">Most countries cap generic prices at a certain level.<wbr> This is the case for instance in Belgium, the Czech Republic, Finland, Italy, Portugal, Spain, and Ireland.<wbr> </div><div style="margin-bottom: 10px;">Markets using this type of generic pricing policy can be divided into two groups: countries that cannot deviate from the pricing policy and countries where the percentage is capped to a certain level, allowing pharmaceutical companies to lower prices below that threshold.<wbr> </div><div style="margin-bottom: 10px;">In Italy and Spain, generic prices are on average 16% and 13% below the originator price (in terms of retail prices).<wbr> These figures were determined on the basis of prices for 10 genericised active ingredients (source: PharmOnline International [POLI], 2011).<wbr> </div><div style="margin-bottom: 10px;">It is not uncommon, however, that in certain countries, pharmaceutical companies decrease their prices far below the required price drop.<wbr> In Finland, for example, when generics enter the market, their prices should be lowered by at least 40% compared with the originator price.<wbr> Nevertheless, an analysis of the prices from POLI shows that generic prices are set on average around 50% below the price that should already be applied (meaning 50% below the 40%).<wbr> Nevertheless, prices of off-patent drugs do not necessarily drop.<wbr> For instance, 15 months after generic versions of pramipexole entered the market, the price of originator drug Sifrol had not changed.<wbr> </div><div style="margin-bottom: 10px;">In those countries using a price-drop policy, when the maximum level of reimbursement is not set by law, there is a certain amount of flexibility in terms of pricing strategies.<wbr> Complexity is caused in countries also implementing reference pricing for reimbursement.<wbr> In this case, it is not rare to see the different competitors on the market bring their prices into line with the reference price, or even below.<wbr> </div><div style="margin-bottom: 10px;">In France, the regulations are strictly followed, with little room for manoeuvre.<wbr> Once generics enter the market, originator prices must drop 20% (in terms of manufacturer prices) and generic prices must be 60% below the originator price before the 20% price cut applies.<wbr> This rule is strictly implemented, as demonstrated with the following example: generics of Zomig (zolmitriptan) entered the French market in January 2011; as seen in table 2, price cuts are strictly implemented for all generics on the market.<wbr> As a consequence, generics are all priced at the same level.<wbr> </div><div style="margin-bottom: 10px;"><TABLE class="table100"><TBODY><TR><TD align="middle" class="tableTitleBold" colspan="4" style="VERTICAL-ALIGN: top">
<P align="center" class="tableTitleBold"><B>Table 2: Zolmitriptan Generic and Off-Patent Price Cut, France</B></P></TD>
</TR>
<TR><TD align="middle" class="tableHeading" style="VERTICAL-ALIGN: top">
<P align="center" class="tableHeading"><B>Zolmitriptan 2.<wbr>5 mg, 6 Orodispersible Tablets</B></P></TD>
<TD align="middle" class="tableHeading" style="VERTICAL-ALIGN: top">
<P align="center" class="tableHeading"><B>Manufacturer Price Before Generic Market Entry (EUR)</B></P></TD>
<TD align="middle" class="tableHeading" style="VERTICAL-ALIGN: top">
<P align="center" class="tableHeading"><B>Manufacturer Price After Generic Market Entry (EUR)</B></P></TD>
<TD align="middle" class="tableHeading" style="VERTICAL-ALIGN: top">
<P align="center" class="tableHeading"><B>Price Cut (%)</B></P></TD>
</TR>
<TR><TD class="tableHeading" style="VERTICAL-ALIGN: top">
<P class="tableHeading"><B>Zomig</B></P></TD>
<TD align="right" class="tableContent" style="VERTICAL-ALIGN: top">
<P align="right" class="tableContent">21.<wbr>46</P></TD>
<TD align="right" class="tableContent" style="VERTICAL-ALIGN: top">
<P align="right" class="tableContent">17.<wbr>17</P></TD>
<TD align="right" class="tableContent" style="VERTICAL-ALIGN: top">
<P align="right" class="tableContent">20.<wbr>0</P></TD>
</TR>
<TR><TD class="tableHeading" style="VERTICAL-ALIGN: top">
<P class="tableHeading"><B>Generics</B></P></TD>
<TD align="right" class="tableContent" style="VERTICAL-ALIGN: top">
<P align="right" class="tableContent">-</P></TD>
<TD align="right" class="tableContent" style="VERTICAL-ALIGN: top">
<P align="right" class="tableContent">8.<wbr>58</P></TD>
<TD align="right" class="tableContent" style="VERTICAL-ALIGN: top">
<P align="right" class="tableContent">60.<wbr>0</P></TD>
</TR>
<TR><TD class="tableNotes" colspan="4" style="VERTICAL-ALIGN: top">
<P class="tableNotes">Source: POLI, April 2012</P></TD>
</TR>
</TBODY>
</TABLE> </div><div style="margin-bottom: 10px;">It should be noted that the French government is becoming more stringent as the percentages of price drops increased in January 2011.<wbr> They were previously set at 55% for generics and 15% for originator drugs.<wbr> </div><div style="margin-bottom: 10px;"><P class="bodyHeading3"><B>Specific Percentage Price Drop Linked to National Generic Launch Sequencing: Few Competitors on Markets</B></P> </div><div style="margin-bottom: 10px;">In a few countries—Austria, Hungary, and recently Greece, for instance—generic pricing is linked to launch sequencing.<wbr> The first market entrant must drop its price as a percentage of the originator price, and the other entrants must then drop their prices to a lower level.<wbr> In those cases, being the first generic to enter the market is crucial for generic companies.<wbr> As such, they must ensure to file their dossiers for reimbursement and/<wbr>or pricing as fast as possible in order to secure the first market entry, all the more so when generic prices are directly linked to the price of the generics that were previously on the market.<wbr> This is notably the case in Austria.<wbr> </div><div style="margin-bottom: 10px;">In this market, specific price drops are requested and incremented over time, to ensure prices of genericised drugs decrease significantly over time.<wbr> </div><div style="margin-bottom: 10px;"><UL type="disc"><LI>The first generic must be priced 48% below the originator.<wbr> After three months, the originator price must decrease by 30%, granting both the originator drug and the first generic product a three-month exclusivity period.<wbr> </LI>
<LI>The second generic entering the market must be priced 15% below the first generic on the market.<wbr> </LI>
<LI>The third generic entering the market must be priced 10% below the price of the second generic.<wbr> </LI>
<LI>Eventually, all prices are brought into line with the price of the third generic on the market, including the originator drug.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;">For the company securing the first market entry, prices will not be as low as for the other generics entering the market (at least for a certain period); this will help the company generate market shares and brand equity.<wbr> IHS Global Insight's pricing database, POLI, shows that prices of the first generic entering the market usually drop below the requirement.<wbr> For instance, the first generic of olanzapine has just entered the Austrian market (in April 2012), and it should be noted that: </div><div style="margin-bottom: 10px;"><UL type="disc"><LI>Only one generic company has entered the market so far.<wbr> </LI>
<LI>The price drop implemented is significantly larger compared with the minimum requested.<wbr> This will put new competitors in an extremely difficult position.<wbr> As such, it is likely that only a few generic companies will enter this market now.<wbr> Indeed, a small number of generic companies are usually on the market for each genericised molecule.<wbr> For instance, 12 generic companies compete for the molecule venlafaxine in Austria, while this figure reaches 34 in Germany.<wbr> </LI>
<LI>The price of the originator drug has not dropped yet, but it will over the next two months.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><TABLE class="table100"><TBODY><TR><TD align="middle" class="tableTitleBold" colspan="4" style="VERTICAL-ALIGN: top">
<P align="center" class="tableTitleBold"><B>Table 3: Olanzapine Generic and Off-Patent Price Cut, Austria</B></P></TD>
</TR>
<TR><TD align="middle" class="tableHeading" style="VERTICAL-ALIGN: top">
<P align="center" class="tableHeading"><B>Olanzapine15 mg, 28 Tablets</B></P></TD>
<TD align="middle" class="tableHeading" style="VERTICAL-ALIGN: top">
<P align="center" class="tableHeading"><B>Manufacturer Price Before Generic Market Entry (EUR)</B></P></TD>
<TD align="middle" class="tableHeading" style="VERTICAL-ALIGN: top">
<P align="center" class="tableHeading"><B>Manufacturer Price After Generic Market Entry (EUR)</B></P></TD>
<TD align="middle" class="tableHeading" style="VERTICAL-ALIGN: top">
<P align="center" class="tableHeading"><B>Price Cut (%)</B></P></TD>
</TR>
<TR><TD class="tableHeading" style="VERTICAL-ALIGN: top">
<P class="tableHeading"><B>Zyprexa</B></P></TD>
<TD align="right" class="tableContent" style="VERTICAL-ALIGN: top">
<P align="right" class="tableContent">163.<wbr>51</P></TD>
<TD align="right" class="tableContent" style="VERTICAL-ALIGN: top">
<P align="right" class="tableContent">163.<wbr>51</P></TD>
<TD align="right" class="tableContent" style="VERTICAL-ALIGN: top">
<P align="right" class="tableContent">0.<wbr>0</P></TD>
</TR>
<TR><TD class="tableHeading" style="VERTICAL-ALIGN: top">
<P class="tableHeading"><B>Olanzapine Bluefish</B></P></TD>
<TD align="right" class="tableContent" style="VERTICAL-ALIGN: top">
<P align="right" class="tableContent">-</P></TD>
<TD align="right" class="tableContent" style="VERTICAL-ALIGN: top">
<P align="right" class="tableContent">42.<wbr>99</P></TD>
<TD align="right" class="tableContent" style="VERTICAL-ALIGN: top">
<P align="right" class="tableContent">73.<wbr>7</P></TD>
</TR>
<TR><TD class="tableNotes" colspan="4" style="VERTICAL-ALIGN: top">
<P class="tableNotes">Source: POLI</P></TD>
</TR>
</TBODY>
</TABLE> </div><div style="margin-bottom: 10px;">In Hungary, the price drops requested also decrease over time, but price drops are linked to the price of the originator drug.<wbr> This means that even if being the first generic company to enter the market is a priority, the pricing strategy implemented by the company marketing the first generic will not be a significant barrier to market entry as is the case in Austria.<wbr> </div><div style="margin-bottom: 10px;">The rules that should apply in Hungary are: </div><div style="margin-bottom: 10px;"><UL type="disc"><LI>The first generic entering the market must be priced 35% below the originator drug.<wbr> </LI>
<LI>The second generic on the market must be priced 45% below the originator drug.<wbr> </LI>
<LI>The third and subsequent generics must be priced 55% below the originator drug.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;">In practice, as soon as a drug loses its patent, several generic companies enter the market during the same month and usually implement a different pricing strategy, which commonly triggers a price drop exceeding 35% but rarely reaching 50%.<wbr> </div><div style="margin-bottom: 10px;"><TABLE class="table100"><TBODY><TR><TD align="middle" class="tableTitleBold" colspan="4" style="VERTICAL-ALIGN: top">
<P align="center" class="tableTitleBold"><B>Table 4: Esomeprazole Generic and Off-Patent Price Cut, Hungary</B></P></TD>
</TR>
<TR><TD align="middle" class="tableHeading" style="VERTICAL-ALIGN: top">
<P align="center" class="tableHeading"><B>Esomeprazole 40 mg, 28 Tablets</B></P></TD>
<TD align="middle" class="tableHeading" style="VERTICAL-ALIGN: top">
<P align="center" class="tableHeading"><B>Manufacturer Price Before Generic Market Entry (HUF)</B></P></TD>
<TD align="middle" class="tableHeading" style="VERTICAL-ALIGN: top">
<P align="center" class="tableHeading"><B>Manufacturer Price After Generic Market Entry (HUF)</B></P></TD>
<TD align="middle" class="tableHeading" style="VERTICAL-ALIGN: top">
<P align="center" class="tableHeading"><B>Price Cut (%)</B></P></TD>
</TR>
<TR><TD class="tableHeading" style="VERTICAL-ALIGN: top">
<P class="tableHeading"><B>Nexium</B></P></TD>
<TD align="right" class="tableContent" style="VERTICAL-ALIGN: top">
<P align="right" class="tableContent">7,457</P></TD>
<TD align="right" class="tableContent" style="VERTICAL-ALIGN: top">
<P align="right" class="tableContent">7,457</P></TD>
<TD align="right" class="tableContent" style="VERTICAL-ALIGN: top">
<P align="right" class="tableContent">0.<wbr>0</P></TD>
</TR>
<TR><TD class="tableHeading" style="VERTICAL-ALIGN: top">
<P class="tableHeading"><B>Esomeprazole Sandoz (first generic)</B></P></TD>
<TD align="right" class="tableContent" style="VERTICAL-ALIGN: top">
<P align="right" class="tableContent">-</P></TD>
<TD align="right" class="tableContent" style="VERTICAL-ALIGN: top">
<P align="right" class="tableContent">4,077</P></TD>
<TD align="right" class="tableContent" style="VERTICAL-ALIGN: top">
<P align="right" class="tableContent">45.<wbr>3</P></TD>
</TR>
<TR><TD class="tableHeading" style="VERTICAL-ALIGN: top">
<P class="tableHeading"><B>Emozul (Krka; second generic)</B></P></TD>
<TD align="right" class="tableContent" style="VERTICAL-ALIGN: top">
<P align="right" class="tableContent">-</P></TD>
<TD align="right" class="tableContent" style="VERTICAL-ALIGN: top">
<P align="right" class="tableContent">3,297</P></TD>
<TD align="right" class="tableContent" style="VERTICAL-ALIGN: top">
<P align="right" class="tableContent">55.<wbr>8</P></TD>
</TR>
<TR><TD class="tableNotes" colspan="4" style="VERTICAL-ALIGN: top">
<P class="tableNotes">Source: POLI</P></TD>
</TR>
</TBODY>
</TABLE> </div><div style="margin-bottom: 10px;">Several case studies also demonstrate that pharmaceutical companies of the newly off-patent drug tend not to lower prices and then withdraw their products from the market.<wbr> This is the case for instance for Aprovel (irbesartan).<wbr> The first generics of irbesartan entered the Hungarian market in January 2011.<wbr> Three months later, prices of Aprovel dropped 10% (manufacturer prices), and the product was eventually withdrawn from the market in January 2012.<wbr> Sanofi (France) kept its generic version of Aprovel (Irbesartan Winthrop) only.<wbr> This is also the case for the example noted in the table above (esomeprazole).<wbr> Prices of Nexium dropped by 38.<wbr>5% only around one year after the first generics entered the market.<wbr> Another strategy used by pharmaceutical companies is to withdraw from the market all presentations of the originator drug but one.<wbr> This was observed for instance for two newly genericised active ingredients: montelukast and donepezil.<wbr> </div><div style="margin-bottom: 10px;"><TABLE class="table45R"><TBODY><TR><TD align="middle" class="tableTitleBold" colspan="2" style="VERTICAL-ALIGN: top">
<P align="center" class="tableTitleBold"><B>Table 5: Pramipexole Generic Competition</B></P></TD>
</TR>
<TR><TD align="middle" class="tableHeading" style="VERTICAL-ALIGN: top">
<P align="center" class="tableHeading"><B>Country</B></P></TD>
<TD align="middle" class="tableHeading" style="VERTICAL-ALIGN: top">
<P align="center" class="tableHeading"><B>Number of Generic Companies Competing for Pramipexole</B></P></TD>
</TR>
<TR><TD class="tableHeading" style="VERTICAL-ALIGN: top">
<P class="tableHeading"><B>Austria</B></P></TD>
<TD align="right" class="tableContent" style="VERTICAL-ALIGN: top">
<P align="right" class="tableContent">9</P></TD>
</TR>
<TR><TD class="tableHeading" style="VERTICAL-ALIGN: top">
<P class="tableHeading"><B>Hungary</B></P></TD>
<TD align="right" class="tableContent" style="VERTICAL-ALIGN: top">
<P align="right" class="tableContent">7</P></TD>
</TR>
<TR><TD class="tableHeading" style="VERTICAL-ALIGN: top">
<P class="tableHeading"><B>Germany</B></P></TD>
<TD align="right" class="tableContent" style="VERTICAL-ALIGN: top">
<P align="right" class="tableContent">39</P></TD>
</TR>
<TR><TD class="tableHeading" style="VERTICAL-ALIGN: top">
<P class="tableHeading"><B>France</B></P></TD>
<TD align="right" class="tableContent" style="VERTICAL-ALIGN: top">
<P align="right" class="tableContent">13</P></TD>
</TR>
<TR><TD class="tableHeading" style="VERTICAL-ALIGN: top">
<P class="tableHeading"><B>Italy</B></P></TD>
<TD align="right" class="tableContent" style="VERTICAL-ALIGN: top">
<P align="right" class="tableContent">14</P></TD>
</TR>
<TR><TD class="tableHeading" style="VERTICAL-ALIGN: top">
<P class="tableHeading"><B>Spain </B></P></TD>
<TD align="right" class="tableContent" style="VERTICAL-ALIGN: top">
<P align="right" class="tableContent">16</P></TD>
</TR>
<TR><TD class="tableNotes" colspan="2" style="VERTICAL-ALIGN: top">
<P class="tableNotes">Source: POLI, 2012</P></TD>
</TR>
</TBODY>
</TABLE> </div><div style="margin-bottom: 10px;">In countries where generic launch sequencing is taken into account for pricing, the number of competitors on the market tends to be lower in comparison with other pharmaceutical markets.<wbr> Indeed, pharmaceutical companies not able to secure their market entry among the first entrants face two main issues: low prices and low brand equity.<wbr> For instance, 39 generic companies compete for the active ingredient pramipexole in Germany, while this figure drops to 9 in Austria and 7 in Hungary.<wbr> </div><div style="margin-bottom: 10px;"><P class="bodyHeading3"><B>Free Pricing</B></P> </div><div style="margin-bottom: 10px;">Generic pricing is nevertheless free in a few countries—although prices are usually indirectly controlled at least with the setting of the maximum level of reimbursement—with prices mainly regulated by market forces.<wbr> This is the case in 4 out of the 24 countries studied: Denmark, Germany, Latvia, and the United Kingdom.<wbr> This method has proven to stimulate competition.<wbr> </div><div style="margin-bottom: 10px;">Germany is a typical example of a country using free pricing for generics.<wbr> Pharmaceutical companies are free to set their own prices, leading to fierce competition.<wbr> For instance, for the active ingredient pramipexole, for one identical presentation (0.<wbr>088 mg, 30 tablets), retail prices range from EUR12.<wbr>72 to EUR29.<wbr>42, with an average price of EUR16.<wbr>43 and 21 companies competing for this specific presentation.<wbr> This case is not isolated and is observed for all the drugs that are genericised.<wbr> </div><div style="margin-bottom: 10px;">The same trend is seen in Denmark, and generally speaking in countries where free pricing exists.<wbr> Pharmaceutical companies implement their own pricing strategies, which lead to a wide range of drug prices, and a large number of generic companies usually enter those pharmaceutical markets.<wbr> </div><div style="margin-bottom: 10px;">The UK is somewhat unique.<wbr> Despite the fact that generic pricing is free, generic companies are nevertheless not allowed to exceed the originator's prices.<wbr> With the Drug Tariff, the government sets the maximum level at which pharmacists will be reimbursed.<wbr> This tariff, however, is an approximation of the market price, which is set at a higher level in a bid to allow pharmacists to achieve a reasonable margin.<wbr> Nevertheless, this usually does not trigger a drop in listing prices.<wbr> POLI data shows that generic prices in the UK are often found to be among the highest in the top five European pharmaceutical markets.<wbr> This mainly lies in the fact that the UK government does not play a significant role in limiting drug prices and, unlike Germany, where maximum levels of reimbursement are set by the government as a basis for patients' reimbursement, maximum prices are used as a basis for pharmacists' reimbursement.<wbr> It should nevertheless be noted that prices are eventually lowered (below the Drug Tariff price) as pharmacists usually negotiate discounts, enabling them to increase their margins.<wbr> This policy does not allow the government to generate savings, as it does not have any impact on the Drug Tariff prices.<wbr> </div><div style="margin-bottom: 10px;"><P class="bodyHeading3"><B>Same Procedure As Innovative Drugs</B></P> </div><div style="margin-bottom: 10px;">A few countries use the same procedure for generic pricing as they do for innovative drugs.<wbr> These include Bulgaria, the Netherlands, Poland, and Sweden, most of which use international reference pricing.<wbr> </div><div style="margin-bottom: 10px;">This is not the case in Sweden, a country using cost effectiveness to set drug prices.<wbr> A price cut is usually required for the off-patent medicine, then generics entering the market must lower their price if they want to provide a cost advantage.<wbr> </div><div style="margin-bottom: 10px;">This methodology significantly lowers prices, notably when the lowest generic price for one molecule in a basket of countries abroad is taken into account.<wbr> Nevertheless, this procedure is more time consuming in comparison with a simple price cut.<wbr> As a consequence, generic market entry in those countries is often delayed.<wbr> </div><div style="margin-bottom: 10px;"><P class="bodyHeading2"><B>Reimbursement Policies: a Tool Used Indirectly to Limit Drug Prices</B></P> </div><div style="margin-bottom: 10px;">Governments have implemented two different policies in order to lower prices indirectly and limit pharmaceutical expenditure.<wbr> </div><div style="margin-bottom: 10px;"><P class="bodyHeading3"><B>Maximum Levels of Reimbursement</B></P> </div><div style="margin-bottom: 10px;">One of the most common ways, used by a great number of governments, and notably in countries where generic companies can freely set drug prices, is to cap the maximum level of reimbursement.<wbr> Around 60% of the countries studied use this tool as a cost-containment policy (14 countries).<wbr> Companies keeping prices above the reference price are likely to lose market shares as patients in this case must bear the cost of the difference between the maximum level at which the drug will be funded and the price of the drug.<wbr> </div><div style="margin-bottom: 10px;">Governments use different ways to set those maximum levels of reimbursement.<wbr> In some, the lowest generic price in the country will be used as a reference, while in others it will be an average of the product prices on the market or even an average of the product prices in a basket of reference countries.<wbr> Prices of drugs significantly drop in countries using this cost-containment policy.<wbr> </div><div style="margin-bottom: 10px;">Nevertheless, table 6 demonstrates that even when governments set maximum levels of reimbursement, strategies employed by pharmaceutical companies can differ.<wbr> In Italy, companies will tend to bring their prices into line with the reference price.<wbr> Even if generics are priced below that level, the average price difference is only EUR6.<wbr>62.<wbr> </div><div style="margin-bottom: 10px;"><TABLE class="table65R"><TBODY><TR><TD align="middle" class="tableTitleBold" colspan="3" style="VERTICAL-ALIGN: top">
<P align="center" class="tableTitleBold"><B>Table 6: Impact of Reference Pricing on Drug Prices in Italy and Germany</B></P></TD>
</TR>
<TR><TD class="tableHeading" style="VERTICAL-ALIGN: top">&nbsp;</TD>
<TD align="middle" class="tableHeading" style="VERTICAL-ALIGN: top">
<P align="center" class="tableHeading"><B>Italy</B></P></TD>
<TD align="middle" class="tableHeading" style="VERTICAL-ALIGN: top">
<P align="center" class="tableHeading"><B>Germany</B></P></TD>
</TR>
<TR><TD class="tableHeading" style="VERTICAL-ALIGN: top">
<P class="tableHeading"><B>Generic Pricing Policy</B></P></TD>
<TD class="tableContent" style="VERTICAL-ALIGN: top">
<P class="tableContent">Price Cut</P></TD>
<TD class="tableContent" style="VERTICAL-ALIGN: top">
<P class="tableContent">Free pricing</P></TD>
</TR>
<TR><TD class="tableHeading" style="VERTICAL-ALIGN: top">
<P class="tableHeading"><B>Prices Above Reference Price (%)</B></P></TD>
<TD align="right" class="tableContent" style="VERTICAL-ALIGN: top">
<P align="right" class="tableContent">44<BR>(average price difference above EUR6.<wbr>62)</P></TD>
<TD align="right" class="tableContent" style="VERTICAL-ALIGN: top">
<P align="right" class="tableContent">12<BR>(average price difference above EUR20.<wbr>52)</P></TD>
</TR>
<TR><TD class="tableHeading" style="VERTICAL-ALIGN: top">
<P class="tableHeading"><B>Prices Equal to Reference Price (%)</B></P></TD>
<TD align="right" class="tableContent" style="VERTICAL-ALIGN: top">
<P align="right" class="tableContent">56</P></TD>
<TD align="right" class="tableContent" style="VERTICAL-ALIGN: top">
<P align="right" class="tableContent">24</P></TD>
</TR>
<TR><TD class="tableHeading" style="VERTICAL-ALIGN: top">
<P class="tableHeading"><B>Prices Below Reference Price (%)</B></P></TD>
<TD align="right" class="tableContent" style="VERTICAL-ALIGN: top">
<P align="right" class="tableContent">0</P></TD>
<TD align="right" class="tableContent" style="VERTICAL-ALIGN: top">
<P align="right" class="tableContent">64<BR>(average price difference below EUR7.<wbr>98)</P></TD>
</TR>
<TR><TD class="tableHeading" style="VERTICAL-ALIGN: top">
<P class="tableHeading"><B>Number of Presentations</B></P></TD>
<TD align="right" class="tableContent" style="VERTICAL-ALIGN: top">
<P align="right" class="tableContent">4,710</P></TD>
<TD align="right" class="tableContent" style="VERTICAL-ALIGN: top">
<P align="right" class="tableContent">32,336</P></TD>
</TR>
<TR><TD class="tableHeading" style="VERTICAL-ALIGN: top">
<P class="tableHeading"><B>Number of Active Ingredients</B></P></TD>
<TD align="right" class="tableContent" style="VERTICAL-ALIGN: top">
<P align="right" class="tableContent">122</P></TD>
<TD align="right" class="tableContent" style="VERTICAL-ALIGN: top">
<P align="right" class="tableContent">261</P></TD>
</TR>
<TR><TD class="tableNotes" colspan="3" style="VERTICAL-ALIGN: top">
<P class="tableNotes">Sources: POLI, 2012</P></TD>
</TR>
</TBODY>
</TABLE> </div><div style="margin-bottom: 10px;">In Germany, with free pricing, competition is fierce, notably as a large number of pharmaceutical companies always compete for each genericised active ingredient.<wbr> In order to incentivise pharmaceutical companies to lower prices, Germany has implemented a policy that cancels patients' co-payments for drugs priced at least 30% below the reference price.<wbr> As demonstrated by an analysis of the prices and reference prices of drugs—for which the maximum level of reimbursement is set—this policy does not seem to stimulate pharmaceutical companies to lower prices significantly.<wbr> Indeed, only 8% of the presentations for which a level of reimbursement is set are priced at least 30% below the reference price.<wbr> </div><div style="margin-bottom: 10px;">Reference prices are also set in France, although maximum levels of reimbursement are set for certain molecules only, when generic market share does not reach a certain level.<wbr> Maximum levels of reimbursement are called TFR in France.<wbr> When drugs are included in a TFR, prices drop significantly.<wbr> </div><div style="margin-bottom: 10px;">In this case, the majority of pharmaceutical companies simply bring their prices in line with the maximum level of reimbursement.<wbr> On a basket of 5,006 presentations for which the level of reimbursement is set by the French government, representing 119 active ingredients, prices were brought into line with the reference price for 75% of them (source: POLI).<wbr> Prices were set at a higher level for 21% of them, including off-patent drugs and generics, and prices were set below the reference price for only 3% of the presentations.<wbr> </div><div style="margin-bottom: 10px;"><P class="bodyHeading3"><B>Market Exclusivity for Cheapest Generics</B></P> </div><div style="margin-bottom: 10px;">This policy has been implemented in a few countries: Sweden, the Netherlands, and Germany.<wbr> It basically consists of granting a period of exclusivity to pharmaceutical companies providing the cheapest generic alternatives.<wbr> </div><div style="margin-bottom: 10px;">In Sweden, since 2002, it has been mandatory for pharmacists to provide patients with the cheapest alternative that month for each genericised active ingredient.<wbr> Recently, pharmacists have also been allowed to substitute the second or third cheapest generic alternatives.<wbr> Each month, the Dental and Pharmaceutical Benefits Agency (TLV) publishes a list of the cheapest alternatives on the market with the specific mention of the cheapest one, as well as the two other options for substitution.<wbr> </div><div style="margin-bottom: 10px;">A survey carried out by the TLV in 2006 already demonstrated that following the implementation of the substitution policy, drug prices have fallen 15%.<wbr> It was reported that for certain genericised active ingredients—statins, for example—prices fell 70%.<wbr> Even if this policy encourages competition, and as such lower prices, it nevertheless triggers stock issues because each month, and for each genericised active ingredient, the cheapest alternative might change.<wbr> This is the reason the government has now enlarged the substitution to the second or third alternative, in case the first one is not available in the pharmacy.<wbr> </div><div style="margin-bottom: 10px;">In the Netherlands, since 2007, most insurers have introduced what is called the preference policy, with varying specificities.<wbr> Some insurers launch a call for tenders and will reimburse their insurees for the product winning the bid, while some others do not use tendering but will reimburse the product with the lowest selling price, with other insurers leaving it to the pharmacists to provide this product or give another one.<wbr> Preference policies, unlike in Sweden, are usually valid for several years, preventing pharmacists from issues linked to stock management.<wbr> </div><div style="margin-bottom: 10px;">Some insurers—usually small ones—do not use the preference policy in a bid to attract people as they will have the possibility to choose the drugs they want.<wbr> </div><div style="margin-bottom: 10px;">Achmea, the largest insurer in the Netherlands, has also launched what is called the Integrated Efficiency Contract of Excellence for Pharmacists (IDEA) model.<wbr> Pharmacists can choose this policy, and in this case they are free to choose which drug to provide patients with and will receive a fixed reimbursement tariff per package, regardless of the brand provided.<wbr> It has been reported that most pharmacists having contracts with Achmea choose the IDEA model.<wbr> Indeed, this model encourages pharmacists to negotiate discounts strongly in a bid to increase their margin.<wbr> </div><div style="margin-bottom: 10px;">In Germany, since April 2007, each individual healthcare fund (the GKV, an umbrella term for approximately 170 individually run health funds) is legally bound to launch calls for tenders for each genericised active ingredient.<wbr> The company winning the bid will enter into an agreement with the GKV fund.<wbr> As such, for each GKV fund patients are enrolled to, pharmacists have to supply the drug from the company that won the bid.<wbr> Despite the fact that this policy also enables a significant lowering of prices, it also leads to significant stock-management issues, with pharmacists having to stock the different brands that are in agreement with the different GKV funds for each active ingredient.<wbr> </div><div style="margin-bottom: 10px;"><P class="bodyHeading2"><B>Outlook and Implications</B></P> </div><div style="margin-bottom: 10px;">As seen with the different policies mentioned in the report, governments rarely use one cost-containment policy in order to lower drug prices once generics enter the market.<wbr> Governments commonly use a combination of at least two policies, often requiring prices to decrease by a certain percentage and setting the maximum level at which patients will be reimbursed.<wbr> </div><div style="margin-bottom: 10px;">Using pricing procedures differing from the ones used for innovative drugs enables governments to speed up generic market access.<wbr> </div><div style="margin-bottom: 10px;">In order to implement their pricing strategy, generic companies must take the following criteria into account in each country: </div><div style="margin-bottom: 10px;"><UL type="disc"><LI>What are the pricing procedures in each country and how will they affect the prices of the originator drug and generics? </LI>
<LI>Are maximum levels of reimbursement used as a way to lower prices and what are the strategies commonly used by the different operators on the market? </LI>
<LI>What are the discounts that can be granted and is the country using an exclusivity period policy?</LI>
</UL> </div><div style="margin-bottom: 10px;">Those three elements are crucial to determine which pricing strategy to adopt in each pharmaceutical market.<wbr> For instance, in Austria and Hungary, pharmaceutical companies must ensure to file their dossier for pricing and reimbursement as quickly as possible, because being one of the first generic companies to enter the market is a determinant factor.<wbr> If not, generic companies usually do not attempt to enter those pharmaceutical markets.<wbr> </div><div style="margin-bottom: 10px;">There are also countries where pricing strategy does not leave room for manoeuvre for pharmaceutical companies' pricing strategies.<wbr> This is the case in France, for instance, where the rule set by law must be implemented strictly and pharmaceutical companies cannot deviate from it.<wbr> Prices of the different competitors for one active ingredient are brought into line.<wbr> Still the number of generics competing for each genericised molecule is not limited, demonstrating that pharmaceutical companies have found other ways to compete.<wbr> It is indeed well known that in France, large discounts are usually provided for generics (although the Chatel law limits those discounts to 17%), enabling competition.<wbr> </div><div style="margin-bottom: 10px;">Nevertheless, most countries use a price cuts of a certain percentage, leaving more room for pricing strategies.<wbr> In those countries, the number of competitors on the market is usually large and price competition fierce.<wbr> </div><div style="margin-bottom: 10px;">Setting the maximum level at which patients are reimbursed is also largely used by governments.<wbr> Although this policy allows the significant lowering of prices, the strategy used by pharmaceutical companies will differ on a country basis.<wbr> For instance, in Germany, generic companies usually lower their prices below the reference price, while in Italy, most pharmaceutical companies will bring their prices into line with the reference price or above it, but will rarely go below this level.<wbr> </div><div style="margin-bottom: 10px;">Finally, the exclusivity period used as a cost-containment tool by three countries is a method that seems to be effective in lowering prices.<wbr> In exchange for the lowest possible prices, a given pharmaceutical company will be given exclusivity and its generic must be given to patients, ensuring drug uptake.<wbr> Sweden was the first country to implement this policy, followed by the Netherlands and Germany.<wbr> Despite the fact that this method usually triggers stock-management issues, other countries might be willing to implement it as a means to lower prices further.<wbr> </div><div style="margin-bottom: 10px;">Full report in PDF format <a href="http://ci.beaufour-ipsen.com/traction?type=np&proj=*&sdate=20120831&edate=20120501&rs=/link%20PharmaWorld9895%401" class="defaultlink">@1</a> </div><div>Source: Global Insight </div><!-- Comment details --><a name="pharmaworld9894attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/9894/1/Generic%20Prices%20in%20EU%5fGlobalInsight20120601.pdf">Generic Prices in EU_GlobalInsight20120601.pdf</a>&nbsp;&nbsp;(146,6 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120831&edate=20120501&rec=9894">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-06-01T10:53:38+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/9894/1/Generic%20Prices%20in%20EU%5fGlobalInsight20120601.pdf" length="150151" type="application/pdf"/></item><item>
<title>re: Update on the Exelixis' Overall Survival Trial with Cabozantinib for mCRPC</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology8302</link>
<description>re: Update on the Exelixis' Overall Survival Trial with Cabozantinib for mCRPC</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology8302</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8302">re: Update on the Exelixis' Overall Survival Trial with Cabozantinib for mCRPC</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8302">Oncology8302</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 31 May 2012 | 12:53</font><br><br><div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Update on the Exelixis' Overall Survival Trial with Cabozantinib for mCRPC</span>&nbsp;<font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=mkt%3aNorthAmerica"><font color="#e95e0b">:PharmaWorld:mkt:NorthAmerica</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=sub%3aClinicalTrial"><font color="#e95e0b">:PharmaWorld:sub:ClinicalTrial</font></a>]</font></font><br><span style="font-size: 12px;">Comment: Clinicaltrials.<wbr>gov is listing the COMET-1 trial which will be conducted in the U.<wbr>S to assess the effect of cabozantinib compared to prednisone on OS in men with previously treated mCRPC with bone-dominant disease who have experienced disease progression on docetaxel-containing chemotherapy and abiraterone or MDV3100.<wbr> The company is intending to go out to a large number of sites (&gt;250) in EU and Asia Pacific.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8296">...</a><br><font size="-1">Brigitte DESCHAMPS / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8296" class="commentpermalink">Oncology8296</a> / <span class="date">25 May 2012</span> /
<span class="time">16:27:21 o'clock CEST</span>
</font></div><div><SPAN style="widows: 2; text-transform: none; text-indent: 0px; display: inline !important; font: 13px arial, sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #222222; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">Exelixis has announced the completed submission of a rolling NDA to the FDA for cabozantinib to treat medullary thyroid cancer, its lead indication.<wbr> The company has requested a Priority Review.<wbr> </SPAN><SPAN style="widows: 2; text-transform: none; text-indent: 0px; display: inline !important; font: 13px arial, sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #222222; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">Exelixis, began the submission of the NDA in December.<wbr></SPAN> </div><!-- Comment details --><font size="-1">Jacquelyne CANTLE MEYRICK / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8302" class="commentpermalink">Oncology8302</a> / <span class="date">31 May 2012</span> /
<span class="time">12:53:58 o'clock CEST</span>
</font><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8302">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8296">View thread  Oncology8296: Update on the Exelixis' Overall Survival Trial with Cabozantinib for mCRPC</a>]]></content:encoded><dc:date>2012-05-31T12:53:58+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>Medivation and Astellas Sponsor Expanded Access Program for Enzalutamide (MDV-3100) in the U.S [dis:Prostate, prod:MDV3100, :PharmaWorld:mkt:NorthAmerica, comp:Astellas]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology8300</link>
<description>Medivation and Astellas Sponsor Expanded Access Program for Enzalutamide (MDV-3100) in the U.S [dis:Prostate, prod:MDV3100, :PharmaWorld:mkt:NorthAmerica, comp:Astellas]</description><category>dis:Prostate</category><category>prod:MDV3100</category><category>mkt:NorthAmerica</category><category>comp:Astellas</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology8300</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8300">Medivation and Astellas Sponsor Expanded Access Program for Enzalutamide (MDV-3100) in the U.<wbr>S</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=comp%3aAstellas"><font color="#e95e0b">:Oncology:comp:Astellas</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=prod%3aMDV3100"><font color="#e95e0b">:Oncology:prod:MDV3100</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=mkt%3aNorthAmerica"><font color="#e95e0b">:PharmaWorld:mkt:NorthAmerica</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8300">Oncology8300</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 30 May 2012 | 15:19</font><br><br><div style="margin-bottom: 10px;">Comment: The expanded access treatment protocol is being conducted while marketing approval of the drug is being sought.<wbr> The companies announced the NDA submission on May 21, 2012.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">EAP Status - <A href="http://www.clinicaltrials.gov/ct2/show/NCT01606982?term=medivation&amp;recr=Open&amp;rank=6">NCT01606982</A></FONT></STRONG> </div><div style="margin-bottom: 10px;">Recruitment: ongoing for men with mCRPC previously treated with docetaxel (no age requirement) </div><div style="margin-bottom: 10px;">Particpating Sites: approx.<wbr> 75 centers in the U.<wbr>S.<wbr> </div><div>Timing: The study will end if the drug is approved for sale to the public by the country's health authority (commercially available) or if the sponsor otherwise decides or is required to end the study.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8300">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-05-30T15:19:04+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Sun Pharm. Appoints Teva Former CEO as Chairman of the Board [:Oncology:sub:Hybrids, :Endocrinology:prod:Octreotide, sub:People, :DKPHybrids:news]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld9890</link>
<description>Sun Pharm. Appoints Teva Former CEO as Chairman of the Board [:Oncology:sub:Hybrids, :Endocrinology:prod:Octreotide, sub:People, :DKPHybrids:news]</description><category>sub:Hybrids</category><category>prod:Octreotide</category><category>sub:People</category><category>news</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld9890</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120831&edate=20120501&rec=9890">Sun Pharm.<wbr> Appoints Teva Former CEO as Chairman of the Board</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=DKPHybrids&sdate=20120831&edate=20120501&cat=news"><font color="#e95e0b">:DKPHybrids:news</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=prod%3aOctreotide"><font color="#e95e0b">:Endocrinology:prod:Octreotide</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=sub%3aHybrids"><font color="#e95e0b">:Oncology:sub:Hybrids</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=sub%3aPeople"><font color="#e95e0b">:PharmaWorld:sub:People</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld9890">PharmaWorld9890</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 30 May 2012 | 12:18</font><br><br><div style="margin-bottom: 10px;">Comment: The company has announced the appointment of Israel Markov, who was instrumental in transforming Teva.<wbr> We see this move as strategic of Sun's aspirations to transform into a global generic company, and to accelerate the integration of Taro (acquired in 2010).<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Highlights of Mr Markov's Profile</FONT></STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>- joined Teva in 1995 and led the company’s global expansion, managing over 12 acquisitions.<wbr></LI>
<LI>- under Mr Makov’s leadership, Teva became the global leader in generic pharmaceutical industry and a global leader for MS.<wbr></LI>
<LI>- holds a B.<wbr>Sc.<wbr> in Agriculture and M.<wbr> Sc in Economics from the Hebrew University, Jerusalem.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Recent Strategic Agreement with Merck</FONT></STRONG> </div><div style="margin-bottom: 10px;">In 2011, Sun Pharma and Merck announced the creation of Sun-MSD JV to develop, manufacture and commercialize new combinations and formulations of branded generics for the emerging markets (Please see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120831&edate=20120501&rec=9261" class="defaultlink">PharmaWorld9261: Sun Pharma & Merck Form Partnership To Target Emerging Markets</a>).<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/9890/3/ScreenCapture3.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Sun Pharma's Strategy</FONT></STRONG> </div><div><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/9890/2/ScreenCapture2.jpg?user-agent=rss"> </div><!-- Comment details --><a name="pharmaworld9890attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/9890/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(57,2 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/9890/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(33,9 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/9890/3/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(17,7 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120831&edate=20120501&rec=9890">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-05-30T12:18:23+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/9890/1/ScreenCapture1.jpg" length="58533" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/9890/2/ScreenCapture2.jpg" length="34679" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/9890/3/ScreenCapture3.jpg" length="18078" type="image/jpeg"/></item><item>
<title>Update Status of Repros' Proellex(R) for Endometriosis and Uterine Fibroids (UF) [:Oncology:dis:Gynea]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology6948</link>
<description>Update Status of Repros' Proellex(R) for Endometriosis and Uterine Fibroids (UF) [:Oncology:dis:Gynea]</description><category>dis:Gynea</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology6948</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120831&edate=20120501&rec=6948">Update Status of Repros' Proellex(R) for Endometriosis and Uterine Fibroids (UF)</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=dis%3aGynea"><font color="#e95e0b">:Oncology:dis:Gynea</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology6948">Endocrinology6948</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 30 May 2012 | 09:51</font><br><br><div style="margin-bottom: 10px;">Comment: FDA has requested an integrated safety analysis of completed studies of the oral anti-progestin prior to commence any additional trials.<wbr> Repros plans to submit this document over the next few weeks, and expects to start Ph2/<wbr>3 for endometriosis if allowed by the U.<wbr>S agency.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Updates Status - Uterine Fibroids</FONT></STRONG> </div><div style="margin-bottom: 10px;"><STRONG>Proellex(R)-V (vaginal delivery formulation) in Ph2</STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>- Studied under a separate IND and not affected by the oral program.<wbr></LI>
<LI>- Enrollment of the ZPV-200 trial is nearing completion (planned for end of June).<wbr></LI>
<LI>- Subjects who complete the ZPV-200 study will be recruited into a one year open label safety trial in order to begin to build toward NDA safety.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG>Proellex(R) (oral formulation) in Ph2</STRONG> </div><div><UL><LI id="yui_3_4_0_1_1338362979376_348">Repros expects to complete and report the Ph2 results in Q4 2012.<wbr></LI>
</UL> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120831&edate=20120501&rec=6948">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-05-30T09:51:31+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>WCNR Intelligence Part 2- Key Spasticity Data [class:BotulinumToxins, comp:Merz, comp:Allergan, dis:Spasticity, headline, :PharmaWorld:congress:WCNR, :PharmaWorld:mkt:Australia, :PharmaWorld:mkt:Intercontinental, prod:Xeomin, prod:Botox]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology6432</link>
<description>WCNR Intelligence Part 2- Key Spasticity Data [class:BotulinumToxins, comp:Merz, comp:Allergan, dis:Spasticity, headline, :PharmaWorld:congress:WCNR, :PharmaWorld:mkt:Australia, :PharmaWorld:mkt:Intercontinental, prod:Xeomin, prod:Botox]</description><category>class:BotulinumToxins</category><category>comp:Merz</category><category>comp:Allergan</category><category>dis:Spasticity</category><category>headline</category><category>congress:WCNR</category><category>mkt:Australia</category><category>mkt:Intercontinental</category><category>prod:Xeomin</category><category>prod:Botox</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology6432</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120831&edate=20120501&rec=6432">WCNR Intelligence Part 2- Key Spasticity Data</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=class%3aBotulinumToxins"><font color="#e95e0b">:Neurology:class:BotulinumToxins</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=comp%3aAllergan"><font color="#e95e0b">:Neurology:comp:Allergan</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=comp%3aMerz"><font color="#e95e0b">:Neurology:comp:Merz</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=dis%3aSpasticity"><font color="#e95e0b">:Neurology:dis:Spasticity</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=headline"><font color="#e95e0b">:Neurology:headline</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=prod%3aBotox"><font color="#e95e0b">:Neurology:prod:Botox</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=prod%3aXeomin"><font color="#e95e0b">:Neurology:prod:Xeomin</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=congress%3aWCNR"><font color="#e95e0b">:PharmaWorld:congress:WCNR</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=mkt%3aAustralia"><font color="#e95e0b">:PharmaWorld:mkt:Australia</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=mkt%3aIntercontinental"><font color="#e95e0b">:PharmaWorld:mkt:Intercontinental</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology6432">Neurology6432</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 29 May 2012 | 18:25</font><br><br><div style="margin-bottom: 10px;">Comment:<STRONG> </STRONG>No new large competitor studies were presented at the WCNR - but two interesting Allergan sponsored spasticity trials were presensented by Theodore Wein (Montreal) who is a member of the Global Stroke Community Advisory Panel and George Sandrini (Italy) presented a study in PD patients with Xeomin.<wbr> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 11pt; FONT-FAMILY: 'Arial','sans-serif'"><FONT face="Verdana" size="2">Thanks to Beth Elliott (CI Dept) who was in attendance at the meeting we have the following report.<wbr></FONT></SPAN> </div><div style="margin-bottom: 10px;"><STRONG><FONT face="Verdana"><FONT size="3"><SPAN lang="EN-US" style="FONT-SIZE: 11pt; FONT-FAMILY: 'Arial','sans-serif'">Soft Intelligence On Merz's Activities</SPAN> </FONT></FONT></STRONG> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 11pt; FONT-FAMILY: 'Arial','sans-serif'"><FONT face="Verdana" size="2">Although Merz was not present, The Medical Affairs Director at Allergan stated that Merz would have a difficult time to gain market share in Australia due to the incumbents (doctors use what they know) and their best guess is that resource will more than likely be pointed towards larger markets.<wbr> He continued by outlining <EM style="mso-bidi-font-style: normal">“we really do not know what they are doing, it is a question of when or if (Merz even launches in Australia) but we have not seen or heard any signals to say they are coming on the market in the near term…that is not to say they are not coming but they had approval in Canada for years but they only launched about 18 months ago…so its anyone’s guess what they are doing”.<wbr></EM> The Medical Affairs Director detailed their tainted reputation in the USA and hoped that if they do enter the Australian market, that this will be a black mark against them.<wbr> </FONT></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 11pt; FONT-FAMILY: 'Arial','sans-serif'"><STRONG><FONT face="Verdana" size="3">Comorbidity profile of spasticity within a cohort of post-stroke survivors</FONT></STRONG></SPAN> </div><div style="margin-bottom: 10px;"><STRONG style="mso-bidi-font-weight: normal"><SPAN lang="EN-US" style="FONT-SIZE: 11pt; FONT-FAMILY: 'Arial','sans-serif'">Dr.<wbr>Theodore Wein - McGill University, Montreal, Canada</SPAN></STRONG> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 11pt; FONT-FAMILY: 'Arial','sans-serif'"><FONT face="Verdana" size="2">The objective of this Allergan sponsored talk was to identify differences in baseline comorbidity profiles between individuals with and without post stroke spasticity (PSS) within a stroke cohort.<wbr> Until this study, this type of data had never been reported.<wbr></FONT></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 11pt; FONT-FAMILY: 'Arial','sans-serif'"><FONT face="Verdana" size="2">Demographic data revealed that PSS patients were younger, more likely to be non-Caucasian, and had higher NIHSS.<wbr></FONT></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 11pt; FONT-FAMILY: 'Arial','sans-serif'"><FONT face="Verdana" size="2">Comorbidities identified with PSS are useful in identifying patients at risk for spasticity development and hopefully, will help with the development of preventative measures to reduce overall burden.<wbr></FONT></SPAN> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/6432/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/6432/2/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 11pt; FONT-FAMILY: 'Arial','sans-serif'; mso-fareast-font-family: 'MS Mincho'; mso-fareast-theme-font: minor-fareast; mso-ansi-language: EN-US; mso-fareast-language: JA; mso-bidi-language: AR-SA"><FONT face="Verdana" size="2">Logistic regression used to compare groups for history of stroke and prestroke Rankin <U>&gt; </U>2 adjusted for age, race and gender.<wbr> A generalized linear model was used to compare groups for estimated NIHSS adjusted for age, race and gender.<wbr></FONT></SPAN> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/6432/3/ScreenCapture3.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 11pt; FONT-FAMILY: 'Arial','sans-serif'"><FONT face="Verdana" size="2">Prevalence and incidence of PSS were of similar magnitudes as had been previously reported in the literature.<wbr></FONT></SPAN> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/6432/4/ScreenCapture4.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 11pt; FONT-FAMILY: 'Arial','sans-serif'"><FONT face="Verdana" size="2">Notable demographic data highlighted in yellow.<wbr></FONT></SPAN> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/6432/5/ScreenCapture5.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><FONT face="Verdana"><FONT size="2"><SPAN lang="EN-US" style="FONT-SIZE: 11pt; FONT-FAMILY: 'Arial','sans-serif'">The data showed comorbidities in individuals with a prior history of </SPAN><EM><SPAN lang="EN-US" style="FONT-SIZE: 11pt; FONT-FAMILY: 'Arial','sans-serif'; mso-fareast-font-family: 'Times New Roman'">transient ischemic attack (</SPAN></EM><SPAN lang="EN-US" style="FONT-SIZE: 11pt; FONT-FAMILY: 'Arial','sans-serif'">TIA) as well as hypertension, carotid artery disease and depression.<wbr> There was a trend in diabetes that did not meet significance.<wbr></SPAN></FONT></FONT> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/6432/6/ScreenCapture7.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 11pt; FONT-FAMILY: 'Arial','sans-serif'"><FONT face="Verdana" size="2">Using logistic regression to adjust for age, race and gender individuals with a prior history of TIA had a three-fold increase in prevalence.<wbr> For hypertension it was a doubling and for individuals with carotid artery disease it was a surprising 4.<wbr>5 increase in PPS prevalence.<wbr> There was a trend in depression that did not meet significance.<wbr></FONT></SPAN> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/6432/7/ScreenCapture8.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/6432/8/ScreenCapture9.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 11pt; FONT-FAMILY: 'Arial','sans-serif'"><FONT face="Verdana" size="2">At the Q&amp;A, several questions centred on the use of measurement scales (including pain) and Dr Wein repeated that the study was based on patient reported PSS and medical record examination.<wbr> </FONT></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 11pt; FONT-FAMILY: 'Arial','sans-serif'"><FONT face="Verdana" size="2">A member of the audience then asked about NIHSS score being correlated with PSS prevalence.<wbr> Although in the unadjusted results there was a link between NIHSS score and PSS, it was not statistically significant when the population was adjusted for age, race and gender.<wbr></FONT></SPAN> </div><div style="margin-bottom: 10px;"><STRONG style="mso-bidi-font-weight: normal"><SPAN lang="EN-US" style="FONT-SIZE: 11pt; FONT-FAMILY: 'Arial','sans-serif'"><FONT face="Verdana" size="2">Resource utilization by patients with adult focal spasticity (AFS) and cerebral palsy (CP) receiving botulinum toxin type A (Botox) in a prospective observational cohort study: MOBILITY STUDY, Dr.<wbr>Theodore Wein- McGill University, Montreal, Canada</FONT></SPAN></STRONG> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 11pt; FONT-FAMILY: 'Arial','sans-serif'"><FONT face="Verdana" size="2"><U>Summary </U></FONT></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 11pt; FONT-FAMILY: 'Arial','sans-serif'"><FONT face="Verdana" size="2">This prospective observational cohort study initiated in 2007 with the aim of completion end 2013.<wbr></FONT></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 11pt; FONT-FAMILY: 'Arial','sans-serif'"><FONT face="Verdana" size="2">In addition to the SF-6D general health questionnaire data that was collected included dosing and subsequent change in dose, dilution, modes of injection and all concomitant medications.<wbr> Other types of services were also recorded including physiotherapy, occupational therapy, speech therapy, nursing services, hospital readmissions, surgery, type of surgery as well as total number of hours of services and duration of a specific service.<wbr></FONT></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 11pt; FONT-FAMILY: 'Arial','sans-serif'"><FONT face="Verdana" size="2">Dr Wein verbally concluded that there are a significant percentage of the AFS and CP patient population being prescribed Botox that are being underserved by rehabilitation support services in Canada.<wbr></FONT></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 11pt; FONT-FAMILY: 'Arial','sans-serif'"><FONT face="Verdana" size="2">The study’s overall goal was to obtain an overview of the rehabilitation services used by individuals with APS and CP reported by the patient themselves.<wbr> Fifty percent of the patients followed in the study were from an academic setting and 50% from general practice with 50%.<wbr> The study cohort was also divided 50/<wbr>50 from those receiving on going Botox treatment and those that were receiving Botox for the first time.<wbr></FONT></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 11pt; FONT-FAMILY: 'Arial','sans-serif'"><FONT face="Verdana" size="2">The analysis of the services used was within the context of a patient either receiving or being initiated on Botox.<wbr> A series of secondary objectives relating to patient reported outcomes of Botox therapy were integral to the study.<wbr> Given that Allergan have been sponsoring this study since its initiation in 2007, a cynics view could be that that the secondary objectives are the principal focus of the study and the primary objective provides a rationale for prescribing Botox in a highly cost constrained environment.<wbr> </FONT></SPAN> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/6432/9/ScreenCapture10.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 11pt; FONT-FAMILY: 'Arial','sans-serif'"><FONT face="Verdana" size="2">Upon enrollment patients were asked to complete a SF-6D questionnaire a widely used general measure of health status, given Botox treatment and the questionnaire being completed on each subsequent follow-up visit.<wbr></FONT></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 11pt; FONT-FAMILY: 'Arial','sans-serif'"><FONT face="Verdana" size="2">Additional data that was collected included dosing and subsequent change in dose, dilution, modes of injection and all concomitant medications.<wbr> Other types of services were also recorded including physiotherapy, occupational therapy, speech therapy, nursing services, hospital readmissions, surgery, type of surgery as well as total number of hours of services and duration of a specific service.<wbr> </FONT></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 11pt; FONT-FAMILY: 'Arial','sans-serif'"><FONT face="Verdana" size="2">At the request of Quebec Ministry of Health an interim analysis of the results was requested to help contribute to discussion on the provinces strategic plan for long term rehabilitation and social integration of patients with AFS and CPS.<wbr> </FONT></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 11pt; FONT-FAMILY: 'Arial','sans-serif'"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/6432/10/ScreenCapture11.jpg?user-agent=rss"> </SPAN> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/6432/11/ScreenCapture12.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 11pt; FONT-FAMILY: 'Arial','sans-serif'"><FONT face="Verdana" size="2">Only 50% of patients receive rehabilitation services.<wbr> Dr Wein expressed concern that only a quarter of patients (his words) were receiving physiotherapy at any specific juncture.<wbr> </FONT></SPAN> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/6432/12/ScreenCapture13.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 11pt; FONT-FAMILY: 'Arial','sans-serif'"><FONT face="Verdana" size="2">Of the 11% of patients who had surgery &lt; 5% of the surgery was to treat spasticity.<wbr> Baclofen was the most commonly prescribed concomitant medication.<wbr></FONT></SPAN> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/6432/13/ScreenCapture14.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 11pt; FONT-FAMILY: 'Arial','sans-serif'; mso-fareast-font-family: 'MS Mincho'; mso-fareast-theme-font: minor-fareast; mso-ansi-language: EN-US; mso-fareast-language: JA; mso-bidi-language: AR-SA"><FONT face="Verdana" size="2">Of the 55% of CP patients receiving surgery virtually all procedures were spasticity related.<wbr></FONT></SPAN> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/6432/14/ScreenCapture15.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/6432/15/ScreenCapture16.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 11pt; FONT-FAMILY: 'Arial','sans-serif'"><FONT face="Verdana" size="2">Dr Wein added to his conclusions that there was a significant percentage of the AFS and CP patient population that were being underserved by rehabilitation support services in Canada.<wbr></FONT></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 11pt; FONT-FAMILY: 'Arial','sans-serif'"><FONT face="Verdana" size="2">Note: Canada is currently updating their stroke strategy, as seen with the EU delegates meeting, Allergan may also be involved with the updating of the Canadian guidelines in some way.<wbr> </FONT></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 11pt; FONT-FAMILY: 'Arial','sans-serif'; mso-fareast-font-family: 'MS Mincho'; mso-fareast-theme-font: minor-fareast; mso-ansi-language: EN-US; mso-fareast-language: JA; mso-bidi-language: AR-SA"><FONT face="Verdana" size="2">During the Q&amp;A, there was one question when a member of the audience asked Dr Wein if usage of FDS (an electrode treatment to stimulate the flexor digitorum to improve hand opening) was captured in the treatment parameters recorded? The response was FDS was not widely used in Eastern Canada and if it were used the </FONT></SPAN><SPAN lang="EN-US" style="FONT-SIZE: 11pt; FONT-FAMILY: 'Arial','sans-serif'"><FONT face="Verdana" size="2">hours and the duration of treatment would have been captured but not the specific treatment</FONT>.<wbr></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 11pt; FONT-FAMILY: 'Arial','sans-serif'"><FONT face="Verdana" size="2">A study presented by George Sandrini titled <STRONG>Botulinum Toxin (Xeomin) in the treatment of Axial Disorders in Parkinson’s Disease – Pisa Syndrome in Parkinson’s Disease: Clinical, Electromyograpic</STRONG> and radiological characteristics in 20 Subjects.<wbr></FONT></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 11pt; FONT-FAMILY: 'Arial','sans-serif'"><FONT face="Verdana" size="2">This study was funded by Merz.<wbr> At this stage, it is understood that Merz is not looking to conduct larger studies although Sandrini stated that he is hoping to receive a grant from Merz for follow up studies.<wbr> </FONT></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 11pt; FONT-FAMILY: 'Arial','sans-serif'"><FONT face="Verdana" size="2">Aims and methodology of the study:</FONT></SPAN> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/6432/16/ScreenCapture17.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/6432/17/ScreenCapture18.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/6432/18/ScreenCapture19.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/6432/19/ScreenCapture20.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 11pt; FONT-FAMILY: 'Arial','sans-serif'"><FONT face="Verdana" size="2">This slide depicts the summary characteristics of the study patients.<wbr> It is mainly balanced bar the FIM score</FONT></SPAN> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/6432/20/ScreenCapture21.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 11pt; FONT-FAMILY: 'Arial','sans-serif'; mso-fareast-language: EN-US; mso-no-proof: yes"><FONT face="Verdana" size="2">The degree of static lateral trunk flexion was significantly higher in the Bont/<wbr>A when compared to placebo and the range of motion of the anterior flexion was significantly more limited in the Bont/<wbr>A group when compared with placebo.<wbr></FONT></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 11pt; FONT-FAMILY: 'Arial','sans-serif'; mso-fareast-language: EN-US; mso-no-proof: yes"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/6432/21/ScreenCapture22.jpg?user-agent=rss"></SPAN> </div><div style="margin-bottom: 10px;"><P style="TEXT-JUSTIFY: inter-ideograph; MARGIN: 0cm 0cm 10pt; TEXT-ALIGN: justify"><SPAN lang="EN-US" style="FONT-SIZE: 11pt; FONT-FAMILY: 'Arial','sans-serif'; mso-fareast-language: EN-US; mso-no-proof: yes"><FONT face="Verdana" size="2">The results showed that toxin induces a signficatnt improvement of serval static (axial deviation) and kinematic (ROM) parametres as well as pain scores being signficantly improved with the combined treatment of rehabilitation and Bont/<wbr>A.<wbr></FONT></SPAN></P> </div><div style="margin-bottom: 10px;"><P style="TEXT-JUSTIFY: inter-ideograph; MARGIN: 0cm 0cm 10pt; TEXT-ALIGN: justify"><SPAN lang="EN-US" style="FONT-SIZE: 11pt; FONT-FAMILY: 'Arial','sans-serif'; mso-fareast-language: EN-US; mso-no-proof: yes"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/6432/22/ScreenCapture23.jpg?user-agent=rss"></SPAN></P> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/6432/23/ScreenCapture24.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/6432/24/ScreenCapture25.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/6432/25/ScreenCapture26.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/6432/26/ScreenCapture27.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/6432/27/ScreenCapture28.jpg?user-agent=rss"> </div><div><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/6432/28/ScreenCapture29.jpg?user-agent=rss"> </div><!-- Comment details --><a name="neurology6432attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/6432/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(103,4 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/6432/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(85,8 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/6432/3/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(80,3 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/6432/4/ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(82,5 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/6432/5/ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(83,9 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/6432/6/ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(76,4 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/6432/7/ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(84,2 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/6432/8/ScreenCapture9.jpg">ScreenCapture9.jpg</a>&nbsp;&nbsp;(77 KB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/6432/9/ScreenCapture10.jpg">ScreenCapture10.jpg</a>&nbsp;&nbsp;(65,4 KB)<br>&nbsp;&nbsp;10.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/6432/10/ScreenCapture11.jpg">ScreenCapture11.jpg</a>&nbsp;&nbsp;(65,7 KB)<br>&nbsp;&nbsp;11.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/6432/11/ScreenCapture12.jpg">ScreenCapture12.jpg</a>&nbsp;&nbsp;(58,3 KB)<br>&nbsp;&nbsp;12.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/6432/12/ScreenCapture13.jpg">ScreenCapture13.jpg</a>&nbsp;&nbsp;(61,3 KB)<br>&nbsp;&nbsp;13.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/6432/13/ScreenCapture14.jpg">ScreenCapture14.jpg</a>&nbsp;&nbsp;(61,9 KB)<br>&nbsp;&nbsp;14.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/6432/14/ScreenCapture15.jpg">ScreenCapture15.jpg</a>&nbsp;&nbsp;(64 KB)<br>&nbsp;&nbsp;15.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/6432/15/ScreenCapture16.jpg">ScreenCapture16.jpg</a>&nbsp;&nbsp;(65,1 KB)<br>&nbsp;&nbsp;16.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/6432/16/ScreenCapture17.jpg">ScreenCapture17.jpg</a>&nbsp;&nbsp;(80 KB)<br>&nbsp;&nbsp;17.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/6432/17/ScreenCapture18.jpg">ScreenCapture18.jpg</a>&nbsp;&nbsp;(90 KB)<br>&nbsp;&nbsp;18.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/6432/18/ScreenCapture19.jpg">ScreenCapture19.jpg</a>&nbsp;&nbsp;(95,9 KB)<br>&nbsp;&nbsp;19.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/6432/19/ScreenCapture20.jpg">ScreenCapture20.jpg</a>&nbsp;&nbsp;(91,3 KB)<br>&nbsp;&nbsp;20.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/6432/20/ScreenCapture21.jpg">ScreenCapture21.jpg</a>&nbsp;&nbsp;(70,3 KB)<br>&nbsp;&nbsp;21.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/6432/21/ScreenCapture22.jpg">ScreenCapture22.jpg</a>&nbsp;&nbsp;(98,4 KB)<br>&nbsp;&nbsp;22.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/6432/22/ScreenCapture23.jpg">ScreenCapture23.jpg</a>&nbsp;&nbsp;(54,9 KB)<br>&nbsp;&nbsp;23.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/6432/23/ScreenCapture24.jpg">ScreenCapture24.jpg</a>&nbsp;&nbsp;(58,1 KB)<br>&nbsp;&nbsp;24.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/6432/24/ScreenCapture25.jpg">ScreenCapture25.jpg</a>&nbsp;&nbsp;(53 KB)<br>&nbsp;&nbsp;25.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/6432/25/ScreenCapture26.jpg">ScreenCapture26.jpg</a>&nbsp;&nbsp;(56,9 KB)<br>&nbsp;&nbsp;26.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/6432/26/ScreenCapture27.jpg">ScreenCapture27.jpg</a>&nbsp;&nbsp;(52 KB)<br>&nbsp;&nbsp;27.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/6432/27/ScreenCapture28.jpg">ScreenCapture28.jpg</a>&nbsp;&nbsp;(62,9 KB)<br>&nbsp;&nbsp;28.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/6432/28/ScreenCapture29.jpg">ScreenCapture29.jpg</a>&nbsp;&nbsp;(65,3 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120831&edate=20120501&rec=6432">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-05-29T18:25:12+02:00</dc:date><dc:creator>jac89886</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/6432/1/ScreenCapture1.jpg" length="105899" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/6432/2/ScreenCapture2.jpg" length="87858" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/6432/3/ScreenCapture3.jpg" length="82236" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/6432/4/ScreenCapture4.jpg" length="84513" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/6432/5/ScreenCapture5.jpg" length="85872" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/6432/6/ScreenCapture7.jpg" length="78263" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/6432/7/ScreenCapture8.jpg" length="86244" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/6432/8/ScreenCapture9.jpg" length="78802" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/6432/9/ScreenCapture10.jpg" length="66938" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/6432/10/ScreenCapture11.jpg" length="67327" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/6432/11/ScreenCapture12.jpg" length="59708" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/6432/12/ScreenCapture13.jpg" length="62782" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/6432/13/ScreenCapture14.jpg" length="63418" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/6432/14/ScreenCapture15.jpg" length="65512" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/6432/15/ScreenCapture16.jpg" length="66700" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/6432/16/ScreenCapture17.jpg" length="81874" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/6432/17/ScreenCapture18.jpg" length="92143" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/6432/18/ScreenCapture19.jpg" length="98227" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/6432/19/ScreenCapture20.jpg" length="93472" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/6432/20/ScreenCapture21.jpg" length="72036" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/6432/21/ScreenCapture22.jpg" length="100760" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/6432/22/ScreenCapture23.jpg" length="56260" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/6432/23/ScreenCapture24.jpg" length="59463" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/6432/24/ScreenCapture25.jpg" length="54300" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/6432/25/ScreenCapture26.jpg" length="58275" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/6432/26/ScreenCapture27.jpg" length="53280" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/6432/27/ScreenCapture28.jpg" length="64439" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/6432/28/ScreenCapture29.jpg" length="66842" type="image/jpeg"/></item><item>
<title>ValiRx' Androgen Receptor-Derived VAL-201 to Enter Ph1 for PCa [dis:Prostate, class:Hormonals, :PharmaWorld:sub:ClinicalTrial, news]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology8298</link>
<description>ValiRx' Androgen Receptor-Derived VAL-201 to Enter Ph1 for PCa [dis:Prostate, class:Hormonals, :PharmaWorld:sub:ClinicalTrial, news]</description><category>dis:Prostate</category><category>class:Hormonals</category><category>sub:ClinicalTrial</category><category>news</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology8298</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8298">ValiRx' Androgen Receptor-Derived VAL-201 to Enter Ph1 for PCa</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=class%3aHormonals"><font color="#e95e0b">:Oncology:class:Hormonals</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=news"><font color="#e95e0b">:Oncology:news</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=sub%3aClinicalTrial"><font color="#e95e0b">:PharmaWorld:sub:ClinicalTrial</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8298">Oncology8298</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 29 May 2012 | 18:02</font><br><br><div style="margin-bottom: 10px;">Comment: VAL-201 has been shown to be highly effective against prostate and breast cancer cell lines and mouse xenografts.<wbr> The life science company has started the regulatory filing process towards a ph1 trial application in the UK and Europe.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Preclinical Findings</FONT></STRONG> </div><div style="margin-bottom: 10px;">VAL-201 significantly inhibits the proliferation of aggressive tumours and decreases the spread and development of secondary tumours by up to 50% at projected therapeutic doses.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8298/3/ScreenCapture3.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Future Developments</FONT></STRONG> </div><div style="margin-bottom: 10px;">The latest studies have also shown a positive effect in the estrogen pathway in women, thereby providing good potential for the development of ovarian and breast cancer therapeutics.<wbr> The compound also has shown efficacy as a potential treatment against endometriosis or hormone induced abnormal cell growth in women.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8298/2/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Drug Mechanism of Action</FONT></STRONG> </div><div><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8298/1/ScreenCapture1.jpg?user-agent=rss"> </div><!-- Comment details --><a name="oncology8298attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8298/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(29,4 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8298/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(27,3 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8298/3/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(53,6 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8298">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-05-29T18:02:02+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8298/1/ScreenCapture1.jpg" length="30129" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8298/2/ScreenCapture2.jpg" length="28003" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8298/3/ScreenCapture3.jpg" length="54932" type="image/jpeg"/></item><item>
<title>Roche Sets Credit Limit for 12 Spanish Hospitals to Avoid Further Payment Delays [mkt:Spain, mkt:Europe]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld9888</link>
<description>Roche Sets Credit Limit for 12 Spanish Hospitals to Avoid Further Payment Delays [mkt:Spain, mkt:Europe]</description><category>mkt:Spain</category><category>mkt:Europe</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld9888</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120831&edate=20120501&rec=9888">Roche Sets Credit Limit for 12 Spanish Hospitals to Avoid Further Payment Delays</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=mkt%3aEurope"><font color="#e95e0b">:PharmaWorld:mkt:Europe</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=mkt%3aSpain"><font color="#e95e0b">:PharmaWorld:mkt:Spain</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld9888">PharmaWorld9888</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 29 May 2012 | 16:37</font><br><br><div style="margin-bottom: 10px;">Comment: According to <EM>Agencia Efe</EM>, among the most affected are three hospitals from the Comunidad Valenciana, three from Andalucia and Castilla y Leon, and two from Leon La Mancha.<wbr> </div><div style="margin-bottom: 10px;">According to <EM>Agencia Efe:</EM> </div><div style="margin-bottom: 10px;"><UL><LI>Roche decided to impose stricter rules to 12 of the hospitals that were failing the most with payments across Spain.<wbr> </LI>
<LI>Minister of Health Ana Mato announced the she will monitor supplies in the hospitals so as to make sure patients are not affected by drug shortages as a consequence of Roche's decision.<wbr> Spanish hospitals are reported to have run up a debt of around EUR500 million (USD626 million) with Roche.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Significance</FONT></STRONG> </div><div style="margin-bottom: 10px;">Despite the recent reforms announced by the Spanish government to tackle healthcare debt and reduce the debt in order to be able to review the situation and keep up to date with payments, Spain needs to engage in a stricter repayment plan with the regional councils in order to be able to cope.<wbr> Although a new financial mechanism to avoid systemic breakdown has recently been announced in order to cope with payment delays to pharmacies and hospitals, this is still too recent to be able to assess its effects in the short-to-medium term.<wbr> Roche's move is understandable from the perspective that at least 80% of Roche's revenues in Spain come from hospital supply.<wbr> </div><div>Source: GlobalInsight </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120831&edate=20120501&rec=9888">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-05-29T16:37:08+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Dongkook Registers Octreotide In Peru [class:SomatostatinAnalogue, sub:Generics, sub:Hybrids, :PharmaWorld:mkt:Brazil, :PharmaWorld:mkt:Intercontinental, :PharmaWorld:mkt:Mexico]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology6946</link>
<description>Dongkook Registers Octreotide In Peru [class:SomatostatinAnalogue, sub:Generics, sub:Hybrids, :PharmaWorld:mkt:Brazil, :PharmaWorld:mkt:Intercontinental, :PharmaWorld:mkt:Mexico]</description><category>class:SomatostatinAnalogue</category><category>sub:Generics</category><category>sub:Hybrids</category><category>mkt:Brazil</category><category>mkt:Intercontinental</category><category>mkt:Mexico</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology6946</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120831&edate=20120501&rec=6946">Dongkook Registers Octreotide In Peru</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=class%3aSomatostatinAnalogue"><font color="#e95e0b">:Endocrinology:class:SomatostatinAnalogue</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=sub%3aGenerics"><font color="#e95e0b">:Endocrinology:sub:Generics</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=sub%3aHybrids"><font color="#e95e0b">:Endocrinology:sub:Hybrids</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=mkt%3aBrazil"><font color="#e95e0b">:PharmaWorld:mkt:Brazil</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=mkt%3aIntercontinental"><font color="#e95e0b">:PharmaWorld:mkt:Intercontinental</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=mkt%3aMexico"><font color="#e95e0b">:PharmaWorld:mkt:Mexico</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology6946">Endocrinology6946</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 29 May 2012 | 16:12</font><br><br><div style="margin-bottom: 10px;">Comment: Our partner Sanofi Peru has informed Ipsen that Dongkook has registered its octreotide 20mg formulation as a generic in Peru.<wbr> </div><div style="margin-bottom: 10px;">Thanks to Harold Dumont (Endocrinology Franchise Marketing) we have learnt that this generic product has already won some small tenders and that first experiences did not satisfy physicians expectations in terms of efficacy or safety.<wbr> </div><div style="margin-bottom: 10px;">At last year's CPHi meeting, it was noted that this 20mg formulation was under registration in Brazil and also expected to be launched in Mexico this year (see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=DKPHybrids&sdate=20120831&edate=20120501&rec=77" class="defaultlink">DKPHybrids77: Key Takeaways From CPhI Frankfurt October 2011</a>).<wbr> </div><div><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6946/1/ScreenCapture1.jpg?user-agent=rss"> </div><!-- Comment details --><a name="endocrinology6946attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6946/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(153,7 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120831&edate=20120501&rec=6946">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-05-29T16:12:55+02:00</dc:date><dc:creator>jac89886</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6946/1/ScreenCapture1.jpg" length="157369" type="image/jpeg"/></item><item>
<title>Bid Speculation Circles Diabetes Company Amylin [class:GLP1, dis:Diabetes]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology6945</link>
<description>Bid Speculation Circles Diabetes Company Amylin [class:GLP1, dis:Diabetes]</description><comments>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology6945</comments><category>class:GLP1</category><category>dis:Diabetes</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology6945</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120831&edate=20120501&rec=6945">Bid Speculation Circles Diabetes Company Amylin</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=class%3aGLP1"><font color="#e95e0b">:Endocrinology:class:GLP1</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=dis%3aDiabetes"><font color="#e95e0b">:Endocrinology:dis:Diabetes</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology6945">Endocrinology6945</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 28 May 2012 | 13:09</font><br><br><div style="margin-bottom: 10px;">Comment: Shares in Amylin have leapt by over 8% as a report on Bloomberg 
claimed that both Sanofi and Merck have made initial takeover bids for the 
diabetes drug specialist that markets and manufactures the GLP-1 analogues 
Byetta and Bydureon.<wbr> </div><div style="margin-bottom: 10px;">Reportedly the offers on the table are at least $25 a share valuing the 
company at mmore than $4bn.<wbr> Last month it was rumoured that Amylin rejected a 
bid from Bristol Myers Squibb of $22 a share.<wbr> </div><div style="margin-bottom: 10px;">BMS is expected to return with a higher offer and Takeda has also indicated 
that it may make a bid.<wbr> </div><div>Source:www.<wbr>bloomberg.<wbr>com </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Endocrinology6986c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">As the auction for Amylin enters the last leg 5 companies are reported to be still interested in acquiring the company for a pirce tag of around $4.<wbr>5bn.<wbr> Interested parties reportedly include Novartis, Sanofi, BMS, Merck and AstraZeneca.<wbr> Final bids are expected by the weekend.<wbr> </div><div>Source: Rueters </div><font size="-1">Jacquelyne CANTLE MEYRICK / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology6986" class="commentpermalink">Endocrinology6986</a> / <span class="date">27 June 2012</span> /
<span class="time">11:20:01 o'clock CEST</span>
</font></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120831&edate=20120501&rec=6945">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-05-28T13:09:58+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>ECE Intelligence Part 2 - Cushing's &amp; NET &amp; Pituitary Adenoma Data [headline, dis:Cushing, dis:MidGutNET, prod:Octreotide, prod:Pasireotide, comp:Novartis, :PharmaWorld:congress:ECE]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology6942</link>
<description>ECE Intelligence Part 2 - Cushing's &amp; NET &amp; Pituitary Adenoma Data [headline, dis:Cushing, dis:MidGutNET, prod:Octreotide, prod:Pasireotide, comp:Novartis, :PharmaWorld:congress:ECE]</description><category>headline</category><category>dis:Cushing</category><category>dis:MidGutNET</category><category>prod:Octreotide</category><category>prod:Pasireotide</category><category>comp:Novartis</category><category>congress:ECE</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology6942</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120831&edate=20120501&rec=6942">ECE Intelligence Part 2 - Cushing's & NET & Pituitary Adenoma Data</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=comp%3aNovartis"><font color="#e95e0b">:Endocrinology:comp:Novartis</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=dis%3aCushing"><font color="#e95e0b">:Endocrinology:dis:Cushing</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=dis%3aMidGutNET"><font color="#e95e0b">:Endocrinology:dis:MidGutNET</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=headline"><font color="#e95e0b">:Endocrinology:headline</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=prod%3aOctreotide"><font color="#e95e0b">:Endocrinology:prod:Octreotide</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=prod%3aPasireotide"><font color="#e95e0b">:Endocrinology:prod:Pasireotide</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=congress%3aECE"><font color="#e95e0b">:PharmaWorld:congress:ECE</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology6942">Endocrinology6942</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 28 May 2012 | 12:49</font><br><br><div style="margin-bottom: 10px;"><SPAN style="font-family: 'Verdana','sans-serif'; font-size: 10pt;">Comment: This second report from the recent ECE meeting highlights the growing interest in sub-clinical Cushing&rsquo;s disease, a potential new treatment for CD in the form of Novartis&rsquo;s LCI699 and some soft intelligence on its new Sandostatin LAR device.<wbr> Also featured is radiopeptide targeting for neuroendocrine tumour visualisaiton, data demonstrating the increasing usage of temozolomide and some scientific data highlighting novel developments in pituitary adenomas and differences in internalisation between octreotide and pasireotide and somatoprim (Aspireo).<wbr></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="font-family: 'Verdana','sans-serif'; font-size: 10pt;"><STRONG>Sub-Clinical Cushing's Disease - Diagnosis and Risk Factor Implications</STRONG></SPAN> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6942/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6942/2/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6942/3/ScreenCapture3.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6942/4/ScreenCapture4.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6942/5/ScreenCapture5.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6942/6/ScreenCapture6.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6942/7/ScreenCapture7.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6942/8/ScreenCapture8.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG>Novartis's POC Data With LC1699 in Cushing's Disease</STRONG> </div><div style="margin-bottom: 10px;">LC1699 is a 11 beta-hydroxylase CYP11B1 inhibitor that Novartis acquired when it purchased.<wbr> Speedel  in 2008.<wbr> It is a potential new treatment for all forms of Cushing's syndrome including Cushing's disease.<wbr> </div><div style="margin-bottom: 10px;">In the study all 12 patients achieved the primary endpoint at day 70 and 11/<wbr>12 patients had normal urinary cortisol at day 70.<wbr> Urinary cortisol returned to baseline within 2-weeks of the washout at the end of the study.<wbr> Many were controlled with 20mg or less.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6942/9/ScreenCapture9.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6942/10/ScreenCapture10.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6942/11/ScreenCapture11.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6942/12/ScreenCapture12.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6942/13/ScreenCapture13.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6942/14/ScreenCapture14.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6942/15/ScreenCapture15.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6942/16/ScreenCapture16.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6942/17/ScreenCapture17.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">At the end of the presentation, the question of hypokalaemia was raised and whether these patients would need to take a concomitant therapy to control this.<wbr> Dr Bertagia stated that it was something that was being considered but an alternative could be K+ supplementation.<wbr> The possibility of hyperandrogenism in women associated with the increased testosterone was also queried but apparently no clinical evidence of hirsutism was seen in the 8 females includes in the study albeit the duration of the trial was very short.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Soft Intelligence Regarding New Sandostatin LAR Device</STRONG> </div><div style="margin-bottom: 10px;">Gathered both at the congress and from Anna Jonasson (Business Unit Manager in Sweden).<wbr>The new device will be introduced in Scandanavia this summer together with a handful of other markets and then elsewhere in all other international markets towards the year-end.<wbr> Features of the new device include:- </div><div style="margin-bottom: 10px;"><UL><LI>A new diluent and vial adaptor
</LI>
<LI>Not a pre-filled device but better than Novartis's current offering
</LI>
<LI>Easier to mis with a shortened mixing time (5 mins)
</LI>
<LI>A smaller needle gauge (21 gauge)
</LI>
<LI>A smaller volume of injection 2 vs.<wbr> 2.<wbr>5 mls (useful it was claimed for thinner patients) - still intramuscular
</LI>
<LI>A safety needle that can retract once used ( a button is pressed to retract the needle).<wbr>
</LI>
<LI>Price is expected to be the same.<wbr>
</LI>
</UL> </div><div style="margin-bottom: 10px;"><SPAN style="font-family: 'Verdana','sans-serif'; font-size: 10pt;"><STRONG>New Developments In NET</STRONG></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="font-family: 'Verdana','sans-serif'; font-size: 10pt;"><STRONG><EM>Radiopeptide Targeting For Neuroendocrine tumour visualisation</EM></STRONG></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="line-height: 115%; font-family: 'Verdana','sans-serif'; font-size: 10pt; mso-fareast-font-family: Calibri; mso-bidi-font-family: 'Times New Roman'; mso-fareast-language: EN-US; mso-ansi-language: EN-GB; mso-bidi-language: AR-SA;">The use of radiopeptide targeting for visualisation of neuroendocrine tumours is an area of increasing application.<wbr> Emanuel Christ gave a very interesting presentation on GLP-1 imaging for localisation of pre-operative localisation of benign insulinomas </SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="line-height: 115%; font-family: 'Verdana','sans-serif'; font-size: 10pt; mso-fareast-font-family: Calibri; mso-bidi-font-family: 'Times New Roman'; mso-fareast-language: EN-US; mso-ansi-language: EN-GB; mso-bidi-language: AR-SA;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6942/18/ScreenCapture18.jpg?user-agent=rss"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="line-height: 115%; font-family: 'Verdana','sans-serif'; font-size: 10pt; mso-fareast-font-family: Calibri; mso-bidi-font-family: 'Times New Roman'; mso-fareast-language: EN-US; mso-ansi-language: EN-GB; mso-bidi-language: AR-SA;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6942/19/ScreenCapture19.jpg?user-agent=rss"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="line-height: 115%; font-family: 'Verdana','sans-serif'; font-size: 10pt; mso-fareast-font-family: Calibri; mso-bidi-font-family: 'Times New Roman'; mso-fareast-language: EN-US; mso-ansi-language: EN-GB; mso-bidi-language: AR-SA;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6942/20/ScreenCapture20.jpg?user-agent=rss"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="line-height: 115%; font-family: 'Verdana','sans-serif'; font-size: 10pt; mso-fareast-font-family: Calibri; mso-bidi-font-family: 'Times New Roman'; mso-fareast-language: EN-US; mso-ansi-language: EN-GB; mso-bidi-language: AR-SA;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6942/21/ScreenCapture21.jpg?user-agent=rss"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="line-height: 115%; font-family: 'Verdana','sans-serif'; font-size: 10pt; mso-fareast-font-family: Calibri; mso-bidi-font-family: 'Times New Roman'; mso-fareast-language: EN-US; mso-ansi-language: EN-GB; mso-bidi-language: AR-SA;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6942/22/ScreenCapture22.jpg?user-agent=rss"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="line-height: 115%; font-family: 'Verdana','sans-serif'; font-size: 10pt; mso-fareast-font-family: Calibri; mso-bidi-font-family: 'Times New Roman'; mso-fareast-language: EN-US; mso-ansi-language: EN-GB; mso-bidi-language: AR-SA;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6942/23/ScreenCapture23.jpg?user-agent=rss"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="line-height: 115%; font-family: 'Verdana','sans-serif'; font-size: 10pt; mso-fareast-font-family: Calibri; mso-bidi-font-family: 'Times New Roman'; mso-fareast-language: EN-US; mso-ansi-language: EN-GB; mso-bidi-language: AR-SA;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6942/24/ScreenCapture24.jpg?user-agent=rss"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="line-height: 115%; font-family: 'Verdana','sans-serif'; font-size: 10pt; mso-fareast-font-family: Calibri; mso-bidi-font-family: 'Times New Roman'; mso-fareast-language: EN-US; mso-ansi-language: EN-GB; mso-bidi-language: AR-SA;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6942/25/ScreenCapture25.jpg?user-agent=rss"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="line-height: 115%; font-family: 'Verdana','sans-serif'; font-size: 10pt; mso-fareast-font-family: Calibri; mso-bidi-font-family: 'Times New Roman'; mso-fareast-language: EN-US; mso-ansi-language: EN-GB; mso-bidi-language: AR-SA;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6942/26/ScreenCapture26.jpg?user-agent=rss"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="line-height: 115%; font-family: 'Verdana','sans-serif'; font-size: 10pt; mso-fareast-font-family: Calibri; mso-bidi-font-family: 'Times New Roman'; mso-fareast-language: EN-US; mso-ansi-language: EN-GB; mso-bidi-language: AR-SA;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6942/27/ScreenCapture27.jpg?user-agent=rss"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="line-height: 115%; font-family: 'Verdana','sans-serif'; font-size: 10pt; mso-fareast-font-family: Calibri; mso-bidi-font-family: 'Times New Roman'; mso-fareast-language: EN-US; mso-ansi-language: EN-GB; mso-bidi-language: AR-SA;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6942/28/ScreenCapture28.jpg?user-agent=rss"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="line-height: 115%; font-family: 'Verdana','sans-serif'; font-size: 10pt; mso-fareast-font-family: Calibri; mso-bidi-font-family: 'Times New Roman'; mso-fareast-language: EN-US; mso-ansi-language: EN-GB; mso-bidi-language: AR-SA;"><STRONG>Growing Enthusiasm For Temozolomide</STRONG></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="line-height: 115%; font-family: 'Verdana','sans-serif'; font-size: 10pt; mso-fareast-font-family: Calibri; mso-bidi-font-family: 'Times New Roman'; mso-fareast-language: EN-US; mso-ansi-language: EN-GB; mso-bidi-language: AR-SA;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6942/29/ScreenCapture29.jpg?user-agent=rss"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="line-height: 115%; font-family: 'Verdana','sans-serif'; font-size: 10pt; mso-fareast-font-family: Calibri; mso-bidi-font-family: 'Times New Roman'; mso-fareast-language: EN-US; mso-ansi-language: EN-GB; mso-bidi-language: AR-SA;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6942/30/ScreenCapture30.jpg?user-agent=rss"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="line-height: 115%; font-family: 'Verdana','sans-serif'; font-size: 10pt; mso-fareast-font-family: Calibri; mso-bidi-font-family: 'Times New Roman'; mso-fareast-language: EN-US; mso-ansi-language: EN-GB; mso-bidi-language: AR-SA;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6942/31/ScreenCapture31.jpg?user-agent=rss"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="line-height: 115%; font-family: 'Verdana','sans-serif'; font-size: 10pt; mso-fareast-font-family: Calibri; mso-bidi-font-family: 'Times New Roman'; mso-fareast-language: EN-US; mso-ansi-language: EN-GB; mso-bidi-language: AR-SA;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6942/32/ScreenCapture32.jpg?user-agent=rss"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="line-height: 115%; font-family: 'Verdana','sans-serif'; font-size: 10pt; mso-fareast-font-family: Calibri; mso-bidi-font-family: 'Times New Roman'; mso-fareast-language: EN-US; mso-ansi-language: EN-GB; mso-bidi-language: AR-SA;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6942/33/ScreenCapture33.jpg?user-agent=rss"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="line-height: 115%; font-family: 'Verdana','sans-serif'; font-size: 10pt; mso-fareast-font-family: Calibri; mso-bidi-font-family: 'Times New Roman'; mso-fareast-language: EN-US; mso-ansi-language: EN-GB; mso-bidi-language: AR-SA;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6942/34/ScreenCapture34.jpg?user-agent=rss"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="line-height: 115%; font-family: 'Verdana','sans-serif'; font-size: 10pt; mso-fareast-font-family: Calibri; mso-bidi-font-family: 'Times New Roman'; mso-fareast-language: EN-US; mso-ansi-language: EN-GB; mso-bidi-language: AR-SA;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6942/35/ScreenCapture35.jpg?user-agent=rss"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="line-height: 115%; font-family: 'Verdana','sans-serif'; font-size: 10pt; mso-fareast-font-family: Calibri; mso-bidi-font-family: 'Times New Roman'; mso-fareast-language: EN-US; mso-ansi-language: EN-GB; mso-bidi-language: AR-SA;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6942/36/ScreenCapture36.jpg?user-agent=rss"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="line-height: 115%; font-family: 'Verdana','sans-serif'; font-size: 10pt; mso-fareast-font-family: Calibri; mso-bidi-font-family: 'Times New Roman'; mso-fareast-language: EN-US; mso-ansi-language: EN-GB; mso-bidi-language: AR-SA;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6942/37/ScreenCapture37.jpg?user-agent=rss"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="line-height: 115%; font-family: 'Verdana','sans-serif'; font-size: 10pt; mso-fareast-font-family: Calibri; mso-bidi-font-family: 'Times New Roman'; mso-fareast-language: EN-US; mso-ansi-language: EN-GB; mso-bidi-language: AR-SA;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6942/38/ScreenCapture38.jpg?user-agent=rss"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="line-height: 115%; font-family: 'Verdana','sans-serif'; font-size: 10pt; mso-fareast-font-family: Calibri; mso-bidi-font-family: 'Times New Roman'; mso-fareast-language: EN-US; mso-ansi-language: EN-GB; mso-bidi-language: AR-SA;"><STRONG>New Developments In Pituitary Adenoma - Cytokines &amp; Other New Genes In Pituitary Adenoma (E Arzt Buenos Aires)</STRONG></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="line-height: 115%; font-family: 'Verdana','sans-serif'; font-size: 10pt; mso-fareast-font-family: Calibri; mso-bidi-font-family: 'Times New Roman'; mso-fareast-language: EN-US; mso-ansi-language: EN-GB; mso-bidi-language: AR-SA;">Eduardo presented data highlighting the role of BMP-4 in the proliferation of prolactinomas and corticotrophs.<wbr> He noted that retinoic acid can be used to treat Cushing's disease and presented data showing how this acts via BMP4.<wbr> He also highlighted a paper highlighting the interaction of SSAs with the BMP4 pathway and conclulded that BMP4 should be a new target for the treatment of pitutary adenomas.<wbr></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="line-height: 115%; font-family: 'Verdana','sans-serif'; font-size: 10pt; mso-fareast-font-family: Calibri; mso-bidi-font-family: 'Times New Roman'; mso-fareast-language: EN-US; mso-ansi-language: EN-GB; mso-bidi-language: AR-SA;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6942/39/ScreenCapture39.jpg?user-agent=rss"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="line-height: 115%; font-family: 'Verdana','sans-serif'; font-size: 10pt; mso-fareast-font-family: Calibri; mso-bidi-font-family: 'Times New Roman'; mso-fareast-language: EN-US; mso-ansi-language: EN-GB; mso-bidi-language: AR-SA;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6942/40/ScreenCapture40.jpg?user-agent=rss"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="line-height: 115%; font-family: 'Verdana','sans-serif'; font-size: 10pt; mso-fareast-font-family: Calibri; mso-bidi-font-family: 'Times New Roman'; mso-fareast-language: EN-US; mso-ansi-language: EN-GB; mso-bidi-language: AR-SA;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6942/41/ScreenCapture41.jpg?user-agent=rss"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="line-height: 115%; font-family: 'Verdana','sans-serif'; font-size: 10pt; mso-fareast-font-family: Calibri; mso-bidi-font-family: 'Times New Roman'; mso-fareast-language: EN-US; mso-ansi-language: EN-GB; mso-bidi-language: AR-SA;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6942/42/ScreenCapture42.jpg?user-agent=rss"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="line-height: 115%; font-family: 'Verdana','sans-serif'; font-size: 10pt; mso-fareast-font-family: Calibri; mso-bidi-font-family: 'Times New Roman'; mso-fareast-language: EN-US; mso-ansi-language: EN-GB; mso-bidi-language: AR-SA;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6942/43/ScreenCapture43.jpg?user-agent=rss"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="line-height: 115%; font-family: 'Verdana','sans-serif'; font-size: 10pt; mso-fareast-font-family: Calibri; mso-bidi-font-family: 'Times New Roman'; mso-fareast-language: EN-US; mso-ansi-language: EN-GB; mso-bidi-language: AR-SA;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6942/44/ScreenCapture44.jpg?user-agent=rss"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="line-height: 115%; font-family: 'Verdana','sans-serif'; font-size: 10pt; mso-fareast-font-family: Calibri; mso-bidi-font-family: 'Times New Roman'; mso-fareast-language: EN-US; mso-ansi-language: EN-GB; mso-bidi-language: AR-SA;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6942/45/ScreenCapture45.jpg?user-agent=rss"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="line-height: 115%; font-family: 'Verdana','sans-serif'; font-size: 10pt; mso-fareast-font-family: Calibri; mso-bidi-font-family: 'Times New Roman'; mso-fareast-language: EN-US; mso-ansi-language: EN-GB; mso-bidi-language: AR-SA;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6942/46/ScreenCapture46.jpg?user-agent=rss"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="line-height: 115%; font-family: 'Verdana','sans-serif'; font-size: 10pt; mso-fareast-font-family: Calibri; mso-bidi-font-family: 'Times New Roman'; mso-fareast-language: EN-US; mso-ansi-language: EN-GB; mso-bidi-language: AR-SA;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6942/47/ScreenCapture47.jpg?user-agent=rss"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="font-family: 'Verdana','sans-serif'; font-size: 10pt;"><STRONG>In Vitro Comparison of The Activity of Octreotide &amp; Pasireotide In GEP-NET (Novartis Sponsored Research)</STRONG></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="font-family: 'Verdana','sans-serif'; font-size: 10pt;"><STRONG><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6942/48/ScreenCapture48.jpg?user-agent=rss"></STRONG></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="font-family: 'Verdana','sans-serif'; font-size: 10pt;"><STRONG><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6942/49/ScreenCapture49.jpg?user-agent=rss"></STRONG></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="font-family: 'Verdana','sans-serif'; font-size: 10pt;"><STRONG><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6942/50/ScreenCapture50.jpg?user-agent=rss"></STRONG></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="font-family: 'Verdana','sans-serif'; font-size: 10pt;"><STRONG><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6942/51/ScreenCapture51.jpg?user-agent=rss"></STRONG></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="font-family: 'Verdana','sans-serif'; font-size: 10pt;"><STRONG><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6942/52/ScreenCapture52.jpg?user-agent=rss"></STRONG></SPAN> </div><div style="margin-bottom: 10px;">One of the final symposia of this year's ECE meeting focused on somatostatin receptors in the pituitary.<wbr> Schulz from the Institue for Pharmcologie Und Toxicology Jena University, highlighted research efforts to develop mAbs to detect SST2 and SST5 receptors in real-time which gives an idea of presence but not necessarily functionality.<wbr> No photography was allowed during the session but there were some interesting observations.<wbr> Namely that:- </div><div style="margin-bottom: 10px;"><UL><LI>All cells expressing GH expressed SST5 receptors but not all expressed SST2
</LI>
<LI>All ACTH cell expressed SST5 but not SST2
</LI>
</UL> </div><div style="margin-bottom: 10px;">Using a fret based probe to measure cAMP Schulz can identify cells which will respond to individual agonists.<wbr> His work has also looked at phosphorylation of specific residues on the SST2 and SST5 receptors and shown that mutation can impede internalisation.<wbr> </div><div style="margin-bottom: 10px;">Phosphorylation of octreotide is similar to somatostatin but that of pasireotide is considerably less.<wbr> Somatoprim (DG3173 Aspireo) looks like octreotide but it does have activity at the SST5 receptors similar to that of pasireotide.<wbr> Schulz concluded therefore that Somatoprim has the combined activity of octreotide and pasireotide.<wbr> </div><div>Interestingly in a recent clinical paper in the European Journal of Endocrinology, Ursulla Plockinger and co-workers demonstrated the activity of somatroprim (DG3173) in human GH secreting adenomas even in octreotide non-responsive tumours (see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120831&edate=20120501&rec=6725" class="defaultlink">Endocrinology6725: Profile of A New Somatostatin Analogue DG3173</a>).<wbr> </div><!-- Comment details --><a name="endocrinology6942attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6942/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(89,9 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6942/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(96,5 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6942/3/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(92,7 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6942/4/ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(85,5 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6942/5/ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(108,7 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6942/6/ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(84,6 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6942/7/ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(99,7 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6942/8/ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(42,9 KB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6942/9/ScreenCapture9.jpg">ScreenCapture9.jpg</a>&nbsp;&nbsp;(77 KB)<br>&nbsp;&nbsp;10.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6942/10/ScreenCapture10.jpg">ScreenCapture10.jpg</a>&nbsp;&nbsp;(42,8 KB)<br>&nbsp;&nbsp;11.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6942/11/ScreenCapture11.jpg">ScreenCapture11.jpg</a>&nbsp;&nbsp;(34,7 KB)<br>&nbsp;&nbsp;12.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6942/12/ScreenCapture12.jpg">ScreenCapture12.jpg</a>&nbsp;&nbsp;(41,1 KB)<br>&nbsp;&nbsp;13.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6942/13/ScreenCapture13.jpg">ScreenCapture13.jpg</a>&nbsp;&nbsp;(36 KB)<br>&nbsp;&nbsp;14.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6942/14/ScreenCapture14.jpg">ScreenCapture14.jpg</a>&nbsp;&nbsp;(56 KB)<br>&nbsp;&nbsp;15.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6942/15/ScreenCapture15.jpg">ScreenCapture15.jpg</a>&nbsp;&nbsp;(39,8 KB)<br>&nbsp;&nbsp;16.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6942/16/ScreenCapture16.jpg">ScreenCapture16.jpg</a>&nbsp;&nbsp;(41,6 KB)<br>&nbsp;&nbsp;17.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6942/17/ScreenCapture17.jpg">ScreenCapture17.jpg</a>&nbsp;&nbsp;(49,8 KB)<br>&nbsp;&nbsp;18.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6942/18/ScreenCapture18.jpg">ScreenCapture18.jpg</a>&nbsp;&nbsp;(67,7 KB)<br>&nbsp;&nbsp;19.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6942/19/ScreenCapture19.jpg">ScreenCapture19.jpg</a>&nbsp;&nbsp;(58 KB)<br>&nbsp;&nbsp;20.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6942/20/ScreenCapture20.jpg">ScreenCapture20.jpg</a>&nbsp;&nbsp;(59,2 KB)<br>&nbsp;&nbsp;21.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6942/21/ScreenCapture21.jpg">ScreenCapture21.jpg</a>&nbsp;&nbsp;(82,9 KB)<br>&nbsp;&nbsp;22.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6942/22/ScreenCapture22.jpg">ScreenCapture22.jpg</a>&nbsp;&nbsp;(77,1 KB)<br>&nbsp;&nbsp;23.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6942/23/ScreenCapture23.jpg">ScreenCapture23.jpg</a>&nbsp;&nbsp;(52 KB)<br>&nbsp;&nbsp;24.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6942/24/ScreenCapture24.jpg">ScreenCapture24.jpg</a>&nbsp;&nbsp;(56 KB)<br>&nbsp;&nbsp;25.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6942/25/ScreenCapture25.jpg">ScreenCapture25.jpg</a>&nbsp;&nbsp;(49,2 KB)<br>&nbsp;&nbsp;26.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6942/26/ScreenCapture26.jpg">ScreenCapture26.jpg</a>&nbsp;&nbsp;(62,6 KB)<br>&nbsp;&nbsp;27.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6942/27/ScreenCapture27.jpg">ScreenCapture27.jpg</a>&nbsp;&nbsp;(66,1 KB)<br>&nbsp;&nbsp;28.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6942/28/ScreenCapture28.jpg">ScreenCapture28.jpg</a>&nbsp;&nbsp;(73,4 KB)<br>&nbsp;&nbsp;29.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6942/29/ScreenCapture29.jpg">ScreenCapture29.jpg</a>&nbsp;&nbsp;(64,6 KB)<br>&nbsp;&nbsp;30.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6942/30/ScreenCapture30.jpg">ScreenCapture30.jpg</a>&nbsp;&nbsp;(69,2 KB)<br>&nbsp;&nbsp;31.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6942/31/ScreenCapture31.jpg">ScreenCapture31.jpg</a>&nbsp;&nbsp;(48,2 KB)<br>&nbsp;&nbsp;32.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6942/32/ScreenCapture32.jpg">ScreenCapture32.jpg</a>&nbsp;&nbsp;(62,3 KB)<br>&nbsp;&nbsp;33.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6942/33/ScreenCapture33.jpg">ScreenCapture33.jpg</a>&nbsp;&nbsp;(54 KB)<br>&nbsp;&nbsp;34.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6942/34/ScreenCapture34.jpg">ScreenCapture34.jpg</a>&nbsp;&nbsp;(71,3 KB)<br>&nbsp;&nbsp;35.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6942/35/ScreenCapture35.jpg">ScreenCapture35.jpg</a>&nbsp;&nbsp;(62,8 KB)<br>&nbsp;&nbsp;36.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6942/36/ScreenCapture36.jpg">ScreenCapture36.jpg</a>&nbsp;&nbsp;(73,1 KB)<br>&nbsp;&nbsp;37.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6942/37/ScreenCapture37.jpg">ScreenCapture37.jpg</a>&nbsp;&nbsp;(87,8 KB)<br>&nbsp;&nbsp;38.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6942/38/ScreenCapture38.jpg">ScreenCapture38.jpg</a>&nbsp;&nbsp;(81 KB)<br>&nbsp;&nbsp;39.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6942/39/ScreenCapture39.jpg">ScreenCapture39.jpg</a>&nbsp;&nbsp;(54,7 KB)<br>&nbsp;&nbsp;40.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6942/40/ScreenCapture40.jpg">ScreenCapture40.jpg</a>&nbsp;&nbsp;(46,9 KB)<br>&nbsp;&nbsp;41.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6942/41/ScreenCapture41.jpg">ScreenCapture41.jpg</a>&nbsp;&nbsp;(52,1 KB)<br>&nbsp;&nbsp;42.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6942/42/ScreenCapture42.jpg">ScreenCapture42.jpg</a>&nbsp;&nbsp;(46,3 KB)<br>&nbsp;&nbsp;43.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6942/43/ScreenCapture43.jpg">ScreenCapture43.jpg</a>&nbsp;&nbsp;(48,5 KB)<br>&nbsp;&nbsp;44.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6942/44/ScreenCapture44.jpg">ScreenCapture44.jpg</a>&nbsp;&nbsp;(53 KB)<br>&nbsp;&nbsp;45.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6942/45/ScreenCapture45.jpg">ScreenCapture45.jpg</a>&nbsp;&nbsp;(54,2 KB)<br>&nbsp;&nbsp;46.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6942/46/ScreenCapture46.jpg">ScreenCapture46.jpg</a>&nbsp;&nbsp;(46,8 KB)<br>&nbsp;&nbsp;47.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6942/47/ScreenCapture47.jpg">ScreenCapture47.jpg</a>&nbsp;&nbsp;(45,1 KB)<br>&nbsp;&nbsp;48.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6942/48/ScreenCapture48.jpg">ScreenCapture48.jpg</a>&nbsp;&nbsp;(76,9 KB)<br>&nbsp;&nbsp;49.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6942/49/ScreenCapture49.jpg">ScreenCapture49.jpg</a>&nbsp;&nbsp;(64 KB)<br>&nbsp;&nbsp;50.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6942/50/ScreenCapture50.jpg">ScreenCapture50.jpg</a>&nbsp;&nbsp;(72,4 KB)<br>&nbsp;&nbsp;51.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6942/51/ScreenCapture51.jpg">ScreenCapture51.jpg</a>&nbsp;&nbsp;(83,5 KB)<br>&nbsp;&nbsp;52.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6942/52/ScreenCapture52.jpg">ScreenCapture52.jpg</a>&nbsp;&nbsp;(55,7 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120831&edate=20120501&rec=6942">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-05-28T12:49:17+02:00</dc:date><dc:creator>jac89886</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6942/1/ScreenCapture1.jpg" length="92019" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6942/2/ScreenCapture2.jpg" length="98795" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6942/3/ScreenCapture3.jpg" length="94943" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6942/4/ScreenCapture4.jpg" length="87509" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6942/5/ScreenCapture5.jpg" length="111269" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6942/6/ScreenCapture6.jpg" length="86616" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6942/7/ScreenCapture7.jpg" length="102044" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6942/8/ScreenCapture8.jpg" length="43924" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6942/9/ScreenCapture9.jpg" length="78814" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6942/10/ScreenCapture10.jpg" length="43818" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6942/11/ScreenCapture11.jpg" length="35494" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6942/12/ScreenCapture12.jpg" length="42068" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6942/13/ScreenCapture13.jpg" length="36841" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6942/14/ScreenCapture14.jpg" length="57334" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6942/15/ScreenCapture15.jpg" length="40729" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6942/16/ScreenCapture16.jpg" length="42632" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6942/17/ScreenCapture17.jpg" length="50974" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6942/18/ScreenCapture18.jpg" length="69306" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6942/19/ScreenCapture19.jpg" length="59413" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6942/20/ScreenCapture20.jpg" length="60572" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6942/21/ScreenCapture21.jpg" length="84911" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6942/22/ScreenCapture22.jpg" length="78909" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6942/23/ScreenCapture23.jpg" length="53258" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6942/24/ScreenCapture24.jpg" length="57324" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6942/25/ScreenCapture25.jpg" length="50384" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6942/26/ScreenCapture26.jpg" length="64056" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6942/27/ScreenCapture27.jpg" length="67653" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6942/28/ScreenCapture28.jpg" length="75137" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6942/29/ScreenCapture29.jpg" length="66106" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6942/30/ScreenCapture30.jpg" length="70891" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6942/31/ScreenCapture31.jpg" length="49366" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6942/32/ScreenCapture32.jpg" length="63822" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6942/33/ScreenCapture33.jpg" length="55261" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6942/34/ScreenCapture34.jpg" length="73005" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6942/35/ScreenCapture35.jpg" length="64309" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6942/36/ScreenCapture36.jpg" length="74805" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6942/37/ScreenCapture37.jpg" length="89865" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6942/38/ScreenCapture38.jpg" length="82981" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6942/39/ScreenCapture39.jpg" length="56052" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6942/40/ScreenCapture40.jpg" length="48061" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6942/41/ScreenCapture41.jpg" length="53361" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6942/42/ScreenCapture42.jpg" length="47449" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6942/43/ScreenCapture43.jpg" length="49651" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6942/44/ScreenCapture44.jpg" length="54284" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6942/45/ScreenCapture45.jpg" length="55459" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6942/46/ScreenCapture46.jpg" length="47934" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6942/47/ScreenCapture47.jpg" length="46211" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6942/48/ScreenCapture48.jpg" length="78760" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6942/49/ScreenCapture49.jpg" length="65545" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6942/50/ScreenCapture50.jpg" length="74125" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6942/51/ScreenCapture51.jpg" length="85544" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6942/52/ScreenCapture52.jpg" length="56995" type="image/jpeg"/></item><item>
<title>Medicis Sued by Revance Therapeutics Over RT001 Agreement [Alert, class:BotulinumToxins, comp:Medicis]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology6430</link>
<description>Medicis Sued by Revance Therapeutics Over RT001 Agreement [Alert, class:BotulinumToxins, comp:Medicis]</description><category>Alert</category><category>class:BotulinumToxins</category><category>comp:Medicis</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology6430</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120831&edate=20120501&rec=6430">Medicis Sued by Revance Therapeutics Over RT001 Agreement</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=Alert"><font color="#e95e0b">:Neurology:Alert</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=class%3aBotulinumToxins"><font color="#e95e0b">:Neurology:class:BotulinumToxins</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=comp%3aMedicis"><font color="#e95e0b">:Neurology:comp:Medicis</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology6430">Neurology6430</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 28 May 2012 | 12:28</font><br><br><div style="margin-bottom: 10px;">Comment: Bloomberg is reporting that Medicis is being sued by Revance Therapeutics for reneging on a 2007 buyout agreement tied to the development of its transdermal toxin RT001.<wbr> </div><div style="margin-bottom: 10px;">Revance officials contend in a Delaware Chancery Court Lawsuit that Medicis executives have refused to acknowledge that Revance has hit pre-specified development targets, covered by a 2007 agreement, that necessitate Medicis making a choice as to whether acquire Revance, pay a licensing fee for rights to the toxin or loose the option to either.<wbr> </div><div style="margin-bottom: 10px;">Revance lawyers are apparently claiming that by disputing the development target Medicis is effectively preventing Revance from raising critical investment funds or finding alternative partners.<wbr> </div><div style="margin-bottom: 10px;">Revance's claim is based on discussions with the FDA which earlier this month gaive Revance the authorisation to proceed to phIII evaluation of RT001.<wbr> </div><div style="margin-bottom: 10px;">That clearance should under the 2007 agreement have triggered Medicis’ obligations to decide whether it wanted to buy Revance, pay for an exclusive license to RT001 or allow Revance to seek out other partners.<wbr> </div><div style="margin-bottom: 10px;">Medicis officials have refused to make that call, demanding instead that Revance “engage in additional lengthy regulatory activities,” according to the suit.<wbr> </div><div style="margin-bottom: 10px;">Revance executives contend that Medicis officials are dragging their feet in honoring the agreement “in an attempt to starve Revance to the point that Medicis can obtain Revance’s technology for a bargain price,” the lawyers claim in the suit.<wbr> </div><div><A href="http://www.bloomberg.com/">www.<wbr>bloomberg.<wbr>com</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120831&edate=20120501&rec=6430">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-05-28T12:28:01+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>1st Data Demonstrating A Potential Treatment Biomarker For Gastric Cancer [headline, class:KinaseInhibitors]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology8297</link>
<description>1st Data Demonstrating A Potential Treatment Biomarker For Gastric Cancer [headline, class:KinaseInhibitors]</description><category>headline</category><category>class:KinaseInhibitors</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology8297</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8297">1st Data Demonstrating A Potential Treatment Biomarker For Gastric Cancer</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=class%3aKinaseInhibitors"><font color="#e95e0b">:Oncology:class:KinaseInhibitors</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=headline"><font color="#e95e0b">:Oncology:headline</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8297">Oncology8297</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 28 May 2012 | 09:46</font><br><br><div style="margin-bottom: 10px;">Comment: Amgen has identified a potential predictive biomarker of response to 
treatment with Rilotumumab (AMG102) and is preparing to move into phIII 
development for advanced gastric cancer.<wbr> </div><div style="margin-bottom: 10px;">Analysis of a previously reported phII study of rilotumumab in patients with 
locally advanced or metastatic gastric or gastroesophageal cancer has shown that 
treatment in combination with chemotherapy improved median overal survival (OS) 
in patients whose tumours exhibited high MET expression.<wbr> </div><div style="margin-bottom: 10px;">The addition of rilotumumab to chemotherapy in patients with gastric tumors 
with high MET expression improved median OS from 5.<wbr>7 months to 11.<wbr>1 months (HR = 
0.<wbr>29, 95 percent CI, 0.<wbr>11 - 0.<wbr>76).<wbr> Conversely, in patients with gastric tumors 
with low MET expression, the addition of rilotumumab to chemotherapy was 
associated with a trend towards unfavorable OS (HR = 1.<wbr>84, 95 percent CI, 0.<wbr>78 - 
4.<wbr>34).<wbr> </div><div style="margin-bottom: 10px;">These results have led <ORG value="NASDAQ-NMS:AMGN">Amgen</ORG> to plan a Phase 3 study to confirm the efficacy 
of rilotumumab in advanced gastric and gastroesophageal cancer with high MET 
expression.<wbr> </div><div style="margin-bottom: 10px;">Rilotumumab is a fully human monoclonal antibody designed to inhibit 
hepartocyte growth factor /<wbr>scallter factor (HGF/<wbr>SF): MET pathway.<wbr> </div><div style="margin-bottom: 10px;">Full results of the biomarker study will be presented in an oral presentation 
at ASCO next weekend </div><div>source: <A href="http://www.amgen.com">www.<wbr>amgen.<wbr>com</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8297">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-05-28T09:46:55+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>Update on the Exelixis' Overall Survival Trial with Cabozantinib for mCRPC [dis:Prostate, :PharmaWorld:sub:ClinicalTrial, :PharmaWorld:mkt:NorthAmerica]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology8296</link>
<description>Update on the Exelixis' Overall Survival Trial with Cabozantinib for mCRPC [dis:Prostate, :PharmaWorld:sub:ClinicalTrial, :PharmaWorld:mkt:NorthAmerica]</description><comments>http://ci.beaufour-ipsen.com/traction/permalink/Oncology8296</comments><category>dis:Prostate</category><category>sub:ClinicalTrial</category><category>mkt:NorthAmerica</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology8296</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8296">Update on the Exelixis' Overall Survival Trial with Cabozantinib for mCRPC</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=mkt%3aNorthAmerica"><font color="#e95e0b">:PharmaWorld:mkt:NorthAmerica</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=sub%3aClinicalTrial"><font color="#e95e0b">:PharmaWorld:sub:ClinicalTrial</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8296">Oncology8296</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 25 May 2012 | 16:27</font><br><br><div style="margin-bottom: 10px;">Comment: Clinicaltrials.<wbr>gov is listing the COMET-1 trial which will be conducted in the U.<wbr>S to assess the effect of cabozantinib compared to prednisone on OS in men with previously treated mCRPC with bone-dominant disease who have experienced disease progression on docetaxel-containing chemotherapy and abiraterone or MDV3100.<wbr> The company is intending to go out to a large number of sites (&gt;250) in EU and Asia Pacific.<wbr> </div><div style="margin-bottom: 10px;"><A href="http://clinicaltrials.gov/ct2/show/NCT01605227?cond=Glabellar+OR+Canthal+OR+spasticity+OR+blepharospasm+OR+prostate+OR+neuroendocrine+OR+acromegaly+OR+hemophilia+OR+botulinum&amp;fund=2&amp;rcv_s=03%2F26%2F2012&amp;rank=5"><STRONG><FONT size="3">Study Details NCT01605227</FONT></STRONG></A> </div><div style="margin-bottom: 10px;">Recruitment: approx.<wbr> 960 participants </div><div style="margin-bottom: 10px;">Start date: June 2012 - Completion date: March 2014 </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Protocol</FONT></STRONG> </div><div><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8296/1/copiedImage%5b0%5d.png?user-agent=rss"> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Oncology8302c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div><SPAN style="widows: 2; text-transform: none; text-indent: 0px; display: inline !important; font: 13px arial, sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #222222; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">Exelixis has announced the completed submission of a rolling NDA to the FDA for cabozantinib to treat medullary thyroid cancer, its lead indication.<wbr> The company has requested a Priority Review.<wbr> </SPAN><SPAN style="widows: 2; text-transform: none; text-indent: 0px; display: inline !important; font: 13px arial, sans-serif; white-space: normal; orphans: 2; float: none; letter-spacing: normal; color: #222222; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;">Exelixis, began the submission of the NDA in December.<wbr></SPAN> </div><font size="-1">Jacquelyne CANTLE MEYRICK / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8302" class="commentpermalink">Oncology8302</a> / <span class="date">31 May 2012</span> /
<span class="time">12:53:58 o'clock CEST</span>
</font></div><a name="oncology8296attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8296/1/copiedImage%5b0%5d.png">copiedImage[0].png</a>&nbsp;&nbsp;(82,3 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8296">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-05-25T16:27:21+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8296/1/copiedImage%5b0%5d.png" length="84274" type="image/x-png"/></item><item>
<title>WCNR Intelligence Part 1 - Allergan's Spasticity Support Initiatives [Alert, class:BotulinumToxins, comp:Allergan, dis:Spasticity, prod:Botox, :PharmaWorld:congress:WCNR, :PharmaWorld:mkt:Brazil, :PharmaWorld:mkt:Intercontinental]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology6428</link>
<description>WCNR Intelligence Part 1 - Allergan's Spasticity Support Initiatives [Alert, class:BotulinumToxins, comp:Allergan, dis:Spasticity, prod:Botox, :PharmaWorld:congress:WCNR, :PharmaWorld:mkt:Brazil, :PharmaWorld:mkt:Intercontinental]</description><category>Alert</category><category>class:BotulinumToxins</category><category>comp:Allergan</category><category>dis:Spasticity</category><category>prod:Botox</category><category>congress:WCNR</category><category>mkt:Brazil</category><category>mkt:Intercontinental</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology6428</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120831&edate=20120501&rec=6428">WCNR Intelligence Part 1 - Allergan's Spasticity Support Initiatives</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=Alert"><font color="#e95e0b">:Neurology:Alert</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=class%3aBotulinumToxins"><font color="#e95e0b">:Neurology:class:BotulinumToxins</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=comp%3aAllergan"><font color="#e95e0b">:Neurology:comp:Allergan</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=dis%3aSpasticity"><font color="#e95e0b">:Neurology:dis:Spasticity</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=prod%3aBotox"><font color="#e95e0b">:Neurology:prod:Botox</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=congress%3aWCNR"><font color="#e95e0b">:PharmaWorld:congress:WCNR</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=mkt%3aBrazil"><font color="#e95e0b">:PharmaWorld:mkt:Brazil</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=mkt%3aIntercontinental"><font color="#e95e0b">:PharmaWorld:mkt:Intercontinental</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology6428">Neurology6428</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 24 May 2012 | 17:26</font><br><br><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 11pt; FONT-FAMILY: 'Arial','sans-serif'"><FONT face="Verdana" size="2">Comment:</FONT> <FONT face="Verdana" size="2">Little ‘new’ competitor data as such was shown at the WCNR but Allergan’ activites were focused on creating awareness and support initiatives for long-term stroke survivors as highlighted in their “Call To Action Symposia”.<wbr> Some useful developmental intelligence was also obtained about the status of the cerebral palsy Botox programme in the US.<wbr></FONT></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 11pt; FONT-FAMILY: 'Arial','sans-serif'">Thanks to Beth Elliott (CI Department) who was in attendance we have an extremely detailed and useful update on all these points.<wbr></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 11pt; FONT-FAMILY: 'Arial','sans-serif'"><STRONG>Key Trial Information</STRONG> </SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 11pt; FONT-FAMILY: 'Arial','sans-serif'">Allergan apparently will proceed with a planned phase III Botox Cerebral Palsy trial in the USA and are in the process of starting recruitment.<wbr> In addition, in planning is a multiple sclerosis patient trial focused on the treatment of lower limb (abductor) spasticity to improve ambulation.<wbr> </SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 11pt; FONT-FAMILY: 'Arial','sans-serif'"><STRONG>Allergan’s Symposia</STRONG></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 11pt; FONT-FAMILY: 'Arial','sans-serif'">Entitled ‘Ensuring Quality Care and Support After Stroke: A World Stroke Campaign Symposia’.<wbr> </SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 11pt; FONT-FAMILY: 'Arial','sans-serif'">Capacity in the hall was 500 with an expected 376 persons attending although on the day, the hall was only half full.<wbr> </SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 11pt; FONT-FAMILY: 'Arial','sans-serif'">At no time during the symposia was Botox mentioned, rather the main objectives of the symposia as highlighted by John Olver in his introductory speech were to highlight: -</SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 11pt; FONT-FAMILY: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol"><SPAN style="mso-list: Ignore">· </SPAN></SPAN><SPAN lang="EN-US" style="FONT-SIZE: 11pt; FONT-FAMILY: 'Arial','sans-serif'">The growing need to improve long term management of stroke (&gt;3 months after stroke) through active involvement of all healthcare professionals involved in the care of stroke survivors – focusing on a multidisciplinary approach.<wbr> </SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 11pt; FONT-FAMILY: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol"><SPAN style="mso-list: Ignore">· </SPAN></SPAN><SPAN lang="EN-US" style="FONT-SIZE: 11pt; FONT-FAMILY: 'Arial','sans-serif'">To examine the role of sustained and customised rehabilitation in facilitating neurologic and functional recovery</SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 11pt; FONT-FAMILY: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol"><SPAN style="mso-list: Ignore">· </SPAN></SPAN><SPAN lang="EN-US" style="FONT-SIZE: 11pt; FONT-FAMILY: 'Arial','sans-serif'">To discuss the clinical evidence supporting early and long term post stroke interventions</SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 11pt; FONT-FAMILY: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol"><SPAN style="mso-list: Ignore">· </SPAN></SPAN><SPAN lang="EN-US" style="FONT-SIZE: 11pt; FONT-FAMILY: 'Arial','sans-serif'">To review procedures and tools, such as best practice guidelines and post stroke checklists that help ensure quality care and continued support for stroke survivors</SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 11pt; FONT-FAMILY: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol"><SPAN style="mso-list: Ignore">· </SPAN></SPAN><SPAN lang="EN-US" style="FONT-SIZE: 11pt; FONT-FAMILY: 'Arial','sans-serif'">To raise a ‘call to action’ for improved long term stroke management</SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 11pt; FONT-FAMILY: 'Arial','sans-serif'">John Olver, also introduced the Advancing Care and Treatment of Long Term Stroke (ACT) Initiative which was borne from the Global Stroke Community Advisory Panel (GSCAP) that Allergan created and supports.<wbr></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 11pt; FONT-FAMILY: 'Arial','sans-serif'">Note: This strategy of implementing a global advisory panel was also seen in Migraine.<wbr> </SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 11pt; FONT-FAMILY: 'Arial','sans-serif'">The mission of this initiative is to improve the quality of long-term stroke management for stroke survivors living with post stroke complications through the implementation of advocacy and educational tools.<wbr></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 11pt; FONT-FAMILY: 'Arial','sans-serif'">GSCAP is made up of a group of global, multidisciplinary experts </SPAN> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/6428/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 11pt; FONT-FAMILY: 'Arial','sans-serif'">The key activities of the group to date are listed below.<wbr> Along with the five review articles published, three more are in press and this same symposia will be presented at the World Stroke Congress in October 2012 (Brazil).<wbr> The slide library will be distributed in the ‘very near future’.<wbr> It is assumed that they will be available at </SPAN><A href="http://www.strokecampaign.org/"><SPAN style="FONT-SIZE: 11pt; COLOR: windowtext; FONT-FAMILY: 'Arial','sans-serif'">www.<wbr>strokecampaign.<wbr>org</SPAN></A> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/6428/2/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/6428/3/ScreenCapture3.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 11pt; FONT-FAMILY: 'Arial','sans-serif'">David Good’s talk on sustained and Customized Rehabilitation Maximises Brain Recovery focused on stroke impairments and implications, mechanisms and trajectory of brain injury and recovery, historical vs current thinking (residual capacity for neurologic recovery) and the potential role for customized and sustained rehabilitation in neurologic recovery.<wbr></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 11pt; FONT-FAMILY: 'Arial','sans-serif'">He noted that 1/<wbr>3 of stroke survivors still have moderate or severe impairment five years after stroke</SPAN> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/6428/4/ScreenCapture4.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 11pt; FONT-FAMILY: 'Arial','sans-serif'">Historically, we believe that most of the recovery seems to occur in the first 30 - 60 days and then plateaus after this.<wbr> It is now clear that this belief is only partially true, recovery does happen early on but can also happen much later.<wbr></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 11pt; FONT-FAMILY: 'Arial','sans-serif'"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/6428/5/ScreenCapture5.jpg?user-agent=rss"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 11pt; FONT-FAMILY: 'Arial','sans-serif'">Various computational models of motor recovery have been defined with the goal of gaining insight into the concept of residual capacity and functional potential in stroke survivors.<wbr> These models, if accurate have shown that brain networks may have greater capacity for post-stroke recovery, with estimates of up to 50%-80% potential residual capacity not previously realised.<wbr> He suggested that if we can access/<wbr>harness this, there are huge ramifications for latent rehabilitation.<wbr></SPAN> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/6428/6/ScreenCapture6.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 11pt; FONT-FAMILY: 'Arial','sans-serif'; mso-fareast-font-family: 'MS Mincho'; mso-fareast-theme-font: minor-fareast; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA">There are a number of rehabilitation programmes available and these should be aimed at patients with residual capacity if possible.<wbr></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 11pt; FONT-FAMILY: 'Arial','sans-serif'; mso-fareast-font-family: 'MS Mincho'; mso-fareast-theme-font: minor-fareast; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/6428/7/ScreenCapture7.jpg?user-agent=rss"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 11pt; FONT-FAMILY: 'Arial','sans-serif'">Dr.<wbr> Good then went on to discuss motor recovery potential and pyramidal tract damage followed by treatments which could aid in enhancing motor function in chronic stroke patients</SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 11pt; FONT-FAMILY: 'Arial','sans-serif'; mso-fareast-font-family: 'MS Mincho'; mso-fareast-theme-font: minor-fareast; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA">The next speaker Katharina Sunnerhagen concentrated on evidence-based support for post stroke interventions.<wbr> She reviewed the topics shown below and provided an evidence rating (low, moderate, strong) on the strength of data available.<wbr> She highlighted that large amounts of data are available but is not being used effectively in daily practice.<wbr></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 11pt; FONT-FAMILY: 'Arial','sans-serif'; mso-fareast-font-family: 'MS Mincho'; mso-fareast-theme-font: minor-fareast; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/6428/8/ScreenCapture8.jpg?user-agent=rss"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 11pt; FONT-FAMILY: 'Arial','sans-serif'">Specifically for Botulinum Toxin, she presented the following:</SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 11pt; FONT-FAMILY: 'Arial','sans-serif'"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/6428/9/ScreenCapture9.jpg?user-agent=rss"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 11pt; FONT-FAMILY: 'Arial','sans-serif'"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/6428/10/ScreenCapture10.jpg?user-agent=rss"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 11pt; FONT-FAMILY: 'Arial','sans-serif'">She concluded the talk by stating the importance of a management plan for stroke rehabilitation, utlising the vast amounts of recent data that is currently under used</SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 11pt; FONT-FAMILY: 'Arial','sans-serif'">The penultimate talk by Anthony Ward entitled Processes and Tools Ensure Quality Care and Support After Stroke reviewed data from the stroke registries, highlighted rehabilitation unmet needs, and focused upon initiatives to improve long-term stroke management and the development and implementation of the Post Stroke Checklist (PSC).<wbr></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 11pt; FONT-FAMILY: 'Arial','sans-serif'"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/6428/11/ScreenCapture11.jpg?user-agent=rss"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 11pt; FONT-FAMILY: 'Arial','sans-serif'">He noted that whilst there are a number of ongoing stroke initiatives around the globe that there are no internationally accepted quality standards for longer-term post stroke management.<wbr> Although, healthcare providers and stroke organisations are implementing strategies/<wbr>guidelines which include references to longer-term stroke management, there is still a need to understand the patient review processes (in primary care and specialist centres).<wbr></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 11pt; FONT-FAMILY: 'Arial','sans-serif'"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/6428/12/ScreenCapture12.jpg?user-agent=rss"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 11pt; FONT-FAMILY: 'Arial','sans-serif'"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/6428/13/ScreenCapture13.jpg?user-agent=rss"></SPAN> </div><div style="margin-bottom: 10px;"><P style="TEXT-JUSTIFY: inter-ideograph; MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: justify"><SPAN lang="EN-US" style="FONT-SIZE: 11pt; FONT-FAMILY: 'Arial','sans-serif'">This paved the way for the introduction of the PSC (generated by GSCAP), which addresses the issue of providing a continuum of care and patient reviews which are not wholly addressed in the strategies/<wbr>guidelines .<wbr> </SPAN></P> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 11pt; FONT-FAMILY: 'Arial','sans-serif'">The checklist is made up of 11 domains with one question attached to each domain.<wbr> Depending on the answer, the <SPAN style="mso-bidi-font-weight: bold">practitioners</SPAN> will be directed down a clinical pathway (which may change from country to country).<wbr> This checklist empowers the patient, allows the primary care team to know what they can do themselves and if they need to refer patients to more specialist centres.<wbr> It takes 10-15 minutes to complete and will be available via mobile devices at a later stage.<wbr> </SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 11pt; FONT-FAMILY: 'Arial','sans-serif'"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/6428/14/ScreenCapture14.jpg?user-agent=rss"></SPAN> </div><div style="margin-bottom: 10px;"><P style="TEXT-JUSTIFY: inter-ideograph; MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: justify"><SPAN lang="EN-US" style="FONT-SIZE: 11pt; FONT-FAMILY: 'Arial','sans-serif'">The checklist will be carried out by the stroke survivor themselves at 3,6, 12 months and then annually thereafter.<wbr> The patient will also be reminded to complete the checklist by their nurse/<wbr>Doctor (at a later stage, mobile devices will remind the patient).<wbr> Once the patient has completed the checklist, the nurse/<wbr>Doctor will review the checklist with the patient to discuss if the issues are important enough to move forward on to specialist care.<wbr> </SPAN></P> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/6428/15/ScreenCapture15.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><P style="TEXT-JUSTIFY: inter-ideograph; MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: justify"><SPAN lang="EN-US" style="FONT-SIZE: 11pt; FONT-FAMILY: 'Arial','sans-serif'">During the pilot (UK, Singapore and other countries), the group also tested the value of the checklist with the patients and <SPAN style="mso-bidi-font-weight: bold">practitioners</SPAN> and have uncovered key leanings to date.<wbr></SPAN></P> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/6428/16/ScreenCapture16.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 11pt; FONT-FAMILY: 'Arial','sans-serif'">Speaking with Dr.<wbr>Ward afterwards, Beth established that the checklist will be published in the autumn with the aim of getting it in as many journals as possible including Stroke, BMJ as well as local/<wbr>regional community nurse/<wbr>therapist magazines.<wbr> They are aiming for the checklist to be launched around July 2013.<wbr> </SPAN> </div><div style="margin-bottom: 10px;"><P style="TEXT-JUSTIFY: inter-ideograph; MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: justify"><SPAN lang="EN-US" style="FONT-SIZE: 11pt; FONT-FAMILY: 'Arial','sans-serif'">The final talk was by Prof Stephan Davis on behalf of the World Stroke Campaign introducing the 1 in 6 campaign.<wbr> It has been translated in multiple languages and the aims and milestones are as follows:</SPAN></P> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/6428/17/ScreenCapture17.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 11pt; FONT-FAMILY: 'Arial','sans-serif'"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/6428/18/ScreenCapture18.jpg?user-agent=rss"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 11pt; FONT-FAMILY: 'Arial','sans-serif'"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/6428/19/ScreenCapture19.jpg?user-agent=rss"></SPAN> </div><div style="margin-bottom: 10px;"><P style="TEXT-JUSTIFY: inter-ideograph; MARGIN: 0cm 0cm 0pt; TEXT-ALIGN: justify"><SPAN lang="EN-US" style="FONT-SIZE: 11pt; FONT-FAMILY: 'Arial','sans-serif'">Other Allergan activities during the congress: </SPAN></P> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 11pt; FONT-FAMILY: 'Arial','sans-serif'">Along with supporting the development of the PSC, it is clear Allergan wants to be ‘at the table’ when countries/<wbr>stroke organisations are collating or updating guidelines.<wbr> It held an invitation only European Delegates Meeting which was an informal group discussion led by Anthony Ward.<wbr> The objective was to look at the implementation of evidence-based guidelines, compare the situation in the different countries of Europe and discuss proposals for a European strategy in neurological rehabilitation.<wbr> </SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 11pt; FONT-FAMILY: 'Arial','sans-serif'">Anthony Ward started the discussion by showing a few slides on the various EU guidelines followed by a short talk by Prof.<wbr> Heinrich Binder from Austria outlining the use and adaptation of guidelines for clinical practice in Europe.<wbr> Once the talks concluded they held an open discussion on proposals for a European strategy in neurological rehabilitation.<wbr> No consensus was reached but topics of the discussion revolved around what information is already available, what questions need to be asked, where and how to store the information.<wbr> Dr.<wbr> Ward then proposed that the 19 delegates in the audience become a ‘quasi think-tank’ to which he will type up the minutes of the meeting and will forward these to the delegates with other thoughts/<wbr>opinions to which the think tank can act as a sound board.<wbr> </SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 11pt; FONT-FAMILY: 'Arial','sans-serif'">In addition, Marion Walker from the UK is in talks with the WSO and supported by Allergan to introduce a European or International patients bill of rights.<wbr></SPAN> </div><div><SPAN lang="EN-US" style="FONT-SIZE: 11pt; FONT-FAMILY: 'Arial','sans-serif'">Finally, it is understood that Allergan was in late stage discussions with an orthotics company but pulled out at the very last minute.<wbr> </SPAN> </div><!-- Comment details --><a name="neurology6428attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/6428/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(83,7 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/6428/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(103,4 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/6428/3/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(83 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/6428/4/ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(101,9 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/6428/5/ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(83,2 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/6428/6/ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(102,4 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/6428/7/ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(92,2 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/6428/8/ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(108,3 KB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/6428/9/ScreenCapture9.jpg">ScreenCapture9.jpg</a>&nbsp;&nbsp;(86 KB)<br>&nbsp;&nbsp;10.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/6428/10/ScreenCapture10.jpg">ScreenCapture10.jpg</a>&nbsp;&nbsp;(87,4 KB)<br>&nbsp;&nbsp;11.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/6428/11/ScreenCapture11.jpg">ScreenCapture11.jpg</a>&nbsp;&nbsp;(67,9 KB)<br>&nbsp;&nbsp;12.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/6428/12/ScreenCapture12.jpg">ScreenCapture12.jpg</a>&nbsp;&nbsp;(74,3 KB)<br>&nbsp;&nbsp;13.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/6428/13/ScreenCapture13.jpg">ScreenCapture13.jpg</a>&nbsp;&nbsp;(77,5 KB)<br>&nbsp;&nbsp;14.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/6428/14/ScreenCapture14.jpg">ScreenCapture14.jpg</a>&nbsp;&nbsp;(99,1 KB)<br>&nbsp;&nbsp;15.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/6428/15/ScreenCapture15.jpg">ScreenCapture15.jpg</a>&nbsp;&nbsp;(146,4 KB)<br>&nbsp;&nbsp;16.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/6428/16/ScreenCapture16.jpg">ScreenCapture16.jpg</a>&nbsp;&nbsp;(110,7 KB)<br>&nbsp;&nbsp;17.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/6428/17/ScreenCapture17.jpg">ScreenCapture17.jpg</a>&nbsp;&nbsp;(97,9 KB)<br>&nbsp;&nbsp;18.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/6428/18/ScreenCapture18.jpg">ScreenCapture18.jpg</a>&nbsp;&nbsp;(112,3 KB)<br>&nbsp;&nbsp;19.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/6428/19/ScreenCapture19.jpg">ScreenCapture19.jpg</a>&nbsp;&nbsp;(91,3 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120831&edate=20120501&rec=6428">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-05-24T17:26:58+02:00</dc:date><dc:creator>jac89886</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/6428/1/ScreenCapture1.jpg" length="85690" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/6428/2/ScreenCapture2.jpg" length="105920" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/6428/3/ScreenCapture3.jpg" length="85038" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/6428/4/ScreenCapture4.jpg" length="104298" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/6428/5/ScreenCapture5.jpg" length="85146" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/6428/6/ScreenCapture6.jpg" length="104895" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/6428/7/ScreenCapture7.jpg" length="94368" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/6428/8/ScreenCapture8.jpg" length="110925" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/6428/9/ScreenCapture9.jpg" length="88057" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/6428/10/ScreenCapture10.jpg" length="89451" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/6428/11/ScreenCapture11.jpg" length="69544" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/6428/12/ScreenCapture12.jpg" length="76111" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/6428/13/ScreenCapture13.jpg" length="79376" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/6428/14/ScreenCapture14.jpg" length="101503" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/6428/15/ScreenCapture15.jpg" length="149891" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/6428/16/ScreenCapture16.jpg" length="113402" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/6428/17/ScreenCapture17.jpg" length="100253" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/6428/18/ScreenCapture18.jpg" length="115004" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/6428/19/ScreenCapture19.jpg" length="93478" type="image/jpeg"/></item><item>
<title>re: NCPE Ireland Rejects Zytiga for Reimbursement in Prostate Cancer</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology8295</link>
<description>re: NCPE Ireland Rejects Zytiga for Reimbursement in Prostate Cancer</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology8295</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8295">re: NCPE Ireland Rejects Zytiga for Reimbursement in Prostate Cancer</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8295">Oncology8295</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/41">Claudia Schymczyk</a> | 24 May 2012 | 09:33</font><br><br><div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">NCPE Ireland Rejects Zytiga for Reimbursement in Prostate Cancer</span>&nbsp;<font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=comp%3aJnJ"><font color="#e95e0b">:Oncology:comp:JnJ</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=prod%3aZytiga"><font color="#e95e0b">:Oncology:prod:Zytiga</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=mkt%3aEurope"><font color="#e95e0b">:PharmaWorld:mkt:Europe</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=sub%3aPricing"><font color="#e95e0b">:PharmaWorld:sub:Pricing</font></a>]</font></font><br><span style="font-size: 12px;">Comment: Following a pharmacoeconomic evaluation completed on May 22nd, the National Centre for PharmacoEconomics (NCPE) believe that, at the submitted price, the drug is not cost-effective for patients with mCRPC who have received prior docetaxel-based chemotherapy.<wbr> We assume that J&amp;J might be forced to discount the price of Zytiga as it did after consultation with NICE.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8291">...</a><br><font size="-1">Brigitte DESCHAMPS / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8291" class="commentpermalink">Oncology8291</a> / <span class="date">23 May 2012</span> /
<span class="time">12:04:29 o'clock CEST</span>
</font></div><div style="margin-bottom: 10px;">Since April 2012 J&amp;J is in price negotiation with German health authority.<wbr> Decision is awaited in Sept.<wbr> J&amp;J expresses incomprehension about the price comparison of Zytiga with chemotherapy.<wbr> Until final price determining in Sept  Zytiga is 100% reimbursed with a price of 5.<wbr>449,91&euro;.<wbr> Total sales since launch (Oct 11 - Mar 12): 37,1 Mio &euro; (source IMS data).<wbr> </div><div>Claudia Schmczyk-Kr&uuml;ger </div><!-- Comment details --><font size="-1">Claudia Schymczyk / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8295" class="commentpermalink">Oncology8295</a> / <span class="date">24 May 2012</span> /
<span class="time">09:33:53 o'clock CEST</span>
</font><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8295">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8291">View thread  Oncology8291: NCPE Ireland Rejects Zytiga for Reimbursement in Prostate Cancer</a>]]></content:encoded><dc:date>2012-05-24T09:33:53+02:00</dc:date><dc:creator>cls54212</dc:creator></item><item>
<title>Allergan to Start Ph3 of Botox for Urinary Incontinence (UI) in MS Patients [comp:Allergan, prod:Botox, :PharmaWorld:sub:ClinicalTrial]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology6426</link>
<description>Allergan to Start Ph3 of Botox for Urinary Incontinence (UI) in MS Patients [comp:Allergan, prod:Botox, :PharmaWorld:sub:ClinicalTrial]</description><category>comp:Allergan</category><category>prod:Botox</category><category>sub:ClinicalTrial</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology6426</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120831&edate=20120501&rec=6426">Allergan to Start Ph3 of Botox for Urinary Incontinence (UI) in MS Patients</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=comp%3aAllergan"><font color="#e95e0b">:Neurology:comp:Allergan</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=prod%3aBotox"><font color="#e95e0b">:Neurology:prod:Botox</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=sub%3aClinicalTrial"><font color="#e95e0b">:PharmaWorld:sub:ClinicalTrial</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology6426">Neurology6426</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 23 May 2012 | 18:36</font><br><br><div style="margin-bottom: 10px;"><P dir="ltr" style="MARGIN-RIGHT: 0px">Comment: Clinicaltrials.<wbr>gov is listing a new Allergan sponsored trial with Botox which will be conducted in approx.<wbr> 184 patients with at least 3 episodes of UI over a 3-day period and a history of multiple sclerosis (MS).<wbr> Primary endpoint will assess the number of UI episodes.<wbr></P> </div><div style="margin-bottom: 10px;"><P dir="ltr" style="MARGIN-RIGHT: 0px"><STRONG><FONT size="3">Study Details </FONT></STRONG><A href="http://clinicaltrials.gov/ct2/show/NCT01600716?fund=2&amp;rcv_s=05%2F09%2F2012&amp;rank=39"><STRONG><FONT size="3">NCT 01600716</FONT></STRONG></A></P> </div><div style="margin-bottom: 10px;"><P dir="ltr" style="MARGIN-RIGHT: 0px">Start date: June 2012 - Completion date: May 2014/<wbr>June 2015</P> </div><div style="margin-bottom: 10px;"><P dir="ltr" style="MARGIN-RIGHT: 0px">Protocol: Botox will be administered into the detrusor at Day1.<wbr> A second treatment, if applicable, will be administered at the earliest 12 weeks after the first treatment.<wbr></P> </div><div><P dir="ltr" style="MARGIN-RIGHT: 0px">Locations: US; Belgium; Canada; Czech Rep.<wbr>; France (Garches); Poland; Portugal; Russian Fed.<wbr></P> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120831&edate=20120501&rec=6426">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-05-23T18:36:50+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Publication Highlights Medy-Tox Prevalidation Test as an Alternative to LD50 Assay [comp:MediTox]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology6422</link>
<description>Publication Highlights Medy-Tox Prevalidation Test as an Alternative to LD50 Assay [comp:MediTox]</description><category>comp:MediTox</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology6422</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120831&edate=20120501&rec=6422">Publication Highlights Medy-Tox Prevalidation Test as an Alternative to LD50 Assay</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=comp%3aMediTox"><font color="#e95e0b">:Neurology:comp:MediTox</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology6422">Neurology6422</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 23 May 2012 | 13:21</font><br><br><div style="margin-bottom: 10px;">Comment: Medy-Tox performed a prevalidation of the compound muscle action potential (CMAP) assay to determine the potency of BoNT-A.<wbr> Results published in the online version of <EM>Toxicon</EM> (2012 May 18) suggest that the assay is an alternative method to the LD50 potency test, and meets the requirement of the 3 R's (in particular Refinement and Reduction).<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">About the CMAP Test</FONT></STRONG> </div><div style="margin-bottom: 10px;">The rat CMAP test is straightforward, highly reproducible, and can directly determine the efficacy of toxin preparations through their inhibition of neuromuscular transmission.<wbr> Thus, this method may be suitable for pharmacology studies and the quality control of toxin preparations (Kaketsuken; Toxicon 2010 Feb-Mar; 55(2-3):407-14 Epub2009 Sept 22).<wbr> </div><div style="margin-bottom: 10px;"><H1><FONT size="3">About the 3 R’s: Replacement, Reduction and Refinement</FONT></H1> </div><div style="margin-bottom: 10px;">The 3 R's are guiding principles for the use of animals in research.<wbr> </div><div style="margin-bottom: 10px;"><UL><LI><B>Replacement</B>: Alternative methods can be used that do not involve experiments on animals.<wbr></LI>
<LI><B>Reduction</B>: The number of animals used for each test will be minimised.<wbr></LI>
<LI><B>Refinement</B>: Animal distress (i.<wbr>e.<wbr> pain/<wbr>discomfort) is minimised before, during and after the test.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><FONT size="3"><STRONG>Publication Reference for Medy-Tox</STRONG></FONT> </div><div>Toxicon 2012 May 18 - <A href="http://www.ncbi.nlm.nih.gov/pubmed/22613167">http:/<wbr>/<wbr>www.<wbr>ncbi.<wbr>nlm.<wbr>nih.<wbr>gov/<wbr>pubmed/<wbr>22613167</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120831&edate=20120501&rec=6422">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-05-23T13:21:34+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>NCPE Ireland Rejects Zytiga for Reimbursement in Prostate Cancer [comp:JnJ, dis:Prostate, prod:Zytiga, :PharmaWorld:sub:Pricing, :PharmaWorld:mkt:Europe]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology8291</link>
<description>NCPE Ireland Rejects Zytiga for Reimbursement in Prostate Cancer [comp:JnJ, dis:Prostate, prod:Zytiga, :PharmaWorld:sub:Pricing, :PharmaWorld:mkt:Europe]</description><comments>http://ci.beaufour-ipsen.com/traction/permalink/Oncology8291</comments><category>comp:JnJ</category><category>dis:Prostate</category><category>prod:Zytiga</category><category>sub:Pricing</category><category>mkt:Europe</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology8291</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8291">NCPE Ireland Rejects Zytiga for Reimbursement in Prostate Cancer</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=comp%3aJnJ"><font color="#e95e0b">:Oncology:comp:JnJ</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=prod%3aZytiga"><font color="#e95e0b">:Oncology:prod:Zytiga</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=mkt%3aEurope"><font color="#e95e0b">:PharmaWorld:mkt:Europe</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=sub%3aPricing"><font color="#e95e0b">:PharmaWorld:sub:Pricing</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8291">Oncology8291</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 23 May 2012 | 12:04</font><br><br><div style="margin-bottom: 10px;">Comment: Following a pharmacoeconomic evaluation completed on May 22nd, the National Centre for PharmacoEconomics (NCPE) believe that, at the submitted price, the drug is not cost-effective for patients with mCRPC who have received prior docetaxel-based chemotherapy.<wbr> We assume that J&amp;J might be forced to discount the price of Zytiga as it did after consultation with NICE.<wbr> </div><div style="margin-bottom: 10px;">Background Please see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8279" class="defaultlink">Oncology8279: NICE Reverses Opinion And Agrees To Fund Zytiga Under the NHS</a>.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Significance</FONT></STRONG> </div><div style="margin-bottom: 10px;">In the economic submission, the cost effectiveness of Zytiga 1,000mg once daily in combination with prednisolone 10mg/<wbr>day for the treatment of patients with mCRPC who have received prior docetaxel-based chemotherapy was considered.<wbr> There were two comparator therapies included in the evaluation: prednisolone 10mg once daily, and a combination of mitoxantrone (12mg/<wbr>sq m every three weeks) and prednisolone 10mg/<wbr>day.<wbr> </div><div style="margin-bottom: 10px;">In the base-case analysis, the incremental cost-effectiveness ratio (ICER) for Zytiga plus prednisolone versus prednisolone monotherapy was found to be EUR135,454 (USD172,945) per quality-adjusted life year (QALY), while the ICER for Zytiga plus prednisolone versus mitoxantrone plus prednisolone was EUR160,388 per QALY.<wbr> </div><div style="margin-bottom: 10px;">All ICER values, including those for a subgroup of patients who had received one prior chemotherapy regimen, exceed the cost-effectiveness threshold levels considered by the Irish Health Service Executive, i.<wbr>e.<wbr> EUR45,000 per QALY and EUR20,000 per QALY.<wbr> Furthermore, the NCPE calculated that the treatment would have a cumulative budget impact of EUR9.<wbr>84 million over the first 5 years.<wbr> </div><div>Source: Global Insight </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Oncology8295c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">Since April 2012 J&amp;J is in price negotiation with German health authority.<wbr> Decision is awaited in Sept.<wbr> J&amp;J expresses incomprehension about the price comparison of Zytiga with chemotherapy.<wbr> Until final price determining in Sept  Zytiga is 100% reimbursed with a price of 5.<wbr>449,91&euro;.<wbr> Total sales since launch (Oct 11 - Mar 12): 37,1 Mio &euro; (source IMS data).<wbr> </div><div>Claudia Schmczyk-Kr&uuml;ger </div><font size="-1">Claudia Schymczyk / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8295" class="commentpermalink">Oncology8295</a> / <span class="date">24 May 2012</span> /
<span class="time">09:33:53 o'clock CEST</span>
</font></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8291">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-05-23T12:04:29+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>New Trials of BOTOX for Ped. UL and LL Spasticity [comp:Allergan, prod:Botox, dis:Spasticity, :PharmaWorld:sub:ClinicalTrial]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology6415</link>
<description>New Trials of BOTOX for Ped. UL and LL Spasticity [comp:Allergan, prod:Botox, dis:Spasticity, :PharmaWorld:sub:ClinicalTrial]</description><category>comp:Allergan</category><category>prod:Botox</category><category>dis:Spasticity</category><category>sub:ClinicalTrial</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology6415</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120831&edate=20120501&rec=6415">New Trials of BOTOX for Ped.<wbr> UL and LL Spasticity</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=comp%3aAllergan"><font color="#e95e0b">:Neurology:comp:Allergan</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=dis%3aSpasticity"><font color="#e95e0b">:Neurology:dis:Spasticity</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=prod%3aBotox"><font color="#e95e0b">:Neurology:prod:Botox</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=sub%3aClinicalTrial"><font color="#e95e0b">:PharmaWorld:sub:ClinicalTrial</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology6415">Neurology6415</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 22 May 2012 | 21:23</font><br><br><div style="margin-bottom: 10px;">Comment: Newly listed in clinicaltrials.<wbr>gov, the four Ph3 trials will assess different units of IM injections of Botox in approx.<wbr> 1,500 participants to be recruited in the U.<wbr>S.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Upper Limb Spasticity</FONT></STRONG> </div><div style="margin-bottom: 10px;"><STRONG>Study Details </STRONG><A href="http://clinicaltrials.gov/ct2/show/NCT01603602?recr=Open&amp;cond=Glabellar+OR+Canthal+OR+spasticity+OR+blepharospasm+OR+prostate+OR+neuroendocrine+OR+acromegaly&amp;fund=2&amp;rcv_s=03%2F23%2F2012&amp;rank=8"><STRONG>NCT01603602</STRONG></A> </div><div style="margin-bottom: 10px;">Recruitment: approx 412 </div><div style="margin-bottom: 10px;">Completion dates: April 2015 /<wbr> May 2015 </div><div style="margin-bottom: 10px;">Subjects will receive IM injection of BOTOX either 3U or 6U per kg of body weight into specified muscles of the upper limb.<wbr> </div><div style="margin-bottom: 10px;">Location: US </div><div style="margin-bottom: 10px;"><STRONG>Study Details </STRONG><A href="http://clinicaltrials.gov/ct2/show/NCT01603615?recr=Open&amp;cond=Glabellar+OR+Canthal+OR+spasticity+OR+blepharospasm+OR+prostate+OR+neuroendocrine+OR+acromegaly&amp;fund=2&amp;rcv_s=03%2F23%2F2012&amp;rank=10"><STRONG>NCT01603615</STRONG></A> </div><div style="margin-bottom: 10px;">Recruitment: approx 360 </div><div style="margin-bottom: 10px;">Startd date: Aug 2012 /<wbr> Completion dates: Sept 2016 </div><div style="margin-bottom: 10px;">Subjects will receive intramuscular injections of botulinum toxin Type A into the upper limb muscles and/<wbr>or lower limb muscles at a minimum of 12 weeks apart for a maximum of 5 treatments.<wbr> Treatment dosing will be according to investigator judgment not to exceed a maximum of 10 U per kg of body weight (10 U/<wbr>kg) per treatment.<wbr> </div><div style="margin-bottom: 10px;">Location: US </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Lower Limb Spasticity</FONT></STRONG> </div><div style="margin-bottom: 10px;"><STRONG>Study Details </STRONG><A href="http://clinicaltrials.gov/ct2/show/NCT01603628?recr=Open&amp;cond=Glabellar+OR+Canthal+OR+spasticity+OR+blepharospasm+OR+prostate+OR+neuroendocrine+OR+acromegaly&amp;fund=2&amp;rcv_s=03%2F23%2F2012&amp;rank=9"><STRONG>NCT01603628</STRONG></A> </div><div style="margin-bottom: 10px;">Recruitment: approx 412 </div><div style="margin-bottom: 10px;">Start date: June 2012 /<wbr> Completion date: MARCH 2016 </div><div style="margin-bottom: 10px;">Subjects will receive IM injection of BOTOX either 4U or 8U per kg of body weight into specified muscles of the lower limb </div><div style="margin-bottom: 10px;">Location: US </div><div style="margin-bottom: 10px;"><STRONG>Study Details </STRONG><A href="http://clinicaltrials.gov/ct2/show/NCT01603641?recr=Open&amp;cond=Glabellar+OR+Canthal+OR+spasticity+OR+blepharospasm+OR+prostate+OR+neuroendocrine+OR+acromegaly&amp;fund=2&amp;rcv_s=03%2F23%2F2012&amp;rank=11"><STRONG>NCT01603641</STRONG></A> </div><div style="margin-bottom: 10px;">Recruitment: approx 350 </div><div style="margin-bottom: 10px;">Startd date: Aug 2012 /<wbr> Completion date: July 2017 </div><div style="margin-bottom: 10px;">Subjects will receive intramuscular injections of botulinum toxin Type A into the lower limb muscles and/<wbr>or upper limb muscles at a minimum of 12 weeks apart for a maximum of 5 treatments.<wbr> Treatment dosing will be according to investigator judgment not to exceed a maximum of 10 U per kg of body weight (10 U/<wbr>kg) per treatment.<wbr> </div><div>Location: US </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120831&edate=20120501&rec=6415">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-05-22T21:23:46+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Dose-Titration Trial of Xeomin for Spasticity in the Leg and Arm [comp:Merz, dis:Spasticity, prod:Xeomin, :PharmaWorld:sub:ClinicalTrial]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology6414</link>
<description>Dose-Titration Trial of Xeomin for Spasticity in the Leg and Arm [comp:Merz, dis:Spasticity, prod:Xeomin, :PharmaWorld:sub:ClinicalTrial]</description><category>comp:Merz</category><category>dis:Spasticity</category><category>prod:Xeomin</category><category>sub:ClinicalTrial</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology6414</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120831&edate=20120501&rec=6414">Dose-Titration Trial of Xeomin for Spasticity in the Leg and Arm</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=comp%3aMerz"><font color="#e95e0b">:Neurology:comp:Merz</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=dis%3aSpasticity"><font color="#e95e0b">:Neurology:dis:Spasticity</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=prod%3aXeomin"><font color="#e95e0b">:Neurology:prod:Xeomin</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=sub%3aClinicalTrial"><font color="#e95e0b">:PharmaWorld:sub:ClinicalTrial</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology6414">Neurology6414</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 22 May 2012 | 20:57</font><br><br><div style="margin-bottom: 10px;">Comment: Clinicaltrials.<wbr>gov is listing a new Ph3, which purpose is to determine whether IM injections with increasing doses (from 400U to 800U) of Xeomin into muscles of the leg and/<wbr>or arm are safe and effective.<wbr> Primary endpoint will assess occurence of AEs.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Study Details - <A href="http://clinicaltrials.gov/ct2/show/NCT01603459?recr=Open&amp;cond=Glabellar+OR+Canthal+OR+spasticity+OR+blepharospasm+OR+prostate+OR+neuroendocrine+OR+acromegaly&amp;fund=2&amp;rcv_s=03%2F23%2F2012&amp;rank=4">NCT01603459</A></FONT></STRONG> </div><div style="margin-bottom: 10px;">Recruitment: approx.<wbr> 150 participants with upper and lower limb spasticity of the same body side due to cerebral causes.<wbr> </div><div style="margin-bottom: 10px;">Start date: May 2012 - Completion date: March 2014 </div><div style="margin-bottom: 10px;">Design: prospective; open-label; non-randomized; single-arm; multi-center study.<wbr> </div><div>Location: 5 sites in Gemany are currently recruiting.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120831&edate=20120501&rec=6414">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-05-22T20:57:35+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Lilly's Once-weekly GLP-1 Analogue Reports Postive Cardiovascular Risk Data At Hypertension Meeting [class:GLP1, comp:EliLilly, dis:Diabetes]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology6938</link>
<description>Lilly's Once-weekly GLP-1 Analogue Reports Postive Cardiovascular Risk Data At Hypertension Meeting [class:GLP1, comp:EliLilly, dis:Diabetes]</description><category>class:GLP1</category><category>comp:EliLilly</category><category>dis:Diabetes</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology6938</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120831&edate=20120501&rec=6938">Lilly's Once-weekly GLP-1 Analogue Reports Postive Cardiovascular Risk Data At Hypertension Meeting</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=class%3aGLP1"><font color="#e95e0b">:Endocrinology:class:GLP1</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=comp%3aEliLilly"><font color="#e95e0b">:Endocrinology:comp:EliLilly</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=dis%3aDiabetes"><font color="#e95e0b">:Endocrinology:dis:Diabetes</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology6938">Endocrinology6938</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 22 May 2012 | 14:43</font><br><br><div style="margin-bottom: 10px;">Comment: Lilly's has reported postive phII data in a non-inferiority study evaluating 24-hour blood pressure control of its invesitgational phIII once-weekly GLP-1 analogue Dulaglutide.<wbr> The data was reported at the Annual American Society of Hypertension Meeting.<wbr> </div><div style="margin-bottom: 10px;">It was noted that cardiologists and hypertensions specialists are increasingly involved with evaluating the cardiovascular effects of diabetes medication.<wbr> </div><div style="margin-bottom: 10px;">Both dulaglutide doses evaluated in the phII study were shown to be non-inferior compared to placebo at week 16 for mean 24-hour SBP, which was the primary objective of the study.<wbr> Since the NI criterion was satisfied, superiority testing was conducted, and the 1.<wbr>5 mg dose demonstrated statistically significant reductions in mean 24-hour SBP compared to placebo.<wbr> </div><div style="margin-bottom: 10px;"><UL type="disc"><LI>Dulaglutide 0.<wbr>75 mg: -1.<wbr>07 mmHg (97.<wbr>3% CI: -2.<wbr>83, 0.<wbr>68)
</LI>
<LI>Dulaglutide 1.<wbr>5 mg: -2.<wbr>79 mmHg (97.<wbr>3% CI: -4.<wbr>58, -1.<wbr>00)
</LI>
</UL> </div><div style="margin-bottom: 10px;">Similar results were observed for comparisons at week 26.<wbr> </div><div style="margin-bottom: 10px;">The study also had several secondary objectives, including effects on mean 24-hour diastolic blood pressure (DBP, or pressure when the heart relaxes between beats) and mean 24-hour heart rate.<wbr> For mean 24-hour DBP, the NI criterion (2.<wbr>5 mmHg) was met for both dulaglutide doses compared to placebo at weeks 16 and 26.<wbr> </div><div style="margin-bottom: 10px;">For mean 24-hour heart rate, the 0.<wbr>75 mg dulaglutide dose met the NI criterion (3 bpm) at both weeks 16 and 26 compared to placebo (1.<wbr>62 bpm [97.<wbr>3% CI: 0.<wbr>32, 2.<wbr>92] and 1.<wbr>26 bpm [97.<wbr>3% CI: -0.<wbr>13, 2.<wbr>64], respectively).<wbr> The 1.<wbr>5 mg dose did not meet the NI criterion at either week 16 (2.<wbr>84 bpm [97.<wbr>3% CI: 1.<wbr>52, 4.<wbr>16] or week 26 (3.<wbr>50 bpm [97.<wbr>3% CI: 2.<wbr>10, 4.<wbr>91]).<wbr> This effect on heart rate is consistent with what has been observed for other compounds in the GLP-1 agonist class.<wbr> </div><div style="margin-bottom: 10px;">Both doses of dulaglutide demonstrated statistically significant reductions in HbA1c (average blood glucose levels over a three-month period) from baseline, compared to placebo, at weeks 16 and 26.<wbr> </div><div style="margin-bottom: 10px;"><DIV id="rpuCopySelection" style="position: fixed; text-align: left; width: 2000px; display: block; color: black; font-size: 12px; top: 0px; left: -5000px;">
<P>Both dulaglutide doses evaluated were shown to be non-inferior compared to placebo at week 16 for mean 24-hour SBP, which was the primary objective of the study.<wbr> Since the NI criterion was satisfied, superiority testing was conducted, and the 1.<wbr>5 mg dose demonstrated statistically significant reductions in mean 24-hour SBP compared to placebo.<wbr></P>
<UL class="discStyle" type="disc"><LI>Dulaglutide 0.<wbr>75 mg: -1.<wbr>07 mmHg (97.<wbr>3% CI: -2.<wbr>83, 0.<wbr>68)
</LI>
<LI>Dulaglutide 1.<wbr>5 mg: -2.<wbr>79 mmHg (97.<wbr>3% CI: -4.<wbr>58, -1.<wbr>00)
</LI>
</UL>
<P>Similar results were observed for comparisons at week 26.<wbr></P>
<P>The study also had several secondary objectives, including effects on mean 24-hour diastolic blood pressure (DBP, or pressure when the heart relaxes between beats) and mean 24-hour heart rate.<wbr> For mean 24-hour DBP, the NI criterion (2.<wbr>5 mmHg) was met for both dulaglutide doses compared to placebo at weeks 16 and 26.<wbr></P>
<P>For mean 24-hour heart rate, the 0.<wbr>75 mg dulaglutide dose met the NI criterion (3 bpm) at both weeks 16 and 26 compared to placebo (1.<wbr>62 bpm [97.<wbr>3% CI: 0.<wbr>32, 2.<wbr>92] and 1.<wbr>26 bpm [97.<wbr>3% CI: -0.<wbr>13, 2.<wbr>64], respectively).<wbr> The 1.<wbr>5 mg dose did not meet the NI criterion at either week 16 (2.<wbr>84 bpm [97.<wbr>3% CI: 1.<wbr>52, 4.<wbr>16] or week 26 (3.<wbr>50 bpm [97.<wbr>3% CI: 2.<wbr>10, 4.<wbr>91]).<wbr> This effect on heart rate is consistent with what has been observed for other compounds in the GLP-1 agonist class.<wbr></P>
<P>Both doses of dulaglutide demonstrated statistically significant reductions in HbA1c (average blood glucose levels over a three-month period) from baseline, compared to placebo, at weeks 16 and 26.<wbr></P>
<P>The most frequently reported adverse events were gastrointestinal (including diarrhea, nausea and vomiting).<wbr> This is consistent with other GLP-1 agonists.<wbr></P>
<P>Source: <A href="http://www.lilly.com">www.<wbr>lilly.<wbr>com</A></P>
</DIV> </div><div>source: <A href="http://www.lilly.com">www.<wbr>lilly.<wbr>com</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120831&edate=20120501&rec=6938">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-05-22T14:43:49+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>re: Astellas &amp; Medivation Announce Format of The MDV3100 Presentations At ASCO</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology8290</link>
<description>re: Astellas &amp; Medivation Announce Format of The MDV3100 Presentations At ASCO</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology8290</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8290">re: Astellas & Medivation Announce Format of The MDV3100 Presentations At ASCO</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8290">Oncology8290</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 22 May 2012 | 14:25</font><br><br><div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Astellas & Medivation Announce Format of The MDV3100 Presentations At ASCO</span>&nbsp;<font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=class%3aAntihormonals"><font color="#e95e0b">:Oncology:class:Antihormonals</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=comp%3aAstellas"><font color="#e95e0b">:Oncology:comp:Astellas</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=headline"><font color="#e95e0b">:Oncology:headline</font></a>]</font></font><br><span style="font-size: 12px;"><SPAN style="font-family: arial,helvetica,sans-serif; font-size: medium;">Comment: Astellas &amp; Medivation have jointly announced the data that will be presented at ASCO on MDV3100 either in oral, poster or during a symposium, which in addtion to more data from the AFFIRM trial will include data on neoadjuvant use in high risk localised prostate cancer, comparative phII data versus bicalutamide and phI breast cancer data.<wbr></SPAN></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8287">...</a><br><font size="-1">Jacquelyne CANTLE MEYRICK / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8287" class="commentpermalink">Oncology8287</a> / <span class="date">21 May 2012</span> /
<span class="time">16:47:50 o'clock CEST</span>
</font></div><div>Comment: Astellas and Medivation have today announced that Medivation has filed an NDA for enzalutamide (formerly MDV3100)  for the treatment of post-docetaxel CRPC, requesting a priority review.<wbr> If granted the FDA goal for completing the review is six months.<wbr> </div><!-- Comment details --><font size="-1">Jacquelyne CANTLE MEYRICK / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8290" class="commentpermalink">Oncology8290</a> / <span class="date">22 May 2012</span> /
<span class="time">14:25:06 o'clock CEST</span>
</font><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8290">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8287">View thread  Oncology8287: Astellas & Medivation Announce Format of The MDV3100 Presentations At ASCO</a>]]></content:encoded><dc:date>2012-05-22T14:25:06+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>Novel Oral Octreotide Formulation Receives US Patent [class:SomatostatinAnalogue, prod:Octreotide, headline]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology6937</link>
<description>Novel Oral Octreotide Formulation Receives US Patent [class:SomatostatinAnalogue, prod:Octreotide, headline]</description><category>class:SomatostatinAnalogue</category><category>prod:Octreotide</category><category>headline</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology6937</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120831&edate=20120501&rec=6937">Novel Oral Octreotide Formulation Receives US Patent</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=class%3aSomatostatinAnalogue"><font color="#e95e0b">:Endocrinology:class:SomatostatinAnalogue</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=headline"><font color="#e95e0b">:Endocrinology:headline</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=prod%3aOctreotide"><font color="#e95e0b">:Endocrinology:prod:Octreotide</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology6937">Endocrinology6937</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 22 May 2012 | 13:18</font><br><br><div style="margin-bottom: 10px;">Comment: Aegis Therapeutics has been awarded a new US patent providing broad protection for different pharmaceutical compositions of octreotide including oral, buccal and metered dose nasal spray formulations.<wbr> </div><div style="margin-bottom: 10px;">Patent No 8,133,863 covers highly stable octreotide formulations incorporating Aegis's Intrvail/<wbr>Protek excipients.<wbr> They stabilize, prevent aggregation and reduce unwanted immunogenicity of protein and peptide therapeutics while avoiding the oxidative damage caused by polysorbate surfactants currently found in manhy protein injectable drugs.<wbr> </div><div style="margin-bottom: 10px;">Back in April 2011 Aegis reported in a press release that scientists at Albany Medical College had demonstrated that the oral bioavailability of the Aegis formulation surpassed that of the injectable formulation in male Swiss webster mice.<wbr> The research undertaken was published in the journal Regulatory Peptides (1) </div><div style="margin-bottom: 10px;">Source: <A href="http://www.aegisthera.com/">www.<wbr>aegisthera.<wbr>com</A> </div><div>1)<A href="http://www.ncbi.nlm.nih.gov/pubmed/21329733#" style="BORDER-TOP-WIDTH: 0px; PADDING-RIGHT: 0px; PADDING-LEFT: 0px; BORDER-LEFT-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; PADDING-BOTTOM: 0px; MARGIN: 0px; WORD-SPACING: 0px; FONT: 11px/15px arial, helvetica, clean, sans-serif; VERTICAL-ALIGN: baseline; TEXT-TRANSFORM: none; COLOR: rgb(102,0,102); TEXT-INDENT: 0px; PADDING-TOP: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); TEXT-ALIGN: left; BORDER-RIGHT-WIDTH: 0px; TEXT-DECORATION: underline; WIDOWS: 2; OUTLINE-WIDTH: 0px; ORPHANS: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; border-image: initial" title="Regulatory peptides.">Regul Pept.<wbr></A><SPAN style="DISPLAY: inline! important; FLOAT: none; WORD-SPACING: 0px; FONT: 11px/15px arial, helvetica, clean, sans-serif; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); TEXT-ALIGN: left; WIDOWS: 2; ORPHANS: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"> 2011 Apr 11;167(2-3):233-8. Epub 2011 Feb 15</SPAN> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120831&edate=20120501&rec=6937">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-05-22T13:18:06+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>Lundbeck and CHDI Foundation Announce Research Collaboration [dis:Huntington, news]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology6413</link>
<description>Lundbeck and CHDI Foundation Announce Research Collaboration [dis:Huntington, news]</description><category>dis:Huntington</category><category>news</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology6413</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120831&edate=20120501&rec=6413">Lundbeck and CHDI Foundation Announce Research Collaboration</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=dis%3aHuntington"><font color="#e95e0b">:Neurology:dis:Huntington</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=news"><font color="#e95e0b">:Neurology:news</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology6413">Neurology6413</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 22 May 2012 | 09:19</font><br><br><div style="margin-bottom: 10px;">Comment: Lundbeck has announced a collaboration with an international network 
of scientists to investigate its preclinical candidate for Huntington's 
Disease.<wbr> </div><div style="margin-bottom: 10px;">CHDI is a privately funded biomedical research organisation that works with 
an international network of scientists to develop and discover new therapies for 
Huntington's disease.<wbr> </div><div style="margin-bottom: 10px;">The CHDI network will conduct preclinical studies with and investigative 
compound from Lundbeck evaluating its activity on P2X receptors, receptors that 
may be implicated in the development of Huntington's disease.<wbr> </div><div>Source: <a href="http://www.lundbeck.com" class="defaultlink" title="www.lundbeck.com">lundbeck.com</a> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120831&edate=20120501&rec=6413">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-05-22T09:19:02+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>Intelligence From The AAN - Merz US Injunction Likely To Last Full 10 Months [Alert, class:BotulinumToxins, comp:Merz, comp:Allergan, prod:Botox, prod:Xeomin]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology6410</link>
<description>Intelligence From The AAN - Merz US Injunction Likely To Last Full 10 Months [Alert, class:BotulinumToxins, comp:Merz, comp:Allergan, prod:Botox, prod:Xeomin]</description><category>Alert</category><category>class:BotulinumToxins</category><category>comp:Merz</category><category>comp:Allergan</category><category>prod:Botox</category><category>prod:Xeomin</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology6410</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120831&edate=20120501&rec=6410">Intelligence From The AAN - Merz US Injunction Likely To Last Full 10 Months</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=Alert"><font color="#e95e0b">:Neurology:Alert</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=class%3aBotulinumToxins"><font color="#e95e0b">:Neurology:class:BotulinumToxins</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=comp%3aAllergan"><font color="#e95e0b">:Neurology:comp:Allergan</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=comp%3aMerz"><font color="#e95e0b">:Neurology:comp:Merz</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=prod%3aBotox"><font color="#e95e0b">:Neurology:prod:Botox</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=prod%3aXeomin"><font color="#e95e0b">:Neurology:prod:Xeomin</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology6410">Neurology6410</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 21 May 2012 | 17:21</font><br><br><div style="margin-bottom: 10px;"><SPAN style="FONT-SIZE: xx-small; FONT-FAMILY: arial,helvetica,sans-serif"><FONT face="Verdana" size="2">Comment: Thanks to Steven Hall and the US Neurology MSL team, we have some interesting feedback on events at the recent American Academy of Neurology meeting in New Orleans, particularly with reference to Merz's US situation and its ambition to apply for a new label based around a shorter treatment interval.<wbr> The latter seemingly to facilitate easier reimbursement.<wbr></FONT></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="FONT-SIZE: xx-small; FONT-FAMILY: arial,helvetica,sans-serif"><SPAN style="FONT-SIZE: x-small; FONT-FAMILY: arial,helvetica,sans-serif"><FONT face="Verdana">Attached are a few of the slides covering some of the notable key competitive observations.<wbr> Attached is the full presentation which includes a review of all relevant abstracts and implications for Ipsen</FONT></SPAN></SPAN><SPAN style="FONT-SIZE: x-small; FONT-FAMILY: arial,helvetica,sans-serif"><FONT face="Verdana">.<wbr></FONT></SPAN> </div><div style="margin-bottom: 10px;"><FONT face="Arial" size="3"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/6410/1/ScreenCapture1.jpg?user-agent=rss"></FONT> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/6410/2/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/6410/3/ScreenCapture3.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/6410/4/ScreenCapture4.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/6410/8/ScreenCapture8.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/6410/5/ScreenCapture5.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/6410/6/ScreenCapture6.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><FONT face="Arial" size="3"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/6410/7/ScreenCapture7.jpg?user-agent=rss"></FONT> </div><div><SPAN style="FONT-SIZE: x-small; FONT-FAMILY: arial,helvetica,sans-serif"><FONT face="Arial" size="3">Contributors to the slide-pack included John Bruins (lead), Dave Cook, Steve Ichishta, Dominic Marchese, Lisette Bunting-Perry, and Joe Schwab.<wbr></FONT></SPAN> </div><!-- Comment details --><a name="neurology6410attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/6410/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(190,8 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/6410/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(206,6 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/6410/3/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(78,7 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/6410/4/ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(133,5 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/6410/5/ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(107,3 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/6410/6/ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(198,9 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/6410/7/ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(94,9 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/6410/8/ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(175,8 KB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/6410/9/AAN%202012%20MSL%20summary%205%2d16%2d12.pptx">AAN 2012 MSL summary 5-16-12.pptx</a>&nbsp;&nbsp;(529,3 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120831&edate=20120501&rec=6410">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-05-21T17:21:48+02:00</dc:date><dc:creator>jac89886</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/6410/1/ScreenCapture1.jpg" length="195376" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/6410/2/ScreenCapture2.jpg" length="211548" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/6410/3/ScreenCapture3.jpg" length="80633" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/6410/4/ScreenCapture4.jpg" length="136700" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/6410/5/ScreenCapture5.jpg" length="109826" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/6410/6/ScreenCapture6.jpg" length="203638" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/6410/7/ScreenCapture7.jpg" length="97194" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/6410/8/ScreenCapture8.jpg" length="180032" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/6410/9/AAN%202012%20MSL%20summary%205%2d16%2d12.pptx" length="541961" type="application/vnd.openxmlformats-officedocument.presentationml.presentation"/></item><item>
<title>Astellas &amp; Medivation Announce Format of The MDV3100 Presentations At ASCO [class:Antihormonals, dis:Prostate, headline, comp:Astellas]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology8287</link>
<description>Astellas &amp; Medivation Announce Format of The MDV3100 Presentations At ASCO [class:Antihormonals, dis:Prostate, headline, comp:Astellas]</description><comments>http://ci.beaufour-ipsen.com/traction/permalink/Oncology8287</comments><category>class:Antihormonals</category><category>dis:Prostate</category><category>headline</category><category>comp:Astellas</category><category>4G</category><category>TPS668</category><category>18B</category><category>TPS4695</category><category>16F</category><category>TPS4698</category><category>17A</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology8287</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8287">Astellas & Medivation Announce Format of The MDV3100 Presentations At ASCO</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=class%3aAntihormonals"><font color="#e95e0b">:Oncology:class:Antihormonals</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=comp%3aAstellas"><font color="#e95e0b">:Oncology:comp:Astellas</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=headline"><font color="#e95e0b">:Oncology:headline</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8287">Oncology8287</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 21 May 2012 | 16:47</font><br><br><div style="margin-bottom: 10px;"><SPAN style="font-family: arial,helvetica,sans-serif; font-size: medium;">Comment: Astellas &amp; Medivation have jointly announced the data that will be presented at ASCO on MDV3100 either in oral, poster or during a symposium, which in addtion to more data from the AFFIRM trial will include data on neoadjuvant use in high risk localised prostate cancer, comparative phII data versus bicalutamide and phI breast cancer data.<wbr></SPAN> </div><div style="margin-bottom: 10px;"><STRONG><FONT face="Arial" size="3">Details of the abstracts are as follows: </FONT></STRONG> </div><div style="margin-bottom: 10px;"><FONT face="Arial" size="3">(Abstract #4519): Primary, secondary, and quality-of-life endpoint results from the phase III AFFIRM study of MDV3100, an androgen receptor signaling inhibitor </FONT> </div><div style="margin-bottom: 10px;"><FONT face="Arial" size="3">&bull; Saturday, June 2 from 8:30 a.<wbr>m.<wbr> &ndash; 8:45 a.<wbr>m.<wbr> </FONT> </div><div style="margin-bottom: 10px;"><FONT face="Arial" size="3">Presenter: Johann S.<wbr> De Bono, MB, ChB, FRCP, MSc, PhD </FONT> </div><div style="margin-bottom: 10px;"><FONT face="Arial" size="3">Clinical Science Symposium: New Paradigms for Hormone Therapy in Prostate Cancer Location: E Arie Crown Theater </FONT> </div><div style="margin-bottom: 10px;"><FONT face="Arial" size="3">(</FONT> </div><div style="margin-bottom: 10px;"><FONT face="Arial" size="3">Abstract #564 <STRONG>/<wbr> </STRONG>Poster ): Effect of MDV3100, an androgen receptor signaling inhibitor, on tumor growth of estrogen and androgen receptor-positive (ER+/<wbr>AR+) breast cancer xenografts </FONT> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=4G"><font color="#e95e0b">:Oncology:4G</font></a>]</font></font></div><div style="margin-bottom: 10px;"><FONT face="Arial" size="3">&bull; Saturday, June 2 from 8:00 a.<wbr>m.<wbr> to noon </FONT> </div><div style="margin-bottom: 10px;"><FONT face="Arial" size="3">Author: Anthony D.<wbr> Elias, MD </FONT> </div><div style="margin-bottom: 10px;"><FONT face="Arial" size="3">General Poster Session: Breast Cancer </FONT><FONT face="Arial" size="3">Location: S Hall A2 </FONT> </div><div style="margin-bottom: 10px;"><FONT face="Arial" size="3">(Abstract /<wbr> Poster ): MDV3100-08: A phase I open-label, dose-escalation study evaluating the safety, tolerability, and pharmacokinetics of MDV3100 in women with incurable breast cancer </FONT> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=18B"><font color="#e95e0b">:Oncology:18B</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=TPS668"><font color="#e95e0b">:Oncology:TPS668</font></a>]</font></font></div><div style="margin-bottom: 10px;"><FONT face="Arial" size="3">&bull; Saturday, June 2 from 8:00 a.<wbr>m.<wbr> to noon </FONT> </div><div style="margin-bottom: 10px;"><FONT face="Arial" size="3">Author: Anthony D.<wbr> Elias, MD </FONT> </div><div style="margin-bottom: 10px;"><FONT face="Arial" size="3">General Poster Session: Breast Cancer </FONT><FONT face="Arial" size="3">Location: S Hall A2</FONT> </div><div style="margin-bottom: 10px;"><FONT face="Arial" size="3">(Abstract /<wbr> Poster ): A randomized, open-label, phase II study of MDV3100 alone or in combination with leuprolide and dutasteride as neoadjuvant therapy to prostatectomy in intermediate and high-risk prostate cancer </FONT> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=16F"><font color="#e95e0b">:Oncology:16F</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=TPS4695"><font color="#e95e0b">:Oncology:TPS4695</font></a>]</font></font></div><div style="margin-bottom: 10px;"><FONT face="Arial" size="3">&bull; Sunday, June 3 from 8:00 a.<wbr>m.<wbr> to noon </FONT> </div><div style="margin-bottom: 10px;"><FONT face="Arial" size="3">Author: Robert B.<wbr> Montgomery, MD </FONT> </div><div style="margin-bottom: 10px;"><FONT face="Arial" size="3">General Poster Session: Genitourinary Cancer </FONT><FONT face="Arial" size="3">Location: S Hall A2 </FONT> </div><div style="margin-bottom: 10px;"><FONT face="Arial" size="3">(Abstract /<wbr> Poster ): TERRAIN: A randomized, double-blind, phase II study comparing MDV3100 with bicalutamide (Bic) in men with metastatic castrate-resistant prostate cancer (CRPC) </FONT> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=17A"><font color="#e95e0b">:Oncology:17A</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=TPS4698"><font color="#e95e0b">:Oncology:TPS4698</font></a>]</font></font></div><div style="margin-bottom: 10px;"><FONT face="Arial" size="3">&bull; Sunday, June 3 from 8:00 a.<wbr>m.<wbr> to noon </FONT> </div><div style="margin-bottom: 10px;"><FONT face="Arial" size="3">Author: Edwina S.<wbr> Baskin-Bey, MD </FONT> </div><div style="margin-bottom: 10px;"><FONT face="Arial" size="3">General Poster Session: Genitourinary Cancer Location: S Hall A2 </FONT> </div><div style="margin-bottom: 10px;"><FONT face="Arial" size="3">(Abstract #3072 /<wbr> Poster ): Effect of MDV3100, a novel androgen receptor signaling inhibitor, on cell proliferation and tumor size in an apocrine breast cancer xenograft model </FONT> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=16F"><font color="#e95e0b">:Oncology:16F</font></a>]</font></font></div><div style="margin-bottom: 10px;"><FONT face="Arial" size="3">&bull; Monday, June 4 from 8:00 a.<wbr>m.<wbr> &ndash; noon </FONT> </div><div style="margin-bottom: 10px;"><FONT face="Arial" size="3">Author: Sebasti&aacute;n Bernales, PhD </FONT> </div><div style="margin-bottom: 10px;"><FONT face="Arial" size="3">General Poster Session: Developmental Therapeutics Location: S Hall A2 </FONT> </div><div><FONT face="Arial" size="3">Source; <A href="http://www.astellas.com">www.<wbr>astellas.<wbr>com</A></FONT> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Oncology8290c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div>Comment: Astellas and Medivation have today announced that Medivation has filed an NDA for enzalutamide (formerly MDV3100)  for the treatment of post-docetaxel CRPC, requesting a priority review.<wbr> If granted the FDA goal for completing the review is six months.<wbr> </div><font size="-1">Jacquelyne CANTLE MEYRICK / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8290" class="commentpermalink">Oncology8290</a> / <span class="date">22 May 2012</span> /
<span class="time">14:25:06 o'clock CEST</span>
</font></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8287">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-05-21T16:47:50+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>Bavarian Nordic Announces PhII Data &amp; Status of PhIII PROSTVAC Trial [class:Vaccines, dis:Prostate, news]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology8284</link>
<description>Bavarian Nordic Announces PhII Data &amp; Status of PhIII PROSTVAC Trial [class:Vaccines, dis:Prostate, news]</description><category>class:Vaccines</category><category>dis:Prostate</category><category>news</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology8284</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8284">Bavarian Nordic Announces PhII Data & Status of PhIII PROSTVAC Trial</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=class%3aVaccines"><font color="#e95e0b">:Oncology:class:Vaccines</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=news"><font color="#e95e0b">:Oncology:news</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8284">Oncology8284</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 21 May 2012 | 16:26</font><br><br><div style="margin-bottom: 10px;"><P align="left"><SPAN style="font-family: arial,helvetica,sans-serif; font-size: medium;">Comment: Bavarian Nordic has announced positive interim data from a Phase II trial in 34 evaluable CRPC patients with bone metastases previously treated with docetaxel.<wbr> It also noted that it expects to complete enrollment in its 1200 pt phIII PROSPECT trial in 2013.<wbr></SPAN></P> </div><div style="margin-bottom: 10px;"><P align="left"><SPAN style="font-family: arial,helvetica,sans-serif; font-size: medium;"><STRONG>PhII Study Data</STRONG></SPAN></P> </div><div style="margin-bottom: 10px;"><P align="left"><SPAN style="font-family: arial,helvetica,sans-serif; font-size: medium;">ProstVac in combination with Quadramet (samrium based radioisotope used to control pain in patients with confirmed osteoblastic bone leisions) led to a PFS rate at 4 months, the primary endpoint, of 29.<wbr>4% vs.<wbr> 11.<wbr>8% for Quadramet alone.<wbr></SPAN></P> </div><div style="margin-bottom: 10px;"><P align="left"><SPAN style="font-family: arial,helvetica,sans-serif; font-size: medium;">Median PFS was 117 days for ProstVac plus Quadramet vs.<wbr> 60 days for Quadramet alone.<wbr> Additionally, 4 of 17 patients receiving ProstVac plus Quadramet achieved a &gt;<FONT color="#231f20" face="GillSans" size="2"><FONT color="#231f20" face="GillSans" size="2"><FONT color="#231f20" face="GillSans" size="2">30% reduction in PSA, while 2 achieved a reduction of &gt;</FONT></FONT></FONT><FONT color="#231f20" face="GillSans" size="2"><FONT color="#231f20" face="GillSans" size="2"><FONT color="#231f20" face="GillSans" size="2">50%.<wbr> </FONT></FONT></FONT></SPAN></P> </div><div style="margin-bottom: 10px;"><P align="left"><SPAN style="font-family: arial,helvetica,sans-serif; font-size: medium;"><FONT color="#231f20" face="GillSans" size="2"><FONT color="#231f20" face="GillSans" size="2"><FONT color="#231f20" face="GillSans" size="2">No patient receiving Quadramet alone (n=17) achieved a &gt;</FONT></FONT></FONT><FONT color="#231f20" face="GillSans" size="2"><FONT color="#231f20" face="GillSans" size="2"><FONT color="#231f20" face="GillSans" size="2">30% PSA reduction.<wbr></FONT></FONT></FONT></SPAN></P> </div><div style="margin-bottom: 10px;"><P align="left"><SPAN style="font-family: arial,helvetica,sans-serif; font-size: medium;">ProstVac plus Quadramet was well tolerated with a similar toxicity profile to that of Quadramet alone.<wbr> The trial plans to enroll 68 patients to receive 1 mCi/<wbr>kg IV Quadramet on day 8 and then every 12 weeks with or without ProstVac given on days 1, 15 and 29 and then every 4 weeks.<wbr></SPAN></P> </div><div style="margin-bottom: 10px;"><P align="left"><SPAN style="font-family: arial,helvetica,sans-serif; font-size: medium;">Bavarian Nordic also stated that it expects to complete enrollment in 2013 of about 1,200 patients with metastatic CRPC who have failed hormone therapy in the Phase III PROSPECT trial of ProstVac.<wbr> This study will be the subject of a "Trials in Progress" abstract, at ASCO which is designed to provide an opportunity for members of the research community to present ongoing trials, foster collaboration, and discuss correlatives and novel trial designs.<wbr></SPAN></P> </div><div style="margin-bottom: 10px;"><P align="left"><SPAN style="font-family: arial,helvetica,sans-serif; font-size: medium;">Details of both studies to be presented are shown below:-</SPAN></P> </div><div style="margin-bottom: 10px;"><UL><LI><SPAN style="font-family: arial,helvetica,sans-serif; font-size: medium;">"Interim analysis of a phase 2 randomized clinical trial of Samarium-153 (Sm-153) with or without PSA-TRICOM vaccine in metastatic castration resistant prostate cancer (mCRPC) after docetaxel", abstract number 2526, Poster Discussion Session, Developmental Therapeutics - Clinical Pharmacology and Immunotherapy from 8:00 AM to 12:00 PM CT on Saturday June 2, 2012.<wbr></SPAN>
</LI>
<LI><SPAN style="font-family: arial,helvetica,sans-serif; font-size: medium;">"Prospect: A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC&reg;", abstract number TPS4699, General Poster Session, Genitourinary Cancer from 8:00 AM to 12:00 PM CT on Sunday June 3, 2012.<wbr></SPAN>
</LI>
</UL> </div><div style="margin-bottom: 10px;"><SPAN style="font-family: arial,helvetica,sans-serif; font-size: medium;">Bavarian Nordic will also be hosting a PROSTVAC&reg; update and reception on Monday, June 4, 2012 in Chicago, Illinois.<wbr> The principal investigators for the PROSPECT trial, James L.<wbr> Gulley, M.<wbr>D.<wbr>, Ph.<wbr>D.<wbr>, Director of the Clinical Trials Group at the Laboratory of Tumor Immunology and Biology at the National Cancer Institute (NCI), and Philip Kantoff M.<wbr>D.<wbr>, Professor of Medicine at Harvard Medical School, will be joined by members of the Company's senior management team to discuss this next-generation prostate cancer vaccine.<wbr></SPAN> </div><div><SPAN style="font-family: arial,helvetica,sans-serif; font-size: medium;">source: <A href="http://www.bavarian-nordic.com">www.<wbr>bavarian-nordic.<wbr>com</A></SPAN> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8284">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-05-21T16:26:31+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>New LHRH-targeted peptide Enters PhII Development [class:Antihormonals, dis:Gynea, headline]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology8283</link>
<description>New LHRH-targeted peptide Enters PhII Development [class:Antihormonals, dis:Gynea, headline]</description><category>class:Antihormonals</category><category>dis:Gynea</category><category>headline</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology8283</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8283">New LHRH-targeted peptide Enters PhII Development</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=class%3aAntihormonals"><font color="#e95e0b">:Oncology:class:Antihormonals</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=dis%3aGynea"><font color="#e95e0b">:Oncology:dis:Gynea</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=headline"><font color="#e95e0b">:Oncology:headline</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8283">Oncology8283</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 18 May 2012 | 18:20</font><br><br><div style="margin-bottom: 10px;">Comment: Esperance Pharmaceuticals has announced the start of a phII multi-centre trial in patients with ovarian cancer with EP-100 , a targeted membrane-disrutping peptide (tMDP) designed to seek and destroy cancer cells that over-express LHRH receptors on their surface.<wbr> </div><div style="margin-bottom: 10px;">EP-100 is the lead candidate from Esperance's Cationic Lytic Peptide technology programme.<wbr> </div><div style="margin-bottom: 10px;">Hecto Alila , CEo claims that based on sucessful phI and preclinical studies, Esperance believes there is compelling rational for the study of EP-100 in ovarian cancer.<wbr> Phase I results will be presented in poster form at ASCO  Abs 3060.<wbr> Results from preclinical studies it is claimed show that the drug can regress established tumours in breast, prostate, ovarian and endometrial cancer.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Study Design</STRONG> </div><div style="margin-bottom: 10px;">The study will initially enrol 5-8 patients in a dose confirmation phase before expanding the cohort to 40 patients randomised in a 1:1 ration to receive either weekly doses of 80mg/<wbr>m2 paclitaxel or the same regimen of paclitaxel plus twice weekly EP-100 for 3 of 4 weeks during each of six cycles.<wbr> </div><div style="margin-bottom: 10px;">Primary outcome will be objective response rate and secondary outcome measures QO, duration of response,  time to progressoin and follow-up for survival.<wbr> </div><div>Source; <A href="http://www.esperancepharma.com/">www.<wbr>esperancepharma.<wbr>com</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8283">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-05-18T18:20:33+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>Express Scripts Survey Highlights Specialty Medicine Cost Concerns [sub:Pricing, mkt:NorthAmerica]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld9885</link>
<description>Express Scripts Survey Highlights Specialty Medicine Cost Concerns [sub:Pricing, mkt:NorthAmerica]</description><category>sub:Pricing</category><category>mkt:NorthAmerica</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld9885</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120831&edate=20120501&rec=9885">Express Scripts Survey Highlights Specialty Medicine Cost Concerns</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=mkt%3aNorthAmerica"><font color="#e95e0b">:PharmaWorld:mkt:NorthAmerica</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=sub%3aPricing"><font color="#e95e0b">:PharmaWorld:sub:Pricing</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld9885">PharmaWorld9885</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 18 May 2012 | 18:02</font><br><br><div style="margin-bottom: 10px;">Comment: A large survey undertaken by Express Scripts of phamacy plan 
managers in the US, has found 36% of managers citing concerns about the 
growing cost of specialty medicines.<wbr> Specialty drug spending in the US last 
year rose by 17.<wbr>1% versus 2.<wbr>7% for overall spending on medicines.<wbr> It is 
suggested that programmes will be put in place over the next two years to 
contain such spending.<wbr> </div><div style="margin-bottom: 10px;">For employers with more than 25,000 members, 58% named specialty costs as 
their top worry.<wbr> </div><div style="margin-bottom: 10px;">Tim Wentworth from Express Scripts is reported on Reuters as saying that 
whilst specialty medicine spending makes up less that 30% of its clients overall 
drug spending it is the fastest growing component and something they want to 
look at ways of containing.<wbr> </div><div style="margin-bottom: 10px;">Seemingly the vast majority of survey respondents expect to institute 
programms that require members to try the lowest cost drug that is appropriate 
before starting on a new drug - so called step therapy - in the next two 
years.<wbr> </div><div>Source: Reuters<BR> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120831&edate=20120501&rec=9885">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-05-18T18:02:09+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>Prolor May Seek Partner to Market hGH-CTP [class:GrowthHormone, dis:GrowthHormoneDeficiency, :PharmaWorld:sub:Partnership]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology6934</link>
<description>Prolor May Seek Partner to Market hGH-CTP [class:GrowthHormone, dis:GrowthHormoneDeficiency, :PharmaWorld:sub:Partnership]</description><category>class:GrowthHormone</category><category>dis:GrowthHormoneDeficiency</category><category>sub:Partnership</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology6934</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120831&edate=20120501&rec=6934">Prolor May Seek Partner to Market hGH-CTP</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=class%3aGrowthHormone"><font color="#e95e0b">:Endocrinology:class:GrowthHormone</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=dis%3aGrowthHormoneDeficiency"><font color="#e95e0b">:Endocrinology:dis:GrowthHormoneDeficiency</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=sub%3aPartnership"><font color="#e95e0b">:PharmaWorld:sub:Partnership</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology6934">Endocrinology6934</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/20">Alison Attard</a> | 18 May 2012 | 12:01</font><br><br><div style="margin-bottom: 10px;">Comment: Prolor has enough cash to conduct late-stage studies of hGH-CTP, in adults with growth-hormone deficiency as well as mid-stage testing in children President Shai Novik said </div><div style="margin-bottom: 10px;">Novik also said that when you look at the marketing and sales channels, it would make much more sense, even if we develop it on our own, to partner with someone, at least for distribution and marketing purposes.<wbr> </div><div style="margin-bottom: 10px;">Bart Classen, an analyst at Summer Street Research Partners, said that any of the companies making short-acting hormone could be interested in buying them.<wbr>.<wbr>.<wbr>there&rsquo;s definitely a strong chance that the company will be acquired or partner up with a number of the larger companies who would have a natural interest in this product.<wbr> </div><div style="margin-bottom: 10px;">See also <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120831&edate=20120501&rec=6930" class="defaultlink">Endocrinology6930: Developments With Long-acting Growth Hormones</a> </div><div>Source: Bloomberg 16 May 2012 </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120831&edate=20120501&rec=6934">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-05-18T12:01:24+02:00</dc:date><dc:creator>ala97794</dc:creator></item><item>
<title>USA: Allergan Announces R&amp;D Expansion in New Jersey [comp:Allergan, :PharmaWorld:func:RnD, :PharmaWorld:mkt:NorthAmerica, prod:Botox]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology6404</link>
<description>USA: Allergan Announces R&amp;D Expansion in New Jersey [comp:Allergan, :PharmaWorld:func:RnD, :PharmaWorld:mkt:NorthAmerica, prod:Botox]</description><category>comp:Allergan</category><category>func:RnD</category><category>mkt:NorthAmerica</category><category>prod:Botox</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology6404</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120831&edate=20120501&rec=6404">USA: Allergan Announces R&D Expansion in New Jersey</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=comp%3aAllergan"><font color="#e95e0b">:Neurology:comp:Allergan</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=prod%3aBotox"><font color="#e95e0b">:Neurology:prod:Botox</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=func%3aRnD"><font color="#e95e0b">:PharmaWorld:func:RnD</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=mkt%3aNorthAmerica"><font color="#e95e0b">:PharmaWorld:mkt:NorthAmerica</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology6404">Neurology6404</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/20">Alison Attard</a> | 18 May 2012 | 11:40</font><br><br><div style="margin-bottom: 10px;">Comment: Allergan will build a $12 million research and development facility in Bridgewater, New Jersey.<wbr> reportedly to support expansion of indications for Botox like therapy.<wbr> </div><div style="margin-bottom: 10px;">Allergan has a smaller facility in Bedminster, where it employs 20 people.<wbr> The new, 93,000-square-foot facility will bring nearly 400 new jobs to the state.<wbr> </div><div style="margin-bottom: 10px;">The company chose the site in New Jersey because of the local talent pool in the pharmaceutical and medical device industry, as well as its proximity to hospitals and universities, said spokeswoman Cathy Taylor.<wbr> </div><div style="margin-bottom: 10px;">The facility will be part of SJP Properties' Somerset Corporate Center campus, a series of energy-efficient office buildings in Bridgewater.<wbr> Allergan first said it was considering expanding in New Jersey in November, when it was awarded a $14.<wbr>9 million grant from the New Jersey Economic Development Authority through the Business Employment Incentive Program.<wbr> </div><div>Star Ledger 17 May 2012 </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120831&edate=20120501&rec=6404">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-05-18T11:40:50+02:00</dc:date><dc:creator>ala97794</dc:creator></item><item>
<title>Unprecedented Abiraterone Data Released Ahead of ASCO [Alert, class:Antihormonals, comp:JnJ, dis:Prostate, prod:Zytiga]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology8282</link>
<description>Unprecedented Abiraterone Data Released Ahead of ASCO [Alert, class:Antihormonals, comp:JnJ, dis:Prostate, prod:Zytiga]</description><category>Alert</category><category>class:Antihormonals</category><category>comp:JnJ</category><category>dis:Prostate</category><category>prod:Zytiga</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology8282</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8282">Unprecedented Abiraterone Data Released Ahead of ASCO</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=Alert"><font color="#e95e0b">:Oncology:Alert</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=class%3aAntihormonals"><font color="#e95e0b">:Oncology:class:Antihormonals</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=comp%3aJnJ"><font color="#e95e0b">:Oncology:comp:JnJ</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=prod%3aZytiga"><font color="#e95e0b">:Oncology:prod:Zytiga</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8282">Oncology8282</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 17 May 2012 | 14:16</font><br><br><div style="margin-bottom: 10px;">Comment: Mary-Ellen Taplin at a press briefing yesterday announced that a 
phII study evaluating neoadjuvant abiraterone in patients with localized 
high-risk prostate cancer eliminated or nearly eliminated cancer in one-third of 
men after 6-months treatment.<wbr> </div><div style="margin-bottom: 10px;">She spoke at a press briefing that precedes the annual ASCO meeting, where 
the data is to be presented.<wbr> </div><div style="margin-bottom: 10px;">Specifically, 34% of men treated with abiraterone for 6 months had either 
pathological complete response<B> </B>(pCR; 3/<wbr>29) or near pCR (7/<wbr>29).<wbr> </div><div style="margin-bottom: 10px;">This was superior to the results in men treated with abiraterone for only 3 
months.<wbr> Only 15% of these men had either pCR (1/<wbr>27) or near pCR (3/<wbr>27).<wbr> </div><div style="margin-bottom: 10px;"><STRONG>All of the men in the study also received standard hormone therapy 
for 6 months</STRONG> and underwent prostatectomy after completing drug 
therapies.<wbr> </div><div style="margin-bottom: 10px;">The difference in response between the 2 study groups was not statistically 
significant, but the response rates among the men who received arbiraterone for 
six months are unprecedented, according to Dr Taplin the study's 
principal investigator.<wbr> Essentially one third of the patients have minimal or no 
tumor when they go to the OR.<wbr> </div><div style="margin-bottom: 10px;">Historically pCR rates have been 5% or less with traditional hormone 
therapies when employed in the neoadjuvant setting and ofter in patients with 
localized disease of lesser risk than evaluated in the abiraterone 
study.<wbr> </div><div style="margin-bottom: 10px;">A randomized phase 3 trial that validates the current study findings is 
needed next but is not currently planned.<wbr> Another phase II study investigating 
the novel androgen signaling inhibitor, MDV3100, in the neoadjuvant setting for 
high risk prostate cancer is underway and a clinical trial evaluating the 
addition of the investigational drug ARN509 to abiraterone and hormone therapy 
is being developed.<wbr> </div><div>source: Medscape news </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8282">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-05-17T14:16:04+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>Sanofi's Update on Lyxumia Its New GLP-1 Agonist [class:GLP1, dis:Diabetes]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology6932</link>
<description>Sanofi's Update on Lyxumia Its New GLP-1 Agonist [class:GLP1, dis:Diabetes]</description><category>class:GLP1</category><category>dis:Diabetes</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology6932</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120831&edate=20120501&rec=6932">Sanofi's Update on Lyxumia Its New GLP-1 Agonist</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=class%3aGLP1"><font color="#e95e0b">:Endocrinology:class:GLP1</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=dis%3aDiabetes"><font color="#e95e0b">:Endocrinology:dis:Diabetes</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology6932">Endocrinology6932</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 17 May 2012 | 11:37</font><br><br><div style="margin-bottom: 10px;">Comment: Sanofi has filed for approval of Lyxumia in the EU and will file for approval in the US in Q412.<wbr> It is also claiming that it will be the first GLP-1 agonist so far and the only GLP-1 agonist that will have a cardiovascular outcomes trial demonstrating a perfect safety profile (a big question surrounding any new diabetes drugs).<wbr> </div><div style="margin-bottom: 10px;">Management claims that the drug has shown a consistent A1c reduction and weight loss, a pronounced effect on post-prandial glucose compared with Victoza (Novo Nordisk) and has a very favorable safety profile with a low-risk of hypoglycemic events.<wbr> </div><div style="margin-bottom: 10px;">Its administration also involves s a simple one-step injection with a pen device.<wbr> This it was emphasised is viewed as important as healthcare reform goes forward.<wbr> In view of the epidemic in diabetes patients, it is seen as important to make drug administration for diabetic patients simpler and simpler for the primary care physician to initiate and maintain therapy.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6932/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">Sanofi will have three positive trials on top of basal insulin, a treatment paradign now very frequently used  It is also developing a combination product that will allow vaiable dosing of Lantus (insulin) with a fixed dose of Lyxumia .<wbr> This it was suggested represents a big opportunity as there are 8 million patients on Lantus or other basal insulins but in terms of being properly controlled the number is only 4 million.<wbr> So, there is an opportunity for Lyxumia to improve control by bringing down A1c further.<wbr> </div><div><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6932/2/ScreenCapture2.jpg?user-agent=rss"> </div><!-- Comment details --><a name="endocrinology6932attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6932/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(176,8 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6932/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(156 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120831&edate=20120501&rec=6932">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-05-17T11:37:38+02:00</dc:date><dc:creator>jac89886</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6932/1/ScreenCapture1.jpg" length="181073" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6932/2/ScreenCapture2.jpg" length="159781" type="image/jpeg"/></item><item>
<title>mTOR-Inhibitor TORISEL® Disappoints In PhIII Renal Cancer Trial [class:KinaseInhibitors, news]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology8281</link>
<description>mTOR-Inhibitor TORISEL® Disappoints In PhIII Renal Cancer Trial [class:KinaseInhibitors, news]</description><category>class:KinaseInhibitors</category><category>news</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology8281</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8281">mTOR-Inhibitor TORISEL® Disappoints In PhIII Renal Cancer Trial</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=class%3aKinaseInhibitors"><font color="#e95e0b">:Oncology:class:KinaseInhibitors</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=news"><font color="#e95e0b">:Oncology:news</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8281">Oncology8281</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 17 May 2012 | 10:58</font><br><br><div style="margin-bottom: 10px;"><P style="widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; font: 11px Arial, Helvetica, verdana, sans-serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;"><SPAN style="font-family: arial,helvetica,sans-serif; font-size: small;">Comment: Pfizer has announced that its Phase 3 INTORSECT study, evaluating the mTOR-inhibitor  TORISEL&reg; (temsirolimus) in patients with advanced renal cell carcinoma whose disease had progressed on or after SUTENT&reg; (sunitinib malate) therapy, did not meet the primary endpoint of prolonging progression free survival when compared to sorafenib.<wbr> </SPAN></P> </div><div style="margin-bottom: 10px;"><P style="widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; font: 11px Arial, Helvetica, verdana, sans-serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;"><SPAN style="font-family: arial,helvetica,sans-serif; font-size: small;">Although PFS was numerically higher in patients treated with temsirolimus, the difference was not statistically significant.<wbr> </SPAN></P> </div><div style="margin-bottom: 10px;"><P style="widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; font: 11px Arial, Helvetica, verdana, sans-serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;"><SPAN style="font-family: arial,helvetica,sans-serif; font-size: small;">Moreover, overall survival, a secondary endpoint in the study, showed statistical significance favoring patients randomized to the sorafenib arm.<wbr> </SPAN></P> </div><div style="margin-bottom: 10px;"><P style="widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; font: 11px Arial, Helvetica, verdana, sans-serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;"><SPAN style="font-family: arial,helvetica,sans-serif; font-size: small;">Adverse events in this study were consistent with the known safety profiles for both drugs.<wbr> Full efficacy and safety data from this study will be presented at ASCO.<wbr></SPAN></P> </div><div style="margin-bottom: 10px;"><P style="widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; font: 11px Arial, Helvetica, verdana, sans-serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;"><STRONG><SPAN style="font-family: arial,helvetica,sans-serif; font-size: small;">Despite this outcome Pfizer noted that :-</SPAN></STRONG></P> </div><div style="margin-bottom: 10px;"><P style="widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; font: 11px Arial, Helvetica, verdana, sans-serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;"><SPAN style="font-family: arial,helvetica,sans-serif; font-size: small;">&ldquo;TORISEL continues to be an important part of Pfizer&rsquo;s portfolio of therapies for advanced kidney cancer.<wbr> </SPAN><SPAN style="font-family: arial,helvetica,sans-serif; font-size: small;">This trial advances our knowledge about TORISEL in RCC.<wbr> TORISEL remains an important drug for treatment of advanced kidney cancer based on its pivotal study in first-line patients with poor prognostic risk,&rdquo; said Dr.<wbr> Mace Rothenberg, senior vice president of clinical development and medical affairs for Pfizer&rsquo;s Oncology Business Unit.<wbr> </SPAN></P> </div><div><P style="widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; font: 11px Arial, Helvetica, verdana, sans-serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;"><SPAN style="font-family: arial,helvetica,sans-serif; font-size: small;">Source: <A href="http://www.pfizer.com">www.<wbr>pfizer.<wbr>com</A></SPAN></P> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8281">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-05-17T10:58:10+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>NICE Reverses Opinion And Agrees To Fund Zytiga Under the NHS [class:Antihormonals, dis:Prostate, news, prod:Zytiga]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology8279</link>
<description>NICE Reverses Opinion And Agrees To Fund Zytiga Under the NHS [class:Antihormonals, dis:Prostate, news, prod:Zytiga]</description><comments>http://ci.beaufour-ipsen.com/traction/permalink/Oncology8279</comments><category>class:Antihormonals</category><category>dis:Prostate</category><category>news</category><category>prod:Zytiga</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology8279</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8279">NICE Reverses Opinion And Agrees To Fund Zytiga Under the NHS</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=class%3aAntihormonals"><font color="#e95e0b">:Oncology:class:Antihormonals</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=news"><font color="#e95e0b">:Oncology:news</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=prod%3aZytiga"><font color="#e95e0b">:Oncology:prod:Zytiga</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8279">Oncology8279</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 16 May 2012 | 15:04</font><br><br><div style="margin-bottom: 10px;">Comment: After further consultation between NICE and J&amp;J during which J&amp;J has agreed a revised patient access scheme with the Department of Health which makes abiraterone (Zytiga) available at a discount price, NICE has agreed to recommend the use of the drug for the treatment of post-docetaxel CRPC.<wbr> </div><div style="margin-bottom: 10px;">The size of the discount has not been disclosed at the request of the manufacturer.<wbr> The list price of abiraterone in the UK is &pound;2,930 for a 30-day supply of 120 tablets.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Other Information Used By J&amp;J During Negotations</STRONG> </div><div style="margin-bottom: 10px;">Further information on a subgroup of patients that may receive the most benefit from the drug was also provided: patients who had previously been treated with one docetaxel-containing chemotherapy regimen.<wbr> The manufacturer also submitted further information on the number of patients for whom abiraterone is licensed, enabling the drug to be considered under NICE's end of life criteria.<wbr> </div><div style="margin-bottom: 10px;">The draft guidance is now with consultees, who have the opportunity to appeal against it.<wbr> Until NICE issues final guidance.<wbr> </div><div>Source: <A href="http://www.nice.org.uk">www.<wbr>nice.<wbr>org.<wbr>uk</A> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Oncology8360c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">On June 28th, NICE issued its final guidance recommending abiraterone (Zytiga, Janssen) in combination with prednisone for mCRPC post docetaxel.<wbr> </div><div>Information provided by Janssen enabled the committee to recommend the drug for use on the NHS.<wbr> </div><font size="-1">Brigitte DESCHAMPS / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8360" class="commentpermalink">Oncology8360</a> / <span class="date">28 June 2012</span> /
<span class="time">12:49:08 o'clock CEST</span>
</font></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8279">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-05-16T15:04:08+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>Developments With Long-acting Growth Hormones [class:GrowthHormone, dis:GrowthHormoneDeficiency, news]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology6930</link>
<description>Developments With Long-acting Growth Hormones [class:GrowthHormone, dis:GrowthHormoneDeficiency, news]</description><category>class:GrowthHormone</category><category>dis:GrowthHormoneDeficiency</category><category>news</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology6930</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120831&edate=20120501&rec=6930">Developments With Long-acting Growth Hormones</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=class%3aGrowthHormone"><font color="#e95e0b">:Endocrinology:class:GrowthHormone</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=dis%3aGrowthHormoneDeficiency"><font color="#e95e0b">:Endocrinology:dis:GrowthHormoneDeficiency</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=news"><font color="#e95e0b">:Endocrinology:news</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology6930">Endocrinology6930</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 15 May 2012 | 12:16</font><br><br><div style="margin-bottom: 10px;">Comment: Within the last week both Prolor and Versatis have reported progress with the development of their long-acting hGH products.<wbr> Prolor reported interim phII data at the ECE meeting and Versartis has announced the completion of enrollment in a 50 patient PhI trial.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Prolor's Activity</FONT></STRONG> </div><div style="margin-bottom: 10px;">Prolor has reported promising phII data demonstrating that once-weekly HGH-CTP leads to an average IGF-1 levels within the normal therapeutic range in 88% of patients at 4 months (n=42).<wbr> </div><div style="margin-bottom: 10px;">The phase II study is a randomised open-label comparative dose finding, safety, tolerabiltiy PK &amp; PD trial conducted in adult GHD patients.<wbr> Dose selection for phII of the study was based on IGF-1 levels during the initial 4-week stage I of the study.<wbr> IGF-1 levels were measured during stage II every 2nd week on day 4 after injection.<wbr> </div><div style="margin-bottom: 10px;">Patients received once-weekly hGH-CTP at an initial dose containing 50% of the equivalent cummulative commercial dose that a patient would normally inject over the course of 7 days.<wbr> </div><div style="margin-bottom: 10px;">Given the potency observed Prolor believe that the drug MOD-4023 has the potential for twice monthly administration.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Next Steps</STRONG> </div><div style="margin-bottom: 10px;">Vera Popovic (Serbia) who presented the data noted that a phIII adult study is in planning and will be initiated in September this year.<wbr> It will include a follow-up period of between 6-18 months.<wbr> The study will be undertaken in countries such as Hungary, Czech Republic, Slovenia and Slovakia.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Versartis</FONT></STRONG> </div><div style="margin-bottom: 10px;">Versatis has completed enrollment in a 50 patients double-blind placebo controlled international phI trial evaluating singel ascending doses of subcutaneous VRS-317.<wbr> </div><div>Versatis has rights to develop VRS-317 from Amunix.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120831&edate=20120501&rec=6930">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-05-15T12:16:46+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>Savitex Gains Approval In A Further 10 Countries [dis:Spasticity, news]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology6402</link>
<description>Savitex Gains Approval In A Further 10 Countries [dis:Spasticity, news]</description><category>dis:Spasticity</category><category>news</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology6402</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120831&edate=20120501&rec=6402">Savitex Gains Approval In A Further 10 Countries</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=dis%3aSpasticity"><font color="#e95e0b">:Neurology:dis:Spasticity</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=news"><font color="#e95e0b">:Neurology:news</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology6402">Neurology6402</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 15 May 2012 | 12:00</font><br><br><div style="margin-bottom: 10px;">Comment: GW Pharma and its partner Allmiral have announced that the mutual recognition process is now closed and they have received approval for Savitex to treat spasticity in a further 10 European countries.<wbr> </div><div style="margin-bottom: 10px;">Savitex is already available in the UK, Spain, Germany and Denmarkt and launches are currently in preparation for Italy, Sweden, Austria and the Czech Republic.<wbr> </div><div style="margin-bottom: 10px;">Closure of the mutual recognition process now means that approval has also been granted in Belguim, Finland, Iceland, Luxembourg, the Netherlands, Norway, Poland, Portugal and Slovakia.<wbr> Launches are expected in these countries from the end of 2012 onwards.<wbr> </div><div style="margin-bottom: 10px;">GW Pharma is due to report its interim figures for teh 6 months to March 31st on the 22nd May.<wbr> Last reported sales as of November 2011 were &pound;4.<wbr>4m (see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120831&edate=20120501&rec=6111" class="defaultlink">Neurology6111: GW Pharma Reports Strong Uptake Of Savitex For Spasticity</a>).<wbr> </div><div>Scource <a href="http://www.gwpharm.com" class="defaultlink" title="http://www.gwpharm.com">gwpharm.com</a> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120831&edate=20120501&rec=6402">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-05-15T12:00:24+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>re: SMC Rejects Zytiga Based On High Cost</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology8278</link>
<description>re: SMC Rejects Zytiga Based On High Cost</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology8278</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8278">re: SMC Rejects Zytiga Based On High Cost</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8278">Oncology8278</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/20">Alison Attard</a> | 15 May 2012 | 11:55</font><br><br><div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-size: 12px;"><UL style="margin: 0px; list-style-type: none; padding: 0px;"><LI style="margin: 0px 0px 10px; line-height: 1.4em; list-style-type: disc; padding: 0px;"><FONT face="Arial" size="2">Comment: Following UK NICE's recent negative judgement on Zytiga (abiraterone) the Scottish Medicines Consortium has similarly ruled that J&amp;J's prostate cancer drug cannot be accepted for use on the NHS because the "balance of costs and benefits".<wbr></FONT>
</LI>
</UL></span>&nbsp;<br><font size="-1">Jacquelyne CANTLE MEYRICK / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8176" class="commentpermalink">Oncology8176</a> / <span class="date">14 March 2012</span> /
<span class="time">18:49:23 o'clock CET</span>
</font></div><div style="margin-bottom: 10px;">According to the newspaper 'The Scotsman'  Janssen-Cilag Ltd  has resubmitted abiraterone to the SMC, the final decision is due in August 2012 </div><div><DIV class="left" id="1.2291862">Source: The Scotsman 12 May 2012</DIV> </div><!-- Comment details --><font size="-1">Alison Attard / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8278" class="commentpermalink">Oncology8278</a> / <span class="date">15 May 2012</span> /
<span class="time">11:55:47 o'clock CEST</span>
</font><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8278">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8176">View thread  Oncology8176: SMC Rejects Zytiga Based On High Cost</a>]]></content:encoded><dc:date>2012-05-15T11:55:47+02:00</dc:date><dc:creator>ala97794</dc:creator></item><item>
<title>Key Highlights from Merck Serono's Q1 2012 [:PharmaWorld:sub:Finance, class:GrowthHormone, comp:MerckSerono, prod:Saizen]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology6929</link>
<description>Key Highlights from Merck Serono's Q1 2012 [:PharmaWorld:sub:Finance, class:GrowthHormone, comp:MerckSerono, prod:Saizen]</description><category>sub:Finance</category><category>class:GrowthHormone</category><category>comp:MerckSerono</category><category>prod:Saizen</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology6929</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120831&edate=20120501&rec=6929">Key Highlights from Merck Serono's Q1 2012</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=class%3aGrowthHormone"><font color="#e95e0b">:Endocrinology:class:GrowthHormone</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=comp%3aMerckSerono"><font color="#e95e0b">:Endocrinology:comp:MerckSerono</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=prod%3aSaizen"><font color="#e95e0b">:Endocrinology:prod:Saizen</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=sub%3aFinance"><font color="#e95e0b">:PharmaWorld:sub:Finance</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology6929">Endocrinology6929</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 15 May 2012 | 10:16</font><br><br><div style="margin-bottom: 10px;">Comment: Merck Serono's sales increased 5.<wbr>4% to € 1,417 million vs € 1,345 million in Q1 2011.<wbr> Sales of Saizen® for the treatment of GH deficiency were € 59 million (7% organic sales growth in the quarter).<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Q1 2012 Sales of Main Products</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6929/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Updated Pipeline (May 15, 2012)</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6929/2/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Merck Guidances for 2012</FONT></STRONG> </div><div><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6929/3/ScreenCapture3.jpg?user-agent=rss"> </div><!-- Comment details --><a name="endocrinology6929attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6929/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(83,9 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6929/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(132,5 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6929/3/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(32,2 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120831&edate=20120501&rec=6929">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-05-15T10:16:46+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6929/1/ScreenCapture1.jpg" length="85953" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6929/2/ScreenCapture2.jpg" length="135711" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6929/3/ScreenCapture3.jpg" length="32987" type="image/jpeg"/></item><item>
<title>ECE Intelligence Part 1 - Key Data From The Novartis &amp; Pfizer Satellite Symposium [Alert, class:SomatostatinAnalogue, comp:Novartis, comp:Pfizer, dis:Acromegaly, dis:Cushing, prod:Pasireotide, :PharmaWorld:congress:ECE]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology6923</link>
<description>ECE Intelligence Part 1 - Key Data From The Novartis &amp; Pfizer Satellite Symposium [Alert, class:SomatostatinAnalogue, comp:Novartis, comp:Pfizer, dis:Acromegaly, dis:Cushing, prod:Pasireotide, :PharmaWorld:congress:ECE]</description><category>Alert</category><category>class:SomatostatinAnalogue</category><category>comp:Novartis</category><category>comp:Pfizer</category><category>dis:Acromegaly</category><category>dis:Cushing</category><category>prod:Pasireotide</category><category>congress:ECE</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology6923</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120831&edate=20120501&rec=6923">ECE Intelligence Part 1 - Key Data From The Novartis & Pfizer Satellite Symposium</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=Alert"><font color="#e95e0b">:Endocrinology:Alert</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=class%3aSomatostatinAnalogue"><font color="#e95e0b">:Endocrinology:class:SomatostatinAnalogue</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=comp%3aNovartis"><font color="#e95e0b">:Endocrinology:comp:Novartis</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=comp%3aPfizer"><font color="#e95e0b">:Endocrinology:comp:Pfizer</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=dis%3aAcromegaly"><font color="#e95e0b">:Endocrinology:dis:Acromegaly</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=dis%3aCushing"><font color="#e95e0b">:Endocrinology:dis:Cushing</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=prod%3aPasireotide"><font color="#e95e0b">:Endocrinology:prod:Pasireotide</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=congress%3aECE"><font color="#e95e0b">:PharmaWorld:congress:ECE</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology6923">Endocrinology6923</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 14 May 2012 | 12:29</font><br><br><div style="margin-bottom: 10px;">Comment: Novartis&rsquo;s Symposium &ldquo;Taking The Next Step&rdquo; provided a strong message about pasireotide&rsquo; s (Signifor) superior disease control in both Cushing&rsquo;s disease and acromegaly against the background of a challenging treatment paradigm and unmet need despite current treatments.<wbr> Hyperglycaemia was described but not discussed as an issue.<wbr> Filing for 1<SUP>st</SUP> line treatment seems a certainty.<wbr> Preliminary results in non-responders were not so impressive.<wbr> Pfizer, by contrast, focused on metabolic control raising the question of why you would use a new drug like pasireotide when you can use a more established choice like Somavert that is not associated with glucose abnormalities.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Novartis Symposium</STRONG> </div><div style="margin-bottom: 10px;">The symposium was chaired by Anna-Marie Calao and included presentations from Paolo Cappalanca (Naples), John Wass (Oxford) and Ilan Shimon (Israel) and was organised into two sections one focused on Cushing&rsquo;s disease, the other on acromegaly.<wbr> </div><div style="margin-bottom: 10px;">The latter included the first detailed presentation (other than earlier that day) of Novartis&rsquo;s phIII acromegaly data generated from one of the largest trials ever undertaken in such patients.<wbr> </div><div style="margin-bottom: 10px;">John Wass set the scene by highlighting some morbidity and mortality statistics from New Zealand which strongly suggest that tight biochemical control reduces mortality to the age adjusted norm </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6923/10/ScreenCapture10.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">He noted how surgical expertise is critical to the success of transphenoidal surgery and how success rates with both surgical and medical therapy has improved over time but how there is still scope to do better in terms of biochemical control (data from the UK Acromegaly register) </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6923/11/ScreenCapture11.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6923/12/ScreenCapture12.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">John Wass emphasised how early open studies in patients previously treated with SSAs had shown a high level of control with octreotide LAR (up to 70%) but how in more recent studies which had included treatment na&iuml;ve patients (including one with lanreotide treatment) lower levels of efficacy had been observed.<wbr> Summarising he listed the variables that have affected outcomes in previously reported trials.<wbr> And emphasised how an improvement in biochemical control rates is needed to increase life expectancy in acromegalic patients.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6923/13/ScreenCapture13.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6923/14/ScreenCapture14.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6923/15/ScreenCapture15.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6923/16/ScreenCapture16.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">Anna-Marie Calao followed focusing initially on real-world levels of IGF-1 control with pegvisoment and combination therapy.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6923/17/ScreenCapture17.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6923/18/ScreenCapture18.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6923/19/ScreenCapture19.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">Details of the design and the results of the first pivotal phIII pasireotide study in acromegaly then followed.<wbr> The primary endpoint of this study was to determine if pasireotide LAR s superior to octreotide LAR in providing full biochemical control.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6923/20/ScreenCapture20.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">The results in terms of primary endpoint are shown below both in post surgery and treatment na&iuml;ve patients:- </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6923/21/ScreenCapture21.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">As control of GH levels was similar it appears that it is the superior control of IGF-1 that leads to this overall superiority in terms of control as tumour volume control is also similar.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6923/22/ScreenCapture22.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6923/23/ScreenCapture23.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6923/24/ScreenCapture24.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><SPAN style="font-size: small; font-family: verdana,geneva; mso-fareast-font-family: 'MS Mincho'; mso-ansi-language: EN-GB; mso-fareast-language: JA; mso-bidi-language: AR-SA;">Then came the interesting point , the comparative safety profile.<wbr> With the exception of hyperglycaemia safety data is similar to octreotide LAR but as the detailed fasting glucose data shown below shows treatment with pasireotide LAR does increase levels relative to baseline.<wbr> </SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="font-size: 12pt; font-family: 'Times New Roman'; mso-fareast-font-family: 'MS Mincho'; mso-ansi-language: EN-GB; mso-fareast-language: JA; mso-bidi-language: AR-SA;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6923/25/ScreenCapture25.jpg?user-agent=rss"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="font-size: 12pt; font-family: 'Times New Roman'; mso-fareast-font-family: 'MS Mincho'; mso-ansi-language: EN-GB; mso-fareast-language: JA; mso-bidi-language: AR-SA;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6923/26/ScreenCapture26.jpg?user-agent=rss"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="font-size: 12pt; font-family: 'Times New Roman'; mso-fareast-font-family: 'MS Mincho'; mso-ansi-language: EN-GB; mso-fareast-language: JA; mso-bidi-language: AR-SA;"><SPAN style="font-size: 10pt; font-family: Verdana; mso-fareast-font-family: 'MS Mincho'; mso-ansi-language: EN-GB; mso-fareast-language: JA; mso-bidi-language: AR-SA; mso-bidi-font-family: 'Times New Roman';">After the 12 month double-blind phase patients could switch therapies in an extended blinded 25 &ndash;week follow-up.<wbr> Data from the first 19 weeks of this period was shown illustrating that 21% of patients previously uncontrolled on octreotide LAR achieved biochemical control when switched to pasireotide LAR compared to 2.<wbr>6% switching from pasireotide LAR to octreotide LAR (see attached poster).<wbr> Interestingly, high HBA1c levels reverted towards baseline levels on switching to octreotide</SPAN></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="font-size: 12pt; font-family: 'Times New Roman'; mso-fareast-font-family: 'MS Mincho'; mso-ansi-language: EN-GB; mso-fareast-language: JA; mso-bidi-language: AR-SA;"><SPAN style="font-size: 10pt; font-family: Verdana; mso-fareast-font-family: 'MS Mincho'; mso-ansi-language: EN-GB; mso-fareast-language: JA; mso-bidi-language: AR-SA; mso-bidi-font-family: 'Times New Roman';"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6923/27/ScreenCapture27.jpg?user-agent=rss"></SPAN></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="font-size: 12pt; font-family: 'Times New Roman'; mso-fareast-font-family: 'MS Mincho'; mso-ansi-language: EN-GB; mso-fareast-language: JA; mso-bidi-language: AR-SA;"><SPAN style="font-size: 10pt; font-family: Verdana; mso-fareast-font-family: 'MS Mincho'; mso-ansi-language: EN-GB; mso-fareast-language: JA; mso-bidi-language: AR-SA; mso-bidi-font-family: 'Times New Roman';"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6923/28/ScreenCapture28.jpg?user-agent=rss"></SPAN></SPAN> </div><div style="margin-bottom: 10px;">A second study in inadequately controlled acromegaly patients remains ongoing and is scheduled to complete in June 2013.<wbr> </div><div style="margin-bottom: 10px;">Anna-Maria summarised her presentation as shown below.<wbr> When questioned about how best to deal with the hyperglycaemia, she suggested that data has shown that the addition of a DPP-IV inhibitor or GLP-1 analogue is the best solution but that metformin could also have some efficacy.<wbr> </div><div style="margin-bottom: 10px;">She was also asked if one had a new patient with acromegaly what should one prescribe as a first-line therapy.<wbr> She hesitated and then suggested that given the 20-years experience with octreotide LAR that this is still likely to be very helpful for many patients but that pasireotide does look to be the more powerful drug.<wbr> She added if could manage the diabetes then I would go for pasireotide.<wbr> So for now she concluded one should start with experience but as time goes by she believes more will use pasiroetide as experience grows.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6923/29/ScreenCapture29.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6923/30/ScreenCapture30.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6923/31/ScreenCapture31.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">Finally when questioned post the event Ilan Shimon stated that Novartis was likely to file for 1<SUP>st</SUP> line usage given the superiority shown and the no of de novo patients included in the trial.<wbr> His expectation was that approval is likely to be similar in terms of label to that of the recently approved Cushing&rsquo;s disease indication i.<wbr>e.<wbr> for whom surgery is not an option or for whom surgery has failed.<wbr> </div><div style="margin-bottom: 10px;">Turning to the other presentations, this time on Cushing&rsquo;s disease, these similarly focused on the challenges, comorbidities and unmet need before highlighting some case studies illustrating the benefit of pasireotide therapy and the outcome of the phIII pasireotide trial presented last year at the Pituitary Meeting and ENDO.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6923/32/ScreenCapture32.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">Some of the key slides shown are highlighted below:- </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6923/33/ScreenCapture33.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6923/34/ScreenCapture34.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6923/35/ScreenCapture35.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6923/36/ScreenCapture36.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6923/37/ScreenCapture37.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6923/38/ScreenCapture38.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6923/39/ScreenCapture39.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">The CI Department would like to acknowledge the valued input of Antoine Clermont (Medical Advisor Endocrinology Franchise) in helping to compile this report on Novartis's PhIII data.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Pfizer Symposium</STRONG> </div><div style="margin-bottom: 10px;">Pfizer&rsquo;s symposium was well attended and focused largely on the metabolic consequences of medical treatment of acromegaly.<wbr> It was co-cjaired by Ezio Ghigo (Turin) and Christian Strasburger (Berlin).<wbr> </div><div style="margin-bottom: 10px;">Ken Ho (Brisbaine) focused on the metabolic perturbations of acromegaly concluding the following points as shown:- </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6923/40/ScreenCapture40.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">Whilst Philippe Chanson (Paris) gave an interesting presentation on body composition changes associated with the treatment of acromegaly both in terms of the reduction in extracellular fluid and the positive impact on various co-morbidities and changes in fat and lipid metabolism.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6923/41/ScreenCapture41.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6923/42/ScreenCapture42.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">One of the key sessions of the symposia, however, was that given by William Drake (Barts UK) which included a powerful slide showing the impact of diabetes on acromegalic mortality.<wbr> He reviewed various sets of data including a meta-analysis demonstrating the overall lack of impact of SSA therapy on glucose metabolism plus data showing that pegvisoment improves glycaemic control and could be particularly beneficial for patients with diabetic acromegaly.<wbr> He then turned his attention to pasiroetide, noting its potential to be diabetogenic and suggesting that this aspect of the drug&rsquo;s profile needs further evaluation.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6923/43/ScreenCapture43.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6923/44/ScreenCapture44.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6923/45/ScreenCapture45.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6923/9/ScreenCapture9.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">.<wbr> </div><div><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6923/7/ScreenCapture7.jpg?user-agent=rss"> </div><!-- Comment details --><a name="endocrinology6923attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6923/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(73,4 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6923/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(103 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6923/3/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(135,1 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6923/4/ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(106,7 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6923/5/ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(90,9 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6923/6/ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(107,3 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6923/7/ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(103,8 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6923/8/ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(80,2 KB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6923/9/ScreenCapture9.jpg">ScreenCapture9.jpg</a>&nbsp;&nbsp;(106,4 KB)<br>&nbsp;&nbsp;10.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6923/10/ScreenCapture10.jpg">ScreenCapture10.jpg</a>&nbsp;&nbsp;(48,9 KB)<br>&nbsp;&nbsp;11.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6923/11/ScreenCapture11.jpg">ScreenCapture11.jpg</a>&nbsp;&nbsp;(30,5 KB)<br>&nbsp;&nbsp;12.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6923/12/ScreenCapture12.jpg">ScreenCapture12.jpg</a>&nbsp;&nbsp;(40,5 KB)<br>&nbsp;&nbsp;13.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6923/13/ScreenCapture13.jpg">ScreenCapture13.jpg</a>&nbsp;&nbsp;(41,5 KB)<br>&nbsp;&nbsp;14.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6923/14/ScreenCapture14.jpg">ScreenCapture14.jpg</a>&nbsp;&nbsp;(40,6 KB)<br>&nbsp;&nbsp;15.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6923/15/ScreenCapture15.jpg">ScreenCapture15.jpg</a>&nbsp;&nbsp;(44,5 KB)<br>&nbsp;&nbsp;16.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6923/16/ScreenCapture16.jpg">ScreenCapture16.jpg</a>&nbsp;&nbsp;(51,6 KB)<br>&nbsp;&nbsp;17.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6923/17/ScreenCapture17.jpg">ScreenCapture17.jpg</a>&nbsp;&nbsp;(37,6 KB)<br>&nbsp;&nbsp;18.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6923/18/ScreenCapture18.jpg">ScreenCapture18.jpg</a>&nbsp;&nbsp;(41,1 KB)<br>&nbsp;&nbsp;19.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6923/19/ScreenCapture19.jpg">ScreenCapture19.jpg</a>&nbsp;&nbsp;(42,8 KB)<br>&nbsp;&nbsp;20.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6923/20/ScreenCapture20.jpg">ScreenCapture20.jpg</a>&nbsp;&nbsp;(38,1 KB)<br>&nbsp;&nbsp;21.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6923/21/ScreenCapture21.jpg">ScreenCapture21.jpg</a>&nbsp;&nbsp;(53 KB)<br>&nbsp;&nbsp;22.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6923/22/ScreenCapture22.jpg">ScreenCapture22.jpg</a>&nbsp;&nbsp;(42,1 KB)<br>&nbsp;&nbsp;23.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6923/23/ScreenCapture23.jpg">ScreenCapture23.jpg</a>&nbsp;&nbsp;(40,7 KB)<br>&nbsp;&nbsp;24.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6923/24/ScreenCapture24.jpg">ScreenCapture24.jpg</a>&nbsp;&nbsp;(38,1 KB)<br>&nbsp;&nbsp;25.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6923/25/ScreenCapture25.jpg">ScreenCapture25.jpg</a>&nbsp;&nbsp;(38,4 KB)<br>&nbsp;&nbsp;26.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6923/26/ScreenCapture26.jpg">ScreenCapture26.jpg</a>&nbsp;&nbsp;(38,8 KB)<br>&nbsp;&nbsp;27.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6923/27/ScreenCapture27.jpg">ScreenCapture27.jpg</a>&nbsp;&nbsp;(56,8 KB)<br>&nbsp;&nbsp;28.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6923/28/ScreenCapture28.jpg">ScreenCapture28.jpg</a>&nbsp;&nbsp;(35,3 KB)<br>&nbsp;&nbsp;29.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6923/29/ScreenCapture29.jpg">ScreenCapture29.jpg</a>&nbsp;&nbsp;(30,5 KB)<br>&nbsp;&nbsp;30.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6923/30/ScreenCapture30.jpg">ScreenCapture30.jpg</a>&nbsp;&nbsp;(36,6 KB)<br>&nbsp;&nbsp;31.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6923/31/ScreenCapture31.jpg">ScreenCapture31.jpg</a>&nbsp;&nbsp;(46,2 KB)<br>&nbsp;&nbsp;32.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6923/32/ScreenCapture32.jpg">ScreenCapture32.jpg</a>&nbsp;&nbsp;(79 KB)<br>&nbsp;&nbsp;33.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6923/33/ScreenCapture33.jpg">ScreenCapture33.jpg</a>&nbsp;&nbsp;(42,1 KB)<br>&nbsp;&nbsp;34.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6923/34/ScreenCapture34.jpg">ScreenCapture34.jpg</a>&nbsp;&nbsp;(41,7 KB)<br>&nbsp;&nbsp;35.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6923/35/ScreenCapture35.jpg">ScreenCapture35.jpg</a>&nbsp;&nbsp;(42,2 KB)<br>&nbsp;&nbsp;36.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6923/36/ScreenCapture36.jpg">ScreenCapture36.jpg</a>&nbsp;&nbsp;(46,9 KB)<br>&nbsp;&nbsp;37.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6923/37/ScreenCapture37.jpg">ScreenCapture37.jpg</a>&nbsp;&nbsp;(35,2 KB)<br>&nbsp;&nbsp;38.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6923/38/ScreenCapture38.jpg">ScreenCapture38.jpg</a>&nbsp;&nbsp;(43 KB)<br>&nbsp;&nbsp;39.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6923/39/ScreenCapture39.jpg">ScreenCapture39.jpg</a>&nbsp;&nbsp;(51,5 KB)<br>&nbsp;&nbsp;40.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6923/40/ScreenCapture40.jpg">ScreenCapture40.jpg</a>&nbsp;&nbsp;(51,9 KB)<br>&nbsp;&nbsp;41.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6923/41/ScreenCapture41.jpg">ScreenCapture41.jpg</a>&nbsp;&nbsp;(55,5 KB)<br>&nbsp;&nbsp;42.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6923/42/ScreenCapture42.jpg">ScreenCapture42.jpg</a>&nbsp;&nbsp;(62,2 KB)<br>&nbsp;&nbsp;43.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6923/43/ScreenCapture43.jpg">ScreenCapture43.jpg</a>&nbsp;&nbsp;(94,7 KB)<br>&nbsp;&nbsp;44.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6923/44/ScreenCapture44.jpg">ScreenCapture44.jpg</a>&nbsp;&nbsp;(105,1 KB)<br>&nbsp;&nbsp;45.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6923/45/ScreenCapture45.jpg">ScreenCapture45.jpg</a>&nbsp;&nbsp;(102,4 KB)<br>&nbsp;&nbsp;46.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6923/46/ECE%20Acromegaly%20Crossover%20poster%20Fleseriu%20FINAL.pdf">ECE Acromegaly Crossover poster Fleseriu FINAL.pdf</a>&nbsp;&nbsp;(115,2 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120831&edate=20120501&rec=6923">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-05-14T12:29:00+02:00</dc:date><dc:creator>jac89886</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6923/1/ScreenCapture1.jpg" length="75178" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6923/2/ScreenCapture2.jpg" length="105425" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6923/3/ScreenCapture3.jpg" length="138362" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6923/4/ScreenCapture4.jpg" length="109233" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6923/5/ScreenCapture5.jpg" length="93033" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6923/6/ScreenCapture6.jpg" length="109922" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6923/7/ScreenCapture7.jpg" length="106320" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6923/8/ScreenCapture8.jpg" length="82120" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6923/9/ScreenCapture9.jpg" length="108999" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6923/10/ScreenCapture10.jpg" length="50124" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6923/11/ScreenCapture11.jpg" length="31270" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6923/12/ScreenCapture12.jpg" length="41435" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6923/13/ScreenCapture13.jpg" length="42510" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6923/14/ScreenCapture14.jpg" length="41618" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6923/15/ScreenCapture15.jpg" length="45541" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6923/16/ScreenCapture16.jpg" length="52887" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6923/17/ScreenCapture17.jpg" length="38479" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6923/18/ScreenCapture18.jpg" length="42085" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6923/19/ScreenCapture19.jpg" length="43788" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6923/20/ScreenCapture20.jpg" length="38970" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6923/21/ScreenCapture21.jpg" length="54256" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6923/22/ScreenCapture22.jpg" length="43074" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6923/23/ScreenCapture23.jpg" length="41653" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6923/24/ScreenCapture24.jpg" length="39005" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6923/25/ScreenCapture25.jpg" length="39283" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6923/26/ScreenCapture26.jpg" length="39710" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6923/27/ScreenCapture27.jpg" length="58131" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6923/28/ScreenCapture28.jpg" length="36102" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6923/29/ScreenCapture29.jpg" length="31243" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6923/30/ScreenCapture30.jpg" length="37517" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6923/31/ScreenCapture31.jpg" length="47318" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6923/32/ScreenCapture32.jpg" length="80938" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6923/33/ScreenCapture33.jpg" length="43149" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6923/34/ScreenCapture34.jpg" length="42750" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6923/35/ScreenCapture35.jpg" length="43260" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6923/36/ScreenCapture36.jpg" length="48001" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6923/37/ScreenCapture37.jpg" length="36031" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6923/38/ScreenCapture38.jpg" length="44034" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6923/39/ScreenCapture39.jpg" length="52770" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6923/40/ScreenCapture40.jpg" length="53117" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6923/41/ScreenCapture41.jpg" length="56787" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6923/42/ScreenCapture42.jpg" length="63739" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6923/43/ScreenCapture43.jpg" length="96991" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6923/44/ScreenCapture44.jpg" length="107606" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6923/45/ScreenCapture45.jpg" length="104874" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/6923/46/ECE%20Acromegaly%20Crossover%20poster%20Fleseriu%20FINAL.pdf" length="117961" type="application/pdf"/></item><item>
<title>Merz Starts Negotiations to Acquier Pierre Fabre's Filler [comp:Merz, prod:Xeomin, sub:Aesthetics, headline]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology6397</link>
<description>Merz Starts Negotiations to Acquier Pierre Fabre's Filler [comp:Merz, prod:Xeomin, sub:Aesthetics, headline]</description><category>comp:Merz</category><category>prod:Xeomin</category><category>sub:Aesthetics</category><category>headline</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology6397</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120831&edate=20120501&rec=6397">Merz Starts Negotiations to Acquier Pierre Fabre's Filler</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=comp%3aMerz"><font color="#e95e0b">:Neurology:comp:Merz</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=headline"><font color="#e95e0b">:Neurology:headline</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=prod%3aXeomin"><font color="#e95e0b">:Neurology:prod:Xeomin</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=sub%3aAesthetics"><font color="#e95e0b">:Neurology:sub:Aesthetics</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology6397">Neurology6397</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 14 May 2012 | 10:52</font><br><br><div style="margin-bottom: 10px;">Comment: With the prospective transaction, kicked-off on May 9th, Merz intends to acquire Glytone(R) filler range.<wbr> Following the acquisition of BioForm Medical in 2010, this new project would further advance Merz' strategy in aesthetics.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Terms of the Prospective Transaction</FONT></STRONG> </div><div style="margin-bottom: 10px;">Merz would become the owner to the WW rights to the Glyton(R) hyaluronic acid fillers and to the rights outside the USA for the brand`s other products.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">About Glytone(R)</FONT></STRONG> </div><div style="margin-bottom: 10px;">Glytone® was acquired by Pierre Fabre in the U.<wbr>S in 2002 and launched in E.<wbr>U in 2008.<wbr> </div><div style="margin-bottom: 10px;">It includes: </div><div style="margin-bottom: 10px;">- a complete range of products of dermatological dispensing sold mainly in the U.<wbr>S </div><div>- professional products used in aesthetic dermatology - glycolic acid peels, injectables with acid hyaluronique used for the filling of wrinkles and the repulpage of lips - sold exclusively outside the U.<wbr>S </div><!-- Comment details --><a name="neurology6397attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/6397/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(7 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120831&edate=20120501&rec=6397">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-05-14T10:52:18+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/6397/1/ScreenCapture1.jpg" length="7145" type="image/jpeg"/></item><item>
<title>Takeda Mid-Range Plan Includes Approval of TAK-700 in All Geographic Regions [dis:Prostate, comp:Takeda, prod:Orteronel, headline]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology8275</link>
<description>Takeda Mid-Range Plan Includes Approval of TAK-700 in All Geographic Regions [dis:Prostate, comp:Takeda, prod:Orteronel, headline]</description><category>dis:Prostate</category><category>comp:Takeda</category><category>prod:Orteronel</category><category>headline</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology8275</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8275">Takeda Mid-Range Plan Includes Approval of TAK-700 in All Geographic Regions</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=comp%3aTakeda"><font color="#e95e0b">:Oncology:comp:Takeda</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=headline"><font color="#e95e0b">:Oncology:headline</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=prod%3aOrteronel"><font color="#e95e0b">:Oncology:prod:Orteronel</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8275">Oncology8275</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 14 May 2012 | 10:48</font><br><br><div style="margin-bottom: 10px;">Comment: On Friday Takeda announced details of its mid-range plan FY12-14, highlighting the significant R&amp;D effort underway in six different therapeutic areas, the greatest investment being in oncology and cardiovascular/<wbr>metabolic medicine.<wbr> Recruitment to its two phIII trials with TAK-700 in CRPC will be complete this year, with the company now anticipating approval in FY2014.<wbr> Meanwhile, from a LCM perspective, Takeda is developing a 6M formulation of Lupron for prostate and breast cancer in Japan.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8275/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8275/2/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8275/3/ScreenCapture3.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8275/4/ScreenCapture4.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8275/6/ScreenCapture6.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8275/7/ScreenCapture7.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG>Development Status Of Other Products Of Note</STRONG> </div><div><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8275/5/ScreenCapture5.jpg?user-agent=rss"> </div><!-- Comment details --><a name="oncology8275attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8275/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(215,4 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8275/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(268,1 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8275/3/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(228,6 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8275/4/ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(216,3 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8275/5/ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(216,2 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8275/6/ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(144,4 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8275/7/ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(123,5 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8275">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-05-14T10:48:47+02:00</dc:date><dc:creator>jac89886</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8275/1/ScreenCapture1.jpg" length="220589" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8275/2/ScreenCapture2.jpg" length="274553" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8275/3/ScreenCapture3.jpg" length="234103" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8275/4/ScreenCapture4.jpg" length="221450" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8275/5/ScreenCapture5.jpg" length="221343" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8275/6/ScreenCapture6.jpg" length="147875" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8275/7/ScreenCapture7.jpg" length="126429" type="image/jpeg"/></item><item>
<title>Astellas - FY2011 Results - Key Takeaways [headline, dis:Prostate, prod:Eligard, class:Antihormonals, comp:Astellas, :PharmaWorld:mkt:Russia, :PharmaWorld:mkt:Intercontinental]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology8271</link>
<description>Astellas - FY2011 Results - Key Takeaways [headline, dis:Prostate, prod:Eligard, class:Antihormonals, comp:Astellas, :PharmaWorld:mkt:Russia, :PharmaWorld:mkt:Intercontinental]</description><comments>http://ci.beaufour-ipsen.com/traction/permalink/Oncology8271</comments><category>headline</category><category>dis:Prostate</category><category>prod:Eligard</category><category>class:Antihormonals</category><category>comp:Astellas</category><category>mkt:Russia</category><category>mkt:Intercontinental</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology8271</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8271">Astellas - FY2011 Results - Key Takeaways</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=class%3aAntihormonals"><font color="#e95e0b">:Oncology:class:Antihormonals</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=comp%3aAstellas"><font color="#e95e0b">:Oncology:comp:Astellas</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=headline"><font color="#e95e0b">:Oncology:headline</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=prod%3aEligard"><font color="#e95e0b">:Oncology:prod:Eligard</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=mkt%3aIntercontinental"><font color="#e95e0b">:PharmaWorld:mkt:Intercontinental</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=mkt%3aRussia"><font color="#e95e0b">:PharmaWorld:mkt:Russia</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8271">Oncology8271</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 14 May 2012 | 10:21</font><br><br><div style="margin-bottom: 10px;">Comment: Astellas reported modest FY sales growth of +1.<wbr>6% but with reduced R&amp;D expenses operating income up 10.<wbr>4%.<wbr> A filing for MDV3100 in the post-decetaxel CPRC setting will be made this month.<wbr> </div><div style="margin-bottom: 10px;">Sales of its main urology products grew by +3.<wbr>8%, whilst Eligard in Europe registerd a similar increase to generated €127m.<wbr> </div><div style="margin-bottom: 10px;">Geographically sales in emerging markets accounted for 6% of consolidated sales and continue to generate strong growth +14% YOY ex forex.<wbr> Astellas is continuing to expand its business in China and Russia.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8271/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">Management highlighted some key milestones in 2011, which included: </div><div style="margin-bottom: 10px;"><UL><LI>the August 2011 of the group's new iOAB drug Mirabegron: </LI>
<LI>the NDA filing of Eligard in Asian Countries; </LI>
<LI>the favourable results for MDV3100 from the AFFIRM CRPC post docetaxel trial NDA/<wbr>MAA filing for which is in preparation and will be filed this month and next with a priority reveiw sought in the US; and </LI>
<LI>the favourable results for tivozanib in the TIVO-1 renal cell cancer study, the NDA/<wbr>MAA for which is also in preparation.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8271/2/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8271/3/ScreenCapture3.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">Enrollment in the PREVAIL pre-chemotherapy trial should complete this month apart from in a few select Asian centres.<wbr> Whether the study will report out at the interim stage remains to be seen as it has a co-primary endpoint of PFS and OS, the event rate for which is being independently monitored.<wbr> <a name="Oncology8314c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div>On June 6th, Medivation and Astellas announced the completion of 1,680 patients in the PREVAIL (pre-chemo) trial apart in a few Asian centres, to gain additional information on this specific population.<wbr> </div><font size="-1">Brigitte DESCHAMPS / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8314" class="commentpermalink">Oncology8314</a> / <span class="date">06 June 2012</span> /
<span class="time">18:52:44 o'clock CEST</span>
</font></div></div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8271/4/ScreenCapture4.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8271/5/ScreenCapture5.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">Additionally, management announced plans to host an R&amp;D Meeting on its oncology pipeline on July11 th in Japan.<wbr> </div><div><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8271/6/ScreenCapture6.jpg?user-agent=rss"> </div><!-- Comment details --><a name="oncology8271attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8271/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(213 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8271/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(168,6 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8271/3/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(222,5 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8271/4/ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(170,5 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8271/5/ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(197,7 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8271/6/ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(239,2 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8271">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-05-14T10:21:47+02:00</dc:date><dc:creator>jac89886</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8271/1/ScreenCapture1.jpg" length="218095" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8271/2/ScreenCapture2.jpg" length="172641" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8271/3/ScreenCapture3.jpg" length="227794" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8271/4/ScreenCapture4.jpg" length="174620" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8271/5/ScreenCapture5.jpg" length="202425" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8271/6/ScreenCapture6.jpg" length="244898" type="image/jpeg"/></item><item>
<title>GSK to Test Botox for Strabismus in Japan [prod:Botox, :PharmaWorld:sub:ClinicalTrial, :PharmaWorld:mkt:Japan, comp:Allergan]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology6396</link>
<description>GSK to Test Botox for Strabismus in Japan [prod:Botox, :PharmaWorld:sub:ClinicalTrial, :PharmaWorld:mkt:Japan, comp:Allergan]</description><category>prod:Botox</category><category>sub:ClinicalTrial</category><category>mkt:Japan</category><category>comp:Allergan</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology6396</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120831&edate=20120501&rec=6396">GSK to Test Botox for Strabismus in Japan</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=comp%3aAllergan"><font color="#e95e0b">:Neurology:comp:Allergan</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=prod%3aBotox"><font color="#e95e0b">:Neurology:prod:Botox</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=mkt%3aJapan"><font color="#e95e0b">:PharmaWorld:mkt:Japan</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=sub%3aClinicalTrial"><font color="#e95e0b">:PharmaWorld:sub:ClinicalTrial</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology6396">Neurology6396</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 11 May 2012 | 15:13</font><br><br><div style="margin-bottom: 10px;">Comment: The Ph3 trial will evaluate the efficacy of single-dose injection (1.<wbr>25U or 2.<wbr>5U) with GSK1358820 (Botox).<wbr> Primary outcome will assess change from baseline in strabismus angle.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Study Details - </FONT></STRONG><A href="http://clinicaltrials.gov/ct2/show/NCT01584843?recr=Open&amp;cond=Glabellar+OR+Canthal+OR+spasticity+OR+blepharospasm+OR+prostate+OR+neuroendocrine+OR+acromegaly+OR+botulinum&amp;fund=2&amp;rcv_s=03%2F12%2F2012&amp;rank=15"><STRONG><FONT size="3">NCT01584843</FONT></STRONG></A> </div><div style="margin-bottom: 10px;"><DIV class="indent1" style="MARGIN-TOP: 3ex">
<DIV class="indent2" style="MARGIN-TOP: 2ex">
<DIV class="indent3">
<DIV class="body3">
<P style="MARGIN-TOP: 1ex; MARGIN-BOTTOM: 1ex">Secondary objective is to evaluate the efficacy and safety of repeated-dose treatment with GSK1358820 in patients with strabismus.<wbr></P></DIV></DIV></DIV></DIV> </div><div style="margin-bottom: 10px;">Start date: May 2012 - Completion: May/<wbr>Nov.<wbr> 2013 </div><div style="margin-bottom: 10px;">Recruitment: approx.<wbr> 66 </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Background</FONT></STRONG> </div><div>In 2005 GSK and Allergan entered into Botox deal for Japan and China.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120831&edate=20120501&rec=6396">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-05-11T15:13:48+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>New Designs for Pre-filled Syringe to be Patented</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld9880</link>
<description>New Designs for Pre-filled Syringe to be Patented</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld9880</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120831&edate=20120501&rec=9880">New Designs for Pre-filled Syringe to be Patented</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld9880">PharmaWorld9880</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 11 May 2012 | 14:35</font><br><br><div style="margin-bottom: 10px;">Comment: Revolutions Medical, a company mainly engaged in the design and development of retractable safety needle devices, has filed an international patent application under the Patent Cooperation Treaty (PCT) directed to novel proprietary designs for pre-filled and non-pre-filled vacuum based retractable syringes.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">About the Designs</FONT></STRONG> </div><div style="margin-bottom: 10px;">Advantages: improve safety and ease of use; reduce the cost and complexity of manufacturing (with Yeso-med in China).<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">About the U.<wbr>S Market</FONT></STRONG> </div><div style="margin-bottom: 10px;">October 1999 - a report released by the Emergency Care Research Institute (ECRI) entitled “Sharps Safety and Needlestick Prevention”, found that all of the safety syringes offered by the major syringe companies have significant limitations or are not acceptable as safety devices.<wbr> </div><div style="margin-bottom: 10px;">In its Feb.<wbr>20 2011 report, Frost and Sullivan listed 9 companies offering safety syringes </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/9880/2/ScreenCapture2.jpg?user-agent=rss"> </div><div>For company information, please visit <A href="http://www.revolutionsmedical.com/">http:/<wbr>/<wbr>www.<wbr>revolutionsmedical.<wbr>com/<wbr></A> </div><!-- Comment details --><a name="pharmaworld9880attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/9880/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(13,2 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/9880/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(88,7 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120831&edate=20120501&rec=9880">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-05-11T14:35:55+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/9880/1/ScreenCapture1.jpg" length="13540" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/9880/2/ScreenCapture2.jpg" length="90791" type="image/jpeg"/></item><item>
<title>Exelixis's Development Plans For Cabozantinib Highlighted At The Deutsche H/C Conference [class:KinaseInhibitors, dis:Prostate, headline]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology8268</link>
<description>Exelixis's Development Plans For Cabozantinib Highlighted At The Deutsche H/C Conference [class:KinaseInhibitors, dis:Prostate, headline]</description><category>class:KinaseInhibitors</category><category>dis:Prostate</category><category>headline</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology8268</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8268">Exelixis's Development Plans For Cabozantinib Highlighted At The Deutsche H/<wbr>C Conference</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=class%3aKinaseInhibitors"><font color="#e95e0b">:Oncology:class:KinaseInhibitors</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=headline"><font color="#e95e0b">:Oncology:headline</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8268">Oncology8268</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 11 May 2012 | 13:04</font><br><br><div style="margin-bottom: 10px;">Comment: Exelixis noted that it has three phIII trials in medullary thyroid cancer with cabozantinib winding down and plans to submit a rolling submission later this quarter.<wbr> Two pivotal tirals in prostate cancer are also ongoing but a number of combination studies with key products such as abiraterone and MDV3100 are planned with a view to facilitating development in earlier treatment settings.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Medullary Thyroid Data</STRONG> </div><div style="margin-bottom: 10px;">Cabozantinib has demonstrated a nearly threefold increase, improvement in progression-free survival over placebo with a hazard ratio of 2.<wbr>8,  a highly statistically significant outcome.<wbr> The full dataset from these trials will be presented in a oral presentation at ASCO next month.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Prostate Cancer</STRONG> </div><div style="margin-bottom: 10px;">One study, preliminary data with which was reported late last yearm, that will be updated at ASCO this year is a low-dose study run by Dr.<wbr> Matthew Smith at Mass General in Boston.<wbr> That study is investigating starting doses of cabo at 40 milligrams and 20 milligrams, using bone scan response as the initial sign of activity, but then following out for other markers of activity as well.<wbr> </div><div style="margin-bottom: 10px;">Exelixis is claiming that these data are critically important to its prostate cancer program for two reasons.<wbr> One, it's helping to qualify the initial starting dose for the pivotal COMET trials, but it also may potentially facilitate the company's ability to move into earlier lines of therapy in prostate cancer as well as in combination.<wbr> </div><div style="margin-bottom: 10px;">In terms of combination studies, Exelixis recently announced two combination studies with cabozantinib, one with Abiraterone and the second with Taxotere.<wbr> This week it also announced that it is in discussions to do a combination study with MDV3100.<wbr><STRONG> It views these trials as critically important to move beyond the metastatic setting into earlier lines of therapy as well.<wbr></STRONG> Additionally, it noted that it also has ISTs looking at various other areas; one in particular is looking at bone mets associated with hormone receptor-positive breast cancer.<wbr> </div><div>From <A href="https://www.callstreet.com/">https:/<wbr>/<wbr>www.<wbr>exelixis.<wbr>com</A>, see <A href="https://www.callstreet.com/getTranscriptCS.jsp?tof=1&amp;site=getTranscriptCS&amp;eventID=1476047&amp;type=t&amp;format=html&amp;id=91516770083&amp;pid=10005&amp;kv=calendar;20120511064948;3374c9ab12088e999fe50d01228efd58">original source</A>.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8268">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-05-11T13:04:09+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>NICE Maintains its Decision Not to Approve Jevtana(R) [comp:SanofiAventis, dis:Prostate, :PharmaWorld:sub:Pricing, :PharmaWorld:mkt:UK]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology8267</link>
<description>NICE Maintains its Decision Not to Approve Jevtana(R) [comp:SanofiAventis, dis:Prostate, :PharmaWorld:sub:Pricing, :PharmaWorld:mkt:UK]</description><category>comp:SanofiAventis</category><category>dis:Prostate</category><category>sub:Pricing</category><category>mkt:UK</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology8267</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8267">NICE Maintains its Decision Not to Approve Jevtana(R)</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=comp%3aSanofiAventis"><font color="#e95e0b">:Oncology:comp:SanofiAventis</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=mkt%3aUK"><font color="#e95e0b">:PharmaWorld:mkt:UK</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=sub%3aPricing"><font color="#e95e0b">:PharmaWorld:sub:Pricing</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8267">Oncology8267</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 11 May 2012 | 12:14</font><br><br><div style="margin-bottom: 10px;">Comment: NICE's decision not to recommend this drug means that men in England with advanced prostate cancer have to access it through the Cancer Drugs Fund.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">NICE Next Step - Abiraterone</FONT></STRONG> </div><div style="margin-bottom: 10px;">See <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8065" class="defaultlink">Oncology8065: J&J's Zytiga (abiraterone) Too Expensive for National Health Service (NHS)</a>.<wbr> </div><div>Prostate cancer patients, their families and charities are now waiting for NICE to issue their decision on abiraterone, which is due imminently.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8267">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-05-11T12:14:36+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>NICE Backs Botox For Migraines [class:BotulinumToxins, comp:Allergan, dis:Migraine, news, prod:Botox]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology6394</link>
<description>NICE Backs Botox For Migraines [class:BotulinumToxins, comp:Allergan, dis:Migraine, news, prod:Botox]</description><category>class:BotulinumToxins</category><category>comp:Allergan</category><category>dis:Migraine</category><category>news</category><category>prod:Botox</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology6394</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120831&edate=20120501&rec=6394">NICE Backs Botox For Migraines</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=class%3aBotulinumToxins"><font color="#e95e0b">:Neurology:class:BotulinumToxins</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=comp%3aAllergan"><font color="#e95e0b">:Neurology:comp:Allergan</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=dis%3aMigraine"><font color="#e95e0b">:Neurology:dis:Migraine</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=news"><font color="#e95e0b">:Neurology:news</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=prod%3aBotox"><font color="#e95e0b">:Neurology:prod:Botox</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology6394">Neurology6394</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 11 May 2012 | 09:16</font><br><br><div style="margin-bottom: 10px;"><FONT face="Arial">Comment: NICE has decided to change its mind and back the use of Allergan's Botox for the treatment of some patients suffering from migraine</FONT> </div><div style="margin-bottom: 10px;"><P style="margin: 0px 0px 10px; word-spacing: 0px; font: 14px/1.6 arial, helvetica, sans; text-transform: none; color: #000000; text-indent: 0px; white-space: normal; letter-spacing: normal; background-color: #ffffff; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; padding: 0px;"><FONT size="2">Botox is licensed to prevent headaches in adults with chronic migraine but NICE had previously said it was not convinced of the value of funding the treatment by the NHS.<wbr></FONT></P> </div><div style="margin-bottom: 10px;"><P style="margin: 0px 0px 10px; word-spacing: 0px; font: 14px/1.6 arial, helvetica, sans; text-transform: none; color: #000000; text-indent: 0px; white-space: normal; letter-spacing: normal; background-color: #ffffff; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; padding: 0px;"><FONT size="2">"Chronic migraines are extremely debilitating and can significantly affect a person's quality of life," said Carole Longson, NICE's director of health technology evaluation.<wbr></FONT></P> </div><div style="margin-bottom: 10px;"><P style="margin: 0px 0px 10px; word-spacing: 0px; font: 14px/1.6 arial, helvetica, sans; text-transform: none; color: #000000; text-indent: 0px; white-space: normal; letter-spacing: normal; background-color: #ffffff; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; padding: 0px;"><FONT size="2">"We are pleased that the committee has been able to recommend Botox as a preventative therapy for those adults whose headaches have not improved despite trying at least three other medications and whose headaches are not caused by medication overuse.<wbr>"</FONT></P> </div><div style="margin-bottom: 10px;"><P style="margin: 0px 0px 10px; word-spacing: 0px; font: 14px/1.6 arial, helvetica, sans; text-transform: none; color: #000000; text-indent: 0px; white-space: normal; letter-spacing: normal; background-color: #ffffff; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px; padding: 0px;"><FONT size="2">The total cost for treatment and administration of treatment for a 12 week cycle is estimated at just over 349 pounds ($560).<wbr></FONT></P> </div><div style="margin-bottom: 10px;"><FONT size="2">It estimated that about a third of diagnosed patients with chronic migraine who have already tried three or more preventative medications and may now be eligible for treatment with Botox.<wbr></FONT> </div><div><FONT face="Arial">From </FONT><A href="http://www.nice.com"><FONT face="Arial">http:/<wbr>/<wbr>www.<wbr>nice.<wbr>com</FONT></A><FONT face="Arial">, see </FONT><A href="http://www.reuters.com/article/2012/05/10/britain-allergan-sanofi-nice-idUSL5E8GA7KI20120510"><FONT face="Arial">original source</FONT></A><FONT face="Arial">.<wbr></FONT> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120831&edate=20120501&rec=6394">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-05-11T09:16:09+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>Theratechnologies' Second Generation GRF Peptide Enters PC Phase [dis:GrowthHormoneDeficiency]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology6922</link>
<description>Theratechnologies' Second Generation GRF Peptide Enters PC Phase [dis:GrowthHormoneDeficiency]</description><comments>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology6922</comments><category>dis:GrowthHormoneDeficiency</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology6922</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120831&edate=20120501&rec=6922">Theratechnologies' Second Generation GRF Peptide Enters PC Phase</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=dis%3aGrowthHormoneDeficiency"><font color="#e95e0b">:Endocrinology:dis:GrowthHormoneDeficiency</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology6922">Endocrinology6922</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 10 May 2012 | 17:43</font><br><br><div style="margin-bottom: 10px;">Comment: According to the company, TH1173 exhibits superior pharmaceutical properties than tesamorelin.<wbr> It is a shorter peptide with better physical and chemical stability.<wbr> FIM is planned in Q1 2013.<wbr> Potential future indication could include growth hormone replacement in growth hormone deficient patient populations.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Drug Advantages</FONT></STRONG> </div><div style="margin-bottom: 10px;"><U>Bioavailability</U> </div><div style="margin-bottom: 10px;">Combined with the company's internally discovered formulations, the drug bioavailability could be improved from 5% to 95%.<wbr> </div><div style="margin-bottom: 10px;"><U>Administration</U> </div><div style="margin-bottom: 10px;">Dr.<wbr> Krishna Peri, VP, Research, noted that studies have confirmed the potential for sub-cutaneous administration, as well as non-invasive delivery of TH1173 via nasal and dermal routes.<wbr> </div><div style="margin-bottom: 10px;"><U>Patent</U> </div><div style="margin-bottom: 10px;">A patent application is currently pending and, if granted, will provide protection beyond 2030.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Future Indications</FONT></STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>- treatment of abdominal obesity in growth-hormone deficient patients, </LI>
<LI>- muscle wasting related to certain chronic diseases</LI>
<LI>- mild cognitive impairment</LI>
<LI>- growth hormone replacement in growth hormone deficient patient populations</LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Business Development</FONT></STRONG> </div><div>TH1173 is unpartnered and wholly-owned by Theratechnologies.<wbr> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Endocrinology7259c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">The US Patent and Trademark Office (USPTO) has granted a patent for the drug, providing for patent protection &gt;2030.<wbr> Of note, TH1173 is unpartnered.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Drug Clinical Program</STRONG> </div><div>The PC phase is completed.<wbr> Results, including those from 7-day and 28-day toxicology trials, warrent the pursuit of clinical stage.<wbr> </div><font size="-1">Brigitte DESCHAMPS / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7259" class="commentpermalink">Endocrinology7259</a> / <span class="date">04 February 2013</span> /
<span class="time">18:32:43 o'clock CET</span>
</font></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120831&edate=20120501&rec=6922">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-05-10T17:43:40+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Bayer to Evaluate Influence Treatment with Visanne on the Endometriosis Related QoL [comp:BayerSchering, dis:Gynea, :PharmaWorld:mkt:Russia, :PharmaWorld:mkt:Intercontinental, :PharmaWorld:sub:ClinicalTrial]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology8266</link>
<description>Bayer to Evaluate Influence Treatment with Visanne on the Endometriosis Related QoL [comp:BayerSchering, dis:Gynea, :PharmaWorld:mkt:Russia, :PharmaWorld:mkt:Intercontinental, :PharmaWorld:sub:ClinicalTrial]</description><category>comp:BayerSchering</category><category>dis:Gynea</category><category>mkt:Russia</category><category>mkt:Intercontinental</category><category>sub:ClinicalTrial</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology8266</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8266">Bayer to Evaluate Influence Treatment with Visanne on the Endometriosis Related QoL</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=comp%3aBayerSchering"><font color="#e95e0b">:Oncology:comp:BayerSchering</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=dis%3aGynea"><font color="#e95e0b">:Oncology:dis:Gynea</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=mkt%3aIntercontinental"><font color="#e95e0b">:PharmaWorld:mkt:Intercontinental</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=mkt%3aRussia"><font color="#e95e0b">:PharmaWorld:mkt:Russia</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=sub%3aClinicalTrial"><font color="#e95e0b">:PharmaWorld:sub:ClinicalTrial</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8266">Oncology8266</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 10 May 2012 | 16:22</font><br><br><div style="margin-bottom: 10px;">Comment: The data will be collected using a special patient questionnaire (Endometriosis Health Profile 5, EHP-5).<wbr> Primary outcome measures will assess percentage of patients who show an improvement of the EHP-5 items, and mean changes of EHP-5 items.<wbr> Many locations in Ukraine and the Russian Federation have been selected to recruit approx.<wbr> 3000 women having endometriosis related pain as leading symptom.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Study Details - </FONT></STRONG><A href="http://clinicaltrials.gov/ct2/show/NCT01595724?recr=Open&amp;fund=2&amp;rcv_s=04%2F26%2F2012&amp;rank=30"><STRONG><FONT size="3">NCT01595724</FONT></STRONG></A> </div><div style="margin-bottom: 10px;">Start date: May 2012 - Completion: June 2014 </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Additional Information</FONT></STRONG> </div><div style="margin-bottom: 10px;">The study will also: </div><div><DIV class="body3">
<P style="MARGIN-TOP: 1ex; MARGIN-BOTTOM: 1ex">- be used to describe the basic disease status and demographic characteristics of patients searching treatment by a gynecologist because of their endometriosis.<wbr> </P>
<P style="MARGIN-TOP: 1ex; MARGIN-BOTTOM: 1ex">- give insight into the typical diagnostic measures the physicians in different countries are using in the field of endometriosis.<wbr></P></DIV> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8266">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-05-10T16:22:19+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>BMS Highlights Immuno-oncology Programme at Deutsche Bank H/C Conference [comp:BMS, dis:Prostate]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology8264</link>
<description>BMS Highlights Immuno-oncology Programme at Deutsche Bank H/C Conference [comp:BMS, dis:Prostate]</description><category>comp:BMS</category><category>dis:Prostate</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology8264</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8264">BMS Highlights Immuno-oncology Programme at Deutsche Bank H/<wbr>C Conference</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=comp%3aBMS"><font color="#e95e0b">:Oncology:comp:BMS</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8264">Oncology8264</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 10 May 2012 | 16:02</font><br><br><div style="margin-bottom: 10px;">Comment: In a rare expose of its exploratory pipeline, Francis Cuss Senior VP R&amp;D presented an update on the portfolio, highlighting what it sees as the gem amongst the early portfolio namely anti PD-1.<wbr> A signficant amount of new data on this drug will be forthcoming at ASCO, including data on its use to treat renal cancer.<wbr> Comments on the use of Sprycil in CRPC and phIII data with Brivanib in HCC in 2H12 were also of interest.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8264/2/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">Francis Cuss noted:- </div><div style="margin-bottom: 10px;">"We have a large pre-clinical through to Phase II portfolio which has about doubled in size over the last five or six years.<wbr> But as I said, it's not just about the numbers; it's about the quality.<wbr> Of course today, I don't have enough time to go into detail here, but I would like to focus on a couple of areas that we think are particularly interesting, which we believe will have an impact over the next few years in terms of our pipeline, our Phase III pipeline.<wbr> The first area is immuno-oncology.<wbr> I think it's fair to say we believe we are leaders in this area with the approval and marketing of YERVOY.<wbr> We believe we lead, certainly in terms of the area, expanding it beyond malignant melanoma with Phase III studies, life-cycle managed studies, ongoing (including CRPC).<wbr>" </div><div style="margin-bottom: 10px;">But we also have behind that a whole series of different assets looking at different aspects of immuno-oncology.<wbr>.<wbr>.<wbr>.<wbr> Anti-PD1, PD-L1 is a pathway &ndash; another inhibitory pathway.<wbr> The CTLA-4 pathway is one inhibitory pathway that cancer cells use to stop the immune system getting rid of them.<wbr> PD1/<wbr>PD-L1 is another one.<wbr> And we are very excited about this particular pathway.<wbr> We will be presenting data at ASCO in June not just in malignant melanoma , but also in renal cell carcinoma and non-small cell lung cancer.<wbr> </div><div style="margin-bottom: 10px;">"There've been traditionally those tumors which have been considered immunogenic like malignant melanoma (sic) [myeloma] (8:07), but others which haven't like non-small cell lung, and we believe we're extending with PD1 the opportunities into more tumor types.<wbr> Beyond these individuals as monotherapy, we also have a longer-term aspirational goal to find ways to put these drugs together to further enhance response rates.<wbr> We know pre-clinically that ipilimumab and PD1 synergize, and we have ongoing studies in the clinic to see whether that is reproduced.<wbr>" </div><div style="margin-bottom: 10px;">With regard to SPRYCEL he commented:- </div><div style="margin-bottom: 10px;">the hope will be here that we will show significant benefit.<wbr> We do believe with SPRYCEL because of its profile and SARC activity and its bone activity that we will actually be showing significant benefit after hormonal failures.<wbr> But that's probably, I think, about 18 months away before we will see that.<wbr> That's ongoing.<wbr> There's certainly a good pre-clinical reason to expect it might have benefit, but of course as always it'll be heavily dependent on the data.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8264/1/ScreenCapture1.jpg?user-agent=rss"> </div><div>From <A href="http://www.bms.com">http:/<wbr>/<wbr>www.<wbr>bms.<wbr>com</A>, see <A href="traction?type=editentry&amp;proj=Neurology&amp;origtype=single&amp;curentry=Neurology6390&amp;curitem=&amp;cacheid=1336657592517">original source</A>.<wbr> </div><!-- Comment details --><a name="oncology8264attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8264/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(244,1 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8264/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(238,5 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8264">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-05-10T16:02:40+02:00</dc:date><dc:creator>jac89886</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8264/1/ScreenCapture1.jpg" length="249965" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8264/2/ScreenCapture2.jpg" length="244264" type="image/jpeg"/></item><item>
<title>Medicis's Comments About The US Facial Aesthetics Market [comp:Medicis, sub:Aesthetics, prod:Xeomin, comp:Merz]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology6388</link>
<description>Medicis's Comments About The US Facial Aesthetics Market [comp:Medicis, sub:Aesthetics, prod:Xeomin, comp:Merz]</description><category>comp:Medicis</category><category>sub:Aesthetics</category><category>prod:Xeomin</category><category>comp:Merz</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology6388</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120831&edate=20120501&rec=6388">Medicis's Comments About The US Facial Aesthetics Market</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=comp%3aMedicis"><font color="#e95e0b">:Neurology:comp:Medicis</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=comp%3aMerz"><font color="#e95e0b">:Neurology:comp:Merz</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=prod%3aXeomin"><font color="#e95e0b">:Neurology:prod:Xeomin</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=sub%3aAesthetics"><font color="#e95e0b">:Neurology:sub:Aesthetics</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology6388">Neurology6388</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 10 May 2012 | 14:59</font><br><br><div style="margin-bottom: 10px;">Comment: During its quarterly earnings call, Medicis made a number of positive comments about the uptake of Dysport and the outlook for facial aesthetic sales which are highlighted below.<wbr> </div><div style="margin-bottom: 10px;">It noted that total revenues for facial aesthetic products grew by 6% during the quarter, with Dysport experiencing its strongest first quarter demand since the product was launched (+8% in units sold).<wbr> </div><div style="margin-bottom: 10px;">Responding to a question about promotional levels and the profitability of Dysport, Jonah Shacknai, noted:- </div><div style="margin-bottom: 10px;"><P class="firstP">"Well, it's actually been pretty flat to slightly up.<wbr> And I think given the fact that the market was deluged with free samples of competitive products, particularly the Merz product, it's actually pretty good.<wbr> I might add that the brand was more profitable this quarter than in quarters previously, I think reflecting our promotional mix as well as customer mix.<wbr> So I think we're pretty pleased with the way Dysport is doing, it's a highly established product, highly recognized.<wbr></P> </div><div style="margin-bottom: 10px;">We just returned from one of the major aesthetic plastic surgery meetings held in Vancouver, Canada, just got back.<wbr> And it's clear that Dysport and its competitor Botox are really the two established, well-regarded brands.<wbr> And then really others are not predicted to play a significant role in the market.<wbr> So I think that's pretty good news and obviously we are intensifying our promotional activity in the field.<wbr> I think customers understand we're a great company to do business with, both because of Dysport and the Restylane family, and we continue to charge forward.<wbr> </div><div style="margin-bottom: 10px;">He went onto note:- </div><div style="margin-bottom: 10px;">"I think the legal difficulties that at least one company has faced certainly curtail their promotional activities until the end of an injunction, basically.<wbr> And we'll have to see what their plan is coming back from that.<wbr> It's obviously a very, very challenging position to be in for them.<wbr>" </div><div>Source: Medicis Q1 Earnings Transcript </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120831&edate=20120501&rec=6388">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-05-10T14:59:53+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>Breakthrough Drugs May Find Pathway To US Approval Becomes Easier [mkt:NorthAmerica, sub:Regulatory]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld9877</link>
<description>Breakthrough Drugs May Find Pathway To US Approval Becomes Easier [mkt:NorthAmerica, sub:Regulatory]</description><category>mkt:NorthAmerica</category><category>sub:Regulatory</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld9877</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120831&edate=20120501&rec=9877">Breakthrough Drugs May Find Pathway To US Approval Becomes Easier</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=mkt%3aNorthAmerica"><font color="#e95e0b">:PharmaWorld:mkt:NorthAmerica</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=sub%3aRegulatory"><font color="#e95e0b">:PharmaWorld:sub:Regulatory</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld9877">PharmaWorld9877</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 10 May 2012 | 14:31</font><br><br><div style="margin-bottom: 10px;">Comment: Reuters is reporting that the US may speed up the approval of breakthrough drugs as part of the new FDA user fee bill necessitating shorter or fewer trials to gain approval.<wbr> </div><div style="margin-bottom: 10px;">The proposal suggests that experimental drugs that show a big effect in early developmental trials for treating serious or life-threatening conditions should get a faster and cheaper path to US appproval.<wbr> </div><div style="margin-bottom: 10px;">Similar comments with reference to the EMA's position were recently raised at a Bioindustry Association meeting in London (see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120831&edate=20120501&rec=9866" class="defaultlink">PharmaWorld9866: A Potentially New Adaptive Development Programme For Innovative Drugs</a>).<wbr> </div><div>Dr Janet Woodcock, Head of the FDA's Drug Division is quoted ass saying that the FDA nees more flexibility to bypass "business as usual" when it sees unepected effects or when a new medicine can substantially help patients </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120831&edate=20120501&rec=9877">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-05-10T14:31:51+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>Key Takeaways from Medivation's Q2 2012 Results [prod:MDV3100, dis:Prostate, news]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology8262</link>
<description>Key Takeaways from Medivation's Q2 2012 Results [prod:MDV3100, dis:Prostate, news]</description><category>prod:MDV3100</category><category>dis:Prostate</category><category>news</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology8262</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8262">Key Takeaways from Medivation's Q2 2012 Results</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=news"><font color="#e95e0b">:Oncology:news</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=prod%3aMDV3100"><font color="#e95e0b">:Oncology:prod:MDV3100</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8262">Oncology8262</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 09 May 2012 | 17:06</font><br><br><div style="margin-bottom: 10px;">Comment: Alongside its financial results, the company indicated that the purpose of its recent meeting with the FDA was to discuss the post-chemo NDA that it will be filing with enzalutamide (formerly MDV3100).<wbr> In addition, Management reported it has a clear strategy for registration in Japan in pre and post chemo settings.<wbr> When it comes to the breast cancer indication (Ph1 ongoing), it was highlighted that the patient population are women who have failed prior hormone therapy.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Enzatulamide Marketing Process</FONT></STRONG> </div><div style="margin-bottom: 10px;">Regarding the sales reps, Cheryl Cohen (CCO) outlined that the company is recruting and 'just getting top-quality candidates in the oncology space'.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Update on the TERRAIN Trial</FONT></STRONG> </div><div style="margin-bottom: 10px;">As this trial is operationalized by Astellas, the company does not have control over the timeline, and no guidance to provide at this point of time.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Strategy for Registration in Japan</FONT></STRONG> </div><div style="margin-bottom: 10px;">This PREVAIL trial will be used as a global registration study in the chemo-naïve population, and according to L.<wbr> Seely (CMO) that includes 'registration in Japan'.<wbr> </div><div style="margin-bottom: 10px;">"In the post-chemotherapy space, we do have a bridging study ongoing in Japan in the post-chemotherapy population.<wbr> And so we have an opportunity to discuss with Japanese authorities the combination of the AFFIRM study and the bridging study.<wbr> So there is a strategy there as well".<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Combination Study</FONT></STRONG> </div><div style="margin-bottom: 10px;">During the quarter, Medivation initiated a Ph1 study evaluating the safety, tolerability and pharmacokinetics of enzalutamide in combination with docetaxel in approx.<wbr> 18 men with advanced prostate cancer.<wbr> </div><div style="margin-bottom: 10px;">Management indicated that ".<wbr>.<wbr>.<wbr> When we talk about sequencing, we are crystal clear that the number one drug in the sequential is enzalutamide.<wbr> So that is the foundational treatment you will see moving forward.<wbr> And then there are a number of combinations which are of great interest to the medical community with MDV3100 as the foundational therapy.<wbr> So I do suspect you will be seeing other combinations in that regard.<wbr> But today we are just announcing that there is a docetaxel combination study, and that largely is because we expect to have approval in the post-chemotherapy space, and we expect to get approval in the chemo-naive space when that PREVAIL data are there.<wbr> And this will just provide the data to continue to dose MDV3100 -- or enzalutamide through chemotherapy.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Leerink Swann's Forecasts on Medivation</FONT></STRONG> </div><div style="margin-bottom: 10px;"><STRONG>Expected Events</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8262/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG>Clinical Pipeline</STRONG> </div><div><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8262/2/ScreenCapture2.jpg?user-agent=rss"> </div><!-- Comment details --><a name="oncology8262attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8262/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(54,3 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8262/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(55,9 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8262">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-05-09T17:06:00+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8262/1/ScreenCapture1.jpg" length="55583" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8262/2/ScreenCapture2.jpg" length="57264" type="image/jpeg"/></item><item>
<title>Novartis Presents PhIII Acromegaly Data At ECE Meeting [:Endocrinology:prod:Pasireotide, :Endocrinology:class:SomatostatinAnalogue, :Endocrinology:comp:Novartis, :Endocrinology:Alert, :PharmaWorld:congress:ECE]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology8259</link>
<description>Novartis Presents PhIII Acromegaly Data At ECE Meeting [:Endocrinology:prod:Pasireotide, :Endocrinology:class:SomatostatinAnalogue, :Endocrinology:comp:Novartis, :Endocrinology:Alert, :PharmaWorld:congress:ECE]</description><category>prod:Pasireotide</category><category>class:SomatostatinAnalogue</category><category>comp:Novartis</category><category>Alert</category><category>congress:ECE</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology8259</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8259">Novartis Presents PhIII Acromegaly Data At ECE Meeting</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=Alert"><font color="#e95e0b">:Endocrinology:Alert</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=class%3aSomatostatinAnalogue"><font color="#e95e0b">:Endocrinology:class:SomatostatinAnalogue</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=comp%3aNovartis"><font color="#e95e0b">:Endocrinology:comp:Novartis</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=prod%3aPasireotide"><font color="#e95e0b">:Endocrinology:prod:Pasireotide</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=congress%3aECE"><font color="#e95e0b">:PharmaWorld:congress:ECE</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8259">Oncology8259</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 09 May 2012 | 12:16</font><br><br><div style="margin-bottom: 10px;">Comment: Novartis has reported final results from its first phIII trial of pasireotide in acromegaly at the ECE meeting in Florence, demonstrating that the drug is more efficacious than Sandostatin LAR in terms of achieving biochemical control of acromegaly.<wbr> This was anticipated (see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120831&edate=20120501&rec=6875" class="defaultlink">Endocrinology6875: 1st Indication of Pasireotide Results In Acromegaly & NET</a>) as was the high incidence of diabetogenic side effects also reported.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Top-line Findings</STRONG> </div><div style="margin-bottom: 10px;">1) The study, the largest underataken in an acromegaly population, met its primary endpoint demonstrating that significantly more patients treated with pasireotide (31.<wbr>3% of patients experienced full control of their disease (defined as the combination of both GH &lt;2.<wbr>3ug/<wbr>l and age and sex matched normalised IGF-1) than those taking octreotide LAR (19.<wbr>2%) (p= 0.<wbr>007).<wbr> </div><div style="margin-bottom: 10px;">2) The level of GH control was similar to Sandostatin LAR but control of IGF-1 was better leading to the overall improved response profile.<wbr> </div><div style="margin-bottom: 10px;">3) Tumour control was similar with both agents.<wbr> </div><div style="margin-bottom: 10px;">4) In terms of adverse events the drug was reasonably well tolerated with the exception of hyperglycaemia which occurred in 28.<wbr>7% of patients in the double-blind randomised phase of the study compared to 8.<wbr>3% with Sandostatin LAR.<wbr> </div><div style="margin-bottom: 10px;">Results from an extension phase of the study out to 19 weeks were also reported.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Full Report To Follow</STRONG> </div><div style="margin-bottom: 10px;">Full results of the trial and the manner in which it was presented by Novartis during its satellite symposium will be reviewed in full in an upcoming report from the congress.<wbr> Suffice to say that the focus was on highlighting the unmet need that exists for new agents given the level of control achieved with existing SSA is only "20 to 25% in patients naive to previous SSA therapy.<wbr>" </div><div style="margin-bottom: 10px;">Signifor (pasireotide) was approved two weeks ago by the EMA for the treatment of Cuhsing's disease but Novartis has yet to file for approval of the acromegaly indication.<wbr> It has a further phIII switch trial that is ongoing.<wbr> Regulatory submissions are slated for this year but the precise timing was not disclosed.<wbr> </div><div>Scource: ECE meeting Florence &amp; <a href="http://www.novartis.com" class="defaultlink" title="http://www.novartis.com">novartis.com</a> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8259">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-05-09T12:16:45+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>Virtual Reality-Based Cystoscopy Simulator for Urologists Injecting BOTOX® for nOAB [dis:nOAB, comp:Allergan, prod:Botox, headline]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology6387</link>
<description>Virtual Reality-Based Cystoscopy Simulator for Urologists Injecting BOTOX® for nOAB [dis:nOAB, comp:Allergan, prod:Botox, headline]</description><category>dis:nOAB</category><category>comp:Allergan</category><category>prod:Botox</category><category>headline</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology6387</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120831&edate=20120501&rec=6387">Virtual Reality-Based Cystoscopy Simulator for Urologists Injecting BOTOX® for nOAB</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=comp%3aAllergan"><font color="#e95e0b">:Neurology:comp:Allergan</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=dis%3anOAB"><font color="#e95e0b">:Neurology:dis:nOAB</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=headline"><font color="#e95e0b">:Neurology:headline</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=prod%3aBotox"><font color="#e95e0b">:Neurology:prod:Botox</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology6387">Neurology6387</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 09 May 2012 | 11:44</font><br><br><div style="margin-bottom: 10px;">Comment: Touch of Life Technologies' Cytoscopy Simulator was developed to support Allergan's commitment to educate and train urologists on the proper technique for injecting BOTOX® to treat incontinence in adults with nOAB.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">About Touch of Life Technologies (ToLTech)</FONT></STRONG> </div><div style="margin-bottom: 10px;">ToLTech products are based on realistic visualizations from the National Library of Medicine's Visible Human Project<SUP>®</SUP> and next generation data.<wbr> </div><div style="margin-bottom: 10px;">The newest product is a <U>Cystoscopy Simulator</U> to train urologists to inject medication in the bladder wall to treat incontinence for certain patients.<wbr> </div><div style="margin-bottom: 10px;"><U>Characteristics</U> </div><div style="margin-bottom: 10px;">.<wbr>.<wbr>.<wbr> "The cystoscopy and injection trainer manipulates image data to simulate the look and feel of a human bladder so that the physician/<wbr>user actually 'feels' the resistance to the needle as it penetrates the detrusor muscle of the bladder wall," said Vic Spitzer, CEO of ToLTech.<wbr> "The bladder is the proper volume and is inflated to the appropriate wall tension that would exist in candidates for this procedure .<wbr>.<wbr>.<wbr>".<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/6387/1/ScreenCapture1.jpg?user-agent=rss"> </div><div>From <A href="http://www.toltech.net/index.htm">http:/<wbr>/<wbr>www.<wbr>toltech.<wbr>net/<wbr>index.<wbr>htm</A> </div><!-- Comment details --><a name="neurology6387attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/6387/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(37,2 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120831&edate=20120501&rec=6387">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-05-09T11:44:30+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/6387/1/ScreenCapture1.jpg" length="38082" type="image/jpeg"/></item><item>
<title>Sandoz Supports FDA's Draft Guidance on Biosimilars [sub:Generics]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld9873</link>
<description>Sandoz Supports FDA's Draft Guidance on Biosimilars [sub:Generics]</description><category>sub:Generics</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld9873</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120831&edate=20120501&rec=9873">Sandoz Supports FDA's Draft Guidance on Biosimilars</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=sub%3aGenerics"><font color="#e95e0b">:PharmaWorld:sub:Generics</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld9873">PharmaWorld9873</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 09 May 2012 | 11:02</font><br><br><div style="margin-bottom: 10px;">Comment: Dr.<wbr> Mark McCamish, Head of Global Biopharmaceutical Dev.<wbr>, will present at the May 11 FDA public hearing on draft guidances related to the development of biosimilar products.<wbr> His message will focus on <FONT size="3"><FONT size="2">a one science-based standard for all biologics, and interchangeability.<wbr> </FONT></FONT> </div><div style="margin-bottom: 10px;"><FONT size="3"><STRONG>Sandoz Key Messages</STRONG></FONT> </div><div style="margin-bottom: 10px;"><UL><LI>One science-based standard for all biologics.<wbr></LI>
<LI>Biosimilar clinical studies are only confirmatory</LI>
<LI>Interchangeability</LI>
</UL> </div><div style="margin-bottom: 10px;">Dr McCamish will highlight a recent study conducted by the IGES Institute in Berlin, which showed that by 2020, 8 countries in the EU could save a cumulative total of between EUR 11.<wbr>8 billion and 33.<wbr>4 billion through the use of biosimilar medicines.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Picture of the Situation</FONT></STRONG> </div><div><UL><LI>Novo Nordisk, Genentech and Amgen have expressed concerns with 39 companies as of April 17th having commented on the guidance.<wbr><WBR> </WBR></LI>
<LI>Some such as Teva are in favour of the new guidance.<wbr></LI>
</UL> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120831&edate=20120501&rec=9873">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-05-09T11:02:19+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>FDA Lifts Hold on GTx' Capesaris for Prostate Cancer [class:Antihormonals, dis:Prostate]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology8258</link>
<description>FDA Lifts Hold on GTx' Capesaris for Prostate Cancer [class:Antihormonals, dis:Prostate]</description><category>class:Antihormonals</category><category>dis:Prostate</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology8258</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8258">FDA Lifts Hold on GTx' Capesaris for Prostate Cancer</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=class%3aAntihormonals"><font color="#e95e0b">:Oncology:class:Antihormonals</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8258">Oncology8258</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 08 May 2012 | 18:01</font><br><br><div style="margin-bottom: 10px;">Comment: The company will test the drug as a secondary treatment for patients who have not responded to initial treatment.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">New Trial for the Drug</FONT></STRONG> </div><div style="margin-bottom: 10px;">The company plans to start a mid-stage trial during Q3 2012.<wbr> It will test 3 lower doses of Capesaris in 75 men with mCRPC.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Recent Background in Traction</FONT></STRONG> </div><div>See <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8214" class="defaultlink">Oncology8214: GTx Strives To Move Forward With Capesaris Development</a>.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8258">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-05-08T18:01:55+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>No Earnings Growth Till 2014 for Actelion [news]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld9870</link>
<description>No Earnings Growth Till 2014 for Actelion [news]</description><category>news</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld9870</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120831&edate=20120501&rec=9870">No Earnings Growth Till 2014 for Actelion</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=news"><font color="#e95e0b">:PharmaWorld:news</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld9870">PharmaWorld9870</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 08 May 2012 | 17:55</font><br><br><div style="margin-bottom: 10px;">Comment: The company has forecast flat core earnings in 2012, and reports that new medicines and cost cuts would take time to offset falling sales of Tracleer (for PAH), the drug that brings in most of its revenue.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Expanding Leadership in the PAH Market<BR></FONT></STRONG> </div><div style="margin-bottom: 10px;">Actelion's priority is to expand its leadership in the market for treating PAH, with Macitentan and Selexipag.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Refocusing R&amp;D on Specialty Areas</FONT></STRONG> </div><div style="margin-bottom: 10px;">Actelion will refocus its future R&amp;D activities towards specialty markets.<wbr> Actelion's current clinical pipeline in immunomodulation and antibiotics provides the company with an opportunity to build a second specialty business franchise.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/9870/2/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Accelerating Cost Saving Initiatives</FONT></STRONG> </div><div>Refocusing of Actelion's research and development efforts into specialty areas is expected to result in lower and more targeted R&amp;D spending, as well as lower overhead costs.<wbr> </div><!-- Comment details --><a name="pharmaworld9870attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/9870/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(23,3 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/9870/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(51,8 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120831&edate=20120501&rec=9870">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-05-08T17:55:17+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/9870/1/ScreenCapture1.jpg" length="23903" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/9870/2/ScreenCapture2.jpg" length="53045" type="image/jpeg"/></item><item>
<title>Almirall Heavily Criticises Spanish Government's Pharma Cuts [mkt:Spain, mkt:Europe]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld9869</link>
<description>Almirall Heavily Criticises Spanish Government's Pharma Cuts [mkt:Spain, mkt:Europe]</description><category>mkt:Spain</category><category>mkt:Europe</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld9869</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120831&edate=20120501&rec=9869">Almirall Heavily Criticises Spanish Government's Pharma Cuts</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=mkt%3aEurope"><font color="#e95e0b">:PharmaWorld:mkt:Europe</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=mkt%3aSpain"><font color="#e95e0b">:PharmaWorld:mkt:Spain</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld9869">PharmaWorld9869</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 08 May 2012 | 17:46</font><br><br><div style="margin-bottom: 10px;">Comment: Almirall's president Jorge Gallardo disclosed in a recent press conference that the pharma cuts undertaken by the government will negatively impact on the country's industry and cost it EUR5 billion (USD6.<wbr>5 billion) in the short term.<wbr> According to Gallardo, cited by <EM>El Economista</EM>, these "short-term policies" will lead to many pharmaceutical companies in the country closing down due to a lack of resources.<wbr> </div><div style="margin-bottom: 10px;"><FONT size="3"><STRONG>Significance</STRONG></FONT> </div><div style="margin-bottom: 10px;">Gallardo's overview on the future of the Spanish pharmaceutical industry seems to paint a realistic picture of the industry's situation in the country, given the further cuts in healthcare and pharma recently announced by the government and the protests triggered by them.<wbr> The Spanish government recently announced a further EUR2 billion in cuts to healthcare and pharma for 2012, cuts that will mostly affect the pharma industry given the fact that austerity measures aimed at cutting drug spending are expected to remain in place.<wbr> </div><div>From: GlobalInsight </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120831&edate=20120501&rec=9869">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-05-08T17:46:04+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Allergan's Model of Success [sub:CompanyProfile, :Neurology:comp:Allergan]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld9868</link>
<description>Allergan's Model of Success [sub:CompanyProfile, :Neurology:comp:Allergan]</description><category>sub:CompanyProfile</category><category>comp:Allergan</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld9868</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120831&edate=20120501&rec=9868">Allergan's Model of Success</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=comp%3aAllergan"><font color="#e95e0b">:Neurology:comp:Allergan</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=sub%3aCompanyProfile"><font color="#e95e0b">:PharmaWorld:sub:CompanyProfile</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld9868">PharmaWorld9868</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/20">Alison Attard</a> | 08 May 2012 | 14:00</font><br><br><div style="margin-bottom: 10px;">Comment:  In an interview in 'Life Science Leader' magazine .<wbr> David Pyott, president and CEO, attributes some of Allergan's growth to the company's extreme success at securing a high proportion of regulatory approvals around the globe.<wbr> Pyott says that success is due to three things: Allergan's business model, expertise through specialization, and an enormous attention to detail.<wbr> </div><div style="margin-bottom: 10px;">The full interview can be seen at:  <A href="http://lifescienceleadermag.epubxp.com/issue/63926/17">http:/<wbr>/<wbr>lifescienceleadermag.<wbr>epubxp.<wbr>com/<wbr>issue/<wbr>63926/<wbr>17</A> </div><div>Source: Life Science Leader May 2012 </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120831&edate=20120501&rec=9868">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-05-08T14:00:37+02:00</dc:date><dc:creator>ala97794</dc:creator></item><item>
<title>Dendreon Reports Modest Quarter Growth of Provenge [class:Vaccines, dis:Prostate, :PharmaWorld:sub:Finance]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology8257</link>
<description>Dendreon Reports Modest Quarter Growth of Provenge [class:Vaccines, dis:Prostate, :PharmaWorld:sub:Finance]</description><category>class:Vaccines</category><category>dis:Prostate</category><category>sub:Finance</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology8257</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8257">Dendreon Reports Modest Quarter Growth of Provenge</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=class%3aVaccines"><font color="#e95e0b">:Oncology:class:Vaccines</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=sub%3aFinance"><font color="#e95e0b">:PharmaWorld:sub:Finance</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8257">Oncology8257</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 08 May 2012 | 12:05</font><br><br><div style="margin-bottom: 10px;">Comment: Q1 sales of the prostate cancer vaccine rose 6.<wbr>5% versus the prior quarter.<wbr> The company expects Q2 sales to still grow by low single digits.<wbr> </div><div>Dendreon reported it was encouraged by growth in large community urology and oncology accounts, and sait 84 new accounts used Provenge in the first quarter.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8257">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-05-08T12:05:24+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Botox Assessed as Potential Therapy for Low Anterior Resection Syndrome (LARS) [comp:Allergan, prod:Botox, :PharmaWorld:sub:ClinicalTrial, :PharmaWorld:mkt:Canada]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology6386</link>
<description>Botox Assessed as Potential Therapy for Low Anterior Resection Syndrome (LARS) [comp:Allergan, prod:Botox, :PharmaWorld:sub:ClinicalTrial, :PharmaWorld:mkt:Canada]</description><category>comp:Allergan</category><category>prod:Botox</category><category>sub:ClinicalTrial</category><category>mkt:Canada</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology6386</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120831&edate=20120501&rec=6386">Botox Assessed as Potential Therapy for Low Anterior Resection Syndrome (LARS)</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=comp%3aAllergan"><font color="#e95e0b">:Neurology:comp:Allergan</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=prod%3aBotox"><font color="#e95e0b">:Neurology:prod:Botox</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=mkt%3aCanada"><font color="#e95e0b">:PharmaWorld:mkt:Canada</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=sub%3aClinicalTrial"><font color="#e95e0b">:PharmaWorld:sub:ClinicalTrial</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology6386">Neurology6386</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 07 May 2012 | 10:32</font><br><br><div style="margin-bottom: 10px;">Comment: Allergan, in collaboration with the Centre hospitalier de l'Université de Montréal (CHUM) will start a POC trial in approx.<wbr> 23 participants diagnosed with LARS, for which current treatments are often ineffective.<wbr> Primary endpoint will evaluate efficacy of intra-rectal (or intra-colic) injection of 100U of Botox.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Trial Details - </FONT></STRONG><A href="http://clinicaltrials.gov/ct2/show/NCT01589471?recr=Open&amp;fund=2&amp;rcv_s=04%2F23%2F2012&amp;rank=129"><STRONG><FONT size="3">NCT01589471</FONT></STRONG></A> </div><div style="margin-bottom: 10px;">Completion date: March 2013 /<wbr> August 2013 </div><div style="margin-bottom: 10px;">Location: Canada </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Rationale</FONT></STRONG> </div><div style="margin-bottom: 10px;">LARS is frequent after treatment for low rectal cancer.<wbr> Increased bowel frequency and urgency with rectal spasms and incontinence have deleterious impacts on QoL in a third of the cases.<wbr> </div><div><P style="MARGIN-TOP: 0ex; MARGIN-BOTTOM: 1ex">One possible physiopathology hypothesis suggests an ongoing spastic process; different mechanisms have been postulated.<wbr> These include alteration of normal anorectal sensation with loss of the recto-anal inhibitory reflex (RAIR), decreased rectal compliance and reduced rectal capacity as well as sphincter damage secondary to preoperative chemoradiation therapy or during surgery.<wbr></P> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120831&edate=20120501&rec=6386">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-05-07T10:32:59+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Erythropoietin Tested as a Potential Therapy for Cerebral Palsy (CP) [dis:Palsy, :PharmaWorld:sub:ClinicalTrial, :PharmaWorld:mkt:Korea, :PharmaWorld:mkt:Intercontinental]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology6384</link>
<description>Erythropoietin Tested as a Potential Therapy for Cerebral Palsy (CP) [dis:Palsy, :PharmaWorld:sub:ClinicalTrial, :PharmaWorld:mkt:Korea, :PharmaWorld:mkt:Intercontinental]</description><category>dis:Palsy</category><category>sub:ClinicalTrial</category><category>mkt:Korea</category><category>mkt:Intercontinental</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology6384</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120831&edate=20120501&rec=6384">Erythropoietin Tested as a Potential Therapy for Cerebral Palsy (CP)</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=dis%3aPalsy"><font color="#e95e0b">:Neurology:dis:Palsy</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=mkt%3aIntercontinental"><font color="#e95e0b">:PharmaWorld:mkt:Intercontinental</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=mkt%3aKorea"><font color="#e95e0b">:PharmaWorld:mkt:Korea</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=sub%3aClinicalTrial"><font color="#e95e0b">:PharmaWorld:sub:ClinicalTrial</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology6384">Neurology6384</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 07 May 2012 | 10:22</font><br><br><div style="margin-bottom: 10px;">Comment: LG LifeSciences in collaboration with Minyoun Kim (M.<wbr>D) has started a Ph1 clinical research for children with CP.<wbr> Primary endpoints will assess safety.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Trial Details - </FONT></STRONG><A href="http://clinicaltrials.gov/ct2/show/NCT01586052?recr=Open&amp;fund=2&amp;rcv_s=04%2F23%2F2012&amp;rank=127"><STRONG><FONT size="3">NCT01586052</FONT></STRONG></A> </div><div style="margin-bottom: 10px;">Recruitment: approx.<wbr> 10 (6 months to 3 years) </div><div style="margin-bottom: 10px;">Start date: March 2012 - Completion date: May 2012 </div><div style="margin-bottom: 10px;">Location: Korea </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Rationale</FONT></STRONG> </div><div>Many experimental animal studies have revealed that erythropoietin is useful to repair neurological injury in brain.<wbr> The main mechanism of erythropoietin is supposed as follows; neuroprotection effect, angiogenesis, and anti-inflammation </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120831&edate=20120501&rec=6384">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-05-07T10:22:57+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Update on Cabozantinib Timelines for Prostate Cancer [dis:Prostate]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology8255</link>
<description>Update on Cabozantinib Timelines for Prostate Cancer [dis:Prostate]</description><category>dis:Prostate</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology8255</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8255">Update on Cabozantinib Timelines for Prostate Cancer</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8255">Oncology8255</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 04 May 2012 | 12:13</font><br><br><div style="margin-bottom: 10px;">Comment: Alongside the results of Q1 2012, management gave an updated overview of the COMET program, and highlighted that Dr Smith's Investigator Sponsored Trial (IST), evaluating cabozantinib at lower doses, could support the use of the drug in earlier lines of therapy or in combination with other compounds for CRPC.<wbr> Combination studies with abiraterone and MDV3100, included in the cabozantinib development programs, are progressing well.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">About the COMET Program</FONT></STRONG> </div><div style="margin-bottom: 10px;">COMET-2, with a focus on pain palliation came online in December.<wbr> </div><div style="margin-bottom: 10px;">Management reported it expects to initiate COMET-1, the overall survival trial in CRPC, in Q2 2012.<wbr> "If these trials are successful, cabozantinib will demonstrate an ability to control pain in patients with CRPC, and prolong overall survival".<wbr> </div><div style="margin-bottom: 10px;">When questioned on enrollment and timelines of COMET-1, management answered it hopes to complete the enrollment in about one year.<wbr> "We are intending to go out to a large number of sites, up to 250 sites in various different parts of the world including Europe, the U.<wbr>S.<wbr>, Asia-Pacific".<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Update of the IST</FONT></STRONG> </div><div style="margin-bottom: 10px;">When it comes to IST, management reported that a new Phase 2 IST has been initiated in chemotherapy naive patients with CRPC.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Cabozantinib Combination Studies</FONT></STRONG> </div><div>Management looks forward to the initiation of multiple combination studies with cabozantinib, including the recently announced combination studies with docetaxel and with Abiraterone.<wbr> The company is also planning a Ph1 trial of cabozantinib in combination with MDV3100.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8255">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-05-04T12:13:40+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>J&amp;J Starts Development Of Abiraterone For The Chinese Market [Alert, class:Antihormonals, comp:JnJ, dis:Prostate, prod:Zytiga, :PharmaWorld:mkt:China, :PharmaWorld:mkt:Intercontinental, :PharmaWorld:sub:ClinicalTrial]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology8252</link>
<description>J&amp;J Starts Development Of Abiraterone For The Chinese Market [Alert, class:Antihormonals, comp:JnJ, dis:Prostate, prod:Zytiga, :PharmaWorld:mkt:China, :PharmaWorld:mkt:Intercontinental, :PharmaWorld:sub:ClinicalTrial]</description><category>Alert</category><category>class:Antihormonals</category><category>comp:JnJ</category><category>dis:Prostate</category><category>prod:Zytiga</category><category>mkt:China</category><category>mkt:Intercontinental</category><category>sub:ClinicalTrial</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology8252</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8252">J&J Starts Development Of Abiraterone For The Chinese Market</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=Alert"><font color="#e95e0b">:Oncology:Alert</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=class%3aAntihormonals"><font color="#e95e0b">:Oncology:class:Antihormonals</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=comp%3aJnJ"><font color="#e95e0b">:Oncology:comp:JnJ</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=prod%3aZytiga"><font color="#e95e0b">:Oncology:prod:Zytiga</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=mkt%3aChina"><font color="#e95e0b">:PharmaWorld:mkt:China</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=mkt%3aIntercontinental"><font color="#e95e0b">:PharmaWorld:mkt:Intercontinental</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=sub%3aClinicalTrial"><font color="#e95e0b">:PharmaWorld:sub:ClinicalTrial</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8252">Oncology8252</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 03 May 2012 | 18:54</font><br><br><div style="margin-bottom: 10px;">Comment: ClinicalTrials.<wbr>gov is listing a new J&amp;J sponsored trial with abiraterone in China which will be conducted in 290 patients with chemonaive metastatic CRPC.<wbr> The trial commenced in March.<wbr> </div><div style="margin-bottom: 10px;">The trial highlights J&amp;J's strategic intent to enter the Chinese market with abiraterone (Zytiga).<wbr> </div><div style="margin-bottom: 10px;">The study will be undertaken in 6 Chinese centres in the cities of Beijing, Guangzhou, Hangzhou, Jinan, Tianjin, and Wuhan.<wbr> An additional 3 centres in Malaysia and Vietnam will also contribute patients to the trial.<wbr> </div><div style="margin-bottom: 10px;">The randomised study will consist of a screening phase (within 28 days prior to randomisation), a treatment phase of 28 day cycles until disease progression and a follow-up phase during which patients will be contacted every 3 months up to month 60 in order to obtain survival data.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Key Outcome Measures</FONT></STRONG> </div><div style="margin-bottom: 10px;"><STRONG>Primary Outcome</STRONG> Time To PSA Progression </div><div style="margin-bottom: 10px;"><STRONG>Secondary Outcomes</STRONG> Overall Survival, Time to initiation of chemotherapy, PSA response rate, ORR, Time to pain progression plus change in ECOG performance scale and safety.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Timelines</STRONG> </div><div style="margin-bottom: 10px;">The study started to recruit in March and should complete in terms of primary endpoint in February 2013.<wbr> Final study completion will be February 2014.<wbr> </div><div><STRONG>Clinical Trial Identifier</STRONG> <SPAN style="DISPLAY: inline! important; FLOAT: none; WORD-SPACING: 0px; FONT: medium sans-serif; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); TEXT-INDENT: 0px; WHITE-SPACE: nowrap; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><FONT face="Verdana" size="2"><A href="http://clinicaltrials.gov/ct2/results?term=NCT01591122">NCT01591122</A></FONT></SPAN> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8252">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-05-03T18:54:04+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>Genomic Health Announce First Diagnostic Partnership [dis:Prostate, sub:Biomarkers]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology8250</link>
<description>Genomic Health Announce First Diagnostic Partnership [dis:Prostate, sub:Biomarkers]</description><category>dis:Prostate</category><category>sub:Biomarkers</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology8250</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8250">Genomic Health Announce First Diagnostic Partnership</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=sub%3aBiomarkers"><font color="#e95e0b">:Oncology:sub:Biomarkers</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8250">Oncology8250</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 03 May 2012 | 17:08</font><br><br><div style="margin-bottom: 10px;">Comment: Genomic Health has announced a strategic alliance agreement with OncoMed for biomarker research and discovery using its next generation sequencing.<wbr> The company develops biopsy-based genomic tests that examines patient's tumor tissue at a molecular level for six different types of cancer.<wbr> The 'Oncotype DX Prostate' is expected to be launched in 2013.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Agreement with OncoMed</FONT></STRONG> </div><div style="margin-bottom: 10px;">Genomic Health will apply its sample preparation, high-throughput sequencing and bioinformatics capacity to identify potential biomarkers in the Notch and Wnt pathways from freshly resected breast, prostate, colon and lung tumor samples provided by OncoMed.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Genomic Health - Selected Pipeline</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8250/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG>Focus on 'Oncotype DX Prostate'</STRONG> </div><div style="margin-bottom: 10px;">This test will be intended to identify those patients with indolent prostate cancer who can be appropriately managed with active surveillance and those who are likely to have aggressive prostate cancer and should be treated with surgery or radiation therapy up-front.<wbr> </div><div>Genomic Health is on track to complete the validation study of Oncotype DX Prostate in 2H12 for potential launch in 2013.<wbr> </div><!-- Comment details --><a name="oncology8250attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8250/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(59,5 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8250">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-05-03T17:08:54+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8250/1/ScreenCapture1.jpg" length="60939" type="image/jpeg"/></item><item>
<title>Cabozantinib Development Program Expanded Through NCI-CTEP Collaboration [class:KinaseInhibitors, news, dis:Bladder]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology8249</link>
<description>Cabozantinib Development Program Expanded Through NCI-CTEP Collaboration [class:KinaseInhibitors, news, dis:Bladder]</description><category>class:KinaseInhibitors</category><category>news</category><category>dis:Bladder</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology8249</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8249">Cabozantinib Development Program Expanded Through NCI-CTEP Collaboration</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=class%3aKinaseInhibitors"><font color="#e95e0b">:Oncology:class:KinaseInhibitors</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=dis%3aBladder"><font color="#e95e0b">:Oncology:dis:Bladder</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=news"><font color="#e95e0b">:Oncology:news</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8249">Oncology8249</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 03 May 2012 | 15:55</font><br><br><div style="margin-bottom: 10px;">Comment: The collaboration will allow Exelixis to increase the number of indications and disease settings of cabozantinib in a cost-efficient manner.<wbr> Under the Cooperative Research And Development Agreement (CRADA) with the NCI's Cancer Therapy Evaluation Program (NCI-CTEP), 3 groups of initial trials have been approved.<wbr> Details are provided below.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Future Development in settings in which cabozantinib has previously shown clinical activity</FONT></STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>4 randomized Ph2 trials have the potential to demonstrate cabozantinib’s utility in 1st-line renal cell carcinoma, 2nde-line hepatocellular carcinoma, platinum-resistant or refractory ovarian cancer, and 2nde-line non-small cell lung cancer </LI>
<LI>Additional non-randomized Ph2 trials in ocular melanoma and non-small cell lung cancer are expected to further expand the data sets from earlier studies which demonstrated the antitumor activity of cabozantinib in these settings.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Indications for further study</FONT></STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>Single arm Ph2 trials are planned to explore cabozantinib’s potential in endometrial cancer, bladder cancer and sarcoma.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Additional Trials</FONT></STRONG> </div><div><UL><LI>Ph1 combination trials in additional tumor types are planned as well as a trial to evaluate cabozantinib in pediatric malignancies.<wbr></LI>
</UL> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8249">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-05-03T15:55:09+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Lexicon Q1 Earnings - Key Takeaways [dis:MidGutNET, news]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology6918</link>
<description>Lexicon Q1 Earnings - Key Takeaways [dis:MidGutNET, news]</description><category>dis:MidGutNET</category><category>news</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology6918</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120831&edate=20120501&rec=6918">Lexicon Q1 Earnings - Key Takeaways</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=dis%3aMidGutNET"><font color="#e95e0b">:Endocrinology:dis:MidGutNET</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=news"><font color="#e95e0b">:Endocrinology:news</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology6918">Endocrinology6918</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 03 May 2012 | 13:06</font><br><br><div style="margin-bottom: 10px;">Comment: Lexicon continues to highlight the good progress it is making with its 5 pipeline products.<wbr> Quarterly revenues however.<wbr> fell by 50 percent to $0.<wbr>3 million and its net loss increased by $0.<wbr>3m to $29.<wbr>9 million, or $0.<wbr>06 per share.<wbr> As of March 31, 2012, Lexicon had $253.<wbr>7 million in cash and investments.<wbr> </div><div style="margin-bottom: 10px;">When questioned about LX1032 and the company's strategic thinking with regard to partnership, Pablo Lapuerta, Senior Vice President of Clinical Development and Chief Medical Officer replied:-<BR>"Our plan is -- as I think we talked about previously, we're planning on taking that forward.<wbr> We have been talking to people about potential partnerships but our base line plan is to take that forward on our own and that continues to be our objective.<wbr>" </div><div style="margin-bottom: 10px;">With regard to a phase II carcinoid syndrome data meeting with the FDA, management confirmed that the meeting was now scheduled for the end of June and that results from its phII POC ulcerative collitis study are expected early Q4, with randomisation running a bit ahead of schedule.<wbr> </div><div style="margin-bottom: 10px;">Most of the call was spent discussing the potential for LX4211, which in addition to showing promise in Type II diabetes has also produced some interesting data in an animal model of Type I diabetes, sufficient to merit moving forward with a POC study.<wbr> The company is in the process of seeking regulatory advice on the size and shape of its phIII programme for LX4211 but realises the costs will be of the order of several $100m and therefore it remains committed to working with a partner on on this product.<wbr> </div><div>Source:www.<wbr>lexgen.<wbr>com </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20120831&edate=20120501&rec=6918">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-05-03T13:06:08+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>Update on Ferring's Degarelix Status in India [dis:Prostate, :PharmaWorld:mkt:India]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology8248</link>
<description>Update on Ferring's Degarelix Status in India [dis:Prostate, :PharmaWorld:mkt:India]</description><category>dis:Prostate</category><category>mkt:India</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology8248</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8248">Update on Ferring's Degarelix Status in India</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=mkt%3aIndia"><font color="#e95e0b">:PharmaWorld:mkt:India</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology8248">Oncology8248</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 03 May 2012 | 12:03</font><br><br><div style="margin-bottom: 10px;">Comment: Ferring told <EM>Scrip</EM> that it is moving towards the potential launch of degarelix late 2013/<wbr>early 2014, and expects to market the drug in India through its domestic subsidiary.<wbr> According to the company, the pricing strategy has not yet been set.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Ferring India</FONT></STRONG> </div><div style="margin-bottom: 10px;"><SPAN class="Apple-style-span" style="DISPLAY: inline! important; FLOAT: none; WORD-SPACING: 0px; FONT: 13px arial, sans-serif; TEXT-TRANSFORM: none; COLOR: rgb(34,34,34); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><FONT face="Verdana" size="2"><U>Marketed Products: </U></FONT></SPAN><SPAN class="Apple-style-span" style="DISPLAY: inline! important; FLOAT: none; WORD-SPACING: 0px; FONT: 13px arial, sans-serif; TEXT-TRANSFORM: none; COLOR: rgb(34,34,34); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><FONT face="Verdana" size="2">Decapeptyl (daily; depot), Menopur (menotropin), Bravelle (urofollitropin), Pentasa (mesalazine) and Zomacton (somatropin).<wbr></FONT></SPAN> </div><div style="margin-bottom: 10px;"><SPAN class="Apple-style-span" style="DISPLAY: inline! important; FLOAT: none; WORD-SPACING: 0px; FONT: 13px arial, sans-serif; TEXT-TRANSFORM: none; COLOR: rgb(34,34,34); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><FONT face="Verdana" size="2"><U>Production Site: </U></FONT></SPAN><SPAN class="Apple-style-span" style="DISPLAY: inline! important; FLOAT: none; WORD-SPACING: 0px; FONT: 13px arial, sans-serif; TEXT-TRANSFORM: none; COLOR: rgb(34,34,34); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><FONT face="Verdana" size="2">As indicated in its website, a new manufacturing facility is being built in Mumbai.<wbr></FONT></SPAN> </div><div style="margin-bottom: 10px;"><FONT face="Verdana" size="2"><SPAN class="Apple-style-span" style="DISPLAY: inline! important; FLOAT: none; WORD-SPACING: 0px; FONT: 13px arial, sans-serif; TEXT-TRANSFORM: none; COLOR: rgb(34,34,34); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><U>Representative Office</U></SPAN></FONT> </div><div style="margin-bottom: 10px;"><FONT face="Verdana"><FONT size="2"><SPAN class="Apple-style-span" style="DISPLAY: inline! important; FLOAT: none; WORD-SPACING: 0px; FONT: 13px arial, sans-serif; TEXT-TRANSFORM: none; COLOR: rgb(34,34,34); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><FONT face="Verdana" size="2">403/<wbr>404 “Sigma” ; 4th floor; Technology Street Central Avenue Hiranandani Gardens Powai Mumbai.<wbr></FONT></SPAN></FONT></FONT> </div><div style="margin-bottom: 10px;"><FONT face="Verdana"><FONT size="2"><SPAN class="Apple-style-span" style="DISPLAY: inline! important; FLOAT: none; WORD-SPACING: 0px; FONT: 13px arial, sans-serif; TEXT-TRANSFORM: none; COLOR: rgb(34,34,34); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><FONT face="Verdana" size="2"><U>R&amp;D Ferring International PharmaScience Center (IPC)</U></FONT></SPAN></FONT></FONT> </div><div><FONT face="Verdana"><FONT size="2"><SPAN class="Apple-style-span" style="DISPLAY: inline! important; FLOAT: none; WORD-SPACING: 0px; FONT: 13px arial, sans-serif; TEXT-TRANSFORM: none; COLOR: rgb(34,34,34); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/8248/2/ScreenCapture2.jpg?user-agent=rss"></SPAN></FONT></FONT> </div><!-- Comment details --><a name="oncology8248attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8248/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(49,3 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/8248/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(53,9 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20120831&edate=20120501&rec=8248">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-05-03T12:03:22+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8248/1/ScreenCapture1.jpg" length="50516" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/8248/2/ScreenCapture2.jpg" length="55206" type="image/jpeg"/></item><item>
<title>Novartis to Create the #1 Global Generic Dermatology Company [:Oncology:comp:Novartis, :Endocrinology:comp:Novartis]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld9867</link>
<description>Novartis to Create the #1 Global Generic Dermatology Company [:Oncology:comp:Novartis, :Endocrinology:comp:Novartis]</description><category>comp:Novartis</category><category>comp:Novartis</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld9867</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120831&edate=20120501&rec=9867">Novartis to Create the #1 Global Generic Dermatology Company</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20120831&edate=20120501&cat=comp%3aNovartis"><font color="#e95e0b">:Endocrinology:comp:Novartis</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20120831&edate=20120501&cat=comp%3aNovartis"><font color="#e95e0b">:Oncology:comp:Novartis</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld9867">PharmaWorld9867</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 03 May 2012 | 10:50</font><br><br><div style="margin-bottom: 10px;">Comment: The $1.<wbr>525 billion acquisition of privately owned Fougeras Pharm.<wbr> makes Sandoz the #1 generic dermatology medicines company globally and in the U.<wbr>S.<wbr>.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Rationale for Novartis</FONT></STRONG> </div><div style="margin-bottom: 10px;">- to help cope with the loss of its own drugs that are going off-patent.<wbr> </div><div style="margin-bottom: 10px;">- a growing number of dermatology creams and ointments are losing patent protection, making companies such as Fougera a source of growth.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Fougera's Snapshot</FONT></STRONG> </div><div style="margin-bottom: 10px;">The company operates under three brands: <A href="http://www.fougera.com/">Fougera</A>, <A href="http://www.pharmaderm.com/pharmaderm/phdrm_web_default.html">PharmaDerm</A> and <A href="http://www.savagelabs.com/">Savage Lab</A>.<wbr> </div><div style="margin-bottom: 10px;">Fougera has 45 products and PharmaDerm, the speciality drug company has 17 brands.<wbr> </div><div style="margin-bottom: 10px;">2011 sales: $429m in a US dermatology generics market estimated at $2.<wbr>1bn.<wbr> </div><div style="margin-bottom: 10px;">Focus: acne, dermatitis, eczema, Fungal Rash, psoriasis, rosacea, actinic keratosis (AK) and external genital warts (EGW).<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Recent News</FONT></STRONG> </div><div style="margin-bottom: 10px;">The US generic dermatology space is very attractive, and competitive.<wbr> </div><div style="margin-bottom: 10px;">On May 3 2012, Zydus filed ANDA with the FDA for generic version of Medicis' Solodyn (for acne).<wbr> </div><div>Last February, Valeant completed divestiture of generic dermatology products to Mylan.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120831&edate=20120501&rec=9867">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-05-03T10:50:25+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Allergan - Weak Aesthetic Picture Contrasts With Strong Therapeutic Toxin Sales [class:BotulinumToxins, comp:Allergan, dis:nOAB, dis:Spasticity, sub:Aesthetics, prod:Xeomin, comp:Merz]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology6379</link>
<description>Allergan - Weak Aesthetic Picture Contrasts With Strong Therapeutic Toxin Sales [class:BotulinumToxins, comp:Allergan, dis:nOAB, dis:Spasticity, sub:Aesthetics, prod:Xeomin, comp:Merz]</description><category>class:BotulinumToxins</category><category>comp:Allergan</category><category>dis:nOAB</category><category>dis:Spasticity</category><category>sub:Aesthetics</category><category>prod:Xeomin</category><category>comp:Merz</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology6379</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120831&edate=20120501&rec=6379">Allergan - Weak Aesthetic Picture Contrasts With Strong Therapeutic Toxin Sales</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=class%3aBotulinumToxins"><font color="#e95e0b">:Neurology:class:BotulinumToxins</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=comp%3aAllergan"><font color="#e95e0b">:Neurology:comp:Allergan</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=comp%3aMerz"><font color="#e95e0b">:Neurology:comp:Merz</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=dis%3anOAB"><font color="#e95e0b">:Neurology:dis:nOAB</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=dis%3aSpasticity"><font color="#e95e0b">:Neurology:dis:Spasticity</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=prod%3aXeomin"><font color="#e95e0b">:Neurology:prod:Xeomin</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=sub%3aAesthetics"><font color="#e95e0b">:Neurology:sub:Aesthetics</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology6379">Neurology6379</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 02 May 2012 | 16:10</font><br><br><div style="margin-bottom: 10px;">Comment: Allergan's Q1 figures released today revealed an underlying sales increase of 10.<wbr>4%, +12.<wbr>2% in the specialty pharma business vs.<wbr> 2% in medical devices.<wbr> Botox therapeutic sales remain bouyant but facial aesthetic sales in general were down, predominantly because of a significant downturn in the filler business.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Aesthetic Downturn</STRONG> </div><div style="margin-bottom: 10px;">Dermal fillers declined significantly in the United States, offset by strong double digit growth internationally.<wbr> Sales in Q1, 2011 grew a spectacular 48% versus first quarter of 2010, and represented the first time that facials aesthetic sales were sequentially higher than the high point of a fourth quarter.<wbr><BR><BR>In the US, the swing was explained in terms of the timing of our so-called duet dividends promotion, whereby Allergan provided incentives to physicians and rebate coupons to their patients to combine orders and treatments of JUVEDERM with BOTOX.<wbr> </div><div style="margin-bottom: 10px;">In 2011, all orders for this successful promotion were in the first quarter.<wbr> This year, the promotion commenced in the middle of April and is expected to last throughout the second quarter.<wbr> In Q2 Allergan claims to have seen a strong response to this campaign.<wbr> The 2012 campaign, was after the XEOMIN cosmetic launch at the American Academy of Dermatology which took place in the middle of March.<wbr> Furthermore, physician office inventory of JUVEDERM was drawn down as the new syringe size was launched, (the 1 ml at the same price as the former 0.<wbr>8 ml syringe, which will no longer be commercialized in the US market).<wbr><BR><BR>Excluding the the channel inventory swings created by the company, management estimated that the US market in Q1 grew in the low double digits, sequentially market share was flat in Q1, at about 39%, but up 200 basis points from Q1 of 2011.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Botox Franchise</STRONG> </div><div style="margin-bottom: 10px;">Sales growth was 9.<wbr>4% in dollars and 10.<wbr>5% in local currencies with greater double digit growth in the therapeutic side of the business, due to the recently approved indications of chronic migraine, neurogenic over active bladder and in the U.<wbr>S.<wbr>, upper limit spasticity.<wbr> Cosmetic growth was "more modest" due to Xeomin's sampling and its capture of 7 to 8% market share.<wbr><BR><BR>Regarding its worldwide market share for all neuromodulators in Q4, 2011, the last period for which the updates are available, Allergan estimates that BOTOX enjoyed just over 76% share, down about 300 basis points from Q4 of 2010 as competitors entered new geographic markets.<wbr> </div><div style="margin-bottom: 10px;">Allergan is now claiming that as of March its BOTOX cosmetic volume share moved up to 78% from 75% in February, gaining both against DYSPORT and XEOMIN.<wbr> The key driver it appeats was the media and promotional launch of the BOTOX ten-year anniversary campaign which enabled patients to capture a discount across three treatments in a market which in Q1 was growing at a double-digit rate.<wbr><BR><BR>In the therapeutic segment growth was reportedly particularly strong in the United States, Canada, Latin America and Asia Pacific.<wbr> In Europe, by contrast Allergan claims to have been impacted by government mandated price cuts </div><div style="margin-bottom: 10px;">In the US, BOTOX therapeutic market Allergan is claiming that its share remains very high at 93%, with the remaining 7% being shared fairly equally by DYSPORT, Myobloc and XEOMIN.<wbr> About 5,000 individual physicians of the approximately 10,000 neurologists in the United States have now been trained on Botox injections for migraine with 50% of practicing neurologists apparently having injected at least one patient for chronic migraine in the past month.<wbr> An unbranded DTC campaign for patient awareness of the condition in September of last year, and in addition, Allergan has been placing BOTOX branded print advertisements in women's magazines since February.<wbr><BR><BR>In the US, in the core movement disorders area, which includes the upper limit spasticity indication, Allergan also reports that it continues to enjoy double digit growth.<wbr> </div><div style="margin-bottom: 10px;">Regarding the Neurogenic overacting bladder launch just over 1,000 individual physicians have so far been trained.<wbr> Regarding insurance access, 60% of commercial lives enjoy policy coverage.<wbr> 82% of Medicare lives and 96% of Medicaid lives.<wbr> It was noted that the next key event in the group's urology franchise is the expected approvals for idiopathic over active bladder by both FDA and the European authorities in 2013.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Full Year Guidance</STRONG> </div><div style="margin-bottom: 10px;">Finally in terms of its full-year guidance management decided to keep the 1.<wbr>75 and the $1.<wbr>8 billion revenue estimate for Botox, claiming that it will try to provide more accurate guidance with its Q2 figures.<wbr> Given the level iof XEOMIN inventory in channel which still had to be used up there was little positive impact of Xeomin's withdrawal on BOTOX sales in Q1 but is expected to provide a benefit during the remainder of the year and additionally a small benefit to JUVEDERM sales.<wbr> </div><div>Source: <A href="http://www.Allergan.com">www.<wbr>Allergan.<wbr>com</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120831&edate=20120501&rec=6379">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-05-02T16:10:25+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>A Potentially New Adaptive Development Programme For Innovative Drugs [mkt:UK, sub:ClinicalTrial, sub:Finance, sub:Partnership]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld9866</link>
<description>A Potentially New Adaptive Development Programme For Innovative Drugs [mkt:UK, sub:ClinicalTrial, sub:Finance, sub:Partnership]</description><category>mkt:UK</category><category>sub:ClinicalTrial</category><category>sub:Finance</category><category>sub:Partnership</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld9866</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120831&edate=20120501&rec=9866">A Potentially New Adaptive Development Programme For Innovative Drugs</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=mkt%3aUK"><font color="#e95e0b">:PharmaWorld:mkt:UK</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=sub%3aClinicalTrial"><font color="#e95e0b">:PharmaWorld:sub:ClinicalTrial</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=sub%3aFinance"><font color="#e95e0b">:PharmaWorld:sub:Finance</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=sub%3aPartnership"><font color="#e95e0b">:PharmaWorld:sub:Partnership</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld9866">PharmaWorld9866</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 02 May 2012 | 16:06</font><br><br><div style="margin-bottom: 10px;"><DIV style="WORD-SPACING: 0px; FONT: 13px arial, sans-serif; TEXT-TRANSFORM: none; COLOR: rgb(34,34,34); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><FONT color="#000066">Comment: The EMEA are considering an adaptive approval process for innovative drugs whereby drugs may undergo an evaluation of effectiveness in hospitals at the end of phase 2, allowing a company to book sales while the data collection process is ongoing.<wbr>  Pilot countries are being considered and the UK believes it is in a good position to be part of the pilot process.<wbr></FONT></DIV> </div><div style="margin-bottom: 10px;"><DIV style="WORD-SPACING: 0px; FONT: 13px arial, sans-serif; TEXT-TRANSFORM: none; COLOR: rgb(34,34,34); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><FONT color="#000066">This is the message that emerged at a meeting organised by he UK Bioindustry Association   (BIA) in association with EMIG (Ethics Medicines Industry Group) and attended by Helen Cohen (Neurology Business Development)  and Steve Hill (UK General Manager).<wbr>  </FONT></DIV> </div><div style="margin-bottom: 10px;"><DIV style="WORD-SPACING: 0px; FONT: 13px arial, sans-serif; TEXT-TRANSFORM: none; COLOR: rgb(34,34,34); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><FONT color="#000066"><STRONG>Thanks to Helen Cohen we have some feedback from the meeting:-</STRONG></FONT></DIV> </div><div style="margin-bottom: 10px;"><DIV style="WORD-SPACING: 0px; FONT: 13px arial, sans-serif; TEXT-TRANSFORM: none; COLOR: rgb(34,34,34); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><FONT color="#000066">The focus was the UK government's health and social care bill which was finally passed in March and will be signed into law despite widespread opposition from the clinical profession with the support of Dept of Health, NICE etc.<wbr>  This was presented as part of the Key Note Address on the subject of "Preparing for tomorrow today"  by Professor John Bell (Regius Professor of Medicine, Oxford University and Chairman of the Strategic Co-ordination of Health)  </FONT></DIV> </div><div style="margin-bottom: 10px;"><DIV style="WORD-SPACING: 0px; FONT: 13px arial, sans-serif; TEXT-TRANSFORM: none; COLOR: rgb(34,34,34); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><FONT color="#000066">As part of the shake up, the NHS has to save £20bn by 2015 whilst trying to integrate social care, the NHS and Public Health together, with the intention to improve overall delivery of care.<wbr>  The conference highlighted the radical shake up to commissioning  processes within the Health Service at National, Regional and Local level and the concerns that the new GP led commissioning groups will struggle to be ready by April 2013.<wbr>   </FONT></DIV> </div><div style="margin-bottom: 10px;"><DIV style="WORD-SPACING: 0px; FONT: 13px arial, sans-serif; TEXT-TRANSFORM: none; COLOR: rgb(34,34,34); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><FONT color="#000066">To be able to afford to introduce new innovations the Department of Health representative clearly stated that something that is not efficient has to be taken out of the system as the budget is flat.<wbr> Innovation as currently presented by industry is often a small change in the treatment paradigm with marginal outcome improvements.<wbr>   The UK has been slow to adopt innovation and Professor Bell outlined initiatives that the government is supporting in its Strategy for Life Sciences to support innovation including opening the UK Clinical Trials Gateway where NHS data becomes available unless patients opt out, creation of UK High Tech Clusters geographically, creation of the Biomedical Catalyst Fund to give grants to small companies to be able to move innovative science into man for POC, funding for Cell therapy approaches and creating more precision medicine targeted to the patient etc  </FONT></DIV> </div><div style="margin-bottom: 10px;"><DIV style="WORD-SPACING: 0px; FONT: 13px arial, sans-serif; TEXT-TRANSFORM: none; COLOR: rgb(34,34,34); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><FONT color="#000066">The chief executive of NICE Sir Andrew Dillon told the conference that NICE has developed quality and financial performance indicatiors to drive the commissioning process for the NHS.<wbr>  We also learnt that products approved within NICE guidelines will automatically appear on formularies and that clinicians will have to indicate where their clinical judgements suggest an alternative approach to the NICE guidelines.<wbr>  Clinical freedom will not be restricted but differences from guidelines will require clinical justification.<wbr>  </FONT></DIV> </div><div style="margin-bottom: 10px;"><DIV style="WORD-SPACING: 0px; FONT: 13px arial, sans-serif; TEXT-TRANSFORM: none; COLOR: rgb(34,34,34); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><FONT color="#000066">From an industry point of view the new approaches on Value Based Pricing (VPB) are not clear and have not moved forward in the last 12 months .<wbr> Government is starting its consultation, with the intention of VBP being in place by April 2014   Tim Fitzgerald (Chief Executive of gfk Bridgehead) indicated that companies are having to factor value based pricing earlier and earlier in the development process ie at research.<wbr>  </FONT></DIV> </div><div style="margin-bottom: 10px;"><DIV style="WORD-SPACING: 0px; FONT: 13px arial, sans-serif; TEXT-TRANSFORM: none; COLOR: rgb(34,34,34); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><FONT color="#000066">Head to head data vs standard of care must be shown in the patient populations and companies are having to project forward to what best standard of care is likely to be at the time of approval.<wbr> New products will be reviewed as part of the disease management process including the product, any technologies and any services.<wbr> Existing marketed products are unlikely to be retrospectively fully assessed but price pressure will continue with the list price being the maximum price and discounted prices being part of the local access process.<wbr>  </FONT></DIV> </div><div><DIV style="WORD-SPACING: 0px; FONT: 13px arial, sans-serif; TEXT-TRANSFORM: none; COLOR: rgb(34,34,34); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><FONT color="#000066">Annual treatment costs for new orphan/<wbr>ultraorphan products with no current standard of care, high unmet need and high society cost will continue to attract the current band of circa £100,000 pa but pressures downwards are expected toward £20-30,000 on innovative medicines that are tackling diseases effectively but where this places a greater burden on Health Authorities.<wbr>  More large pharma are looking at this category of product which are medium to higher costs for the current standard of care.<wbr>  All pharma is leaving their value based assessment to late in the process.<wbr> </FONT></DIV> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20120831&edate=20120501&rec=9866">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-05-02T16:06:46+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>Prana Biotech Commences PhII Huntington Disease Study [dis:Huntington, news, :PharmaWorld:mkt:Australia, :PharmaWorld:mkt:Intercontinental]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology6378</link>
<description>Prana Biotech Commences PhII Huntington Disease Study [dis:Huntington, news, :PharmaWorld:mkt:Australia, :PharmaWorld:mkt:Intercontinental]</description><category>dis:Huntington</category><category>news</category><category>mkt:Australia</category><category>mkt:Intercontinental</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology6378</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120831&edate=20120501&rec=6378">Prana Biotech Commences PhII Huntington Disease Study</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=dis%3aHuntington"><font color="#e95e0b">:Neurology:dis:Huntington</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=news"><font color="#e95e0b">:Neurology:news</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=mkt%3aAustralia"><font color="#e95e0b">:PharmaWorld:mkt:Australia</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=mkt%3aIntercontinental"><font color="#e95e0b">:PharmaWorld:mkt:Intercontinental</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology6378">Neurology6378</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 02 May 2012 | 14:33</font><br><br><div style="margin-bottom: 10px;"><P style="WORD-SPACING: 0px; FONT: 11px Arial, Helvetica, verdana, sans-serif; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><FONT face="Verdana" size="2">Comment: Prana Biotechnology has dosed the first patient in its "Reach2HD Trial" - a 6 month Phase IIa clinical trial testing PBT2 for Huntington disease.<wbr> Reach2HD, a double blind placebo controlled study, is enrolling 100 patients with early to mid-stage Huntington Disease.<wbr></FONT></P> </div><div style="margin-bottom: 10px;"><P style="WORD-SPACING: 0px; FONT: 11px Arial, Helvetica, verdana, sans-serif; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><FONT face="Verdana" size="2"><STRONG>Development Rational </STRONG></FONT></P> </div><div style="margin-bottom: 10px;"><P style="WORD-SPACING: 0px; FONT: 11px Arial, Helvetica, verdana, sans-serif; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><FONT face="Verdana" size="2">There is only one marketed drug for Huntington disease, with limited utility and notably there are no drugs either available or in development that have established clinical evidence for treating the cognitive decline associated with Huntington disease.<wbr> In this study, Prana aims to demonstrate cognitive improvements as already demonstrated in a Phase IIa study in mild Alzheimer's patients treated with PBT2.<wbr> The study will also investigate safety, functional, behavioural and motor benefits in this Huntington patient population.<wbr></FONT></P> </div><div style="margin-bottom: 10px;"><P style="WORD-SPACING: 0px; FONT: 11px Arial, Helvetica, verdana, sans-serif; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><FONT face="Verdana" size="2"><STRONG>Alzheimer Disease Effects Stimulated Interest In Application In HD</STRONG></FONT></P> </div><div style="margin-bottom: 10px;"><P style="WORD-SPACING: 0px; FONT: 11px Arial, Helvetica, verdana, sans-serif; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><FONT face="Verdana" size="2">Professor Ira Shoulson, Professor of Neurology, Pharmacology and Human Science at Georgetown University (Washington, DC) and the Chair of the Executive Committee of the Huntington Study Group, said, "PBT2 attracted our attention as an experimental drug with the potential to bring real benefit to Huntington disease patients who suffer from a range of motor, behavioural and cognitive symptoms.<wbr> The favourable signals from the PBT2 trial in Alzheimer's disease are particularly promising.<wbr>"</FONT></P> </div><div style="margin-bottom: 10px;"><P style="WORD-SPACING: 0px; FONT: 11px Arial, Helvetica, verdana, sans-serif; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><FONT face="Verdana" size="2">The trial will be conducted in approximately 20 sites across the US and Australia.<wbr> More details can be found at the following site <FONT face="Arial"><A href="http://www.huntington-study-group.org">www.<wbr>huntington-study-group.<wbr>org</A></FONT></FONT></P> </div><div style="margin-bottom: 10px;"><P style="WORD-SPACING: 0px; FONT: 11px Arial, Helvetica, verdana, sans-serif; TEXT-TRANSFORM: none; COLOR: rgb(0,0,0); TEXT-INDENT: 0px; WHITE-SPACE: normal; LETTER-SPACING: normal; BACKGROUND-COLOR: rgb(255,255,255); orphans: 2; widows: 2; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px"><FONT size="2"><STRONG>Background Regarding Development Of PBT2</STRONG></FONT></P> </div><div style="margin-bottom: 10px;">The development of Prana's library of Metal-Protein Attenuating Compounds ('MPACs') commenced with the observation that Prana's first proof-of-concept MPAC - clioquinol ('PBT1'), abolished Alzheimer's-like changes in the brains of genetically engineered mice.<wbr> Subsequent work demonstrated a significant reduction in cognitive decline in a pilot phase IIa study in Alzheimer's patients receiving PBT1.<wbr> Due to an unrectifiable manufacturing impurity, PBT1 was retired and immediately succeeded by an improved and novel MPAC – 'PBT2' , the leading candidate to arise out of Prana's unique drug discovery platform.<wbr> PBT2, while sharing a similar mechanism of action to PBT1, demonstrates superior technical and medicinal properties.<wbr> </div><div>From <A href="http://www.pranabio.com">http:/<wbr>/<wbr>www.<wbr>pranabio.<wbr>com</A> see <A href="http://www.pipelinereview.com/index.php/2012043047780/Small-Molecules/Prana-Enrolls-First-Patient-in-the-Reach2HD-Phase-II-Huntington-Disease-Trial.html">original source</A>.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120831&edate=20120501&rec=6378">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-05-02T14:33:05+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>Vernalis ' A2A Antagonist to Enter Ph2 Trial for Parkinson [dis:Parkinson]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology6377</link>
<description>Vernalis ' A2A Antagonist to Enter Ph2 Trial for Parkinson [dis:Parkinson]</description><category>dis:Parkinson</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology6377</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120831&edate=20120501&rec=6377">Vernalis ' A2A Antagonist to Enter Ph2 Trial for Parkinson</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=dis%3aParkinson"><font color="#e95e0b">:Neurology:dis:Parkinson</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology6377">Neurology6377</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 02 May 2012 | 13:27</font><br><br><div style="margin-bottom: 10px;">Comment: The outcomes of the Ph1 study have shown that the drug has good safey and tolerability profile.<wbr> POC trial is planned for H2 2012.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Potential Advantages</FONT></STRONG> </div><div style="margin-bottom: 10px;">- Experts believe that A2A receptor antagonists could have advantages over conventional dopaminegic strategies.<wbr> They may be able to help restore motor function in patients with Parkinson’s disease, without side effects such as nausea and dyskinesia often associated with current treatments.<wbr> </div><div style="margin-bottom: 10px;">- Few A2A receptor antagonists in development </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Business Development</FONT></STRONG> </div><div>The drug was partnered with Biogen Idec in 2004, but Vernalis regained the programme in April 2011.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120831&edate=20120501&rec=6377">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-05-02T13:27:48+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>New POC Trial of Medy-Tox' MT10109 Versus Botox(R) for Cervical Dystonia [comp:MediTox, dis:Dystonia, headline, :PharmaWorld:mkt:Australia, :PharmaWorld:mkt:Intercontinental, :PharmaWorld:sub:ClinicalTrial]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology6371</link>
<description>New POC Trial of Medy-Tox' MT10109 Versus Botox(R) for Cervical Dystonia [comp:MediTox, dis:Dystonia, headline, :PharmaWorld:mkt:Australia, :PharmaWorld:mkt:Intercontinental, :PharmaWorld:sub:ClinicalTrial]</description><category>comp:MediTox</category><category>dis:Dystonia</category><category>headline</category><category>mkt:Australia</category><category>mkt:Intercontinental</category><category>sub:ClinicalTrial</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology6371</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120831&edate=20120501&rec=6371">New POC Trial of Medy-Tox' MT10109 Versus Botox(R) for Cervical Dystonia</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=comp%3aMediTox"><font color="#e95e0b">:Neurology:comp:MediTox</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=dis%3aDystonia"><font color="#e95e0b">:Neurology:dis:Dystonia</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20120831&edate=20120501&cat=headline"><font color="#e95e0b">:Neurology:headline</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=mkt%3aAustralia"><font color="#e95e0b">:PharmaWorld:mkt:Australia</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=mkt%3aIntercontinental"><font color="#e95e0b">:PharmaWorld:mkt:Intercontinental</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20120831&edate=20120501&cat=sub%3aClinicalTrial"><font color="#e95e0b">:PharmaWorld:sub:ClinicalTrial</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology6371">Neurology6371</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 02 May 2012 | 11:35</font><br><br><div style="margin-bottom: 10px;">Comment: Clinicaltrials.<wbr>gov is listing a new Ph2 study with Medy-Tox' HSA-free botulinum toxin preparation, planned to start next month in Australia.<wbr> The primary endpoint will assess the number of AEs.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Study Details - <A href="http://clinicaltrials.gov/ct2/show/NCT01588574?recr=Open&amp;fund=2&amp;rcv_s=04%2F18%2F2012&amp;rank=82">NCT01588574</A></FONT></STRONG> </div><div style="margin-bottom: 10px;">Recruitment: approx.<wbr> 60 </div><div style="margin-bottom: 10px;">Start date: June 2012 - Completion dates: Feb.<wbr> 2013 /<wbr>April 2013 </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Background in Traction</FONT></STRONG> </div><div>Ongoing trials with MT10109 in Aesthetic (See <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120831&edate=20120501&rec=6149" class="defaultlink">Neurology6149: New Study of Medy-Tox' s New BTA Formulation Versus Botox(R) in Glabellar Frown Lines</a>).<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20120831&edate=20120501&rec=6371">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2012-05-02T11:35:12+02:00</dc:date><dc:creator>brd97880</dc:creator></item></channel>
</rss>